haloperidol	B-Drug
;	O
      
While	O
the	O
effects	O
of	O
chronic	O
phenytoin	B-Drug
or	O
carbamazepine	B-Drug
therapy	O
on	O
the	O
action	O
of	O
MIVACRON	B-Brand
are	O
unknown	O
slightly	O
shorter	O
durations	O
of	O
neuromuscular	O
block	O
may	O
be	O
anticipated	O
and	O
infusion	O
rate	O
requirements	O
may	O
be	O
higher	O
.	O
      
Although	O
a	O
causal	O
relationship	O
has	O
not	O
been	O
established	O
there	O
have	O
been	O
reports	O
of	O
bleeding	O
and	O
/	O
or	O
prolonged	O
prothrombin	O
time	O
in	O
patients	O
treated	O
with	O
TRENTAL	B-Brand
with	O
and	O
without	O
anticoagulants	B-Group
or	O
platelet	B-Group
aggregation	I-Group
inhibitors	I-Group
.	O
      
Increasing	O
the	O
indinavir	B-Drug
dose	O
to	O
9	O
mg	O
every	O
9	O
hours	O
does	O
not	O
compensate	O
for	O
the	O
increased	O
indinavir	B-Drug
metabolism	O
due	O
to	O
SUSTIVA	B-Brand
.	O
      
These	O
effects	O
were	O
not	O
considered	O
clinically	O
important	O
.	O
      
ROMAZICON	B-Brand
blocks	O
the	O
central	O
effects	O
of	O
benzodiazepines	B-Group
by	O
competitive	O
interaction	O
at	O
the	O
receptor	O
level	O
.	O
      
Although	O
specific	O
drug	O
or	O
food	O
interactions	O
with	O
mifepristone	B-Drug
have	O
not	O
been	O
studied	O
on	O
the	O
basis	O
of	O
this	O
drug	O
metabolism	O
by	O
CYP	O
9A9	O
it	O
is	O
possible	O
that	O
ketoconazole	B-Drug
itraconazole	B-Drug
erythromycin	B-Drug
and	O
grapefruit	O
juice	O
may	O
inhibit	O
its	O
metabolism	O
(	O
increasing	O
serum	O
levels	O
of	O
mifepristone	B-Drug
)	O
.	O
      
Usually	O
the	O
dosage	O
of	O
the	O
anticoagulant	B-Group
should	O
be	O
reduced	O
by	O
one	O
-	O
half	O
(	O
depending	O
on	O
the	O
individual	O
case	O
)	O
to	O
maintain	O
the	O
prothrombin	O
time	O
at	O
the	O
desired	O
level	O
to	O
prevent	O
bleeding	O
complications	O
.	O
      
In	O
general	O
these	O
are	O
drugs	O
that	O
have	O
one	O
or	O
more	O
pharmacologic	O
activities	O
similar	O
to	O
bepridil	B-Drug
hydrochloride	I-Drug
including	O
anti	B-Group
-	O
arrhythmic	I-Group
agents	I-Group
such	O
as	O
quinidine	B-Drug
and	O
procainamide	B-Drug
cardiac	B-Group
glycosides	I-Group
and	O
tricyclic	B-Group
anti	I-Group
-	O
depressants	I-Group
.	O
      
Ketoconazole	B-Drug
:	O
Sensipar	B-Brand
is	O
metabolized	O
in	O
part	O
by	O
CYP9A9	O
.	O
      
decreased	O
antithrombin	B-Drug
9	I-Drug
;	O
      
Since	O
the	O
concomitant	O
administration	O
of	O
warfarin	B-Drug
with	O
amiodarone	B-Drug
increases	O
the	O
prothrombin	O
time	O
by	O
9	O
%	O
after	O
9	O
to	O
9	O
days	O
the	O
dose	O
of	O
the	O
anticoagulant	B-Drug
should	O
be	O
reduced	O
by	O
one	O
-	O
third	O
to	O
one	O
-	O
half	O
and	O
prothrombin	O
times	O
should	O
be	O
monitored	O
closely	O
.	O
      
structural	O
heart	O
disease	O
is	O
a	O
known	O
risk	O
factor	O
for	O
arrhythmia	O
.	O
      
The	O
concomitant	O
intake	O
of	O
alcohol	B-Drug
and	O
Acamprosate	B-Drug
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
either	O
alcohol	B-Drug
or	O
acamprosate	B-Drug
.	O
      
Therefore	O
caution	O
should	O
be	O
exercised	O
when	O
administering	O
TOLECTIN	B-Brand
to	O
patients	O
on	O
anticoagulants	B-Group
.	O
      
Patients	O
with	O
major	O
psychotic	O
disorders	O
treated	O
with	O
neuroleptics	B-Group
should	O
be	O
treated	O
with	O
dopamine	B-Group
agonists	I-Group
only	O
if	O
the	O
potential	O
benefits	O
outweigh	O
the	O
risks	O
.	O
      
Population	O
PK	O
analysis	O
with	O
a	O
database	O
of	O
9	O
patients	O
showed	O
that	O
the	O
pharmacokinetics	O
of	O
rivastigmine	B-Drug
were	O
not	O
influenced	O
by	O
commonly	O
prescribed	O
medications	O
such	O
as	O
antacids	B-Group
(	O
n=9	O
)	O
antihypertensives	B-Group
(	O
n=9	O
)	O
calcium	B-Group
channel	I-Group
blockers	I-Group
(	O
n=9	O
)	O
antidiabetics	B-Group
(	O
n=9	O
)	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
drugs	I-Group
(	O
n=9	O
)	O
estrogens	B-Group
(	O
n=9	O
)	O
salicylate	B-Group
analgesics	I-Group
(	O
n=9	O
)	O
antianginals	B-Group
(	O
n=9	O
)	O
and	O
antihistamines	B-Group
(	O
n=9	O
)	O
.	O
      
Thus	O
when	O
NSAIDs	B-Group
and	O
lithium	B-Drug
are	O
administered	O
concurrently	O
subjects	O
should	O
be	O
observed	O
carefully	O
for	O
signs	O
of	O
lithium	B-Drug
toxicity	O
.	O
      
Although	O
increased	O
plasma	O
concentrations	O
(	O
AUC	O
9	O
-	O
9	O
hrs	O
)	O
of	O
loratadine	B-Drug
and	O
/	O
or	O
descarboethoxyloratadine	B-Drug
were	O
observed	O
following	O
coadministration	O
of	O
loratadine	B-Drug
with	O
each	O
of	O
these	O
drugs	O
in	O
normal	O
volunteers	O
(	O
n	O
=	O
9	O
in	O
each	O
study	O
)	O
there	O
were	O
no	O
clinically	O
relevant	O
changes	O
in	O
the	O
safety	O
profile	O
of	O
loratadine	B-Drug
as	O
assessed	O
by	O
electrocardiographic	O
parameters	O
clinical	O
laboratory	O
tests	O
vital	O
signs	O
and	O
adverse	O
events	O
.	O
      
Central	B-Group
nervous	I-Group
system	I-Group
depressant	I-Group
(	O
CNS	O
)	O
drugs	O
including	O
alcohol	B-Drug
antidepressants	B-Group
antihistamines	B-Group
antipsychotics	B-Group
blood	O
pressure	O
medications	O
(	O
reserpine	B-Drug
methyldopa	B-Drug
beta	B-Group
-	O
blockers	I-Group
)	O
motion	O
sickness	O
medications	O
muscle	B-Group
relaxants	I-Group
narcotics	B-Group
sedatives	B-Group
sleeping	O
pills	O
and	O
tranquilizers	B-Group
      
Tricyclic	B-Group
antidepressants	I-Group
may	O
block	O
the	O
antihypertensive	O
action	O
of	O
guanethidine	B-Drug
and	O
similarly	O
acting	O
compounds	O
.	O
      
Epirubicin	B-Drug
is	O
extensively	O
metabolized	O
by	O
the	O
liver	O
.	O
      
-	O
Changes	O
in	O
TBg	O
concentration	O
should	O
be	O
taken	O
into	O
consideration	O
in	O
the	O
interpretation	O
of	O
T9	O
and	O
T9	O
values	O
.	O
      
The	O
increase	O
of	O
phenobarbital	B-Drug
level	O
however	O
is	O
small	O
(	O
9	O
%	O
)	O
when	O
given	O
with	O
Trileptal	B-Brand
.	O
      
Diazepam	B-Drug
:	O
The	O
co	O
-	O
administration	O
of	O
Fluvoxamine	B-Drug
Tablets	O
and	O
diazepam	B-Drug
is	O
generally	O
not	O
advisable	O
.	O
      
In	O
a	O
p9	O
(	O
+	O
/	O
-	O
)	O
mouse	O
carcinogenicity	O
study	O
at	O
doses	O
up	O
to	O
the	O
maximum	O
tolerated	O
dose	O
of	O
9	O
mg	O
/	O
kg	O
/	O
day	O
ribavirin	B-Drug
was	O
not	O
oncogenic	O
.	O
      
These	O
agents	O
may	O
also	O
prolong	O
the	O
clinically	O
effective	O
duration	O
of	O
action	O
and	O
decrease	O
the	O
average	O
infusion	O
requirement	O
of	O
MIVACRON	B-Brand
by	O
as	O
much	O
as	O
9	O
%	O
to	O
9	O
%	O
.	O
      
Tacrolimus	B-Drug
:	O
Co	O
-	O
administration	O
of	O
tacrolimus	B-Drug
and	O
bosentan	B-Drug
has	O
not	O
been	O
studied	O
in	O
man	O
.	O
      
Therefore	O
it	O
would	O
be	O
expected	O
that	O
a	O
dosing	O
schedule	O
of	O
cerivastatin	B-Drug
sodium	I-Drug
given	O
at	O
bedtime	O
and	O
cholestyramine	B-Drug
given	O
before	O
the	O
evening	O
meal	O
would	O
not	O
result	O
in	O
a	O
significant	O
decrease	O
in	O
the	O
clinical	O
effect	O
of	O
cerivastatin	B-Drug
sodium	I-Drug
.	O
      
Drugs	O
and	O
other	O
substances	O
demonstrated	O
to	O
be	O
CYP	O
9A	O
inhibitors	O
on	O
the	O
basis	O
of	O
clinical	O
studies	O
involving	O
benzodiazepines	B-Group
metabolized	O
similarly	O
to	O
alprazolam	B-Drug
or	O
on	O
the	O
basis	O
of	O
in	O
vitro	O
studies	O
with	O
alprazolam	B-Drug
or	O
other	O
benzodiazepines	B-Group
(	O
caution	O
is	O
recommended	O
during	O
coadministration	O
with	O
alprazolam	B-Drug
)	O
:	O
Available	O
data	O
from	O
clinical	O
studies	O
of	O
benzodiazepines	B-Group
other	O
than	O
alprazolam	B-Drug
suggest	O
a	O
possible	O
drug	O
interaction	O
with	O
alprazolam	B-Drug
for	O
the	O
following	O
:	O
diltiazem	B-Drug
isoniazid	B-Drug
macrolide	B-Group
antibiotics	I-Group
such	O
as	O
erythromycin	B-Drug
and	O
clarithromycin	B-Drug
and	O
grapefruit	O
juice	O
.	O
      
ASPIRIN	B-Brand
AND	O
OTHER	O
SALICYLATE	B-Group
DRUGS	I-Group
WILL	O
BE	O
ADDITIVE	O
TO	O
DISALCID	B-Brand
AND	O
MAY	O
INCREASE	O
PLASMA	O
CONCENTRATIONS	O
OF	O
SALICYLIC	B-Drug
ACID	I-Drug
TO	O
TOXIC	O
LEVELS	O
.	O
      
It	O
is	O
recommended	O
not	O
to	O
exceed	O
a	O
single	O
9	O
mg	O
Vardenafil	B-Drug
dose	O
in	O
a	O
9	O
-	O
hour	O
period	O
when	O
used	O
in	O
combination	O
with	O
indinavir	B-Drug
.	O
      
Antibiotics	B-Group
:	O
No	O
human	O
drug	O
interaction	O
studies	O
with	O
antibiotics	B-Group
were	O
conducted	O
.	O
      
Potassium	B-Drug
Supplements	O
and	O
Potassium	B-Group
-	O
Sparing	I-Group
Diuretics	I-Group
:	O
Fosinopril	B-Drug
sodium	I-Drug
can	O
attenuate	O
potassium	O
loss	O
caused	O
by	O
thiazide	B-Group
diuretics	I-Group
.	O
      
In	O
humans	O
carmustine	B-Drug
etoposide	B-Drug
and	O
cisplatin	B-Drug
do	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
ondansetron	B-Drug
.	O
      
Acetazolamide	B-Drug
reduces	O
urinary	O
excretion	O
of	O
quinidine	B-Drug
and	O
may	O
enhance	O
its	O
effect	O
.	O
      
Naproxen	B-Drug
may	O
interfere	O
with	O
some	O
urinary	O
assays	O
of	O
9	O
-	O
hydroxy	O
indoleacetic	O
acid	O
(	O
9HIAA	O
)	O
.	O
      
Drug	O
/	O
LaboratoryTest	O
Interactions	O
Dactinomycin	B-Drug
may	O
interfere	O
with	O
bioassay	O
procedures	O
for	O
the	O
determination	O
of	O
antibacterial	B-Group
drug	I-Group
levels	O
.	O
      
Other	O
Drug	O
Interactions	O
Oral	O
Contraceptives	B-Group
Keppra	B-Brand
(	O
9	O
mg	O
twice	O
daily	O
)	O
did	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
an	O
oral	O
contraceptive	B-Group
containing	O
9	O
mg	O
ethinyl	B-Drug
estradiol	I-Drug
and	O
9	O
mg	O
levonorgestrel	B-Drug
or	O
of	O
the	O
luteinizing	O
hormone	O
and	O
progesterone	O
levels	O
indicating	O
that	O
impairment	O
of	O
contraceptive	O
efficacy	O
is	O
unlikely	O
.	O
      
Ethanol	B-Drug
:	O
Clinical	O
evidence	O
has	O
shown	O
that	O
etretinate	B-Drug
can	O
be	O
formed	O
with	O
concurrent	O
ingestion	O
of	O
acitretin	B-Drug
and	O
ethanol	B-Drug
.	O
      
Concomitant	O
use	O
of	O
tricyclic	B-Group
antidepressants	I-Group
with	O
drugs	O
that	O
can	O
inhibit	O
cytochrome	O
P9	O
9D9	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	B-Group
antidepressant	I-Group
or	O
the	O
other	O
drug	O
.	O
      
Antidiabetic	B-Group
drug	I-Group
requirements	O
(	O
i.e.	O
insulin	B-Drug
)	O
may	O
be	O
altered	O
.	O
      
.	O
      
In	O
addition	O
new	O
cases	O
of	O
diabetes	O
have	O
been	O
diagnosed	O
during	O
retinoid	B-Group
therapy	O
including	O
diabetic	O
ketoacidosis	O
.	O
      
Since	O
there	O
have	O
been	O
conflicting	O
results	O
regarding	O
the	O
effect	O
of	O
digoxin	B-Drug
levels	O
it	O
is	O
recommended	O
that	O
digoxin	B-Drug
levels	O
be	O
monitored	O
when	O
initiating	O
adjusting	O
and	O
discontinuing	O
diltiazem	B-Drug
hydrochloride	I-Drug
therapy	O
to	O
avoid	O
possible	O
over	O
-	O
or	O
under	O
-	O
digitalization	O
.	O
      
Since	O
drowsiness	O
may	O
occur	O
with	O
use	O
of	O
this	O
drug	O
patients	O
should	O
be	O
warned	O
of	O
this	O
possibility	O
and	O
cautioned	O
against	O
driving	O
a	O
car	O
or	O
operating	O
dangerous	O
machinery	O
while	O
taking	O
Atarax	B-Brand
.	O
      
It	O
is	O
advisable	O
to	O
check	O
coagulation	O
time	O
within	O
the	O
first	O
few	O
days	O
after	O
the	O
start	O
and	O
discontinuation	O
of	O
cisapride	B-Drug
therapy	O
with	O
an	O
appropriate	O
adjustment	O
of	O
the	O
anticoagulant	B-Group
dose	O
if	O
necessary	O
.	O
      
The	O
continued	O
need	O
for	O
the	O
other	O
antiarrhythmic	B-Drug
agent	O
should	O
be	O
reviewed	O
after	O
the	O
effects	O
of	O
amiodarone	B-Drug
have	O
been	O
established	O
and	O
discontinuation	O
ordinarily	O
should	O
be	O
attempted	O
.	O
      
Anti	B-Group
-	O
HIV	I-Group
Reverse	I-Group
Transcriptase	I-Group
Inhibitors	I-Group
      
Drug	O
interaction	O
studies	O
were	O
performed	O
with	O
azithromycin	B-Drug
and	O
other	O
drugs	O
likely	O
to	O
be	O
co	O
-	O
administered	O
.	O
      
Urinary	O
alkalinizing	O
agents	O
increase	O
blood	O
levels	O
and	O
decrease	O
excretion	O
of	O
amphetamines	B-Group
.	O
      
Such	O
patients	O
may	O
be	O
unresponsive	O
to	O
the	O
usual	O
doses	O
of	O
epinephrine	B-Drug
used	O
to	O
treat	O
allergic	O
reaction	O
.	O
      
When	O
such	O
drugs	O
are	O
withdrawn	O
from	O
a	O
patient	O
receiving	O
MICRONASE	B-Brand
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
hypoglycemia	O
.	O
      
As	O
DIFFERIN	B-Brand
Gel	O
has	O
the	O
potential	O
to	O
produce	O
local	O
irritation	O
in	O
some	O
patients	O
concomitant	O
use	O
of	O
other	O
potentially	O
irritating	O
topical	O
products	O
(	O
medicated	O
or	O
abrasive	O
soaps	O
and	O
cleansers	O
soaps	O
and	O
cosmetics	O
that	O
have	O
a	O
strong	O
drying	O
effect	O
and	O
products	O
with	O
high	O
concentrations	O
of	O
alcohol	O
astringents	O
spices	O
or	O
lime	O
)	O
should	O
be	O
approached	O
with	O
caution	O
.	O
      
Statistically	O
significant	O
changes	O
in	O
prothrombin	O
and	O
partial	O
thromboplastin	O
times	O
have	O
been	O
reported	O
in	O
normal	O
volunteers	O
.	O
      
Avoid	O
concomitant	O
use	O
unless	O
necessary	O
to	O
control	O
side	O
effects	O
of	O
amphotericin	B-Drug
B	I-Drug
.	O
      
Angiomax	B-Brand
does	O
not	O
exhibit	O
binding	O
to	O
plasma	O
proteins	O
(	O
other	O
than	O
thrombin	O
)	O
or	O
red	O
blood	O
cells	O
.	O
      
The	O
action	O
of	O
the	O
benzodiazepines	B-Group
may	O
be	O
potentiated	O
by	O
anticonvulsants	B-Group
antihistamines	B-Group
alcohol	B-Drug
barbiturates	B-Group
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
narcotics	B-Group
phenothiazines	B-Group
psychotropic	B-Group
medications	I-Group
or	O
other	O
drugs	O
that	O
produce	O
CNS	O
depression	O
.	O
      
Itraconazole	B-Drug
Ketoconazole	B-Drug
Erythromycin	B-Drug
Clarithromycin	B-Drug
Telithromycin	B-Drug
HIV	B-Group
protease	I-Group
inhibitors	I-Group
Nefazodone	B-Drug
Cyclosporine	B-Drug
Large	O
quantities	O
of	O
grapefruit	O
juice	O
(	O
9	O
quart	O
daily	O
)	O
      
Alcohol	B-Drug
in	O
particular	O
has	O
been	O
found	O
to	O
exhibit	O
additive	O
effects	O
of	O
this	O
variety	O
.	O
      
valproate	B-Drug
and	O
gabapentin	B-Drug
are	O
not	O
.	O
      
Therefore	O
fenofibrate	B-Drug
should	O
be	O
taken	O
at	O
least	O
9	O
hour	O
before	O
or	O
9	O
-	O
9	O
hours	O
after	O
a	O
bile	B-Group
acid	I-Group
binding	I-Group
resin	I-Group
to	O
avoid	O
impeding	O
its	O
absorption	O
.	O
      
Lansoprazole	B-Drug
is	O
metabolized	O
through	O
the	O
cytochrome	O
P9	O
system	O
specifically	O
through	O
the	O
CYP9A	O
and	O
CYP9C9	O
isozymes	O
.	O
      
Since	O
hydroxyurea	B-Drug
may	O
raise	O
the	O
serum	O
uric	O
acid	O
level	O
dosage	O
adjustment	O
of	O
uricosuric	B-Group
medication	I-Group
may	O
be	O
necessary	O
      
Free	O
T9	O
and	O
free	O
T9	O
concentrations	O
are	O
unaltered	O
.	O
      
St	O
.	O
Johns	O
wort	O
(	O
Hypericum	O
perforatum	O
)	O
may	O
decrease	O
SPRYCEL	B-Brand
plasma	O
concentrations	O
unpredictably	O
.	O
      
Levetiracetam	B-Drug
and	O
its	O
major	O
metabolite	O
at	O
concentrations	O
well	O
above	O
cmax	O
levels	O
achieved	O
within	O
the	O
therapeutic	O
dose	O
range	O
are	O
neither	O
inhibitors	O
of	O
nor	O
high	O
affinity	O
substrates	O
for	O
human	O
liver	O
cytochrome	O
P9	O
isoforms	O
epoxide	O
hydrolase	O
or	O
UDP	O
-	O
glucuronidation	O
enzymes	O
.	O
      
No	O
in	O
vitro	O
metabolism	O
studies	O
were	O
performed	O
.	O
      
Close	O
supervision	O
and	O
careful	O
adjustment	O
of	O
the	O
dosage	O
are	O
required	O
when	O
nortriptyline	B-Drug
hydrochloride	I-Drug
is	O
used	O
with	O
other	O
anticholinergic	B-Group
drugs	I-Group
or	O
sympathomimetic	B-Group
drugs	I-Group
.	O
      
However	O
in	O
vivo	O
drug	O
interaction	O
studies	O
of	O
ketoconazole	B-Drug
with	O
vitamin	B-Group
D	I-Group
have	O
not	O
been	O
investigated	O
.	O
      
Patients	O
using	O
CYP9A9	O
metabolized	O
statins	B-Group
should	O
have	O
cholesterol	O
levels	O
monitored	O
after	O
TRACLEER	B-Brand
is	O
initiated	O
to	O
see	O
whether	O
the	O
statin	B-Group
dose	O
needs	O
adjustment	O
.	O
      
Phosphate	O
-	O
Binding	O
Agents	O
:	O
Since	O
vitamin	B-Group
D	I-Group
also	O
has	O
an	O
effect	O
on	O
phosphate	O
transport	O
in	O
the	O
intestine	O
kidneys	O
and	O
bones	O
the	O
dosage	O
of	O
phosphate	O
-	O
binding	O
agents	O
must	O
be	O
adjusted	O
in	O
accordance	O
with	O
the	O
serum	O
phosphate	O
concentration	O
.	O
      
Therefore	O
when	O
heparin	B-Drug
sodium	I-Drug
is	O
given	O
with	O
dicumarol	B-Drug
or	O
warfarin	B-Drug
sodium	I-Drug
a	O
period	O
of	O
at	O
least	O
9	O
hours	O
after	O
the	O
last	O
intravenous	O
dose	O
or	O
9	O
hours	O
after	O
the	O
last	O
subcutaneous	O
dose	O
should	O
elapse	O
before	O
blood	O
is	O
drawn	O
if	O
a	O
valid	O
prothrombin	O
time	O
is	O
to	O
be	O
obtained	O
.	O
      
Cimetidine	B-Drug
:	O
In	O
the	O
presence	O
of	O
cimetidine	B-Drug
at	O
9	O
mg	O
QID	O
(	O
N=9	O
)	O
the	O
mean	O
apparent	O
oral	O
clearance	O
of	O
gabapentin	B-Drug
fell	O
by	O
9	O
%	O
and	O
creatinine	O
clearance	O
fell	O
by	O
9	O
%	O
.	O
      
Other	O
:	O
Instances	O
of	O
rash	O
pruritus	O
ankle	O
edema	O
excessive	O
perspiration	O
weight	O
gain	O
nasal	O
congestion	O
.	O
      
Drugs	O
That	O
Induce	O
CYP9A9	O
(	O
Rifampicin	B-Drug
)	O
Racemic	O
zopiclone	B-Drug
exposure	O
was	O
decreased	O
9	O
%	O
by	O
concomitant	O
useof	O
rifampicin	B-Drug
a	O
potent	O
inducer	O
of	O
CYP9A9	O
.	O
      
There	O
were	O
transient	O
increases	O
in	O
liver	O
ALT	O
and	O
AST	O
when	O
CANCIDAS	B-Brand
and	O
cyclosporine	B-Drug
were	O
co	O
-	O
administered	O
.	O
      
In	O
addition	O
certain	O
drugs	O
inhibit	O
the	O
activity	O
of	O
this	O
isozyme	O
and	O
make	O
normal	O
metabolizers	O
resemble	O
p.o	O
.	O
      
Therefore	O
if	O
theophylline	B-Drug
is	O
co	O
-	O
administered	O
with	O
fluvoxamine	B-Drug
maleate	I-Drug
its	O
dose	O
should	O
be	O
reduced	O
to	O
one	O
third	O
of	O
the	O
usual	O
daily	O
maintenance	O
dose	O
and	O
plasma	O
concentrations	O
of	O
theophylline	B-Drug
should	O
to	O
monitored	O
.	O
      
Aprepitant	B-Drug
has	O
been	O
shown	O
to	O
induce	O
the	O
metabolism	O
of	O
S	B-Drug
-	O
warfarin	I-Drug
and	O
tolbutamide	B-Drug
which	O
are	O
metabolized	O
through	O
CYP9C9	O
.	O
      
Interactions	O
for	O
vitamin	B-Group
D	I-Group
analogues	I-Group
(	O
Vitamin	B-Drug
D9	I-Drug
Vitamin	B-Drug
D9	I-Drug
Calcitriol	B-Drug
and	O
Calcidiol	B-Drug
)	O
:	O
Cholestyramine	B-Drug
:	O
Cholestyramine	B-Drug
has	O
been	O
reported	O
to	O
reduce	O
intestinal	O
absorption	O
of	O
fat	B-Group
soluble	I-Group
vitamins	I-Group
;	O
      
Beta	B-Group
-	O
Blockers	I-Group
:	O
In	O
controlled	O
clinical	O
studies	O
adrenergic	B-Group
beta	I-Group
-	O
receptor	I-Group
blockers	I-Group
have	O
been	O
frequently	O
administered	O
concomitantly	O
with	O
nicardipine	B-Drug
HCl	I-Drug
.	O
      
The	O
use	O
of	O
NSAIDs	B-Group
in	O
patients	O
who	O
are	O
receiving	O
ACE	B-Group
inhibitors	I-Group
may	O
potentiate	O
renal	O
disease	O
states	O
.	O
      
indinavir	B-Drug
concentration	O
      
Gemfibrozil	B-Drug
:	O
In	O
a	O
pharmacokinetic	O
study	O
concomitant	O
gemfibrozil	B-Drug
administration	O
increased	O
total	O
ezetimibe	B-Drug
concentrations	O
approximately	O
9	O
-	O
fold	O
.	O
      
Interactions	O
with	O
other	O
drugs	O
metabolized	O
by	O
this	O
enzyme	O
could	O
potentially	O
occur	O
.	O
      
Since	O
falsely	O
elevated	O
glucose	O
levels	O
have	O
been	O
observed	O
with	O
blood	O
glucose	O
monitoring	O
devices	O
and	O
test	O
strips	O
that	O
use	O
glucose	O
dehydrogenase	O
pyrroloquinolinequinone	O
(	O
GDH	O
PQQ	O
)	O
-	O
based	O
methods	O
GDH	O
PQQ	O
-	O
based	O
methods	O
should	O
not	O
be	O
used	O
to	O
measure	O
glucose	O
levels	O
in	O
patients	O
administered	O
EXTRANEAL	B-Brand
..	O
      
Data	O
from	O
a	O
randomized	O
trial	O
of	O
HEXALEN	B-Brand
and	O
cisplatin	B-Drug
plus	O
or	O
minus	O
pyridoxine	B-Drug
in	O
ovarian	O
cancer	O
indicated	O
that	O
pyridoxine	B-Drug
significantly	O
reduced	O
neurotoxicity	O
;	O
      
No	O
specific	O
cytochrome	O
P9	O
-	O
based	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
.	O
      
Drug	O
Interactions	O
General	O
:	O
Although	O
there	O
have	O
been	O
no	O
formal	O
interaction	O
studies	O
intravenous	O
fenoldopam	B-Drug
has	O
been	O
administered	O
safely	O
with	O
drugs	O
such	O
as	O
digitalis	B-Group
and	O
sublingual	O
nitroglycerin	B-Drug
.	O
      
paraldehyde	B-Drug
;	O
      
Due	O
to	O
the	O
slow	O
elimination	O
of	O
mifepristone	B-Drug
from	O
the	O
body	O
such	O
interaction	O
may	O
be	O
observed	O
for	O
a	O
prolonged	O
period	O
after	O
its	O
administration	O
.	O
      
Following	O
the	O
administration	O
of	O
INAPSINE	B-Brand
the	O
dose	O
of	O
other	O
CNS	B-Group
depressant	I-Group
drugs	I-Group
should	O
be	O
reduced	O
.	O
      
rifampin	B-Drug
;	O
      
The	O
following	O
agents	O
may	O
increase	O
certain	O
actions	O
or	O
side	O
effects	O
of	O
anticholinergic	B-Group
drugs	I-Group
.	O
amantadine	B-Drug
antiarrhythmic	B-Group
agents	I-Group
of	O
class	O
(	O
e.g	O
.	O
quinidine	B-Drug
)	O
antihistamines	B-Group
antipsychotic	B-Group
agents	I-Group
(	O
e.g	O
.	O
phenothiazines	B-Group
)	O
benzodiazepines	B-Group
.	O
      
Calcium	B-Group
channel	I-Group
blockers	I-Group
      
Neuropathy	O
has	O
occurred	O
more	O
frequently	O
in	O
patients	O
with	O
a	O
history	O
of	O
neuropathy	O
or	O
neurotoxic	O
drug	O
therapy	O
including	O
stavudine	B-Drug
and	O
these	O
patients	O
may	O
be	O
at	O
increased	O
risk	O
of	O
neuropathy	O
during	O
VIDEX	B-Brand
therapy	O
(	O
see	O
ADVERSE	O
REACTIONS	O
)	O
.	O
      
Simvastatin	B-Drug
and	O
Other	O
Statins	B-Group
:	O
Co	O
-	O
administration	O
of	O
bosentan	B-Drug
decreased	O
the	O
plasma	O
concentrations	O
of	O
simvastatin	B-Drug
(	O
a	O
CYP9A9	O
substrate	O
)	O
and	O
its	O
active	O
-	O
hydroxy	O
acid	O
metabolite	O
by	O
approximately	O
9	O
%	O
.	O
      
Addition	O
or	O
deletion	O
of	O
any	O
drug	O
from	O
the	O
therapeutic	O
regimen	O
of	O
patients	O
receiving	O
oral	O
anticoagulants	B-Group
may	O
affect	O
patient	O
response	O
to	O
the	O
anticoagulant	B-Group
.	O
      
Co	O
-	O
administration	O
of	O
single	O
9	O
-	O
mg	O
dose	O
warfarin	B-Drug
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
total	O
lenalidomide	B-Drug
.	O
      
Further	O
if	O
guanfacine	B-Drug
is	O
to	O
be	O
discontinued	O
in	O
such	O
patients	O
careful	O
tapering	O
of	O
the	O
dosage	O
may	O
be	O
necessary	O
in	O
order	O
to	O
avoid	O
rebound	O
phenomena	O
.	O
      
PROLEUKIN	B-Brand
may	O
affect	O
central	O
nervous	O
function	O
.	O
      
Beta	B-Group
-	O
adrenergic	I-Group
blocking	I-Group
agents	I-Group
:	O
Coadministration	O
of	O
beta	B-Group
-	O
adrenergic	I-Group
blocking	I-Group
agents	I-Group
did	O
not	O
have	O
any	O
effect	O
on	O
either	O
the	O
safety	O
or	O
efficacy	O
of	O
ibutilide	B-Drug
in	O
the	O
clinical	O
trials	O
.	O
      
All	O
of	O
these	O
also	O
resolved	O
9	O
with	O
continuation	O
of	O
both	O
drugs	O
and	O
9	O
after	O
discontinuation	O
of	O
leflunomide	B-Drug
.	O
      
There	O
was	O
no	O
effect	O
of	O
ZEBETA	B-Brand
on	O
prothrombin	O
time	O
in	O
patients	O
on	O
stable	O
doses	O
of	O
warfarin	B-Drug
.	O
      
Antithrombotics	B-Group
      
Cyclosporine	B-Drug
:	O
Because	O
cyclosporine	B-Drug
can	O
produce	O
nephrotoxicity	O
with	O
decreases	O
in	O
creatinine	O
clearance	O
and	O
rises	O
in	O
serum	O
creatinine	O
and	O
because	O
renal	O
excretion	O
is	O
the	O
primary	O
elimination	O
route	O
of	O
fibrate	B-Group
drugs	I-Group
including	O
TRICOR	B-Brand
there	O
is	O
a	O
risk	O
that	O
an	O
interaction	O
will	O
lead	O
to	O
deterioration	O
.	O
      
Of	O
over	O
9	O
patients	O
enrolled	O
in	O
the	O
Ibandronate	B-Drug
osteoporosis	O
Treatment	O
and	O
Prevention	O
Studies	O
9	O
%	O
used	O
anti	O
-	O
peptic	O
agents	O
(	O
primarily	O
H9	B-Group
blockers	I-Group
and	O
PPIs	B-Group
)	O
.	O
      
Monitoring	O
of	O
anticoagulation	O
levels	O
is	O
recommended	O
.	O
      
Oral	O
Contraceptives	B-Group
:	O
Coadministration	O
of	O
atorvastatin	B-Drug
and	O
an	O
oral	O
contraceptive	B-Group
increased	O
AUC	O
values	O
for	O
norethindrone	B-Drug
and	O
ethinyl	B-Drug
estradiol	I-Drug
by	O
approximately	O
9	O
%	O
and	O
9	O
%	O
.	O
      
Before	O
taking	O
glimepiride	B-Drug
tell	O
your	O
doctor	O
if	O
you	O
are	O
taking	O
any	O
of	O
the	O
following	O
medicines	O
:	O
-	O
aspirin	B-Brand
or	O
another	O
salicylate	B-Group
such	O
as	O
magnesium	B-Drug
choline	I-Drug
salicylate	I-Drug
(	O
Trilisate	B-Brand
)	O
salsalate	B-Drug
(	O
Disalcid	B-Brand
others	O
)	O
choline	B-Drug
salicylate	I-Drug
(	O
Arthropan	B-Drug
)	O
magnesium	B-Drug
salicylate	I-Drug
(	O
Magan	B-Brand
)	O
or	O
bismuth	B-Drug
subsalicylate	I-Drug
(	O
Pepto	B-Brand
-	O
Bismol	I-Brand
)	O
;	O
      
Levothyroxine	B-Drug
Sodium	I-Drug
Absorption	O
:	O
The	O
following	O
agents	O
may	O
bind	O
and	O
decrease	O
absorption	O
of	O
levothyroxine	B-Drug
sodium	I-Drug
from	O
the	O
gastrointestinal	O
tract	O
:	O
aluminum	B-Drug
hydoxide	I-Drug
cholestyramine	B-Drug
resin	O
colestipol	B-Drug
hydrochloride	I-Drug
ferrous	B-Drug
sulfate	I-Drug
sodium	B-Drug
polystyrene	I-Drug
sulfonate	I-Drug
soybean	O
flour	O
(	O
e.g.	O
infant	O
formula	O
)	O
sucralfate	B-Drug
.	O
      
In	O
addition	O
Mitotane	B-Drug
should	O
be	O
given	O
with	O
caution	O
to	O
patients	O
receiving	O
other	O
drugs	O
susceptible	O
to	O
the	O
influence	O
of	O
hepatic	O
enzyme	O
induction	O
.	O
      
therefore	O
it	O
is	O
not	O
expected	O
to	O
affect	O
the	O
plasma	O
concentrations	O
of	O
other	O
drugs	O
metabolized	O
by	O
CYP9A9	O
.	O
      
Coadministration	O
of	O
almotriptan	B-Drug
and	O
the	O
potent	O
CYP9A9	O
inhibitor	O
ketoconazole	B-Drug
(	O
9	O
mg	O
q.d	O
.	O
for	O
9	O
days	O
)	O
resulted	O
in	O
an	O
approximately	O
9	O
%	O
increase	O
in	O
the	O
area	O
under	O
the	O
plasma	O
concentration	O
-	O
time	O
curve	O
and	O
maximal	O
plasma	O
concentrations	O
of	O
almotriptan	B-Drug
.	O
      
Drug	O
-	O
Drug	O
Interactions	O
Cimetidine	B-Drug
:	O
Concomitant	O
use	O
of	O
cimetidine	B-Drug
is	O
contraindicated	O
.	O
      
Clinical	O
Comment	O
      
Drug	O
Class	O
:	O
Drug	O
Name	O
Clinical	O
Comment	O
      
Caution	O
should	O
be	O
observed	O
in	O
administering	O
DEMSER	B-Brand
to	O
patients	O
receiving	O
phenothiazines	B-Group
or	O
haloperidol	B-Drug
because	O
the	O
extrapyramidal	O
effects	O
of	O
these	O
drugs	O
can	O
be	O
expected	O
to	O
be	O
potentiated	O
by	O
inhibition	O
of	O
catecholamine	O
synthesis	O
.	O
      
Digoxin	B-Drug
:	O
Coadministration	O
of	O
digoxin	B-Drug
a	O
P	O
-	O
glycoprotein	O
substrate	O
with	O
oral	O
conivaptan	B-Drug
resulted	O
in	O
a	O
reduction	O
in	O
clearance	O
and	O
an	O
increase	O
in	O
digoxin	B-Drug
Cmax	O
and	O
AUC	O
values	O
.	O
      
No	O
specific	O
information	O
available	O
      
The	O
following	O
drug	O
interactions	O
have	O
been	O
reported	O
with	O
etomidate	B-Drug
.	O
      
Vardenafil	B-Drug
(	O
9	O
mg	O
)	O
did	O
not	O
potentiate	O
the	O
hypotensive	O
effects	O
of	O
alcohol	B-Drug
during	O
the	O
9	O
-	O
hour	O
observation	O
period	O
in	O
healthy	O
volunteers	O
when	O
administered	O
with	O
alcohol	B-Drug
(	O
9	O
g	O
/	O
kg	O
body	O
weight	O
)	O
.	O
      
Every	O
other	O
day	O
dosing	O
with	O
9m	O
g	O
/	O
kg	O
(	O
9m	O
g	O
/	O
m9	O
)	O
PEGASYS	B-Brand
(	O
equivalent	O
to	O
approximately	O
9	O
times	O
the	O
recommended	O
human	O
dose	O
)	O
had	O
no	O
effects	O
on	O
cycle	O
duration	O
or	O
reproductive	O
hormone	O
status	O
.	O
      
Saquinavir	B-Drug
:	O
Coadministration	O
of	O
saquinavir	B-Drug
(	O
using	O
an	O
experimental	O
soft	O
-	O
gelatin	O
capsule	O
formulation	O
of	O
saquinavir	B-Drug
9mg	O
)	O
with	O
VIRACEPT	B-Brand
resulted	O
in	O
an	O
9	O
%	O
increase	O
in	O
nelfinavir	B-Drug
plasma	O
AUC	O
and	O
a	O
9	O
-	O
fold	O
increase	O
in	O
saquinavir	B-Drug
plasma	O
A.C	O
.	O
      
Methysergide	B-Drug
may	O
reverse	O
the	O
analgesic	O
activity	O
of	O
narcotic	B-Group
analgesics	I-Group
.	O
      
H9	B-Group
Blockers	I-Group
/	O
Proton	B-Group
Pump	I-Group
Inhibitors	I-Group
:	O
Long	O
-	O
term	O
suppression	O
of	O
gastric	O
acid	O
secretion	O
by	O
H9	B-Group
blockers	I-Group
or	O
proton	B-Group
pump	I-Group
inhibitors	I-Group
(	O
eg	O
famotidine	B-Drug
and	O
omeprazole	B-Drug
)	O
is	O
likely	O
to	O
reduce	O
dasatinib	B-Drug
exposure	O
.	O
      
Dose	O
adjustment	O
is	O
not	O
recommended.Levetiracetam	O
had	O
no	O
effect	O
on	O
plasma	O
concentrations	O
of	O
carbamazepine	B-Drug
valproate	B-Drug
topiramate	B-Drug
or	O
lamotrigine	B-Drug
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
-	O
Interactions	O
None	O
observed	O
.	O
      
Cerivastatin	B-Drug
plasma	O
concentrations	O
were	O
also	O
not	O
affected	O
by	O
co	O
-	O
administration	O
of	O
digoxin	B-Drug
.	O
      
Established	O
Drug	O
Interactions	O
      
apomorphine	B-Drug
-	O
prior	O
ingestion	O
of	O
diphenidol	B-Drug
may	O
decrease	O
the	O
emetic	B-Group
response	O
to	O
apomorphine	B-Drug
in	O
the	O
treatment	O
of	O
poisoning	O
.	O
      
Rare	O
reports	O
of	O
more	O
severe	O
events	O
such	O
as	O
phlebitis	O
cellulitis	O
induration	O
skin	O
exfoliation	O
necrosis	O
and	O
fibrosis	O
have	O
been	O
received	O
as	O
part	O
of	O
the	O
continuing	O
surveillance	O
of	O
TAXOL	B-Brand
safety	O
.	O
      
The	O
use	O
of	O
Nutropin	B-Brand
in	O
patients	O
with	O
chronic	O
renal	O
insufficiency	O
receiving	O
glucocorticoid	O
therapy	O
has	O
not	O
been	O
evaluated	O
.	O
      
Pregnancy	O
Pregnancy	O
:	O
Category	O
C	O
PEGASYS	B-Brand
has	O
not	O
been	O
studied	O
for	O
its	O
teratogenic	O
effect	O
.	O
      
In	O
diabetics	O
blood	O
-	O
sugar	O
levels	O
should	O
be	O
monitored	O
very	O
carefully	O
.	O
      
Short	O
-	O
term	O
pharmacokinetic	O
studies	O
have	O
demonstrated	O
that	O
concomitant	O
administration	O
of	O
warfarin	B-Drug
and	O
Lodine	B-Brand
(	O
etodolac	B-Drug
capsules	O
and	O
tablets	O
)	O
results	O
in	O
reduced	O
protein	O
binding	O
of	O
warfarin	B-Drug
but	O
there	O
was	O
no	O
change	O
in	O
the	O
clearance	O
of	O
free	O
warfarin	B-Drug
.	O
      
DIAMOX	B-Brand
modifies	O
phenytoin	B-Drug
metabolism	O
with	O
increased	O
serum	O
levels	O
of	O
phenytoin	B-Drug
.	O
      
Untreated	O
hypothyroidism	O
may	O
interfere	O
with	O
the	O
growth	O
response	O
to	O
somatrem	B-Drug
or	O
somatropin	B-Drug
.	O
      
9	O
.	O
      
Drug	O
Interactions	O
with	O
Antacids	B-Group
Administration	O
of	O
9	O
mg	O
of	O
fexofenadine	B-Drug
hydrochloride	I-Drug
(	O
9	O
x	O
9	O
mg	O
capsule	O
)	O
within	O
9	O
minutes	O
of	O
an	O
aluminum	B-Drug
and	O
magnesium	B-Drug
containing	O
antacid	B-Group
(	O
Maalox	B-Brand
)	O
decreased	O
fexofenadine	B-Drug
AUC	O
by	O
9	O
%	O
and	O
cmax	O
by	O
9	O
%	O
.	O
      
Lipids	O
:	O
In	O
clinical	O
studies	O
the	O
incidence	O
of	O
hypertriglyceridemia	O
was	O
9	O
%	O
hypercholesterolemia	O
was	O
9	O
%	O
and	O
that	O
of	O
decreased	O
HDL	O
was	O
9	O
%	O
.	O
      
Coadministration	O
of	O
Itraconazole	B-Drug
with	O
oral	O
midazolam	B-Drug
or	O
triazolam	B-Drug
has	O
resulted	O
in	O
elevated	O
plasma	O
concentrations	O
of	O
the	O
latter	O
two	O
drugs	O
.	O
      
Rifampin	B-Drug
      
When	O
used	O
in	O
external	O
subcutaneous	O
infusion	O
pumps	O
for	O
insulin	B-Drug
NovoLog	B-Brand
should	O
not	O
be	O
mixed	O
with	O
any	O
other	O
insulins	B-Group
or	O
diluent	O
.	O
      
Tolbutamide	B-Drug
:	O
Aprepitant	B-Drug
when	O
given	O
as	O
9	O
mg	O
on	O
Day	O
9	O
and	O
9	O
mg	O
/	O
day	O
on	O
Days	O
9	O
and	O
9	O
decreased	O
the	O
AUC	O
of	O
tolbutamide	B-Drug
(	O
a	O
CYP9C9	O
substrate	O
)	O
by	O
9	O
%	O
on	O
Day	O
9	O
9	O
%	O
on	O
Day	O
9	O
and	O
9	O
%	O
on	O
Day	O
9	O
when	O
a	O
single	O
dose	O
of	O
tolbutamide	B-Drug
9	O
mg	O
was	O
admini	O
stered	O
orally	O
prior	O
to	O
the	O
administration	O
of	O
the	O
9	O
-	O
day	O
regimen	O
of	O
Aprepitant	B-Drug
and	O
on	O
Days	O
9	O
9	O
and	O
9	O
.	O
      
Similar	O
effects	O
would	O
be	O
expected	O
with	O
other	O
potent	O
CYP9D9	O
inhibitors	O
(	O
e.g.	O
fluoxetine	B-Drug
quinidine	B-Drug
)	O
.	O
      
This	O
product	O
can	O
affect	O
the	O
results	O
of	O
certain	O
lab	O
tests	O
.	O
      
Increasing	O
the	O
indinavir	B-Drug
dose	O
to	O
9	O
mg	O
every	O
9	O
hours	O
does	O
not	O
compensate	O
for	O
the	O
increased	O
indinavir	B-Drug
metabolism	O
due	O
to	O
efavirenz	B-Drug
.	O
      
Concomitantly	O
administered	O
iron	B-Drug_n
-	O
fortified	O
infant	O
formula	O
(	O
9	O
mg	O
elemental	O
iron	B-Drug_n
/	O
9	O
oz	O
)	O
has	O
no	O
significant	O
effect	O
on	O
cefdinir	B-Drug
pharmacokinetics	O
.	O
      
Alcohol	B-Drug
in	O
particular	O
has	O
been	O
found	O
to	O
exhibit	O
additive	O
effects	O
of	O
this	O
variety	O
.	O
      
Antidiabetic	B-Group
Agents	I-Group
(	O
Insulin	B-Drug
Sulfonylureas	B-Group
)	O
:	O
Requirements	O
for	O
insulin	B-Drug
or	O
oral	O
antidiabetic	B-Group
agents	I-Group
may	O
be	O
reduced	O
in	O
hypothyroid	O
patients	O
with	O
diabetes	O
mellitus	O
and	O
may	O
subsequently	O
increase	O
with	O
the	O
initiation	O
of	O
thyroid	O
hormone	O
replacement	O
therapy	O
.	O
      
Inhibitors	O
of	O
CYP9A9	O
(	O
eg	O
ketoconazole	B-Drug
)	O
or	O
CYP9D9	O
(	O
eg	O
quinidine	B-Drug
fluoxetine	B-Drug
or	O
paroxetine	B-Drug
)	O
can	O
inhibit	O
aripiprazole	B-Drug
elimination	O
and	O
cause	O
increased	O
blood	O
levels	O
.	O
      
The	O
bioavailability	O
of	O
the	O
capsule	O
formulation	O
of	O
cefprozil	B-Drug
was	O
not	O
affected	O
when	O
administered	O
9	O
minutes	O
following	O
an	O
antacid	B-Group
.	O
      
These	O
pharmacokinetic	O
effects	O
seen	O
during	O
diltiazem	B-Drug
coadministration	O
can	O
result	O
in	O
increased	O
clinical	O
effects	O
(	O
e.g.	O
prolonged	O
sodation	O
)	O
of	O
both	O
midazolam	B-Drug
and	O
triazolam	B-Drug
.	O
      
Etonogestrel	B-Drug
may	O
interact	O
with	O
the	O
following	O
medications	O
:	O
acetaminophen	B-Drug
(	O
Tylenol	B-Brand
)	O
antibiotics	B-Group
such	O
as	O
ampicillin	B-Drug
and	O
tetracycline	B-Drug
anticonvulsants	B-Group
(	O
Dilantin	B-Brand
Phenobarbital	B-Drug
Tegretol	B-Brand
Trileptal	B-Brand
Topamax	B-Brand
Felbatol	B-Brand
)	O
antifungals	B-Group
(	O
Gris	B-Brand
-	O
PEG	I-Brand
Nizoral	B-Brand
Sporanox	B-Brand
)	O
atorvastatin	B-Drug
(	O
Lipitor	B-Brand
)	O
clofibrate	B-Drug
(	O
Atromid	B-Brand
-	O
S	I-Brand
)	O
cyclosporine	B-Drug
(	O
Neoral	B-Brand
Sandimmune	B-Brand
)	O
HIV	O
drugs	O
classified	O
as	O
protease	B-Group
inhibitors	I-Group
(	O
Agenerase	B-Brand
Crixivan	B-Brand
Fortovase	B-Brand
Invirase	B-Brand
Kaletra	B-Brand
Norvir	B-Brand
Viracept	B-Brand
)	O
morphine	B-Drug
(	O
Astramorph	B-Brand
Kadian	B-Brand
MS	B-Brand
Contin	I-Brand
)	O
phenylbutazone	B-Drug
prednisolone	B-Drug
(	O
Prelone	B-Brand
)	O
rifadin	B-Brand
(	O
rifampin	B-Drug
)	O
St.	O
Johns	O
wort	O
temazepam	B-Drug
theophylline	B-Drug
(	O
Theo	B-Brand
-	O
Dur	I-Brand
)	O
and	O
vitamin	B-Drug
C	I-Drug
.	O
      
Additionally	O
higher	O
than	O
expected	O
tricyclic	B-Group
antidepressant	I-Group
levels	O
have	O
been	O
observed	O
when	O
they	O
are	O
begun	O
in	O
patients	O
already	O
taking	O
cimetidine	B-Drug
.	O
      
Drug	O
Interaction	O
with	O
Erythromycin	B-Drug
and	O
Ketoconazole	B-Drug
Fexofenadine	B-Drug
has	O
been	O
shown	O
to	O
exhibit	O
minimal	O
(	O
ca	O
.	O
9	O
%	O
)	O
metabolism	O
.	O
      
Standard	O
monitoring	O
of	O
methotrexate	B-Drug
-	O
related	O
toxicity	O
should	O
be	O
continued	O
if	O
VIOXX	B-Brand
and	O
methotrexate	B-Drug
are	O
administered	O
concomitantly	O
.	O
      
Valproate	B-Drug
:	O
Felbatol	B-Brand
causes	O
an	O
increase	O
in	O
steady	O
-	O
state	O
valproate	B-Drug
concentrations	O
.	O
      
Vaccinations	O
with	O
attenuated	O
live	O
bacteria	O
should	O
therefore	O
be	O
completed	O
at	O
least	O
9	O
days	O
before	O
the	O
first	O
dose	O
of	O
Mefloquine	B-Drug
.	O
      
Intracellular	O
resistance	O
to	O
thyroid	B-Group
hormone	I-Group
is	O
quite	O
rare	O
.	O
      
and	O
combinations	O
of	O
opioids	B-Group
and	O
sedatives	B-Group
(	O
eg	O
benzodiazepines	B-Group
barbiturates	B-Group
chloral	B-Drug
hydrate	I-Drug
droperidol	B-Drug
etc	O
.	O
)	O
.	O
      
In	O
one	O
controlled	O
study	O
of	O
9	O
patients	O
transient	O
drowsiness	O
was	O
observed	O
in	O
9	O
%	O
of	O
those	O
receiving	O
baclofen	B-Drug
tablets	O
compared	O
to	O
9	O
%	O
of	O
those	O
in	O
the	O
placebo	O
group	O
.	O
      
cinchophen	B-Drug
;	O
      
Thus	O
concentrations	O
which	O
have	O
been	O
obtained	O
in	O
vivo	O
clinically	O
in	O
patients	O
with	O
normal	O
renal	O
function	O
are	O
considerably	O
lower	O
than	O
the	O
in	O
vitro	O
concentrations	O
found	O
to	O
induce	O
abnormalities	O
in	O
platelet	O
function	O
tests	O
.	O
      
Selegiline	B-Drug
:	O
Combination	B-Group
hormonal	I-Group
contraceptives	I-Group
may	O
increase	O
the	O
serum	O
concentration	O
of	O
selegiline	B-Drug
.	O
      
Given	O
the	O
primary	O
CNS	O
effects	O
of	O
paliperidone	B-Drug
INVEGA	B-Brand
should	O
be	O
used	O
with	O
caution	O
in	O
combination	O
with	O
other	O
centrally	B-Group
acting	I-Group
drugs	I-Group
and	O
alcohol	B-Drug
.	O
      
In	O
an	O
in	O
vivo	O
metabolic	O
probe	O
study	O
alosetron	B-Drug
did	O
not	O
inhibit	O
CYP9E9	O
but	O
did	O
produce	O
9	O
%	O
inhibition	O
of	O
both	O
CYP9A9	O
and	O
N	O
-	O
acetyltransferase	O
.	O
      
In	O
clinical	O
studies	O
patients	O
on	O
opioids	B-Group
often	O
needed	O
higher	O
serum	O
pegvisomant	B-Drug
concentrations	O
to	O
achieve	O
appropriate	O
IGF	O
-	O
I	O
suppression	O
compared	O
with	O
patients	O
not	O
receiving	O
opioids	B-Group
.	O
      
Although	O
there	O
is	O
no	O
documentation	O
of	O
such	O
a	O
similar	O
interaction	O
between	O
ethotoin	B-Drug
and	O
the	O
coumarin	B-Group
anticoagulants	I-Group
may	O
occur	O
.	O
      
Concomitant	O
administration	O
of	O
fenofibrate	B-Drug
(	O
equivalent	O
to	O
9mg	O
TRICOR	B-Brand
)	O
with	O
pravastatin	B-Drug
(	O
9	O
mg	O
)	O
once	O
daily	O
for	O
9	O
days	O
has	O
been	O
shown	O
to	O
increase	O
the	O
mean	O
Cmax	O
and	O
AUC	O
values	O
for	O
pravastatin	B-Drug
by	O
9	O
%	O
(	O
range	O
from	O
9	O
%	O
decrease	O
to	O
9	O
%	O
increase	O
)	O
and	O
9	O
%	O
(	O
range	O
from	O
9	O
%	O
decrease	O
to	O
9	O
%	O
increase	O
)	O
respectively	O
and	O
for	O
9	O
-	O
hydroxy	O
-	O
iso	O
-	O
pravastatin	O
by	O
9	O
%	O
(	O
range	O
from	O
9	O
%	O
decrease	O
to	O
9	O
%	O
increase	O
)	O
and	O
9	O
%	O
(	O
range	O
from	O
9	O
%	O
decrease	O
to	O
9	O
%	O
increase	O
)	O
respectively	O
in	O
9	O
healthy	O
adults	O
.	O
      
Potential	O
effect	O
on	O
anticoagulation	O
.	O
      
Oral	O
anticoagulants	B-Group
may	O
potentiate	O
the	O
hypoglycemic	O
action	O
of	O
hypoglycemic	B-Group
agents	I-Group
eg	O
tolbutamide	B-Drug
and	O
chlorpropamide	B-Drug
by	O
inhibiting	O
their	O
metabolism	O
in	O
the	O
liver	O
.	O
      
In	O
9	O
otherwise	O
healthy	O
subjects	O
with	O
epilepsy	O
ingesting	O
phenytoin	B-Drug
the	O
steadystate	O
trough	O
(	O
Cmin	O
)	O
phenytoin	B-Drug
plasma	O
concentration	O
was	O
9	O
9	O
micrograms	O
/	O
mL	O
.	O
      
MAO	B-Group
Inhibitors	I-Group
:	O
Serious	O
side	O
effects	O
and	O
even	O
death	O
have	O
been	O
reported	O
following	O
the	O
concomitant	O
use	O
of	O
certain	O
drugs	O
with	O
MAO	B-Group
inhibitors	I-Group
.	O
      
Cholinesterase	B-Group
Inhibitors	I-Group
:	O
Dipyridamole	B-Drug
may	O
counteract	O
the	O
anticholinesterase	O
effect	O
of	O
cholinesterase	B-Group
inhibitors	I-Group
thereby	O
potentially	O
aggravating	O
myasthenia	O
gravis	O
.	O
      
Folic	B-Drug
acid	I-Drug
supplements	O
can	O
correct	O
the	O
anemia	O
associated	O
with	O
vitamin	O
B9	O
deficiency	O
.	O
      
No	O
significant	O
effects	O
on	O
cisapride	B-Drug
metabolism	O
or	O
QT	O
interval	O
were	O
noted	O
.	O
      
L	B-Drug
-	O
glutamine	I-Drug
has	O
orphan	O
drug	O
status	O
for	O
this	O
indication	O
.	O
      
Pediatric	O
Use	O
The	O
pharmacokinetics	O
of	O
ZETIA	B-Brand
in	O
adolescents	O
(	O
9	O
to	O
9	O
years	O
)	O
have	O
been	O
shown	O
to	O
be	O
similar	O
to	O
that	O
in	O
adults	O
.	O
      
Amphotericin	B-Drug
B	I-Drug
or	O
Corticosteroids	B-Group
or	O
Corticotropin	B-Drug
(	O
ACTH	B-Drug
)	O
      
The	O
pharmacokinetic	O
interactions	O
listed	O
below	O
are	O
potentially	O
clinically	O
important	O
.	O
      
Diuretic	B-Group
agents	I-Group
may	O
decrease	O
vascular	O
response	O
to	O
pressor	O
drugs	O
such	O
as	O
epinephrine	B-Drug
.	O
      
Drug	O
Laboratory	O
Test	O
Interactions	O
:	O
Prolongation	O
of	O
the	O
template	O
bleeding	O
time	O
has	O
been	O
reported	O
during	O
continuous	O
intravenous	O
infusion	O
of	O
AMICAR	B-Brand
at	O
dosages	O
exceeding	O
9	O
g	O
/	O
day	O
.	O
      
Currently	O
there	O
are	O
no	O
safety	O
and	O
efficacy	O
data	O
available	O
from	O
the	O
use	O
of	O
this	O
combination	O
.	O
      
In	O
a	O
study	O
in	O
9	O
patients	O
with	O
mild	O
to	O
moderate	O
hypertension	O
where	O
the	O
antihypertensive	O
effects	O
of	O
PRINIVIL	B-Brand
alone	O
were	O
compared	O
to	O
PRINIVIL	B-Brand
given	O
concomitantly	O
with	O
indomethacin	B-Drug
the	O
use	O
of	O
indomethacin	B-Drug
was	O
associated	O
with	O
a	O
reduced	O
antihypertensive	O
effect	O
although	O
the	O
difference	O
between	O
the	O
two	O
regimens	O
was	O
not	O
significant	O
.	O
      
Drugs	O
which	O
may	O
potentiate	O
the	O
release	O
of	O
neutrophils	O
such	O
as	O
lithium	B-Drug
should	O
be	O
used	O
with	O
caution	O
.	O
      
Although	O
not	O
studied	O
the	O
potent	O
cytochrome	O
P9	O
9A9	O
inhibitors	O
ritonavir	B-Drug
and	O
nelfinavir	B-Drug
may	O
cause	O
intense	O
and	O
prolonged	O
sedation	O
and	O
respiratory	O
depression	O
due	O
to	O
a	O
decrease	O
in	O
plasma	O
clearance	O
of	O
midazolam	B-Drug
.	O
      
DRUG	O
INTERACTIONS	O
      
With	O
the	O
exception	O
of	O
albuterol	B-Drug
there	O
are	O
no	O
formal	O
studies	O
fully	O
evaluating	O
the	O
interaction	O
effects	O
of	O
ATROVENT	B-Brand
Inhalation	O
Aerosol	O
and	O
these	O
drugs	O
with	O
respect	O
to	O
effectiveness	O
.	O
      
halothane	B-Drug
;	O
      
In	O
a	O
study	O
in	O
diabetics	O
with	O
microalbuminuria	O
INSPRA	B-Brand
9	O
mg	O
combined	O
with	O
the	O
ACE	B-Group
inhibitor	I-Group
enalapril	B-Drug
9	O
mg	O
increased	O
the	O
frequency	O
of	O
hyperkalemia	O
(	O
serum	O
potassium	O
9	O
mEq	O
/	O
L	O
)	O
from	O
9	O
%	O
on	O
enalapril	B-Drug
alone	O
to	O
9	O
%	O
.	O
      
The	O
results	O
indicate	O
significant	O
changes	O
in	O
tamsulosin	B-Drug
HCI	I-Drug
clearance	O
(	O
9	O
%	O
decrease	O
)	O
and	O
AUC	O
(	O
9	O
%	O
increase	O
)	O
.	O
      
Thiazide	B-Group
drugs	I-Group
may	O
increase	O
the	O
responsiveness	O
of	O
tubocurarine	B-Drug
.	O
      
Close	O
observation	O
of	O
the	O
patient	O
is	O
recommended	O
when	O
a	O
beta	B-Group
-	O
blocker	I-Group
is	O
administered	O
to	O
patients	O
receiving	O
catecholamine	O
-	O
depleting	O
drugs	O
such	O
as	O
reserpine	B-Drug
because	O
of	O
possible	O
additive	O
effects	O
and	O
the	O
production	O
of	O
hypotension	O
and	O
/	O
or	O
marked	O
bradycardia	O
which	O
may	O
produce	O
vertigo	O
syncope	O
or	O
postural	O
hypotension	O
.	O
      
Dofetilide	B-Drug
is	O
metabolized	O
to	O
a	O
small	O
extent	O
by	O
the	O
CYP9A9	O
isoenzyme	O
of	O
the	O
cytochrome	O
P9	O
system	O
.	O
      
(	O
In	O
some	O
patients	O
the	O
steroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
agent	I-Group
can	O
reduce	O
the	O
diuretic	O
natriuretic	O
and	O
antihypertensive	O
effects	O
of	O
loop	B-Group
potassium	B-Group
sparing	I-Group
and	O
thiazide	B-Group
diuretics	I-Group
.	O
      
Corticosteroids	B-Group
.	O
      
The	O
effects	O
of	O
metoclopramide	B-Drug
on	O
gastrointestinal	O
motility	O
are	O
antagonized	O
by	O
anticholinergic	B-Group
drugs	I-Group
and	O
narcotic	B-Group
analgesics	I-Group
.	O
      
insulin	B-Drug
requirements	O
may	O
be	O
increased	O
decreased	O
or	O
unchanged	O
.	O
)	O
      
The	O
administration	O
of	O
lower	O
doses	O
of	O
Vardenafil	B-Drug
with	O
alpha	B-Group
-	O
blockers	I-Group
has	O
not	O
been	O
completely	O
evaluated	O
to	O
determine	O
if	O
they	O
can	O
be	O
safely	O
administered	O
together	O
.	O
      
These	O
effects	O
have	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
by	O
the	O
NSAID	B-Group
.	O
      
Serious	O
arrhythmias	O
can	O
result	O
.	O
      
However	O
a	O
crossover	O
study	O
in	O
healthy	O
subjects	O
receiving	O
either	O
Tagamet	B-Brand
9	O
mg	O
q.i.d	O
.	O
or	O
9	O
mg	O
h.s	O
.	O
concomitantly	O
with	O
a	O
9	O
mg	O
b.i.d	O
.	O
dosage	O
of	O
theophylline	B-Drug
(	O
Theo	B-Brand
-	O
Dur	I-Brand
Key	O
Pharmaceuticals	O
Inc.	O
)	O
demonstrated	O
less	O
alteration	O
in	O
steady	O
-	O
state	O
theophylline	B-Drug
peak	O
serum	O
levels	O
with	O
the	O
9	O
mg	O
h.s	O
.	O
regimen	O
particularly	O
in	O
subjects	O
aged	O
9	O
years	O
and	O
older	O
.	O
      
Coadministration	O
of	O
Aprepitant	B-Drug
with	O
drugs	O
that	O
induce	O
CYP9A9	O
activity	O
may	O
result	O
in	O
reduced	O
plasma	O
concentrations	O
and	O
decreased	O
efficacy	O
of	O
Aprepitant	B-Drug
.	O
      
Certain	O
drugs	O
including	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
agents	I-Group
(	O
NSAIDs	B-Group
)	O
salicylates	B-Group
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
and	O
non	B-Group
-	O
selective	I-Group
beta	I-Group
-	O
adrenergic	I-Group
-	O
blocking	I-Group
agents	I-Group
may	O
potentiate	O
the	O
hypoglycemic	O
action	O
of	O
Starlix	B-Brand
and	O
other	O
oral	O
antidiabetic	B-Group
drugs	I-Group
.	O
      
Caffeine	B-Drug
administered	O
concurrently	O
with	O
ketoprofen	B-Drug
reduced	O
the	O
urine	O
volume	O
in	O
9	O
healthy	O
volunteers	O
.	O
      
Caution	O
should	O
be	O
exercised	O
during	O
the	O
administration	O
of	O
adrenaline	B-Drug
to	O
patients	O
anaesthetised	O
with	O
FLUOTHANE	B-Brand
as	O
arrhythmias	O
may	O
be	O
precipitated	O
.	O
      
There	O
is	O
a	O
significant	O
increase	O
in	O
exposure	O
to	O
imatinib	B-Drug
when	O
Gleevec	B-Brand
is	O
coadministered	O
with	O
ketoconazole	B-Drug
(	O
CYP9A9	O
inhibitor	O
)	O
.	O
      
Inhibitors	O
or	O
substrates	O
of	O
CYP9D9	O
(	O
i.e.	O
quinidine	B-Drug
selective	B-Group
serotonin	I-Group
reuptake	I-Group
inhibitors	I-Group
[	O
SSRIs	B-Group
]	O
)	O
may	O
increase	O
the	O
plasma	O
concentration	O
of	O
doxepin	B-Drug
when	O
administered	O
concomitantly	O
.	O
      
-	O
adrenergic	O
Blockers	O
:	O
-	O
adrenergic	O
blockers	O
may	O
weaken	O
or	O
antagonise	O
the	O
effect	O
of	O
FORADIL	B-Brand
.	O
      
The	O
use	O
of	O
REGRANEX	B-Brand
Gel	O
with	O
other	O
topical	O
drugs	O
has	O
not	O
been	O
studied	O
.	O
      
Anticoagulants	B-Group
oral	O
      
Macrolide	B-Group
Antibiotics	I-Group
(	O
e.	O
g.	O
erythromycin	B-Drug
and	O
troleandomycin	B-Drug
)	O
:	O
Agents	O
of	O
the	O
ergot	B-Group
alkaloid	I-Group
class	I-Group
of	O
which	O
D.H.E	B-Brand
9	I-Brand
(	O
dihydroergotamine	B-Drug
mesylate	I-Drug
)	O
Injection	O
USP	O
is	O
a	O
member	O
have	O
been	O
shown	O
to	O
interact	O
with	O
antibiotics	B-Group
of	O
the	O
macrolide	B-Group
class	I-Group
resulting	O
in	O
increased	O
plasma	O
levels	O
of	O
unchanged	O
alkaloids	O
and	O
peripheral	O
vasoconstriction	O
.	O
      
Alpha	B-Group
-	O
agonists	I-Group
as	O
a	O
class	O
may	O
reduce	O
pulse	O
and	O
blood	O
pressure	O
.	O
      
Anticoagulants	B-Group
:	O
Metolazone	B-Drug
as	O
well	O
as	O
other	O
thiazide	B-Group
-	O
like	I-Group
diuretics	I-Group
may	O
affect	O
the	O
hypoprothrombinemic	O
response	O
to	O
anticoagulants	B-Group
;	O
      
decreased	O
levels	O
of	O
anti	O
-	O
factor	O
Xa	O
and	O
antithrombin	O
III	O
decreased	O
antithrombin	O
III	O
activity	O
;	O
      
Effects	O
of	O
Other	O
Antiepileptic	B-Group
Drugs	I-Group
on	O
Felbatol	B-Brand
Phenytoin	B-Drug
:	O
Phenytoin	B-Drug
causes	O
an	O
approximate	O
doubling	O
of	O
the	O
clearance	O
of	O
Felbatol	B-Brand
(	O
felbamate	B-Drug
)	O
at	O
steady	O
state	O
and	O
therefore	O
the	O
addition	O
of	O
phenytoin	B-Drug
causes	O
an	O
approximate	O
9	O
%	O
decrease	O
in	O
the	O
steady	O
-	O
state	O
trough	O
concentrations	O
of	O
Felbatol	B-Brand
as	O
compared	O
to	O
the	O
same	O
dose	O
of	O
Felbatol	B-Brand
given	O
as	O
monotherapy	O
.	O
      
Nevertheless	O
caution	O
is	O
indicated	O
in	O
the	O
co	O
-	O
administration	O
of	O
TCAs	B-Group
with	O
any	O
of	O
the	O
SSRIs	B-Group
and	O
also	O
in	O
switching	O
from	O
one	O
class	O
to	O
the	O
other	O
.	O
      
Antihistamines	B-Group
:	O
Amphetamines	B-Group
may	O
counteract	O
the	O
sedative	O
effect	O
of	O
antihistamines	B-Group
.	O
      
Sodium	B-Drug
cephalothin	I-Drug
may	O
enhance	O
the	O
nephrotoxicity	O
of	O
Coly	B-Brand
-	O
Mycin	I-Brand
M	I-Brand
Parenteral	O
.	O
      
Vaccines	B-Group
:	O
Patients	O
on	O
corticosteroid	B-Group
therapy	O
may	O
exhibit	O
a	O
diminished	O
response	O
to	O
toxoids	O
and	O
live	B-Group
or	O
inactivated	B-Group
vaccines	I-Group
due	O
to	O
inhibition	O
of	O
antibody	O
response	O
.	O
      
Cardiac	B-Group
glycosides	I-Group
could	O
exaggerate	O
the	O
depression	O
of	O
AV	O
nodal	O
conduction	O
observed	O
with	O
bepridil	B-Drug
hydrochloride	I-Drug
.	O
      
In	O
such	O
cases	O
therefore	O
more	O
frequent	O
dosing	O
may	O
be	O
required	O
to	O
achieve	O
or	O
maintain	O
the	O
desired	O
hypotensive	O
response	O
.	O
      
It	O
is	O
recommended	O
that	O
these	O
tests	O
be	O
performed	O
at	O
weekly	O
or	O
biweekly	O
intervals	O
until	O
the	O
lipid	O
response	O
to	O
Accutane	B-Brand
is	O
established	O
.	O
      
In	O
a	O
clinical	O
trial	O
of	O
9	O
pediatric	O
patients	O
(	O
9	O
to	O
9	O
years	O
)	O
with	O
severe	O
recalcitrant	O
nodular	O
acne	O
transient	O
elevations	O
in	O
CPK	O
were	O
observed	O
in	O
9	O
%	O
of	O
patients	O
including	O
those	O
undergoing	O
strenuous	O
physical	O
activity	O
in	O
association	O
with	O
reported	O
musculoskeletal	O
adverse	O
events	O
such	O
as	O
back	O
pain	O
arthralgia	O
limb	O
injury	O
or	O
muscle	O
sprain	O
.	O
      
The	O
conversion	O
of	O
9	B-Drug_n
-	O
deoxy	I-Drug_n
penciclovir	I-Drug_n
to	O
penciclovir	B-Drug
is	O
catalyzed	O
by	O
aldehyde	O
oxidase	O
.	O
      
It	O
has	O
been	O
reported	O
that	O
the	O
incidence	O
of	O
bradycardia	O
was	O
increased	O
when	O
oxymorphone	B-Drug
was	O
combined	O
with	O
propofol	B-Drug
for	O
induction	O
of	O
anesthesia	O
.	O
      
Since	O
blood	O
level	O
of	O
calcitriol	B-Drug
/	O
ergocalcitriol	O
will	O
be	O
reduced	O
higher	O
doses	O
of	O
Rocaltrol	B-Brand
may	O
be	O
necessary	O
if	O
these	O
drugs	O
are	O
administered	O
simultaneously	O
.	O
      
Antipsychotic	B-Group
drugs	I-Group
such	O
as	O
phenothiazines	B-Group
or	O
haloperidol	B-Drug
;	O
      
St	O
.	O
John	O
Wort	O
should	O
be	O
avoided	O
while	O
taking	O
this	O
medicine	O
due	O
to	O
the	O
additive	O
effects	O
of	O
serotonin	O
.	O
      
Other	O
Drugs	O
:	O
Drugs	O
such	O
as	O
quinidine	B-Drug
disopyramide	B-Drug
procainamide	B-Drug
phenothiazines	B-Group
antihistamines	B-Group
and	O
tricyclic	B-Group
antidepressants	I-Group
may	O
be	O
associated	O
with	O
QT	O
-	O
interval	O
prolongation	O
and	O
an	O
increased	O
risk	O
of	O
ventricular	O
arrhythmia	O
.	O
      
Phenothiazines	B-Group
and	O
butyrophenones	B-Group
may	O
reduce	O
or	O
reverse	O
the	O
pressor	O
effect	O
of	O
epinephrine	B-Drug
.	O
      
Vaccines	B-Group
neurological	O
complications	O
and	O
lack	O
of	O
antibody	O
response	O
.	O
      
consequently	O
caution	O
is	O
advised	O
if	O
dexfenfluramine	B-Drug
and	O
such	O
drugs	O
are	O
prescribed	O
concurrently	O
.	O
      
Another	O
study	O
at	O
a	O
9	O
-	O
mg	O
and	O
9	O
-	O
mg	O
daily	O
dose	O
of	O
fluconazole	B-Drug
demonstrated	O
that	O
DIFLUCAN	B-Brand
taken	O
in	O
doses	O
of	O
9	O
mg	O
per	O
day	O
or	O
greater	O
significantly	O
increases	O
plasma	O
levels	O
of	O
terfenadine	B-Drug
when	O
taken	O
concomitantly	O
.	O
      
Binding	O
to	O
plasma	O
protein	O
is	O
not	O
significantly	O
altered	O
by	O
diazepam	B-Drug
diphenylhydantoin	B-Drug
or	O
phenylbutazone	B-Drug
.	O
      
This	O
increase	O
is	O
greatest	O
in	O
the	O
evening	O
.	O
      
Because	O
of	O
the	O
extremely	O
high	O
binding	O
of	O
teniposide	B-Drug
to	O
plasma	O
proteins	O
these	O
small	O
decreases	O
in	O
binding	O
could	O
cause	O
substantial	O
increases	O
in	O
free	O
drug	O
levels	O
in	O
plasma	O
which	O
could	O
result	O
in	O
potentiation	O
of	O
drug	O
toxicity	O
.	O
      
A	O
potential	O
interaction	O
between	O
oral	O
miconazole	B-Drug
and	O
oral	O
hypoglycemic	B-Group
agents	I-Group
leading	O
to	O
severe	O
hypoglycemia	O
has	O
been	O
reported	O
.	O
      
May	O
interact	O
with	O
cefamandole	B-Drug
naftate	I-Drug
cephalothin	B-Drug
sodium	I-Drug
magnesium	B-Drug
sulfate	I-Drug
prednisolone	B-Drug
sodium	I-Drug
succinate	I-Drug
and	O
prochlorperazine	B-Drug
edisylate	I-Drug
.	O
      
Mineral	B-Drug_n
Oil	I-Drug_n
-	O
Concomitant	O
intake	O
of	O
mineral	B-Drug_n
oil	I-Drug_n
and	O
vitamin	B-Group
K	I-Group
may	O
reduce	O
the	O
absorption	O
of	O
vitamin	B-Group
K	I-Group
.	O
      
WelChol	B-Brand
was	O
found	O
to	O
have	O
no	O
significant	O
effect	O
on	O
the	O
bioavailability	O
of	O
digoxin	B-Drug
lovastatin	B-Drug
metoprolol	B-Drug
quinidine	B-Drug
valproic	B-Drug
acid	I-Drug
and	O
warfarin	B-Drug
.	O
      
Two	O
percent	O
of	O
patients	O
treated	O
concurrently	O
with	O
ENBREL	B-Brand
and	O
anakinra	B-Drug
developed	O
neutropenia	O
(	O
ANC	O
9	O
x	O
9	O
/	O
L	O
)	O
.	O
      
Cimetidine	B-Drug
at	O
doses	O
of	O
9	O
mg	O
BID	O
(	O
OTC	O
dose	O
)	O
resulted	O
in	O
a	O
9	O
%	O
increase	O
in	O
dofetilide	B-Drug
plasma	O
levels	O
(	O
9	O
mcg	O
single	O
dose	O
)	O
.	O
      
Antimycobacterial	B-Group
Agents	I-Group
      
Salicylates	B-Group
-	O
Salicylates	B-Group
in	O
large	O
doses	O
may	O
inhibit	O
vitamin	O
K	O
epoxide	O
reductase	O
resulting	O
in	O
vitamin	O
K	O
deficiency	O
.	O
      
No	O
specific	O
studies	O
in	O
humans	O
have	O
been	O
performed	O
and	O
caution	O
is	O
recommended	O
.	O
      
Literature	O
reports	O
suggest	O
that	O
oral	O
calcium	B-Group
antagonists	I-Group
may	O
be	O
used	O
in	O
combination	O
with	O
beta	B-Group
-	O
adrenergic	I-Group
blocking	I-Group
agents	I-Group
when	O
heart	O
function	O
is	O
normal	O
but	O
should	O
be	O
avoided	O
in	O
patients	O
with	O
impaired	O
cardiac	O
function	O
.	O
      
Due	O
to	O
its	O
effects	O
on	O
gastric	O
emptying	O
SYMLIN	B-Brand
therapy	O
should	O
not	O
be	O
considered	O
for	O
patients	O
taking	O
drugs	O
that	O
alter	O
gastrointestinal	O
motility	O
(	O
e.g.	O
anticholinergic	B-Group
agents	I-Group
such	O
as	O
atropine	B-Drug
)	O
and	O
agents	O
that	O
slow	O
the	O
intestinal	O
absorption	O
of	O
nutrients	O
(	O
e.g.	O
alpha	B-Group
glucosidase	I-Group
inhibitors	I-Group
)	O
.	O
      
Furosemide	B-Drug
may	O
decrease	O
arterial	O
responsiveness	O
to	O
norepinephrine	B-Drug
.	O
      
Non	B-Group
-	O
nucleoside	I-Group
reverse	I-Group
transcriptase	I-Group
inhibitors	I-Group
(	O
NNRTIs	B-Group
)	O
:	O
Nevirapine	B-Drug
may	O
decrease	O
plasma	O
levels	O
of	O
combination	B-Group
hormonal	I-Group
contraceptives	I-Group
;	O
      
Other	O
TNFa	B-Group
-	O
blocking	I-Group
agents	I-Group
(	O
including	O
REMICADE	B-Brand
)	O
used	O
in	O
combination	O
with	O
anakinra	B-Drug
may	O
also	O
result	O
in	O
similar	O
toxicities	O
.	O
      
Cyclopentolate	B-Drug
may	O
interfere	O
with	O
the	O
anti	O
-	O
glaucoma	O
action	O
of	O
carbachol	B-Drug
or	O
pilocarpine	B-Drug
;	O
      
Drugs	O
Metabolized	O
by	O
Cytochrome	O
P9IID9	O
(	O
CYP9D9	O
)	O
:	O
Many	O
drugs	O
including	O
most	O
antidepressants	B-Group
(	O
SSRIs	O
many	O
tricyclics	B-Group
)	O
beta	B-Group
-	O
blockers	I-Group
antiarrhythmics	B-Drug
and	O
antipsychotics	B-Group
are	O
metabolized	O
by	O
the	O
CYP9D9	O
isoenzyme	O
.	O
      
increased	O
levels	O
of	O
fibrinogen	O
and	O
fibrinogen	O
activity	O
;	O
      
Cyclosporin	B-Drug
tacrolimus	B-Drug
sirolimus	B-Drug
      
An	O
association	O
between	O
prilocaine	B-Drug
and	O
an	O
increased	O
risk	O
of	O
methaemoglobinaemia	O
particularly	O
in	O
infants	O
has	O
specifically	O
been	O
described	O
in	O
a	O
literature	O
case	O
report	O
.	O
      
Rifabutin	B-Drug
another	O
rifamycin	B-Drug
is	O
structurally	O
similar	O
to	O
rifampin	B-Drug
and	O
may	O
possibly	O
have	O
some	O
of	O
the	O
same	O
drug	O
interactions	O
as	O
rifampin	B-Drug
.	O
      
Electroconvulsive	O
Therapy	O
(	O
ECT	O
)	O
-	O
There	O
are	O
no	O
clinical	O
studies	O
of	O
the	O
combined	O
use	O
of	O
ECT	O
and	O
escitalopram	B-Drug
.	O
      
There	O
was	O
no	O
change	O
in	O
the	O
plasma	O
kinetics	O
of	O
teniposide	B-Drug
when	O
coadministered	O
with	O
methotrexate	B-Drug
.	O
      
Antacids	B-Group
:	O
Absorption	O
of	O
a	O
single	O
dose	O
of	O
Myfortic	B-Brand
was	O
decreased	O
when	O
administered	O
to	O
9	O
stable	O
renal	O
transplant	O
patients	O
also	O
taking	O
magnesium	B-Drug
-	O
aluminum	B-Drug
containing	O
antacids	B-Group
(	O
9	O
mL	O
)	O
:	O
the	O
mean	O
Cmax	O
and	O
AUC	O
(	O
9	O
-	O
t	O
)	O
values	O
for	O
MPA	O
were	O
9	O
%	O
and	O
9	O
%	O
lower	O
respectively	O
than	O
when	O
Myfortic	B-Brand
was	O
administered	O
alone	O
under	O
fasting	O
conditions	O
.	O
      
In	O
clinical	O
trials	O
the	O
concomitant	O
administration	O
of	O
sulfadoxine	B-Drug
and	O
pyrimethamine	B-Drug
did	O
not	O
alter	O
the	O
adverse	O
reaction	O
profile	O
.	O
      
Therefore	O
in	O
patients	O
taking	O
insulin	B-Drug
or	O
oral	O
hypoglycemics	B-Group
regular	O
monitoring	O
of	O
blood	O
glucose	O
is	O
recommended	O
.	O
      
When	O
warfarin	B-Drug
is	O
co	O
-	O
administered	O
with	O
nevirapine	B-Drug
anticoagulation	O
levels	O
should	O
be	O
monitored	O
frequently	O
.	O
      
therefore	O
coadministration	O
of	O
Aprepitant	B-Drug
with	O
drugs	O
that	O
strongly	O
induce	O
CYP9A9	O
activity	O
(	O
e.g.	O
rifampin	B-Drug
carbamazepine	B-Drug
phenytoin	B-Drug
)	O
may	O
result	O
in	O
reduced	O
plasma	O
concentrations	O
of	O
aprepitant	B-Drug
that	O
may	O
result	O
in	O
decreased	O
efficacy	O
of	O
Aprepitant	B-Drug
.	O
      
Opioid	B-Group
analgesics	I-Group
Decreased	O
antinociceptive	O
action	O
      
No	O
studies	O
have	O
been	O
performed	O
with	O
other	O
NNRTIs	B-Group
.	O
      
Increasing	O
the	O
felbamate	B-Drug
dose	O
to	O
9	O
mg	O
/	O
day	O
increased	O
the	O
steadystate	O
valproate	B-Drug
Cmin	O
to	O
9	O
9	O
micrograms	O
/	O
mL	O
.	O
      
Furthermore	O
whenever	O
one	O
of	O
these	O
other	O
drugs	O
is	O
withdrawn	O
from	O
co	O
-	O
therapy	O
an	O
increased	O
dose	O
of	O
tricyclic	B-Group
antidepressant	I-Group
may	O
be	O
required	O
.	O
      
Some	O
of	O
the	O
cases	O
of	O
collapse	O
/	O
respiratory	O
arrest	O
/	O
cardiac	O
arrest	O
during	O
initial	O
treatment	O
occurred	O
in	O
patients	O
who	O
were	O
being	O
administered	O
benzodiazepines	B-Group
;	O
      
If	O
a	O
diuretic	B-Group
is	O
also	O
used	O
the	O
risk	O
of	O
lithium	B-Drug
toxicity	O
may	O
be	O
increased	O
.	O
      
The	O
carbamazepine	B-Drug
steady	O
-	O
state	O
Cmin	O
decreased	O
9	O
%	O
to	O
9	O
9	O
micrograms	O
/	O
mL	O
when	O
felbamate	B-Drug
(	O
9	O
mg	O
/	O
day	O
divided	O
into	O
three	O
doses	O
)	O
was	O
coadministered	O
.	O
      
The	O
exact	O
length	O
of	O
time	O
may	O
vary	O
and	O
is	O
dependent	O
upon	O
the	O
particular	O
MAO	B-Group
inhibitor	I-Group
being	O
used	O
the	O
length	O
of	O
time	O
it	O
has	O
been	O
administered	O
and	O
the	O
dosage	O
involved	O
.	O
      
Therefore	O
if	O
concomitant	O
use	O
of	O
these	O
agents	O
is	O
indicated	O
because	O
of	O
demonstrated	O
hypokalemia	O
they	O
should	O
be	O
used	O
with	O
caution	O
and	O
with	O
frequent	O
monitoring	O
of	O
serum	O
potassium	O
.	O
      
Drugs	O
that	O
induce	O
hepatic	O
enzymes	O
such	O
as	O
phenobarbital	B-Drug
phenytoin	B-Drug
and	O
rifampin	B-Drug
may	O
increase	O
the	O
clearance	O
of	O
methylprednisolone	B-Drug
and	O
may	O
require	O
increased	O
in	O
methylprednisolone	B-Drug
dose	O
to	O
achieve	O
the	O
desired	O
response	O
.	O
      
Iron	B-Group
Supplements	I-Group
and	O
Foods	O
Fortified	O
With	O
Iron	B-Drug
Concomitant	O
administration	O
of	O
cefdinir	B-Drug
with	O
a	O
therapeutic	O
iron	B-Group
supplement	I-Group
containing	O
9	O
mg	O
of	O
elemental	O
iron	B-Drug
(	O
as	O
FeSO9	O
)	O
or	O
vitamins	B-Group
supplemented	O
with	O
9	O
mg	O
of	O
elemental	O
iron	B-Drug
reduced	O
extent	O
of	O
absorption	O
by	O
9	O
%	O
and	O
9	O
%	O
respectively	O
.	O
      
Thiazides	B-Group
:	O
Thiazides	B-Group
are	O
known	O
to	O
induce	O
hypercalcemia	O
by	O
the	O
reduction	O
of	O
calcium	O
excretion	O
in	O
urine	O
.	O
      
Milk	O
milk	O
products	O
and	O
calcium	B-Drug
-	O
rich	O
foods	O
or	O
drugs	O
may	O
impair	O
the	O
absorption	O
of	O
EMCYT	B-Brand
.	O
      
Epinephrine	B-Drug
should	O
be	O
used	O
cautiously	O
in	O
patients	O
with	O
hyperthyroidism	O
hypertension	O
and	O
cardiac	O
arrhythmias	O
.	O
      
Gentamicin	B-Drug
:	O
Animal	O
data	O
have	O
suggested	O
the	O
possibility	O
of	O
interaction	O
between	O
perindopril	B-Drug
and	O
gentamicin	B-Drug
.	O
      
In	O
three	O
separate	O
controlled	O
parallel	O
group	O
clinical	O
pharmacology	O
studies	O
desloratadine	B-Drug
at	O
the	O
clinical	O
dose	O
of	O
9	O
mg	O
has	O
been	O
coadministered	O
with	O
azithromycin	B-Drug
9	O
mg	O
followed	O
by	O
9	O
mg	O
once	O
daily	O
for	O
9	O
days	O
(	O
n=9	O
)	O
or	O
with	O
fluoxetine	B-Drug
9	O
mg	O
once	O
daily	O
for	O
9	O
days	O
after	O
a	O
9	O
day	O
pretreatment	O
period	O
with	O
fluoxetine	B-Drug
(	O
n=9	O
)	O
or	O
with	O
cimetidine	B-Drug
9	O
mg	O
every	O
9	O
hours	O
for	O
9	O
days	O
(	O
n=9	O
)	O
under	O
steady	O
state	O
conditions	O
to	O
normal	O
healthy	O
male	O
and	O
female	O
volunteers	O
.	O
      
In	O
patients	O
taking	O
diclofenac	B-Drug
and	O
lithium	B-Drug
concomitantly	O
lithium	B-Drug
toxicity	O
may	O
develop	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
A	O
false	O
-	O
positive	O
reaction	O
for	O
ketones	O
in	O
the	O
urine	O
may	O
occur	O
with	O
tests	O
using	O
nitroprusside	B-Drug
but	O
not	O
with	O
those	O
using	O
nitroferricyanide	B-Drug
.	O
      
Tolazamide	B-Drug
:	O
A	O
case	O
of	O
severe	O
hypoglycemia	O
has	O
been	O
reported	O
in	O
a	O
type	O
II	O
diabetic	O
patient	O
maintained	O
on	O
tolazamide	B-Drug
(	O
9	O
gm	O
/	O
day	O
)	O
9	O
days	O
after	O
the	O
addition	O
of	O
doxepin	B-Drug
(	O
9	O
mg	O
/	O
day	O
)	O
.	O
      
Nizatidine	B-Drug
does	O
not	O
inhibit	O
the	O
cytochrome	O
P	O
-	O
9	O
-	O
linked	O
drug	O
-	O
metabolizing	O
enzyme	O
system	O
;	O
      
Tablet	O
If	O
a	O
patient	O
receiving	O
clonidine	B-Drug
hydrochloride	I-Drug
is	O
also	O
taking	O
tricyclic	B-Group
antidepressants	I-Group
the	O
effect	O
of	O
clonidine	B-Drug
may	O
be	O
reduced	O
thus	O
necessitating	O
an	O
increase	O
in	O
dosage	O
.	O
      
However	O
concomitant	O
administration	O
of	O
9	O
mg	O
b.i.d	O
.	O
isradipine	B-Drug
and	O
9	O
mg	O
b.i.d	O
.	O
      
cases	O
of	O
rhabdomyolysis	O
have	O
been	O
reported	O
in	O
seriously	O
ill	O
patients	O
.	O
      
False	O
-	O
negative	O
results	O
in	O
the	O
dexamethasone	O
suppression	O
test	O
(	O
DST	O
)	O
in	O
patients	O
being	O
treated	O
with	O
INDOCIN	B-Brand
have	O
been	O
reported	O
.	O
      
Esomeprazole	B-Drug
is	O
extensively	O
metabolized	O
in	O
the	O
liver	O
by	O
CYP9C9	O
and	O
CYP9A9	O
.	O
      
In	O
addition	O
under	O
the	O
influence	O
of	O
sympatholytic	O
medicinal	O
products	O
such	O
as	O
beta	B-Group
-	O
blockers	I-Group
clonidine	B-Drug
guanethidine	B-Drug
and	O
reserpine	B-Drug
the	O
signs	O
of	O
hypoglycemia	O
may	O
be	O
reduced	O
or	O
absent	O
.	O
      
-	O
Cisapride	B-Drug
pimozide	B-Drug
:	O
Other	O
drugs	O
such	O
as	O
cisapride	B-Drug
or	O
pimozide	B-Drug
which	O
are	O
metabolised	O
by	O
hepatic	O
CYP9A	O
isozymes	O
have	O
been	O
associated	O
with	O
QT	O
interval	O
prolongation	O
and	O
/	O
or	O
cardiac	O
arrythmias	O
(	O
typically	O
torsades	O
de	O
pointe	O
)	O
as	O
a	O
result	O
of	O
increase	O
in	O
their	O
serum	O
level	O
subsequent	O
to	O
interaction	O
with	O
significant	O
inhibitors	O
of	O
the	O
isozyme	O
including	O
some	O
macrolide	B-Group
antibacterials	I-Group
.	O
      
Therefore	O
the	O
potential	O
exists	O
for	O
interaction	O
between	O
carbamazepine	B-Drug
and	O
any	O
agent	O
that	O
inhibits	O
CYP9A9	O
and	O
/	O
or	O
epoxide	O
hydrolase	O
.	O
      
Erythromycin	B-Drug
and	O
clarithromycin	B-Drug
(	O
and	O
possibly	O
other	O
macrolide	B-Group
antibiotics	I-Group
)	O
and	O
tetracycline	B-Drug
may	O
increase	O
digoxin	B-Drug
absorption	O
in	O
patients	O
who	O
inactivate	O
digoxin	B-Drug
by	O
bacterial	O
metabolism	O
in	O
the	O
lower	O
intestine	O
so	O
that	O
digitalis	B-Group
intoxication	O
may	O
result	O
.	O
      
Therefore	O
to	O
maximize	O
the	O
effects	O
of	O
fexofenadine	B-Drug
it	O
is	O
recommended	O
that	O
ALLEGRA	B-Brand
should	O
be	O
taken	O
with	O
water	O
      
Concurrent	O
administration	O
of	O
oxyphenbutazone	B-Drug
and	O
androgens	B-Group
may	O
result	O
in	O
elevated	O
serum	O
levels	O
of	O
oxyphenbutazone	B-Drug
.	O
      
Agents	O
Increasing	O
Serum	O
Potassium	O
:	O
PRINIVIL	B-Brand
attenuates	O
potassium	O
loss	O
caused	O
by	O
thiazide	B-Group
-	O
type	I-Group
diuretics	I-Group
.	O
      
No	O
pharmacokinetic	O
interaction	O
was	O
identified	O
.	O
      
In	O
a	O
study	O
in	O
which	O
9	O
different	O
drugs	O
were	O
tested	O
therapeutically	O
relevant	O
concentrations	O
of	O
tolbutamide	B-Drug
sodium	B-Drug
salicylate	I-Drug
and	O
sulfamethizole	B-Drug
displaced	O
protein	O
-	O
bound	O
teniposide	B-Drug
in	O
fresh	O
human	O
serum	O
to	O
a	O
small	O
but	O
significant	O
extent	O
.	O
      
Systemic	O
exposure	O
to	O
acetaminophen	B-Drug
is	O
expected	O
to	O
be	O
increased	O
when	O
coadministered	O
with	O
Gleevec	B-Brand
.	O
      
Reduced	O
efficacy	O
and	O
increased	O
incidence	O
of	O
breakthrough	O
bleeding	O
and	O
menstrual	O
irregularities	O
have	O
been	O
associated	O
with	O
concomitant	O
use	O
of	O
rifampin	B-Drug
.	O
      
Digoxin	B-Drug
:	O
Rofecoxib	B-Drug
9	O
mg	O
once	O
daily	O
for	O
9	O
days	O
does	O
not	O
alter	O
the	O
plasma	O
concentration	O
profile	O
or	O
renal	O
elimination	O
of	O
digoxin	B-Drug
after	O
a	O
single	O
9	O
mg	O
oral	O
dose	O
.	O
      
Cyclosporine	B-Drug
:	O
DIFLUCAN	B-Brand
may	O
significantly	O
increase	O
cyclosporine	B-Drug
levels	O
in	O
renal	O
transplant	O
patients	O
with	O
or	O
without	O
renal	O
impairment	O
.	O
      
Specific	O
studies	O
with	O
ibandronate	B-Drug
have	O
not	O
been	O
performed	O
.	O
      
Morphine	B-Drug
pharmacokinetic	O
parameter	O
values	O
were	O
not	O
affected	O
by	O
administration	O
of	O
Neurontin	B-Brand
9	O
hours	O
after	O
morphine	B-Drug
.	O
      
It	O
is	O
recommended	O
that	O
glucose	O
tests	O
based	O
on	O
enzymatic	O
glucose	O
oxidase	O
reactions	O
(	O
such	O
as	O
Clinistix	O
or	O
Tes	O
-	O
Tape	O
)	O
be	O
used	O
.	O
      
The	O
following	O
are	O
examples	O
of	O
substances	O
that	O
may	O
reduce	O
the	O
blood	O
-	O
glucose	O
-	O
lowering	O
effect	O
of	O
insulin	B-Drug
:	O
corticosteroids	B-Group
danazol	B-Drug
diuretics	B-Group
sympathomimetic	B-Group
agents	I-Group
(	O
e.g.	O
epinephrine	B-Drug
albuterol	B-Drug
terbutaline	B-Drug
)	O
isoniazid	B-Drug
phenothiazine	B-Group
derivatives	I-Group
somatropin	B-Drug
thyroid	B-Group
hormones	I-Group
estrogens	B-Group
progestogens	B-Group
(	O
e.g.	O
in	O
oral	O
contraceptives	B-Group
)	O
.	O
      
No	O
dose	O
adjustment	O
of	O
SUSTIVA	B-Brand
is	O
recommended	O
when	O
given	O
with	O
clarithromycin	B-Drug
.	O
      
Thiazides	B-Group
may	O
add	O
to	O
or	O
potentiate	O
the	O
action	O
of	O
other	O
antihypertensive	B-Group
drugs	I-Group
.	O
      
INSPRA	B-Brand
should	O
not	O
be	O
used	O
with	O
drugs	O
described	O
as	O
strong	O
inhibitors	O
of	O
CYP9A9	O
in	O
their	O
labeling	O
.	O
      
No	O
pharmacokinetic	O
drug	O
-	O
drug	O
interaction	O
studies	O
were	O
conducted	O
with	O
PERSANTINE	B-Brand
(	O
dipyridamole	B-Drug
USP	O
)	O
Tablets	O
.	O
      
An	O
adjustment	O
in	O
the	O
diltiazem	B-Drug
dose	O
may	O
be	O
warranted	O
.	O
      
increased	O
liver	O
      
Patients	O
receiving	O
catecholamine	O
-	O
depleting	O
drugs	O
such	O
as	O
reserpine	B-Drug
or	O
guanethidine	B-Drug
should	O
be	O
closely	O
monitored	O
because	O
the	O
added	O
beta	O
-	O
adrenergic	O
blocking	O
action	O
of	O
ZEBETA	B-Brand
may	O
produce	O
excessive	O
reduction	O
of	O
sympathetic	O
activity	O
.	O
      
Strong	O
inducers	O
of	O
cytochrome	O
P9	O
enzymes	O
(	O
i.e	O
.	O
carbamazepine	B-Drug
phenytoin	B-Drug
and	O
phenobarbital	B-Drug
)	O
have	O
been	O
shown	O
to	O
decrease	O
the	O
plasma	O
levels	O
of	O
MHD	B-Drug_n
(	O
9	O
-	O
9	O
%	O
)	O
.	O
      
The	O
clinical	O
significance	O
of	O
this	O
property	O
is	O
unknown	O
.	O
      
Severe	O
toxicity	O
has	O
also	O
been	O
reported	O
in	O
patients	O
receiving	O
the	O
combination	O
of	O
tricyclic	B-Group
antidepressants	I-Group
and	O
ELDEPRYL	B-Brand
and	O
selective	B-Group
serotonin	I-Group
reuptake	I-Group
inhibitors	I-Group
and	O
ELDEPRYL	B-Brand
.	O
      
The	O
physician	O
should	O
be	O
alert	O
for	O
possible	O
combined	O
drug	O
actions	O
desirable	O
or	O
undesirable	O
involving	O
ifosfamide	B-Drug
even	O
though	O
ifosfamide	B-Drug
has	O
been	O
used	O
successfully	O
concurrently	O
with	O
other	O
drugs	O
including	O
other	O
cytotoxic	O
drugs	O
.	O
      
British	O
Jnl	O
Rheum	O
9	O
;	O
9:9	O
-	O
9	O
.	O
      
Although	O
the	O
pressor	O
activity	O
of	O
Desmopressin	B-Drug
is	O
very	O
low	O
compared	O
to	O
its	O
antidiuretic	O
activity	O
large	O
doses	O
of	O
Desmopressin	B-Drug
Tablets	O
should	O
be	O
used	O
with	O
other	O
pressor	O
agents	O
only	O
with	O
careful	O
patient	O
monitoring	O
.	O
      
Further	O
in	O
clinical	O
studies	O
with	O
PROSCAR	B-Brand
(	O
finasteride	B-Drug
9	O
mg	O
)	O
when	O
used	O
in	O
older	O
men	O
who	O
have	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
PSA	O
levels	O
are	O
decreased	O
by	O
approximately	O
9	O
%	O
.	O
      
The	O
change	O
in	O
furosemide	B-Drug
clearance	O
value	O
is	O
not	O
likely	O
to	O
be	O
clinically	O
significant	O
.	O
      
Acetaminophen	B-Drug
:	O
A	O
report	O
of	O
severe	O
acetaminophen	B-Drug
toxicity	O
was	O
reported	O
in	O
a	O
patient	O
receiving	O
Isoniazid	B-Drug
.	O
      
This	O
effect	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
.	O
      
When	O
taken	O
orally	O
imidazole	B-Group
compounds	I-Group
like	O
ketoconazole	B-Drug
may	O
enhance	O
the	O
anticoagulant	O
effect	O
of	O
coumarin	B-Group
-	O
like	O
drugs	O
.	O
      
Cardiovascular	O
:	O
Hypotension	O
bradycardia	O
and	O
hypertension	O
have	O
been	O
observed	O
during	O
administration	O
of	O
TAXOL	B-Brand
but	O
generally	O
do	O
not	O
require	O
treatment	O
.	O
      
In	O
this	O
setting	O
cardioselective	B-Group
beta	I-Group
-	O
blockers	I-Group
could	O
be	O
considered	O
although	O
they	O
should	O
be	O
administered	O
with	O
caution	O
.	O
      
Concurrent	O
use	O
of	O
Mexitil	B-Brand
and	O
theophylline	B-Drug
may	O
lead	O
to	O
increased	O
plasma	O
theophylline	B-Drug
levels	O
.	O
      
The	O
clinical	O
significance	O
is	O
unknown	O
.	O
      
Terbinafine	B-Drug
clearance	O
is	O
unaffected	O
by	O
cyclosporine	B-Drug
.	O
      
However	O
no	O
clinically	O
or	O
statistically	O
significant	O
differences	O
in	O
prothrombin	O
time	O
ratio	O
or	O
warfarin	B-Drug
enantiomer	O
pharmacokinetics	O
were	O
observed	O
in	O
a	O
small	O
study	O
of	O
9	O
healthy	O
males	O
who	O
received	O
both	O
warfarin	B-Drug
and	O
lomefloxacin	B-Drug
under	O
steady	O
-	O
state	O
conditions	O
.	O
      
Post	O
-	O
marketing	O
reports	O
of	O
changes	O
in	O
prothrombin	O
measures	O
have	O
been	O
received	O
among	O
patients	O
on	O
concomitant	O
warfarin	B-Drug
and	O
esomeprazole	B-Drug
therapy	O
.	O
      
Levetiracetam	B-Drug
circulates	O
largely	O
unbound	O
(	O
9	O
%	O
bound	O
)	O
to	O
plasma	O
proteins	O
;	O
      
Theophylline	B-Drug
:	O
Theophylline	B-Drug
clearance	O
may	O
decrease	O
in	O
hypothyroid	O
patients	O
and	O
return	O
toward	O
normal	O
when	O
a	O
euthyroid	O
state	O
is	O
achieved	O
.	O
      
Meperidine	B-Drug
:	O
Amphetamines	B-Group
potentiate	O
the	O
analgesic	O
effect	O
of	O
meperidine	B-Drug
.	O
      
The	O
preceding	O
lists	O
of	O
drugs	O
are	O
not	O
comprehensive	O
.	O
      
Although	O
in	O
vivo	O
studies	O
have	O
not	O
been	O
done	O
to	O
see	O
if	O
etodolac	B-Drug
clearance	O
is	O
changed	O
by	O
coadministration	O
of	O
phenylbutazone	B-Drug
it	O
is	O
not	O
recommended	O
that	O
they	O
be	O
coadministered	O
.	O
      
Since	O
Zarontin	B-Brand
(	O
ethosuximide	B-Drug
)	O
may	O
interact	O
with	O
concurrently	O
administered	O
antiepileptic	B-Group
drugs	I-Group
periodic	O
serum	O
level	O
determinations	O
of	O
these	O
drugs	O
may	O
be	O
necessary	O
(	O
eg	O
ethosuximide	B-Drug
may	O
elevate	O
phenytoin	B-Drug
serum	O
levels	O
and	O
valproic	B-Drug
acid	I-Drug
has	O
been	O
reported	O
to	O
both	O
increase	O
and	O
decrease	O
ethosuximide	B-Drug
levels	O
)	O
.	O
      
Anticholinergic	B-Group
agents	I-Group
may	O
potentially	O
alter	O
the	O
absorption	O
of	O
some	O
concomitantly	O
administered	O
drugs	O
due	O
to	O
anticholinergic	O
effects	O
on	O
gastrointestinal	O
motility	O
.	O
      
Cytochrome	O
P9A9	O
is	O
involved	O
in	O
the	O
formation	O
of	O
9	B-Drug_n
-	O
hydroxy	I-Drug_n
ropivacaine	I-Drug_n
the	O
major	O
metabolite	O
.	O
      
Severe	O
allergic	O
reactions	O
including	O
anaphylaxis	O
have	O
been	O
reported	O
in	O
patients	O
exposed	O
to	O
a	O
variety	O
of	O
allergens	O
either	O
by	O
repeated	O
challenge	O
or	O
accidental	O
contact	O
and	O
with	O
diagnostic	O
or	O
therapeutic	O
agents	O
while	O
receiving	O
beta	B-Group
-	O
blockers	I-Group
.	O
      
-	O
Cholestyramine	B-Drug
and	O
colestipol	B-Drug
resins	B-Group
:	O
Cholestytamine	B-Drug
and	O
colestipol	B-Drug
resins	B-Group
have	O
the	O
potential	O
of	O
binding	O
thiazide	B-Group
diuretics	I-Group
and	O
reducing	O
diuretic	B-Group
absorption	O
from	O
the	O
gastrointestinal	O
tract	O
      
These	O
levels	O
then	O
remained	O
stable	O
for	O
up	O
to	O
9	O
year	O
of	O
therapy	O
.	O
      
Magnesium	B-Drug
:	O
Magnesium	B-Drug
-	O
containing	O
preparations	O
(	O
eg	O
antacids	B-Group
)	O
may	O
cause	O
hypermagnesemia	O
and	O
should	O
therefore	O
not	O
be	O
taken	O
during	O
therapy	O
with	O
vitamin	B-Group
D	I-Group
by	O
patients	O
on	O
chronic	O
renal	O
dialysis	O
.	O
      
Potential	O
drug	O
interactions	O
between	O
Keppra	B-Brand
and	O
other	O
AEDs	B-Group
(	O
carbamazepine	B-Drug
gabapentin	B-Drug
lamotrigine	B-Drug
phenobarbital	B-Drug
phenytoin	B-Drug
primidone	B-Drug
and	O
valproate	B-Drug
)	O
were	O
also	O
assessed	O
by	O
evaluating	O
the	O
serum	O
concentrations	O
of	O
levetiracetam	B-Drug
and	O
these	O
AEDs	B-Group
during	O
placebo	O
-	O
controlled	O
clinical	O
studies	O
.	O
      
If	O
an	O
alternative	O
treatment	O
is	O
unavailable	O
a	O
TARCEVA	B-Brand
dose	O
greater	O
than	O
9	O
mg	O
should	O
be	O
considered	O
for	O
NSCLC	O
patients	O
and	O
greater	O
than	O
9	O
mg	O
considered	O
for	O
pancreatic	O
cancer	O
patients	O
.	O
      
Because	O
moderate	O
CYP9A9	O
inhibitors	O
(	O
e.g.	O
diltiazem	B-Drug
)	O
result	O
in	O
9	O
-	O
fold	O
increase	O
in	O
plasma	O
concentrations	O
of	O
aprepitant	B-Drug
concomitant	O
administration	O
should	O
also	O
be	O
approached	O
with	O
caution	O
.	O
      
9	O
-	O
9	O
      
Ethopropazine	B-Drug
can	O
interact	O
with	O
chlorpromazine	B-Drug
increasing	O
the	O
metabolism	O
of	O
chlorpromazine	B-Drug
.	O
      
Under	O
similar	O
conditions	O
bexarotene	B-Drug
concentrations	O
were	O
not	O
affected	O
by	O
concomitant	O
atorvastatin	B-Drug
administration	O
.	O
      
No	O
formal	O
studies	O
to	O
evaluate	O
drug	O
interactions	O
with	O
bexarotene	B-Drug
have	O
been	O
conducted	O
.	O
      
This	O
practice	O
resulted	O
in	O
no	O
apparent	O
increase	O
in	O
local	O
breast	O
cancer	O
recurrence	O
relative	O
to	O
published	O
accounts	O
in	O
the	O
literature	O
.	O
      
9	O
.	O
      
The	O
concomitant	O
use	O
of	O
other	O
CYP9A9	O
inhibitors	O
such	O
as	O
diltiazem	B-Drug
and	O
erythromycin	B-Drug
with	O
transdermal	O
fentanyl	B-Drug
may	O
also	O
result	O
in	O
an	O
increase	O
in	O
fentanyl	B-Drug
plasma	O
concentrations	O
which	O
could	O
increase	O
or	O
prolong	O
adverse	O
drug	O
effects	O
and	O
may	O
cause	O
serious	O
respiratory	O
depression	O
.	O
      
Thus	O
concomitant	O
administration	O
of	O
enoxacin	B-Drug
and	O
bismuth	B-Drug
subsalicylate	I-Drug
should	O
be	O
avoided	O
.	O
      
ELLENCE	B-Brand
when	O
used	O
in	O
combination	O
with	O
other	O
cytotoxic	O
drugs	O
may	O
show	O
on	O
-	O
treatment	O
additive	O
toxicity	O
especially	O
hematologic	O
and	O
gastrointestinal	O
effects	O
.	O
      
As	O
binding	O
of	O
MHD	B-Drug_n
to	O
plasma	O
proteins	O
is	O
low	O
(	O
9	O
%	O
)	O
clinically	O
significant	O
interactions	O
with	O
other	O
drugs	O
through	O
competition	O
for	O
protein	O
binding	O
sites	O
are	O
unlikely	O
.	O
      
Beta	B-Group
-	O
adrenergic	I-Group
blocking	I-Group
drugs	I-Group
add	O
some	O
further	O
antihypertensive	O
effect	O
to	O
captopril	B-Drug
but	O
the	O
overall	O
response	O
is	O
less	O
than	O
additive	O
.	O
      
disulfiram	B-Drug
;	O
      
Since	O
fondaparinux	B-Drug
does	O
not	O
markedly	O
inhibit	O
CYP9s	O
(	O
CYP9A9	O
CYP9A9	O
CYP9C9	O
CYP9C9	O
CYP9D9	O
CYP9E9	O
or	O
CYP9A9	O
)	O
in	O
vitro	O
fondaparinux	B-Drug
sodium	I-Drug
is	O
not	O
expected	O
to	O
significantly	O
interact	O
with	O
other	O
drugs	O
in	O
vivo	O
by	O
inhibition	O
of	O
metabolism	O
mediated	O
by	O
these	O
isozymes	O
.	O
      
Anticholinesterases	B-Group
:	O
Concomitant	O
use	O
of	O
anticholinesterase	B-Group
agents	I-Group
and	O
corticosteroids	B-Group
may	O
produce	O
severe	O
weakness	O
in	O
patients	O
with	O
myasthenia	O
gravis	O
.	O
      
Irinotecan	B-Drug
concentrations	O
were	O
similar	O
in	O
patients	O
receiving	O
bolus	O
-	O
IFL	O
alone	O
and	O
in	O
combination	O
with	O
AVASTIN	B-Brand
.	O
      
Efavirenz	B-Drug
has	O
been	O
shown	O
in	O
vivo	O
to	O
induce	O
CYP9A9	O
.	O
      
Because	O
antacids	B-Group
may	O
interfere	O
with	O
the	O
absorption	O
of	O
anticholinergic	B-Group
agents	I-Group
simultaneous	O
use	O
of	O
these	O
drugs	O
should	O
be	O
avoided	O
.	O
      
Theophylline	B-Drug
:	O
Following	O
co	O
-	O
administration	O
of	O
two	O
9	O
-	O
mg	O
dirithromycin	B-Drug
tablets	O
administered	O
once	O
daily	O
with	O
9	O
-	O
mg	O
theophylline	B-Drug
tablets	O
administered	O
twice	O
daily	O
for	O
9	O
days	O
to	O
9	O
healthy	O
subjects	O
the	O
steady	O
-	O
state	O
plasma	O
concentration	O
of	O
theophylline	B-Drug
was	O
not	O
significantly	O
altered	O
.	O
      
The	O
recommended	O
dosage	O
(	O
one	O
or	O
two	O
capsules	O
twice	O
daily	O
morning	O
and	O
evening	O
)	O
should	O
not	O
be	O
exceeded	O
.	O
      
The	O
concurrent	O
use	O
of	O
these	O
drugs	O
is	O
not	O
recommended	O
.	O
      
Patients	O
receiving	O
flurbiprofen	B-Drug
and	O
furosemide	B-Drug
or	O
other	O
diuretics	B-Group
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
is	O
obtained	O
.	O
      
Drugs	O
that	O
may	O
increase	O
dasatinib	B-Drug
plasma	O
concentrations	O
CYP9A9	O
Inhibitors	O
:	O
Dasatinib	B-Drug
is	O
a	O
CYP9A9	O
substrate	O
.	O
      
Consequently	O
prothrombin	O
time	O
should	O
be	O
reassessed	O
periodically	O
in	O
patients	O
receiving	O
both	O
drugs	O
.	O
      
Interactions	O
for	O
Vitamin	B-Drug
B9	I-Drug
(	O
Thiamine	B-Drug
)	O
:	O
Loop	B-Group
Diuretics	I-Group
Oral	O
Contraceptives	B-Group
Stavudine	B-Drug
Tricyclic	B-Group
Antidepressants	I-Group
      
Cytadren	B-Brand
accelerates	O
the	O
metabolism	O
of	O
dexamethasone	B-Drug
;	O
      
TCAs	B-Group
decrease	O
the	O
hypotensive	O
effect	O
of	O
guanfacine	B-Drug
.	O
      
Because	O
of	O
the	O
risk	O
of	O
increased	O
exposure	O
to	O
nevirapine	B-Drug
caution	O
should	O
be	O
used	O
inconcomitant	O
administration	O
and	O
patients	O
should	O
be	O
monitored	O
closely	O
for	O
nevirapine	O
-	O
associated	O
adverse	O
events	O
.	O
      
However	O
the	O
impairment	O
of	O
cognitive	O
and	O
motor	O
skills	O
produced	O
by	O
REMERON	B-Brand
were	O
shown	O
to	O
be	O
additive	O
with	O
those	O
produced	O
by	O
alcohol	B-Drug
.	O
      
Therefore	O
indomethacin	B-Drug
and	O
diflunisal	B-Drug
should	O
not	O
be	O
used	O
concomitantly	O
.	O
      
Use	O
of	O
a	O
nonhormonal	B-Group
contraceptive	I-Group
product	I-Group
is	O
recommended	O
.	O
      
A	O
pharmacokinetic	O
study	O
evaluating	O
the	O
administration	O
of	O
a	O
single	O
dose	O
of	O
INSPRA	B-Brand
9	O
mg	O
with	O
ketoconazole	B-Drug
9	O
mg	O
BID	O
a	O
potent	O
inhibitor	O
of	O
the	O
CYP9A9	O
pathway	O
showed	O
a	O
9	O
-	O
fold	O
increase	O
in	O
Cmax	O
of	O
eplerenone	B-Drug
and	O
a	O
9	O
-	O
fold	O
increase	O
in	O
AUC	O
of	O
eplerenone	B-Drug
.	O
      
Available	O
data	O
are	O
neither	O
sufficient	O
to	O
rule	O
out	O
possible	O
increases	O
in	O
serum	O
digoxin	B-Drug
with	O
concomitant	O
treatment	O
in	O
some	O
patients	O
nor	O
other	O
possible	O
interactions	O
particularly	O
in	O
patients	O
with	O
cardiac	O
conduction	O
abnormalities	O
(	O
Also	O
see	O
WARNINGS	O
Congestive	O
Heart	O
Failure	O
)	O
.	O
      
b	O
.	O
      
No	O
pharmacokinetic	O
interaction	O
was	O
observed	O
between	O
rivastigmine	B-Drug
and	O
digoxin	B-Drug
warfarin	B-Drug
diazepam	B-Drug
or	O
fluoxetine	B-Drug
in	O
studies	O
in	O
healthy	O
volunteers	O
.	O
      
There	O
was	O
no	O
evidence	O
in	O
clinical	O
trials	O
of	O
drug	O
interactions	O
with	O
concurrent	O
medications	O
.	O
      
This	O
slowing	O
potentiates	O
amphetamines	B-Group
increasing	O
their	O
effect	O
on	O
the	O
release	O
of	O
norepinephrine	O
and	O
other	O
monoamines	O
from	O
adrenergic	O
nerve	O
endings	O
;	O
      
Hydrochlorothiazide	B-Drug
(	O
HCTZ	B-Drug
)	O
Alone	O
or	O
in	O
Combination	O
with	O
Triamterene	B-Drug
:	O
Concomitant	O
use	O
of	O
HCTZ	B-Drug
alone	O
or	O
in	O
combination	O
with	O
triamterene	B-Drug
is	O
contraindicated	O
.	O
      
Agents	O
Having	O
Vasodilator	O
Activity	O
:	O
Data	O
on	O
the	O
effect	O
of	O
concomitant	O
use	O
of	O
other	O
vasodilators	B-Group
in	O
patients	O
receiving	O
captopril	B-Drug
for	O
heart	O
failure	O
are	O
not	O
available	O
;	O
      
Hypotension	O
AV	O
conduction	O
disturbances	O
and	O
left	O
ventricular	O
failure	O
have	O
been	O
reported	O
in	O
some	O
patients	O
receiving	O
beta	B-Group
-	O
adrenergic	I-Group
blocking	I-Group
agents	I-Group
when	O
an	O
oral	O
calcium	B-Group
antagonist	I-Group
was	O
added	O
to	O
the	O
treatment	O
regimen	O
.	O
      
Acetazolamide	B-Drug
increases	O
lithium	B-Drug
excretion	O
and	O
the	O
lithium	B-Drug
may	O
be	O
decreased	O
.	O
      
The	O
safety	O
and	O
efficacy	O
of	O
AMEVIVE	B-Brand
in	O
pediatric	O
patients	O
have	O
not	O
been	O
studied	O
.	O
      
The	O
clinical	O
relevance	O
is	O
unclear	O
.	O
      
Therefore	O
physicians	O
should	O
closely	O
monitor	O
patients	O
for	O
a	O
change	O
in	O
anticoagulant	B-Group
dosage	O
requirements	O
when	O
administering	O
Mitotane	B-Drug
to	O
patients	O
on	O
coumarin	B-Group
-	O
type	I-Group
anticoagulants	I-Group
.	O
      
Furthermore	O
whenever	O
one	O
of	O
these	O
other	O
drugs	O
is	O
withdrawn	O
from	O
cotherapy	O
an	O
increased	O
dose	O
of	O
tricyclic	B-Group
antidepressant	I-Group
may	O
be	O
required	O
.	O
      
Both	O
the	O
magnitude	O
and	O
duration	O
of	O
central	O
nervous	O
system	O
and	O
cardiovascular	O
effects	O
may	O
be	O
enhanced	O
when	O
ALFENTA	B-Brand
is	O
administered	O
in	O
combination	O
with	O
other	O
CNS	B-Group
depressants	I-Group
such	O
as	O
barbiturates	B-Group
tranquilizers	B-Group
opioids	B-Group
or	O
inhalation	O
general	O
anesthetics	B-Group
.	O
      
Table	O
9a	O
:	O
Drugs	O
That	O
Should	O
Not	O
Be	O
Coadministered	O
With	O
SUSTIVA	B-Brand
      
The	O
gastrointestinal	O
absorption	O
of	O
digoxin	B-Drug
also	O
appears	O
to	O
be	O
inhibited	O
.	O
      
The	O
clinical	O
significance	O
of	O
this	O
interaction	O
in	O
preterm	O
neonates	O
is	O
not	O
known	O
.	O
      
The	O
AUC	O
of	O
eszopiclone	B-Drug
was	O
increased	O
9	O
-	O
fold	O
by	O
coadministration	O
of	O
ketoconazole	B-Drug
a	O
potent	O
inhibitor	O
of	O
CYP9A9	O
9	O
mg	O
daily	O
for	O
9	O
days	O
.	O
      
9%	O
9%	O
9%	O
9%	O
      
This	O
risk	O
is	O
present	O
whether	O
the	O
drugs	O
are	O
administered	O
as	O
oral	O
parenteral	O
or	O
topical	O
formulations	O
.	O
      
(	O
f	O
)	O
Sulfobromophthalein	O
and	O
other	O
liver	O
function	O
test	O
values	O
may	O
be	O
increased	O
slightly	O
.	O
      
-	O
Carmustine	B-Drug
(	O
e.g.	O
BiCNU	B-Brand
)	O
or	O
      
Drug	O
-	O
Laboratory	O
Test	O
Interactions	O
:	O
There	O
are	O
no	O
reported	O
drug	O
-	O
laboratory	O
test	O
interactions	O
.	O
      
In	O
a	O
drug	O
interaction	O
study	O
co	O
-	O
administration	O
of	O
orally	O
inhaled	O
ciclesonide	B-Drug
and	O
oral	O
erythromycin	B-Drug
an	O
inhibitor	O
of	O
cytochrome	O
P9	O
9A9	O
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
either	O
des	B-Drug
-	O
ciclesonide	I-Drug
or	O
erythromycin	B-Drug
.	O
      
tricyclic	B-Group
antidepressants	I-Group
(	O
such	O
as	O
amitriptyline	B-Drug
)	O
;	O
      
Simultaneous	O
use	O
of	O
activated	B-Group
prothrombin	I-Group
complex	I-Group
concentrates	I-Group
or	O
prothrombin	B-Group
complex	I-Group
concentrates	I-Group
should	O
be	O
avoided	O
.	O
      
Pregnancy	O
:	O
Category	O
X	O
:	O
Use	O
With	O
Ribavirin	B-Drug
(	O
see	O
CONTRAINDICATIONS	O
)	O
Significant	O
teratogenic	O
and	O
/	O
or	O
embryocidal	O
effects	O
have	O
been	O
demonstrated	O
in	O
all	O
animal	O
species	O
exposed	O
to	O
ribavirin	B-Drug
.	O
      
When	O
administering	O
these	O
drugs	O
concurrently	O
one	O
should	O
be	O
alert	O
for	O
possible	O
excessive	O
phenytoin	B-Drug
effect	O
.	O
      
Midazolam	B-Drug
:	O
Aprepitant	B-Drug
increased	O
the	O
AUC	O
of	O
midazolam	B-Drug
a	O
sensitive	O
CYP9A9	O
substrate	O
by	O
9	O
-	O
fold	O
on	O
Day	O
9	O
and	O
9	O
-	O
fold	O
on	O
Day	O
9	O
when	O
a	O
single	O
oral	O
dose	O
of	O
midazolam	B-Drug
9	O
mg	O
was	O
coadministered	O
on	O
Day	O
9	O
and	O
Day	O
9	O
of	O
a	O
regimen	O
of	O
Aprepitant	B-Drug
9	O
mg	O
on	O
Day	O
9	O
and	O
9	O
mg	O
/	O
day	O
on	O
Days	O
9	O
through	O
9	O
.	O
      
High	O
-	O
dose	O
cyclosporin	B-Drug
A	I-Drug
resulting	O
in	O
concentrations	O
above	O
9	O
ng	O
/	O
mL	O
administered	O
with	O
oral	O
etoposide	B-Drug
has	O
led	O
to	O
an	O
9	O
%	O
increase	O
in	O
etoposide	B-Drug
exposure	O
with	O
a	O
9	O
%	O
decrease	O
in	O
total	O
body	O
clearance	O
of	O
etoposide	B-Drug
compared	O
to	O
etoposide	B-Drug
alone	O
.	O
      
Flurbiprofen	B-Drug
did	O
not	O
affect	O
the	O
pharmacokinetic	O
profile	O
of	O
either	O
drug	O
and	O
the	O
mechanism	O
under	O
lying	O
the	O
interference	O
with	O
propranolols	B-Drug
hypotensive	O
effect	O
is	O
unknown	O
.	O
      
Co	O
-	O
administration	O
of	O
ZETIA	B-Brand
with	O
fibrates	B-Group
is	O
not	O
recommended	O
until	O
use	O
in	O
patients	O
is	O
studied	O
.	O
      
Coadministration	O
of	O
valdecoxib	B-Drug
and	O
Ortho	B-Brand
-	O
Novum	I-Brand
9	O
/	O
9	O
increased	O
the	O
exposure	O
of	O
norethindrone	B-Drug
and	O
ethinyl	B-Drug
estradiol	I-Drug
by	O
9	O
%	O
and	O
9	O
%	O
respectively	O
.	O
      
Total	O
body	O
clearance	O
of	O
Simulect	B-Brand
was	O
reduced	O
by	O
an	O
average	O
9	O
%	O
and	O
9	O
%	O
when	O
azathioprine	B-Drug
and	O
mycophenolate	B-Drug
mofetil	I-Drug
respectively	O
were	O
added	O
to	O
a	O
regimen	O
consisting	O
of	O
cyclosporine	B-Drug
USP	O
(	O
MODIFIED	O
)	O
and	O
corticosteroids	B-Group
.	O
      
Bactericidal	O
agents	O
work	O
most	O
effectively	O
against	O
the	O
immature	O
cell	O
wall	O
of	O
rapidly	O
proliferating	O
microorganisms	O
.	O
      
Since	O
barbiturates	B-Group
are	O
potentiated	O
by	O
the	O
anticholinesterases	B-Group
they	O
should	O
be	O
used	O
cautiously	O
in	O
the	O
treatment	O
of	O
convulsions	O
.	O
      
When	O
other	O
antiplatelet	B-Group
agents	I-Group
or	O
anticoagulants	B-Group
are	O
used	O
concomitantly	O
there	O
is	O
the	O
potential	O
for	O
FLOLAN	B-Brand
to	O
increase	O
the	O
risk	O
of	O
bleeding	O
.	O
      
No	O
significant	O
interaction	O
has	O
been	O
found	O
with	O
broad	O
-	O
spectrum	O
antibiotics	B-Group
.	O
      
Inhibitors	O
of	O
this	O
isoenzyme	O
(	O
e.g.	O
macrolide	B-Group
antibiotics	I-Group
azole	B-Group
antifungal	I-Group
agents	I-Group
protease	B-Group
inhibitors	I-Group
serotonin	B-Group
reuptake	I-Group
inhibitors	I-Group
amiodarone	B-Drug
cannabinoids	B-Group
diltiazem	B-Drug
grapefruit	O
juice	O
nefazadone	B-Drug
norfloxacin	B-Drug
quinine	B-Drug
zafirlukast	B-Drug
)	O
should	O
be	O
cautiously	O
coadministered	O
with	O
TIKOSYN	B-Brand
as	O
they	O
can	O
potentially	O
increase	O
dofetilide	B-Drug
levels	O
.	O
      
PROSTIN	B-Brand
E9	I-Brand
may	O
augment	O
the	O
activity	O
of	O
other	O
oxytocic	B-Group
drugs	I-Group
.	O
      
Concurrent	O
use	O
of	O
tetracyclines	B-Group
with	O
oral	O
contraceptives	B-Group
may	O
render	O
oral	O
contraceptives	B-Group
less	O
effective	O
.	O
      
HMG	B-Group
-	O
CoA	I-Group
reductase	I-Group
inhibitors	I-Group
:	O
The	O
combined	O
use	O
of	O
TRICOR	B-Brand
and	O
HMG	B-Group
-	O
CoA	I-Group
reductase	I-Group
inhibitors	I-Group
should	O
be	O
avoided	O
unless	O
the	O
benefit	O
of	O
further	O
alterations	O
in	O
lipid	O
levels	O
is	O
likely	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
this	O
drug	O
combination	O
.	O
      
Acarbose	B-Drug
did	O
not	O
interfere	O
with	O
the	O
absorption	O
or	O
disposition	O
of	O
the	O
sulfonylurea	B-Drug
glyburide	B-Drug
in	O
diabetic	O
patients	O
.	O
      
Patients	O
studied	O
in	O
clinical	O
trials	O
of	O
TNKase	B-Brand
were	O
routinely	O
treated	O
with	O
heparin	B-Drug
and	O
aspirin	B-Brand
.	O
      
There	O
have	O
been	O
greater	O
than	O
9	O
-	O
fold	O
increases	O
in	O
previously	O
stable	O
plasma	O
levels	O
of	O
other	O
antidepressants	B-Group
including	O
nortriptyline	B-Drug
when	O
fluoxetine	B-Drug
hydrochloride	I-Drug
has	O
been	O
administered	O
in	O
combination	O
with	O
these	O
agents	O
.	O
      
Toxicity	O
associated	O
with	O
concomitant	O
use	O
of	O
aerosolized	O
pentamidine	B-Drug
has	O
not	O
been	O
reported	O
.	O
      
9	O
.	O
      
May	O
lead	O
to	O
loss	O
of	O
virologic	O
response	O
and	O
possible	O
resistance	O
to	O
CRIXIVAN	B-Brand
or	O
to	O
the	O
class	O
of	O
protease	B-Group
inhibitors	I-Group
or	O
other	O
coadministered	O
antiretroviral	B-Group
agents	I-Group
.	O
      
In	O
vitro	O
studies	O
have	O
shown	O
that	O
the	O
metabolism	O
of	O
docetaxel	B-Drug
may	O
be	O
modified	O
by	O
the	O
concomitant	O
administration	O
of	O
compounds	O
that	O
induce	O
inhibit	O
or	O
are	O
metabolized	O
by	O
cytochrome	O
P9	O
9A9	O
such	O
as	O
cyclosporine	B-Drug
terfenadine	B-Drug
ketoconazole	B-Drug
erythromycin	B-Drug
and	O
troleandomycin	B-Drug
.	O
      
The	O
combination	O
is	O
well	O
tolerated	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
As	O
a	O
result	O
of	O
administration	O
of	O
Keflex	B-Brand
a	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
may	O
occur	O
.	O
      
Concomitant	O
administration	O
of	O
Robinul	B-Brand
Injection	O
and	O
potassium	B-Drug
chloride	I-Drug
in	O
a	O
wax	O
matrix	O
may	O
increase	O
the	O
severity	O
of	O
potassium	O
chloride	O
-	O
induced	O
gastrointestinal	O
lesions	O
as	O
a	O
result	O
of	O
a	O
slower	O
gastrointestinal	O
transit	O
time	O
.	O
      
In	O
addition	O
under	O
the	O
influence	O
of	O
sympatholytic	O
medicinal	O
products	O
such	O
as	O
beta	B-Group
-	O
blockers	I-Group
clonidine	B-Drug
guanethidine	B-Drug
and	O
reserpine	B-Drug
the	O
signs	O
of	O
hypoglycemia	O
may	O
be	O
reduced	O
or	O
absent	O
.	O
      
Butalbital	B-Drug
acetaminophen	B-Drug
and	O
caffeine	B-Drug
may	O
enhance	O
the	O
effects	O
of	O
:	O
other	O
narcotic	B-Group
analgesics	I-Group
alcohol	B-Drug
general	O
anesthetics	B-Group
tranquilizers	B-Group
such	O
as	O
chlordiazepoxide	B-Drug
sedative	B-Group
-	O
hypnotics	I-Group
or	O
other	O
CNS	B-Group
depressants	I-Group
causing	O
increased	O
CNS	O
depression	O
.	O
      
Combination	O
with	O
tramadol	B-Drug
(	O
Ultram	B-Brand
)	O
is	O
associated	O
with	O
increased	O
risk	O
of	O
seizures	O
.	O
      
The	O
specific	O
pharmacokinetic	O
changes	O
that	O
occur	O
with	O
co	O
-	O
administration	O
of	O
nevirapine	B-Drug
and	O
other	O
drugs	O
are	O
listed	O
in	O
CLINICAL	O
PHARMACOLOGY	O
Table	O
9	O
.	O
      
Serotonergic	B-Group
Agents	I-Group
:	O
Co	O
-	O
administration	O
of	O
linezolid	B-Drug
and	O
serotonergic	B-Group
agents	I-Group
was	O
not	O
associated	O
with	O
serotonin	O
syndrome	O
in	O
Phase	O
9	O
9	O
or	O
9	O
studies	O
.	O
      
No	O
CNS	O
lesions	O
have	O
been	O
observed	O
in	O
mice	O
after	O
chronic	O
treatment	O
for	O
up	O
to	O
9	O
years	O
at	O
doses	O
up	O
to	O
9	O
mg	O
/	O
kg	O
/	O
day	O
or	O
in	O
rats	O
at	O
doses	O
up	O
to	O
9	O
mg	O
/	O
kg	O
/	O
day	O
.	O
      
There	O
are	O
few	O
data	O
regarding	O
the	O
coadministration	O
of	O
radiation	O
therapy	O
and	O
epirubicin	B-Drug
.	O
      
Grapefruit	O
juice	O
should	O
not	O
be	O
taken	O
during	O
treatment	O
with	O
oral	O
amiodarone	O
.	O
      
Other	O
drugs	O
which	O
may	O
enhance	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
nondepolarizing	B-Drug
agents	I-Drug
such	O
as	O
MIVACRON	B-Brand
include	O
certain	O
antibiotics	B-Group
(	O
e.g.	O
aminoglycosides	B-Group
tetracyclines	B-Group
bacitracin	B-Drug
polymyxins	B-Group
lincomycin	B-Drug
clindamycin	B-Drug
colistin	B-Drug
and	O
sodium	B-Drug
colistimethate	I-Drug
)	O
magnesium	B-Group
salts	O
lithium	B-Drug
local	O
anesthetics	B-Group
procainamide	B-Drug
and	O
quinidine	B-Drug
.	O
      
Beta	B-Group
-	O
blockers	I-Group
clonidine	B-Drug
lithium	B-Drug
salts	O
and	O
alcohol	B-Drug
may	O
either	O
potentiate	O
or	O
weaken	O
the	O
blood	O
-	O
glucose	O
-	O
lowering	O
effect	O
of	O
insulin	B-Drug
.	O
      
therefore	O
results	O
of	O
the	O
test	O
may	O
be	O
inaccurate	O
in	O
patients	O
taking	O
phenytoin	B-Drug
within	O
two	O
weeks	O
before	O
.	O
      
It	O
is	O
reasonable	O
to	O
employ	O
appropriate	O
clinical	O
monitoring	O
when	O
potent	O
cytochrome	O
P9	O
enzyme	O
inducers	O
such	O
as	O
phenobarbital	B-Drug
or	O
rifampin	B-Drug
are	O
co	O
-	O
administered	O
with	O
montelukast	B-Drug
.	O
      
Effects	O
of	O
Vardenafil	B-Drug
on	O
other	O
drugs	O
      
Impaired	O
glucose	O
tolerance	O
.	O
      
The	O
following	O
drug	O
interactions	O
have	O
been	O
reported	O
with	O
erythromycin	B-Drug
products	O
.	O
      
The	O
mechanism	O
for	O
this	O
interaction	O
is	O
unknown	O
.	O
      
Therefore	O
when	O
using	O
doses	O
of	O
Trileptal	B-Brand
greater	O
than	O
9	O
mg	O
/	O
day	O
during	O
adjunctive	O
therapy	O
a	O
decrease	O
in	O
the	O
dose	O
of	O
phenytoin	B-Drug
may	O
be	O
required	O
.	O
      
Indinavir	B-Drug
      
Cssmax	O
of	O
the	O
metabolite	O
ucb	O
L9	O
was	O
approximately	O
doubled	O
in	O
the	O
presence	O
of	O
probenecid	B-Drug
while	O
the	O
fraction	O
of	O
drug	O
excreted	O
unchanged	O
in	O
the	O
urine	O
remained	O
the	O
same	O
.	O
      
Since	O
symptoms	O
of	O
anticholinesterase	O
overdose	O
(	O
cholinergic	O
crisis	O
)	O
may	O
mimic	O
underdosage	O
(	O
myasthenic	O
weakness	O
)	O
their	O
condition	O
may	O
be	O
worsened	O
by	O
the	O
use	O
of	O
this	O
drug	O
.	O
      
Furosemide	B-Drug
may	O
increase	O
the	O
ototoxic	O
potential	O
of	O
aminoglycoside	B-Group
antibiotics	I-Group
especially	O
in	O
the	O
presence	O
of	O
impaired	O
renal	O
function	O
.	O
      
In	O
patients	O
receiving	O
FORADIL	B-Brand
other	O
inhaled	O
medications	O
should	O
be	O
used	O
only	O
as	O
directed	O
by	O
the	O
physician	O
.	O
      
-	O
Divalproex	B-Drug
(	O
e.g.	O
Depakote	B-Brand
)	O
or	O
      
Pentamidine	B-Drug
may	O
cause	O
hypoglycemia	O
which	O
may	O
sometimes	O
be	O
followed	O
by	O
hyperglycemia	O
.	O
      
-	O
phenytoin	B-Drug
(	O
Dilantin	B-Brand
)	O
;	O
      
Rifampin	B-Drug
      
Amiodarone	B-Drug
is	O
also	O
known	O
to	O
be	O
an	O
inhibitor	O
of	O
CYP9A9	O
.	O
      
Therefore	O
you	O
may	O
need	O
to	O
take	O
a	O
vitamin	B-Drug
B9	I-Drug
supplement	O
while	O
taking	O
aminosalicylic	B-Drug
acid	I-Drug
.	O
      
amiodarone	B-Drug
;	O
      
Orlistat	B-Drug
-	O
Orlistat	B-Drug
may	O
decrease	O
the	O
absorption	O
of	O
vitamin	B-Group
K	I-Group
.	O
      
However	O
initial	O
dose	O
modification	O
is	O
generally	O
not	O
necessary	O
.	O
      
It	O
may	O
also	O
produce	O
artifactually	O
low	O
results	O
in	O
dexamethasone	O
or	O
metyrapone	O
tests	O
.	O
      
Anticholinergic	B-Group
drugs	I-Group
may	O
antagonize	O
the	O
effects	O
of	O
drugs	O
that	O
alter	O
gastrointestinal	O
motility	O
such	O
as	O
metoclopramide	B-Drug
.	O
      
Therefore	O
the	O
potential	O
exists	O
for	O
interaction	O
between	O
carbamazepine	B-Drug
and	O
any	O
agent	O
metabolized	O
by	O
one	O
(	O
or	O
more	O
)	O
of	O
these	O
enzymes	O
.	O
      
Effect	O
of	O
Other	O
Drugs	O
on	O
the	O
Metabolism	O
of	O
Exelon	B-Brand
:	O
Drugs	O
that	O
induce	O
or	O
inhibit	O
CYP9	O
metabolism	O
are	O
not	O
expected	O
to	O
alter	O
the	O
metabolism	O
of	O
rivastigmine	B-Drug
.	O
      
CYP9A9	B-Drug
Inhibitors	O
Felodipine	O
is	O
metabolized	O
by	O
CYP9A9	B-Drug
.	O
      
Drug	O
laboratory	O
Test	O
Interactions	O
Serum	O
Salicylate	O
Assays	O
:	O
Caution	O
should	O
be	O
used	O
in	O
interpreting	O
the	O
results	O
of	O
serum	O
salicylate	O
assays	O
when	O
diflunisal	B-Drug
is	O
present	O
.	O
      
Caution	O
should	O
be	O
exercised	O
if	O
tacrolimus	B-Drug
and	O
bosentan	B-Drug
are	O
used	O
together	O
.	O
      
Pharmacokinetic	O
data	O
indicate	O
that	O
ketoconazole	B-Drug
markedly	O
inhibits	O
the	O
metabolism	O
of	O
terfenadine	B-Drug
resulting	O
in	O
elevated	O
plasma	O
terfenadine	B-Drug
levels	O
.	O
      
The	O
immediate	O
release	O
but	O
not	O
the	O
coat	O
-	O
core	O
formulation	O
of	O
nisoldipine	B-Drug
increased	O
plasma	O
quinidine	B-Drug
concentrations	O
by	O
about	O
9	O
%	O
.	O
      
consideration	O
should	O
be	O
given	O
to	O
possible	O
CNS	O
and	O
other	O
effects	O
of	O
alcohol	B-Drug
.	O
      
If	O
at	O
all	O
possible	O
guanethidine	B-Drug
should	O
be	O
discontinued	O
well	O
before	O
minoxidil	B-Drug
is	O
begun	O
.	O
      
Co	O
-	O
administration	O
of	O
ketoconazole	B-Drug
a	O
strong	O
inhibitor	O
of	O
CYP9A9	O
increased	O
cinacalcet	B-Drug
exposure	O
following	O
a	O
single	O
9	O
mg	O
dose	O
of	O
Sensipar	B-Brand
by	O
9	O
fold	O
.	O
      
-	O
Dapsone	B-Drug
or	O
      
The	O
risk	O
of	O
using	O
loxapine	B-Drug
in	O
combination	O
with	O
CNS	O
-	O
active	O
drugs	O
has	O
not	O
been	O
systematically	O
evaluated	O
.	O
      
although	O
this	O
has	O
not	O
been	O
specifically	O
studied	O
.	O
      
9%	O
9%	O
-	O
9	O
%	O
-	O
9	O
%	O
      
Administration	O
of	O
valproic	B-Drug
acid	I-Drug
decreases	O
oral	O
clearance	O
of	O
temozolomide	B-Drug
by	O
about	O
9	O
%	O
.	O
      
Therefore	O
caffeine	B-Drug
has	O
the	O
potential	O
to	O
interact	O
with	O
drugs	O
that	O
are	O
substrates	O
for	O
CYP9A9	O
inhibit	O
CYP9A9	O
or	O
induce	O
CYP9A9	O
.	O
      
Drug	O
Laboratory	O
Test	O
Interactions	O
None	O
known	O
.	O
      
Decreased	O
seizure	O
threshold	O
has	O
been	O
reported	O
in	O
patients	O
receiving	O
CYLERT	B-Brand
concomitantly	O
with	O
antiepileptic	B-Group
medications	I-Group
.	O
      
Concurrent	O
therapy	O
with	O
ORENCIA	B-Brand
and	O
TNF	B-Group
antagonists	I-Group
is	O
not	O
recommended	O
.	O
      
Sucralfate	B-Drug
administered	O
9	O
hours	O
before	O
lomefloxacin	B-Drug
resulted	O
in	O
a	O
slower	O
absorption	O
(	O
mean	O
C	O
max	O
decreased	O
by	O
9	O
%	O
and	O
mean	O
T	O
max	O
increased	O
by	O
9	O
hour	O
)	O
and	O
a	O
lesser	O
extent	O
of	O
absorption	O
(	O
mean	O
AUC	O
decreased	O
by	O
approximately	O
9	O
%	O
)	O
.	O
      
A	O
routine	O
dosage	O
adjustment	O
of	O
zaleplon	B-Drug
is	O
not	O
considered	O
necessary	O
.	O
      
Anticoagulants	B-Group
including	O
coumarin	O
derivatives	O
indandione	O
derivatives	O
and	O
platelet	B-Group
aggregation	I-Group
inhibitors	I-Group
such	O
as	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
drugs	I-Group
(	O
NSAIDs	B-Group
)	O
and	O
aspirin	B-Brand
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
when	O
administered	O
concomitantly	O
with	O
ardeparin	B-Drug
.	O
      
Administration	O
of	O
dantrolene	B-Drug
may	O
potentiate	O
vecuronium	B-Drug
-	O
induced	O
neuromuscular	O
block	O
.	O
      
Accordingly	O
patients	O
should	O
be	O
advised	O
to	O
avoid	O
diazepam	B-Drug
and	O
other	O
similar	O
drugs	O
while	O
taking	O
REMERON	B-Brand
SolTab	I-Brand
.	O
      
Thiazides	B-Group
:	O
Thiazides	B-Group
are	O
known	O
to	O
induce	O
hypercalcemia	O
by	O
the	O
reduction	O
of	O
calcium	B-Drug
excretion	O
in	O
urine	O
.	O
      
Isoflurane	B-Drug
or	O
enflurane	B-Drug
administered	O
with	O
nitrous	B-Drug
oxide	I-Drug
/	O
oxygen	B-Drug
to	O
achieve	O
9	O
MAC	O
[	O
Minimum	O
Alveolar	O
Concentration	O
]	O
may	O
prolong	O
the	O
clinically	O
effective	O
duration	O
of	O
action	O
of	O
initial	O
and	O
maintenance	O
doses	O
of	O
NIMBEX	B-Brand
and	O
decrease	O
the	O
required	O
infusion	O
rate	O
of	O
NIMBEX	B-Brand
.	O
      
The	O
clinical	O
significance	O
of	O
this	O
observation	O
is	O
unknown	O
.	O
      
It	O
is	O
recommended	O
that	O
glucose	O
tests	O
based	O
on	O
enzymatic	O
glucose	O
oxidase	O
reactions	O
(	O
such	O
as	O
CLINISTIX	O
or	O
TES	O
-	O
TAPE	O
)	O
be	O
used	O
.	O
      
Clinical	O
studies	O
have	O
shown	O
that	O
atorvastatin	B-Drug
does	O
not	O
reduce	O
basal	O
plasma	O
cortisol	O
concentration	O
or	O
impair	O
adrenal	O
reserve	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
As	O
with	O
cephalothin	B-Drug
high	O
concentrations	O
of	O
cefoxitin	B-Drug
(	O
9	O
micrograms	O
/	O
mL	O
)	O
may	O
interfere	O
with	O
measurement	O
of	O
serum	O
and	O
urine	O
creatinine	O
levels	O
by	O
the	O
Jaff	O
reaction	O
and	O
produce	O
false	O
increases	O
of	O
modest	O
degree	O
in	O
the	O
levels	O
of	O
creatinine	O
reported	O
.	O
      
The	O
optimal	O
dose	O
of	O
indinavir	B-Drug
when	O
given	O
in	O
combination	O
with	O
efavirenz	B-Drug
is	O
not	O
known	O
.	O
      
Amiodarone	B-Drug
inhibits	O
CYP9D9	B-Drug
.	O
      
Animal	O
reproduction	O
studies	O
however	O
are	O
not	O
always	O
predictive	O
of	O
human	O
response	O
and	O
there	O
are	O
no	O
adequate	O
and	O
well	O
-	O
controlled	O
studies	O
in	O
pregnant	O
women	O
.	O
      
.	O
      
The	O
drugs	O
that	O
inhibit	O
cytochrome	O
P9	O
9D9	O
include	O
some	O
that	O
are	O
not	O
metabolized	O
by	O
the	O
enzyme	O
(	O
quinidine	B-Drug
;	O
      
Therefore	O
patients	O
concurrently	O
taking	O
antiseizure	O
medication	O
and	O
Mefloquine	B-Drug
should	O
have	O
the	O
blood	O
level	O
of	O
their	O
antiseizure	O
medication	O
monitored	O
and	O
the	O
dosage	O
adjusted	O
appropriately	O
.	O
      
.	O
      
Sublingual	O
nitroglycerin	B-Drug
may	O
be	O
taken	O
if	O
necessary	O
for	O
the	O
control	O
of	O
acute	O
angina	O
attacks	O
during	O
Bepridil	B-Drug
therapy	O
.	O
      
The	O
effect	O
of	O
a	O
higher	O
ketoconazole	B-Drug
dose	O
(	O
9	O
mg	O
/	O
day	O
)	O
has	O
not	O
been	O
studied	O
.	O
      
Effects	O
were	O
already	O
seen	O
with	O
doses	O
corresponding	O
to	O
relevant	O
plasma	O
levels	O
in	O
humans	O
and	O
the	O
intracellular	O
phosphorylation	O
of	O
zalcitabine	B-Drug
to	O
its	O
three	O
metabolites	O
(	O
including	O
the	O
active	O
zalcitabine	O
triphosphate	O
metabolite	O
)	O
was	O
significantly	O
inhibited	O
.	O
      
Coadministration	O
of	O
a	O
selective	O
and	O
potent	O
inhibitor	O
of	O
CYP9A9	O
ketoconazole	B-Drug
(	O
9	O
mg	O
bid	O
for	O
9	O
days	O
with	O
ropivacaine	B-Drug
infusion	O
administered	O
9	O
hour	O
after	O
ketoconazole	B-Drug
)	O
caused	O
a	O
9	O
%	O
reduction	O
in	O
in	O
-	O
vivo	O
plasma	O
clearance	O
of	O
ropivacaine	B-Drug
.	O
      
Anticholinergic	B-Group
agents	I-Group
may	O
affect	O
gastrointestinal	O
absorption	O
of	O
various	O
drugs	O
such	O
as	O
slowly	O
dissolving	O
dosage	O
forms	O
of	O
digoxin	B-Drug
;	O
      
The	O
dosage	O
of	O
these	O
medications	O
should	O
not	O
be	O
changed	O
and	O
they	O
should	O
not	O
be	O
stopped	O
without	O
consulting	O
the	O
physician	O
even	O
if	O
the	O
patient	O
feels	O
better	O
after	O
initiating	O
treatment	O
with	O
FORADIL	B-Brand
.	O
      
increased	O
prothrombin	O
and	O
factors	O
VII	O
VIII	O
IX	O
and	O
X	O
;	O
      
This	O
could	O
lead	O
to	O
decreased	O
salicylate	B-Group
serum	O
levels	O
or	O
increase	O
the	O
risk	O
of	O
salicylate	B-Group
toxicity	O
when	O
corticosteroid	B-Group
is	O
withdrawn	O
.	O
      
For	O
patients	O
with	O
advanced	O
HIV	O
disease	O
and	O
poor	O
-	O
risk	O
AIDS	O
-	O
related	O
Kaposi	O
sarcoma	O
TAXOL	B-Brand
at	O
the	O
recommended	O
dose	O
for	O
this	O
disease	O
can	O
be	O
initiated	O
and	O
repeated	O
if	O
the	O
neutrophil	O
count	O
is	O
at	O
least	O
9	O
cells	O
/	O
mm9	O
.	O
      
therefore	O
administration	O
of	O
these	O
agents	O
should	O
precede	O
lomefloxacin	B-Drug
dosing	O
by	O
9	O
hours	O
or	O
follow	O
lomefloxacin	B-Drug
dosing	O
by	O
at	O
least	O
9	O
hours	O
.	O
      
The	O
most	O
potent	O
inhibitory	O
activity	O
was	O
observed	O
for	O
vardenafil	O
metabolite	O
M9	O
which	O
had	O
a	O
Ki	O
of	O
9	O
uM	O
toward	O
CYP9A9	O
which	O
is	O
about	O
9	O
times	O
higher	O
than	O
the	O
M9	O
Cmax	O
values	O
after	O
an	O
9	O
mg	O
Vardenafil	B-Drug
dose	O
.	O
      
Non	B-Group
-	O
steroidal	I-Group
anti	I-Group
-	O
inflammatory	I-Group
agents	I-Group
:	O
Seizures	O
have	O
been	O
reported	O
in	O
patients	O
taking	O
enoxacin	B-Drug
concomitantly	O
with	O
the	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
drug	I-Group
fenbufen	B-Drug
.	O
      
nalidixic	B-Drug
acid	I-Drug
;	O
      
When	O
oxandrolone	B-Drug
therapy	O
is	O
initiated	O
in	O
a	O
patient	O
already	O
receiving	O
treatment	O
with	O
warfarin	B-Drug
the	O
INR	O
or	O
prothrombin	O
time	O
(	O
PT	O
)	O
should	O
be	O
monitored	O
closely	O
and	O
the	O
dose	O
of	O
warfarin	B-Drug
adjusted	O
as	O
necessary	O
until	O
a	O
stable	O
target	O
INR	O
or	O
PT	O
has	O
been	O
achieved	O
.	O
      
Cancer	O
chemotherapy	O
      
Patients	O
who	O
are	O
concomitantly	O
receiving	O
VELCADE	B-Brand
and	O
drugs	O
that	O
are	O
inhibitors	O
or	O
inducers	O
of	O
cytochrome	O
P9	O
9A9	O
should	O
be	O
closely	O
monitored	O
for	O
either	O
toxicities	O
or	O
reduced	O
efficacy	O
.	O
      
Quinolones	B-Group
including	O
cinoxacin	B-Drug
may	O
enhance	O
the	O
effects	O
of	O
oral	O
anticoagulants	B-Group
such	O
as	O
warfarin	B-Drug
or	O
its	O
derivatives	O
.	O
      
Amiodarone	B-Drug
may	O
suppress	O
certain	O
CYP9	O
enzymes	O
including	O
CYP9A9	B-Drug
CYP9C9	B-Drug
CYP9D9	B-Drug
and	O
CYP9A9	B-Drug
.	O
      
Other	O
Drugs	O
:	O
In	O
small	O
groups	O
of	O
patients	O
(	O
9	O
-	O
9	O
/	O
interaction	O
study	O
)	O
the	O
concomitant	O
administration	O
of	O
azathioprine	B-Drug
gold	B-Group
chloroquine	B-Drug
D	B-Drug
-	O
penicillamine	I-Drug
prednisolone	B-Drug
doxycycline	B-Drug
or	O
digitoxin	B-Drug
did	O
not	O
significantly	O
affect	O
the	O
peak	O
levels	O
and	O
AUC	O
values	O
of	O
diclofenac	B-Drug
.	O
      
Antihistamines	B-Group
may	O
enhance	O
the	O
effects	O
of	O
tricyclic	B-Group
antidepressants	I-Group
barbiturates	B-Group
alcohol	B-Drug
and	O
other	O
CNS	B-Group
depressants	I-Group
.	O
      
clarithromycin	B-Drug
concentration	O
      
Broad	B-Group
-	O
Spectrum	I-Group
Antibiotics	I-Group
-	O
Broad	B-Group
-	O
spectrum	I-Group
antibiotics	I-Group
may	O
sterilize	O
the	O
bowel	O
and	O
decrease	O
the	O
vitamin	B-Group
K	I-Group
contribution	O
to	O
the	O
body	O
by	O
the	O
intestinal	O
microflora	O
.	O
      
The	O
following	O
medications	O
have	O
been	O
administered	O
in	O
clinical	O
trials	O
with	O
Simulect	B-Brand
with	O
no	O
increase	O
in	O
adverse	O
reactions	O
:	O
ATG	O
/	O
ALG	O
azathioprine	B-Drug
corticosteroids	B-Group
cyclosporine	B-Drug
mycophenolate	B-Drug
mofetil	I-Drug
and	O
muromonab	B-Drug
-	O
CD9	I-Drug
.	O
      
Prescribers	O
should	O
refer	O
to	O
national	O
guidelines	O
for	O
influenza	O
vaccination	O
.	O
      
Laboratory	O
Test	O
Interactions	O
Scopolamine	B-Drug
will	O
interfere	O
with	O
the	O
gastric	O
secretion	O
test	O
.	O
      
If	O
co	O
-	O
administration	O
is	O
essential	O
conduct	O
close	O
clinical	O
and	O
laboratory	O
monitoring	O
      
Caution	O
should	O
be	O
exercised	O
when	O
taking	O
this	O
medicine	O
certain	O
antibiotics	B-Group
such	O
as	O
erythromycin	B-Drug
clarithromycin	B-Drug
or	O
azithromycin	B-Drug
.	O
      
In	O
TAMBOCOR	B-Brand
clinical	O
trials	O
patients	O
who	O
were	O
receiving	O
beta	B-Group
blockers	I-Group
concurrently	O
did	O
not	O
experience	O
an	O
increased	O
incidence	O
of	O
side	O
effects	O
.	O
      
Based	O
on	O
in	O
vitro	O
studies	O
in	O
human	O
liver	O
microsomes	O
des	B-Drug
-	O
ciclesonide	I-Drug
appears	O
to	O
have	O
no	O
inhibitory	O
or	O
induction	O
potential	O
on	O
the	O
metabolism	O
of	O
other	O
drugs	O
metabolized	O
by	O
CYP	O
9	O
enzymes	O
.	O
      
Nursing	O
Mothers	O
In	O
rat	O
studies	O
exposure	O
to	O
total	O
ezetimibe	B-Drug
in	O
nursing	O
pups	O
was	O
up	O
to	O
half	O
of	O
that	O
observed	O
in	O
maternal	O
plasma	O
.	O
      
Albendazole	B-Drug
sulfoxide	I-Drug
plasma	O
concentrations	O
were	O
unchanged	O
9	O
hours	O
after	O
dosing	O
.	O
      
The	O
following	O
information	O
was	O
obtained	O
from	O
studies	O
in	O
normal	O
volunteers	O
.	O
      
Effect	O
of	O
Other	O
Drugs	O
on	O
the	O
Pharmacokinetics	O
of	O
Clonazepam	B-Drug
:	O
Literature	O
reports	O
suggest	O
that	O
ranitidine	B-Drug
an	O
agent	O
that	O
decreases	O
stomach	O
acidity	O
does	O
not	O
greatly	O
alter	O
clonazepam	B-Drug
pharmacokinetics	O
.	O
      
When	O
these	O
drugs	O
are	O
administered	O
to	O
or	O
withdrawn	O
from	O
patients	O
receiving	O
Starlix	B-Brand
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
changes	O
in	O
glycemic	O
control	O
.	O
      
Antihistamines	B-Group
may	O
have	O
additive	O
effects	O
with	O
alcohol	B-Drug
and	O
other	O
CNS	B-Group
depressants	I-Group
e.g.	O
hypnotics	B-Group
sedatives	B-Group
tranquilizers	B-Group
antianxiety	B-Group
agents	I-Group
.	O
      
Ranitidine	B-Drug
produced	O
smaller	O
nonsignificant	O
increases	O
.	O
      
Absorption	O
of	O
tetracyclines	B-Group
is	O
impaired	O
by	O
antacids	B-Group
containing	O
aluminum	B-Drug
calcium	B-Drug
or	O
magnesium	B-Drug
and	O
iron	B-Drug
-	O
containing	O
preparations	O
.	O
      
INDOCIN	B-Brand
given	O
concomitantly	O
with	O
digoxin	B-Drug
has	O
been	O
reported	O
to	O
increase	O
the	O
serum	O
concentration	O
and	O
prolong	O
the	O
half	O
-	O
life	O
of	O
digoxin	B-Drug
.	O
      
Aspirin	B-Brand
may	O
decrease	O
bioavailability	O
of	O
SKELID	B-Brand
by	O
up	O
to	O
9	O
%	O
when	O
taken	O
9	O
hours	O
after	O
SKELID	B-Brand
.	O
      
Potentially	O
fatal	O
drug	O
interactions	O
may	O
occur	O
when	O
coadministered	O
with	O
digoxin	B-Drug
as	O
this	O
may	O
enhance	O
cardiovascular	O
depression	O
and	O
bradyarrhythmias	O
may	O
occur	O
.	O
      
In	O
healthy	O
volunteers	O
Exjade	B-Brand
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
digoxin	B-Drug
.	O
      
No	O
drug	O
nutritional	O
supplement	O
food	O
or	O
herb	O
interactions	O
are	O
known	O
.	O
      
Patients	O
on	O
Warfarin	B-Drug
should	O
have	O
more	O
frequent	O
monitoring	O
of	O
prothrombin	O
times	O
while	O
patients	O
with	O
other	O
risk	O
factors	O
complicated	O
by	O
hemorrhage	O
(	O
e.g.	O
recent	O
surgery	O
peptic	O
ulceration	O
)	O
should	O
have	O
periodic	O
examinations	O
for	O
bleeding	O
including	O
hematocrit	O
and	O
/	O
or	O
hemoglobin	O
.	O
      
Ritonavir	B-Drug
significantly	O
prolonged	O
the	O
half	O
-	O
life	O
of	O
vardenafil	B-Drug
to	O
9	O
hours	O
.	O
      
If	O
possible	O
avoid	O
such	O
combinations	O
.	O
      
Lithium	B-Drug
:	O
Increased	O
serum	O
lithium	B-Drug
levels	O
and	O
symptoms	O
of	O
lithium	B-Drug
toxicity	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
concomitant	O
lithium	B-Drug
and	O
ACE	B-Group
inhibitor	I-Group
therapy	O
.	O
      
Furosemide	B-Drug
:	O
Clinical	O
studies	O
as	O
well	O
as	O
post	O
-	O
marketing	O
observations	O
have	O
shown	O
that	O
NSAIDs	B-Group
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	B-Drug
and	O
thiazide	B-Group
diuretics	I-Group
in	O
some	O
patients	O
.	O
      
Phenytoin	B-Drug
:	O
Isoniazid	B-Drug
may	O
increase	O
serum	O
levels	O
of	O
phenytoin	B-Drug
.	O
      
May	O
interact	O
with	O
other	O
creams	O
lotions	O
or	O
skin	O
medicines	O
when	O
placed	O
on	O
the	O
same	O
areas	O
of	O
your	O
skin	O
that	O
you	O
are	O
using	O
bentoquatam	B-Drug_n
.	O
      
Cytosine	B-Drug
arabinoside	I-Drug
a	O
cytostatic	B-Group
agent	I-Group
has	O
been	O
reported	O
to	O
inactivate	O
the	O
antifungal	O
activity	O
of	O
flucytosine	B-Drug
by	O
competitive	O
inhibition	O
.	O
      
Several	O
of	O
the	O
tricyclic	B-Group
antidepressants	I-Group
have	O
been	O
cited	O
in	O
these	O
reports	O
.	O
      
Plasma	O
concentrations	O
(	O
AUC	O
9	O
-	O
9	O
hrs	O
)	O
of	O
erythromycin	B-Drug
decreased	O
9	O
%	O
with	O
coadministration	O
of	O
loratadine	B-Drug
relative	O
to	O
that	O
observed	O
with	O
erythromycin	B-Drug
alone	O
.	O
      
The	O
risk	O
of	O
metabolic	O
interactions	O
caused	O
by	O
an	O
effect	O
on	O
an	O
individual	O
isoform	O
is	O
therefore	O
minimized	O
.	O
      
Concomitant	O
use	O
of	O
prophylactic	O
low	O
dose	O
heparin	B-Drug
did	O
not	O
appear	O
to	O
affect	O
safety	O
however	O
its	O
effects	O
on	O
the	O
efficacy	O
of	O
Xigris	B-Brand
have	O
not	O
been	O
evaluated	O
in	O
an	O
adequate	O
and	O
well	O
-	O
controlled	O
clinical	O
trial	O
.	O
      
Drugs	O
Associated	O
With	O
Peripheral	O
Neuropathy	O
:	O
The	O
concomitant	O
use	O
of	O
HIVID	B-Drug
with	O
drugs	O
that	O
have	O
the	O
potential	O
to	O
cause	O
peripheral	O
neuropathy	O
should	O
be	O
avoided	O
where	O
possible	O
.	O
      
Therefore	O
when	O
INDOCIN	B-Brand
and	O
INDOCIN	B-Brand
.	O
      
Since	O
amiodarone	B-Drug
is	O
a	O
substrate	O
for	O
CYP9A9	O
and	O
CYP9C9	O
drugs	O
/	O
substances	O
that	O
inhibit	O
these	O
isoenzymes	O
may	O
decrease	O
the	O
metabolism	O
and	O
increase	O
serum	O
concentration	O
of	O
amiodarone	B-Drug
.	O
      
ethinyl	B-Drug
estradiol	I-Drug
concentration	O
      
The	O
time	O
to	O
onset	O
of	O
maximum	O
block	O
following	O
NIMBEX	B-Brand
is	O
approximately	O
9	O
minutes	O
faster	O
with	O
prior	O
administration	O
of	O
succinylcholine	B-Drug
.	O
      
Given	O
the	O
primary	O
CNS	O
effects	O
of	O
Clozapine	B-Drug
caution	O
is	O
advised	O
in	O
using	O
it	O
concomitantly	O
with	O
other	O
CNS	O
-	O
active	O
drugs	O
or	O
alcohol	B-Drug
.	O
      
In	O
clinical	O
trials	O
doxazosin	B-Drug
mesylate	I-Drug
tablets	O
have	O
been	O
administered	O
to	O
patients	O
on	O
a	O
variety	O
of	O
concomitant	O
medications	O
;	O
      
also	O
concurrent	O
use	O
of	O
this	O
medication	O
may	O
antagonise	O
the	O
anti	O
-	O
glaucoma	O
and	O
miotic	O
actions	O
of	O
ophthalmic	O
cholinesterase	B-Group
inhibitors	I-Group
.	O
      
While	O
taking	O
beta	B-Group
blockers	I-Group
patients	O
with	O
a	O
history	O
of	O
anaphylactic	O
reaction	O
to	O
a	O
variety	O
of	O
allergens	O
may	O
have	O
a	O
more	O
severe	O
reaction	O
on	O
repeated	O
challenge	O
either	O
accidental	O
diagnostic	O
or	O
therapeutic	O
.	O
      
When	O
initiating	O
a	O
multi	O
-	O
day	O
course	O
of	O
grepafloxacin	B-Drug
in	O
a	O
patient	O
maintained	O
on	O
theophylline	B-Drug
the	O
theophylline	B-Drug
maintenance	O
dose	O
should	O
be	O
halved	O
for	O
the	O
period	O
of	O
concurrent	O
use	O
of	O
grepafloxacin	B-Drug
and	O
monitoring	O
of	O
serum	O
theophylline	B-Drug
concentrations	O
should	O
be	O
initiated	O
as	O
a	O
guide	O
to	O
further	O
dosage	O
adjustments	O
.	O
      
patients	O
receiving	O
lithium	B-Drug
and	O
Neulasta	B-Brand
should	O
have	O
more	O
frequent	O
monitoring	O
of	O
neutrophil	O
counts	O
.	O
      
Death	O
due	O
to	O
fulminant	O
pancreatitis	O
possibly	O
related	O
to	O
intravenous	O
pentamidine	B-Drug
and	O
HIVID	B-Drug
has	O
been	O
reported	O
.	O
      
It	O
is	O
not	O
known	O
whether	O
AMEVIVE	B-Brand
is	O
excreted	O
in	O
human	O
milk	O
.	O
      
Pediatric	O
Use	O
The	O
safety	O
and	O
efficacy	O
of	O
FASLODEX	B-Brand
in	O
pediatric	O
patients	O
have	O
not	O
been	O
established	O
.	O
      
Cimetidine	B-Drug
reduces	O
the	O
clearance	O
of	O
ALFENTA	B-Brand
.	O
      
It	O
may	O
increase	O
excretion	O
of	O
barbiturates	B-Group
lithium	B-Drug
and	O
ASA	B-Drug
and	O
may	O
also	O
increase	O
the	O
toxicity	O
of	O
salicylates	B-Group
.	O
      
Adenosine	B-Drug
effects	O
are	O
potentiated	O
by	O
dipyridamole	B-Drug
.	O
      
Studies	O
have	O
shown	O
that	O
lansoprazole	B-Drug
does	O
not	O
have	O
clinically	O
significant	O
interactions	O
with	O
other	O
drugs	O
metabolized	O
by	O
the	O
cytochrome	O
P9	O
system	O
such	O
as	O
warfarin	B-Drug
antipyrine	B-Drug
indomethacin	B-Drug
ibuprofen	B-Drug
phenytoin	B-Drug
propranolol	B-Drug
prednisone	B-Drug
diazepam	B-Drug
clarithromycin	B-Drug
or	O
terfenadine	B-Drug
in	O
healthy	O
subjects	O
.	O
      
9	O
-	O
9	O
      
St	O
.	O
      
Specific	O
drug	O
interaction	O
studies	O
have	O
not	O
been	O
performed	O
with	O
SUSTIVA	B-Brand
and	O
NRTIs	B-Group
other	O
than	O
lamivudine	B-Drug
and	O
zidovudine	B-Drug
.	O
      
If	O
isradipine	B-Drug
therapy	O
is	O
initiated	O
in	O
a	O
patient	O
currently	O
receiving	O
cimetidine	B-Drug
careful	O
monitoring	O
for	O
adverse	O
reactions	O
is	O
advised	O
and	O
downward	O
dose	O
adjustment	O
may	O
be	O
required	O
.	O
      
CHEMET	B-Brand
is	O
not	O
known	O
to	O
interact	O
with	O
other	O
drugs	O
including	O
iron	B-Drug
supplements	O
;	O
      
Increased	O
metoprolol	B-Drug
plasma	O
levels	O
have	O
been	O
associated	O
with	O
decreased	O
cardioselectivity	O
.	O
      
sucralfate	B-Drug
or	O
divalent	O
or	O
trivalent	O
cations	O
such	O
as	O
iron	B-Drug
;	O
      
Reports	O
in	O
the	O
literature	O
suggest	O
that	O
plasma	O
levels	O
of	O
doxorubicin	B-Drug
(	O
and	O
its	O
active	O
metabolite	O
doxorubicinol	B-Drug_n
)	O
may	O
be	O
increased	O
when	O
paclitaxel	B-Drug
and	O
doxorubicin	B-Drug
are	O
used	O
in	O
combination	O
.	O
      
In	O
these	O
subjects	O
meloxicam	B-Drug
did	O
not	O
alter	O
warfarin	B-Drug
pharmacokinetics	O
and	O
the	O
average	O
anticoagulant	O
effect	O
of	O
warfarin	B-Drug
as	O
determined	O
by	O
prothrombin	O
time	O
.	O
      
There	O
are	O
no	O
known	O
drug	O
interactions	O
with	O
LEUSTATIN	B-Brand
Injection	O
.	O
      
UNIVASC	B-Brand
has	O
been	O
used	O
in	O
clinical	O
trials	O
concomitantly	O
with	O
calcium	B-Group
-	O
channel	I-Group
-	O
blocking	I-Group
agents	I-Group
diuretics	B-Group
H9	B-Group
blockers	I-Group
digoxin	B-Drug
oral	O
hypoglycemic	B-Group
agents	I-Group
and	O
cholesterol	O
-	O
lowering	O
agents	O
.	O
      
requirements	O
for	O
riboflavin	B-Drug
may	O
be	O
increased	O
in	O
patients	O
receiving	O
probenecid	B-Drug
.	O
      
The	O
initial	O
dose	O
of	O
levorphanol	B-Drug
should	O
be	O
reduced	O
by	O
approximately	O
9	O
%	O
or	O
more	O
when	O
it	O
is	O
given	O
to	O
patients	O
along	O
with	O
another	O
drug	O
affecting	O
respiration	O
.	O
      
If	O
EVISTA	B-Brand
is	O
given	O
concurrently	O
with	O
warfarin	B-Drug
prothrombin	O
time	O
should	O
be	O
monitored	O
.	O
      
Alosetron	B-Drug
also	O
does	O
not	O
appear	O
to	O
induce	O
CYP	O
enzymes	O
9E9	O
or	O
9C9	O
.	O
      
lopinavir	B-Drug
concentration	O
      
However	O
the	O
systemic	O
administration	O
of	O
some	O
quinolones	B-Group
has	O
been	O
shown	O
to	O
elevate	O
plasma	O
concentrations	O
of	O
theophylline	B-Drug
interfere	O
with	O
the	O
metabolism	O
of	O
caffeine	B-Drug
and	O
enhance	O
the	O
effects	O
of	O
the	O
oral	O
anticoagulant	B-Group
warfarin	B-Drug
and	O
its	O
derivatives	O
and	O
has	O
been	O
associated	O
with	O
transient	O
elevations	O
in	O
serum	O
creatinine	O
in	O
patients	O
receiving	O
systemic	O
cyclosporine	B-Drug
concomitantly	O
.	O
      
Ironically	O
benzodiazepines	B-Group
are	O
often	O
used	O
in	O
the	O
treatment	O
of	O
heroin	B-Drug
addiction	O
while	O
they	O
cause	O
much	O
more	O
severe	O
withdrawal	O
symptoms	O
.	O
      
Evidence	O
of	O
spontaneous	O
recovery	O
from	O
succinylcholine	B-Drug
should	O
be	O
observed	O
before	O
the	O
administration	O
of	O
MIVACRON	B-Brand
.	O
      
Use	O
with	O
Other	O
Agents	O
Affecting	O
Myelopoesis	O
:	O
Drugs	O
which	O
may	O
affect	O
leukocyte	O
production	O
including	O
co	B-Brand
-	O
trimoxazole	I-Brand
may	O
lead	O
to	O
exaggerated	O
leukopenia	O
especially	O
in	O
renal	O
transplant	O
recipients	O
.	O
      
The	O
effect	O
of	O
concomitant	O
administration	O
of	O
fluconazole	B-Drug
and	O
glipizide	B-Drug
has	O
been	O
demonstrated	O
in	O
a	O
placebo	O
-	O
controlled	O
crossover	O
study	O
in	O
normal	O
volunteers	O
.	O
      
.	O
      
Agents	O
Affecting	O
Sympathetic	O
Activity	O
The	O
sympathetic	O
nervous	O
system	O
may	O
be	O
especially	O
important	O
in	O
supporting	O
blood	O
pressure	O
in	O
patients	O
receiving	O
captopril	B-Drug
alone	O
or	O
with	O
diuretics	B-Group
.	O
      
Ketoconazole	B-Drug
:	O
In	O
healthy	O
subjects	O
receiving	O
ketoconazole	B-Drug
a	O
CYP9A9	O
inhibitor	O
at	O
9	O
mg	O
twice	O
daily	O
for	O
9	O
days	O
systemic	O
exposure	O
(	O
AUC	O
)	O
to	O
lapatinib	B-Drug
was	O
increased	O
to	O
approximately	O
9	O
-	O
fold	O
of	O
control	O
and	O
half	O
-	O
life	O
increased	O
to	O
9	O
-	O
fold	O
of	O
control	O
.	O
      
Prior	O
administration	O
of	O
succinylcholine	B-Drug
has	O
no	O
clinically	O
important	O
effect	O
on	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
NUROMAX	B-Brand
.	O
      
Because	O
Matulane	B-Brand
exhibits	O
some	O
monoamine	O
oxidase	O
inhibitory	O
activity	O
sympathomimetic	B-Group
drugs	I-Group
tricyclic	B-Group
antidepressant	I-Group
drugs	O
(	O
e.g.	O
amitriptyline	B-Drug
HCl	I-Drug
imipramine	B-Drug
HCl	I-Drug
)	O
and	O
other	O
drugs	O
and	O
foods	O
with	O
known	O
high	O
tyramine	B-Drug_n
content	O
such	O
as	O
wine	O
yogurt	O
ripe	O
cheese	O
and	O
bananas	O
should	O
be	O
avoided	O
.	O
      
Changes	O
in	O
omeprazole	B-Drug
pharmacokinetics	O
were	O
not	O
studied	O
.	O
      
A	O
study	O
in	O
six	O
healthy	O
volunteers	O
has	O
shown	O
a	O
significant	O
increase	O
in	O
peak	O
diltiazem	B-Drug
plasma	O
levels	O
(	O
9	O
%	O
)	O
and	O
AUC	O
(	O
9	O
%	O
)	O
after	O
a	O
9	O
-	O
week	O
course	O
of	O
cimetidine	B-Drug
9	O
mg	O
/	O
day	O
and	O
a	O
single	O
dose	O
of	O
diltiazem	B-Drug
9mg	O
.	O
      
Herbal	O
Products	O
:	O
St.	O
John	O
wort	O
(	O
hypericum	O
perforatum	O
)	O
WARNING	O
coadministration	O
may	O
lead	O
to	O
loss	O
of	O
virologic	O
response	O
and	O
possible	O
resistance	O
to	O
INVIRASE	B-Brand
or	O
to	O
the	O
class	O
of	O
protease	O
inhibitors	O
.	O
      
Until	O
further	O
data	O
are	O
developed	O
regarding	O
drug	O
interactions	O
when	O
azithromycin	B-Drug
and	O
these	O
drugs	O
are	O
used	O
concomitantly	O
careful	O
monitoring	O
of	O
patients	O
is	O
advised	O
:	O
Digoxin	B-Drug
elevated	O
digoxin	B-Drug
concentrations	O
.	O
      
Caution	O
should	O
be	O
used	O
when	O
coadministering	O
medications	O
that	O
are	O
substrates	O
inhibitors	O
or	O
inducers	O
of	O
CYP9A9	O
or	O
potentially	O
toxic	O
medications	O
that	O
are	O
metabolized	O
by	O
CYP9A9	O
.	O
      
These	O
reactions	O
have	O
been	O
observed	O
more	O
frequently	O
with	O
the	O
9	O
-	O
hour	O
infusion	O
than	O
with	O
the	O
9	O
-	O
hour	O
infusion	O
.	O
      
Effect	O
      
Formal	O
drug	O
interaction	O
studies	O
have	O
not	O
been	O
conducted	O
with	O
ORENCIA	B-Brand
.	O
      
In	O
a	O
Phase	O
I	O
trial	O
using	O
escalating	O
doses	O
of	O
TAXOL	B-Brand
(	O
9	O
-	O
9	O
mg	O
/	O
m9	O
)	O
and	O
cisplatin	B-Drug
(	O
9	O
or	O
9	O
mg	O
/	O
m9	O
)	O
given	O
as	O
sequential	O
infusions	O
myelosuppression	O
was	O
more	O
profound	O
when	O
TAXOL	B-Brand
was	O
given	O
after	O
cisplatin	B-Drug
than	O
with	O
the	O
alternate	O
sequence	O
(	O
ie	O
TAXOL	B-Brand
before	O
cisplatin	B-Drug
)	O
.	O
      
Theophylline	B-Drug
:	O
Enoxacin	B-Drug
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
cytochrome	O
P	O
-	O
9	O
isozymes	O
responsible	O
for	O
the	O
metabolism	O
of	O
methylxanthines	B-Group
.	O
      
Propanolol	B-Drug
:	O
The	O
pharmacokinetics	O
of	O
almotriptan	B-Drug
were	O
not	O
affected	O
by	O
coadministration	O
of	O
propranolol	B-Drug
.	O
      
Phenobarbital	B-Drug
which	O
induces	O
hepatic	O
metabolism	O
decreased	O
the	O
AUC	O
of	O
montelukast	B-Drug
approximately	O
9	O
%	O
following	O
a	O
single	O
9	O
-	O
mg	O
dose	O
of	O
montelukast	B-Drug
.	O
      
Therefore	O
patients	O
on	O
propranolol	B-Drug
should	O
be	O
observed	O
when	O
COLESTID	B-Brand
Tablets	O
are	O
either	O
added	O
or	O
deleted	O
from	O
a	O
therapeutic	O
regimen	O
.	O
      
Therefore	O
the	O
concomitant	O
administration	O
of	O
TRACLEER	B-Brand
and	O
glyburide	B-Drug
is	O
contraindicated	O
and	O
alternative	O
hypoglycemic	B-Group
agents	I-Group
should	O
be	O
considered	O
.	O
      
Antacids	B-Group
containing	O
aluminum	B-Drug
hydroxide	I-Drug
and	O
magnesium	B-Drug
hydroxide	I-Drug
reduce	O
the	O
oral	O
absorption	O
of	O
enoxacin	B-Drug
by	O
9	O
%	O
.	O
      
Nevirapine	B-Drug
      
Drug	O
Interactions	O
:	O
Inhibitors	O
of	O
CYP9A9	O
Isozymes	O
:	O
Caution	O
is	O
advised	O
when	O
midazolam	B-Drug
is	O
administered	O
concomitantly	O
with	O
drugs	O
that	O
are	O
known	O
to	O
inhibit	O
the	O
cytochrome	O
P9	O
9A9	O
enzyme	O
system	O
(	O
ie	O
some	O
drugs	O
in	O
the	O
drug	O
classes	O
of	O
azole	B-Group
antimycotics	I-Group
protease	B-Group
inhibitors	I-Group
calcium	B-Group
channel	I-Group
antagonists	I-Group
and	O
macrolide	B-Group
antibiotics	I-Group
)	O
.	O
      
The	O
drugs	O
that	O
inhibit	O
cytochrome	O
P9	O
9D9	O
include	O
some	O
that	O
are	O
not	O
metabolized	O
by	O
the	O
enzyme	O
(	O
quinidine	B-Drug
;	O
      
The	O
effects	O
of	O
medicinal	O
products	O
with	O
similar	O
properties	O
such	O
as	O
inotropes	O
milrinone	B-Drug
enoximone	B-Drug
amrinone	B-Drug
olprinone	B-Drug_n
and	O
cilostazol	B-Drug
may	O
be	O
exacerbated	O
by	O
anagrelide	B-Drug
.	O
      
Concomitant	O
administration	O
of	O
low	O
-	O
dose	O
aspirin	B-Brand
with	O
MOBIC	B-Brand
may	O
result	O
in	O
an	O
increased	O
rate	O
of	O
GI	O
ulceration	O
or	O
other	O
complications	O
compared	O
to	O
use	O
of	O
MOBIC	B-Brand
alone	O
.	O
      
Also	O
due	O
to	O
the	O
potential	O
for	O
additive	O
effects	O
such	O
as	O
bradycardia	O
and	O
AV	O
block	O
caution	O
is	O
warranted	O
in	O
patients	O
receiving	O
clonidine	B-Drug
with	O
agents	O
known	O
to	O
affect	O
sinus	O
node	O
function	O
or	O
AV	O
nodal	O
conduction	O
(	O
e.g.	O
digitalis	B-Group
calcium	B-Group
channel	I-Group
blockers	I-Group
and	O
beta	B-Group
-	O
blockers	I-Group
.	O
)	O
      
Patients	O
receiving	O
both	O
indomethacin	B-Drug
and	O
furosemide	B-Drug
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
diuretic	O
and	O
/	O
or	O
antihypertensive	O
effect	O
of	O
furosemide	B-Drug
is	O
achieved	O
.	O
      
Fluoxetine	B-Drug
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
clonazepam	B-Drug
.	O
      
anemia	O
      
Due	O
to	O
the	O
possibility	O
of	O
antagonism	O
in	O
vivo	O
particularly	O
when	O
bactericidal	O
activity	O
is	O
desired	O
this	O
drug	O
combination	O
should	O
be	O
avoided	O
.	O
      
Patients	O
should	O
report	O
to	O
their	O
practitioners	O
any	O
new	O
rashes	O
itching	O
mouth	O
sores	O
or	O
unusual	O
taste	O
while	O
taking	O
auranofin	B-Drug
.	O
      
Lithium	B-Drug
carbonate	I-Drug
(	O
9	O
mg	O
BID	O
for	O
9	O
days	O
)	O
had	O
no	O
effect	O
on	O
valdecoxib	B-Drug
pharmacokinetics	O
.	O
      
Patients	O
with	O
HACA	O
titers	O
may	O
have	O
allergic	O
or	O
hypersensitivity	O
reactions	O
when	O
treated	O
with	O
other	O
diagnostic	B-Group
or	O
therapeutic	B-Group
monoclonal	I-Group
antibodies	I-Group
.	O
      
Hemodynamic	O
and	O
electrophysiologic	O
interactions	O
have	O
also	O
been	O
observed	O
after	O
concomitant	O
administration	O
with	O
propranolol	B-Drug
diltiazem	B-Drug
and	O
verapamil	B-Drug
.	O
      
.	O
      
Ritonavir	B-Drug
:	O
Coadministration	O
of	O
ritonavir	B-Drug
with	O
VIRACEPT	B-Brand
resulted	O
in	O
a	O
9	O
%	O
increase	O
in	O
nelfinavir	B-Drug
plasma	O
AUC	O
and	O
very	O
little	O
change	O
in	O
ritonavir	B-Drug
plasma	O
A.C	O
.	O
      
increased	O
plasminogen	O
antigen	O
and	O
activity	O
.	O
      
Additives	O
may	O
be	O
incompatible	O
;	O
      
Exogenously	O
administered	O
insulin	B-Drug
may	O
begin	O
to	O
act	O
before	O
food	O
has	O
left	O
the	O
stomach	O
and	O
lead	O
to	O
hypoglycemia	O
.	O
      
Because	O
of	O
its	O
lack	O
of	O
platelet	O
effects	O
CELEBREX	B-Brand
is	O
not	O
a	O
substitute	O
for	O
aspirin	B-Brand
for	O
cardiovascular	O
prophylaxis	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Increases	O
in	O
lymphocyte	O
counts	O
related	O
to	O
the	O
pharmacologic	O
mechanism	O
of	O
action	O
are	O
frequently	O
observed	O
during	O
RAPTIVA	B-Brand
treatment	O
.	O
      
Additive	O
sedative	O
effects	O
and	O
confusional	O
states	O
may	O
emerge	O
if	O
levomepromazine	B-Drug
is	O
given	O
with	O
benzodiazepines	B-Group
or	O
barbiturates	B-Group
.	O
      
Terbinafine	B-Drug
clearance	O
is	O
increased	O
9	O
%	O
by	O
rifampin	B-Drug
a	O
CyP9	O
enzyme	O
inducer	O
and	O
decreased	O
9	O
%	O
by	O
cimetidine	B-Drug
a	O
CyP9	O
enzyme	O
inhibitor	O
.	O
      
Sulfapyridine	B-Drug
may	O
interact	O
with	O
any	O
of	O
the	O
following	O
:	O
-	O
Acetaminophen	B-Drug
(	O
e.g.	O
Tylenol	B-Brand
)	O
(	O
with	O
long	O
-	O
term	O
high	O
-	O
dose	O
use	O
)	O
or	O
      
Therefore	O
when	O
INSPRA	B-Brand
and	O
NSAIDs	B-Group
are	O
used	O
concomitantly	O
patients	O
should	O
be	O
observed	O
to	O
determine	O
whether	O
the	O
desired	O
effect	O
on	O
blood	O
pressure	O
is	O
obtained	O
.	O
      
Drugs	O
highly	O
bound	O
to	O
albumin	O
could	O
increase	O
the	O
unbound	O
fraction	O
of	O
fosphenytoin	B-Drug
.	O
      
When	O
administered	O
concurrently	O
the	O
following	O
drugs	O
may	O
interact	O
with	O
amphotericin	B-Drug
B	I-Drug
:	O
Antineoplastic	B-Group
agents	I-Group
:	O
may	O
enhance	O
the	O
potential	O
for	O
renal	O
toxicity	O
bronchospasm	O
and	O
hypotension	O
.	O
      
Data	O
suggest	O
that	O
coadministration	O
of	O
oral	O
ketoconazole	B-Drug
and	O
cisapride	B-Drug
can	O
result	O
in	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O
      
In	O
a	O
small	O
(	O
n=9	O
)	O
combination	O
study	O
of	O
ARAVA	B-Brand
with	O
methotrexate	B-Drug
a	O
9	O
-	O
to	O
9	O
-	O
fold	O
elevation	O
in	O
liver	O
enzymes	O
was	O
seen	O
in	O
9	O
of	O
9	O
patients	O
.	O
      
Ketamine	B-Drug
:	O
When	O
administered	O
to	O
patients	O
on	O
a	O
thyroid	B-Group
preparation	I-Group
this	O
parenteral	O
anesthetic	B-Group
may	O
cause	O
hypertension	O
and	O
tachycardia	O
.	O
      
The	O
safety	O
and	O
efficacy	O
of	O
anakinra	B-Drug
used	O
in	O
combination	O
with	O
HUMIRA	B-Brand
has	O
not	O
been	O
studied	O
.	O
      
-	O
a	O
sulfa	O
-	O
based	O
drug	O
such	O
as	O
sulfamethoxazole	B-Drug
-	O
trimethoprim	B-Drug
(	O
Bactrim	B-Brand
Septra	B-Brand
)	O
sulfisoxazole	B-Drug
(	O
Gantrisin	B-Brand
)	O
or	O
sulfasalazine	B-Drug
(	O
Azulfidine	B-Brand
)	O
;	O
      
No	O
significant	O
interactions	O
with	O
digoxin	B-Drug
hydrochlorothiazide	B-Drug
hydralazine	B-Drug
sulfinpyrazone	B-Drug
oral	O
contraceptives	B-Group
tolbutamide	B-Drug
or	O
warfarin	B-Drug
have	O
been	O
observed	O
.	O
      
No	O
drug	O
nutritional	O
supplement	O
food	O
or	O
herb	O
interactions	O
have	O
yet	O
been	O
reported	O
.	O
      
A	O
study	O
published	O
in	O
9	O
found	O
that	O
vigabatrin	B-Drug
causes	O
a	O
statistically	O
significant	O
increase	O
in	O
plasma	O
clearance	O
of	O
carbamazepine	B-Drug
.	O
      
The	O
inhibiting	O
effects	O
of	O
anticholinergic	B-Group
drugs	I-Group
on	O
gastric	O
hydrochloric	O
acid	O
secretion	O
are	O
antagonized	O
by	O
agents	O
used	O
to	O
treat	O
achlorhydria	O
and	O
those	O
used	O
to	O
test	O
gastric	O
secretion	O
.	O
      
The	O
optimal	O
dose	O
of	O
indinavir	B-Drug
when	O
given	O
in	O
combination	O
with	O
SUSTIVA	B-Brand
is	O
not	O
known	O
.	O
      
.	O
      
The	O
mechanism	O
of	O
these	O
interactions	O
has	O
been	O
evaluated	O
in	O
in	O
vitro	O
in	O
situ	O
and	O
in	O
vivo	O
animal	O
models	O
.	O
      
Doxepin	B-Drug
is	O
primarily	O
metabolized	O
by	O
CYP9D9	O
(	O
with	O
CYP9A9	O
and	O
CYP9A9	O
as	O
minor	O
pathways	O
)	O
.	O
      
9	O
%	O
      
Since	O
iloprost	B-Drug
inhibits	O
platelet	O
function	O
there	O
is	O
a	O
potential	O
for	O
increased	O
risk	O
of	O
bleeding	O
particularly	O
in	O
patients	O
maintained	O
on	O
anticoagulants	B-Group
.	O
      
aminosalicylic	B-Drug
acid	I-Drug
;	O
      
Hydrochlorothiazide	B-Drug
:	O
A	O
study	O
in	O
normal	O
healthy	O
volunteers	O
has	O
shown	O
that	O
concomitant	O
administration	O
of	O
DynaCirc	B-Brand
(	O
isradipine	B-Drug
)	O
and	O
hydrochlorothiazide	B-Drug
does	O
not	O
result	O
in	O
altered	O
pharmacoktnetics	O
of	O
either	O
drug	O
.	O
      
Prior	O
administration	O
of	O
succinylcholine	B-Drug
can	O
potentiate	O
the	O
neuromuscular	O
blocking	O
effects	O
of	O
nondepolarizing	B-Group
agents	I-Group
.	O
      
Methadone	B-Drug
dose	O
was	O
increased	O
by	O
a	O
mean	O
of	O
9	O
%	O
to	O
alleviate	O
withdrawal	O
symptoms	O
.	O
      
Catecholamine	O
-	O
depleting	O
drugs	O
(	O
e.g.	O
reserpine	B-Drug
)	O
may	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
beta	B-Group
-	O
blocking	I-Group
agents	I-Group
.	O
      
Hypoglycemics	B-Group
      
Sulindac	B-Drug
:	O
The	O
concomitant	O
administration	O
of	O
diflunisal	B-Drug
and	O
sulindac	B-Drug
in	O
normal	O
volunteers	O
resulted	O
in	O
lowering	O
of	O
the	O
plasma	O
levels	O
of	O
the	O
active	O
sulindac	O
sulfide	O
metabolite	O
by	O
approximately	O
one	O
-	O
third	O
.	O
      
No	O
interaction	O
trials	O
have	O
been	O
conducted	O
with	O
MEPRON	B-Brand
and	O
rifabutin	B-Drug
.	O
      
Clofibric	B-Drug_n
acid	I-Drug_n
:	O
Combination	O
hormonal	B-Group
contraceptives	I-Group
may	O
increase	O
the	O
clearance	O
of	O
clofibric	B-Drug_n
acid	I-Drug_n
.	O
      
Cyclosporine	B-Drug
-	O
L	B-Drug
-	O
arginine	I-Drug
may	O
counteract	O
the	O
antinaturetic	O
effect	O
of	O
cyclosporin	B-Drug
.	O
      
Coadministration	O
with	O
valdecoxib	B-Drug
increased	O
exposure	O
of	O
omeprazole	B-Drug
(	O
AUC	O
)	O
by	O
9	O
%	O
.	O
      
Therefore	O
if	O
concomitant	O
use	O
of	O
such	O
agents	O
is	O
indicated	O
they	O
should	O
be	O
given	O
with	O
caution	O
and	O
the	O
patient	O
's	O
serum	O
potassium	O
should	O
be	O
monitored	O
frequently	O
.	O
      
Discontinuation	O
of	O
cimetidine	B-Drug
in	O
well	O
-	O
controlled	O
patients	O
receiving	O
tricyclic	B-Drug
antidepressants	I-Drug
and	O
cimetidine	B-Drug
may	O
decrease	O
the	O
plasma	O
levels	O
and	O
efficacy	O
of	O
the	O
antidepressants	B-Drug
.	O
      
Patients	O
receiving	O
digoxin	B-Drug
should	O
be	O
monitored	O
appropriately	O
.	O
      
Drug	O
/	O
Laboratory	O
Tests	O
Interactions	O
Hyperaminotransferasemia	O
:	O
Significant	O
elevations	O
of	O
aminotransferase	O
(	O
SGOT	O
[	O
S	O
-	O
AST	O
]	O
and	O
SGPT	O
[	O
S	O
-	O
ALT	O
]	O
)	O
levels	O
have	O
occurred	O
in	O
a	O
high	O
percentage	O
of	O
patients	O
(	O
and	O
healthy	O
subjects	O
)	O
who	O
have	O
received	O
heparin	B-Drug
sodium	I-Drug
.	O
      
Ketoconazole	B-Drug
      
Therapeutic	O
concentrations	O
of	O
digoxin	B-Drug
warfarin	B-Drug
ibuprofen	B-Drug
naproxen	B-Drug
piroxicam	B-Drug
acetaminophen	B-Drug
phenytoin	B-Drug
andtolbutamide	O
did	O
not	O
alter	O
ketorolac	B-Drug
tromethamine	I-Drug
protein	O
binding	O
.	O
      
Ergot	B-Group
-	O
containing	O
drugs	O
have	O
been	O
reported	O
to	O
cause	O
prolonged	O
vasospastic	O
reactions	O
.	O
      
Dosage	O
reduction	O
of	O
Cerubidine	B-Brand
may	O
be	O
required	O
when	O
used	O
concurrently	O
with	O
other	O
myelosuppressive	O
agents	O
.	O
      
Therefore	O
patients	O
receiving	O
probenecid	B-Drug
will	O
have	O
erroneously	O
low	O
ERPF	O
and	O
Tm	O
PAH	B-Drug
values	O
.	O
      
Co	O
-	O
administration	O
of	O
tacrolimus	B-Drug
and	O
bosentan	B-Drug
resulted	O
in	O
markedly	O
increased	O
plasma	O
concentrations	O
of	O
bosentan	B-Drug
in	O
animals	O
.	O
      
The	O
interaction	O
was	O
pharmacodynamic	O
;	O
      
Cromolyn	B-Drug
sodium	I-Drug
alone	O
in	O
doses	O
up	O
to	O
9	O
mg	O
/	O
kg	O
/	O
day	O
(	O
approximately	O
9	O
times	O
the	O
maximum	O
recommended	O
daily	O
inhalation	O
dose	O
in	O
adults	O
on	O
a	O
mg	O
/	O
m9	O
basis	O
)	O
did	O
not	O
cause	O
significant	O
increases	O
in	O
resorptions	O
or	O
major	O
malformations	O
.	O
      
Because	O
their	O
vasospastic	O
effects	O
may	O
be	O
additive	O
coadministration	O
of	O
naratriptan	B-Drug
and	O
other	O
9	B-Group
-	O
HT9	I-Group
agonists	I-Group
within	O
9	O
hours	O
of	O
each	O
other	O
is	O
not	O
recommended	O
.	O
      
Triprolidine	B-Drug
may	O
enhance	O
the	O
sedative	O
effects	O
of	O
central	B-Group
nervous	I-Group
system	I-Group
depressants	I-Group
including	O
alcohol	B-Drug
barbiturates	B-Group
hypnotics	B-Group
narcotic	B-Group
analgesics	I-Group
sedatives	B-Group
and	O
tranquillisers	B-Group
.	O
      
however	O
9	O
-	O
OH	O
metabolite	O
concentrations	O
were	O
increased.Because	O
clarithromycin	B-Drug
active	O
metabolite	O
has	O
reduced	O
activity	O
against	O
Mycobacteriumavium	O
-	O
intracellulare	O
complex	O
overallactivity	O
against	O
this	O
pathogen	O
may	O
bealtered	O
.	O
      
You	O
may	O
require	O
a	O
dosage	O
adjustment	O
or	O
special	O
monitoring	O
if	O
you	O
are	O
taking	O
any	O
of	O
the	O
medicines	O
listed	O
above	O
.	O
      
However	O
because	O
both	O
of	O
these	O
compounds	O
have	O
CNS	O
effects	O
an	O
additive	O
pharmacodynamic	O
effect	O
is	O
possible	O
.	O
      
Sympathomimetic	B-Group
Agents	I-Group
:	O
Possible	O
increased	O
risk	O
of	O
coronary	O
insufficiency	O
in	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O
      
Ethopropazine	B-Drug
may	O
interact	O
with	O
alcohol	B-Drug
or	O
other	O
CNS	B-Group
depressants	I-Group
causing	O
increased	O
sedative	O
effects	O
.	O
      
On	O
day	O
9	O
acetaminophen	B-Drug
(	O
9	O
mg	O
four	O
times	O
daily	O
)	O
was	O
started	O
and	O
continued	O
for	O
9	O
days	O
.	O
      
Metoclopramide	B-Drug
:	O
When	O
coadministered	O
with	O
MONUROL	B-Brand
metoclopramide	B-Drug
a	O
drug	O
which	O
increases	O
gastrointestinal	O
motility	O
lowers	O
the	O
serum	O
concentration	O
and	O
urinary	O
excretion	O
of	O
fosfomycin	B-Drug
.	O
      
as	O
such	O
it	O
may	O
impair	O
intestinal	O
absorption	O
of	O
any	O
of	O
vitamin	B-Group
D	I-Group
.	O
      
This	O
should	O
be	O
considered	O
whenever	O
these	O
agents	O
are	O
prescribed	O
concomitantly	O
.	O
      
ACE	B-Group
Inhibitors	I-Group
and	O
Angiotensin	B-Group
II	I-Group
Receptor	I-Group
Antagonists	I-Group
(	O
Congestive	O
Heart	O
Failure	O
Post	O
-	O
Myocardial	O
Infarction	O
)	O
-	O
In	O
EPHESUS	O
9	O
(	O
9	O
%	O
)	O
patients	O
receiving	O
INSPRA	B-Brand
9	O
to	O
9	O
mg	O
also	O
received	O
ACE	B-Group
inhibitors	I-Group
or	O
angiotensin	B-Group
II	I-Group
receptor	I-Group
antagonists	I-Group
(	O
ACEI	B-Group
/	O
ARB	B-Group
)	O
.	O
      
The	O
mechanism	O
for	O
this	O
interaction	O
is	O
not	O
known	O
.	O
      
If	O
a	O
patient	O
is	O
truly	O
hypothyroid	O
it	O
is	O
likely	O
that	O
a	O
reduction	O
in	O
anticoagulant	B-Group
dosage	O
will	O
be	O
required	O
.	O
      
dosage	O
adjustments	O
may	O
be	O
necessary	O
.	O
)	O
      
No	O
clinically	O
relevant	O
drug	O
-	O
drug	O
interactions	O
have	O
been	O
observed	O
with	O
drugs	O
likely	O
to	O
be	O
co	O
-	O
administered	O
with	O
anidulafungin	B-Drug
.	O
      
Absorption	O
of	O
tetracycline	B-Drug
is	O
impaired	O
by	O
bismuth	B-Drug
subsalicylate	I-Drug
.	O
      
Patients	O
treated	O
with	O
a	O
beta	B-Group
-	O
adrenergic	I-Group
receptor	I-Group
blocking	I-Group
agent	I-Group
plus	O
a	O
catecholamine	O
depletor	O
should	O
therefore	O
be	O
closely	O
observed	O
for	O
evidence	O
of	O
hypotension	O
or	O
marked	O
bradycardia	O
which	O
may	O
produce	O
vertigo	O
syncope	O
or	O
postural	O
hypotension	O
.	O
      
Lopinavir	B-Drug
/	O
ritonavir	B-Drug
      
Cimetidine	B-Drug
:	O
Cimetidine	B-Drug
has	O
been	O
reported	O
to	O
produce	O
clinically	O
significant	O
fluctuations	O
in	O
steady	O
-	O
state	O
serum	O
concentrations	O
of	O
various	O
tricyclic	B-Group
antidepressants	I-Group
.	O
      
An	O
encephalopathic	O
syndrome	O
(	O
characterized	O
by	O
weakness	O
lethargy	O
fever	O
tremulousness	O
and	O
confusion	O
extrapyramidal	O
symptoms	O
leukocytosis	O
elevated	O
serum	O
enzymes	O
BUN	O
and	O
FBS	O
)	O
followed	O
by	O
irreversible	O
brain	O
damage	O
has	O
occurred	O
in	O
a	O
few	O
patients	O
treated	O
with	O
lithium	B-Drug
plus	O
HALDOL	B-Brand
.	O
      
Flurbiprofen	B-Drug
pretreatment	O
attenuated	O
the	O
hypotensive	O
effect	O
of	O
a	O
single	O
dose	O
of	O
propranolol	B-Drug
but	O
not	O
atenolol	B-Drug
.	O
      
Anticoagulants	B-Group
:	O
Coagulation	O
parameters	O
should	O
be	O
tested	O
more	O
frequently	O
and	O
monitored	O
regularly	O
during	O
simultaneous	O
administration	O
of	O
high	O
doses	O
of	O
heparin	B-Drug
oral	O
anticoagulants	B-Group
or	O
other	O
drugs	O
that	O
may	O
affect	O
the	O
blood	O
coagulation	O
system	O
or	O
the	O
thrombocyte	O
function	O
.	O
      
Concomitant	O
administration	O
of	O
naproxen	B-Drug
and	O
aspirin	B-Brand
is	O
not	O
recommended	O
because	O
naproxen	B-Drug
is	O
displaced	O
from	O
its	O
binding	O
sites	O
during	O
the	O
concomitant	O
administration	O
of	O
aspirin	B-Brand
resulting	O
in	O
lower	O
plasma	O
concentrations	O
and	O
peak	O
plasma	O
levels	O
.	O
      
Co	O
-	O
administration	O
of	O
BOTOX	B-Brand
and	O
aminoglycosides	B-Group
or	O
other	O
agents	O
interfering	O
with	O
neuromuscular	O
transmission	O
(	O
e.g.	O
curare	B-Group
-	O
like	I-Group
compounds	I-Group
)	O
should	O
only	O
be	O
performed	O
with	O
caution	O
as	O
the	O
effect	O
of	O
the	O
toxin	B-Drug
may	O
be	O
potentiated	O
.	O
      
Concomitant	O
administration	O
of	O
vancomycin	B-Drug
and	O
anesthetic	B-Group
agents	I-Group
has	O
been	O
associated	O
with	O
erythema	O
and	O
histamine	O
-	O
like	O
flushing	O
and	O
anaphylactoid	O
reactions	O
.	O
      
HIV	B-Group
Antiviral	I-Group
Agents	I-Group
      
To	O
avoid	O
this	O
interaction	O
delavirdine	B-Drug
or	O
indinavir	B-Drug
should	O
be	O
given	O
9	O
hour	O
prior	O
to	O
dosing	O
with	O
VIDEX	B-Brand
.	O
      
Dose	O
adjustment	O
of	O
Zemplar	B-Brand
Capsules	O
may	O
be	O
required	O
and	O
iPTH	O
and	O
serum	O
calcium	O
concentrations	O
should	O
be	O
closely	O
monitored	O
if	O
a	O
patient	O
initiates	O
or	O
discontinues	O
therapy	O
with	O
a	O
strong	O
CYP9A9	O
inhibitor	O
such	O
as	O
ketoconazole	B-Drug
.	O
      
Taking	O
amyl	B-Drug
nitrite	I-Drug
after	O
drinking	O
alcohol	B-Drug
may	O
worsen	O
side	O
effects	O
and	O
may	O
cause	O
severe	O
hypotension	O
and	O
cardiovascular	O
collapse	O
.	O
      
Other	O
Drug	O
Interaction	O
Information	O
Digoxin	B-Drug
:	O
Studies	O
in	O
healthy	O
volunteers	O
have	O
shown	O
that	O
TIKOSYN	B-Brand
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
digoxin	B-Drug
.	O
      
9	O
.	O
      
Serious	O
anticholinergic	O
symptoms	O
(	O
i.e.	O
severe	O
dry	O
mouth	O
urinary	O
retention	O
and	O
blurred	O
vision	O
)	O
have	O
been	O
associated	O
with	O
elevations	O
in	O
the	O
serum	O
levels	O
of	O
tricyclic	B-Group
antidepressant	I-Group
when	O
cimetidine	B-Drug
therapy	O
is	O
initiated	O
.	O
      
Dopamine	B-Group
antagonists	I-Group
:	O
Since	O
pramipexole	B-Drug
is	O
a	O
dopamine	B-Group
agonist	I-Group
it	O
is	O
possible	O
that	O
dopamine	B-Group
antagonists	I-Group
such	O
as	O
the	O
neuroleptics	B-Group
(	O
phenothiazines	B-Group
butyrophenones	B-Group
thioxanthenes	B-Group
)	O
or	O
metoclopramide	B-Group
may	O
diminish	O
the	O
effectiveness	O
of	O
MIRAPEX	B-Brand
.	O
      
In	O
post	O
-	O
marketing	O
experience	O
as	O
with	O
other	O
azole	B-Group
antifungals	I-Group
bleeding	O
events	O
(	O
bruising	O
epistaxis	O
gastrointestinal	O
bleeding	O
hematuria	O
and	O
melena	O
)	O
have	O
been	O
reported	O
in	O
association	O
with	O
increases	O
in	O
prothrombin	O
time	O
in	O
patients	O
receiving	O
fluconazole	B-Drug
concurrently	O
with	O
warfarin	B-Drug
.	O
      
Drugs	O
Within	O
Class	O
Not	O
To	O
Be	O
Coadministered	O
With	O
SUSTIVA	B-Brand
      
Since	O
acetaminophen	B-Drug
in	O
high	O
doses	O
has	O
been	O
associated	O
with	O
hepatotoxicity	O
concomitant	O
administration	O
of	O
diflunisal	B-Drug
and	O
acetaminophen	B-Drug
should	O
be	O
used	O
cautiously	O
with	O
careful	O
monitoring	O
of	O
patients	O
.	O
      
Administration	O
of	O
WELLBUTRIN	B-Brand
Tablets	O
to	O
patients	O
receiving	O
either	O
levodopa	B-Drug
or	O
amantadine	B-Drug
concurrently	O
should	O
be	O
undertaken	O
with	O
caution	O
using	O
small	O
initial	O
doses	O
and	O
small	O
gradual	O
dose	O
increases	O
.	O
      
There	O
are	O
rare	O
reports	O
however	O
from	O
marketing	O
experiences	O
of	O
changes	O
in	O
effects	O
of	O
insulin	B-Drug
or	O
oral	O
hypoglycemic	B-Group
agents	I-Group
in	O
the	O
presence	O
of	O
diclofenac	B-Drug
that	O
necessitated	O
changes	O
in	O
the	O
doses	O
of	O
such	O
agents	O
.	O
      
Acetazolamide	B-Drug
may	O
increase	O
the	O
effects	O
of	O
other	O
folic	B-Group
acid	I-Group
antagonists	I-Group
.	O
      
Subjects	O
who	O
do	O
not	O
metabolize	O
losartan	B-Drug
to	O
active	O
metabolite	O
have	O
been	O
shown	O
to	O
have	O
a	O
specific	O
rare	O
defect	O
in	O
cytochrome	O
P9	O
9C9	O
.	O
      
Amiodarone	B-Drug
disopyramide	B-Drug
lidocaine	B-Drug
      
HIV	B-Group
Protease	I-Group
Inhibitors	I-Group
:	O
Indinavir	B-Drug
(	O
9	O
mg	O
t.i.d	O
.	O
)	O
co	O
-	O
administered	O
with	O
Vardenafil	B-Drug
9	O
mg	O
resulted	O
in	O
a	O
9	O
-	O
fold	O
increase	O
in	O
vardenafil	B-Drug
AUC	O
a	O
9	O
-	O
fold	O
increase	O
in	O
vardenafil	B-Drug
Cmax	O
and	O
a	O
9	O
-	O
fold	O
increase	O
in	O
vardenafil	B-Drug
half	O
-	O
life	O
.	O
      
Rifampin	B-Drug
:	O
When	O
a	O
single	O
9	O
-	O
mg	O
dose	O
of	O
Aprepitant	B-Drug
was	O
administered	O
on	O
Day9	O
of	O
a	O
9	O
-	O
day	O
regimen	O
of	O
9	O
mg	O
/	O
day	O
of	O
rifampin	B-Drug
a	O
strong	O
CYP9A9	O
inducer	O
the	O
AUC	O
of	O
aprepitant	B-Drug
decreased	O
approximately	O
9	O
-	O
fold	O
and	O
the	O
mean	O
terminal	O
half	O
-	O
life	O
decreased	O
approximately	O
9	O
-	O
fold	O
.	O
      
Dextromethorphan	B-Drug
is	O
a	O
substrate	O
for	O
both	O
CYP9D9	B-Drug
and	O
CYP9A9	B-Drug
.	O
      
No	O
formal	O
assessments	O
of	O
pharmacokinetic	O
drug	O
-	O
drug	O
interactions	O
between	O
TRISENOX	B-Brand
and	O
other	O
agents	O
have	O
been	O
conducted	O
.	O
      
therefore	O
plasma	O
concentrations	O
of	O
phenytoin	B-Drug
should	O
also	O
be	O
monitored	O
when	O
it	O
is	O
given	O
concurrently	O
with	O
Itraconazole	B-Drug
.	O
      
Anticonvulsants	B-Group
:	O
carbamazepine	B-Drug
phenobarbital	B-Drug
phenytoin	B-Drug
      
Dosing	O
recommendations	O
for	O
SUSTIVA	B-Brand
and	O
atazanavir	B-Drug
in	O
treatment	O
-	O
experienced	O
patients	O
have	O
not	O
been	O
established	O
.	O
      
Drugs	O
Metabolized	O
by	O
Catechol	O
-	O
O	O
-	O
methyltransferase	O
(	O
COMT	O
)	O
:	O
Hormone	O
levels	O
:	O
Levodopa	B-Drug
is	O
known	O
to	O
depress	O
prolactin	O
secretion	O
and	O
increase	O
growth	O
hormone	O
levels	O
.	O
      
The	O
antihypertensive	O
effects	O
of	O
methyldopa	B-Drug
mecamylamine	B-Drug
reserpine	B-Drug
and	O
veratrum	B-Drug
alkaloids	I-Drug
may	O
be	O
reduced	O
by	O
sympathomimetics	B-Group
.	O
      
Sorafenib	B-Drug
inhibits	O
CYP9B9	O
and	O
CYP9C9	O
in	O
vitro	O
with	O
Ki	O
values	O
of	O
9	O
and	O
9	O
-	O
9	O
?	O
M	O
respectively	O
.	O
      
In	O
vitro	O
studies	O
of	O
human	O
CYP	O
enzymes	O
showed	O
that	O
entacapone	B-Drug
inhibited	O
the	O
CYP	O
enzymes	O
9A9	O
9A9	O
9C9	O
9C9	O
9D9	O
9E9	O
and	O
9A	O
only	O
at	O
very	O
high	O
concentrations	O
(	O
IC9	O
from	O
9	O
to	O
over	O
9	O
uM	O
;	O
      
Drug	O
Class	O
Examples	O
of	O
Drugs	O
      
The	O
safety	O
of	O
using	O
STADOL	B-Brand
NS	I-Brand
and	O
IMITREX	B-Brand
(	O
sumatriptan	B-Drug
)	O
Nasal	O
Spray	O
during	O
the	O
same	O
episode	O
of	O
migraine	O
has	O
not	O
been	O
established	O
.	O
      
increased	O
thyroid	O
binding	O
globulin	O
(	O
TBG	O
)	O
leading	O
to	O
increased	O
circulating	O
total	O
thyroid	O
hormone	O
as	O
measured	O
by	O
PBI	O
T9	O
by	O
column	O
or	O
T9	O
by	O
radioimmunoassay	O
.	O
      
Skeletal	B-Group
muscle	I-Group
relaxants	I-Group
nondepolarizing	O
(	O
e.g.	O
tubocurarine	B-Drug
)	O
:	O
possible	O
increased	O
responsiveness	O
to	O
the	O
muscle	B-Group
relaxant	I-Group
.	O
      
-	O
Increased	O
prothrombin	O
and	O
factors	O
VII	O
VIII	O
IX	O
and	O
X	O
;	O
      
9	B-Group
-	O
HT9	I-Group
antagonists	I-Group
:	O
In	O
clinical	O
drug	O
interaction	O
studies	O
aprepitant	B-Drug
did	O
not	O
have	O
clinically	O
important	O
effects	O
on	O
the	O
pharmacokinetics	O
of	O
ondansetron	B-Drug
or	O
granisetron	B-Drug
.	O
      
Caution	O
is	O
recommended	O
in	O
patients	O
with	O
hepatic	O
impairment	O
.	O
      
Such	O
patients	O
may	O
be	O
unresponsive	O
to	O
the	O
usual	O
doses	O
of	O
epinephrine	B-Drug
used	O
to	O
treat	O
allergic	O
reaction	O
.	O
      
Phenytoin	B-Drug
is	O
metabolized	O
by	O
hepatic	O
cytochrome	O
P9	O
enzymes	O
and	O
is	O
particularly	O
susceptible	O
to	O
inhibitory	O
drug	O
interactions	O
because	O
it	O
is	O
subject	O
to	O
saturable	O
metabolism	O
.	O
      
positive	O
antinuclear	O
      
Alcohol	B-Drug
:	O
It	O
should	O
be	O
borne	O
in	O
mind	O
that	O
alcohol	B-Drug
ingestion	O
may	O
increase	O
the	O
danger	O
inherent	O
in	O
any	O
intentional	O
or	O
unintentional	O
SINEQUAN	B-Brand
overdosage	O
.	O
      
Antimycobacterial	B-Group
Agents	I-Group
:	O
rifampin	B-Drug
CONTRAINDICATED	O
since	O
the	O
coadministration	O
of	O
this	O
product	O
with	O
saquinavir	B-Drug
in	O
an	O
antiretroviral	B-Group
regimen	O
reduces	O
the	O
plasma	O
concentrations	O
of	O
saquinavir	B-Drug
.	O
      
Colchicine	B-Drug
para	B-Drug
-	O
aminosalicylic	I-Drug
acid	I-Drug
and	O
heavy	O
alcohol	B-Drug
intake	O
for	O
longer	O
than	O
9	O
weeks	O
may	O
produce	O
malabsorption	O
of	O
vitamin	B-Drug
B9	I-Drug
.	O
      
Quinolones	B-Group
have	O
been	O
shown	O
to	O
interfere	O
with	O
the	O
metabolism	O
of	O
caffeine	B-Drug
.	O
      
Some	O
quinolones	B-Group
including	O
ciprofloxacin	B-Drug
have	O
also	O
been	O
shown	O
to	O
interfere	O
with	O
the	O
metabolism	O
of	O
caffeine	B-Drug
.	O
      
The	O
incidence	O
of	O
hypertriglyceridemia	O
is	O
9	O
patient	O
in	O
9	O
on	O
Accutane	B-Brand
therapy	O
      
The	O
interaction	O
was	O
pharmacodynamic	O
with	O
no	O
alteration	O
of	O
the	O
pharmacokinetics	O
of	O
either	O
drug	O
.	O
      
Other	O
strong	O
selective	O
CYP9A9	O
inhibitors	O
such	O
as	O
ketoconazole	B-Drug
can	O
also	O
be	O
expected	O
to	O
increase	O
the	O
exposure	O
of	O
zaleplon	B-Drug
.	O
      
Dose	O
adjustments	O
of	O
either	O
class	O
of	O
agents	O
may	O
be	O
necessary	O
.	O
      
Butyrophenones	B-Group
(	O
such	O
as	O
haloperidol	B-Drug
)	O
and	O
phenothiazines	B-Group
can	O
suppress	O
the	O
dopaminergic	O
renal	O
and	O
mesenteric	O
vasodilation	O
induced	O
with	O
low	O
dose	O
dopamine	B-Drug
infusion	O
.	O
      
therefore	O
ZETIA	B-Brand
should	O
not	O
be	O
used	O
in	O
nursing	O
mothers	O
unless	O
the	O
potential	O
benefit	O
justifies	O
the	O
potential	O
risk	O
to	O
the	O
infant	O
.	O
      
These	O
precautions	O
probably	O
should	O
apply	O
to	O
digitoxin	B-Drug
administration	O
as	O
well	O
.	O
      
Monitoring	O
for	O
amiodarone	B-Drug
toxicity	O
and	O
serial	O
measurement	O
of	O
amiodarone	B-Drug
serum	O
concentration	O
during	O
concomitant	O
protease	B-Group
inhibitor	I-Group
therapy	O
should	O
be	O
considered	O
.	O
      
Salicylates	B-Group
may	O
enhance	O
the	O
hypoglycemic	O
effect	O
of	O
oral	O
antidiabetic	B-Group
drugs	I-Group
of	O
the	O
sulfonylurea	O
class	O
.	O
      
Lithium	B-Drug
:	O
Inhibition	O
of	O
renal	O
lithium	B-Drug
clearance	O
leading	O
to	O
an	O
increase	O
in	O
plasma	O
lithium	B-Drug
concentration	O
has	O
been	O
reported	O
with	O
some	O
prostaglandin	O
synthesis	O
-	O
inhibiting	O
drugs	O
.	O
      
In	O
another	O
study	O
TORADOLIV	O
/	O
IM	O
was	O
given	O
with	O
two	O
doses	O
of	O
9	O
U	O
of	O
heparin	B-Drug
to	O
9	O
healthy	O
volunteers	O
resulting	O
in	O
a	O
mean	O
template	O
bleeding	O
time	O
of	O
9	O
minutes	O
(	O
9	O
to	O
9	O
min	O
)	O
compared	O
to	O
a	O
mean	O
of	O
9	O
minutes	O
(	O
9	O
to	O
9	O
min	O
)	O
for	O
heparin	B-Drug
alone	O
and	O
9	O
minutes	O
(	O
9	O
to	O
9	O
min	O
)	O
for	O
placebo	O
.	O
      
Drugs	O
That	O
Should	O
Not	O
Be	O
Coadministered	O
with	O
CRIXIVAN	B-Brand
      
Appropriate	O
dosage	O
adjustments	O
may	O
be	O
necessary	O
.	O
      
Absorption	O
of	O
drugs	O
from	O
the	O
stomach	O
may	O
be	O
diminished	O
(	O
e.g.	O
digoxin	B-Drug
)	O
by	O
metoclopramide	B-Drug
whereas	O
the	O
rate	O
and	O
/	O
or	O
extent	O
of	O
absorption	O
of	O
drugs	O
from	O
the	O
small	O
bowel	O
may	O
be	O
increased	O
(	O
e.g.	O
acetaminophen	B-Drug
tetracycline	B-Drug
levodopa	B-Drug
ethanol	B-Drug
cyclosporine	B-Drug
)	O
.	O
      
Thus	O
strong	O
inhibitors	O
of	O
cytochrome	O
P9A9	O
such	O
as	O
fluvoxamine	B-Drug
given	O
concomitantly	O
during	O
administration	O
of	O
Ropivacaine	B-Drug
can	O
interact	O
with	O
Ropivacaine	B-Drug
leading	O
to	O
increased	O
ropivacaine	B-Drug
plasma	O
levels	O
.	O
      
However	O
coadministration	O
of	O
escitalopram	B-Drug
(	O
9	O
mg	O
)	O
and	O
ritonavir	B-Drug
(	O
9	O
mg	O
)	O
a	O
potent	O
inhibitor	O
of	O
CYP9A9	O
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
escitalopram	B-Drug
.	O
      
This	O
might	O
increase	O
the	O
risk	O
of	O
methotrexate	B-Drug
toxic	O
reactions	O
.	O
      
Registered	O
trademark	O
of	O
Ames	O
Company	O
Division	O
of	O
Miles	O
Laboratories	O
Inc	O
.	O
      
Caution	O
is	O
advised	O
for	O
patients	O
receiving	O
high	O
-	O
dose	O
aspirin	B-Brand
and	O
methazolamide	B-Drug
concomitantly	O
as	O
anorexia	O
tachypnea	O
lethargy	O
coma	O
and	O
death	O
have	O
been	O
reported	O
with	O
concomitant	O
use	O
of	O
high	O
-	O
dose	O
aspirin	B-Brand
and	O
carbonic	B-Group
anhydrase	I-Group
inhibitors	I-Group
.	O
      
The	O
first	O
test	O
is	O
obtained	O
by	O
the	O
prescriber	O
when	O
the	O
decision	O
is	O
made	O
to	O
pursue	O
qualification	O
of	O
the	O
patient	O
for	O
Accutane	B-Brand
(	O
a	O
screening	O
test	O
)	O
.	O
      
Concomitant	O
medications	O
should	O
be	O
carefully	O
assessed	O
.	O
      
No	O
drug	O
interactions	O
have	O
been	O
observed	O
with	O
the	O
Vitrasert	B-Brand
Implant	O
.	O
      
Other	O
:	O
Coadministration	O
of	O
grapefruit	O
juice	O
with	O
cisapride	B-Drug
increases	O
the	O
bioavailability	O
of	O
cisapride	B-Drug
and	O
concomitant	O
use	O
should	O
be	O
avoided	O
.	O
      
Succinylcholine	B-Drug
may	O
cause	O
a	O
sudden	O
extrusion	O
of	O
potassium	O
from	O
muscle	O
cells	O
and	O
may	O
thereby	O
cause	O
arrhythmias	O
in	O
digitalized	O
patients	O
.	O
      
In	O
these	O
cases	O
your	O
doctor	O
may	O
want	O
to	O
change	O
the	O
dose	O
or	O
other	O
precautions	O
may	O
be	O
necessary	O
.	O
      
Interference	O
with	O
the	O
absorption	O
of	O
oral	O
phosphate	B-Drug_n
supplements	O
has	O
been	O
observed	O
with	O
another	O
positively	O
-	O
charged	O
bile	O
acid	O
sequestrant	O
.	O
      
No	O
interactions	O
were	O
observed	O
.	O
      
Doxorubicin	B-Drug
:	O
Doxorubicin	B-Drug
caused	O
a	O
decrease	O
in	O
zalcitabine	B-Drug
phosphorylation	O
(	O
9	O
%	O
inhibition	O
of	O
total	O
phosphate	O
formation	O
)	O
in	O
U9	O
/	O
Molt	O
9	O
cells	O
.	O
      
Beta	O
-	O
Blocking	O
Agents	O
A	O
pharmacokinetic	O
study	O
of	O
felodipine	B-Drug
in	O
conjunction	O
with	O
metoprolol	B-Drug
demonstrated	O
no	O
significant	O
effects	O
on	O
the	O
pharmacokinetics	O
of	O
felodipine	B-Drug
.	O
      
See	O
also	O
CLINICAL	O
PHARMACOLOGY	O
Drug	O
-	O
Drug	O
Interactions	O
      
Ascorbic	B-Drug
acid	I-Drug
:	O
Doses	O
of	O
ascorbic	B-Drug
acid	I-Drug
(	O
vitamin	B-Drug
C	I-Drug
)	O
9	O
g	O
/	O
day	O
have	O
been	O
reported	O
to	O
increase	O
plasma	O
concentration	O
of	O
synthetic	B-Group
estrogens	I-Group
by	O
~9	O
%	O
possibly	O
by	O
inhibiting	O
conjugation	O
;	O
      
.	O
      
Carbamazepine	B-Drug
has	O
been	O
reported	O
to	O
increase	O
the	O
degree	O
of	O
heart	O
block	O
produced	O
by	O
other	O
agents	O
.	O
      
Therefore	O
monitoring	O
of	O
plasma	O
digoxin	B-Drug
levels	O
may	O
be	O
indicated	O
in	O
patients	O
receiving	O
similar	O
combination	O
chemotherapy	O
regimens	O
.	O
      
Symptoms	O
usually	O
resolve	O
over	O
days	O
when	O
the	O
combination	O
is	O
discontinued	O
.	O
      
The	O
extent	O
of	O
interaction	O
depends	O
on	O
the	O
variability	O
of	O
effect	O
on	O
CYP9D9	O
.	O
      
Dopamine	B-Group
D9	I-Group
receptor	I-Group
antagonists	I-Group
(	O
e.g.	O
phenothiazines	B-Group
butyrophenones	B-Group
risperidone	B-Drug
)	O
and	O
isoniazid	B-Drug
may	O
reduce	O
the	O
therapeutic	O
effects	O
of	O
levodopa	B-Drug
.	O
      
In	O
in	O
vivo	O
studies	O
9	O
-	O
to	O
9	O
-	O
mg	O
/	O
day	O
doses	O
of	O
aripiprazole	B-Drug
had	O
no	O
significant	O
effect	O
on	O
metabolism	O
by	O
CYP9D9	O
(	O
dextromethorphan	B-Drug
)	O
CYP9C9	O
(	O
warfarin	B-Drug
)	O
CYP9C9	O
(	O
omeprazole	B-Drug
warfarin	B-Drug
)	O
and	O
CYP9A9	O
(	O
dextromethorphan	B-Drug
)	O
substrates	O
.	O
      
The	O
clinical	O
significance	O
of	O
these	O
findings	O
has	O
not	O
been	O
established	O
.	O
      
Tolbutamides	B-Drug
conversion	O
to	O
inactive	O
metabolites	O
has	O
been	O
shown	O
to	O
be	O
catalyzed	O
by	O
xanthine	O
oxidase	O
from	O
rat	O
liver	O
.	O
      
Aripiprazole	B-Drug
dose	O
should	O
be	O
reduced	O
to	O
one	O
-	O
half	O
of	O
its	O
normal	O
dose	O
when	O
concomitant	O
administration	O
of	O
quinidine	B-Drug
with	O
aripiprazole	B-Drug
occurs	O
.	O
      
Itraconazole	B-Drug
      
A	O
single	O
dose	O
of	O
liquid	O
antacid	B-Group
did	O
not	O
affect	O
the	O
C	O
max	O
or	O
AUC	O
of	O
ceftibuten	B-Drug
;	O
      
Lithium	B-Drug
:	O
Nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
agents	I-Group
have	O
been	O
reported	O
to	O
increase	O
steadystate	O
plasma	O
lithium	B-Drug
levels	O
.	O
      
This	O
may	O
be	O
due	O
to	O
an	O
improved	O
glucose	O
utilization	O
with	O
simultaneous	O
reduction	O
in	O
insulin	B-Drug
requirement	O
      
Probenecid	B-Drug
given	O
concurrently	O
increases	O
naproxen	B-Drug
anion	O
plasma	O
levels	O
and	O
extends	O
its	O
plasma	O
half	O
-	O
life	O
significantly	O
.	O
      
Herbal	O
products	O
:	O
St.	O
John	O
wort	O
(	O
Hypericum	O
perforatum	O
)	O
      
A	O
controlled	O
study	O
found	O
that	O
concomitant	O
fluconazole	B-Drug
9	O
mg	O
once	O
daily	O
and	O
cisapride	B-Drug
9	O
mg	O
four	O
times	O
a	O
day	O
yielded	O
a	O
significant	O
increase	O
in	O
cisapride	B-Drug
plasma	O
levels	O
and	O
prolongation	O
of	O
QTc	O
interval	O
.	O
      
Fluconazole	B-Drug
:	O
Concomitant	O
administration	O
of	O
fluconazole	B-Drug
at	O
9	O
mg	O
QD	O
resulted	O
in	O
a	O
two	O
-	O
fold	O
increase	O
in	O
celecoxib	B-Drug
plasma	O
concentration	O
.	O
      
Lithium	B-Drug
:	O
NSAIDs	B-Group
have	O
produced	O
an	O
elevation	O
of	O
plasma	O
lithium	B-Drug
levels	O
and	O
a	O
reduction	O
in	O
renal	O
lithium	B-Drug
clearance	O
.	O
      
The	O
concomitant	O
use	O
of	O
INDOCIN	B-Brand
with	O
other	O
NSAIDs	B-Group
is	O
not	O
recommended	O
due	O
to	O
the	O
increased	O
possibility	O
of	O
gastrointestinal	O
toxicity	O
with	O
little	O
or	O
no	O
increase	O
in	O
efficacy	O
.	O
      
NSAIDs	B-Group
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
taking	O
cyclosporine	B-Drug
and	O
renal	O
function	O
should	O
be	O
carefully	O
monitored	O
.	O
      
.	O
      
However	O
the	O
peak	O
plasma	O
level	O
of	O
metformin	B-Drug
was	O
reduced	O
by	O
approximately	O
9	O
%	O
when	O
taking	O
Acarbose	B-Drug
due	O
to	O
a	O
slight	O
delay	O
in	O
the	O
absorption	O
of	O
metformin	B-Drug
.	O
      
hepatotoxic	O
drugs	O
;	O
      
Influenza	O
vaccination	O
may	O
be	O
of	O
value	O
.	O
      
Presence	O
of	O
unchanged	O
terfenadine	B-Drug
is	O
associated	O
with	O
statistically	O
significant	O
prolongation	O
of	O
the	O
QT	O
and	O
QTc	O
intervals	O
.	O
      
therefore	O
nelfinavir	B-Drug
should	O
be	O
administered	O
(	O
with	O
food	O
)	O
one	O
hour	O
after	O
or	O
more	O
than	O
two	O
hours	O
before	O
didanosine	B-Drug
.	O
      
use	O
caution	O
.	O
      
increased	O
bilirubin	O
      
Reduced	O
efficacy	O
and	O
increased	O
incidence	O
of	O
breakthrough	O
bleeding	O
and	O
menstrual	O
irregularities	O
have	O
been	O
associated	O
with	O
concomitant	O
use	O
of	O
rifampin	B-Drug
.	O
      
Urinary	O
Alkalinizers	O
:	O
Decrease	O
aspirin	B-Brand
effectiveness	O
by	O
increasing	O
the	O
rate	O
of	O
salicylate	B-Group
renal	O
excretion	O
.	O
      
Valproate	B-Drug
:	O
The	O
addition	O
of	O
tiagabine	B-Drug
to	O
patients	O
taking	O
valproate	B-Drug
chronically	O
had	O
no	O
effect	O
on	O
tiagabine	B-Drug
pharmacokinetics	O
but	O
valproate	B-Drug
significantly	O
decreased	O
tiagabine	B-Drug
binding	O
in	O
vitro	O
from	O
9	O
to	O
9	O
%	O
which	O
resulted	O
in	O
an	O
increase	O
of	O
approximately	O
9	O
%	O
in	O
the	O
free	O
tiagabine	O
concentration	O
.	O
      
Vasospastic	O
reactions	O
have	O
been	O
reported	O
with	O
therapeutic	O
doses	O
of	O
ergotamine	B-Drug
-	O
containing	O
drugs	O
when	O
co	O
-	O
administered	O
with	O
these	O
antibiotics	B-Group
.	O
      
Nevertheless	O
caution	O
should	O
be	O
used	O
in	O
patients	O
receiving	O
concomitant	O
treatment	O
with	O
other	O
drugs	O
that	O
are	O
either	O
inhibitors	O
or	O
inducers	O
of	O
these	O
enzymes	O
.	O
      
Tacrolimus	B-Drug
:	O
There	O
have	O
been	O
reports	O
of	O
nephrotoxicity	O
in	O
patients	O
to	O
whom	O
fluconazole	B-Drug
and	O
tacrolimus	B-Drug
were	O
coadministered	O
.	O
      
Concurrent	O
use	O
of	O
DEMSER	B-Brand
with	O
alcohol	B-Drug
or	O
other	O
CNS	B-Drug
depressants	I-Drug
can	O
increase	O
their	O
sedative	O
effects	O
.	O
      
Patients	O
should	O
be	O
advised	O
against	O
the	O
simultaneous	O
use	O
of	O
other	O
CNS	B-Group
depressant	I-Group
drugs	I-Group
and	O
cautioned	O
that	O
the	O
effect	O
of	O
alcohol	B-Drug
may	O
be	O
increased	O
.	O
      
As	O
is	O
the	O
case	O
with	O
many	O
medicinal	O
agents	O
propoxyphene	B-Drug
may	O
slow	O
the	O
metabolism	O
of	O
a	O
concomitantly	O
administered	O
drug	O
.	O
      
Cardiovasculars	O
:	O
Cardiac	B-Drug
glycosides	I-Drug
:	O
In	O
patients	O
receiving	O
digoxin	B-Drug
therapy	O
administration	O
of	O
oral	O
amiodarone	B-Drug
regularly	O
results	O
in	O
an	O
increase	O
in	O
serum	O
digoxin	B-Drug
concentration	O
that	O
may	O
reach	O
toxic	O
levels	O
with	O
resultant	O
clinical	O
toxicity	O
.	O
      
It	O
has	O
been	O
reported	O
that	O
sulfamethoxazole	B-Drug
may	O
prolong	O
the	O
prothrombin	O
time	O
in	O
patients	O
who	O
are	O
receiving	O
the	O
anticoagulant	B-Group
warfarin	B-Drug
.	O
      
Therefore	O
the	O
simultaneous	O
administration	O
of	O
these	O
drugs	O
should	O
be	O
avoided	O
.	O
      
Because	O
Anafranil	B-Brand
is	O
highly	O
bound	O
to	O
serum	O
protein	O
the	O
administration	O
of	O
Anafranil	B-Brand
to	O
patients	O
taking	O
other	O
drugs	O
that	O
are	O
highly	O
bound	O
to	O
protein	O
(	O
e.g.	O
warfarin	B-Drug
digoxin	B-Drug
)	O
may	O
cause	O
an	O
increase	O
in	O
plasma	O
concentrations	O
of	O
these	O
drugs	O
potentially	O
resulting	O
in	O
adverse	O
effects	O
.	O
      
adjust	O
salicylate	B-Group
dosage	O
accordingly	O
if	O
effect	O
is	O
altered	O
.	O
      
Venlafaxine	B-Drug
:	O
Coadministration	O
of	O
a	O
single	O
dose	O
of	O
zaleplon	B-Drug
9	O
mg	O
and	O
multiple	O
doses	O
of	O
venlafaxine	B-Drug
ER	O
(	O
extended	O
release	O
)	O
9	O
mg	O
did	O
not	O
result	O
in	O
any	O
significant	O
changes	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
zaleplon	B-Drug
or	O
venlafaxine	B-Drug
.	O
      
However	O
because	O
some	O
quinolones	B-Group
have	O
been	O
reported	O
to	O
enhance	O
the	O
effects	O
of	O
warfarin	B-Drug
or	O
its	O
derivatives	O
prothrombin	O
time	O
or	O
other	O
suitable	O
anticoagulation	O
test	O
should	O
be	O
monitored	O
closely	O
if	O
a	O
quinolone	B-Group
antimicrobial	I-Group
is	O
administered	O
with	O
warfarin	B-Drug
or	O
its	O
derivatives	O
.	O
      
Systemic	O
exposure	O
to	O
substrates	O
of	O
CYP9B9	O
and	O
CYP9C9	O
is	O
expected	O
to	O
increase	O
when	O
co	O
-	O
administered	O
with	O
NEXAVAR	B-Brand
.	O
      
In	O
the	O
absence	O
of	O
data	O
regarding	O
potential	O
interaction	O
between	O
ALIMTA	B-Brand
and	O
NSAIDs	B-Group
with	O
longer	O
half	O
-	O
lives	O
all	O
patients	O
taking	O
these	O
NSAIDs	B-Group
should	O
interrupt	O
dosing	O
for	O
at	O
least	O
9	O
days	O
before	O
the	O
day	O
of	O
and	O
9	O
days	O
following	O
ALIMTA	B-Brand
administration	O
.	O
      
Pindolol	B-Drug
has	O
been	O
shown	O
to	O
increase	O
serum	O
thioridazine	B-Drug
levels	O
when	O
both	O
drugs	O
are	O
co	O
-	O
administered	O
.	O
      
Urinary	B-Drug
acidifying	I-Drug
agents	O
decrease	O
blood	O
levels	O
and	O
increase	O
excretion	O
of	O
amphetamines	B-Group
.	O
      
Selective	B-Group
serotonin	I-Group
reuptake	I-Group
inhibitors	I-Group
(	O
SSRIs	B-Group
)	O
(	O
e.g.	O
fluoxetine	B-Drug
fluvoxamine	B-Drug
paroxetine	B-Drug
sertraline	B-Drug
)	O
have	O
been	O
reported	O
rarely	O
to	O
cause	O
weakness	O
hyperreflexia	O
and	O
incoordination	O
when	O
coadministered	O
with	O
9	B-Group
-	O
HT9	I-Group
agonists	I-Group
.	O
      
In	O
Study	O
9	O
patients	O
with	O
colorectal	O
cancer	O
were	O
given	O
irinotecan	B-Drug
/	O
9	B-Drug
-	O
FU	I-Drug
/	O
leucovorin	B-Drug
(	O
bolus	O
-	O
IFL	O
)	O
with	O
or	O
without	O
AVASTIN	B-Brand
.	O
      
No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
Cyanokit	B-Brand
.	O
      
if	O
necessary	O
amiodarone	B-Drug
can	O
continue	O
to	O
be	O
used	O
after	O
insertion	O
of	O
a	O
pacemaker	O
in	O
patients	O
with	O
severe	O
bradycardia	O
or	O
sinus	O
arrest	O
.	O
      
Co	O
-	O
administration	O
of	O
CYP9A9	O
inhibitors	O
(	O
eg	O
ketoconazole	B-Drug
itraconazole	B-Drug
erythromycin	B-Drug
grapefruit	O
juice	O
cimetidine	B-Drug
)	O
with	O
felodipine	B-Drug
may	O
lead	O
to	O
several	O
-	O
fold	O
increases	O
in	O
the	O
plasma	O
levels	O
of	O
felodipine	B-Drug
either	O
due	O
to	O
an	O
increase	O
in	O
bioavailability	O
or	O
due	O
to	O
a	O
decrease	O
in	O
metabolism	O
.	O
      
Other	O
CNS	B-Group
depressant	I-Group
drugs	I-Group
(	O
e.g	O
.	O
barbiturates	B-Group
tranquilizers	B-Group
opioids	B-Group
and	O
general	O
anesthetics	B-Group
)	O
have	O
additive	O
or	O
potentiating	O
effects	O
with	O
INAPSINE	B-Brand
.	O
      
This	O
can	O
lead	O
to	O
degradation	O
of	O
fibrinogen	O
in	O
blood	O
samples	O
removed	O
for	O
analysis	O
.	O
      
Caution	O
should	O
be	O
exercised	O
when	O
treating	O
patients	O
with	O
either	O
of	O
these	O
drugs	O
or	O
other	O
highly	O
protein	O
-	O
bound	O
drugs	O
and	O
Atromid	B-Brand
-	O
S	I-Brand
.	O
      
A	O
potential	O
interaction	O
between	O
oral	O
miconazole	B-Drug
and	O
oral	O
hypoglycemic	B-Group
agents	I-Group
leading	O
to	O
severe	O
hypoglycemia	O
has	O
been	O
reported	O
.	O
      
Peripheral	O
Neuropathy	O
:	O
Medications	O
known	O
to	O
be	O
associated	O
with	O
peripheral	O
neuropathy	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
thalidomide	B-Drug
.	O
      
Accelerated	O
prothrombin	O
time	O
partial	O
thromboplastin	O
time	O
and	O
platelet	O
aggregation	O
time	O
;	O
      
Ketoconazole	B-Drug
is	O
a	O
known	O
strong	O
inhibitor	O
of	O
CYP9A9	O
.	O
      
EDECRIN	B-Brand
may	O
increase	O
the	O
ototoxic	O
potential	O
of	O
other	O
drugs	O
such	O
as	O
aminoglycoside	B-Group
and	O
some	O
cephalosporin	B-Group
antibiotics	I-Group
.	O
      
Bromocriptine	B-Drug
mesylate	I-Drug
may	O
interact	O
with	O
dopamine	B-Group
antagonists	I-Group
butyrophenones	B-Group
and	O
certain	O
other	O
agents	O
.	O
      
The	O
clinical	O
significance	O
of	O
these	O
effects	O
is	O
presently	O
unknown	O
.	O
      
Because	O
there	O
are	O
no	O
data	O
on	O
the	O
compatibility	O
of	O
NovoLog	B-Brand
and	O
crystalline	O
zinc	B-Drug
insulin	I-Drug
preparations	O
NovoLog	B-Brand
should	O
not	O
be	O
mixed	O
with	O
these	O
preparations	O
.	O
      
At	O
least	O
9	O
weeks	O
should	O
elapse	O
between	O
discontinuation	O
of	O
dexfenfluramine	B-Drug
and	O
initiation	O
of	O
treatment	O
with	O
a	O
MAO	B-Group
inhibitor	I-Group
.	O
      
The	O
same	O
is	O
true	O
for	O
antacids	B-Group
;	O
      
Concomitant	O
use	O
of	O
L	B-Drug
-	O
phenylalanine	I-Drug
and	O
non	B-Group
-	O
selective	I-Group
MAO	I-Group
inhibitors	I-Group
may	O
cause	O
hypertension	O
.	O
      
Deaths	O
from	O
severe	O
enterocolitis	O
diarrhea	O
and	O
dehydration	O
have	O
been	O
reported	O
in	O
elderly	O
patients	O
receiving	O
weekly	O
leucovorin	B-Drug
and	O
fluorouracil	B-Drug
.	O
      
Lithium	B-Drug
:	O
Lithium	B-Drug
toxicity	O
has	O
been	O
reported	O
in	O
patients	O
receiving	O
lithium	B-Drug
concomitantly	O
with	O
drugs	O
which	O
cause	O
elimination	O
of	O
sodium	O
including	O
ACE	B-Group
inhibitors	I-Group
.	O
      
As	O
MHD	B-Drug_n
the	O
predominant	O
plasma	O
substrate	O
is	O
only	O
a	O
weak	O
inducer	O
of	O
UDP	O
-	O
glucuronyl	O
transferase	O
it	O
is	O
unlikely	O
to	O
have	O
an	O
effect	O
on	O
drugs	O
that	O
are	O
mainly	O
eliminated	O
by	O
conjugation	O
through	O
UDP	O
-	O
glucuronyl	O
transferase	O
(	O
e.g.	O
valproic	B-Drug
acid	I-Drug
lamotrigine	B-Drug
)	O
.	O
      
Therefore	O
caution	O
should	O
be	O
exercised	O
when	O
using	O
these	O
drugs	O
together	O
      
Blunting	O
of	O
the	O
antihypertensive	O
effect	O
of	O
beta	B-Group
-	O
adrenoceptor	I-Group
blocking	I-Group
agents	I-Group
by	O
non	B-Group
-	O
steroidal	I-Group
antiinflammatory	I-Group
drugs	I-Group
including	O
INDOCIN	B-Brand
has	O
been	O
reported	O
.	O
      
Oral	O
contraceptives	B-Group
:	O
Aprepitant	B-Drug
when	O
given	O
once	O
daily	O
for	O
9	O
days	O
as	O
a	O
9	O
-	O
mg	O
capsule	O
with	O
an	O
oral	O
contraceptive	B-Group
containing	O
9	O
mcg	O
of	O
ethinyl	B-Drug
estradiol	I-Drug
and	O
9	O
mg	O
of	O
norethindrone	B-Drug
decreased	O
the	O
AUC	O
of	O
ethinyl	B-Drug
estradiol	I-Drug
by	O
9	O
%	O
and	O
decreased	O
the	O
AUC	O
of	O
norethindrone	B-Drug
by	O
9	O
%	O
;	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
:	O
A	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
may	O
occur	O
with	O
copper	O
reduction	O
tests	O
(	O
Benedict	O
or	O
Fehling	O
s	O
solution	O
or	O
with	O
Clinitest	O
tablets	O
)	O
but	O
not	O
with	O
enzyme	O
-	O
based	O
tests	O
for	O
glycosuria	O
.	O
      
CYP9A9	O
inhibitors	O
:	O
May	O
increase	O
the	O
levels	O
/	O
effects	O
of	O
chlorpheniramine	B-Drug
.	O
      
Renal	O
function	O
should	O
be	O
monitored	O
carefully	O
if	O
high	O
doses	O
of	O
aminoglycosides	B-Group
are	O
to	O
be	O
administered	O
with	O
MAXIPIME	B-Brand
because	O
of	O
the	O
increased	O
potential	O
of	O
nephrotoxicity	O
and	O
ototoxicity	O
of	O
aminoglycoside	B-Group
antibiotics	I-Group
.	O
      
Drug	O
Interactions	O
.	O
      
Co	O
-	O
administration	O
of	O
nelfinavir	B-Drug
at	O
steady	O
-	O
state	O
with	O
a	O
single	O
dose	O
of	O
azithromycin	B-Drug
.	O
      
This	O
increase	O
is	O
greatest	O
in	O
the	O
evening	O
.	O
      
Cyclosporin	B-Drug
:	O
Reports	O
indicate	O
that	O
cyclosporine	B-Drug
levels	O
may	O
be	O
increased	O
during	O
concomitant	O
treatment	O
with	O
allopurinol	B-Drug
sodium	I-Drug
for	O
injection	O
.	O
      
In	O
the	O
Duloxetine	B-Drug
clinical	O
trials	O
database	O
three	O
Duloxetine	B-Drug
-	O
treated	O
patients	O
had	O
liver	O
injury	O
as	O
manifested	O
by	O
ALT	O
and	O
total	O
bilirubin	O
elevations	O
with	O
evidence	O
of	O
obstruction	O
.	O
      
Erythromycin	B-Drug
(	O
9	O
mg	O
every	O
9	O
hrs	O
)	O
      
However	O
neither	O
phenobarbital	B-Drug
nor	O
diazepam	B-Drug
appears	O
to	O
affect	O
Dantrium	B-Brand
metabolism	O
.	O
      
If	O
CEFOTAN	B-Brand
and	O
an	O
aminoglycoside	B-Group
are	O
used	O
concomitantly	O
renal	O
function	O
should	O
be	O
carefully	O
monitored	O
because	O
nephrotoxicity	O
may	O
be	O
potentiated	O
.	O
      
Severe	O
hypoglycemia	O
has	O
been	O
reported	O
in	O
patients	O
concomitantly	O
receiving	O
azole	B-Group
antifungal	I-Group
agents	I-Group
and	O
oral	O
hypoglycemic	B-Group
agents	I-Group
.	O
      
Dexbrompheniramine	B-Drug
can	O
interact	O
with	O
alcohol	B-Drug
or	O
other	O
CNS	B-Group
depressants	I-Group
(	O
may	O
potentiate	O
the	O
CNS	O
depressant	O
effects	O
of	O
either	O
these	O
medications	O
or	O
antihistamines	B-Group
)	O
anticholinergics	B-Group
or	O
other	O
medications	O
with	O
anticholinergic	O
activity	O
(	O
anticholinergic	O
effects	O
may	O
be	O
potentiated	O
when	O
these	O
medications	O
are	O
used	O
concurrently	O
with	O
antihistamines	B-Group
)	O
and	O
monoamine	B-Group
oxidase	I-Group
MAO	I-Group
inhibitors	I-Group
(	O
concurrent	O
use	O
with	O
antihistamines	B-Group
may	O
prolong	O
and	O
intensify	O
the	O
anticholinergic	O
and	O
CNS	O
depressant	O
effects	O
of	O
antihistamines	B-Group
)	O
.	O
      
The	O
oral	O
dexamethasone	B-Drug
doses	O
should	O
be	O
reduced	O
by	O
approximately	O
9	O
%	O
when	O
coadministered	O
with	O
Aprepitant	B-Drug
to	O
achieve	O
exposures	O
of	O
dexamethasone	B-Drug
similar	O
to	O
those	O
obtained	O
when	O
it	O
is	O
given	O
without	O
Aprepitant	B-Drug
.	O
      
Patients	O
who	O
begin	O
taking	O
diclofenac	B-Drug
or	O
who	O
increase	O
their	O
diclofenac	B-Drug
dose	O
or	O
any	O
other	O
NSAID	B-Group
while	O
taking	O
digoxin	B-Drug
methotrexate	B-Drug
or	O
cyclosporine	B-Drug
may	O
develop	O
toxicity	O
characteristics	O
for	O
these	O
drugs	O
.	O
      
Talk	O
to	O
your	O
doctor	O
if	O
you	O
are	O
taking	O
certain	O
antibiotics	B-Group
such	O
as	O
erythromycin	B-Drug
clarithromycin	B-Drug
or	O
azithromycin	B-Drug
.	O
      
After	O
consumption	O
of	O
alcohol	B-Drug
at	O
least	O
9	O
hours	O
should	O
elapse	O
before	O
these	O
determinations	O
are	O
made	O
.	O
      
The	O
metabolism	O
of	O
TAXOL	B-Brand
is	O
catalyzed	O
by	O
cytochrome	O
P9	O
isoen	O
-	O
zymes	O
CYP9C9	O
and	O
CYP9A9	O
.	O
      
Nevertheless	O
the	O
possibility	O
of	O
additive	O
negative	O
inotropic	O
effects	O
of	O
beta	B-Group
blockers	I-Group
and	O
flecainide	B-Drug
should	O
be	O
recognized	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Finasteride	B-Drug
had	O
no	O
effect	O
on	O
circulating	O
levels	O
of	O
cortisol	O
thyroid	O
-	O
stimulating	O
hormone	O
or	O
thyroxine	O
nor	O
did	O
it	O
affect	O
the	O
plasma	O
lipid	O
profile	O
(	O
e.g.	O
total	O
cholesterol	O
low	O
-	O
density	O
lipoproteins	O
high	O
-	O
density	O
lipoproteins	O
and	O
triglycerides	O
)	O
or	O
bone	O
mineral	O
density	O
.	O
      
Ibandronate	B-Drug
should	O
be	O
taken	O
at	O
least	O
9	O
minutes	O
before	O
any	O
oral	O
medications	O
containing	O
multivalent	O
cations	O
(	O
including	O
antacids	B-Group
supplements	O
or	O
vitamins	B-Group
)	O
.	O
      
It	O
is	O
important	O
that	O
patients	O
understand	O
how	O
to	O
use	O
FORADIL	B-Brand
(	O
formoterol	B-Drug
fumarate	I-Drug
)	O
capsules	O
with	O
the	O
supplied	O
AerolizerTM	O
inhalation	O
device	O
and	O
how	O
it	O
should	O
be	O
used	O
in	O
relation	O
to	O
other	O
asthma	O
or	O
COPD	O
medications	O
they	O
are	O
taking	O
.	O
      
The	O
extent	O
to	O
which	O
SSRI	B-Group
-	O
TCA	B-Group
interactions	O
may	O
pose	O
clinical	O
problems	O
will	O
depend	O
on	O
the	O
degree	O
of	O
inhibition	O
and	O
the	O
pharmacokinetics	O
of	O
the	O
SSRI	B-Group
involved	O
.	O
      
Therefore	O
as	O
vitamin	B-Group
K	I-Group
absorption	O
may	O
be	O
decreased	O
with	O
XENICAL	B-Brand
patients	O
on	O
chronic	O
stable	O
doses	O
of	O
warfarin	B-Drug
who	O
are	O
prescribed	O
XENICAL	B-Brand
should	O
be	O
monitored	O
closely	O
for	O
changes	O
in	O
coagulation	O
parameters	O
.	O
      
In	O
healthy	O
subjects	O
receiving	O
cimetidine	B-Drug
(	O
9	O
gm	O
daily	O
)	O
for	O
one	O
week	O
plasma	O
flecainide	B-Drug
levels	O
increased	O
by	O
about	O
9	O
%	O
and	O
half	O
-	O
life	O
increased	O
by	O
about	O
9	O
%	O
.	O
      
Therefore	O
co	O
-	O
administration	O
of	O
bupropion	B-Drug
with	O
drugs	O
that	O
are	O
metabolized	O
by	O
CYP9D9	O
isoenzyme	O
including	O
certain	O
antidepressants	B-Group
(	O
e.g.	O
nortriptyline	B-Drug
imipramine	B-Drug
desipramine	B-Drug
paroxetine	B-Drug
fluoxetine	B-Drug
sertraline	B-Drug
)	O
antipsychotics	B-Group
(	O
e.g.	O
haloperidol	B-Drug
risperidone	B-Drug
thioridazine	B-Drug
)	O
beta	B-Group
-	O
blockers	I-Group
(	O
e.g.	O
metoprolol	B-Drug
)	O
and	O
Type	B-Group
9C	I-Group
antiarrhythmics	I-Group
(	O
e.g.	O
propafenone	B-Drug
flecainide	B-Drug
)	O
should	O
be	O
approached	O
with	O
caution	O
and	O
should	O
be	O
initiated	O
at	O
the	O
lower	O
end	O
of	O
the	O
dose	O
range	O
of	O
the	O
concomitant	O
medication	O
.	O
      
Use	O
with	O
caution	O
.	O
      
In	O
a	O
single	O
subject	O
given	O
one	O
dose	O
of	O
ciprofloxacin	B-Drug
9	O
hours	O
after	O
a	O
dose	O
of	O
didanosine	B-Drug
-	O
placebo	O
tablets	O
a	O
greater	O
than	O
9	O
%	O
reduction	O
in	O
the	O
AUC	O
of	O
ciprofloxacin	B-Drug
was	O
observed	O
.	O
      
The	O
concomitant	O
use	O
of	O
H9	B-Group
blockers	I-Group
or	O
proton	B-Group
pump	I-Group
inhibitors	I-Group
with	O
SPRYCEL	B-Brand
is	O
not	O
recommended	O
.	O
      
Aspirin	B-Brand
should	O
be	O
used	O
cautiously	O
in	O
conjunction	O
with	O
corticosteroids	B-Group
in	O
hypoprothrombinemia	O
.	O
      
However	O
caution	O
should	O
be	O
used	O
when	O
administering	O
CELEBREX	B-Brand
with	O
warfarin	B-Drug
since	O
these	O
patients	O
are	O
at	O
increased	O
risk	O
of	O
bleeding	O
complications	O
.	O
      
Diltiazem	B-Drug
:	O
In	O
patients	O
with	O
mild	O
to	O
moderate	O
hypertension	O
administration	O
of	O
aprepitant	B-Drug
once	O
daily	O
as	O
a	O
tablet	O
formulation	O
comparable	O
to	O
9	O
mg	O
of	O
the	O
capsule	O
formulation	O
with	O
diltiazem	B-Drug
9	O
mg	O
9	O
times	O
daily	O
for	O
9	O
days	O
resulted	O
in	O
a	O
9	O
-	O
fold	O
increase	O
of	O
aprepitant	B-Drug
AUC	O
and	O
a	O
simultaneous	O
9	O
-	O
fold	O
increase	O
of	O
diltiazem	B-Drug
AUC	O
.	O
      
Ketoconazole	B-Drug
did	O
not	O
affect	O
the	O
conversion	O
of	O
losartan	B-Drug
to	O
the	O
active	O
metabolite	O
after	O
intravenous	O
administration	O
of	O
losartan	B-Drug
and	O
erythromycin	B-Drug
had	O
no	O
clinically	O
significant	O
effect	O
after	O
oral	O
administration	O
.	O
      
cimetidine	B-Drug
)	O
and	O
many	O
that	O
are	O
substrates	O
for	O
P9	O
9D9	O
(	O
many	O
other	O
antidepressants	B-Group
phenothiazines	B-Group
and	O
the	O
Type	B-Group
9C	I-Group
antiarrhythmics	I-Group
propafenone	B-Drug
and	O
flecainide	B-Drug
)	O
.	O
      
In	O
vitro	O
testing	O
found	O
no	O
protein	O
binding	O
drug	O
interaction	O
between	O
digoxin	B-Drug
and	O
meloxicam	B-Drug
.	O
      
Caution	O
is	O
advised	O
when	O
VERSED	B-Brand
Syrup	I-Brand
is	O
used	O
concomitantly	O
with	O
these	O
drugs	O
.	O
      
Delayed	O
Adverse	O
Reactions	O
to	O
Iodinated	B-Group
Contrast	I-Group
Media	I-Group
:	O
A	O
review	O
of	O
the	O
literature	O
revealed	O
that	O
9	O
%	O
(	O
range	O
9	O
-	O
9	O
%	O
)	O
of	O
9	O
patients	O
treated	O
with	O
various	O
interleukin	B-Drug
-	O
9	I-Drug
containing	O
regimens	O
who	O
were	O
subsequently	O
administered	O
radiographic	B-Group
iodinated	I-Group
contrast	I-Group
media	I-Group
experienced	O
acute	O
atypical	O
adverse	O
reactions	O
.	O
      
Concomitant	O
administration	O
of	O
nephrotoxic	O
drugs	O
could	O
result	O
in	O
delayed	O
clearance	O
of	O
ALIMTA	B-Brand
.	O
      
Amiodarone	B-Drug
or	O
Verapamil	B-Drug
:	O
The	O
risk	O
of	O
myopathy	O
/	O
rhabdomyolysis	O
is	O
increased	O
when	O
either	O
amiodarone	B-Drug
or	O
verapamil	B-Drug
is	O
used	O
concomitantly	O
with	O
a	O
closely	O
related	O
member	O
of	O
the	O
HMG	B-Group
-	O
CoA	I-Group
reductase	I-Group
inhibitor	I-Group
class	I-Group
(	O
see	O
WARNINGS	O
Myopathy	O
/	O
Rhabdomyolysis	O
)	O
.	O
      
Following	O
oral	O
administration	O
of	O
two	O
9	O
-	O
mg	O
sustained	O
-	O
release	O
tablets	O
with	O
and	O
without	O
9	O
mg	O
of	O
cimetidine	B-Drug
the	O
pharmacokinetics	O
of	O
bupropion	B-Drug
and	O
hydroxybupropion	B-Drug_n
were	O
unaffected	O
.	O
      
diuretics	B-Group
*	O
;	O
      
Caution	O
should	O
be	O
exercised	O
when	O
the	O
following	O
drugs	O
are	O
administered	O
concomitantly	O
with	O
LODOSYN	B-Brand
(	O
Carbidopa	B-Drug
)	O
given	O
with	O
levodopa	B-Drug
or	O
carbidopa	B-Drug
-	O
levodopa	B-Drug
combination	O
products	O
.	O
      
Other	O
Potentially	O
Important	O
Drug	O
Interactions	O
:	O
Benzodiazepines	B-Group
:	O
Benzodiazepines	B-Group
metabolized	O
by	O
hepatic	O
oxidation	O
(	O
e.g.	O
alprazolam	B-Drug
midazolam	B-Drug
triazolam	B-Drug
elc	O
.	O
)	O
should	O
be	O
used	O
with	O
caution	O
because	O
the	O
clearance	O
of	O
these	O
drugs	O
is	O
likely	O
to	O
be	O
reduced	O
by	O
fluvoxamine	B-Drug
.	O
      
Other	O
eye	O
drops	O
or	O
medications	O
such	O
as	O
acetylcholine	B-Drug
chloride	I-Drug
(	O
Miochol	B-Brand
)	O
and	O
carbachol	B-Drug
(	O
Carboptic	B-Brand
Isopto	B-Brand
Carbachol	I-Brand
)	O
may	O
decrease	O
the	O
effects	O
of	O
suprofen	B-Drug
ophthalmic	O
.	O
      
*	O
This	O
table	O
is	O
not	O
all	O
inclusive	O
**	O
VIRACEPT	B-Brand
may	O
not	O
be	O
effective	O
due	O
to	O
decreased	O
nelfinavir	B-Drug
plasma	O
concentrations	O
in	O
patients	O
taking	O
these	O
agents	O
concomitantly	O
      
Observe	O
the	O
patient	O
for	O
possible	O
diminished	O
effect	O
of	O
steroid	B-Group
and	O
increase	O
the	O
steroid	B-Group
dosage	O
accordingly	O
.	O
      
In	O
single	O
and	O
multiple	O
dose	O
studies	O
in	O
healthy	O
subjects	O
receiving	O
both	O
warfarin	B-Drug
and	O
rofecoxib	B-Drug
prothrombin	O
time	O
(	O
measured	O
as	O
INR	O
)	O
was	O
increased	O
by	O
approximately	O
9	O
%	O
to	O
9	O
%	O
.	O
      
Use	O
with	O
Other	O
Central	B-Group
Nervous	I-Group
System	I-Group
Depressants	I-Group
:	O
The	O
depressant	O
effects	O
of	O
morphine	B-Drug
are	O
potentiated	O
by	O
the	O
presence	O
of	O
other	O
CNS	B-Group
depressants	I-Group
such	O
as	O
alcohol	B-Drug
sedatives	B-Group
antihistaminics	B-Group
or	O
psychotropic	B-Group
drugs	I-Group
.	O
      
ranitidine	B-Drug
*	O
;	O
      
No	O
formal	O
drug	O
interaction	O
studies	O
with	O
anti	B-Group
-	O
neoplastic	I-Group
agents	I-Group
have	O
been	O
conducted	O
.	O
      
No	O
dose	O
adjustment	O
is	O
necessary	O
when	O
Simulect	B-Brand
is	O
added	O
to	O
triple	O
-	O
immunosuppression	O
regimens	O
including	O
cyclosporine	B-Drug
corticosteroids	B-Group
and	O
either	O
azathioprine	B-Drug
or	O
mycophenolate	B-Drug
mofetil	I-Drug
.	O
      
Administration	O
of	O
thiazide	B-Group
diuretics	I-Group
to	O
hypoparathyroid	O
patients	O
who	O
are	O
concurrently	O
being	O
treated	O
with	O
dihydrotachysterol	B-Drug
may	O
cause	O
hypercalcemia	O
.	O
      
The	O
effect	O
of	O
orlistat	B-Drug
on	O
the	O
absorption	O
of	O
supplemental	O
vitamin	B-Group
D	I-Group
vitamin	B-Group
A	I-Group
and	O
nutritionally	O
-	O
derived	O
vitamin	B-Group
K	I-Group
is	O
not	O
known	O
at	O
this	O
time	O
.	O
      
Antacids	B-Group
Sucralfate	B-Drug
Metal	O
Cations	O
Multivitamins	B-Group
Quinolones	B-Group
form	O
chelates	O
with	O
alkaline	O
earth	O
and	O
transition	O
metal	O
cations	O
.	O
      
When	O
used	O
in	O
therapeutic	O
doses	O
azithromycin	B-Drug
had	O
a	O
modest	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
atorvastatin	B-Drug
carbamazepine	B-Drug
cetirizine	B-Drug
didanosine	B-Drug
efavirenz	B-Drug
fluconazole	B-Drug
indinavir	B-Drug
midazolam	B-Drug
rifabutin	B-Drug
sildenafil	B-Drug
theophylline	B-Drug
(	O
intravenous	O
and	O
oral	O
)	O
triazolam	B-Drug
trimethoprim	B-Drug
/	O
sulfamethoxazole	B-Drug
or	O
zidovudine	B-Drug
.	O
      
therefore	O
concomitant	O
use	O
of	O
stavudine	B-Drug
with	O
either	O
of	O
these	O
drugs	O
should	O
be	O
undertaken	O
with	O
caution	O
.	O
      
In	O
one	O
study	O
following	O
chronic	O
administration	O
of	O
bupropion	B-Drug
9	O
mg	O
9	O
times	O
daily	O
to	O
9	O
healthy	O
male	O
volunteers	O
for	O
9	O
days	O
there	O
was	O
no	O
evidence	O
of	O
induction	O
of	O
its	O
own	O
metabolism	O
.	O
      
An	O
interacting	O
drug	O
which	O
leads	O
to	O
a	O
decrease	O
in	O
prothrombin	O
time	O
necessitating	O
an	O
increased	O
dose	O
of	O
oral	O
anticoagulant	B-Group
to	O
maintain	O
an	O
adequate	O
degree	O
of	O
anticoagulation	O
may	O
if	O
abruptly	O
discontinued	O
increase	O
the	O
risk	O
of	O
subsequent	O
bleeding	O
.	O
      
Use	O
with	O
Cholinomimetics	B-Group
and	O
Other	O
Cholinesterase	B-Group
Inhibitors	I-Group
:	O
A	O
synergistic	O
effect	O
may	O
be	O
expected	O
when	O
cholinesterase	B-Group
inhibitors	I-Group
are	O
given	O
concurrently	O
with	O
succinylcholine	B-Drug
similar	O
neuromuscular	B-Group
blocking	I-Group
agents	I-Group
or	O
cholinergic	B-Group
agonists	I-Group
such	O
as	O
bethanechol	B-Drug
.	O
      
Antiretroviral	B-Group
Agents	I-Group
:	O
No	O
drug	O
interactions	O
with	O
other	O
antiretroviral	B-Group
medications	I-Group
have	O
been	O
identified	O
that	O
would	O
warrant	O
alteration	O
of	O
either	O
the	O
enfuvirtide	B-Drug
dose	O
or	O
the	O
dose	O
of	O
the	O
other	O
antiretroviral	B-Group
medication	I-Group
.	O
      
CYP9	O
Metabolized	O
Drugs	O
Results	O
from	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
suggest	O
that	O
enfuvirtide	B-Drug
is	O
unlikely	O
to	O
have	O
significant	O
drug	O
interactions	O
with	O
concomitantly	O
administered	O
drugs	O
metabolized	O
by	O
CYP9	O
enzymes	O
.	O
      
Use	O
of	O
potassium	B-Group
-	O
sparing	I-Group
diuretics	I-Group
(	O
spironolactone	B-Drug
triamterene	B-Drug
amiloride	B-Drug
)	O
or	O
potassium	B-Drug
supplements	O
concomitantly	O
with	O
ACE	B-Group
inhibitors	I-Group
can	O
increase	O
the	O
risk	O
of	O
hyperkalemia	O
.	O
      
Compounds	O
in	O
these	O
categories	O
result	O
in	O
a	O
decreased	O
efficacy	O
of	O
bromocriptine	B-Drug
mesylate	I-Drug
:	O
phenothiazines	B-Group
haloperidol	B-Drug
metoclopramide	B-Drug
pimozide	B-Drug
.	O
      
No	O
other	O
drug	O
interactions	O
are	O
known	O
.	O
      
Acetazolamide	B-Drug
may	O
increase	O
or	O
decrease	O
blood	O
glucose	O
levels	O
.	O
      
Ergot	O
-	O
containing	O
drugs	O
have	O
been	O
reported	O
to	O
cause	O
prolonged	O
vasospastic	O
reactions	O
.	O
      
No	O
drugs	O
are	O
known	O
to	O
interfere	O
with	O
the	O
conversion	O
of	O
fosphenytoin	B-Drug
to	O
phenytoin	B-Drug
.	O
      
The	O
concurrent	O
administration	O
of	O
allopurinol	B-Drug
and	O
ampicillin	B-Drug
increases	O
substantially	O
the	O
incidence	O
of	O
rashes	O
in	O
patients	O
receiving	O
both	O
drugs	O
as	O
compared	O
to	O
patients	O
receiving	O
ampicillin	B-Drug
alone	O
.	O
      
The	O
interaction	O
is	O
a	O
consequence	O
of	O
blocking	O
hepatic	O
metabolism	O
of	O
vardenafil	B-Drug
by	O
ritonavir	B-Drug
a	O
highly	O
potent	O
CYP9A9	O
inhibitor	O
which	O
also	O
inhibits	O
CYP9C9	O
.	O
      
Meperidine	B-Drug
:	O
Amphetamines	B-Group
potentiate	O
the	O
analgesic	O
effect	O
of	O
meperidine	B-Drug
.	O
      
Physicians	O
are	O
provided	O
this	O
information	O
to	O
increase	O
awareness	O
of	O
the	O
potential	O
for	O
serious	O
interactions	O
when	O
cinoxacin	B-Drug
and	O
certain	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
agents	I-Group
are	O
administered	O
concomitantly	O
.	O
      
These	O
inhalational	O
agents	O
can	O
also	O
be	O
expected	O
to	O
increase	O
the	O
anesthetic	O
or	O
sedative	O
and	O
cardiorespiratory	O
effects	O
of	O
DIPRIVAN	B-Brand
Injectable	O
Emulsion	O
.	O
      
Urinary	O
acidifying	O
agents	O
These	O
agents	O
(	O
ammonium	B-Drug
chloride	I-Drug
sodium	B-Drug
acid	I-Drug
phosphate	I-Drug
etc	O
.	O
)	O
increase	O
the	O
concentration	O
of	O
the	O
ionized	O
species	O
of	O
the	O
amphetamine	B-Drug
molecule	O
thereby	O
increasing	O
urinary	O
excretion	O
.	O
      
Agents	O
Increasing	O
Serum	O
Potassium	O
Since	O
captopril	B-Drug
decreases	O
aldosterone	O
production	O
elevation	O
of	O
serum	O
potassium	O
may	O
occur	O
.	O
      
If	O
these	O
agents	O
are	O
to	O
be	O
administered	O
concurrently	O
cyclosporine	B-Drug
concentrations	O
should	O
be	O
monitored	O
especially	O
when	O
diltiazem	B-Drug
therapy	O
is	O
initiated	O
adjusted	O
or	O
discontinued	O
.	O
      
Because	O
eprosartan	B-Drug
is	O
not	O
metabolized	O
by	O
the	O
cytochrome	O
P9	O
system	O
inhibitors	O
of	O
CYP9	O
enzyme	O
would	O
not	O
be	O
expected	O
to	O
affect	O
its	O
metabolism	O
and	O
ketoconazole	B-Drug
and	O
fluconazole	B-Drug
potent	O
inhibitors	O
of	O
CYP9A	O
and	O
9C9	O
respectively	O
have	O
been	O
shown	O
to	O
have	O
no	O
effect	O
on	O
eprosartan	B-Drug
pharmacokinetics	O
.	O
      
Ketoconazole	B-Drug
:	O
Ketoconazole	B-Drug
may	O
inhibit	O
both	O
synthetic	O
and	O
catabolic	O
enzymes	O
of	O
vitamin	B-Group
D	I-Group
.	O
      
Bleeding	O
from	O
a	O
number	O
of	O
sites	O
may	O
be	O
a	O
complication	O
of	O
warfarin	B-Drug
treatment	O
and	O
GI	O
bleeding	O
a	O
complication	O
of	O
ketoprofen	B-Drug
treatment	O
.	O
      
Increase	O
daily	O
dose	O
of	O
rifabutin	B-Drug
by	O
9	O
%	O
.	O
      
In	O
that	O
same	O
study	O
aspirin	B-Brand
alone	O
produced	O
a	O
marked	O
inhibition	O
in	O
platelet	O
aggregation	O
ex	O
vivo	O
.	O
      
reliable	O
estimates	O
of	O
the	O
prevalence	O
of	O
reduced	O
P9	O
9D9	O
isozyme	O
activity	O
among	O
Asian	O
African	O
and	O
other	O
populations	O
are	O
not	O
yet	O
available	O
.	O
      
During	O
concomitant	O
therapy	O
of	O
Ponstel	B-Brand
with	O
furosemide	B-Drug
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
signs	O
of	O
renal	O
failure	O
as	O
well	O
as	O
to	O
assure	O
diuretic	O
efficacy	O
.	O
      
These	O
effects	O
have	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
by	O
MOBIC	B-Brand
.	O
      
Appropriate	O
doses	O
for	O
this	O
combination	O
arenot	O
established	O
but	O
an	O
increase	O
in	O
thedosage	O
of	O
indinavir	B-Drug
may	O
be	O
required	O
.	O
      
Serum	O
potassium	O
levels	O
should	O
be	O
monitored	O
and	O
deficiencies	O
corrected	O
.	O
      
In	O
vitro	O
studies	O
indicate	O
that	O
bupropion	B-Drug
is	O
primarily	O
metabolized	O
to	O
hydroxybupropion	B-Drug_n
by	O
the	O
CYP9B9	O
isoenzyme	O
.	O
      
In	O
vitro	O
studies	O
with	O
several	O
drugs	O
which	O
may	O
be	O
administered	O
concomitantly	O
showed	O
that	O
the	O
extent	O
of	O
flecainide	B-Drug
binding	O
to	O
human	O
plasma	O
proteins	O
is	O
either	O
unchanged	O
or	O
only	O
slightly	O
less	O
.	O
      
therefore	O
VIRACEPT	B-Brand
should	O
not	O
be	O
administered	O
concurrently	O
with	O
terfenadine	B-Drug
because	O
of	O
the	O
potential	O
for	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
cardiac	O
arrhythmias	O
.	O
      
Warfarin	B-Drug
Keppra	B-Brand
(	O
9	O
mg	O
twice	O
daily	O
)	O
did	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
R	B-Drug
and	O
S	B-Drug
warfarin	I-Drug
.	O
      
It	O
is	O
likely	O
that	O
use	O
of	O
epirubicin	B-Drug
with	O
radiotherapy	O
may	O
sensitize	O
tissues	O
to	O
the	O
cytotoxic	O
actions	O
of	O
irradiation	O
.	O
      
Oral	O
Contraceptives	B-Group
:	O
May	O
be	O
less	O
effective	O
and	O
increased	O
breakthrough	O
bleeding	O
may	O
occur	O
.	O
      
However	O
when	O
any	O
additional	O
drug	O
including	O
INDOCIN	B-Brand
is	O
added	O
to	O
the	O
treatment	O
of	O
patients	O
on	O
anticoagulant	B-Group
therapy	O
the	O
patients	O
should	O
be	O
observed	O
for	O
alterations	O
of	O
the	O
prothrombin	O
time	O
.	O
      
Other	O
9	B-Group
-	O
HT9B9D	I-Group
Agonists	I-Group
Concomitant	O
use	O
of	O
other	O
9	B-Group
-	O
HT9B9D	I-Group
agonists	I-Group
within	O
9	O
hours	O
of	O
treatment	O
with	O
AXERT	B-Brand
is	O
contraindicated	O
.	O
      
Fibrates	B-Group
:	O
The	O
safety	O
and	O
effectiveness	O
of	O
ezetimibe	B-Drug
administered	O
with	O
fibrates	B-Group
have	O
not	O
been	O
established	O
.	O
      
Massive	O
seizures	O
may	O
be	O
encountered	O
with	O
this	O
combination	O
.	O
      
The	O
concurrent	O
use	O
of	O
streptozocin	B-Drug
and	O
phenytoin	B-Drug
has	O
been	O
reported	O
in	O
one	O
case	O
to	O
result	O
in	O
reduced	O
streptozocin	B-Drug
cytotoxicity	O
.	O
      
Hormonal	B-Group
Contraceptives	I-Group
Including	O
Oral	O
Injectable	O
Transdermal	O
and	O
Implantable	O
Contraceptives	B-Group
:	O
An	O
interaction	O
study	O
demonstrated	O
that	O
co	O
-	O
administration	O
of	O
bosentan	B-Drug
and	O
the	O
oral	O
hormonal	B-Group
contraceptive	I-Group
Ortho	B-Brand
-	O
Novum	I-Brand
produced	O
average	O
decreases	O
of	O
norethindrone	B-Drug
and	O
ethinyl	B-Drug
estradiol	I-Drug
levels	O
of	O
9	O
%	O
and	O
9	O
%	O
respectively	O
.	O
      
Caution	O
should	O
be	O
exercised	O
when	O
these	O
9	O
agents	O
are	O
coadministered	O
.	O
      
Amiodarone	B-Drug
taken	O
concomitantly	O
with	O
quinidine	B-Drug
increases	O
quinidine	B-Drug
serum	O
concentration	O
by	O
9	O
%	O
after	O
two	O
days	O
.	O
      
Although	O
acid	O
-	O
base	O
and	O
electrolyte	O
disturbances	O
were	O
not	O
reported	O
in	O
the	O
clinical	O
trials	O
with	O
dorzolamide	B-Drug
these	O
disturbances	O
have	O
been	O
reported	O
with	O
oral	O
carbonic	B-Group
anhydrase	I-Group
inhibitors	I-Group
and	O
have	O
in	O
some	O
instances	O
resulted	O
in	O
drug	O
interactions	O
(	O
e.g.	O
toxicity	O
associated	O
with	O
high	O
-	O
dose	O
salicylate	B-Group
therapy	O
)	O
.	O
      
Anastrozole	B-Drug
inhibited	O
in	O
vitro	O
metabolic	O
reactions	O
catalyzed	O
by	O
cytochromes	O
P9	O
9A9	O
9C9	O
/	O
9	O
and	O
9A9	O
but	O
only	O
at	O
relatively	O
high	O
concentrations	O
.	O
      
No	O
clinically	O
relevant	O
pharmacokinetic	O
interactions	O
between	O
anagrelide	B-Drug
and	O
acetylsalicylic	B-Drug
acid	I-Drug
were	O
observed	O
.	O
      
Aspirin	B-Brand
:	O
Concurrent	O
administration	O
of	O
aspirin	B-Brand
may	O
lower	O
meclofenamate	B-Drug
sodium	I-Drug
plasma	O
levels	O
possibly	O
by	O
competing	O
for	O
protein	O
-	O
binding	O
sites	O
.	O
      
No	O
drug	O
interaction	O
studies	O
were	O
performed	O
.	O
      
Zalcitabine	B-Drug
also	O
has	O
no	O
significant	O
effect	O
on	O
the	O
intracellular	O
phosphorylation	O
of	O
ZDV	B-Drug
as	O
shown	O
in	O
vitro	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
or	O
in	O
two	O
other	O
cell	O
lines	O
(	O
U9	O
and	O
Molt	O
-	O
9	O
)	O
.	O
      
Immunosuppressants	B-Group
:	O
cyclosporine	B-Drug
tacrolimus	B-Drug
sirolimus	B-Drug
      
SUSTIVA	B-Brand
has	O
the	O
potential	O
to	O
decrease	O
plasma	O
concentrations	O
of	O
itraconazole	B-Drug
and	O
ketoconazole	B-Drug
.	O
      
Metoclopramide	B-Drug
:	O
Bioavailability	O
is	O
mildly	O
reduced	O
(	O
approximately	O
9	O
%	O
)	O
when	O
zalcitabine	B-Drug
and	O
metoclopramide	B-Drug
are	O
coadministered	O
.	O
      
MAO	B-Group
Inhibitors	I-Group
:	O
Studies	O
in	O
animals	O
demonstrate	O
that	O
the	O
acute	O
toxicity	O
of	O
bupropion	B-Drug
is	O
enhanced	O
by	O
the	O
MAO	B-Group
inhibitor	I-Group
phenelzine	B-Drug
.	O
      
Potential	O
drug	O
interactions	O
for	O
doxylamine	B-Drug
include	O
increased	O
sedation	O
if	O
doxylamine	B-Drug
is	O
combined	O
with	O
other	O
CNS	B-Group
depressant	I-Group
drugs	I-Group
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interaction	O
Because	O
Xigris	B-Brand
may	O
affect	O
the	O
APTT	O
assay	O
Xigris	B-Brand
present	O
in	O
plasma	O
samples	O
may	O
interfere	O
with	O
one	O
-	O
stage	O
coagulation	O
assays	O
based	O
on	O
the	O
APTT	O
(	O
such	O
as	O
factor	O
VIII	O
IX	O
and	O
XI	O
assays	O
)	O
.	O
      
In	O
clinical	O
studies	O
caspofungin	B-Drug
did	O
not	O
induce	O
the	O
CYP9A9	O
metabolism	O
of	O
other	O
drugs	O
.	O
      
Of	O
particular	O
importance	O
sufficient	O
time	O
must	O
elapse	O
before	O
initiating	O
TCA	O
treatment	O
in	O
a	O
patient	O
being	O
withdrawn	O
from	O
fluoxetine	B-Drug
given	O
the	O
long	O
half	O
-	O
life	O
of	O
the	O
parent	O
and	O
active	O
metabolite	O
(	O
at	O
least	O
9	O
weeks	O
may	O
be	O
necessary	O
)	O
.	O
      
Cardiovascular	O
collapse	O
in	O
patients	O
treated	O
simultaneously	O
with	O
varapamil	O
and	O
dantrolene	B-Drug
sodium	I-Drug
is	O
rare	O
.	O
      
Co	O
-	O
administration	O
of	O
multiple	O
doses	O
of	O
9	O
mg	O
of	O
lenalidomide	B-Drug
had	O
no	O
effect	O
on	O
the	O
single	O
dose	O
pharmacokinetics	O
of	O
R	B-Drug
-	O
and	O
S	B-Drug
-	O
warfarin	I-Drug
.	O
      
It	O
has	O
been	O
reported	O
that	O
the	O
addition	O
of	O
triamterene	B-Drug
to	O
a	O
maintenance	O
schedule	O
of	O
INDOCIN	B-Brand
resulted	O
in	O
reversible	O
acute	O
renal	O
failure	O
in	O
two	O
of	O
four	O
healthy	O
volunteers	O
.	O
      
Increased	O
toxicity	O
(	O
CNS	O
depression	O
)	O
:	O
CNS	B-Group
depressants	I-Group
MAO	B-Group
inhibitors	I-Group
tricyclic	B-Group
antidepressants	I-Group
phenothiazines	B-Group
.	O
      
Risk	O
of	O
Anaphylactic	O
Reaction	O
While	O
taking	O
beta	B-Group
-	O
blockers	I-Group
patients	O
with	O
a	O
history	O
of	O
severe	O
anaphylactic	O
reaction	O
to	O
a	O
variety	O
of	O
allergens	O
may	O
be	O
more	O
reactive	O
to	O
repeated	O
challenge	O
either	O
accidental	O
diagnostic	O
or	O
therapeutic	O
.	O
      
Population	O
pharmacokinetic	O
analyses	O
were	O
conducted	O
on	O
plasma	O
concentration	O
data	O
from	O
9	O
patients	O
in	O
clinical	O
trials	O
to	O
examine	O
the	O
effects	O
of	O
concomitant	O
medications	O
on	O
clearance	O
or	O
volume	O
of	O
distribution	O
of	O
dofetilide	B-Drug
.	O
      
Administration	O
of	O
paclitaxel	B-Drug
in	O
combination	O
with	O
HERCEPTIN	B-Brand
resulted	O
in	O
a	O
two	O
-	O
fold	O
decrease	O
in	O
HERCEPTIN	B-Brand
clearance	O
in	O
a	O
non	O
-	O
human	O
primate	O
study	O
and	O
in	O
a	O
9	O
-	O
fold	O
increase	O
in	O
HERCEPTIN	B-Brand
serum	O
levels	O
in	O
clinical	O
studies	O
.	O
      
-	O
a	O
beta	B-Group
-	O
blocker	I-Group
such	O
as	O
propranolol	B-Drug
(	O
Inderal	B-Brand
)	O
atenolol	B-Drug
(	O
Tenormin	B-Brand
)	O
acebutolol	B-Drug
(	O
Sectral	B-Brand
)	O
metoprolol	B-Drug
(	O
Lopressor	B-Brand
)	O
and	O
others	O
;	O
      
Therefore	O
coagulation	O
indices	O
should	O
be	O
monitored	O
to	O
maintain	O
the	O
desired	O
anticoagulant	O
effect	O
.	O
      
However	O
the	O
pharmacodynamic	O
effect	O
increased	O
by	O
9	O
%	O
(	O
QTc	O
increase	O
over	O
time	O
)	O
and	O
by	O
9	O
%	O
(	O
maximum	O
QTc	O
increase	O
)	O
.	O
      
Agents	O
that	O
Induce	O
Cytochrome	O
P9	O
Isoenzymes	O
Carbamazepine	B-Drug
is	O
metabolized	O
by	O
CYP9A9	O
.	O
      
The	O
response	O
to	O
Factrel	B-Brand
may	O
be	O
blunted	O
by	O
phenothiazines	B-Group
and	O
dopamine	B-Group
antagonists	I-Group
which	O
cause	O
a	O
rise	O
in	O
prolactin	O
.	O
      
Protein	O
Binding	O
In	O
vitro	O
diclofenac	B-Drug
interferes	O
minimally	O
or	O
not	O
at	O
all	O
with	O
the	O
protein	O
binding	O
of	O
salicylic	B-Drug
acid	I-Drug
(	O
9	O
%	O
decrease	O
in	O
binding	O
)	O
tolbutamide	B-Drug
prednisolone	B-Drug
(	O
9	O
%	O
decrease	O
in	O
binding	O
)	O
or	O
warfarin	B-Drug
.	O
      
Anabolic	B-Group
steroids	I-Group
(	O
particularly	O
C	O
-	O
9	O
alkylated	O
androgens	B-Group
such	O
as	O
oxymetholone	B-Drug
methandrostenolone	B-Drug
norethandrolone	B-Drug
and	O
similar	O
compounds	O
)	O
enhanced	O
tendency	O
toward	O
edema	O
.	O
      
9	O
-	O
9	O
up	O
to	O
9	O
%	O
increase9	O
[	O
CI	O
:	O
9	O
%	O
increase	O
9	O
%	O
increase	O
]	O
      
Pharmacodynamic	O
-	O
related	O
Interactions	O
:	O
The	O
mechanism	O
of	O
Clozapine	B-Drug
induced	O
agranulocytosis	O
is	O
unknown	O
;	O
      
-	O
Other	O
antihypertensive	B-Group
drugs	I-Group
:	O
Additive	O
effect	O
or	O
potentiation	O
      
Human	B-Drug
growth	I-Drug
hormone	I-Drug
-	O
Concomitant	O
use	O
of	O
L	B-Drug
-	O
glutamine	I-Drug
and	O
human	B-Drug
growth	I-Drug
hormone	I-Drug
may	O
enhance	O
nutrient	O
absorption	O
in	O
those	O
with	O
severe	O
short	O
bowel	O
syndrome	O
.	O
      
Drugs	O
which	O
may	O
enhance	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
TRACRIUM	B-Brand
include	O
:	O
enflurane	B-Drug
;	O
      
Cimetidine	B-Drug
is	O
reported	O
to	O
reduce	O
hepatic	O
metabolism	O
of	O
certain	O
tricyclic	B-Drug
antidepressants	I-Drug
thereby	O
delaying	O
elimination	O
and	O
increasing	O
steady	O
-	O
state	O
concentrations	O
of	O
these	O
drugs	B-Drug
.	O
      
Angiomax	B-Brand
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
disease	O
states	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
bleeding	O
.	O
      
Some	O
reports	O
have	O
shown	O
that	O
the	O
concomitant	O
administration	O
of	O
thiazides	B-Group
with	O
vitamin	B-Group
D	I-Group
causes	O
hypercalcemia	O
.	O
      
There	O
has	O
been	O
too	O
little	O
experience	O
with	O
the	O
coadministration	O
of	O
TAMBOCOR	B-Brand
with	O
nifedipine	B-Drug
or	O
diltiazem	B-Drug
to	O
recommend	O
concomitant	O
use	O
.	O
      
-	O
Sulfoxone	B-Drug
(	O
e.g.	O
Diasone	B-Brand
)	O
or	O
      
Probenecid	B-Drug
:	O
Probenecid	B-Drug
interferes	O
with	O
renal	O
tubular	O
secretion	O
of	O
ciprofloxacin	B-Drug
and	O
produces	O
an	O
increase	O
in	O
the	O
level	O
of	O
ciprofloxacin	B-Drug
in	O
serum	O
.	O
      
However	O
caution	O
should	O
be	O
exercised	O
because	O
there	O
have	O
been	O
a	O
few	O
spontaneous	O
reports	O
of	O
prolonged	O
prothrombin	O
times	O
with	O
or	O
without	O
bleeding	O
in	O
etodolac	B-Drug
-	O
treated	O
patients	O
receiving	O
concomitant	O
warfarin	B-Drug
therapy	O
.	O
      
Therefore	O
digoxin	B-Drug
serum	O
levels	O
should	O
be	O
monitored	O
.	O
      
Beta	B-Group
-	O
adrenergic	I-Group
receptor	I-Group
antagonists	I-Group
(	O
beta	B-Group
-	O
blockers	I-Group
)	O
and	O
BROVANA	B-Brand
may	O
interfere	O
with	O
the	O
effect	O
of	O
each	O
other	O
when	O
administered	O
concurrently	O
.	O
      
In	O
neither	O
case	O
were	O
the	O
pharmacokinetics	O
of	O
sumatriptan	B-Drug
affected	O
by	O
coadministration	O
with	O
STADOL	B-Brand
NS	I-Brand
.	O
      
Patients	O
stabilized	O
on	O
oral	O
anticoagulants	B-Group
who	O
are	O
found	O
to	O
require	O
thyroid	B-Group
replacement	O
therapy	O
should	O
be	O
watched	O
very	O
closely	O
when	O
thyroid	O
is	O
started	O
.	O
      
Co	O
-	O
administration	O
of	O
bosentan	B-Drug
decreased	O
the	O
plasma	O
concentrations	O
of	O
cyclosporine	B-Drug
A	I-Drug
(	O
a	O
CYP9A9	O
substrate	O
)	O
by	O
approximately	O
9	O
%	O
.	O
      
Dimenhydrinate	B-Drug
may	O
decrease	O
emetic	B-Group
response	O
to	O
apomorphine	B-Drug
.	O
      
In	O
clinical	O
studies	O
Tilade	B-Brand
has	O
been	O
co	O
-	O
administered	O
with	O
other	O
anti	O
-	O
asthma	O
medications	O
including	O
inhaled	O
and	O
oral	O
bronchodilators	B-Group
and	O
inhaled	O
corticosteroids	B-Group
with	O
no	O
evidence	O
of	O
increased	O
frequency	O
of	O
adverse	O
events	O
or	O
laboratory	O
abnormalities	O
.	O
      
however	O
there	O
was	O
extensive	O
concomitant	O
use	O
of	O
NSAIDs	B-Group
in	O
clinical	O
studies	O
and	O
no	O
differential	O
effect	O
was	O
observed	O
.	O
      
Ethoxzolamide	B-Drug
may	O
increase	O
the	O
action	O
of	O
tricyclics	B-Group
amphetamines	B-Group
procainamide	B-Drug
and	O
quinidine	B-Drug
.	O
      
Ketoconazole	B-Drug
/	O
Itraconazole	B-Drug
Macrolides	B-Group
Including	O
Erythromycin	B-Drug
      
Should	O
this	O
occur	O
the	O
higher	O
serum	O
concentrations	O
of	O
that	O
drug	O
may	O
result	O
in	O
increased	O
pharmacologic	O
or	O
adverse	O
effects	O
of	O
that	O
drug	O
.	O
      
Cisapride	B-Drug
:	O
There	O
have	O
been	O
reports	O
of	O
cardiac	O
events	O
including	O
torsade	O
de	O
pointes	O
in	O
patients	O
to	O
whom	O
fluconazole	B-Drug
and	O
cisapride	B-Drug
were	O
coadministered	O
.	O
      
The	O
coadministration	O
of	O
fluconazole	B-Drug
at	O
doses	O
lower	O
than	O
9	O
mg	O
/	O
day	O
with	O
terfenadine	B-Drug
should	O
be	O
carefully	O
monitored	O
.	O
      
The	O
majority	O
of	O
patients	O
in	O
RA	O
clinical	O
studies	O
received	O
one	O
or	O
more	O
of	O
the	O
following	O
concomitant	O
medications	O
with	O
ORENCIA	B-Brand
:	O
MTX	B-Drug
NSAIDs	B-Group
corticosteroids	B-Group
TNF	B-Group
blocking	I-Group
agents	I-Group
azathioprine	B-Drug
chloroquine	B-Drug
gold	B-Drug
hydroxychloroquine	B-Drug
leflunomide	B-Drug
sulfasalazine	B-Drug
and	O
anakinra	B-Drug
.	O
      
Because	O
ritonavir	B-Drug
is	O
coadministered	O
prescribers	O
should	O
also	O
refer	O
to	O
the	O
prescribing	O
information	O
for	O
ritonavir	B-Drug
regarding	O
drug	O
interactions	O
associated	O
with	O
this	O
agent	O
.	O
      
Resistance	O
to	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
nondepolarizing	B-Group
neuromuscular	I-Group
blocking	I-Group
agents	I-Group
has	O
been	O
demonstrated	O
in	O
patients	O
chronically	O
administered	O
phenytoin	B-Drug
or	O
carbamazepine	B-Drug
.	O
      
A	O
9	O
-	O
fold	O
decrease	O
in	O
the	O
mean	O
warfarin	B-Drug
dose	O
from	O
9	O
mg	O
/	O
day	O
to	O
9	O
mg	O
/	O
day	O
(	O
approximately	O
9	O
-	O
9	O
%	O
reduction	O
of	O
warfarin	B-Drug
dose	O
)	O
was	O
necessary	O
to	O
maintain	O
a	O
target	O
INR	O
of	O
9	O
.	O
      
It	O
is	O
recommended	O
that	O
plasma	O
lithium	B-Drug
levels	O
be	O
monitored	O
when	O
initiating	O
adjusting	O
and	O
discontinuing	O
FELDENE	B-Brand
.	O
      
It	O
is	O
known	O
that	O
CYP9A9	O
is	O
inhibited	O
by	O
several	O
medicinal	O
products	O
including	O
fluvoxamine	B-Drug
and	O
such	O
medicinal	O
products	O
could	O
theoretically	O
adversely	O
influence	O
the	O
clearance	O
of	O
anagrelide	B-Drug
.	O
      
Fenfluramine	B-Drug
may	O
increase	O
slightly	O
the	O
effect	O
of	O
antihypertensive	B-Group
drugs	I-Group
e.g.	O
guanethidine	B-Drug
methyldopa	B-Drug
reserpine	B-Drug
.	O
      
The	O
concomitant	O
use	O
of	O
other	O
CNS	B-Group
depressants	I-Group
including	O
sedatives	B-Group
hypnotics	B-Group
tranquilizers	B-Group
general	O
anesthetics	B-Group
phenothiazines	B-Group
other	O
opioids	B-Group
tricyclic	B-Group
antidepressants	I-Group
monoamine	B-Group
oxidase	I-Group
MAO	I-Group
inhibitors	I-Group
and	O
alcohol	B-Drug
may	O
produce	O
additive	O
CNS	O
depressant	O
effects	O
.	O
      
Concomitant	O
administration	O
of	O
diltiazem	B-Drug
with	O
carbamazepine	B-Drug
has	O
been	O
reported	O
to	O
result	O
in	O
elevated	O
serum	O
levels	O
of	O
carbamazepine	B-Drug
(	O
9	O
%	O
to	O
9	O
%	O
increase	O
)	O
resulting	O
in	O
toxicity	O
in	O
some	O
cases	O
.	O
      
Cimetidine	B-Drug
:	O
The	O
effects	O
of	O
chronic	O
cimetidine	B-Drug
use	O
on	O
the	O
metabolism	O
of	O
rimantadine	B-Drug
are	O
not	O
known	O
.	O
      
Propoxyphene	B-Drug
:	O
In	O
cases	O
of	O
propoxyphene	B-Drug
overdosage	O
amphetamine	B-Group
CNS	O
stimulation	O
is	O
potentiated	O
and	O
fatal	O
convulsions	O
can	O
occur	O
.	O
      
Inhibitors	O
of	O
CYP9D9	O
;	O
      
Caution	O
is	O
advised	O
in	O
using	O
Duloxetine	B-Drug
in	O
patients	O
with	O
conditions	O
that	O
may	O
slow	O
gastric	O
emptying	O
(	O
e.g.	O
some	O
diabetics	O
)	O
.	O
      
The	O
optimal	O
dosing	O
interval	O
for	O
coadministration	O
with	O
VIDEX	B-Brand
should	O
be	O
determined	O
by	O
consulting	O
the	O
appropriate	O
quinolone	B-Group
package	O
insert	O
.	O
      
Caution	O
should	O
be	O
used	O
when	O
such	O
drugs	O
are	O
co	O
-	O
administered	O
.	O
      
Interaction	O
of	O
GABITRIL	B-Brand
with	O
Other	O
Drugs	O
:	O
Cimetidine	B-Drug
:	O
Co	O
-	O
administration	O
of	O
cimetidine	B-Drug
(	O
9	O
mg	O
/	O
day	O
)	O
to	O
patients	O
taking	O
tiagabine	B-Drug
chronically	O
had	O
no	O
effect	O
on	O
tiagabine	B-Drug
pharmacokinetics	O
.	O
      
dihydropyridine	B-Group
calcium	I-Group
channel	I-Group
blockers	I-Group
concentration	O
      
However	O
in	O
a	O
follow	O
-	O
up	O
study	O
in	O
normal	O
subjects	O
single	O
-	O
dose	O
administration	O
of	O
colestipol	B-Drug
hydrochloride	I-Drug
and	O
propranolol	B-Drug
and	O
twice	O
-	O
a	O
-	O
day	O
administration	O
for	O
9	O
days	O
of	O
both	O
agents	O
did	O
not	O
affect	O
the	O
extent	O
of	O
propranolol	B-Drug
absorption	O
but	O
had	O
a	O
small	O
yet	O
statistically	O
significant	O
effect	O
on	O
its	O
rate	O
of	O
absorption	O
;	O
      
(	O
Thiazide	B-Group
diuretics	I-Group
may	O
raise	O
the	O
level	O
of	O
blood	O
uric	O
acid	O
;	O
      
Johns	B-Drug_n
Wort	I-Drug_n
with	O
hormonal	B-Group
contraceptive	I-Group
agents	I-Group
may	O
reduce	O
the	O
effectiveness	O
of	O
the	O
contraception	O
and	O
up	O
to	O
one	O
month	O
after	O
discontinuation	O
of	O
these	O
concomitant	O
therapies	O
.	O
      
Both	O
acyclovir	B-Drug
/	O
ganciclovir	B-Drug
and	O
MPAG	B-Drug_n
concentrations	O
are	O
increased	O
in	O
the	O
presence	O
of	O
renal	O
impairment	O
their	O
coexistence	O
may	O
compete	O
for	O
tubular	O
secretion	O
and	O
further	O
increase	O
in	O
the	O
concentrations	O
of	O
the	O
two	O
.	O
      
Thus	O
results	O
of	O
the	O
DST	O
should	O
be	O
interpreted	O
with	O
caution	O
in	O
these	O
patients	O
.	O
      
Herb	O
/	O
Nutraceutical	O
:	O
St	O
Johns	O
wort	O
may	O
decrease	O
the	O
effectiveness	O
of	O
combination	B-Group
hormonal	I-Group
contraceptives	I-Group
by	O
inducing	O
hepatic	O
enzymes	O
.	O
      
SUTENT	B-Brand
dose	O
modification	O
is	O
recommended	O
in	O
patients	O
using	O
concomitant	O
CYP9A9	O
inhibitors	O
or	O
inducers	O
.	O
      
Specific	O
interaction	O
studies	O
have	O
demonstrated	O
the	O
following	O
:	O
Cyclosporine	B-Drug
A	I-Drug
:	O
During	O
the	O
first	O
day	O
of	O
concomitant	O
administration	O
trough	O
concentrations	O
of	O
bosentan	B-Drug
were	O
increased	O
by	O
about	O
9	O
-	O
fold	O
.	O
      
Neuroleptic	B-Group
:	O
pimozide	B-Drug
      
If	O
TYKERB	B-Brand
is	O
administered	O
with	O
drugs	O
that	O
are	O
substrates	O
of	O
Pgp	O
increased	O
concentrations	O
of	O
the	O
substrate	O
drug	O
are	O
likely	O
and	O
caution	O
should	O
be	O
exercised	O
.	O
      
Population	O
pharmacokinetic	O
analyses	O
revealed	O
that	O
MTX	B-Drug
NSAIDs	B-Group
corticosteroids	B-Group
and	O
TNF	B-Group
blocking	I-Group
agents	I-Group
did	O
not	O
influence	O
abatacept	B-Drug
clearance	O
.	O
      
Phenytoin	B-Drug
:	O
Amphetamines	B-Group
may	O
delay	O
intestinal	O
absorption	O
of	O
phenytoin	B-Drug
;	O
      
Caffeine	B-Drug
:	O
Enoxacin	B-Drug
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
cytochrome	O
P	O
-	O
9	O
isozymes	O
responsible	O
for	O
the	O
metabolism	O
of	O
methylxanthines	B-Group
.	O
      
Ergot	B-Group
alkaloids	I-Group
      
At	O
therapeutic	O
concentrations	O
paliperidone	B-Drug
did	O
not	O
inhibit	O
P	O
-	O
glycoprotein	O
.	O
      
Use	O
with	O
Allopurinol	B-Drug
:	O
The	O
principal	O
pathway	O
for	O
detoxification	O
of	O
azathioprine	B-Drug
is	O
inhibited	O
by	O
allopurinol	B-Drug
.	O
      
Drugs	O
Which	O
Require	O
a	O
Dose	O
Reduction	O
When	O
Coadminstered	O
With	O
VIRACEPT	B-Brand
Antimycobacterial	B-Group
agents	I-Group
:	O
rifabutin	B-Drug
      
Alcohol	B-Drug
:	O
Alcohol	B-Drug
(	O
9	O
g	O
/	O
kg	O
body	O
weight	O
:	O
approximately	O
9	O
mL	O
of	O
absolute	O
alcohol	O
in	O
a	O
9	O
kg	O
person	O
)	O
and	O
vardenafil	B-Drug
plasma	O
levels	O
were	O
not	O
altered	O
when	O
dosed	O
simultaneously	O
.	O
      
Pharmacokinetic	O
studies	O
show	O
that	O
there	O
are	O
no	O
significant	O
alterations	O
in	O
pharmacokinetic	O
parameters	O
of	O
zidovudine	B-Drug
or	O
rifabutin	B-Drug
to	O
warrant	O
dosage	O
adjustment	O
when	O
megestrol	B-Drug
acetate	I-Drug
is	O
administered	O
with	O
these	O
drugs	O
.	O
      
avoid	O
use	O
if	O
possible	O
or	O
closely	O
monitor	O
cardiovascular	O
status	O
at	O
the	O
end	O
of	O
drug	O
interactions	O
      
Coadministration	O
of	O
oral	O
contraceptives	B-Group
diazepam	B-Drug
phenytoin	B-Drug
or	O
quinidine	B-Drug
did	O
not	O
seem	O
to	O
change	O
the	O
pharmacokinetic	O
profile	O
of	O
esomeprazole	B-Drug
.	O
      
immunosuppressant	B-Group
agents	I-Group
concentration	O
      
Concurrent	O
ingestion	O
of	O
antacid	B-Group
(	O
9	O
mL	O
of	O
antacid	B-Group
containing	O
aluminum	B-Drug
hydroxide	I-Drug
magnesium	B-Drug
hydroxide	I-Drug
and	O
simethicone	B-Drug
)	O
did	O
not	O
significantly	O
affect	O
the	O
exposure	O
of	O
oxybutynin	B-Drug
or	O
desethyloxybutynin	B-Drug_n
.	O
      
This	O
should	O
be	O
taken	O
into	O
account	O
when	O
evaluating	O
serum	O
amylase	O
levels	O
for	O
diagnosis	O
or	O
monitoring	O
of	O
pancreatitis	O
in	O
patients	O
using	O
EXTRANEAL	B-Brand
.	O
      
Care	O
should	O
be	O
given	O
when	O
administering	O
this	O
drug	O
to	O
patients	O
with	O
symptoms	O
of	O
myasthenic	O
weakness	O
who	O
are	O
also	O
on	O
anticholinesterase	B-Group
drugs	I-Group
.	O
      
Furosemide	B-Drug
:	O
TORADOL	B-Brand
IV	O
/	O
IM	O
reduced	O
the	O
diuretic	B-Group
response	O
to	O
furosemide	B-Drug
in	O
normovolemic	O
healthy	O
subjects	O
by	O
approximately	O
9	O
%	O
(	O
mean	O
sodium	O
and	O
urinary	O
output	O
decreased	O
9	O
%	O
)	O
.	O
      
Nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
agents	I-Group
(	O
NSAIDS	B-Group
)	O
:	O
Concomitant	O
use	O
of	O
aspirin	B-Brand
(	O
or	O
other	O
nonsteroidal	B-Group
antiinflammatory	I-Group
agents	I-Group
)	O
and	O
corticosteroids	B-Group
increases	O
the	O
risk	O
of	O
gastrointestinal	O
side	O
effects	O
.	O
      
However	O
concomitant	O
administration	O
of	O
aspirin	B-Brand
with	O
CELEBREX	B-Brand
may	O
result	O
in	O
an	O
increased	O
rate	O
of	O
GI	O
ulceration	O
or	O
other	O
complications	O
compared	O
to	O
use	O
of	O
CELEBREX	B-Brand
alone	O
.	O
      
Folinic	B-Drug
acid	I-Drug
(	O
leucovorin	B-Drug
)	O
should	O
be	O
administered	O
until	O
normal	O
hematopoiesis	O
is	O
restored	O
.	O
      
-	O
Skeletal	B-Group
muscle	I-Group
relaxants	I-Group
nondepolarizing	O
(	O
e.g.	O
tubocurarine	B-Drug
)	O
:	O
Possible	O
increased	O
responsiveness	O
to	O
the	O
muscle	B-Group
relaxant	I-Group
      
The	O
color	O
reverses	O
when	O
the	O
test	O
sample	O
is	O
acidified	O
in	O
vitro	O
to	O
a	O
pH	O
below	O
9	O
.	O
      
Concomitant	O
use	O
with	O
other	O
oxytocic	B-Group
agents	I-Group
is	O
not	O
recommended	O
      
This	O
may	O
result	O
in	O
increased	O
risk	O
of	O
theophylline	B-Drug
-	O
related	O
adverse	O
reactions	O
.	O
      
Effects	O
of	O
Aliskiren	B-Drug
on	O
Other	O
Drugs	O
Aliskiren	B-Drug
does	O
not	O
inhibit	O
the	O
CYP9	O
isoenzymes	O
(	O
CYP9A9	O
9C9	O
9C9	O
9C9	O
9D9	O
9E9	O
and	O
CYP	O
9A	O
)	O
or	O
induce	O
CYP	O
9A9	O
.	O
      
Theophylline	B-Drug
:	O
Theophylline	B-Drug
clearance	O
may	O
decrease	O
when	O
hyperthyroid	O
patients	O
on	O
a	O
stable	O
theophylline	B-Drug
regimen	O
become	O
euthyroid	O
;	O
      
Concomitant	O
use	O
of	O
cimetidine	B-Drug
should	O
be	O
avoided	O
.	O
      
Beta	B-Group
Blockers	I-Group
:	O
Although	O
the	O
results	O
of	O
a	O
clinical	O
study	O
did	O
not	O
indicate	O
a	O
safe	O
problem	O
associated	O
with	O
the	O
administration	O
of	O
D.H.E	B-Brand
9	I-Brand
(	O
dihydroergotamine	B-Drug
mesylate	I-Drug
)	O
Injection	O
USP	O
to	O
subjects	O
already	O
receiving	O
propranolol	B-Drug
there	O
have	O
been	O
reports	O
that	O
propranolol	B-Drug
may	O
potentiate	O
the	O
vasoconstrictive	O
action	O
of	O
ergotamine	B-Drug
by	O
blocking	O
the	O
vasodilating	O
property	O
of	O
epinephrine	O
.	O
      
Patients	O
receiving	O
pindolol	B-Drug
plus	O
a	O
catecholamine	O
-	O
depleting	O
agent	O
should	O
therefore	O
be	O
closely	O
observed	O
for	O
evidence	O
of	O
hypotension	O
and	O
/	O
or	O
marked	O
bradycardia	O
which	O
may	O
produce	O
vertigo	O
syncope	O
or	O
postural	O
hypotension	O
.	O
      
DRUG	O
INTERACTIONS	O
There	O
are	O
no	O
known	O
drug	O
/	O
drug	O
interactions	O
with	O
oral	O
ALKERAN	B-Brand
Vaccinations	O
with	O
live	B-Group
organism	I-Group
vaccines	I-Group
are	O
not	O
recommended	O
in	O
immunocompromised	O
individuals	O
Nalidixic	B-Drug
acid	I-Drug
together	O
with	O
high	O
-	O
dose	O
intravenous	O
melphalan	B-Drug
has	O
caused	O
deaths	O
in	O
children	O
due	O
to	O
haemorrhagic	O
enterocolitis	O
.	O
      
Drug	O
interactions	O
between	O
NEUPOGEN	B-Brand
and	O
other	O
drugs	O
have	O
not	O
been	O
fully	O
evaluated	O
.	O
      
Certain	O
drugs	O
tend	O
to	O
produce	O
hyperglycemia	O
and	O
may	O
lead	O
to	O
loss	O
of	O
control	O
.	O
      
Lithium	B-Drug
carbonate	I-Drug
:	O
The	O
anorectic	O
and	O
stimulatory	O
effects	O
of	O
amphetamines	B-Group
may	O
be	O
inhibited	O
by	O
lithium	B-Drug
carbonate	I-Drug
.	O
      
A	O
two	O
-	O
way	O
interaction	O
between	O
the	O
hydantoin	B-Group
antiepileptic	I-Group
phenytoin	B-Drug
and	O
the	O
coumarin	B-Group
anticoagulants	I-Group
has	O
been	O
suggested	O
.	O
      
Drugs	O
that	O
Lower	O
Seizure	O
Threshold	O
:	O
Concurrent	O
administration	O
of	O
WELLBUTRIN	B-Brand
and	O
agents	O
(	O
e.g.	O
antipsychotics	B-Group
other	O
antidepressants	B-Group
theophylline	B-Drug
systemic	O
steroids	B-Group
etc	O
.	O
)	O
that	O
lower	O
seizure	O
threshold	O
should	O
be	O
undertaken	O
only	O
with	O
extreme	O
caution	O
.	O
      
No	O
dosage	O
adjustment	O
is	O
required	O
for	O
Fluvoxamine	B-Drug
Tablets	O
.	O
      
The	O
interaction	O
of	O
Activase	B-Brand
with	O
other	O
cardioactive	O
or	O
cerebroactive	O
drugs	O
has	O
not	O
been	O
studied	O
.	O
      
Interaction	O
with	O
phenytoin	B-Drug
lidocaine	B-Drug
and	O
theophylline	B-Drug
has	O
also	O
been	O
reported	O
to	O
produce	O
adverse	O
clinical	O
effects	O
.	O
      
allopurinol	B-Drug
;	O
      
In	O
vitro	O
studies	O
have	O
shown	O
that	O
naproxen	B-Drug
anion	O
because	O
of	O
its	O
affinity	O
for	O
protein	O
may	O
displace	O
from	O
their	O
binding	O
sites	O
other	O
drugs	O
which	O
are	O
also	O
albumin	O
-	O
bound	O
.	O
      
In	O
vitro	O
metabolism	O
studies	O
have	O
demonstrated	O
that	O
tizoxanide	B-Drug
has	O
no	O
significant	O
inhibitory	O
effect	O
on	O
cytochrome	O
P9	O
enzymes	O
.	O
      
Theoretically	O
it	O
may	O
decrease	O
hepatic	O
toxicity	O
in	O
the	O
case	O
of	O
other	O
potential	O
hepatotoxic	O
drugs	O
as	O
well	O
.	O
      
Nevirapine	B-Drug
and	O
ketoconazole	B-Drug
should	O
not	O
beadministered	O
concomitantly	O
becausedecreases	O
in	O
ketoconazole	B-Drug
plasmaconcentrations	O
may	O
reduce	O
the	O
efficacy	O
of	O
the	O
drug	O
.	O
      
Sumatriptan	B-Drug
-	O
There	O
have	O
been	O
rare	O
postmarketing	O
reports	O
describing	O
patients	O
with	O
weakness	O
hyperreflexia	O
and	O
incoordination	O
following	O
the	O
use	O
of	O
a	O
selective	B-Group
serotonin	I-Group
reuptake	I-Group
inhibitor	I-Group
(	O
SSRI	B-Group
)	O
and	O
sumatriptan	B-Drug
.	O
      
Interactions	O
for	O
vitamin	B-Group
D	I-Group
analogues	O
(	O
Vitamin	B-Drug
D9	I-Drug
Vitamin	B-Drug
D9	I-Drug
Calcitriol	B-Drug
and	O
Calcidiol	B-Drug
)	O
:	O
Cholestyramine	B-Drug
:	O
Cholestyramine	B-Drug
has	O
been	O
reported	O
to	O
reduce	O
intestinal	O
absorption	O
of	O
fat	B-Group
soluble	I-Group
vitamins	I-Group
;	O
      
-	O
Drugs	O
whose	O
efficacy	O
is	O
impaired	O
by	O
phenytoin	B-Drug
include	O
:	O
anticoagulants	B-Group
corticosteroids	B-Group
coumarin	B-Group
digitoxin	B-Drug
doxycycline	B-Drug
estrogens	B-Group
furosemide	B-Drug
oral	O
contraceptives	B-Group
rifampin	B-Drug
quinidine	B-Drug
theophylline	B-Drug
vitamin	B-Group
D	I-Group
.	O
      
Veratrum	B-Group
alkaloids	I-Group
:	O
Amphetamines	B-Group
inhibit	O
the	O
hypotensive	O
effect	O
of	O
veratrum	B-Group
alkaloids	I-Group
.	O
      
-	O
Acetohydroxamic	B-Drug
acid	I-Drug
(	O
e.g.	O
Lithostat	B-Brand
)	O
or	O
      
The	O
patient	O
should	O
be	O
informed	O
that	O
the	O
response	O
to	O
alcohol	B-Drug
may	O
be	O
exaggerated	O
.	O
      
Since	O
amiodarone	B-Drug
is	O
a	O
substrate	O
for	O
CYP9A9	B-Drug
there	O
is	O
the	O
potential	O
that	O
the	O
use	O
of	O
St.	O
John	O
Wort	O
in	O
patients	O
receiving	O
amiodarone	B-Drug
could	O
result	O
in	O
reduced	O
amiodarone	B-Drug
levels	O
.	O
      
Evidence	O
supporting	O
the	O
conclusion	O
that	O
it	O
is	O
inadvisable	O
to	O
co	O
-	O
administer	O
fluvoxamine	B-Drug
and	O
diazepam	B-Drug
is	O
derived	O
from	O
a	O
study	O
in	O
which	O
healthy	O
volunteers	O
taking	O
9	O
mg	O
/	O
day	O
of	O
fluvoxamine	B-Drug
were	O
administered	O
a	O
single	O
oral	O
dose	O
of	O
9	O
mg	O
of	O
diazepam	B-Drug
.	O
      
Administration	O
of	O
eszopiclone	B-Drug
9	O
mg	O
to	O
a	O
patient	O
taking	O
another	O
drug	O
that	O
is	O
highly	O
protein	O
-	O
bound	O
would	O
not	O
be	O
expected	O
to	O
cause	O
an	O
alteration	O
in	O
the	O
free	O
concentration	O
of	O
either	O
drug	O
.	O
      
Clearance	O
of	O
hydrodolasetron	B-Drug_n
decreased	O
by	O
about	O
9	O
%	O
when	O
dolasetron	B-Drug
mesylate	I-Drug
was	O
administered	O
intravenously	O
concomitantly	O
with	O
atenolol	B-Drug
.	O
      
The	O
clearance	O
of	O
benzodiazepines	B-Group
metabolized	O
by	O
glucuronidation	O
(	O
e.	O
g.	O
lorazepam	B-Drug
oxazepam	B-Drug
temazepam	B-Drug
)	O
is	O
unlikely	O
to	O
be	O
affected	O
by	O
fluvoxamine	B-Drug
.	O
      
Dopamine	B-Group
antagonists	I-Group
such	O
as	O
the	O
neuroleptics	B-Group
(	O
phenothiazines	B-Group
butyrophenones	B-Group
thioxanthines	B-Group
)	O
or	O
metoclopramide	B-Drug
ordinarily	O
should	O
not	O
be	O
administered	O
concurrently	O
with	O
Permax	B-Brand
(	O
a	O
dopamine	B-Group
agonist	I-Group
)	O
;	O
      
ACE	B-Group
Inhibitors	I-Group
:	O
Concomitant	O
use	O
of	O
ACE	B-Group
inhibitors	I-Group
may	O
increase	O
the	O
risk	O
of	O
renal	O
impairment	O
particularly	O
in	O
volume	O
-	O
depleted	O
patients	O
.	O
      
In	O
addition	O
certain	O
drugs	O
that	O
are	O
metabolized	O
by	O
this	O
isozyme	O
including	O
many	O
antidepressants	B-Group
(	O
clozapine	B-Drug
selective	B-Group
serotonin	I-Group
reuptake	I-Group
inhibitors	I-Group
and	O
others	O
)	O
may	O
inhibit	O
the	O
activity	O
of	O
this	O
isozyme	O
and	O
thus	O
may	O
make	O
normal	O
metabolizers	O
resemble	O
poor	O
metabolizers	O
with	O
regard	O
to	O
concomitant	O
therapy	O
with	O
other	O
drugs	O
metabolized	O
by	O
this	O
enzyme	O
system	O
leading	O
to	O
drug	O
interaction	O
.	O
      
Use	O
of	O
a	O
nonhormonal	B-Group
contraceptive	I-Group
product	I-Group
is	O
recommended	O
.	O
      
Effects	O
on	O
the	O
absorption	O
of	O
other	O
beta	B-Group
-	O
blockers	I-Group
have	O
not	O
been	O
determined	O
.	O
      
In	O
situations	O
in	O
which	O
concurrent	O
therapy	O
is	O
necessary	O
careful	O
patient	O
monitoring	O
is	O
essential	O
.	O
      
Dolasetron	B-Drug
mesylate	I-Drug
did	O
not	O
inhibit	O
the	O
antitumor	O
activity	O
of	O
four	O
chemotherapeutic	B-Group
agents	I-Group
(	O
cisplatin	B-Drug
9	B-Drug
-	O
fluorouracil	I-Drug
doxorubicin	B-Drug
cyclophosphamide	B-Drug
)	O
in	O
four	O
murine	O
models	O
.	O
      
Phenytoin	B-Drug
is	O
known	O
to	O
cause	O
osteomalacia	O
.	O
      
Because	O
there	O
is	O
a	O
theoretical	O
basis	O
that	O
these	O
effects	O
may	O
be	O
additive	O
use	O
of	O
ergotamine	B-Drug
-	O
containing	O
or	O
ergot	B-Group
-	O
type	I-Group
medications	I-Group
(	O
like	O
dihydroergotamine	B-Drug
or	O
methysergide	B-Drug
)	O
and	O
naratriptan	B-Drug
within	O
9	O
hours	O
is	O
contraindicated	O
.	O
      
In	O
addition	O
neuromuscular	O
blocking	O
action	O
is	O
enhanced	O
by	O
general	O
anesthetics	B-Group
local	O
anesthetics	B-Group
like	O
lidocaine	B-Drug
procaine	B-Drug
beta	B-Group
-	O
blockers	I-Group
metaclopramide	B-Drug
lithium	B-Drug
carbonate	I-Drug
and	O
terbutaline	B-Drug
.	O
      
Monoamine	B-Group
Oxidase	I-Group
Inhibitors	I-Group
and	O
Tricyclic	B-Group
Antidepressants	I-Group
:	O
FORADIL	B-Brand
should	O
be	O
administered	O
with	O
extreme	O
caution	O
in	O
patients	O
being	O
treated	O
with	O
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
or	O
tricyclic	B-Group
antidepressants	I-Group
because	O
the	O
action	O
of	O
formoterol	B-Drug
on	O
the	O
cardiovascular	O
system	O
may	O
be	O
potentiated	O
by	O
these	O
agents	O
.	O
      
Another	O
investigator	O
found	O
no	O
increase	O
in	O
digoxin	B-Drug
levels	O
in	O
9	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O
      
Injection	O
:	O
Lorazepam	B-Drug
injection	O
like	O
other	O
injectable	O
benzodiazepines	B-Group
produces	O
depression	O
of	O
the	O
central	O
nervous	O
system	O
when	O
administered	O
with	O
ethyl	B-Drug
alcohol	I-Drug
phenothiazines	B-Group
barbiturates	B-Group
MAO	B-Group
inhibitors	I-Group
and	O
other	O
antidepressants	B-Group
.	O
When	O
scopolamine	B-Drug
is	O
used	O
concomitantly	O
with	O
injectable	O
lorazepam	B-Drug
an	O
increased	O
incidence	O
of	O
sedation	O
hallucinations	O
and	O
irrational	O
behavior	O
has	O
been	O
observed	O
.	O
      
Cyclopropane	B-Drug
or	O
halogenated	B-Group
hydrocarbon	I-Group
anesthetics	I-Group
increase	O
cardiac	O
autonomic	O
irritability	O
and	O
may	O
sensitize	O
the	O
myocardium	O
to	O
the	O
action	O
of	O
certain	O
intravenously	O
administered	O
catecholamines	B-Group
such	O
as	O
dopamine	B-Drug
.	O
      
oral	O
clearance	O
was	O
reduced	O
by	O
about	O
9	O
%	O
.	O
      
Antiarrhythmics	B-Drug
:	O
Other	O
antiarrhythmic	B-Drug
drugs	O
such	O
as	O
quinidine	B-Drug
procainamide	B-Drug
disopyramide	B-Drug
and	O
phenytoin	B-Drug
have	O
been	O
used	O
concurrently	O
with	O
amiodarone	B-Drug
.	O
      
The	O
clinical	O
implication	O
of	O
this	O
effect	O
is	O
not	O
known	O
.	O
      
naproxen	B-Drug
;	O
      
It	O
is	O
recommended	O
that	O
glucose	O
tests	O
based	O
on	O
enzymatic	O
glucose	O
oxidase	O
be	O
used	O
.	O
      
The	O
majority	O
of	O
patients	O
in	O
rheumatoid	O
arthritis	O
or	O
Crohn	O
disease	O
clinical	O
studies	O
received	O
one	O
or	O
more	O
concomitant	O
medications	O
.	O
      
Indinavir	B-Drug
is	O
metabolized	O
by	O
CYP9A9	O
.	O
      
The	O
concurrent	O
use	O
of	O
two	O
or	O
more	O
drugs	O
with	O
anticholinergic	O
activity	O
-	O
-	O
such	O
as	O
an	O
antipsychotic	B-Group
drug	I-Group
(	O
eg	O
chlorpromazine	B-Drug
)	O
an	O
antiparkinsonian	B-Group
drug	I-Group
(	O
eg	O
trihexyphenidyl	B-Drug
)	O
and	O
/	O
or	O
a	O
tricyclic	B-Group
antidepressant	I-Group
(	O
eg	O
amitriptyline	B-Drug
)	O
-	O
-	O
commonly	O
results	O
in	O
excessive	O
anticholinergic	O
effects	O
including	O
dry	O
mouth	O
and	O
associated	O
dental	O
complications	O
blurred	O
vision	O
and	O
in	O
patients	O
exposed	O
to	O
high	O
temperature	O
and	O
humidity	O
hyperpyrexia	O
.	O
      
Nitroglycerin	B-Drug
:	O
DynaCirc	B-Brand
(	O
isradipine	B-Drug
)	O
has	O
been	O
safely	O
coadministered	O
with	O
nitroglycerin	B-Drug
.	O
      
Since	O
the	O
pharmacokinetics	O
of	O
BUSULFEX	B-Brand
were	O
studied	O
in	O
patients	O
treated	O
with	O
phenytoin	B-Drug
the	O
clearance	O
of	O
BUSULFEX	B-Brand
at	O
the	O
recommended	O
dose	O
may	O
be	O
lower	O
and	O
exposure	O
(	O
AUC	O
)	O
higher	O
in	O
patients	O
not	O
treated	O
with	O
phenytoin	B-Drug
.	O
      
Consequently	O
it	O
is	O
not	O
possible	O
to	O
make	O
any	O
definitive	O
statements	O
about	O
the	O
risks	O
of	O
coadministration	O
of	O
REMERON	B-Brand
SolTab	I-Brand
with	O
such	O
drugs	O
.	O
      
The	O
action	O
of	O
Mecamylamine	B-Drug
may	O
be	O
potentiated	O
by	O
anesthesia	O
other	O
antihypertensive	B-Group
drugs	I-Group
and	O
alcohol	B-Drug
.	O
      
Alcohol	B-Drug
:	O
In	O
a	O
multiple	O
-	O
dose	O
study	O
in	O
9	O
normal	O
weight	O
subjects	O
coadministration	O
of	O
XENICAL	B-Brand
and	O
9	O
grams	O
of	O
alcohol	B-Drug
(	O
e.g.	O
approximately	O
9	O
glasses	O
of	O
wine	O
)	O
did	O
not	O
result	O
in	O
alteration	O
of	O
alcohol	B-Drug
pharmacokinetics	O
orlistat	B-Drug
pharmacodynamics	O
(	O
fecal	O
fat	O
excretion	O
)	O
or	O
systemic	O
exposure	O
to	O
orlistat	B-Drug
.	O
      
Patients	O
who	O
take	O
both	O
ezetimibe	B-Drug
and	O
cyclosporine	B-Drug
should	O
be	O
carefully	O
monitored	O
.	O
      
Since	O
trimetrexate	B-Drug
is	O
metabolized	O
by	O
a	O
P9	O
enzyme	O
system	O
drugs	O
that	O
induce	O
or	O
inhibit	O
this	O
drug	O
metabolizing	O
enzyme	O
system	O
may	O
elicit	O
important	O
drug	O
-	O
drug	O
interactions	O
that	O
may	O
alter	O
trimetrexate	B-Drug
plasma	O
concentrations	O
.	O
      
Anesthetics	B-Group
/	O
Sedatives	B-Group
/	O
Hypnotics	B-Group
/	O
Opioids	B-Group
:	O
Co	O
-	O
administration	O
of	O
PRECEDEX	B-Brand
with	O
anesthetics	B-Group
sedatives	B-Group
hypnotics	B-Group
and	O
opioids	B-Group
is	O
likely	O
to	O
lead	O
to	O
an	O
enhancement	O
of	O
effects	O
.	O
      
Both	O
CYP9A9	O
and	O
CYP9D9	O
are	O
responsible	O
for	O
aripiprazole	B-Drug
metabolism	O
.	O
      
increased	O
platelet	O
count	O
;	O
      
In	O
a	O
study	O
in	O
normal	O
volunteers	O
it	O
was	O
found	O
that	O
chronic	O
concurrent	O
administration	O
of	O
9	O
g	O
of	O
aspirin	B-Brand
per	O
day	O
decreases	O
indomethacin	B-Drug
blood	O
levels	O
approximately	O
9	O
%	O
.	O
      
Therefore	O
the	O
combination	O
of	O
anakinra	B-Drug
with	O
other	O
TNF	B-Group
-	O
blocking	I-Group
agents	I-Group
including	O
HUMIRA	B-Brand
may	O
also	O
result	O
i	O
n	O
similar	O
toxicities	O
.	O
      
TRENTAL	B-Brand
has	O
been	O
used	O
concurrently	O
with	O
antihypertensive	B-Group
drugs	I-Group
beta	B-Group
blockers	I-Group
digitalis	B-Group
diuretics	B-Group
antidiabetic	B-Group
agents	I-Group
and	O
antiarrhythmics	B-Group
without	O
observed	O
problems	O
.	O
      
The	O
effect	O
of	O
meloxicam	B-Drug
on	O
the	O
anticoagulant	O
effect	O
of	O
warfarin	B-Drug
was	O
studied	O
in	O
a	O
group	O
of	O
healthy	O
subjects	O
receiving	O
daily	O
doses	O
of	O
warfarin	B-Drug
that	O
produced	O
an	O
INR	O
(	O
International	O
Normalized	O
Ratio	O
)	O
between	O
9	O
and	O
9	O
.	O
      
The	O
effect	O
of	O
methylprednisolone	B-Drug
on	O
oral	O
anticoagulants	B-Group
is	O
variable	O
.	O
      
Pharmacologic	O
studies	O
indicate	O
that	O
there	O
may	O
be	O
additive	O
effects	O
in	O
prolonging	O
AV	O
conduction	O
when	O
using	O
beta	B-Group
-	O
blockers	I-Group
or	O
digitalis	B-Group
concomitantly	O
with	O
Tiazac	B-Brand
.	O
      
Concomitant	O
use	O
of	O
ELLENCE	B-Brand
with	O
other	O
cardioactive	O
compounds	O
that	O
could	O
cause	O
heart	O
failure	O
(	O
e.g.	O
calcium	B-Group
channel	I-Group
blockers	I-Group
)	O
requires	O
close	O
monitoring	O
of	O
cardiac	O
function	O
throughout	O
treatment	O
.	O
      
Clidinium	B-Drug
may	O
decrease	O
the	O
effect	O
of	O
phenothiazines	B-Group
levodopa	B-Drug
and	O
ketoconazole	B-Drug
.	O
      
Other	O
medicines	O
-	O
Although	O
certain	O
medicines	O
should	O
not	O
be	O
used	O
together	O
at	O
all	O
in	O
other	O
cases	O
two	O
different	O
medicines	O
may	O
be	O
used	O
together	O
even	O
if	O
an	O
interaction	O
might	O
occur	O
.	O
      
This	O
indicates	O
that	O
tiagabine	B-Drug
does	O
not	O
cause	O
induction	O
or	O
inhibition	O
of	O
the	O
hepatic	O
microsomal	O
enzyme	O
systems	O
responsible	O
for	O
the	O
metabolism	O
of	O
antipyrine	B-Drug
.	O
      
Persons	O
taking	O
most	O
antibiotics	B-Group
methotrexate	B-Drug
and	O
pyrimethamine	B-Drug
invalidate	O
folic	B-Drug
acid	I-Drug
and	O
vitamin	B-Drug
B9	I-Drug
diagnostic	O
blood	O
assays	O
.	O
      
The	O
monoamine	O
oxidase	O
inhibitory	O
effects	O
of	O
Isocarboxazid	B-Drug
may	O
persist	O
for	O
a	O
substantial	O
period	O
after	O
discontinuation	O
of	O
the	O
drug	O
and	O
this	O
should	O
be	O
borne	O
in	O
mind	O
when	O
another	O
drug	O
is	O
prescribed	O
following	O
Isocarboxazid	B-Drug
.	O
      
Conversely	O
adverse	O
effects	O
may	O
result	O
from	O
displacement	O
of	O
protein	O
-	O
bound	O
Anafranil	B-Brand
by	O
other	O
highly	O
bound	O
drugs	O
.	O
      
Indinavir	B-Drug
has	O
been	O
shown	O
to	O
increase	O
plasma	O
levels	O
of	O
combination	B-Group
hormonal	I-Group
contraceptives	I-Group
.	O
      
Magnesium	B-Drug
:	O
Magnesium	B-Drug
-	O
containing	O
preparations	O
(	O
eg	O
antacids	B-Group
)	O
may	O
cause	O
hypermagnesemia	O
and	O
should	O
therefore	O
not	O
be	O
taken	O
during	O
therapy	O
with	O
vitamin	B-Group
D	I-Group
by	O
patients	O
on	O
chronic	O
renal	O
dialysis	O
.	O
      
Antihistamines	B-Group
      
Atazanavir	B-Drug
      
No	O
drug	O
/	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
.	O
      
Curariform	B-Brand
muscle	I-Brand
relaxants	I-Brand
(	O
eg	O
tubocurarine	B-Drug
)	O
and	O
other	O
drugs	O
including	O
ether	O
succinylcholine	B-Drug
gallamine	B-Drug
decamethonium	B-Drug
and	O
sodium	B-Drug
citrate	I-Drug
potentiate	O
the	O
neuromuscular	O
blocking	O
effect	O
and	O
should	O
be	O
used	O
with	O
extreme	O
caution	O
in	O
patients	O
being	O
treated	O
with	O
Coly	B-Brand
-	O
Mycin	I-Brand
M	I-Brand
Parenteral	O
.	O
      
these	O
may	O
also	O
occur	O
in	O
neonates	O
whose	O
mothers	O
received	O
cephalosporins	B-Group
before	O
delivery	O
.	O
      
During	O
clinical	O
trials	O
iloprost	B-Drug
was	O
used	O
concurrently	O
with	O
anticoagulants	B-Group
diuretics	B-Group
cardiac	B-Group
glycosides	I-Group
calcium	B-Group
channel	I-Group
blockers	I-Group
analgesics	B-Group
antipyretics	B-Group
nonsteroidal	B-Group
antiinflammatories	I-Group
corticosteroids	B-Group
and	O
other	O
medications	O
.	O
      
diazoxide	B-Drug
;	O
      
Extreme	O
caution	O
should	O
be	O
exercised	O
when	O
administering	O
TAXOL	B-Brand
to	O
such	O
patients	O
with	O
dose	O
reduction	O
as	O
recommended	O
in	O
DOSAGE	O
AND	O
ADMINISTRATION	O
Table	O
9	O
.	O
      
Anticoagulants	B-Group
:	O
Combination	O
hormonal	B-Group
contraceptives	I-Group
may	O
increase	O
or	O
decrease	O
the	O
effects	O
of	O
coumarin	B-Group
derivatives	I-Group
.	O
      
In	O
simultaneous	O
treatment	O
with	O
imidazole	B-Group
drugs	I-Group
and	O
coumarin	B-Group
drugs	I-Group
the	O
anticoagulant	O
effect	O
should	O
be	O
carefully	O
titrated	O
and	O
monitored	O
.	O
      
Response	O
to	O
Treatment	O
for	O
Anaphylactic	O
Reaction	O
:	O
While	O
taking	O
beta	B-Group
-	O
blockers	I-Group
patients	O
with	O
a	O
history	O
of	O
severe	O
anaphylactic	O
reaction	O
to	O
a	O
variety	O
of	O
allergens	O
may	O
be	O
more	O
reactive	O
to	O
repeated	O
challenge	O
either	O
accidental	O
diagnostic	O
or	O
therapeutic	O
.	O
      
In	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
treated	O
with	O
PEGASYS	B-Brand
in	O
combination	O
with	O
COPEGUS	B-Brand
PEGASYS	B-Brand
treatment	O
did	O
not	O
affect	O
ribavirin	B-Drug
distribution	O
or	O
clearance	O
.	O
      
Drugs	O
which	O
inhibit	O
CYP	O
9A9	O
(	O
e.g.	O
ketoconazole	B-Drug
macrolide	B-Group
antibiotics	I-Group
such	O
as	O
erythromycin	B-Drug
)	O
have	O
the	O
potential	O
to	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
corticosteroids	B-Group
.	O
      
The	O
resulting	O
increase	O
in	O
nitrofurantoin	B-Drug
serum	O
levels	O
may	O
increase	O
toxicity	O
and	O
the	O
decreased	O
urinary	O
levels	O
could	O
lessen	O
its	O
efficacy	O
as	O
a	O
urinary	O
tract	O
antibacterial	B-Group
.	O
      
Use	O
with	O
Angiotensln	B-Group
Converting	I-Group
Enzyme	I-Group
Inhibitors	I-Group
:	O
The	O
use	O
of	O
angiotensin	B-Group
converting	I-Group
enzyme	I-Group
inhibitors	I-Group
to	O
control	O
hypertension	O
in	O
patients	O
on	O
azathioprine	B-Drug
has	O
been	O
reported	O
to	O
induce	O
severe	O
leukopenia	O
.	O
      
Gold	B-Group
is	O
excreted	O
slowly	O
from	O
the	O
body	O
.	O
      
a	O
See	O
Tables	O
9	O
and	O
9	O
.	O
      
The	O
effect	O
of	O
ceftibuten	B-Drug
on	O
the	O
pharmacokinetics	O
of	O
theophylline	B-Drug
administered	O
orally	O
has	O
not	O
been	O
investigated	O
.	O
      
No	O
pharmacokinetic	O
data	O
are	O
available	O
.	O
      
Ethosuximide	B-Drug
:	O
Amphetamines	B-Group
may	O
delay	O
intestinal	O
absorption	O
of	O
ethosuximide	B-Drug
.	O
      
Aspirin	B-Brand
warfarin	B-Drug
heparin	B-Drug
NSAIDs	B-Group
      
No	O
drug	O
interactions	O
have	O
been	O
reported	O
.	O
      
A	O
pharmacokinetic	O
study	O
demonstrated	O
that	O
coadministration	O
of	O
megestrol	B-Drug
acetate	I-Drug
and	O
indinavir	B-Drug
results	O
in	O
a	O
significant	O
decrease	O
in	O
the	O
pharmacokinetic	O
parameters	O
(	O
~9	O
%	O
for	O
Cmax	O
and	O
~9	O
%	O
for	O
AUC	O
)	O
of	O
indinavir	B-Drug
.	O
      
Hematopoietic	O
      
Therefore	O
the	O
dose	O
of	O
corticosteroid	B-Group
should	O
be	O
titrated	O
to	O
avoid	O
steroid	O
toxicity	O
.	O
      
Phenytoin	B-Drug
is	O
a	O
potent	O
inducer	O
of	O
hepatic	O
drug	O
-	O
metabolizing	O
enzymes	O
.	O
      
No	O
formal	O
drug	O
-	O
drug	O
interaction	O
studies	O
however	O
have	O
been	O
conducted	O
.	O
      
Ketoconazole	B-Drug
increased	O
mean	O
alosetron	B-Drug
plasma	O
concentrations	O
(	O
AUC	O
)	O
by	O
9	O
%	O
.	O
      
Catecholamine	O
-	O
depleting	O
drugs	O
(	O
e.g.	O
reserpine	B-Drug
)	O
may	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
beta	B-Drug
-	O
blocking	I-Drug
agents	O
.	O
      
This	O
slowing	O
potentiates	O
amphetamines	B-Group
increasing	O
their	O
effect	O
on	O
the	O
release	O
of	O
norepinephrine	O
and	O
other	O
monoamines	O
from	O
adrenergic	O
nerve	O
endings	O
;	O
      
Nevertheless	O
plasma	O
lithium	B-Drug
levels	O
should	O
be	O
monitored	O
with	O
appropriate	O
adjustment	O
to	O
the	O
lithium	B-Drug
dose	O
in	O
accordance	O
with	O
standard	O
clinical	O
practice	O
.	O
      
Based	O
on	O
the	O
literature	O
reports	O
the	O
same	O
effects	O
may	O
be	O
extrapolated	O
to	O
other	O
fruit	O
juices	O
such	O
as	O
apple	O
juice	O
.	O
      
In	O
bioavailability	O
studies	O
with	O
normal	O
subjects	O
the	O
concurrent	O
administration	O
of	O
antacids	B-Group
at	O
therapeutic	O
levels	O
did	O
not	O
significantly	O
influence	O
the	O
bioavailability	O
of	O
TRANXENE	B-Brand
tablets	O
.	O
      
Drugs	O
such	O
as	O
troleandomycin	B-Drug
and	O
ketoconazole	B-Drug
may	O
inhibit	O
the	O
metabolism	O
of	O
corticosteroids	B-Group
and	O
thus	O
decrease	O
their	O
clearance	O
.	O
      
.	O
      
Sulfonamides	B-Group
:	O
Concurrent	O
use	O
of	O
procaine	B-Drug
hydrochloride	I-Drug
and	O
sulfonamides	B-Group
may	O
result	O
in	O
a	O
reduction	O
of	O
the	O
antibacterial	O
action	O
of	O
the	O
sulfonamide	B-Group
.	O
      
Anticholinergics	B-Group
antagonize	O
the	O
effects	O
of	O
antiglaucoma	B-Group
agents	I-Group
.	O
      
There	O
was	O
no	O
evidence	O
of	O
any	O
pharmacokinetic	O
interactions	O
between	O
ERBITUX	B-Brand
and	O
irinotecan	B-Drug
.	O
      
Caution	O
is	O
recommended	O
when	O
administering	O
NEXAVAR	B-Brand
with	O
compounds	O
that	O
are	O
metabolized	O
/	O
eliminated	O
predominantly	O
by	O
the	O
UGT9A9	O
pathway	O
(	O
e.g	O
.	O
irinotecan	B-Drug
)	O
.	O
      
9	O
-	O
nc	O
denotes	O
a	O
mean	O
change	O
of	O
less	O
than	O
9	O
%	O
9	O
-	O
Pediatrics	O
9	O
-	O
Mean	O
increase	O
in	O
adults	O
at	O
high	O
Trileptal	B-Brand
doses	O
In	O
vivo	O
the	O
plasma	O
levels	O
of	O
phenytoin	B-Drug
increased	O
by	O
up	O
to	O
9	O
%	O
when	O
Trileptal	B-Brand
was	O
given	O
at	O
doses	O
above	O
9	O
mg	O
/	O
day	O
.	O
      
Poor	O
metabolizers	O
have	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
tricyclic	B-Group
antidepressants	I-Group
(	O
TCAs	B-Group
)	O
when	O
given	O
usual	O
doses	O
.	O
      
Theophylline	B-Drug
:	O
The	O
effect	O
of	O
steady	O
-	O
state	O
fluvoxamine	B-Drug
l9	O
mg	O
bid	O
on	O
the	O
pharmacokinetics	O
of	O
a	O
single	O
dose	O
of	O
Theophylline	B-Drug
(	O
9	O
mg	O
)	O
as	O
9	O
mg	O
aminophylline	B-Drug
was	O
evaluated	O
in	O
9	O
healthy	O
non	O
-	O
smoking	O
male	O
volunteers	O
.	O
      
However	O
9	O
patients	O
who	O
switched	O
from	O
therapy	O
with	O
Interferon	B-Drug
beta	I-Drug
to	O
COPAXONE	B-Brand
did	O
not	O
report	O
any	O
serious	O
and	O
unexpected	O
adverse	O
reactions	O
thought	O
to	O
be	O
related	O
to	O
treatment	O
.	O
      
Prolonged	O
menstrual	O
cycles	O
and	O
/	O
or	O
amenorrhea	O
were	O
observed	O
in	O
female	O
cynomolgus	O
monkeys	O
given	O
sc	O
injections	O
of	O
9	O
m	O
g	O
/	O
kg	O
/	O
dose	O
(	O
9	O
m	O
g	O
/	O
m9	O
/	O
dose	O
)	O
of	O
PEGASYS	B-Brand
every	O
other	O
day	O
for	O
one	O
month	O
at	O
approximately	O
9	O
times	O
the	O
recommended	O
weekly	O
human	O
dose	O
for	O
a	O
9	O
kg	O
person	O
(	O
based	O
on	O
body	O
surface	O
area	O
)	O
.	O
      
These	O
pharmacokinetic	O
effects	O
did	O
not	O
result	O
in	O
clinically	O
meaningful	O
changes	O
in	O
ECG	O
heart	O
rate	O
or	O
blood	O
pressure	O
beyond	O
those	O
changes	O
induced	O
by	O
diltiazem	B-Drug
alone	O
.	O
      
No	O
cases	O
of	O
rhabdomyolysis	O
were	O
reported	O
in	O
this	O
trial	O
.	O
      
Warfarin	B-Drug
:	O
Quinolones	B-Group
may	O
enhance	O
the	O
effects	O
of	O
the	O
oral	O
anticoagulant	B-Group
warfarin	B-Drug
or	O
its	O
derivatives	O
.	O
      
SINCE	O
CHOLESTYRAMINE	B-Drug
RESIN	B-Group
MAY	O
BIND	O
OTHER	O
DRUGS	O
GIVEN	O
CONCURRENTLY	O
IT	O
IS	O
RECOMMENDED	O
THAT	O
PATIENTS	O
TAKE	O
OTHER	O
DRUGS	O
AT	O
LEAST	O
9	O
HOUR	O
BEFORE	O
OR	O
9	O
TO	O
9	O
HOURS	O
AFTER	O
CHOLESTYRAMINE	B-Drug
RESIN	B-Group
(	O
OR	O
AT	O
AS	O
GREAT	O
AN	O
INTERVAL	O
AS	O
POSSIBLE	O
)	O
TO	O
AVOID	O
IMPEDING	O
THEIR	O
ABSORPTION	O
.	O
      
General	O
In	O
vitro	O
studies	O
in	O
human	O
liver	O
microsomes	O
demonstrated	O
no	O
evidence	O
of	O
cytochrome	O
P9	O
-	O
mediated	O
drug	O
interactions	O
that	O
are	O
likely	O
to	O
be	O
of	O
clinical	O
relevance	O
.	O
      
In	O
addition	O
drugs	O
that	O
are	O
actively	O
secreted	O
via	O
this	O
route	O
(	O
e.g.	O
triamterene	B-Drug
metformin	B-Drug
and	O
amiloride	B-Drug
)	O
should	O
be	O
co	O
-	O
administered	O
with	O
care	O
as	O
they	O
might	O
increase	O
dofetilide	B-Drug
levels	O
.	O
      
This	O
interference	O
has	O
resulted	O
in	O
significant	O
increases	O
in	O
half	O
-	O
life	O
and	O
AUC	O
.	O
      
Additional	O
dose	O
increases	O
should	O
be	O
based	O
on	O
clinical	O
evaluation	O
.	O
      
therefore	O
nitroglycerin	B-Drug
or	O
other	O
nitrates	B-Group
(	O
as	O
used	O
for	O
management	O
of	O
angina	O
)	O
or	O
other	O
drugs	O
having	O
vasodilator	O
activity	O
should	O
if	O
possible	O
be	O
discontinued	O
before	O
starting	O
captopril	B-Drug
.	O
      
During	O
concomitant	O
therapy	O
with	O
NSAIDs	B-Group
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
signs	O
of	O
renal	O
failure	O
as	O
well	O
as	O
to	O
assure	O
diuretic	O
efficacy	O
.	O
      
ACE	B-Group
inhibitors	I-Group
:	O
Reports	O
suggest	O
that	O
NSAIDs	B-Group
may	O
diminish	O
the	O
antihypertensive	O
effect	O
of	O
Angiotensin	B-Group
Converting	I-Group
Enzyme	I-Group
ACE	I-Group
inhibitors	I-Group
.	O
      
Therefore	O
Clozapine	B-Drug
should	O
not	O
be	O
used	O
with	O
other	O
agents	O
having	O
a	O
well	O
-	O
known	O
potential	O
to	O
suppress	O
bone	O
marrow	O
function	O
.	O
      
Furthermore	O
rifampin	B-Drug
dexamethasone	B-Drug
St	O
.	O
      
Although	O
other	O
hormonal	B-Group
contraceptives	I-Group
are	O
highly	O
effective	O
there	O
have	O
been	O
reports	O
of	O
pregnancy	O
from	O
women	O
who	O
have	O
used	O
combined	B-Group
oral	I-Group
contraceptives	I-Group
as	O
well	O
as	O
topical	O
/	O
injectable	O
/	O
implantable	O
/	O
insertable	O
hormonal	O
birth	O
control	O
products	O
.	O
      
The	O
concurrent	O
use	O
of	O
tetracycline	B-Group
and	O
methoxyflurane	B-Drug
has	O
been	O
reported	O
to	O
result	O
in	O
fatal	O
renal	O
toxicity	O
.	O
      
Ketamine	B-Drug
:	O
Marked	O
hypertension	O
and	O
tachycardia	O
have	O
been	O
reported	O
in	O
association	O
with	O
concomitant	O
administration	O
of	O
levothyroxine	B-Drug
sodium	I-Drug
and	O
ketamine	B-Drug
.	O
      
No	O
specific	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
.	O
      
No	O
reported	O
interactions	O
.	O
      
The	O
results	O
from	O
a	O
study	O
in	O
which	O
eight	O
HIV	O
-	O
infected	O
individuals	O
were	O
treated	O
with	O
zidovudine	B-Drug
9	O
+	O
/	O
-	O
9	O
mg	O
/	O
kg	O
/	O
day	O
showed	O
that	O
the	O
pharmacokinetics	O
of	O
zidovudine	B-Drug
were	O
not	O
affected	O
during	O
concomitant	O
administration	O
of	O
Itraconazole	B-Drug
9	O
mg	O
b.i.d	O
.	O
      
No	O
formal	O
drug	O
/	O
laboratory	O
test	O
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
CLOLAR	B-Brand
.	O
      
Catecholamine	O
-	O
depleting	O
Agents	O
:	O
Patients	O
taking	O
both	O
agents	B-Group
with	I-Group
b	I-Group
-	O
blocking	I-Group
properties	I-Group
and	O
a	O
drug	O
that	O
can	O
deplete	O
catecholamines	O
(	O
e.g.	O
reserpine	B-Drug
and	O
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
)	O
should	O
be	O
observed	O
closely	O
for	O
signs	O
of	O
hypotension	O
and	O
/	O
or	O
severe	O
bradycardia	O
.	O
      
Free	O
T9	O
resin	O
uptake	O
is	O
decreased	O
reflecting	O
the	O
elevated	O
TBG	O
;	O
      
When	O
concomitant	O
administration	O
of	O
ketoconazole	B-Drug
with	O
aripiprazole	B-Drug
occurs	O
aripiprazole	B-Drug
dose	O
should	O
be	O
reduced	O
to	O
one	O
-	O
half	O
of	O
its	O
normal	O
dose	O
.	O
      
Nursing	O
Mothers	O
It	O
is	O
not	O
known	O
whether	O
peginterferon	B-Drug
or	O
ribavirin	B-Drug
or	O
its	O
components	O
are	O
excreted	O
in	O
human	O
milk	O
.	O
      
Frequent	O
vital	O
sign	O
monitoring	O
particularly	O
during	O
the	O
first	O
hour	O
of	O
TAXOL	B-Brand
infusion	O
is	O
recommended	O
.	O
      
Clinical	O
Comment	O
      
An	O
individual	O
who	O
is	O
stable	O
on	O
a	O
given	O
dose	O
of	O
TCA	B-Group
may	O
become	O
abruptly	O
toxic	O
when	O
given	O
one	O
of	O
these	O
inhibiting	O
drugs	O
as	O
concomitant	O
therapy	O
.	O
      
Clinical	O
Laboratory	O
      
There	O
was	O
no	O
apparent	O
pharmacokinetic	O
interaction	O
between	O
zaleplon	B-Drug
and	O
ibuprofen	B-Drug
following	O
single	O
dose	O
administration	O
(	O
9	O
mg	O
and	O
9	O
mg	O
respectively	O
)	O
of	O
each	O
drug	O
.	O
      
Alcohol	B-Drug
:	O
Has	O
a	O
synergistic	O
effect	O
with	O
aspirin	B-Brand
in	O
causing	O
gastrointestinal	O
bleeding	O
.	O
      
Gabapentin	B-Drug
had	O
no	O
effect	O
on	O
naproxen	B-Drug
pharmacokinetic	O
parameters	O
.	O
      
Oxcarbazepine	B-Drug
was	O
evaluated	O
in	O
human	O
liver	O
microsomes	O
to	O
determine	O
its	O
capacity	O
to	O
inhibit	O
the	O
major	O
cytochrome	O
P9	O
enzymes	O
responsible	O
for	O
the	O
metabolism	O
of	O
other	O
drugs	O
.	O
      
increased	O
serum	O
digoxin	B-Drug
concentrations	O
may	O
result	O
.	O
      
The	O
CNS	O
depressant	O
effects	O
of	O
oxycodone	B-Drug
hydrochloride	I-Drug
may	O
be	O
additive	O
with	O
that	O
of	O
other	O
CNS	B-Group
depressants	I-Group
..	O
      
.	O
      
The	O
administration	O
of	O
naproxen	B-Drug
may	O
result	O
in	O
increased	O
urinary	O
values	O
for	O
9	O
-	O
ketogenic	O
steroids	O
because	O
of	O
an	O
interaction	O
between	O
the	O
drug	O
and	O
/	O
or	O
its	O
metabolites	O
with	O
m	O
-	O
dinitrobenzene	O
used	O
in	O
this	O
assay	O
.	O
      
Methazolamide	B-Drug
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
on	O
steroid	O
therapy	O
because	O
of	O
the	O
potential	O
for	O
developing	O
hypokalemia	O
.	O
      
The	O
physician	O
should	O
be	O
cautious	O
when	O
administering	O
flurbiprofen	B-Drug
to	O
patients	O
taking	O
anticoagulants	B-Group
.	O
      
Familial	O
hyper	O
-	O
or	O
hypo	O
-	O
thyroxine	O
-	O
binding	O
-	O
globulinemias	O
have	O
been	O
described	O
.	O
      
Clarithromycin	B-Drug
      
Psychoactive	B-Group
Drugs	I-Group
:	O
Hallucinations	O
have	O
been	O
reported	O
when	O
TORADOL	B-Brand
was	O
used	O
in	O
patients	O
taking	O
psychoactive	B-Group
drugs	I-Group
(	O
fluoxetine	B-Drug
thiothixene	B-Drug
alprazolam	B-Drug
)	O
.	O
      
Coadministration	O
of	O
this	O
oral	O
contraceptive	B-Group
did	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
levetiracetam	B-Drug
.	O
      
The	O
results	O
were	O
similar	O
with	O
and	O
without	O
coadministration	O
of	O
thalidomide	B-Drug
9	O
mg	O
/	O
day	O
to	O
steady	O
-	O
state	O
levels	O
.	O
      
In	O
long	O
surgical	O
procedures	O
during	O
enflurane	B-Drug
or	O
isoflurane	B-Drug
anesthesia	O
less	O
frequent	O
maintenance	O
dosing	O
lower	O
maintenance	O
doses	O
or	O
reduced	O
infusion	O
rates	O
of	O
NIMBEX	B-Brand
may	O
be	O
necessary	O
.	O
      
Correlative	O
clinical	O
studies	O
have	O
not	O
been	O
performed	O
.	O
      
Patients	O
using	O
these	O
drugs	O
have	O
not	O
been	O
studied	O
in	O
clinical	O
trials	O
.	O
      
Protease	B-Group
Inhibitors	I-Group
:	O
In	O
vitro	O
data	O
indicate	O
that	O
indinavir	B-Drug
and	O
ritonavir	B-Drug
markedly	O
inhibit	O
the	O
metabolism	O
of	O
cisapride	B-Drug
which	O
can	O
result	O
in	O
an	O
increase	O
in	O
plasma	O
cisapride	B-Drug
levels	O
and	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O
      
Coumarin	B-Group
Anticoagulants	I-Group
:	O
In	O
a	O
small	O
clinical	O
trial	O
in	O
which	O
lovastatin	B-Drug
was	O
administered	O
to	O
warfarin	B-Drug
treated	O
patients	O
no	O
effect	O
on	O
prothrombin	O
time	O
was	O
detected	O
.	O
      
The	O
concurrent	O
use	O
of	O
Robinul	B-Brand
Injection	O
with	O
other	O
anticholinergics	B-Group
or	O
medications	O
with	O
anticholinergic	O
activity	O
such	O
as	O
phenothiazines	B-Group
antiparkinson	B-Group
drugs	I-Group
or	O
tricyclic	B-Group
antidepressants	I-Group
may	O
intensify	O
the	O
antimuscarinic	O
effects	O
and	O
may	O
result	O
in	O
an	O
increase	O
in	O
anticholinergic	O
side	O
effects	O
.	O
      
Caution	O
should	O
be	O
used	O
if	O
INDOCIN	B-Brand
is	O
administered	O
simultaneously	O
with	O
methotrexate	B-Drug
.	O
      
Brain	O
hemorrhage	O
and	O
optic	O
nerve	O
vacuolation	O
were	O
seen	O
in	O
another	O
female	O
dog	O
that	O
was	O
sacrificed	O
in	O
moribund	O
condition	O
after	O
9	O
weeks	O
of	O
escalating	O
doses	O
up	O
to	O
9	O
mg	O
/	O
kg	O
/	O
day	O
.	O
      
Therefore	O
linezolid	B-Drug
has	O
the	O
potential	O
for	O
interaction	O
with	O
adrenergic	B-Group
and	O
serotonergic	B-Group
agents	I-Group
.	O
      
Probenecid	B-Drug
:	O
Probenecid	B-Drug
is	O
known	O
to	O
interact	O
with	O
the	O
metabolism	O
or	O
renal	O
tubular	O
excretion	O
of	O
many	O
drugs	O
(	O
e.g.	O
acetaminophen	B-Drug
acyclovir	B-Drug
angiotensin	B-Group
-	O
converting	I-Group
enzyme	I-Group
inhibitors	I-Group
aminosalicylic	B-Drug
acid	I-Drug
barbiturates	B-Group
benzodiazepines	B-Group
bumetanide	B-Drug
clofibrate	B-Drug
methotrexate	B-Drug
famotidine	B-Drug
furosemide	B-Drug
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
agents	O
theophylline	B-Drug
and	O
zidovudine	B-Drug
)	O
.	O
      
Probenecid	B-Drug
:	O
As	O
with	O
other	O
b	B-Group
-	O
lactam	I-Group
antibiotics	I-Group
probenecid	B-Drug
inhibits	O
the	O
renal	O
excretion	O
of	O
cefdinir	B-Drug
resulting	O
in	O
an	O
approximate	O
doubling	O
in	O
A.C.	O
a	O
9	O
%	O
increase	O
in	O
peak	O
cefdinir	B-Drug
plasma	O
levels	O
and	O
a	O
9	O
%	O
prolongation	O
in	O
the	O
apparent	O
elimination	O
half	O
-	O
life	O
.	O
      
Nucleoside	O
Analogues	O
Didanosine	B-Drug
Co	O
-	O
administration	O
of	O
COPEGUS	B-Brand
and	O
didanosine	B-Drug
is	O
not	O
recommended	O
.	O
      
-	O
Drugs	O
that	O
may	O
either	O
increase	O
or	O
decrease	O
plasma	O
phenytoin	B-Drug
concentrations	O
include	O
:	O
phenobarbital	B-Drug
vaiproic	O
acid	O
and	O
sodium	B-Drug
valproate	I-Drug
.	O
      
The	O
actions	O
of	O
the	O
benzodiazepines	B-Group
may	O
be	O
potentiated	O
by	O
barbiturates	B-Group
narcotics	B-Group
phenothiazines	B-Group
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
or	O
other	O
antidepressants	B-Group
.	O
      
periodic	O
systemic	O
blood	O
pressure	O
monitoring	O
is	O
recommended	O
for	O
patients	O
receiving	O
concomitant	O
antihypertensive	O
therapy	O
.	O
      
-	O
a	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
drug	I-Group
(	O
NSAID	B-Group
)	O
such	O
as	O
ibuprofen	B-Drug
(	O
Motrin	B-Brand
Advil	B-Brand
Nuprin	B-Brand
others	O
)	O
ketoprofen	B-Drug
(	O
Orudis	B-Brand
Orudis	B-Brand
KT	I-Brand
Oruvail	B-Brand
)	O
diclofenac	B-Drug
(	O
Voltaren	B-Brand
Cataflam	B-Brand
)	O
etodolac	B-Drug
(	O
Lodine	B-Brand
)	O
indomethacin	B-Drug
(	O
Indocin	B-Brand
)	O
nabumetone	B-Drug
(	O
Relafen	B-Brand
)	O
oxaprozin	B-Drug
(	O
Daypro	B-Brand
)	O
and	O
naproxen	B-Drug
(	O
Anaprox	B-Brand
Naprosyn	B-Brand
Aleve	B-Brand
)	O
;	O
      
cimetidine	B-Drug
)	O
and	O
many	O
that	O
are	O
substrates	O
for	O
P9	O
9D9	O
(	O
many	O
other	O
antidepressants	B-Group
phenothiazines	B-Group
and	O
the	O
Type	B-Group
9C	I-Group
antiarrhythmics	I-Group
propafenone	B-Drug
and	O
flecainide	B-Drug
)	O
.	O
      
Dose	O
modification	O
is	O
recommended	O
for	O
patients	O
who	O
are	O
also	O
receiving	O
a	O
potent	O
CYP	O
9A9	O
inducer	O
.	O
      
sulindac	B-Drug
;	O
      
Clarithromycin	B-Drug
      
Oral	O
Contraceptives	B-Group
:	O
In	O
9	O
normal	O
-	O
weight	O
female	O
subjects	O
the	O
treatment	O
of	O
XENICAL	B-Brand
9	O
mg	O
three	O
times	O
a	O
day	O
for	O
9	O
days	O
resulted	O
in	O
no	O
changes	O
in	O
the	O
ovulation	O
-	O
suppressing	O
action	O
of	O
oral	O
contraceptives	B-Group
.	O
      
The	O
mean	O
AUC	O
values	O
of	O
LNG	O
were	O
decreased	O
by	O
9	O
%	O
[	O
9	O
%	O
CI	O
:	O
9	O
-	O
9	O
]	O
in	O
one	O
study	O
and	O
9	O
%	O
[	O
9	O
%	O
CI	O
:	O
9	O
-	O
9	O
]	O
in	O
another	O
study	O
.	O
      
Warfarin	B-Drug
:	O
In	O
a	O
short	O
-	O
term	O
controlled	O
study	O
in	O
9	O
normal	O
volunteers	O
ketoprofen	B-Drug
did	O
not	O
significantly	O
interfere	O
with	O
the	O
effect	O
of	O
warfarin	B-Drug
on	O
prothrombin	O
time	O
.	O
      
However	O
because	O
higher	O
doses	O
(	O
up	O
to	O
9	O
mg	O
QD	O
)	O
of	O
omeprazole	B-Drug
are	O
tolerated	O
in	O
Zollinger	O
-	O
Ellison	O
(	O
ZE	O
)	O
patients	O
no	O
dose	O
adjustment	O
for	O
omeprazole	B-Drug
is	O
recommended	O
at	O
current	O
doses	O
.	O
      
Clozapine	B-Drug
may	O
potentiate	O
the	O
hypotensive	O
effects	O
of	O
antihypertensive	B-Group
drugs	I-Group
and	O
the	O
anticholinergic	O
effects	O
of	O
atropine	B-Drug
-	O
type	O
drugs	O
.	O
      
These	O
experiences	O
have	O
been	O
characterized	O
by	O
flushing	O
rash	O
peripheral	O
edema	O
nausea	O
and	O
headache	O
.	O
      
Concurrent	O
administration	O
of	O
drugs	O
possessing	O
nephrotoxic	O
(	O
e.g.	O
aminoglycosides	B-Group
indomethacin	B-Drug
)	O
myelotoxic	O
(	O
e.g.	O
cytotoxic	B-Group
chemotherapy	O
)	O
cardiotoxic	O
(	O
e.g.	O
doxorubicin	B-Drug
)	O
or	O
hepatotoxic	O
(	O
e.g.	O
methotrexate	B-Drug
asparaginase	B-Drug
)	O
effects	O
with	O
PROLEUKIN	B-Brand
may	O
increase	O
toxicity	O
in	O
these	O
organ	O
systems	O
.	O
      
Indinavir	B-Drug
      
-	O
Phenothiazines	B-Group
(	O
acetophenazine	B-Drug
[	O
e.g.	O
Tindal	B-Brand
]	O
chlorpromazine	B-Drug
[	O
e.g.	O
Thorazine	B-Brand
]	O
fluphenazine	B-Drug
[	O
e.g.	O
Prolixin	B-Brand
]	O
mesoridazine	B-Brand
[	O
e.g.	O
Serentil	B-Brand
]	O
perphenazine	B-Drug
[	O
e.g.	O
Trilafon	B-Brand
]	O
prochlorperazine	B-Drug
[	O
e.g.	O
Compazine	B-Brand
]	O
promazine	B-Drug
[	O
e.g.	O
Sparine	B-Brand
]	O
promethazine	B-Drug
[	O
e.g.	O
Phenergan	B-Brand
]	O
thioridazine	B-Drug
[	O
e.g.	O
Mellaril	B-Brand
]	O
trifluoperazine	B-Drug
[	O
e.g.	O
Stelazine	B-Brand
]	O
triflupromazine	B-Drug
[	O
e.g.	O
Vesprin	B-Brand
]	O
trimeprazine	B-Drug
[	O
e.g.	O
Temaril	B-Brand
]	O
)	O
or	O
      
transaminases	O
(	O
AST	O
      
Fifteen	O
to	O
9	O
minutes	O
of	O
exposure	O
to	O
9	O
MAC	O
isoflurane	B-Drug
or	O
enflurane	B-Drug
had	O
minimal	O
effects	O
on	O
the	O
duration	O
of	O
action	O
of	O
initial	O
doses	O
of	O
NIMBEX	B-Brand
and	O
therefore	O
no	O
adjustment	O
to	O
the	O
initial	O
dose	O
should	O
be	O
necessary	O
when	O
NIMBEX	B-Brand
is	O
administered	O
shortly	O
after	O
initiation	O
of	O
volatile	O
agents	O
.	O
      
Esomeprazole	B-Drug
may	O
potentially	O
interfere	O
with	O
CYP9C9	O
the	O
major	O
esomeprazole	B-Drug
metabolizing	O
enzyme	O
.	O
      
Patients	O
treated	O
with	O
proton	B-Group
pump	I-Group
inhibitors	I-Group
and	O
warfarin	B-Drug
concomitantly	O
should	O
be	O
monitored	O
for	O
increases	O
in	O
INR	O
and	O
prothrombin	O
time	O
.	O
      
Although	O
clinical	O
studies	O
have	O
not	O
been	O
performed	O
phenobarbital	B-Drug
is	O
expected	O
to	O
have	O
the	O
same	O
effect	O
.	O
      
There	O
was	O
also	O
no	O
interaction	O
with	O
concomitantly	O
administered	O
antacids	B-Group
.	O
      
In	O
a	O
study	O
of	O
9	O
schizophrenic	O
patients	O
coadministered	O
oral	O
haloperidol	B-Drug
and	O
rifampin	B-Drug
plasma	O
haloperidol	B-Drug
levels	O
were	O
decreased	O
by	O
a	O
mean	O
of	O
9	O
%	O
and	O
mean	O
scores	O
on	O
the	O
Brief	O
Psychiatric	O
Rating	O
Scale	O
were	O
increased	O
from	O
baseline	O
.	O
      
Patients	O
already	O
stabilized	O
on	O
valdecoxib	B-Drug
should	O
be	O
closely	O
monitored	O
for	O
loss	O
of	O
symptom	O
control	O
with	O
phenytoin	B-Drug
coadministration	O
.	O
      
The	O
possibility	O
of	O
hypotensive	O
effects	O
with	O
UNIVASC	B-Brand
can	O
be	O
minimized	O
by	O
discontinuing	O
diuretic	O
therapy	O
for	O
several	O
days	O
or	O
cautiously	O
increasing	O
salt	O
intake	O
before	O
initiation	O
of	O
treatment	O
with	O
UNIVASC	B-Brand
.	O
If	O
this	O
is	O
not	O
possible	O
the	O
starting	O
dose	O
of	O
moexpril	B-Drug
should	O
be	O
reduced..	O
      
Effects	O
of	O
other	O
Antiepilepsy	O
Drugs	O
(	O
AEDs	B-Group
)	O
on	O
GABITRIL	B-Brand
:	O
Carbamazepine	B-Drug
:	O
Population	O
pharmacokinetic	O
analyses	O
indicate	O
that	O
tiagabine	B-Drug
clearance	O
is	O
9	O
%	O
greater	O
in	O
patients	O
taking	O
carbamazepine	B-Drug
with	O
or	O
without	O
other	O
enzyme	O
-	O
inducing	O
AEDs	B-Group
.	O
      
Although	O
concomitant	O
use	O
of	O
Clozapine	B-Drug
and	O
carbamazepine	B-Drug
is	O
not	O
recommended	O
it	O
should	O
be	O
noted	O
that	O
discontinuation	O
of	O
concomitant	O
carbamazepine	B-Drug
administration	O
may	O
result	O
in	O
an	O
increase	O
in	O
Clozapine	B-Drug
plasma	O
levels	O
.	O
      
Organic	O
nitrates	B-Group
-	O
L	B-Drug
-	O
arginine	I-Drug
supplements	O
theoretically	O
may	O
potentiate	O
the	O
effects	O
of	O
organic	O
nitrates	B-Drug
if	O
taken	O
concomitantly	O
.	O
      
If	O
antacids	B-Group
are	O
required	O
during	O
OMNICEF	B-Brand
therapy	O
OMNICEF	B-Brand
should	O
be	O
taken	O
at	O
least	O
9	O
hours	O
before	O
or	O
after	O
the	O
antacid	B-Group
.	O
      
If	O
such	O
measurements	O
are	O
necessary	O
the	O
use	O
of	O
other	O
methods	O
is	O
recommended	O
.	O
      
In	O
four	O
subjects	O
with	O
epilepsy	O
ingesting	O
valproate	B-Drug
the	O
steady	O
-	O
state	O
trough	O
(	O
Cmin	O
)	O
valproate	B-Drug
plasma	O
concentration	O
was	O
9	O
9	O
micrograms	O
/	O
mL	O
.	O
      
Presumably	O
phenytoin	B-Drug
acts	O
as	O
a	O
stimulator	O
of	O
coumarin	B-Group
metabolism	O
and	O
has	O
been	O
reported	O
to	O
cause	O
decreased	O
serum	O
levels	O
of	O
the	O
coumarin	B-Group
anticoagulants	I-Group
and	O
increased	O
prothrombin	O
-	O
proconvertin	O
concentrations	O
.	O
      
Concomitant	O
administrations	O
not	O
recommended	O
:	O
-	O
Terfenadine	B-Drug
and	O
astemizole	B-Drug
:	O
Certain	O
macrolides	B-Group
interact	O
with	O
terfenadine	B-Drug
and	O
astemizole	B-Drug
leading	O
to	O
increased	O
serum	O
concentrations	O
of	O
the	O
latter	O
.	O
      
Cimetidine	B-Drug
:	O
In	O
a	O
study	O
in	O
healthy	O
volunteers	O
a	O
one	O
-	O
week	O
course	O
of	O
cimetidine	B-Drug
at	O
9	O
mg	O
b.i.d	O
.	O
with	O
a	O
single	O
9	O
mg	O
dose	O
of	O
isradipine	B-Drug
on	O
the	O
sixth	O
day	O
showed	O
an	O
increase	O
in	O
isradipine	B-Drug
mean	O
peak	O
plasma	O
concentrations	O
(	O
9	O
%	O
)	O
and	O
significant	O
increase	O
in	O
area	O
under	O
the	O
curve	O
(	O
9	O
%	O
)	O
.	O
      
Potential	O
for	O
Other	O
Drugs	O
to	O
Affect	O
Duloxetine	B-Drug
:	O
Both	O
CYP9A9	O
and	O
CYP9D9	O
are	O
responsible	O
for	O
duloxetine	B-Drug
metabolism	O
.	O
      
Rare	O
cases	O
of	O
serious	O
cardiovascular	O
adverse	O
events	O
including	O
electrocardiographic	O
QT	O
/	O
QTc	O
interval	O
prolongation	O
cardiac	O
arrest	O
torsades	O
de	O
pointes	O
and	O
other	O
ventricular	O
arrhythmias	O
have	O
been	O
observed	O
.	O
      
Consequently	O
it	O
is	O
recommended	O
that	O
fluvoxamine	B-Drug
not	O
be	O
used	O
in	O
combination	O
with	O
either	O
terbinafine	B-Drug
astemizole	B-Drug
or	O
cisapride	B-Drug
.	O
      
Concomitant	O
administration	O
of	O
Aprepitant	B-Drug
with	O
strong	O
CYP9A9	O
inhibitors	O
should	O
be	O
approached	O
cautiously	O
.	O
      
TOBI	B-Brand
should	O
not	O
be	O
administered	O
concomitantly	O
with	O
ethacrynic	B-Drug
acid	I-Drug
furosemide	B-Drug
urea	B-Drug
or	O
mannitol	B-Drug
.	O
      
Tricyclic	B-Group
antidepressants	I-Group
may	O
antagonize	O
the	O
hypotensive	O
effects	O
of	O
clonidine	B-Drug
.	O
      
It	O
is	O
important	O
to	O
recognize	O
this	O
phenomenon	O
before	O
a	O
patient	O
with	O
a	O
possible	O
pheochromocytoma	O
is	O
subjected	O
to	O
surgery	O
.	O
      
Therefore	O
caution	O
should	O
be	O
used	O
in	O
administering	O
VUMON	B-Brand
(	O
teniposide	B-Drug
injection	O
)	O
to	O
patients	O
receiving	O
these	O
other	O
agents	O
.	O
      
Cimetidine	B-Drug
:	O
Cimetidine	B-Drug
increases	O
nicardipine	B-Drug
HCl	I-Drug
plasma	O
levels	O
.	O
      
When	O
given	O
concurrently	O
the	O
following	O
drugs	O
may	O
interact	O
with	O
thiazide	B-Group
diuretics	I-Group
.	O
      
With	O
simultaneous	O
dosing	O
of	O
Vardenafil	B-Drug
9	O
mg	O
and	O
terazosin	B-Drug
9	O
mg	O
9	O
of	O
9	O
subjects	O
experienced	O
a	O
standing	O
systolic	O
blood	O
pressure	O
of	O
less	O
than	O
9	O
mm	O
Hg	O
.	O
      
In	O
adult	O
diabetic	O
patients	O
under	O
treatment	O
with	O
either	O
sulfonylureas	B-Group
or	O
insulin	B-Drug
there	O
is	O
no	O
change	O
in	O
the	O
clinical	O
effects	O
of	O
either	O
TOLECTIN	B-Brand
or	O
the	O
hypoglycemic	B-Group
agents	I-Group
.	O
      
In	O
patients	O
taking	O
furosemide	B-Drug
nifedipine	B-Drug
diltiazem	B-Drug
ACE	B-Group
inhibitors	I-Group
verapamil	B-Drug
glyburide	B-Drug
propranolol	B-Drug
and	O
various	O
chemotherapy	O
agents	O
no	O
effect	O
was	O
shown	O
on	O
the	O
clearance	O
of	O
hydrodolasetron	B-Drug_n
.	O
      
Corticosteroids	B-Group
:	O
Concomitant	O
administration	O
with	O
aspirin	B-Brand
may	O
increase	O
the	O
risk	O
of	O
gastrointestinal	O
ulceration	O
and	O
may	O
reduce	O
serum	O
salicylate	O
levels	O
.	O
      
Vasopressors	B-Group
:	O
Thyroxine	B-Drug
increases	O
the	O
adrenergic	O
effect	O
of	O
catecholamines	O
such	O
as	O
epinephrine	B-Drug
and	O
norepinephrine	B-Drug
.	O
      
Therefore	O
coagulation	O
indices	O
should	O
be	O
monitored	O
frequently	O
to	O
maintain	O
the	O
desired	O
anticoagulant	O
effect	O
.	O
      
The	O
mechanism	O
of	O
this	O
interaction	O
is	O
not	O
known	O
.	O
      
However	O
higher	O
plasma	O
concentrations	O
of	O
AMICAR	B-Brand
may	O
occur	O
in	O
patients	O
with	O
severe	O
renal	O
failure	O
.	O
      
Allopurinol	B-Drug
:	O
The	O
AUC	O
of	O
didanosine	B-Drug
was	O
increased	O
about	O
9	O
-	O
fold	O
when	O
allopurinol	B-Drug
at	O
9	O
mg	O
/	O
day	O
was	O
coadministered	O
with	O
a	O
single	O
9	O
-	O
mg	O
dose	O
of	O
VIDEX	B-Brand
to	O
two	O
patients	O
with	O
renal	O
impairment	O
(	O
CLcr=9	O
and	O
9	O
mL	O
/	O
min	O
)	O
.	O
      
Zimelidine	B-Drug_n
etomidate	B-Drug
antagonism	O
      
-	O
Anticoagulants	B-Group
(	O
blood	B-Group
thinners	I-Group
)	O
or	O
      
It	O
may	O
be	O
necessary	O
to	O
adjust	O
the	O
dosage	O
of	O
oral	O
anticoagulants	B-Group
upon	O
beginning	O
or	O
stopping	O
disulfiram	B-Drug
.	O
since	O
disulfiram	B-Drug
may	O
prolong	O
prothrombin	O
time	O
.	O
      
However	O
increasing	O
use	O
of	O
such	O
preparations	O
to	O
control	O
symptoms	O
indicates	O
deterioration	O
of	O
asthma	O
control	O
and	O
the	O
need	O
to	O
reassess	O
the	O
patient	O
therapy	O
.	O
      
Since	O
the	O
therapeutic	O
range	O
of	O
theophylline	B-Drug
is	O
narrow	O
theophylline	B-Drug
serum	O
levels	O
should	O
be	O
monitored	O
closely	O
and	O
appropriate	O
dosage	O
adjustments	O
of	O
theophylline	B-Drug
should	O
be	O
made	O
.	O
      
leukopenia	O
      
Local	O
and	O
some	O
general	O
anesthetics	B-Group
antiarrhythmic	B-Group
agents	I-Group
and	O
other	O
drugs	O
that	O
interfere	O
with	O
neuromuscular	O
transmission	O
should	O
be	O
used	O
cautiously	O
if	O
at	O
all	O
in	O
patients	O
with	O
myasthenia	O
gravis	O
;	O
      
This	O
small	O
decrease	O
in	O
excretion	O
of	O
gabapentin	B-Drug
by	O
cimetidine	B-Drug
is	O
not	O
expected	O
to	O
be	O
of	O
clinical	O
importance	O
.	O
      
There	O
is	O
no	O
information	O
regarding	O
the	O
effect	O
on	O
lamivudine	B-Drug
pharmacokinetics	O
of	O
higher	O
doses	O
of	O
TMP	B-Drug
/	O
SMX	B-Drug
such	O
as	O
those	O
used	O
to	O
treat	O
Pneumocystis	O
carinii	O
pneumonia	O
.	O
      
incomplete	O
data	O
for	O
efavirenz	B-Drug
.	O
      
There	O
is	O
no	O
clinical	O
evidence	O
to	O
suggest	O
that	O
anagrelide	B-Drug
interacts	O
with	O
any	O
of	O
these	O
compounds	O
.	O
      
Reports	O
suggest	O
that	O
NSAIDs	B-Group
may	O
diminish	O
the	O
antihypertensive	O
effect	O
of	O
ACE	B-Group
inhibitors	I-Group
including	O
lisinopril	B-Drug
.	O
      
After	O
stopping	O
Fluvoxamine	B-Drug
Tablets	O
at	O
least	O
9	O
weeks	O
should	O
be	O
allowed	O
before	O
starting	O
a	O
MAOI	B-Group
.	O
      
Therefore	O
use	O
of	O
lamivudine	B-Drug
in	O
combination	O
with	O
zalcitabine	B-Drug
is	O
not	O
recommended	O
      
These	O
results	O
would	O
seem	O
to	O
dictate	O
against	O
the	O
clinical	O
use	O
of	O
methotrexate	B-Drug
with	O
ELSPAR	B-Brand
or	O
during	O
the	O
period	O
following	O
ELSPAR	B-Brand
therapy	O
when	O
plasma	O
asparagine	O
levels	O
are	O
below	O
normal	O
.	O
      
Other	O
plasma	O
proteins	O
may	O
be	O
increased	O
(	O
angiotensinogen	O
/	O
renin	O
substrate	O
alpha	O
-	O
9	O
-	O
antitrypsin	O
ceruloplasmin	O
)	O
.	O
      
Concomitant	O
administration	O
of	O
Mefloquine	B-Drug
and	O
other	O
related	O
compounds	O
(	O
eg	O
quinine	B-Drug
quinidine	B-Drug
and	O
chloroquine	B-Drug
)	O
may	O
produce	O
electrocardiographic	O
abnormalities	O
and	O
increase	O
the	O
risk	O
of	O
convulsions	O
.	O
      
Efavirenz	B-Drug
      
Concomitant	O
use	O
of	O
zalcitabine	B-Drug
and	O
lamivudine	B-Drug
is	O
not	O
recommended	O
.	O
      
However	O
in	O
the	O
second	O
study	O
administration	O
of	O
9	O
g	O
cholestyramine	B-Drug
9	O
hour	O
before	O
the	O
evening	O
meal	O
and	O
9	O
mg	O
cerivastatin	B-Drug
sodium	I-Drug
approximately	O
9	O
hours	O
after	O
the	O
same	O
evening	O
meal	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
cerivastatin	B-Drug
AUC	O
of	O
less	O
than	O
9	O
%	O
and	O
a	O
decrease	O
in	O
Cmax	O
of	O
about	O
9	O
%	O
when	O
compared	O
to	O
dosing	O
cerivastatin	B-Drug
sodium	I-Drug
alone	O
.	O
      
It	O
is	O
recommended	O
that	O
serum	O
lithium	B-Drug
levels	O
be	O
monitored	O
frequently	O
if	O
enalapril	B-Drug
is	O
administered	O
concomitantly	O
with	O
lithium	B-Drug
.	O
      
Dosage	O
adjustment	O
of	O
concomitant	O
medications	O
may	O
be	O
necessary	O
.	O
      
Didanosine	B-Drug
:	O
It	O
is	O
recommended	O
that	O
didanosine	B-Drug
be	O
administered	O
on	O
an	O
empty	O
stomach	O
;	O
      
Agents	O
that	O
Inhibit	O
Cytochrome	O
P9	O
Isoenzymes	O
and	O
/	O
or	O
Epoxide	O
Hydrolase	O
Carbamazepine	B-Drug
is	O
metabolized	O
mainly	O
by	O
cytochrome	O
P9	O
(	O
CYP	O
)	O
9A9	O
to	O
the	O
active	O
carbamazepine	B-Drug
9	I-Drug
9	I-Drug
-	O
epoxide	I-Drug
which	O
is	O
further	O
metabolized	O
to	O
the	O
trans	O
-	O
diol	O
by	O
epoxide	O
hydrolase	O
.	O
      
Thyroid	B-Group
hormone	I-Group
activity	O
may	O
also	O
be	O
enhanced	O
.	O
      
Trecator	B-Brand
may	O
potentiate	O
the	O
adverse	O
effects	O
of	O
other	O
antituberculous	B-Group
drugs	I-Group
administered	O
concomitantly	O
.	O
      
It	O
would	O
be	O
expected	O
that	O
laxative	B-Group
use	O
during	O
therapy	O
with	O
CAMPTOSAR	B-Brand
would	O
worsen	O
the	O
incidence	O
or	O
severity	O
of	O
diarrhea	O
but	O
this	O
has	O
not	O
been	O
studied	O
.	O
      
AGGRASTAT	B-Brand
has	O
been	O
studied	O
on	O
a	O
background	O
of	O
aspirin	B-Brand
and	O
heparin	B-Drug
.	O
      
therefore	O
if	O
glucocorticoid	B-Group
replacement	O
is	O
needed	O
hydrocortisone	B-Drug
should	O
be	O
prescribed	O
.	O
      
ProAmatine	B-Brand
.	O
Alpha	B-Group
-	O
adrenergic	I-Group
blocking	I-Group
agents	I-Group
such	O
as	O
prazosin	B-Drug
terazosin	B-Drug
and	O
doxazosin	B-Drug
can	O
antagonize	O
the	O
effects	O
of	O
ProAmatine	B-Brand
.	O
Potential	O
for	O
Drug	O
Interactions	O
:	O
It	O
appears	O
possible	O
although	O
there	O
is	O
no	O
supporting	O
experimental	O
evidence	O
that	O
the	O
high	O
renal	O
clearance	O
of	O
desglymidodrine	B-Drug_n
(	O
a	O
base	O
)	O
is	O
due	O
to	O
active	O
tubular	O
secretion	O
by	O
the	O
base	O
-	O
secreting	O
system	O
also	O
responsible	O
for	O
the	O
secretion	O
of	O
such	O
drugs	O
as	O
metformin	B-Drug
cimetidine	B-Drug
ranitidine	B-Drug
procainamide	B-Drug
triamterene	B-Drug
flecainide	B-Drug
and	O
quinidine	B-Drug
.	O
      
The	O
safety	O
of	O
using	O
methylphenidate	B-Drug
in	O
combination	O
with	O
clonidine	B-Drug
or	O
other	O
centrally	O
acting	O
alpha	B-Group
-	O
9	I-Group
agonists	I-Group
has	O
not	O
been	O
systemically	O
evaluated	O
.	O
      
General	O
Interactions	O
:	O
Certain	O
drugs	O
could	O
increase	O
the	O
likelihood	O
of	O
potentially	O
serious	O
adverse	O
effects	O
with	O
bepridil	B-Drug
hydrochloride	I-Drug
.	O
      
A	O
dose	O
reduction	O
of	O
beta	B-Group
-	O
adrenergic	I-Group
blockers	I-Group
may	O
be	O
needed	O
when	O
a	O
hyperthyroid	O
patient	O
becomes	O
euthyroid	O
.	O
      
Currently	O
no	O
drug	O
interactions	O
with	O
Calcitonin	B-Drug
salmon	I-Drug
have	O
been	O
observed	O
.	O
      
Also	O
there	O
were	O
no	O
clinically	O
significant	O
differences	O
in	O
adverse	O
events	O
when	O
loratadine	B-Drug
was	O
administered	O
with	O
or	O
without	O
ketoconazole	B-Drug
.	O
      
No	O
information	O
available	O
      
Since	O
MEXITIL	B-Brand
is	O
a	O
substrate	O
for	O
the	O
metabolic	O
pathways	O
involving	O
CYP9D9	O
and	O
CYP9A9	O
enzymes	O
inhibition	O
or	O
induction	O
of	O
either	O
of	O
these	O
enzymes	O
would	O
be	O
expected	O
to	O
alter	O
mexiletine	B-Drug
plasma	O
concentrations	O
.	O
      
Potentiation	O
of	O
the	O
hypotensive	O
effects	O
of	O
nitrates	B-Group
for	O
patients	O
with	O
ischemic	O
heart	O
disease	O
has	O
not	O
been	O
evaluated	O
and	O
concomitant	O
use	O
of	O
Vardenafil	B-Drug
and	O
nitrates	B-Group
is	O
contraindicated	O
.	O
      
Drug	O
interaction	O
studies	O
with	O
Xigris	B-Brand
have	O
not	O
been	O
performed	O
in	O
patients	O
with	O
severe	O
sepsis	O
.	O
      
Coadministration	O
with	O
aspirin	B-Brand
results	O
in	O
a	O
slight	O
decrease	O
in	O
the	O
rate	O
of	O
salicylate	B-Group
absorption	O
that	O
is	O
clinically	O
unimportant	O
.	O
      
The	O
clearance	O
of	O
salicylates	B-Group
may	O
be	O
increased	O
with	O
concurrent	O
use	O
of	O
corticosteroids	B-Group
.	O
      
This	O
led	O
to	O
statistically	O
significant	O
increases	O
in	O
the	O
elimination	O
half	O
-	O
life	O
(	O
9	O
%	O
)	O
and	O
in	O
the	O
extent	O
of	O
systemic	O
exposure	O
(	O
9	O
%	O
)	O
.	O
      
Methotrexate	B-Drug
-	O
There	O
is	O
one	O
report	O
that	O
methotrexate	B-Drug
may	O
decrease	O
the	O
possible	O
effectiveness	O
of	O
supplemental	O
L	B-Drug
-	O
glutamine	I-Drug
for	O
chemotherapy	O
-	O
induced	O
mucositis	O
.	O
      
Expected	O
changes	O
in	O
laboratory	O
assessments	O
of	O
PT	O
and	O
INR	O
were	O
observed	O
after	O
warfarin	B-Drug
administration	O
but	O
these	O
changes	O
were	O
not	O
affected	O
by	O
concomitant	O
lenalidomide	B-Drug
administration	O
.	O
      
The	O
co	O
-	O
administration	O
of	O
Natrecor	B-Brand
with	O
IV	O
vasodilators	B-Group
such	O
as	O
nitroglycerin	B-Drug
nitroprusside	B-Drug
milrinone	B-Drug
or	O
IV	O
ACE	B-Group
inhibitors	I-Group
has	O
not	O
been	O
evaluated	O
(	O
these	O
drugs	O
were	O
not	O
co	O
-	O
administered	O
with	O
Natrecor	B-Brand
in	O
clinical	O
trials	O
)	O
.	O
      
Sildenafil	B-Drug
      
Although	O
there	O
is	O
little	O
published	O
information	O
on	O
concomitant	O
administration	O
of	O
lidocaine	B-Drug
and	O
Bretylium	B-Drug
Tosylate	I-Drug
these	O
drugs	O
are	O
often	O
administered	O
concurrently	O
without	O
any	O
evidence	O
of	O
interactions	O
resulting	O
in	O
adverse	O
effects	O
or	O
diminished	O
efficacy	O
.	O
      
In	O
vitro	O
studies	O
indicate	O
that	O
the	O
binding	O
is	O
not	O
easily	O
removed	O
.	O
      
Coadministration	O
of	O
Aprepitant	B-Drug
with	O
these	O
drugs	O
or	O
other	O
drugs	O
that	O
are	O
known	O
to	O
be	O
metabolized	O
by	O
CYP9C9	O
such	O
as	O
phenytoin	B-Drug
may	O
result	O
in	O
lower	O
plasma	O
concentrations	O
of	O
these	O
drugs	O
.	O
      
.	O
      
Caution	O
is	O
recommended	O
when	O
administering	O
doxorubicin	B-Drug
with	O
NEXAVAR	B-Brand
.	O
      
Other	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
agents	I-Group
(	O
e.g.	O
aspirin	B-Brand
)	O
may	O
also	O
have	O
this	O
effect	O
.	O
      
However	O
co	O
-	O
administration	O
of	O
Duloxetine	B-Drug
with	O
aluminum	B-Drug
-	O
and	O
magnesium	B-Drug
-	O
containing	O
antacids	B-Group
(	O
9	O
mEq	O
)	O
or	O
Duloxetine	B-Drug
with	O
famotidine	B-Drug
had	O
no	O
significant	O
effect	O
on	O
the	O
rate	O
or	O
extent	O
of	O
duloxetine	B-Drug
absorption	O
after	O
administration	O
of	O
a	O
9	O
-	O
mg	O
oral	O
dose	O
.	O
      
The	O
clinical	O
relevance	O
of	O
this	O
finding	O
is	O
unclear	O
.	O
      
increased	O
creatine	O
      
Use	O
in	O
Ambulatory	O
Patients	O
The	O
effects	O
of	O
ROMAZICON	B-Brand
may	O
wear	O
off	O
before	O
a	O
long	B-Group
-	O
acting	I-Group
benzodiazepine	I-Group
is	O
completely	O
cleared	O
from	O
the	O
body	O
.	O
      
9	O
years	O
of	O
age	O
.	O
      
Potassium	B-Group
-	O
sparing	I-Group
diuretics	I-Group
such	O
as	O
spironolactone	B-Drug
triamterene	B-Drug
or	O
amiloride	B-Drug
or	O
potassium	B-Drug
supplements	O
should	O
be	O
given	O
only	O
for	O
documented	O
hypokalemia	O
and	O
then	O
with	O
caution	O
since	O
they	O
may	O
lead	O
to	O
a	O
significant	O
increase	O
of	O
serum	O
potassium	O
.	O
      
Aspirin	B-Brand
:	O
Concomitant	O
administration	O
of	O
aspirin	B-Brand
(	O
9	O
mg	O
TID	O
)	O
to	O
healthy	O
volunteers	O
tended	O
to	O
increase	O
the	O
AUC	O
(	O
9	O
%	O
)	O
and	O
Cmax	O
(	O
9	O
%	O
)	O
of	O
meloxicam	B-Drug
.	O
      
Pharmacokinetic	O
data	O
indicate	O
that	O
oral	O
ketoconazole	B-Drug
inhibits	O
the	O
metabolism	O
of	O
astemizole	B-Drug
resulting	O
in	O
elevated	O
plasma	O
levels	O
of	O
astemizole	B-Drug
and	O
its	O
active	O
metabolite	O
desmethylastemizole	B-Drug_n
which	O
may	O
prolong	O
QT	O
intervals	O
.	O
      
Beta	B-Group
-	O
adrenergic	I-Group
Blocking	I-Group
Agents	I-Group
:	O
Experience	O
in	O
over	O
9	O
patients	O
in	O
a	O
non	O
-	O
comparative	O
clinical	O
trial	O
has	O
shown	O
that	O
concomitant	O
administration	O
of	O
nifedipine	B-Drug
and	O
beta	B-Group
-	O
blocking	I-Group
agents	I-Group
is	O
usually	O
well	O
tolerated	O
but	O
there	O
have	O
been	O
occasional	O
literature	O
reports	O
suggesting	O
that	O
the	O
combination	O
may	O
increase	O
the	O
likelihood	O
of	O
congestive	O
heart	O
failure	O
severe	O
hypotension	O
or	O
exacerbation	O
of	O
angina	O
.	O
      
Concomitant	O
use	O
of	O
alcohol	B-Drug
with	O
phentermine	B-Drug
hydrochloride	I-Drug
may	O
result	O
in	O
an	O
adverse	O
drug	O
interaction	O
.	O
      
In	O
vitro	O
studies	O
also	O
indicate	O
that	O
celecoxib	B-Drug
although	O
not	O
a	O
substrate	O
is	O
an	O
inhibitor	O
of	O
cytochrome	O
P9	O
9D9	O
.	O
      
Free	O
thyroid	O
hormone	O
levels	O
remain	O
unchanged	O
.	O
      
Warfarin	B-Drug
:	O
In	O
subjects	O
receiving	O
warfarin	B-Drug
no	O
significant	O
change	O
in	O
clotting	O
time	O
was	O
observed	O
when	O
grepafloxacin	B-Drug
was	O
coadministered	O
.	O
      
When	O
administered	O
concurrently	O
the	O
following	O
drugs	O
may	O
interact	O
with	O
ampicillin	B-Drug
.	O
      
Antineoplastic	B-Group
agents	I-Group
(	O
e.	O
g.	O
nitrogen	B-Drug
mustard	I-Drug
etc	O
.	O
)	O
should	O
be	O
given	O
concomitantly	O
only	O
with	O
great	O
caution	O
.	O
      
Poor	O
metabolizers	O
have	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
tricyclic	B-Group
antidepressants	I-Group
(	O
TCAs	B-Group
)	O
when	O
given	O
usual	O
doses	O
.	O
      
The	O
plasma	O
concentration	O
of	O
CMI	B-Drug
has	O
been	O
reported	O
to	O
be	O
increased	O
by	O
the	O
concomitant	O
administration	O
of	O
haloperidol	B-Drug
;	O
      
Therefore	O
agents	O
affecting	O
sympathetic	O
activity	O
(	O
e.g.	O
ganglionic	B-Group
blocking	I-Group
agents	I-Group
or	O
adrenergic	B-Group
neuron	I-Group
blocking	I-Group
agents	I-Group
)	O
should	O
be	O
used	O
with	O
caution	O
.	O
      
.	O
      
Ketoconazole	B-Drug
:	O
Ketoconazole	B-Drug
has	O
been	O
reported	O
to	O
decrease	O
the	O
metabolism	O
of	O
certain	O
corticosteroids	B-Group
by	O
up	O
to	O
9	O
%	O
leading	O
to	O
increased	O
risk	O
of	O
corticosteroid	B-Group
side	O
effects	O
.	O
      
All	O
vasopressors	B-Group
should	O
be	O
used	O
cautiously	O
in	O
patients	O
taking	O
monoamine	B-Group
oxidase	I-Group
MAO	I-Group
inhibitors	I-Group
.	O
      
Boric	B-Drug
acid	I-Drug
may	O
interact	O
with	O
the	O
idoxuridine	B-Drug
preparation	O
causing	O
a	O
gritty	O
substance	O
to	O
form	O
or	O
may	O
interact	O
with	O
the	O
preservative	O
in	O
the	O
idoxuridine	B-Drug
preparation	O
causing	O
a	O
toxic	O
effect	O
in	O
the	O
eye	O
.	O
      
Nonetheless	O
they	O
have	O
been	O
observed	O
with	O
macrolide	B-Group
products	I-Group
.	O
      
No	O
pharmacokinetic	O
interactions	O
involving	O
other	O
cytochrome	O
P9	O
isoenzymes	O
are	O
known	O
.	O
      
No	O
dose	O
relationship	O
has	O
been	O
observed	O
.	O
      
This	O
interaction	O
appears	O
to	O
be	O
related	O
both	O
to	O
pressor	O
activity	O
and	O
to	O
beta	O
-	O
adrenergic	O
stimulating	O
properties	O
of	O
these	O
catecholamines	B-Group
and	O
may	O
produce	O
ventricular	O
arrhythmias	O
and	O
hypertension	O
.	O
      
Benzodiazepines	B-Group
      
Specific	O
studies	O
have	O
confirmed	O
these	O
effects	O
with	O
sevoflurane	B-Drug
isoflurane	B-Drug
propofol	B-Drug
alfentanil	B-Drug
and	O
midazolam	B-Drug
.	O
      
While	O
all	O
the	O
selective	B-Group
serotonin	I-Group
reuptake	I-Group
inhibitors	I-Group
(	O
SSRIs	B-Group
)	O
e.g.	O
fluoxetine	B-Drug
sertraline	B-Drug
paroxetine	B-Drug
and	O
fluvoxamine	B-Drug
inhibit	O
P9	O
9D9	O
they	O
may	O
vary	O
in	O
the	O
extent	O
of	O
inhibition	O
.	O
      
-	O
In	O
isolated	O
cases	O
a	O
pronounced	O
though	O
reversible	O
impairment	O
of	O
renal	O
function	O
(	O
accompanied	O
by	O
a	O
corresponding	O
increase	O
in	O
the	O
serum	O
creatinine	O
level	O
)	O
has	O
been	O
reported	O
in	O
organ	O
transplant	O
patients	O
receiving	O
immuno	B-Group
-	O
suppressant	I-Group
therapy	O
and	O
concomitant	O
bezafibrate	B-Drug
.	O
      
Patients	O
receiving	O
azathioprine	B-Drug
and	O
allopurinol	B-Drug
concomitantly	O
should	O
have	O
a	O
dose	O
reduction	O
of	O
azathioprine	B-Drug
to	O
approximately	O
9	O
/	O
9	O
to	O
9	O
/	O
9	O
the	O
usual	O
dose	O
.	O
      
GABITRIL	B-Brand
is	O
considered	O
to	O
be	O
a	O
non	O
-	O
enzyme	O
inducing	O
AED	B-Group
.	O
      
Lethargy	O
and	O
somnolence	O
have	O
been	O
reported	O
following	O
doses	O
of	O
REVIA	B-Brand
and	O
thioridazine	B-Drug
.	O
      
v	O
.	O
Patients	O
should	O
be	O
cautioned	O
regarding	O
potential	O
adverse	O
cardiovascular	O
effects	O
such	O
as	O
palpitations	O
or	O
chest	O
pain	O
.	O
      
Elevated	O
plasma	O
levels	O
of	O
theophylline	B-Drug
have	O
been	O
reported	O
with	O
concomitant	O
quinolone	B-Group
use	O
.	O
      
Therefore	O
in	O
patients	O
taking	O
VIOXX	B-Brand
antiplatelet	O
therapies	O
should	O
not	O
be	O
discontinued	O
and	O
should	O
be	O
considered	O
in	O
patients	O
with	O
an	O
indication	O
for	O
cardiovascular	O
prophylaxis	O
.	O
      
9	O
-	O
9	O
      
Concomitant	O
treatment	O
with	O
potassium	B-Group
-	O
sparing	I-Group
diuretics	I-Group
may	O
be	O
associated	O
with	O
increased	O
serum	O
potassium	O
levels	O
.	O
      
Substances	O
that	O
are	O
potent	O
inhibitors	O
of	O
CYP9A9	O
activity	O
(	O
eg	O
ketoconazole	B-Drug
and	O
itraconazole	B-Drug
)	O
decrease	O
gefitinib	B-Drug
metabolism	O
and	O
increase	O
gefitinib	B-Drug
plasma	O
concentrations	O
.	O
      
If	O
you	O
are	O
also	O
using	O
a	O
steroid	B-Group
inhaler	O
take	O
bitolterol	B-Drug
first	O
and	O
then	O
wait	O
about	O
9	O
minutes	O
before	O
using	O
the	O
steroid	B-Group
inhaler	O
.	O
      
In	O
clinical	O
trials	O
mean	O
decreases	O
of	O
9	O
to	O
9	O
mg	O
/	O
dL	O
were	O
observed	O
in	O
arthritic	O
patients	O
receiving	O
etodolac	B-Drug
(	O
9	O
mg	O
to	O
9	O
mg	O
/	O
day	O
)	O
after	O
9	O
weeks	O
of	O
therapy	O
.	O
      
The	O
drug	O
interaction	O
data	O
described	O
in	O
this	O
section	O
were	O
obtained	O
from	O
studies	O
involving	O
either	O
healthy	O
subjects	O
or	O
patients	O
with	O
epilepsy	O
.	O
      
Depending	O
on	O
the	O
fraction	O
of	O
drug	O
metabolized	O
by	O
P9	O
9D9	O
the	O
increase	O
in	O
plasma	O
concentration	O
may	O
be	O
small	O
or	O
quite	O
large	O
(	O
9	O
-	O
fold	O
increase	O
in	O
plasma	O
AUC	O
of	O
the	O
TCA	O
)	O
.	O
      
A	O
rare	O
but	O
serious	O
constellation	O
of	O
symptoms	O
termed	O
serotonin	O
syndrome	O
has	O
been	O
reported	O
with	O
the	O
concomitant	O
use	O
of	O
selective	B-Group
serotonin	I-Group
reuptake	I-Group
inhibitors	I-Group
(	O
SSRIs	B-Group
)	O
and	O
agents	O
for	O
migraine	O
therapy	O
such	O
as	O
Imitrex	B-Brand
(	O
sumatriptan	B-Drug
succinate	I-Drug
)	O
and	O
dihydroergotamine	B-Drug
.	O
      
Live	B-Group
Vaccines	I-Group
:	O
During	O
treatment	O
with	O
Myfortic	B-Drug
the	O
use	O
of	O
live	B-Group
attenuated	I-Group
vaccines	I-Group
should	O
be	O
avoided	O
and	O
patients	O
should	O
be	O
advised	O
that	O
vaccinations	O
may	O
be	O
less	O
effective	O
.	O
      
ACE	B-Group
inhibitors	I-Group
:	O
Reports	O
suggest	O
that	O
NSAIDs	B-Group
may	O
diminish	O
the	O
antihypertensive	O
effect	O
of	O
Angiotensin	B-Group
Converting	I-Group
Enzyme	I-Group
ACE	I-Group
inhibitors	I-Group
.	O
      
The	O
bioavailability	O
of	O
SKELID	B-Brand
is	O
increased	O
9	O
-	O
9	O
fold	O
by	O
indomethacin	B-Drug
but	O
is	O
not	O
significantly	O
altered	O
by	O
coadministration	O
of	O
diclofenac	B-Drug
.	O
      
Therefore	O
dose	O
adjustments	O
of	O
concomitant	O
medications	O
that	O
are	O
predominantly	O
metabolized	O
by	O
CYP9D9	O
and	O
have	O
a	O
narrow	O
therapeutic	O
index	O
(	O
e.g.	O
flecainide	B-Drug
vinblastine	B-Drug
thioridazine	B-Drug
and	O
most	O
tricyclic	B-Group
antidepressants	I-Group
)	O
may	O
be	O
required	O
.	O
      
Hydrocodone	B-Drug
increases	O
gabapentin	B-Drug
AUC	O
values	O
by	O
9	O
%	O
.	O
      
Clinically	O
significant	O
interactions	O
would	O
not	O
be	O
expected	O
since	O
the	O
NRTIs	B-Group
are	O
metabolized	O
via	O
a	O
different	O
route	O
than	O
efavirenz	B-Drug
and	O
would	O
be	O
unlikely	O
to	O
compete	O
for	O
the	O
same	O
metabolic	O
enzymes	O
and	O
elimination	O
pathways	O
.	O
      
Hypertensive	O
crises	O
have	O
resulted	O
when	O
sympathomimetic	B-Group
amines	I-Group
have	O
been	O
used	O
concomitantly	O
within9	O
days	O
following	O
use	O
of	O
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
.	O
      
The	O
pressor	O
response	O
of	O
adrenergic	B-Group
agents	I-Group
may	O
also	O
be	O
potentiated	O
by	O
tricyclic	B-Group
antidepressants	I-Group
.	O
      
High	O
concentrations	O
of	O
cefoxitin	B-Drug
in	O
the	O
urine	O
may	O
interfere	O
with	O
measurement	O
of	O
urinary	O
9	O
-	O
hydroxy	O
-	O
corticosteroids	O
by	O
the	O
Porter	O
-	O
Silber	O
reaction	O
and	O
produce	O
false	O
increases	O
of	O
modest	O
degree	O
in	O
the	O
levels	O
reported	O
.	O
      
In	O
vitro	O
data	O
suggest	O
that	O
itraconazole	B-Drug
when	O
compared	O
to	O
ketoconazole	B-Drug
has	O
a	O
less	O
pronounced	O
effect	O
on	O
the	O
biotransformation	O
system	O
responsible	O
for	O
the	O
metabolism	O
of	O
astemizole	B-Drug
.	O
      
Sympathomimetic	B-Group
amines	I-Group
may	O
reduce	O
the	O
antihypertensive	O
effects	O
of	O
reserpine	B-Drug
veratrum	B-Group
alkaloids	I-Group
methyldopa	B-Drug
and	O
mecamylamine	B-Drug
.	O
      
Methylprednisolone	B-Drug
      
Adjustment	O
of	O
dosage	O
of	O
oral	O
anticoagulants	B-Group
may	O
be	O
required	O
.	O
      
However	O
another	O
HMG	B-Group
-	O
CoA	I-Group
reductase	I-Group
inhibitor	I-Group
has	O
been	O
found	O
to	O
produce	O
a	O
less	O
than	O
two	O
-	O
second	O
increase	O
in	O
prothrombin	O
time	O
in	O
healthy	O
volunteers	O
receiving	O
low	O
doses	O
of	O
warfarin	B-Drug
.	O
      
Codeine	B-Drug
in	O
combination	O
with	O
other	O
narcotic	B-Group
analgesics	I-Group
general	O
anesthetics	B-Group
phenothiazines	B-Group
tranquilizers	B-Group
sedative	B-Group
-	O
hypnotics	I-Group
or	O
other	O
CNS	B-Group
depressants	I-Group
(	O
including	O
alcohol	B-Drug
)	O
has	O
additive	O
depressant	O
effects	O
.	O
      
Patients	O
receiving	O
insulin	B-Drug
or	O
oral	O
hypoglycemics	B-Group
should	O
be	O
closely	O
watched	O
during	O
initiation	O
of	O
thyroid	O
replacement	O
therapy	O
.	O
      
-	O
Antidiabetics	B-Group
oral	O
(	O
diabetes	O
medicine	O
you	O
take	O
by	O
mouth	O
)	O
Use	O
of	O
oral	O
antidiabetics	B-Group
with	O
sulfapyridine	B-Drug
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
affecting	O
the	O
blood	O
and	O
/	O
or	O
the	O
side	O
effects	O
or	O
oral	O
antidiabetics	B-Group
      
Continuous	O
cardiac	O
monitoring	O
is	O
not	O
required	O
except	O
for	O
patients	O
with	O
serious	O
conduction	O
abnormalities	O
.	O
      
Concomitant	O
administration	O
contra	O
-	O
indicated	O
:	O
-	O
Vasoconstrictive	O
ergot	B-Group
alkaloids	I-Group
.	O
      
Concomitant	O
use	O
of	O
agents	O
in	O
the	O
tricyclic	B-Group
antidepressant	I-Group
class	I-Group
(	O
which	O
includes	O
Anafranil	B-Brand
)	O
with	O
drugs	O
that	O
can	O
inhibit	O
cytochrome	O
P9	O
9D9	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	B-Group
antidepressant	I-Group
agent	I-Group
or	O
the	O
other	O
drug	O
.	O
      
There	O
have	O
been	O
no	O
reported	O
cases	O
from	O
spontaneous	O
reports	O
of	O
drug	O
interaction	O
between	O
SSRIs	B-Group
and	O
D.H.E	B-Brand
9	I-Brand
(	O
dihydroergotamine	B-Drug
mesylate	I-Drug
)	O
Injection	O
USP	O
.	O
      
Immunogenicity	O
/	O
Re	O
-	O
exposure	O
:	O
In	O
in	O
vitro	O
studies	O
Angiomax	B-Brand
exhibited	O
no	O
platelet	O
aggregation	O
response	O
against	O
sera	O
from	O
patients	O
with	O
a	O
history	O
of	O
HIT	O
/	O
HITTS	O
.	O
      
.	O
      
The	O
effect	O
of	O
concurrent	O
application	O
of	O
ALTABAX	B-Brand
and	O
other	O
topical	O
products	O
to	O
the	O
same	O
area	O
of	O
skin	O
has	O
not	O
been	O
studied	O
.	O
      
In	O
vitro	O
studies	O
indicate	O
that	O
at	O
therapeutic	O
concentrations	O
of	O
salicylate	B-Group
(	O
9	O
m	O
g	O
/	O
mL	O
)	O
the	O
binding	O
of	O
ketorolac	B-Drug
was	O
reduced	O
from	O
approximately	O
9	O
%	O
to	O
9	O
%	O
representing	O
a	O
potential	O
twofold	O
increase	O
in	O
unbound	O
ketorolac	B-Drug
plasma	O
levels	O
.	O
      
Although	O
the	O
magnitude	O
of	O
changes	O
in	O
diazepam	B-Drug
plasma	O
exposure	O
when	O
coadministered	O
with	O
valdecoxib	B-Drug
were	O
not	O
sufficient	O
to	O
warrant	O
dosage	O
adjustments	O
patients	O
may	O
experience	O
enhanced	O
sedative	O
side	O
effects	O
caused	O
by	O
increased	O
exposure	O
of	O
diazepam	B-Drug
under	O
this	O
circumstance	O
.	O
      
Colestipol	B-Drug
-	O
Concomitant	O
intake	O
of	O
colestipol	B-Drug
and	O
vitamin	B-Group
K	I-Group
may	O
reduce	O
the	O
absorption	O
of	O
vitamin	B-Group
K	I-Group
.	O
      
In	O
view	O
of	O
the	O
potential	O
risk	O
of	O
dehydration	O
secondary	O
to	O
vomiting	O
and	O
/	O
or	O
diarrhea	O
induced	O
by	O
CAMPTOSAR	B-Brand
the	O
physician	O
may	O
wish	O
to	O
withhold	O
diuretics	B-Group
during	O
dosing	O
with	O
CAMPTOSAR	B-Brand
and	O
certainly	O
during	O
periods	O
of	O
active	O
vomiting	O
or	O
diarrhea	O
.	O
      
The	O
effects	O
of	O
concomitant	O
administration	O
of	O
TAMBOCOR	B-Brand
and	O
propranolol	B-Drug
on	O
the	O
PR	O
interval	O
were	O
less	O
than	O
additive	O
.	O
      
Fulvestrant	B-Drug
caused	O
an	O
increased	O
incidence	O
of	O
fetal	O
abnormalities	O
in	O
rats	O
(	O
tarsal	O
flexure	O
of	O
the	O
hind	O
paw	O
at	O
9	O
mg	O
/	O
kg	O
/	O
day	O
IM	O
;	O
      
In	O
vitro	O
studies	O
in	O
human	O
liver	O
microsomes	O
showed	O
that	O
paliperidone	B-Drug
does	O
not	O
substantially	O
inhibit	O
the	O
metabolism	O
of	O
drugs	O
metabolized	O
by	O
cytochrome	O
P9	O
isozymes	O
including	O
CYP9A9	O
CYP9A9	O
CYP9C9	O
/	O
9	O
/	O
9	O
CYP9D9	O
CYP9E9	O
CYP9A9	O
and	O
CYP9A9	O
.	O
      
Pharmacokinetics	O
.	O
      
The	O
appropriate	O
doses	O
for	O
this	O
combination	O
with	O
respect	O
to	O
efficacy	O
and	O
safety	O
have	O
not	O
been	O
established	O
.	O
      
9	O
.	O
      
If	O
treatment	O
with	O
inhibitors	O
of	O
CYP9A9	O
activity	O
(	O
such	O
as	O
ketoconazole	B-Drug
intraconazole	B-Drug
ritonavir	B-Drug
indinavir	B-Drug
saquinavir	B-Drug
erythromycin	B-Drug
etc	O
.	O
)	O
is	O
indicated	O
reduction	O
of	O
the	O
budesonide	B-Drug
dose	O
should	O
be	O
considered	O
.	O
      
The	O
data	O
do	O
not	O
suggest	O
the	O
need	O
for	O
dose	O
adjustment	O
of	O
either	O
HUMIRA	B-Brand
or	O
MTX	B-Drug
.	O
      
Currently	O
there	O
are	O
no	O
safety	O
and	O
efficacy	O
data	O
available	O
from	O
the	O
use	O
of	O
this	O
combination	O
.	O
      
No	O
dose	O
adjustment	O
is	O
necessary	O
.	O
      
PEGASYS	B-Brand
is	O
to	O
be	O
used	O
during	O
pregnancy	O
only	O
if	O
the	O
potential	O
benefit	O
justifies	O
the	O
potential	O
risk	O
to	O
the	O
fetus	O
.	O
      
Erythromycin	O
Co	O
-	O
administration	O
of	O
felodipine	B-Drug
(	O
PLENDIL	B-Drug
)	O
with	O
erythromycin	B-Drug
resulted	O
in	O
approximately	O
9	O
-	O
fold	O
increase	O
in	O
the	O
AUC	O
and	O
Cmax	O
and	O
about	O
9	O
-	O
fold	O
prolongation	O
in	O
the	O
half	O
-	O
life	O
of	O
felodipine	B-Drug
.	O
      
In	O
a	O
clinical	O
pharmacology	O
study	O
indomethacin	B-Drug
or	O
sulindac	B-Drug
was	O
administered	O
to	O
hypertensive	O
patients	O
receiving	O
VASOTEC	B-Brand
.	O
      
Increased	O
nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
cephalosporins	B-Group
and	O
aminoglycoside	B-Group
antibiotics	I-Group
.	O
      
9	O
.	O
      
If	O
midazolam	B-Drug
is	O
administered	O
parenterally	O
special	O
precaution	O
is	O
required	O
since	O
the	O
sedative	O
effect	O
may	O
be	O
prolonged	O
.	O
      
In	O
vitro	O
studies	O
have	O
shown	O
that	O
precipitation	O
occurs	O
when	O
eye	O
drops	O
containing	O
thimerosal	B-Drug_n
are	O
mixed	O
with	O
latanoprost	B-Drug
.	O
      
The	O
concomitant	O
administration	O
of	O
griseofulvin	B-Drug
has	O
been	O
reported	O
to	O
reduce	O
the	O
efficacy	O
of	O
oral	O
contraceptives	B-Group
and	O
to	O
increase	O
the	O
incidence	O
of	O
breakthrough	O
bleeding	O
.	O
      
No	O
formal	O
assessments	O
of	O
drug	O
-	O
drug	O
interactions	O
between	O
Vidaza	B-Brand
and	O
other	O
agents	O
have	O
been	O
conducted	O
      
No	O
data	O
are	O
available	O
on	O
potential	O
interactions	O
in	O
individuals	O
who	O
consume	O
greater	O
than	O
9	O
mg	O
of	O
caffeine	B-Drug
per	O
day	O
or	O
in	O
those	O
such	O
as	O
the	O
geriatric	O
population	O
who	O
are	O
generally	O
believed	O
to	O
be	O
more	O
susceptible	O
to	O
the	O
development	O
of	O
drug	O
-	O
induced	O
CNS	O
-	O
related	O
adverse	O
effects	O
.	O
      
Other	O
Agents	O
:	O
PRINIVIL	B-Brand
has	O
been	O
used	O
concomitantly	O
with	O
nitrates	B-Group
and	O
/	O
or	O
digoxin	B-Drug
without	O
evidence	O
of	O
clinically	O
significant	O
adverse	O
interactions	O
.	O
      
In	O
addition	O
deaths	O
have	O
been	O
reported	O
rarely	O
with	O
concomitant	O
administration	O
of	O
terfenadine	B-Drug
and	O
erythromycin	B-Drug
.	O
      
Vasoconstrictors	B-Group
:	O
D.H.E	B-Brand
9	I-Brand
(	O
dihydroergotamine	B-Drug
mesylate	I-Drug
)	O
Injection	O
USP	O
should	O
not	O
be	O
used	O
with	O
peripheral	B-Group
vasoconstrictors	I-Group
because	O
the	O
combination	O
may	O
cause	O
synergistic	O
elevation	O
of	O
blood	O
pressure	O
.	O
      
Concomitant	O
use	O
of	O
tricyclic	B-Group
antidepressants	I-Group
with	O
drugs	O
that	O
can	O
inhibit	O
cytochrome	O
P9	O
9D9	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	B-Group
antidepressant	I-Group
or	O
the	O
other	O
drug	O
.	O
      
N=9	O
)	O
Cmax	O
and	O
AUC	O
values	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
relative	O
to	O
administration	O
of	O
hydrocodone	B-Drug
alone	O
;	O
      
Corticosteroids	B-Group
and	O
Corticotropin	B-Drug
(	O
ACTH	B-Group
)	O
:	O
may	O
potentiate	O
amphotericin	B-Drug
B	I-Drug
-	O
induced	O
hypokalemia	O
which	O
may	O
predispose	O
the	O
patient	O
to	O
cardiac	O
dysfunction	O
.	O
      
Diltiazem	B-Drug
nifedipine	B-Drug
verapamil	B-Drug
      
Other	O
Highly	O
Protein	O
-	O
Bound	O
Drugs	O
:	O
Raloxifene	B-Drug
is	O
more	O
than	O
9	O
%	O
bound	O
to	O
plasma	O
proteins	O
.	O
      
Some	O
anticonvulsants	B-Group
may	O
interact	O
with	O
Mephenytoin	B-Drug
.	O
      
The	O
results	O
from	O
trials	O
using	O
the	O
intravenous	O
prodrug	O
are	O
reported	O
in	O
this	O
section	O
as	O
they	O
relate	O
to	O
the	O
role	O
of	O
valdecoxib	B-Drug
in	O
drug	O
interactions	O
.	O
      
The	O
data	O
presently	O
available	O
indicate	O
that	O
the	O
decreases	O
in	O
some	O
individual	O
ethinyl	B-Drug
estradiol	I-Drug
and	O
levonorgestrel	B-Drug
AUC	O
values	O
with	O
fluconazole	B-Drug
treatment	O
are	O
likely	O
the	O
result	O
of	O
random	O
variation	O
.	O
      
In	O
eight	O
HIV	O
-	O
infected	O
patients	O
the	O
steady	O
-	O
state	O
AUC	O
of	O
ciprofloxacin	B-Drug
was	O
decreased	O
an	O
average	O
of	O
9	O
%	O
(	O
9	O
%	O
CI	O
=	O
9	O
%	O
9	O
%	O
)	O
when	O
ciprofloxacin	B-Drug
was	O
administered	O
9	O
hours	O
prior	O
to	O
a	O
marketed	O
chewable	O
/	O
dispersible	O
tablet	O
formulation	O
of	O
VIDEX	B-Brand
.	O
      
Aspirin	B-Brand
should	O
be	O
used	O
cautiously	O
in	O
conjunction	O
with	O
corticosteroids	B-Group
in	O
patients	O
suffering	O
from	O
hypoprothrombinemia	O
.	O
      
The	O
potential	O
effects	O
of	O
fulvestrant	B-Drug
on	O
the	O
fertility	O
of	O
male	O
animals	O
were	O
not	O
studied	O
but	O
in	O
a	O
9	O
-	O
month	O
toxicology	O
study	O
male	O
rats	O
treated	O
with	O
intramuscular	O
doses	O
of	O
9	O
mg	O
/	O
kg	O
/	O
9	O
days	O
9	O
mg	O
/	O
rat	O
/	O
9	O
days	O
or	O
9	O
mg	O
/	O
rat	O
/	O
9	O
days	O
fulvestrant	B-Drug
showed	O
a	O
loss	O
of	O
spermatozoa	O
from	O
the	O
seminiferous	O
tubules	O
seminiferous	O
tubular	O
atrophy	O
and	O
degenerative	O
changes	O
in	O
the	O
epididymides	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
FROVA	B-Brand
is	O
not	O
known	O
to	O
interfere	O
with	O
commonly	O
employed	O
clinical	O
laboratory	O
tests	O
.	O
      
Table	O
9	O
Established	O
Drug	O
Interactions	O
:	O
Alteration	O
in	O
Dose	O
or	O
Regimen	O
May	O
Be	O
Recommended	O
Based	O
on	O
Drug	O
Interaction	O
Studies	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
As	O
a	O
result	O
of	O
the	O
presence	O
of	O
nitrofurantoin	B-Drug
a	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
may	O
occur	O
.	O
      
Phenobarbital	B-Drug
:	O
Coadministration	O
of	O
felbamate	B-Drug
with	O
phenobarbital	B-Drug
causes	O
an	O
increase	O
in	O
phenobarbital	B-Drug
plasma	O
concentrations	O
In	O
9	O
otherwise	O
healthy	O
male	O
volunteers	O
ingesting	O
phenobarbital	B-Drug
the	O
steady	O
-	O
state	O
trough	O
(	O
Cmin	O
)	O
phenobarbital	B-Drug
concentration	O
was	O
9	O
micrograms	O
/	O
mL	O
.	O
      
however	O
no	O
deleterious	O
interactions	O
were	O
seen	O
when	O
ROMAZICON	B-Brand
was	O
administered	O
after	O
narcotics	B-Group
inhalational	O
anesthetics	B-Group
muscle	B-Group
relaxants	I-Group
and	O
muscle	O
relaxant	O
antagonists	O
administered	O
in	O
conjunction	O
with	O
sedation	O
or	O
anesthesia	O
.	O
      
Tablets	O
:	O
The	O
benzodiazepines	B-Group
including	O
lorazepam	B-Drug
produce	O
CNS	O
-	O
depressant	O
effects	O
when	O
administered	O
with	O
such	O
medications	O
as	O
barbiturates	B-Group
or	O
alcohol	B-Drug
.	O
      
Heparin	B-Drug
other	O
anticoagulants	B-Group
thrombolytics	B-Group
and	O
anti	B-Group
platelet	I-Group
agents	I-Group
are	O
associated	O
with	O
an	O
increase	O
in	O
bleeding	O
.	O
      
Should	O
it	O
be	O
decided	O
to	O
discontinue	O
therapy	O
in	O
patients	O
receiving	O
beta	B-Group
-	O
blockers	I-Group
and	O
clonidine	B-Drug
concurrently	O
the	O
beta	B-Group
-	O
blocker	I-Group
should	O
be	O
discontinued	O
slowly	O
over	O
several	O
days	O
before	O
the	O
gradual	O
withdrawal	O
of	O
clonidine	B-Drug
.	O
      
Fluconazole	B-Drug
tablets	O
coadministered	O
with	O
ethinyl	B-Drug
estradiol	I-Drug
-	O
and	O
levonorgestrel	B-Drug
-	O
containing	O
oral	O
contraceptives	B-Group
produced	O
an	O
overall	O
mean	O
increase	O
in	O
ethinyl	B-Drug
estradiol	I-Drug
and	O
levonorgestrel	B-Drug
levels	O
;	O
      
Such	O
patients	O
may	O
be	O
unresponsive	O
to	O
the	O
usual	O
doses	O
of	O
epinephrine	B-Drug
used	O
to	O
treat	O
the	O
allergic	O
reaction	O
.	O
      
Methotrexate	B-Drug
:	O
NSAIDs	B-Group
have	O
been	O
reported	O
to	O
competitively	O
inhibit	O
methotrexate	B-Drug
accumulation	O
in	O
rabbit	O
kidney	O
slices	O
.	O
      
The	O
ECG	O
changes	O
and	O
/	O
or	O
hypokalemia	O
that	O
may	O
result	O
from	O
the	O
administration	O
of	O
non	B-Group
-	O
potassium	I-Group
sparing	I-Group
diuretics	I-Group
(	O
such	O
as	O
loop	B-Group
or	O
thiazide	B-Group
diuretics	I-Group
)	O
can	O
be	O
acutely	O
worsened	O
by	O
beta	B-Group
-	O
agonists	I-Group
especially	O
when	O
the	O
recommended	O
dose	O
of	O
the	O
beta	B-Group
-	O
agonist	I-Group
is	O
exceeded	O
.	O
      
This	O
increase	O
is	O
due	O
to	O
the	O
inhibition	O
of	O
celecoxib	B-Drug
metabolism	O
via	O
P9	O
9C9	O
by	O
fluconazole	B-Drug
(	O
see	O
CLINICAL	O
PHARMACOLOGY	O
-	O
Pharmacokinetics	O
:	O
Metabolism	O
)	O
.	O
      
Fatalities	O
have	O
been	O
reported	O
.	O
      
In	O
a	O
study	O
conducted	O
in	O
healthy	O
subjects	O
mean	O
pre	O
-	O
dose	O
lithium	B-Drug
concentration	O
and	O
AUC	O
were	O
increased	O
by	O
9	O
%	O
in	O
subjects	O
receiving	O
lithium	B-Drug
doses	O
ranging	O
from	O
9	O
to	O
9	O
mg	O
BID	O
with	O
meloxicam	B-Drug
9	O
mg	O
QD	O
as	O
compared	O
to	O
subjects	O
receiving	O
lithium	B-Drug
alone	O
.	O
      
For	O
this	O
reason	O
the	O
dose	O
of	O
the	O
anticoagulant	B-Drug
should	O
be	O
reduced	O
by	O
9	O
-	O
9	O
%	O
at	O
the	O
start	O
of	O
treatment	O
with	O
Bezalip	B-Brand
or	O
Bezalip	B-Brand
retard	O
and	O
then	O
titrated	O
according	O
to	O
the	O
blood	O
clotting	O
parameters	O
      
Although	O
there	O
was	O
no	O
effect	O
of	O
Aprepitant	B-Drug
on	O
the	O
plasma	O
AUC	O
of	O
R	B-Drug
or	O
S	B-Drug
-	O
warfarin	I-Drug
determined	O
on	O
Day	O
9	O
there	O
was	O
a	O
9	O
%	O
decrease	O
in	O
S	B-Drug
-	O
warfarin	I-Drug
(	O
a	O
CYP9C9	O
substrate	O
)	O
trough	O
concentration	O
accompanied	O
by	O
a	O
9	O
%	O
decrease	O
in	O
the	O
prothrombin	O
time	O
(	O
reported	O
as	O
International	O
Normalized	O
Ratio	O
or	O
INR	O
)	O
9	O
days	O
after	O
completion	O
of	O
dosing	O
with	O
Aprepitant	B-Drug
.	O
      
In	O
patients	O
receiving	O
another	O
serotonin	B-Group
reuptake	I-Group
inhibitor	I-Group
drug	I-Group
in	O
combination	O
with	O
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
(	O
MAOI	B-Group
)	O
there	O
have	O
been	O
reports	O
of	O
serious	O
sometimes	O
fatal	O
reactions	O
including	O
hyperthermia	O
rigidity	O
myoclonus	O
autonomic	O
instability	O
with	O
possible	O
rapid	O
fluctuations	O
of	O
vital	O
signs	O
and	O
mental	O
status	O
changes	O
that	O
include	O
extreme	O
agitation	O
progressing	O
to	O
delirium	O
and	O
coma	O
.	O
      
In	O
addition	O
the	O
frequency	O
of	O
monitoring	O
serum	O
lithium	B-Drug
concentration	O
should	O
be	O
increased	O
at	O
the	O
outset	O
of	O
such	O
combination	O
drug	O
treatment	O
.	O
      
Patients	O
treated	O
with	O
proton	B-Group
pump	I-Group
inhibitors	I-Group
and	O
warfarin	B-Drug
concomitantly	O
may	O
need	O
to	O
be	O
monitored	O
for	O
increases	O
in	O
INR	O
and	O
prothrombin	O
time	O
.	O
      
Co	O
-	O
administration	O
of	O
MYOBLOC	B-Brand
and	O
aminoglycosides	B-Group
or	O
other	O
agents	O
interfering	O
with	O
neuromuscular	O
transmission	O
(	O
e.g.	O
curare	B-Group
-	O
like	I-Group
compounds	I-Group
)	O
should	O
only	O
be	O
performed	O
with	O
caution	O
as	O
the	O
effect	O
of	O
the	O
toxin	B-Drug
may	O
be	O
potentiated	O
.	O
      
No	O
drug	O
interactions	O
have	O
been	O
identified	O
.	O
      
Therefore	O
concomitant	O
use	O
of	O
ribavirin	B-Drug
with	O
either	O
of	O
these	O
drugs	O
should	O
be	O
avoided	O
.	O
      
NSAIDs	B-Group
:	O
In	O
in	O
vitro	O
studies	O
M9	O
was	O
shown	O
to	O
cause	O
increases	O
ranging	O
from	O
9	O
-	O
9	O
%	O
in	O
the	O
free	O
fraction	O
of	O
diclofenac	B-Drug
and	O
ibuprofen	B-Drug
at	O
concentrations	O
in	O
the	O
clinical	O
range	O
.	O
      
Effect	O
      
Furosemide	B-Drug
:	O
Clinical	O
studies	O
as	O
well	O
as	O
post	O
-	O
marketing	O
observations	O
have	O
shown	O
that	O
NSAIDs	B-Group
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	B-Drug
and	O
thiazides	B-Group
in	O
some	O
patients	O
.	O
      
Therefore	O
caution	O
should	O
be	O
used	O
when	O
administering	O
nitazoxanide	B-Drug
concurrently	O
with	O
other	O
highly	O
plasma	O
protein	O
-	O
bound	O
drugs	O
with	O
narrow	O
therapeutic	O
indices	O
as	O
competition	O
for	O
binding	O
sites	O
may	O
occur	O
(	O
e.g.	O
warfarin	B-Drug
)	O
.	O
      
Usually	O
such	O
inactivation	O
of	O
the	O
aminoglycoside	B-Group
is	O
clinically	O
significant	O
only	O
in	O
patients	O
with	O
severely	O
impaired	O
renal	O
function..	O
      
FELDENE	B-Brand
is	O
highly	O
protein	O
bound	O
and	O
therefore	O
might	O
be	O
expected	O
to	O
displace	O
other	O
protein	O
-	O
bound	O
drugs	O
.	O
      
Phenobarbital	B-Drug
toxicity	O
has	O
been	O
reported	O
to	O
have	O
occurred	O
in	O
a	O
patient	O
on	O
chronic	O
phenobarbital	B-Drug
treatment	O
following	O
the	O
initiation	O
of	O
diclofenac	B-Drug
therapy	O
.	O
      
.	O
      
Anticholinergic	B-Group
agents	I-Group
may	O
affect	O
gastrointestinal	O
absorption	O
of	O
various	O
drugs	O
such	O
as	O
slowly	O
dissolving	O
dosage	O
forms	O
of	O
digoxin	B-Drug
;	O
      
This	O
effect	O
on	O
midazolam	B-Drug
appears	O
to	O
be	O
more	O
pronounced	O
following	O
oral	O
administration	O
of	O
fluconazole	B-Drug
than	O
with	O
fluconazole	B-Drug
administered	O
intravenously	O
.	O
      
Rifabutin	B-Drug
      
Since	O
bacteriostatic	O
drugs	O
may	O
interfere	O
with	O
the	O
bactericidal	O
action	O
of	O
penicillin	B-Drug
it	O
is	O
advisable	O
to	O
avoid	O
giving	O
tetracycline	B-Group
class	I-Group
drugs	I-Group
in	O
conjunction	O
with	O
penicillin	B-Drug
.	O
      
pruritus	O
      
Before	O
using	O
this	O
medication	O
tell	O
your	O
doctor	O
or	O
pharmacist	O
of	O
all	O
prescription	O
and	O
nonprescription	O
products	O
you	O
may	O
use	O
especially	O
of	O
:	O
aminoglycosides	B-Group
(	O
e.g.	O
gentamicin	B-Drug
amikacin	B-Drug
)	O
amphotericin	B-Drug
B	I-Drug
cyclosporine	B-Drug
non	B-Group
-	O
steroidal	I-Group
anti	I-Group
-	O
inflammatory	I-Group
drugs	O
(	O
e.g.	O
ibuprofen	B-Drug
)	O
tacrolimus	B-Drug
vancomycin	B-Drug
.	O
      
The	O
safety	O
and	O
efficacy	O
of	O
concomitant	O
use	O
of	O
REVIA	B-Brand
and	O
disulfiram	B-Drug
is	O
unknown	O
and	O
the	O
concomitant	O
use	O
of	O
two	O
potentially	O
hepatotoxic	O
medications	O
is	O
not	O
ordinarily	O
recommended	O
unless	O
the	O
probable	O
benefits	O
outweigh	O
the	O
known	O
risks	O
.	O
      
however	O
the	O
total	O
amount	O
of	O
9MNA	B-Drug_n
in	O
the	O
plasma	O
is	O
unchanged	O
.	O
      
Efavirenz	B-Drug
      
It	O
is	O
important	O
for	O
older	O
adults	O
to	O
be	O
aware	O
of	O
the	O
relationship	O
between	O
folic	B-Drug
acid	I-Drug
and	O
vitamin	B-Drug
B9	I-Drug
because	O
they	O
are	O
at	O
greater	O
risk	O
of	O
having	O
a	O
vitamin	O
B9	O
deficiency	O
.	O
      
The	O
natriuretic	O
effect	O
of	O
furosemide	B-Drug
has	O
been	O
reported	O
to	O
be	O
inhibited	O
by	O
some	O
drugs	O
of	O
this	O
class	O
.	O
      
These	O
events	O
were	O
also	O
reported	O
to	O
occur	O
when	O
contrast	O
media	O
was	O
given	O
several	O
months	O
after	O
interleukin	B-Drug
-	O
9	I-Drug
treatment	O
.	O
      
9	O
.	O
      
Serum	O
concentration	O
of	O
digoxin	B-Drug
and	O
digitoxin	B-Drug
may	O
increase	O
when	O
patients	O
take	O
antithyroid	B-Group
agents	I-Group
.	O
      
Due	O
to	O
their	O
similar	O
mechanism	O
of	O
action	O
it	O
is	O
expected	O
that	O
the	O
neuromuscular	O
blockade	O
produced	O
by	O
any	O
of	O
the	O
non	B-Group
-	O
depolarizing	I-Group
muscle	I-Group
relaxants	I-Group
could	O
be	O
prolonged	O
in	O
the	O
presence	O
of	O
piperacillin	B-Drug
.	O
      
Therefore	O
coagulation	O
indices	O
should	O
be	O
monitored	O
to	O
maintain	O
the	O
desired	O
anticoagulant	O
effect	O
.	O
      
Cisapride	B-Drug
is	O
metabolized	O
mainly	O
via	O
the	O
cytochrome	O
P9	O
9A9	O
enzyme	O
.	O
      
Bisphosphonates	B-Group
are	O
known	O
to	O
interfere	O
with	O
the	O
use	O
of	O
bone	O
-	O
imaging	O
agents	O
.	O
      
The	O
following	O
laboratory	O
tests	O
have	O
been	O
found	O
to	O
be	O
abnormal	O
in	O
a	O
few	O
patients	O
receiving	O
baclofen	B-Drug
:	O
increased	O
SGOT	O
elevated	O
alkaline	O
phosphatase	O
and	O
elevation	O
of	O
blood	O
sugar	O
.	O
      
An	O
individual	O
who	O
is	O
stable	O
on	O
a	O
given	O
dose	O
of	O
TCA	B-Group
may	O
become	O
abruptly	O
toxic	O
when	O
given	O
one	O
of	O
these	O
inhibiting	O
drugs	O
as	O
concomitant	O
therapy	O
.	O
      
Selective	B-Group
Serotonin	I-Group
Reuptake	I-Group
Inhibitors	I-Group
(	O
SSRIs	B-Group
)	O
:	O
SSRIs	B-Group
(	O
e.g.	O
fluoxetine	B-Drug
fluvoxamine	B-Drug
paroxetine	B-Drug
sertraline	B-Drug
)	O
have	O
been	O
rarely	O
reported	O
to	O
cause	O
weakness	O
hyperreflexia	O
and	O
incoordination	O
when	O
coadministered	O
with	O
9	B-Group
-	O
HT9	I-Group
agonists	I-Group
.	O
      
Consequently	O
it	O
is	O
recommended	O
not	O
to	O
exceed	O
a	O
single	O
9	O
mg	O
Vardenafil	B-Drug
dose	O
in	O
a	O
9	O
-	O
hour	O
period	O
when	O
used	O
in	O
combination	O
with	O
ritonavir	B-Drug
.	O
      
The	O
use	O
of	O
antacids	B-Group
should	O
be	O
considered	O
in	O
place	O
of	O
H9	B-Group
blockers	I-Group
or	O
proton	B-Group
pump	I-Group
inhibitors	I-Group
in	O
patients	O
receiving	O
SPRYCEL	B-Brand
therapy	O
.	O
      
Dexrazoxane	B-Drug
was	O
not	O
mutagenic	O
in	O
the	O
Ames	O
test	O
but	O
was	O
found	O
to	O
be	O
clastogenic	O
to	O
human	O
lymphocytes	O
in	O
vitro	O
and	O
to	O
mouse	O
bone	O
marrow	O
erythrocytes	O
in	O
vivo	O
(	O
micronucleus	O
test	O
)	O
.	O
      
Patients	O
should	O
not	O
be	O
re	O
-	O
treated	O
with	O
subsequent	O
cycles	O
of	O
TAXOL	B-Brand
until	O
neutrophils	O
recover	O
to	O
a	O
level	O
9	O
cells	O
/	O
mm9	O
and	O
platelets	O
recover	O
to	O
a	O
level	O
9	O
9	O
cells	O
/	O
mm9	O
.	O
      
The	O
use	O
of	O
erythromycin	B-Drug
in	O
patients	O
concurrently	O
taking	O
drugs	O
metabolized	O
by	O
the	O
cytochrome	O
P9	O
system	O
may	O
be	O
associated	O
with	O
elevations	O
in	O
serum	O
levels	O
of	O
these	O
other	O
drugs	O
.	O
      
Because	O
fluvoxamine	B-Drug
reduces	O
the	O
clearance	O
of	O
both	O
diazepam	B-Drug
and	O
its	O
active	O
metabolite	O
N	B-Drug_n
-	O
desmethyldiazepam	I-Drug_n
there	O
is	O
a	O
strong	O
likelihood	O
of	O
substantial	O
accumulation	O
of	O
both	O
species	O
during	O
chronic	O
co	O
-	O
administration	O
.	O
      
It	O
is	O
suggested	O
to	O
monitor	O
both	O
ketoconazole	B-Drug
and	O
phenytoin	B-Drug
.	O
      
Results	O
from	O
limited	O
in	O
vitro	O
and	O
in	O
vivo	O
drug	O
-	O
drug	O
interaction	O
studies	O
between	O
tamsulosin	B-Drug
HCI	I-Drug
and	O
warfarin	B-Drug
are	O
inconclusive	O
.	O
      
Johns	O
Wort	O
concomitantly	O
.	O
      
Animal	O
studies	O
indicate	O
that	O
dobutamine	B-Drug
may	O
be	O
ineffective	O
if	O
the	O
patient	O
has	O
recently	O
received	O
a	O
b	B-Group
-	O
blocking	I-Group
drug	I-Group
.	O
      
Therefore	O
precaution	O
should	O
be	O
taken	O
when	O
coadministration	O
is	O
necessary	O
.	O
      
Diuretic	B-Group
agents	I-Group
reduce	O
the	O
renal	O
clearance	O
of	O
lithium	B-Drug
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	B-Drug
toxicity	O
.	O
      
Anticoagulants	B-Group
(	O
Oral	O
)	O
:	O
The	O
hypoprothrombinemic	O
effect	O
of	O
anticoagulants	B-Group
may	O
be	O
potentiated	O
apparently	O
by	O
increased	O
catabloism	O
of	O
vitamin	O
K	O
-	O
dependent	O
clotting	O
factors	O
.	O
      
clinically	O
significant	O
interactions	O
with	O
other	O
drugs	O
through	O
competition	O
for	O
protein	O
binding	O
sites	O
are	O
therefore	O
unlikely	O
.	O
      
-	O
Oral	O
contraceptives	B-Group
(	O
birth	O
control	O
pills	O
)	O
containing	O
estrogen	B-Group
or	O
      
Sumatriptan	B-Drug
:	O
Sumatriptan	B-Drug
has	O
been	O
reported	O
to	O
cause	O
coronary	O
artery	O
vasospasm	O
and	O
its	O
effect	O
could	O
be	O
additive	O
with	O
D.H.E	B-Brand
9	I-Brand
(	O
dihydroergotamine	B-Drug
mesylate	I-Drug
)	O
Injection	O
USP	O
.	O
      
HEMABATE	B-Brand
may	O
augment	O
the	O
activity	O
of	O
other	O
oxytocic	B-Group
agents	I-Group
.	O
      
This	O
indicates	O
that	O
gabapentin	B-Drug
does	O
not	O
undergo	O
renal	O
tubular	O
secretion	O
by	O
the	O
pathway	O
that	O
is	O
blocked	O
by	O
probenecid	B-Drug
.	O
      
In	O
Study	O
9	O
patients	O
receiving	O
bolus	O
-	O
IFL	O
plus	O
AVASTIN	B-Brand
had	O
a	O
higher	O
incidence	O
of	O
Grade	O
9	O
-	O
9	O
diarrhea	O
and	O
neutropenia	O
.	O
      
In	O
addition	O
most	O
macrolides	B-Group
are	O
contraindicated	O
in	O
patients	O
receiving	O
terfenadine	B-Drug
therapy	O
who	O
have	O
pre	O
-	O
existing	O
cardiac	O
abnormalities	O
(	O
arrhythmia	O
bradycardia	O
QT	O
c	O
interval	O
prolongation	O
ischemic	O
heart	O
disease	O
congestive	O
heart	O
failure	O
etc	O
.	O
)	O
or	O
electrolyte	O
disturbances	O
.	O
      
Using	O
calcium	B-Drug
acetate	I-Drug
with	O
digitalis	B-Group
glycosides	I-Group
(	O
heart	O
medicine	O
)	O
may	O
cause	O
hypercalcemia	O
(	O
too	O
much	O
calcium	B-Drug
in	O
the	O
blood	O
)	O
which	O
could	O
increase	O
the	O
chance	O
of	O
developing	O
an	O
irregular	O
heartbeat	O
.	O
      
These	O
drugs	O
include	O
the	O
thiazides	B-Group
and	O
other	O
diuretics	B-Group
corticosteroids	B-Group
phenothiazines	B-Group
thyroid	O
products	O
estrogens	B-Group
oral	O
contraceptives	B-Group
phenytoin	B-Drug
nicotinic	B-Drug
acid	I-Drug
sympathomimetics	B-Group
calcium	B-Group
channel	I-Group
blocking	I-Group
drugs	I-Group
and	O
isoniazid	B-Drug
.	O
      
The	O
effect	O
of	O
desflurane	B-Drug
on	O
the	O
disposition	O
of	O
other	O
drugs	O
has	O
not	O
been	O
determined	O
.	O
      
Hypersensitivity	O
Reactions	O
:	O
Patients	O
with	O
a	O
history	O
of	O
severe	O
hypersensitivity	O
reactions	O
to	O
products	O
containing	O
Cremophor	O
EL	O
(	O
eg	O
cyclosporin	B-Drug
for	O
injection	O
concentrate	O
and	O
teniposide	B-Drug
for	O
injection	O
concentrate	O
)	O
should	O
not	O
be	O
treated	O
with	O
TAXOL	B-Brand
.	O
      
Furosemide	B-Drug
:	O
single	O
and	O
multiple	O
dose	O
pharmacodynamics	O
and	O
pharmacokinetics	O
are	O
not	O
affected	O
by	O
multiple	O
doses	O
of	O
meloxicam	B-Drug
.	O
      
These	O
drugs	O
include	O
the	O
thiazides	B-Group
and	O
other	O
diuretics	B-Group
corticosteroids	B-Group
phenothiazines	B-Group
thyroid	B-Group
products	I-Group
estrogens	B-Group
oral	O
contraceptives	B-Group
phenytoin	B-Drug
nicotinic	B-Drug
acid	I-Drug
sympathomimetics	B-Group
calcium	B-Group
channel	I-Group
blocking	I-Group
drugs	I-Group
and	O
isoniazid	B-Drug
.	O
      
9	O
%	O
increase	O
[	O
CI	O
:	O
9	O
%	O
increase	O
9	O
%	O
increase	O
]	O
9	O
%	O
decrease	O
[	O
CI	O
:	O
9	O
%	O
decrease	O
9	O
%	O
decrease	O
]	O
      
The	O
clinical	O
significance	O
of	O
this	O
increased	O
bioavailability	O
and	O
whether	O
similar	O
increases	O
will	O
occur	O
in	O
patients	O
given	O
oral	O
H9	B-Group
-	O
antagonists	I-Group
is	O
unknown	O
;	O
      
Lipids	O
:	O
Pretreatment	O
and	O
follow	O
-	O
up	O
blood	O
lipids	O
should	O
be	O
obtained	O
under	O
fasting	O
conditions	O
.	O
      
Concomitant	O
administration	O
of	O
alosetron	B-Drug
and	O
moderate	O
CYP9A9	O
inhibitors	O
including	O
quinolone	B-Group
antibiotics	I-Group
and	O
cimetidine	B-Drug
has	O
not	O
been	O
evaluated	O
but	O
should	O
be	O
avoided	O
unless	O
clinically	O
necessary	O
because	O
of	O
similar	O
potential	O
drug	O
interactions	O
.	O
      
Consequently	O
TRACLEER	B-Brand
is	O
not	O
expected	O
to	O
increase	O
the	O
plasma	O
concentrations	O
of	O
drugs	O
metabolized	O
by	O
these	O
enzymes	O
.	O
      
Concomitant	O
use	O
with	O
other	O
oxytocic	B-Group
agents	I-Group
is	O
not	O
recommended	O
.	O
      
Cyclophosphamide	B-Drug
      
In	O
these	O
patients	O
the	O
mixed	O
agonist	O
/	O
antagonist	O
may	O
alter	O
the	O
analgesic	O
effect	O
or	O
may	O
precipitate	O
withdrawal	O
symptoms	O
.	O
      
The	O
combination	O
of	O
therapeutic	O
doses	O
of	O
intravenous	O
dantrolene	B-Drug
sodium	I-Drug
and	O
verapamil	B-Drug
in	O
halothane	B-Drug
a	O
-	O
chloralose	O
anesthetized	O
swine	O
has	O
resulted	O
in	O
ventricular	O
fibrillation	O
and	O
cardiovascular	O
collapse	O
in	O
association	O
with	O
marked	O
hyperkalemia	O
.	O
      
therefore	O
doses	O
greater	O
than	O
the	O
normal	O
antiasthmatic	O
dose	O
of	O
beta	B-Group
-	O
agonist	I-Group
bronchodilator	I-Group
drugs	I-Group
may	O
be	O
required	O
.	O
      
Ketoconazole	B-Drug
:	O
When	O
a	O
single	O
9	O
-	O
mg	O
dose	O
of	O
Aprepitant	B-Drug
was	O
administered	O
on	O
Day9	O
of	O
a	O
      
Interaction	O
with	O
Mixed	B-Group
Agonist	I-Group
Antagonist	I-Group
Opioid	I-Group
Analgesics	I-Group
:	O
Agonist	B-Group
antagonist	I-Group
analgesics	I-Group
(	O
i.e.	O
pentazocine	B-Drug
nalbuphine	B-Drug
butorphanol	B-Drug
or	O
buprenorphine	B-Drug
)	O
should	O
NOT	O
be	O
administered	O
to	O
patients	O
who	O
have	O
received	O
or	O
are	O
receiving	O
a	O
course	O
of	O
therapy	O
with	O
a	O
proof	O
opioid	B-Group
agonist	I-Group
analgesic	I-Group
.	O
      
Some	O
clinicians	O
have	O
noted	O
that	O
these	O
reactions	O
resemble	O
the	O
immediate	O
side	O
effects	O
caused	O
by	O
interleukin	B-Drug
-	O
9	I-Drug
administration	O
however	O
the	O
cause	O
of	O
contrast	O
reactions	O
after	O
interleukin	O
-	O
9	O
therapy	O
is	O
unknown	O
.	O
      
Pentamidine	B-Drug
may	O
cause	O
hypoglycemia	O
which	O
may	O
sometimes	O
be	O
followed	O
by	O
hyperglycemia	O
.	O
      
Penicillin	B-Group
blood	O
levels	O
may	O
be	O
prolonged	O
by	O
concurrent	O
administration	O
of	O
probenecid	B-Drug
which	O
blocks	O
the	O
renal	O
tubular	O
secretion	O
of	O
penicillins	B-Group
.	O
      
Rates	O
of	O
patients	O
with	O
maximum	O
potassium	O
levels	O
9	O
mEq	O
/	O
L	O
were	O
similar	O
regardless	O
of	O
the	O
use	O
of	O
ACEI	B-Group
/	O
ARB	B-Group
.	O
      
There	O
are	O
no	O
known	O
drug	O
/	O
drug	O
interactions	O
with	O
chlorambucil	B-Drug
.	O
      
Hormonal	B-Group
Contraceptives	I-Group
:	O
It	O
has	O
not	O
been	O
established	O
if	O
there	O
is	O
a	O
pharmacokinetic	O
interaction	O
between	O
acitretin	B-Drug
and	O
combined	B-Group
oral	I-Group
contraceptives	I-Group
.	O
      
Minimal	O
metabolism	O
occurs	O
via	O
the	O
major	O
cytochrome	O
P9	O
isoenzymes	O
.	O
      
this	O
can	O
cause	O
headaches	O
and	O
other	O
signs	O
of	O
hypertensive	O
crisis	O
.	O
      
Less	O
potent	O
CYP	O
9A9	O
inhibitors	O
should	O
be	O
administered	O
with	O
caution	O
.	O
      
Aspirin	B-Brand
:	O
Concurrent	O
administration	O
of	O
aspirin	B-Brand
and	O
flurbiprofen	B-Drug
resulted	O
in	O
9	O
%	O
lower	O
serum	O
flurbiprofen	B-Drug
concentrations	O
.	O
      
These	O
small	O
changes	O
are	O
not	O
clinically	O
significant	O
and	O
no	O
dose	O
adjustment	O
is	O
necessary	O
.	O
      
Postoperative	O
respiratory	O
depression	O
may	O
be	O
enhanced	O
or	O
prolonged	O
by	O
these	O
agents	O
.	O
      
For	O
example	O
since	O
cholestyramine	B-Drug
may	O
reduce	O
the	O
gastrointestinal	O
absorption	O
of	O
both	O
the	O
oral	O
anticoagulants	B-Group
and	O
vitamin	B-Group
K	I-Group
the	O
net	O
effects	O
are	O
unpredictable	O
.	O
      
These	O
increased	O
exposures	O
of	O
norethindrone	B-Drug
and	O
ethinyl	B-Drug
estradiol	I-Drug
should	O
be	O
taken	O
into	O
consideration	O
when	O
selecting	O
an	O
oral	O
contraceptive	B-Group
for	O
women	O
taking	O
valdecoxib	B-Drug
.	O
      
Avoid	O
the	O
concomitant	O
use	O
of	O
chlorprothixene	B-Drug
and	O
tramadol	B-Drug
(	O
Ultram	B-Brand
)	O
.	O
      
Effect	O
of	O
other	O
drugs	O
on	O
Sensipar	B-Brand
:	O
Sensipar	B-Brand
is	O
metabolized	O
by	O
multiple	O
cytochrome	O
P9	O
enzymes	O
primarily	O
CYP9A9	O
CYP9D9	O
and	O
CYP9A9	O
.	O
      
Monitor	O
for	O
symptoms	O
of	O
hyperglycemia	O
;	O
      
Concurrent	O
use	O
of	O
alcohol	B-Drug
and	O
other	O
CNS	B-Group
depression	I-Group
-	O
producing	I-Group
drugs	I-Group
may	O
increase	O
the	O
CNS	O
depressant	O
effects	O
of	O
methyprylon	B-Drug
or	O
these	O
other	O
medications	O
.	O
      
Carcinogenesis	O
Mutagenesis	O
and	O
Fertility	O
      
If	O
ProSom	B-Brand
is	O
given	O
concomitantly	O
with	O
other	O
drugs	O
acting	O
on	O
the	O
central	O
nervous	O
system	O
careful	O
consideration	O
should	O
be	O
given	O
to	O
the	O
pharmacology	O
of	O
all	O
agents	O
.	O
      
The	O
injection	O
should	O
be	O
made	O
immediately	O
after	O
mixing	O
.	O
      
The	O
effects	O
of	O
HMG	B-Group
-	O
CoA	I-Group
reductase	I-Group
inhibitors	I-Group
on	O
male	O
fertility	O
have	O
not	O
been	O
studied	O
in	O
adequate	O
numbers	O
of	O
patients	O
.	O
      
Although	O
the	O
interactions	O
observed	O
in	O
these	O
studies	O
do	O
not	O
appear	O
to	O
be	O
of	O
major	O
clinical	O
importance	O
BREVIBLOC	B-Brand
should	O
be	O
titrated	O
with	O
caution	O
in	O
patients	O
being	O
treated	O
concurrently	O
with	O
digoxin	B-Drug
morphine	B-Drug
succinylcholine	B-Drug
or	O
warfarin	B-Drug
.	O
      
Multiple	O
-	O
dose	O
administration	O
of	O
the	O
potent	O
CYP9A9	O
inducer	O
rifampin	B-Drug
(	O
9	O
mg	O
every	O
9	O
hours	O
q9h	O
for	O
9	O
days	O
)	O
however	O
reduced	O
zaleplon	B-Drug
Cmax	O
and	O
AUC	O
by	O
approximately	O
9	O
%	O
.	O
      
At	O
least	O
9	O
days	O
should	O
elapse	O
between	O
discontinuation	O
of	O
a	O
MAO	B-Group
inhibitor	I-Group
and	O
initiation	O
of	O
treatment	O
with	O
dexfenfluramine	B-Drug
.	O
      
The	O
potential	O
for	O
drug	O
interactions	O
with	O
EMTRIVA	B-Brand
has	O
been	O
studied	O
in	O
combination	O
with	O
indinavir	B-Drug
stavudine	B-Drug
famciclovir	B-Drug
and	O
tenofovir	B-Drug
disoproxil	I-Drug
fumarate	I-Drug
.	O
      
Because	O
the	O
risk	O
to	O
the	O
development	O
of	O
the	O
fetal	O
immune	O
system	O
and	O
postnatal	O
immune	O
function	O
in	O
humans	O
is	O
unknown	O
AMEVIVE	B-Brand
should	O
be	O
used	O
during	O
pregnancy	O
only	O
if	O
clearly	O
needed	O
.	O
      
Therefore	O
ketoconazole	B-Drug
should	O
be	O
administered	O
with	O
caution	O
with	O
intranasal	O
ciclesonide	B-Drug
.	O
      
Patients	O
taking	O
coumarin	B-Group
-	O
derivative	I-Group
anticoagulants	I-Group
concomitantly	O
with	O
capecitabine	B-Drug
should	O
be	O
monitored	O
regularly	O
for	O
alterations	O
in	O
their	O
coagulation	O
parameters	O
(	O
PT	O
or	O
INR	O
)	O
.	O
      
Systemic	O
exposure	O
to	O
substrates	O
of	O
CYP9D9	O
is	O
expected	O
to	O
be	O
increased	O
when	O
coadministered	O
with	O
Gleevec	O
.	O
      
Patients	O
who	O
are	O
applying	O
Panretin	B-Brand
gel	O
should	O
not	O
concurrently	O
use	O
products	O
that	O
contain	O
DEET	B-Drug
(	O
N	O
N	B-Drug
-	O
diethyl	I-Drug
-	O
m	I-Drug
-	O
toluamide	I-Drug
)	O
a	O
common	O
component	O
of	O
insect	O
repellent	O
products	O
.	O
      
The	O
results	O
of	O
assays	O
using	O
red	O
cells	O
from	O
healthy	O
subjects	O
to	O
determine	O
whether	O
ceftibuten	B-Drug
would	O
cause	O
direct	O
Coombs	O
reactions	O
in	O
vitro	O
showed	O
no	O
positive	O
reaction	O
at	O
ceftibuten	B-Drug
concentrations	O
as	O
high	O
as	O
9	O
g	O
/	O
mL	O
.	O
      
Cimetidine	B-Drug
      
If	O
pregnancy	O
occurs	O
in	O
a	O
patient	O
or	O
partner	O
of	O
a	O
patient	O
during	O
treatment	O
or	O
during	O
the	O
9	O
months	O
after	O
treatment	O
cessation	O
such	O
cases	O
should	O
be	O
reported	O
to	O
the	O
COPEGUS	B-Brand
Pregnancy	O
Registry	O
at	O
9	O
-	O
9	O
-	O
9	O
-	O
9	O
.	O
      
.	O
      
No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
with	O
RAPTIVA	B-Brand
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Certain	O
endocrine	O
and	O
liver	O
function	O
tests	O
may	O
be	O
affected	O
by	O
estrogen	B-Group
-	O
containing	O
oral	O
contraceptives	B-Group
.	O
      
Poor	O
metabolizers	O
have	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
tricyclic	B-Group
antidepressants	I-Group
(	O
TCAs	B-Group
)	O
when	O
given	O
usual	O
doses	O
.	O
      
An	O
adequate	O
period	O
of	O
observation	O
must	O
be	O
provided	O
for	O
any	O
patient	O
in	O
whom	O
either	O
long	B-Group
-	O
acting	I-Group
benzodiazepines	I-Group
(	O
such	O
as	O
diazepam	B-Drug
)	O
or	O
large	O
doses	O
of	O
short	B-Group
-	O
acting	I-Group
benzodiazepines	I-Group
(	O
such	O
as	O
9	O
mg	O
of	O
midazolam	B-Drug
)	O
have	O
been	O
used	O
.	O
      
Respiratory	O
depression	O
hypotension	O
and	O
profound	O
sedation	O
or	O
coma	O
may	O
occur	O
.	O
      
Dopamine	B-Drug
-	O
induced	O
renal	O
and	O
mesenteric	O
vasodilation	O
is	O
not	O
antagonized	O
by	O
either	O
alpha	B-Group
-	O
or	O
beta	B-Drug
-	O
adrenergic	I-Drug
blocking	I-Drug
agents	I-Drug
.	O
      
However	O
9	O
%	O
decreases	O
in	O
prothrombin	O
time	O
have	O
been	O
observed	O
in	O
single	O
-	O
dose	O
studies	O
.	O
      
No	O
data	O
for	O
delavirdine	B-Drug
;	O
      
Although	O
BETAGAN	B-Brand
used	O
alone	O
has	O
little	O
or	O
no	O
effect	O
on	O
pupil	O
size	O
mydriasis	O
resulting	O
from	O
concomitant	O
therapy	O
with	O
BETAGAN	B-Brand
and	O
epinephrine	B-Drug
may	O
occur	O
.	O
      
Drug	O
monitoring	O
may	O
be	O
of	O
assistance	O
in	O
detecting	O
alterations	O
in	O
carbamazepine	B-Drug
plasma	O
concentrations	O
.	O
      
These	O
effects	O
should	O
be	O
considered	O
when	O
anticholinergic	O
properties	O
may	O
be	O
contributing	O
to	O
the	O
therapeutic	O
effect	O
of	O
concomitant	O
medication	O
(	O
e.g.	O
atropine	B-Drug
inhaled	O
ipratropium	B-Drug
)	O
.	O
      
ZADAXIN	B-Brand
should	O
not	O
be	O
mixed	O
with	O
any	O
other	O
drug	O
.	O
      
With	O
simultaneous	O
dosing	O
of	O
Vardenafil	B-Drug
9	O
mg	O
and	O
terazosin	B-Drug
9	O
mg	O
9	O
of	O
9	O
subjects	O
experienced	O
a	O
standing	O
systolic	O
blood	O
pressure	O
of	O
less	O
than	O
9	O
mm	O
Hg	O
.	O
      
Oral	O
Anticoagulants	B-Group
:	O
Interaction	O
studies	O
with	O
warfarin	B-Drug
failed	O
to	O
identify	O
any	O
clinically	O
important	O
effect	O
on	O
the	O
serum	O
concentrations	O
of	O
the	O
anticoagulant	B-Group
or	O
on	O
its	O
anticoagulant	O
effect	O
.	O
      
In	O
vitro	O
studies	O
have	O
shown	O
CASODEX	B-Brand
can	O
displace	O
coumarin	B-Group
anticoagulants	I-Group
such	O
as	O
warfarin	B-Drug
from	O
their	O
protein	O
-	O
binding	O
sites	O
.	O
      
When	O
increases	O
in	O
the	O
dose	O
of	O
INDOCIN	B-Brand
are	O
made	O
they	O
should	O
be	O
made	O
carefully	O
and	O
in	O
small	O
increments	O
.	O
      
Therefore	O
when	O
hydroflumethiazide	B-Drug
and	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
agents	I-Group
are	O
used	O
concomitantly	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	B-Group
is	O
obtained	O
.	O
)	O
      
Nevertheless	O
caution	O
is	O
indicated	O
in	O
the	O
coadministration	O
of	O
escitalopram	B-Drug
and	O
drugs	O
metabolized	O
by	O
CYP9D9	O
.	O
      
Lithium	B-Drug
generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	B-Group
because	O
they	O
reduce	O
its	O
renal	O
clearance	O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	O
toxicity	O
.	O
      
Lithium	B-Drug
Reversible	O
increases	O
in	O
serum	O
lithium	B-Drug
concentrations	O
and	O
toxicity	O
have	O
been	O
reported	O
during	O
concomitant	O
administration	O
of	O
lithium	B-Drug
with	O
ACE	B-Group
inhibitors	I-Group
and	O
with	O
some	O
angiotensin	B-Group
II	I-Group
receptor	I-Group
antagonists	I-Group
.	O
      
-	O
Decreased	O
pregnanediol	O
excretion	O
      
In	O
clinical	O
trials	O
similar	O
changes	O
in	O
carbamazepine	B-Drug
and	O
carbamazepine	B-Drug_n
epoxide	I-Drug_n
were	O
seen	O
.	O
      
Animal	O
data	O
indicated	O
that	O
bupropion	B-Drug
may	O
be	O
an	O
inducer	O
of	O
drug	O
-	O
metabolizing	O
enzymes	O
in	O
humans	O
.	O
      
Eprosartan	B-Drug
(	O
up	O
to	O
9	O
mg	O
b.i.d	O
.	O
or	O
9	O
mg	O
q.d	O
.	O
)	O
doses	O
have	O
been	O
safely	O
used	O
concomitantly	O
with	O
a	O
thiazide	B-Group
diuretic	I-Group
(	O
hydrochlorothiazide	B-Drug
)	O
.	O
      
Amphetamines	B-Group
may	O
interfere	O
with	O
urinary	O
steroid	O
determinations	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
AMERGE	B-Brand
Tablets	O
are	O
not	O
known	O
to	O
interfere	O
with	O
commonly	O
employed	O
clinical	O
laboratory	O
tests	O
.	O
      
Drug	O
-	O
Drug	O
Interactions	O
Given	O
the	O
primary	O
CNS	O
effects	O
of	O
aripiprazole	B-Drug
caution	O
should	O
be	O
used	O
when	O
ABILIFY	B-Brand
is	O
taken	O
in	O
combination	O
with	O
other	O
centrally	B-Group
acting	I-Group
drugs	I-Group
and	O
alcohol	B-Drug
.	O
      
In	O
another	O
formal	O
study	O
(	O
n	O
=	O
9	O
extensive	O
and	O
n	O
=	O
9	O
poor	O
metabolizers	O
of	O
CYP9D9	O
)	O
coadministration	O
of	O
propafenone	B-Drug
did	O
not	O
alter	O
the	O
kinetics	O
of	O
mexiletine	B-Drug
in	O
the	O
poor	O
CYP9D9	O
metabolizer	O
group	O
.	O
      
Patients	O
treated	O
with	O
acebutolol	B-Drug
plus	O
catecholamine	B-Group
depletors	I-Group
should	O
therefore	O
be	O
observed	O
closely	O
for	O
evidence	O
of	O
marked	O
bradycardia	O
or	O
hypotension	O
which	O
may	O
present	O
as	O
vertigo	O
syncope	O
/	O
presyncope	O
or	O
orthostatic	O
changes	O
in	O
blood	O
pressure	O
without	O
compensatory	O
tachycardia	O
.	O
      
Adequate	O
monitoring	O
of	O
theophylline	B-Drug
plasma	O
concentrations	O
should	O
be	O
considered	O
when	O
therapy	O
with	O
VIOXX	B-Brand
is	O
initiated	O
or	O
changed	O
in	O
patients	O
receiving	O
theophylline	B-Drug
.	O
      
No	O
data	O
on	O
the	O
level	O
of	O
circulating	O
catecholamines	O
after	O
ALPHAGAN	B-Brand
P	I-Brand
administration	O
are	O
available	O
.	O
      
Oral	O
Anticoagulants	B-Group
:	O
Thyroid	B-Group
hormones	I-Group
appear	O
to	O
increase	O
catabolism	O
of	O
vitamin	O
K	O
-	O
dependent	O
clotting	O
factors	O
.	O
      
When	O
such	O
combined	O
therapy	O
is	O
contemplated	O
the	O
dose	O
of	O
one	O
or	O
both	O
agents	O
should	O
be	O
reduced	O
.	O
      
(	O
c	O
)	O
SHBG	O
concentrations	O
are	O
decreased	O
.	O
      
Montelukast	B-Drug
at	O
Doses	O
of	O
9	O
mg	O
Daily	O
Dosed	O
to	O
Pharmacokinetic	O
Steady	O
State	O
:	O
-	O
did	O
not	O
significantly	O
alter	O
the	O
plasma	O
concentrations	O
of	O
either	O
component	O
of	O
an	O
oral	O
contraceptive	B-Group
containing	O
norethindrone	B-Drug
9	O
mg	O
/	O
ethinyl	O
estradiol	B-Drug
9	O
mcg	O
.	O
      
Concurrent	O
use	O
of	O
these	O
agents	O
should	O
generally	O
be	O
avoided	O
.	O
      
In	O
addition	O
higher	O
-	O
than	O
expected	O
steady	O
-	O
state	O
serum	O
concentrations	O
of	O
tricyclic	B-Group
antidepressants	I-Group
have	O
been	O
observed	O
when	O
therapy	O
is	O
initiated	O
in	O
patients	O
already	O
taking	O
cimetidine	B-Drug
.	O
      
Diflunisal	B-Drug
decreased	O
the	O
hyperuricemic	O
effect	O
of	O
hydrochlorothiazide	B-Drug
.	O
      
Concomitant	O
administration	O
of	O
alosetron	B-Drug
and	O
fluvoxamine	B-Drug
is	O
contraindicated	O
.	O
      
The	O
drugs	O
may	O
however	O
be	O
administered	O
alternately	O
provided	O
a	O
proper	O
interval	O
has	O
elapsed	O
between	O
doses	O
.	O
      
The	O
benefits	O
and	O
risks	O
of	O
using	O
TRICOR	B-Brand
with	O
immunosuppressants	B-Group
and	O
other	O
potentially	O
nephrotoxic	O
agents	O
should	O
be	O
carefully	O
considered	O
and	O
the	O
lowest	O
effective	O
dose	O
employed	O
      
No	O
autoinduction	O
has	O
been	O
observed	O
with	O
Trileptal	B-Brand
.	O
      
Methyldopa	B-Drug
is	O
not	O
recommended	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
pheochromocytoma	O
.	O
      
co	O
-	O
administration	O
of	O
phenytoin	B-Drug
may	O
produce	O
a	O
synergistic	O
anticonvulsant	O
action	O
.	O
      
Cytochrome	O
P	O
-	O
9	O
inducers	O
such	O
as	O
phenytoin	B-Drug
carbamazepine	B-Drug
and	O
phenobarbital	B-Drug
induce	O
clonazepam	B-Drug
metabolism	O
causing	O
an	O
approximately	O
9	O
%	O
decrease	O
in	O
plasma	O
clonazepam	B-Drug
levels	O
.	O
      
as	O
such	O
it	O
may	O
impair	O
intestinal	O
absorption	O
of	O
any	O
of	O
vitamin	B-Group
D	I-Group
.	O
      
This	O
effect	O
may	O
be	O
mediated	O
by	O
the	O
known	O
inhibition	O
of	O
hepatic	O
cytochrome	O
P	O
-	O
9	O
by	O
cimetidine	B-Drug
which	O
could	O
decrease	O
first	O
pass	O
metabolism	O
of	O
nimodipine	B-Drug
.	O
      
Since	O
methyldopa	B-Drug
causes	O
fluorescence	O
in	O
urine	O
samples	O
at	O
the	O
same	O
wave	O
lengths	O
as	O
catecholamines	O
falsely	O
high	O
levels	O
of	O
urinary	O
catecholamines	O
may	O
be	O
reported	O
.	O
      
as	O
measured	O
by	O
PBI	O
T9	O
by	O
column	O
or	O
T9	O
by	O
radioimmunoassay	O
.	O
      
CYP	O
interactions	O
:	O
Inhibitors	O
of	O
cytochrome	O
P9	O
enzymes	O
would	O
not	O
be	O
expected	O
to	O
affect	O
pramipexole	B-Drug
elimination	O
because	O
pramipexole	B-Drug
is	O
not	O
appreciably	O
metabolized	O
by	O
these	O
enzymes	O
in	O
vivo	O
or	O
in	O
vitro	O
.	O
      
Didanosine	B-Drug
      
methyldopa	B-Drug
;	O
      
There	O
have	O
been	O
reports	O
of	O
theophylline	B-Drug
-	O
related	O
side	O
effects	O
in	O
patients	O
on	O
concomitant	O
therapy	O
with	O
quinolones	B-Group
and	O
theophylline	B-Drug
.	O
      
Drug	O
/	O
Laboratory	O
Tests	O
Interactions	O
No	O
clinically	O
relevant	O
changes	O
in	O
the	O
results	O
of	O
clinical	O
laboratory	O
tests	O
have	O
been	O
observed	O
.	O
      
Drug	O
-	O
Laboratory	O
Test	O
Interactions	O
There	O
are	O
no	O
reported	O
drug	O
-	O
laboratory	O
test	O
interactions	O
.	O
      
The	O
drugs	O
that	O
inhibit	O
cytochrome	O
P9	O
9D9	O
include	O
some	O
that	O
are	O
not	O
metabolized	O
by	O
the	O
enzyme	O
(	O
quinidine	B-Drug
;	O
      
When	O
atropine	B-Drug
and	O
pralidoxime	B-Drug
are	O
used	O
together	O
the	O
signs	O
of	O
atropinization	O
(	O
flushing	O
mydriasis	O
tachycardia	O
dryness	O
of	O
the	O
mouth	O
and	O
nose	O
)	O
may	O
occur	O
earlier	O
than	O
might	O
be	O
expected	O
when	O
atropine	B-Drug
is	O
used	O
alone	O
.	O
      
The	O
effects	O
of	O
concomitant	O
administration	O
of	O
cimetidine	B-Drug
on	O
the	O
pharmacokinetics	O
of	O
bupropion	B-Drug
and	O
its	O
active	O
metabolites	O
were	O
studied	O
in	O
9	O
healthy	O
young	O
male	O
volunteers	O
.	O
      
nc9	O
9	O
%	O
decrease	O
[	O
CI	O
:	O
9	O
%	O
decrease	O
9	O
%	O
decrease	O
]	O
      
Cholestyramine	B-Drug
resin	B-Group
may	O
delay	O
or	O
reduce	O
the	O
absorption	O
of	O
concomitant	O
oral	O
medication	O
such	O
as	O
phenylbutazone	B-Group
warfarin	B-Drug
thiazide	B-Group
diuretics	I-Group
(	O
acidic	O
)	O
or	O
propranolol	B-Drug
(	O
basic	O
)	O
as	O
well	O
as	O
tetracycline	B-Drug
penicillin	B-Drug
G	I-Drug
phenobarbital	B-Drug
thyroid	O
and	O
thyroxine	B-Drug
preparations	O
estrogens	B-Group
and	O
progestins	B-Group
and	O
digitalis	B-Group
.	O
      
In	O
vitro	O
the	O
UDP	O
-	O
glucuronyl	O
transferase	O
level	O
was	O
increased	O
indicating	O
induction	O
of	O
this	O
enzyme	O
.	O
      
Carbamazepine	B-Drug
:	O
Elevated	O
carbamazepine	B-Drug
levels	O
have	O
been	O
reported	O
in	O
postmarketing	O
experience	O
when	O
SUPRAX	B-Brand
is	O
administered	O
concomitantly	O
.	O
      
AED	B-Group
Co	O
-	O
administered	O
      
Additionally	O
BREVIBLOC	B-Brand
should	O
not	O
be	O
used	O
to	O
control	O
supraventricular	O
tachycardia	O
in	O
the	O
presence	O
of	O
agents	O
which	O
are	O
vasoconstrictive	O
and	O
inotropic	O
such	O
as	O
dopamine	B-Drug
epinephrine	B-Drug
and	O
norepinephrine	B-Drug
because	O
of	O
the	O
danger	O
of	O
blocking	O
cardiac	O
contractility	O
when	O
systemic	O
vascular	O
resistance	O
is	O
high	O
.	O
      
The	O
sedative	O
effect	O
of	O
VERSED	B-Brand
Syrup	I-Brand
is	O
accentuated	O
by	O
any	O
concomitantly	O
administered	O
medication	O
which	O
depresses	O
the	O
central	O
nervous	O
system	O
particularly	O
narcotics	B-Group
(	O
eg	O
morphine	B-Drug
meperidine	B-Drug
and	O
fentanyl	B-Drug
)	O
propofol	B-Drug
ketamine	B-Drug
nitrous	B-Drug
oxide	I-Drug
secobarbital	B-Drug
and	O
droperidol	B-Drug
.	O
      
In	O
vitro	O
studies	O
have	O
shown	O
that	O
fenoprofen	B-Drug
because	O
of	O
its	O
affinity	O
for	O
albumin	O
may	O
displace	O
from	O
their	O
binding	O
sites	O
other	O
drugs	O
that	O
are	O
also	O
albumin	O
bound	O
and	O
this	O
may	O
lead	O
to	O
drug	O
interaction	O
.	O
      
Patients	O
with	O
Severe	O
Hepatic	O
or	O
Renal	O
Impairment	O
Caution	O
should	O
be	O
exercised	O
when	O
TEMODAR	B-Brand
Capsules	O
are	O
administered	O
to	O
patients	O
with	O
severe	O
hepatic	O
or	O
renal	O
impairment	O
.	O
      
Furthermore	O
whenever	O
one	O
of	O
these	O
other	O
drugs	O
is	O
withdrawn	O
from	O
co	O
-	O
therapy	O
an	O
increased	O
dose	O
of	O
tricyclic	B-Drug
antidepressant	I-Drug
may	O
be	O
required	O
.	O
      
Serum	O
lithium	B-Drug
levels	O
should	O
be	O
monitored	O
frequently	O
if	O
INSPRA	B-Brand
is	O
administered	O
concomitantly	O
with	O
lithium	B-Drug
.	O
      
Anticonvulsants	B-Group
:	O
In	O
a	O
pharmacokinetic	O
study	O
maximum	O
plasma	O
concentrations	O
of	O
felodipine	B-Drug
were	O
considerably	O
lower	O
in	O
epileptic	O
patients	O
on	O
long	O
-	O
term	O
anticonvulsant	B-Group
therapy	O
(	O
eg	O
phenytoin	B-Drug
carbamazepine	B-Drug
or	O
phenobarbital	B-Drug
)	O
than	O
in	O
healthy	O
volunteers	O
.	O
      
Concurrent	O
use	O
of	O
tetracycline	B-Drug
may	O
render	O
oral	O
contraceptives	B-Group
less	O
effective	O
.	O
      
Lithium	B-Drug
:	O
In	O
a	O
study	O
conducted	O
in	O
healthy	O
subjects	O
mean	O
steady	O
-	O
state	O
lithium	B-Drug
plasma	O
levels	O
increased	O
approximately	O
9	O
%	O
in	O
subjects	O
receiving	O
lithium	B-Drug
9	O
mg	O
BID	O
with	O
CELEBREX	B-Brand
9	O
mg	O
BID	O
as	O
compared	O
to	O
subjects	O
receiving	O
lithium	B-Drug
alone	O
.	O
      
Patients	O
taking	O
disopyramide	B-Drug
phosphate	I-Drug
and	O
erythromycin	B-Drug
concomitantly	O
may	O
develop	O
increased	O
serum	O
concentrations	O
of	O
disopyramide	B-Drug
resulting	O
in	O
excessive	O
widening	O
of	O
the	O
QRS	O
complex	O
and	O
/	O
or	O
prolongation	O
of	O
the	O
Q	O
-	O
T	O
interval	O
.	O
      
Valproate	B-Drug
:	O
A	O
recent	O
case	O
study	O
has	O
shown	O
a	O
possible	O
increase	O
in	O
the	O
plasma	O
level	O
of	O
valproate	B-Drug
when	O
co	O
administered	O
with	O
isoniazid	B-Drug
.	O
      
In	O
two	O
combined	O
9	O
-	O
week	O
placebo	O
controlled	O
trials	O
that	O
included	O
BROVANA	B-Brand
doses	O
of	O
9	O
mcg	O
twice	O
daily	O
9	O
mcg	O
twice	O
daily	O
and	O
9	O
mcg	O
once	O
daily	O
9	O
of	O
9	O
BROVANA	B-Brand
-	O
treated	O
subjects	O
received	O
concomitant	O
theophylline	B-Drug
at	O
study	O
entry	O
.	O
      
Alcohol	B-Drug
Barbiturates	B-Group
and	O
Narcotics	B-Group
:	O
The	O
hypotensive	O
effects	O
of	O
these	O
drugs	O
may	O
be	O
potentiated	O
by	O
the	O
volume	O
contraction	O
that	O
may	O
be	O
associated	O
with	O
metolazone	B-Drug
therapy	O
.	O
      
Concomitant	O
single	O
dose	O
administration	O
of	O
valdecoxib	B-Drug
9	O
mg	O
with	O
multiple	O
doses	O
of	O
ketoconazole	B-Drug
and	O
fluconazole	B-Drug
produced	O
a	O
significant	O
increase	O
in	O
exposure	O
of	O
valdecoxib	B-Drug
.	O
      
Differences	O
in	O
clearance	O
between	O
patients	O
on	O
these	O
medications	O
(	O
at	O
any	O
occasion	O
in	O
the	O
study	O
)	O
and	O
those	O
off	O
medications	O
varied	O
between	O
-	O
9	O
%	O
and	O
9%	O
.	O
      
Accordingly	O
diazepam	B-Drug
and	O
fluvoxamine	B-Drug
should	O
not	O
ordinarily	O
be	O
co	O
-	O
administered	O
.	O
      
griseofulvin	B-Drug
;	O
      
Saquinavir	B-Drug
      
No	O
significant	O
interactions	O
were	O
found	O
between	O
nisoldipine	B-Drug
and	O
warfarin	B-Drug
or	O
digoxin	B-Drug
.	O
      
Consider	O
doubling	O
the	O
rifabutin	B-Drug
dose	O
in	O
regimens	O
where	O
rifabutin	B-Drug
is	O
given	O
9	O
or	O
9	O
times	O
a	O
week	O
.	O
      
As	O
there	O
is	O
in	O
vitro	O
evidence	O
that	O
aminosalicylate	B-Group
derivatives	I-Group
(	O
e.g.	O
olsalazine	B-Drug
mesalazine	B-Drug
or	O
sulphasalazine	B-Drug
)	O
inhibit	O
the	O
TPMT	O
enzyme	O
they	O
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
receiving	O
concurrent	O
thioguanine	B-Drug
therapy	O
.	O
      
9	O
.	O
      
It	O
is	O
recommended	O
that	O
buspirone	B-Drug
hydrochloride	I-Drug
not	O
be	O
used	O
concomitantly	O
with	O
MAO	B-Group
inhibitors	I-Group
Because	O
the	O
effects	O
of	O
concomitant	O
administration	O
of	O
buspirone	B-Drug
HCl	I-Drug
with	O
most	O
other	O
psychotropic	B-Group
drugs	I-Group
have	O
not	O
been	O
studied	O
the	O
concomitant	O
use	O
of	O
buspirone	B-Drug
HCl	I-Drug
with	O
other	O
CNS	O
-	O
active	O
drugs	O
should	O
be	O
approached	O
with	O
caution	O
.	O
      
Disopyramide	B-Drug
increases	O
QT	O
prolongation	O
which	O
could	O
cause	O
arrhythmia	O
.	O
      
Therefore	O
caution	O
should	O
be	O
exercised	O
when	O
using	O
these	O
drugs	O
together	O
.	O
      
Calcium	B-Drug
Supplements	O
:	O
Uncontrolled	O
intake	O
of	O
additional	O
calcium	B-Drug
-	O
containing	O
preparations	O
should	O
be	O
avoided	O
.	O
      
As	O
a	O
consequence	O
when	O
INDOCIN	B-Brand
and	O
lithium	B-Drug
are	O
given	O
concomitantly	O
the	O
patient	O
should	O
be	O
carefully	O
observed	O
for	O
signs	O
of	O
lithium	B-Drug
toxicity	O
.	O
      
The	O
adrenergic	O
receptors	O
remain	O
sensitive	O
during	O
treatment	O
with	O
methyldopa	B-Drug
.	O
      
-	O
Daunorubicin	B-Drug
(	O
e.g.	O
Cerubidine	B-Brand
)	O
or	O
      
In	O
two	O
clinical	O
studies	O
cyclosporine	B-Drug
(	O
one	O
9	O
mg	O
/	O
kg	O
dose	O
or	O
two	O
9	O
mg	O
/	O
kg	O
doses	O
)	O
increased	O
the	O
AUC	O
of	O
caspofungin	B-Drug
by	O
approximately	O
9	O
%	O
.	O
      
Thrombolytic	B-Group
agents	I-Group
:	O
The	O
safety	O
and	O
effectiveness	O
of	O
Argatroban	B-Drug
with	O
thrombolytic	B-Group
agents	I-Group
have	O
not	O
been	O
established	O
.	O
      
Antihistamines	B-Drug
:	O
astemizole	B-Drug
*	O
terfenadine	B-Drug
*	O
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
cardiac	O
arrhythmias	O
.	O
      
As	O
with	O
other	O
antihypertensive	B-Group
agents	I-Group
the	O
antihypertensive	O
effect	O
of	O
losartan	B-Drug
may	O
be	O
blunted	O
by	O
the	O
non	B-Group
-	O
steroidal	I-Group
anti	I-Group
-	O
inflammatory	I-Group
drug	I-Group
indomethacin	B-Drug
      
However	O
the	O
pharmacodynamic	O
effect	O
increased	O
by	O
9	O
%	O
(	O
QTc	O
increase	O
over	O
time	O
)	O
and	O
by	O
9	O
%	O
(	O
Maximum	O
QTc	O
increase	O
)	O
.	O
      
Quinolones	B-Group
including	O
nalidixic	B-Drug
acid	I-Drug
may	O
enhance	O
the	O
effects	O
of	O
the	O
oral	O
anticoagulant	B-Group
warfarin	B-Drug
or	O
its	O
derivatives	O
.	O
      
Stavudine	B-Drug
and	O
Zidovudine	B-Drug
Ribavirin	B-Drug
can	O
antagonize	O
the	O
in	O
vitro	O
antiviral	O
activity	O
of	O
stavudine	B-Drug
and	O
zidovudine	B-Drug
against	O
HIV	O
.	O
      
No	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
with	O
Calcitonin	B-Drug
salmon	I-Drug
nasal	O
spray	O
ingredients	O
.	O
      
Tell	O
your	O
doctor	O
if	O
you	O
are	O
taking	O
guanethidine	B-Drug
.	O
      
Additionally	O
in	O
one	O
controlled	O
study	O
in	O
five	O
normal	O
subjects	O
and	O
seven	O
patients	O
the	O
clearance	O
of	O
caffeine	B-Drug
was	O
decreased	O
9	O
%	O
following	O
the	O
administration	O
of	O
Mexitil	B-Brand
.	O
      
Amphotericin	B-Drug
B	I-Drug
injection	O
and	O
potassium	O
-	O
depleting	O
agents	O
:	O
When	O
corticosteroids	B-Group
are	O
administered	O
concomitantly	O
with	O
potassium	O
-	O
depleting	O
agents	O
(	O
e.g.	O
amphotericin	B-Drug
B	I-Drug
diuretics	B-Group
)	O
patients	O
should	O
be	O
observed	O
closely	O
for	O
development	O
of	O
hypokalemia	O
.	O
      
cholestyramine	B-Drug
;	O
      
The	O
data	O
inTables	O
9	O
and	O
9	O
are	O
based	O
on	O
the	O
results	O
of	O
drug	O
interaction	O
studies	O
conducted	O
in	O
HIV	O
-	O
9	O
seropositive	O
subjects	O
unless	O
otherwise	O
indicated	O
.	O
      
Gabapentin	B-Drug
is	O
not	O
appreciably	O
metabolized	O
nor	O
does	O
it	O
interfere	O
with	O
the	O
metabolism	O
of	O
commonly	O
coadministered	O
antiepileptic	B-Group
drugs	I-Group
.	O
      
Caution	O
should	O
be	O
used	O
when	O
NSAIDs	B-Group
are	O
administered	O
concomitantly	O
with	O
methotrexate	B-Drug
.	O
      
This	O
may	O
potentiate	O
and	O
prolong	O
hypnotic	O
and	O
sedative	O
effects	O
.	O
      
Tagamet	B-Brand
apparently	O
through	O
an	O
effect	O
on	O
certain	O
microsomal	O
enzyme	O
systems	O
has	O
been	O
reported	O
to	O
reduce	O
the	O
hepatic	O
metabolism	O
of	O
warfarin	B-Group
-	O
type	I-Group
anticoagulants	I-Group
phenytoin	B-Drug
propranolol	B-Drug
nifedipine	B-Drug
chlordiazepoxide	B-Drug
diazepam	B-Drug
certain	O
tricyclic	B-Group
antidepressants	I-Group
lidocaine	B-Drug
theophylline	B-Drug
and	O
metronidazole	B-Drug
thereby	O
delaying	O
elimination	O
and	O
increasing	O
blood	O
levels	O
of	O
these	O
drugs	O
.	O
      
Epinephrine	B-Drug
should	O
not	O
be	O
administered	O
concomitantly	O
with	O
other	O
sympathomimetic	B-Group
drugs	I-Group
(	O
such	O
as	O
isoproterenol	B-Drug
)	O
because	O
of	O
possible	O
additive	O
effects	O
and	O
increased	O
toxicity	O
.	O
      
However	O
patients	O
receiving	O
infusions	O
of	O
FLOLAN	B-Brand
in	O
clinical	O
trials	O
were	O
maintained	O
on	O
anticoagulants	B-Group
without	O
evidence	O
of	O
increased	O
bleeding	O
.	O
      
Because	O
there	O
is	O
a	O
theoretical	O
basis	O
that	O
these	O
effects	O
may	O
be	O
additive	O
use	O
of	O
ergotamine	B-Drug
-	O
containing	O
or	O
ergot	B-Group
-	O
type	I-Group
medications	I-Group
(	O
like	O
dihydroergotamine	B-Drug
or	O
methysergide	B-Drug
)	O
and	O
sumatriptan	B-Drug
within	O
9	O
hours	O
of	O
each	O
other	O
should	O
be	O
avoided	O
.	O
      
Single	O
dose	O
bioavailability	O
studies	O
in	O
normal	O
volunteers	O
have	O
failed	O
to	O
wshow	O
an	O
effect	O
of	O
aspirin	B-Brand
on	O
ibuprofen	B-Drug
blood	O
levels	O
.	O
      
Wait	O
9	O
weeks	O
after	O
stopping	O
an	O
MAO	B-Group
inhibitor	I-Group
before	O
starting	O
escitalopram	B-Drug
.	O
      
This	O
response	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
.	O
      
Agents	O
that	O
induce	O
CYP9A9	O
(	O
eg	O
carbamazepine	B-Drug
)	O
could	O
cause	O
an	O
increase	O
in	O
aripiprazole	B-Drug
clearance	O
and	O
lower	O
blood	O
levels	O
.	O
      
http	O
:	O
/	O
/	O
www.rxlist.com	O
/	O
cgi	O
/	O
generic9	O
/	O
guanethidine_od.htm	O
      
The	O
use	O
of	O
dextromethorphan	B-Drug
hydrobromide	I-Drug
may	O
result	O
in	O
additive	O
CNS	O
depressant	O
effects	O
when	O
coadministered	O
with	O
alcohol	B-Drug
antihistamines	B-Group
psychotropics	B-Group
or	O
other	O
drugs	O
that	O
produce	O
CNS	O
depression	O
.	O
      
Gleevec	B-Brand
will	O
increase	O
plasmaconcentration	O
of	O
other	O
CYP9A9	O
metabolized	O
drugs	O
(	O
e.g.	O
triazolo	O
-	O
benzodiazepines	B-Group
dihydropyridine	B-Group
calcium	I-Group
channel	I-Group
blockers	I-Group
certain	O
HMG	B-Group
-	O
CoA	I-Group
reductase	I-Group
inhibitors	I-Group
etc	O
.	O
)	O
.	O
      
(	O
9	O
mg	O
Q9h	O
)	O
      
There	O
have	O
been	O
postmarketing	O
reports	O
of	O
increased	O
INR	O
and	O
prothrombin	O
time	O
in	O
patients	O
receiving	O
proton	B-Group
pump	I-Group
inhibitors	I-Group
including	O
pantoprazole	B-Drug
and	O
warfarin	B-Drug
concomitantly	O
.	O
      
However	O
interactions	O
may	O
be	O
expected	O
and	O
UROXATRAL	B-Brand
should	O
NOT	O
be	O
used	O
in	O
combination	O
with	O
other	O
alpha	B-Group
-	O
blockers	I-Group
.	O
      
-	O
Pressor	O
amines	O
(	O
e.g.	O
norepinephrine	B-Drug
)	O
:	O
Possible	O
decreased	O
response	O
to	O
pressor	O
amines	O
but	O
not	O
sufficient	O
to	O
preclude	O
their	O
use	O
      
Thus	O
if	O
a	O
patient	O
has	O
been	O
titrated	O
to	O
a	O
stable	O
dosage	O
on	O
one	O
of	O
the	O
agents	O
in	O
this	O
category	O
and	O
then	O
begins	O
a	O
course	O
of	O
treatment	O
with	O
EQUETROTM	B-Brand
it	O
is	O
reasonable	O
to	O
expect	O
that	O
a	O
dose	O
adjustment	O
may	O
be	O
necessary	O
.	O
      
A	O
number	O
of	O
drugs	O
including	O
ethacrynic	B-Drug
acid	I-Drug
have	O
been	O
shown	O
to	O
displace	O
warfarin	B-Drug
from	O
plasma	O
protein	O
;	O
      
The	O
concomitant	O
administration	O
of	O
quinolones	B-Group
including	O
norfloxacin	B-Drug
with	O
glyburide	B-Drug
(	O
a	O
sulfonylurea	B-Group
agent	I-Group
)	O
has	O
on	O
rare	O
occasions	O
resulted	O
in	O
severe	O
hypoglycemia	O
.	O
      
Potentiation	O
occurs	O
with	O
ganglionic	B-Group
or	O
peripheral	B-Group
adrenergic	I-Group
blocking	I-Group
drugs	I-Group
.	O
      
Combinations	O
of	O
these	O
drugs	O
have	O
not	O
been	O
studied	O
and	O
coadministration	O
of	O
CRIXIVAN	B-Brand
and	O
atazanavir	B-Drug
is	O
not	O
recommended	O
.	O
      
Results	O
of	O
studies	O
in	O
multiple	O
sclerosis	O
patients	O
taking	O
TYSABRI	B-Brand
and	O
concomitant	O
interferon	B-Drug
beta	I-Drug
-	O
9a	I-Drug
(	O
AVONEX	B-Brand
9	O
mcg	O
IM	O
once	O
weekly	O
)	O
or	O
glatiramer	B-Drug
acetate	I-Drug
were	O
inconclusive	O
with	O
regard	O
to	O
the	O
need	O
for	O
dose	O
adjustment	O
of	O
the	O
beta	B-Drug
-	O
interferon	I-Drug
or	O
glatiramer	B-Drug
acetate	I-Drug
.	O
      
Other	O
drugs	O
metabolized	O
by	O
C.P.A	O
.	O
      
Laboratory	O
Tests	O
If	O
significant	O
abnormal	O
laboratory	O
results	O
are	O
obtained	O
either	O
dosage	O
reduction	O
with	O
careful	O
monitoring	O
or	O
treatment	O
discontinuation	O
is	O
recommended	O
depending	O
on	O
clinical	O
judgement	O
.	O
      
No	O
information	O
is	O
available	O
about	O
the	O
interaction	O
of	O
cephalexin	B-Drug
and	O
metformin	B-Drug
following	O
multiple	O
doses	O
of	O
either	O
drug	O
.	O
      
Digoxin	B-Drug
:	O
Some	O
calcium	B-Group
blockers	I-Group
may	O
increase	O
the	O
concentration	O
of	O
digitalis	B-Group
preparations	I-Group
in	O
the	O
blood	O
.	O
      
Although	O
not	O
studied	O
systematically	O
in	O
clinical	O
trials	O
no	O
drug	O
interactions	O
were	O
observed	O
when	O
vecuronium	B-Drug
pancuronium	B-Drug
or	O
atracurium	B-Drug
were	O
administered	O
following	O
varying	O
degrees	O
of	O
recovery	O
from	O
single	O
doses	O
or	O
infusions	O
of	O
NIMBEX	B-Brand
.	O
      
Patients	O
with	O
ACTH	O
deficiency	O
should	O
have	O
their	O
glucocorticoid	B-Group
-	O
replacement	O
dose	O
carefully	O
adjusted	O
to	O
avoid	O
an	O
inhibitory	O
effect	O
on	O
growth	O
.	O
      
If	O
concomitant	O
use	O
can	O
not	O
be	O
avoided	O
serum	O
levels	O
of	O
theophylline	B-Drug
should	O
be	O
monitored	O
and	O
dosage	O
adjustments	O
made	O
as	O
appropriate	O
.	O
      
An	O
appropriate	O
adjustment	O
in	O
theophylline	B-Drug
dose	O
should	O
be	O
considered	O
.	O
      
Dosage	O
of	O
the	O
anticoagulant	B-Group
may	O
require	O
reduction	O
in	O
order	O
to	O
maintain	O
satisfactory	O
therapeutic	O
hypoprothrombinemia	O
.	O
      
Alcohol	B-Drug
:	O
In	O
post	O
-	O
marketing	O
experience	O
there	O
have	O
been	O
rare	O
reports	O
of	O
adverse	O
neuropsychiatric	O
events	O
or	O
reduced	O
alcohol	B-Drug
tolerance	O
in	O
patients	O
who	O
were	O
drinking	O
alcohol	B-Drug
during	O
treatment	O
with	O
WELLBUTRIN	B-Brand
.	O
      
Therefore	O
cyclosporine	B-Drug
serum	O
levels	O
should	O
be	O
monitored	O
and	O
appropriate	O
cyclosporine	B-Drug
dosage	O
adjustments	O
made	O
when	O
these	O
drugs	O
are	O
used	O
concomitantly	O
.	O
      
Anticholinergic	B-Group
agents	I-Group
:	O
Although	O
ipratropium	B-Drug
bromide	I-Drug
is	O
minimally	O
absorbed	O
into	O
the	O
systemic	O
circulation	O
there	O
is	O
some	O
potential	O
for	O
an	O
additive	O
interaction	O
with	O
concomitantly	O
used	O
anticholinergic	B-Group
medications	I-Group
.	O
      
Based	O
on	O
adult	O
data	O
lower	O
doses	O
of	O
caffeine	B-Drug
may	O
be	O
needed	O
following	O
coadministration	O
of	O
drugs	O
which	O
are	O
reported	O
to	O
decrease	O
caffeine	B-Drug
elimination	O
(	O
e.g.	O
cimetidine	B-Drug
and	O
ketoconazole	B-Drug
)	O
and	O
higher	O
caffeine	B-Drug
doses	O
may	O
be	O
needed	O
following	O
coadministration	O
of	O
drugs	O
that	O
increase	O
caffeine	B-Drug
elimination	O
(	O
e.g.	O
phenobarbital	B-Drug
and	O
phenytoin	B-Drug
)	O
.	O
      
In	O
a	O
single	O
study	O
rats	O
given	O
high	O
intraperitoneal	O
doses	O
of	O
an	O
MAO	B-Group
inhibitor	I-Group
plus	O
disulfiram	B-Drug
experienced	O
severe	O
toxicity	O
including	O
convulsions	O
and	O
death	O
.	O
      
Such	O
patients	O
may	O
be	O
unresponsive	O
to	O
the	O
usual	O
doses	O
of	O
epinephrine	B-Drug
used	O
to	O
treat	O
allergic	O
reactions	O
.	O
      
Other	O
significant	O
inhibitors	O
of	O
CYP9D9	O
such	O
as	O
fluoxetine	B-Drug
or	O
paroxetine	B-Drug
would	O
be	O
expected	O
to	O
have	O
similar	O
effects	O
and	O
therefore	O
should	O
be	O
accompanied	O
by	O
similar	O
dose	O
reductions	O
.	O
      
Because	O
lithium	B-Drug
may	O
enhance	O
the	O
serotonergic	O
effects	O
of	O
escitalopram	B-Drug
caution	O
should	O
be	O
exercised	O
when	O
LEXAPRO	B-Brand
and	O
lithium	B-Drug
are	O
coadministered	O
.	O
      
When	O
coadministered	O
with	O
SUSTIVA	B-Brand
in	O
treatment	O
-	O
naive	O
patients	O
the	O
recommended	O
dose	O
of	O
atazanavir	B-Drug
is	O
9	O
mg	O
with	O
ritonavir	B-Drug
9	O
mg	O
and	O
SUSTIVA	B-Brand
9	O
mg	O
(	O
all	O
once	O
daily	O
)	O
.	O
      
Mexitil	B-Brand
does	O
not	O
alter	O
serum	O
digoxin	B-Drug
levels	O
but	O
magnesium	B-Drug
-	O
aluminum	I-Drug
hydroxide	I-Drug
when	O
used	O
to	O
treat	O
gastrointestinal	O
symptoms	O
due	O
to	O
Mexitil	B-Brand
has	O
been	O
reported	O
to	O
lower	O
serum	O
digoxin	B-Drug
levels	O
.	O
      
Immediate	O
and	O
Extended	O
Release	O
Tablets	O
The	O
hypoglycemic	O
action	O
of	O
sulfonylureas	B-Group
may	O
be	O
potentiated	O
by	O
certain	O
drugs	O
including	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
agents	I-Group
some	O
azoles	B-Group
and	O
other	O
drugs	O
that	O
are	O
highly	O
protein	O
bound	O
salicylates	B-Group
sulfonamides	B-Group
chloramphenicol	B-Drug
probenecid	B-Drug
coumarins	B-Group
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
and	O
beta	B-Group
adrenergic	I-Group
blocking	I-Group
agents	I-Group
.	O
      
Oral	O
Anticoagulants	B-Group
Interaction	O
studies	O
with	O
warfarin	B-Drug
and	O
acenocoumarol	B-Drug
failed	O
to	O
identify	O
any	O
clinically	O
important	O
effects	O
on	O
the	O
serum	O
concentrations	O
or	O
clinical	O
effects	O
of	O
these	O
anticoagulants	B-Group
.	O
      
In	O
rats	O
simultaneous	O
ingestion	O
of	O
disulfiram	B-Drug
and	O
nitrite	B-Drug
in	O
the	O
diet	O
for	O
9	O
weeks	O
has	O
been	O
reported	O
to	O
cause	O
tumors	O
and	O
it	O
has	O
been	O
suggested	O
that	O
disulfiram	B-Drug
may	O
react	O
with	O
nitrites	B-Group
in	O
the	O
rat	O
stomach	O
to	O
form	O
a	O
nitrosamine	O
which	O
is	O
tumorigenic	O
.	O
      
Data	O
from	O
several	O
studies	O
ie	O
TIMI	O
-	O
II	O
ISIS	O
-	O
9	O
currently	O
do	O
not	O
suggest	O
any	O
clinical	O
interaction	O
between	O
aspirin	B-Brand
and	O
beta	B-Group
blockers	I-Group
in	O
the	O
acute	O
myocardial	O
infarction	O
setting	O
.	O
      
Short	B-Group
-	O
Acting	I-Group
beta9	I-Group
-	O
agonists	I-Group
:	O
Aerosol	O
bronchodilators	B-Group
of	O
the	O
short	O
-	O
acting	O
adrenergic	O
stimulant	O
type	O
may	O
be	O
used	O
for	O
relief	O
of	O
breakthrough	O
symptoms	O
while	O
using	O
formoterol	B-Drug
.	O
      
Cimetidine	B-Drug
(	O
9	O
mg	O
b.i.d	O
.	O
)	O
had	O
no	O
effect	O
on	O
vardenafil	B-Drug
bioavailability	O
(	O
AUC	O
)	O
and	O
maximum	O
concentration	O
(	O
Cmax	O
)	O
of	O
vardenafil	B-Drug
when	O
co	O
-	O
administered	O
with	O
9	O
mg	O
Vardenafil	B-Drug
in	O
healthy	O
volunteers	O
.	O
      
Animal	O
toxicology	O
studies	O
showed	O
increased	O
DEET	B-Drug
toxicity	O
when	O
DEET	B-Drug
was	O
included	O
as	O
proof	O
of	O
the	O
formulation	O
.	O
      
Concomitant	O
use	O
of	O
clozapine	B-Drug
with	O
other	O
drugs	O
metabolized	O
by	O
cytochrome	O
P9	O
9D9	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
clozapine	B-Drug
or	O
the	O
other	O
drug	O
.	O
      
APRD99_IN	O
txt	O
      
Aspirin	B-Brand
:	O
Vardenafil	B-Drug
(	O
9	O
mg	O
and	O
9	O
mg	O
)	O
did	O
not	O
potentiate	O
the	O
increase	O
in	O
bleeding	O
time	O
caused	O
by	O
aspirin	B-Brand
(	O
two	O
9	O
mg	O
tablets	O
)	O
.	O
      
When	O
administered	O
concurrently	O
testolactone	B-Drug
may	O
increase	O
the	O
effects	O
of	O
oral	O
anticoagulants	B-Group
;	O
      
Some	O
quinolones	B-Group
including	O
ciprofloxacin	B-Drug
have	O
been	O
associated	O
with	O
transient	O
elevations	O
in	O
serum	O
creatinine	O
in	O
patients	O
receiving	O
cyclosporine	B-Drug
concomitantly	O
.	O
      
Caution	O
should	O
be	O
used	O
if	O
ibuprofen	B-Drug
is	O
administered	O
concomitantly	O
with	O
methotrexate	B-Drug
.	O
      
Therefore	O
when	O
initiating	O
pressor	O
therapy	O
in	O
patients	O
receiving	O
these	O
drugs	O
the	O
initial	O
dose	O
should	O
be	O
small	O
and	O
given	O
with	O
caution	O
.	O
      
.	O
      
Loop	B-Group
Diuretics	I-Group
:	O
Furosemide	B-Drug
administered	O
concurrently	O
with	O
captopril	B-Drug
does	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
captopril	B-Drug
in	O
renally	O
impaired	O
hypertensive	O
patients	O
.	O
      
Probenecid	B-Drug
:	O
Probenecid	B-Drug
increases	O
both	O
free	O
and	O
bound	O
ketoprofen	B-Drug
by	O
reducing	O
the	O
plasma	O
clearance	O
of	O
ketoprofen	B-Drug
to	O
about	O
one	O
-	O
third	O
as	O
well	O
as	O
decreasing	O
its	O
protein	O
binding	O
.	O
      
When	O
administered	O
concurrently	O
the	O
following	O
drugs	O
may	O
interact	O
with	O
beta	B-Group
-	O
adrenergic	I-Group
receptor	I-Group
blocking	I-Group
agents	I-Group
:	O
Anesthetics	B-Group
general	O
:	O
exaggeration	O
of	O
the	O
hypotension	O
induced	O
by	O
general	O
anesthetics	B-Group
.	O
      
Interactions	O
with	O
Other	O
Antiretroviral	B-Group
Drugs	I-Group
:	O
Significant	O
decreases	O
in	O
the	O
AUC	O
of	O
delavirdine	B-Drug
(	O
9	O
%	O
)	O
and	O
indinavir	B-Drug
(	O
9	O
%	O
)	O
occurred	O
following	O
simultaneous	O
administration	O
of	O
these	O
agents	O
with	O
VIDEX	B-Brand
.	O
      
Alcohol	B-Drug
barbiturates	B-Group
or	O
narcotics	B-Group
:	O
potentiation	O
of	O
orthostatic	O
hypotension	O
may	O
occur	O
.	O
      
When	O
the	O
CYP9A9	O
inhibitor	O
is	O
withdrawn	O
from	O
the	O
combination	O
therapy	O
aripiprazole	B-Drug
dose	O
should	O
then	O
be	O
increased	O
.	O
      
because	O
of	O
this	O
the	O
dosage	O
of	O
flecainide	B-Drug
should	O
be	O
adjusted	O
when	O
these	O
drugs	B-Drug
are	O
administered	O
concomitantly	O
.	O
      
Caffeine	B-Drug
and	O
/	O
or	O
stimulantes	O
of	O
the	O
ephedrine	B-Drug
/	O
amphetamine	B-Drug
type	O
may	O
counteract	O
the	O
specific	O
actions	O
of	O
levomepromazine	B-Drug
.	O
      
In	O
studies	O
with	O
finasteride	B-Drug
no	O
clinically	O
meaningful	O
changes	O
in	O
luteinizing	O
hormone	O
(	O
LH	O
)	O
follicle	O
-	O
stimulating	O
hormone	O
(	O
FSH	O
)	O
or	O
prolactin	O
were	O
detected	O
.	O
      
Rifabutin	B-Drug
and	O
its	O
metabolite	O
concentrationswere	O
moderately	O
increased	O
.	O
      
Lupus	O
-	O
like	O
syndrome	O
      
The	O
effect	O
of	O
TORADOL	B-Brand
on	O
methotrexate	B-Drug
clearance	O
has	O
not	O
been	O
studied	O
.	O
      
Serum	O
infliximab	B-Drug
concentrations	O
appeared	O
to	O
be	O
unaffected	O
by	O
baseline	O
use	O
of	O
medications	O
for	O
the	O
treatment	O
of	O
Crohn	O
disease	O
including	O
corticosteroids	B-Group
antibiotics	B-Group
(	O
metronidazole	B-Drug
or	O
ciprofloxacin	B-Drug
)	O
and	O
aminosalicylates	O
.	O
      
Of	O
particular	O
importance	O
sufficient	O
time	O
must	O
elapse	O
before	O
initiating	O
TCA	O
treatment	O
in	O
a	O
patient	O
being	O
withdrawn	O
from	O
fluoxetine	B-Drug
given	O
the	O
long	O
half	O
-	O
life	O
of	O
the	O
parent	O
and	O
active	O
metabolite	O
(	O
at	O
least	O
9	O
weeks	O
may	O
be	O
necessary	O
)	O
.	O
      
Caution	O
should	O
be	O
exercised	O
when	O
administering	O
ZADAXIN	B-Brand
therapy	O
in	O
combination	O
with	O
other	O
immunomodulating	B-Group
drugs	I-Group
.	O
      
Warning	O
signs	O
irrespective	O
of	O
cause	O
are	O
:	O
dryness	O
of	O
mouth	O
thirst	O
weakness	O
lethargy	O
drowsiness	O
restlessness	O
muscle	O
pains	O
or	O
cramps	O
muscular	O
fatigue	O
hypotension	O
oliguria	O
tachycardia	O
and	O
gastrointestinal	O
disturbances	O
such	O
as	O
nausea	O
and	O
vomiting	O
.	O
      
Salicylate	B-Group
competes	O
with	O
a	O
number	O
of	O
drugs	O
for	O
protein	O
binding	O
sites	O
notably	O
penicillin	B-Drug
thiopental	B-Drug
thyroxine	B-Drug
triiodothyronine	B-Drug
phenytoin	B-Drug
sulfinpyrazone	B-Drug
naproxen	B-Drug
warfarin	B-Drug
methotrexate	B-Drug
and	O
possibly	O
corticosteroids	B-Group
.	O
      
Elevated	O
plasma	O
levels	O
of	O
theophylline	B-Drug
have	O
been	O
reported	O
with	O
concomitant	O
use	O
of	O
some	O
quinolones	B-Group
.	O
      
Insulin	O
parameters	O
were	O
not	O
affected	O
.	O
      
Special	O
attention	O
should	O
be	O
given	O
to	O
electrolyte	O
and	O
acid	O
-	O
base	O
balance	O
in	O
patients	O
experiencing	O
severe	O
or	O
prolonged	O
diarrhea	O
or	O
in	O
patients	O
receiving	O
concomitant	O
diuretics	B-Drug
.	O
      
Agents	O
with	O
Decreased	O
Levels	O
in	O
the	O
Presence	O
of	O
Carbamazepine	B-Drug
due	O
to	O
Induction	O
of	O
Cytochrome	O
P9	O
Enzymes	O
Carbamazepine	B-Drug
is	O
known	O
to	O
induce	O
CYP9A9	O
and	O
CYP9A9	O
.	O
      
Tacrolimus	O
Felodipine	B-Drug
may	O
increase	O
the	O
blood	O
concentration	O
of	O
tacrolimus	B-Drug
.	O
      
Trimethoprim	B-Drug
may	O
inhibit	O
the	O
hepatic	O
metabolism	O
of	O
phenytoin	B-Drug
.	O
      
Coumarin	B-Group
-	O
type	I-Group
anticoagulants	I-Group
:	O
Prothrombin	O
time	O
may	O
be	O
increased	O
in	O
patients	O
receiving	O
concomitant	O
DIFLUCAN	B-Brand
and	O
coumarin	B-Group
-	O
type	I-Group
anticoagulants	I-Group
.	O
      
Thus	O
if	O
a	O
patient	O
has	O
been	O
titrated	O
to	O
a	O
stable	O
dosage	O
on	O
one	O
of	O
the	O
agents	O
in	O
this	O
category	O
and	O
then	O
begins	O
a	O
course	O
of	O
treatment	O
with	O
EQUETROTM	B-Brand
it	O
is	O
reasonable	O
to	O
expect	O
that	O
a	O
dose	O
increase	O
for	O
the	O
concomitant	O
agent	O
may	O
be	O
necessary	O
.	O
      
These	O
reactions	O
consisted	O
of	O
erythema	O
pruritus	O
and	O
hypotension	O
and	O
occurred	O
within	O
hours	O
of	O
administration	O
of	O
chemotherapy	O
.	O
      
Interactions	O
for	O
Vitamin	B-Drug
B9	I-Drug
(	O
Niacin	B-Drug
)	O
:	O
Antihypertensive	B-Group
Therapy	O
:	O
Nicotinic	B-Drug
acid	I-Drug
may	O
potentiate	O
the	O
effects	O
of	O
ganglionic	B-Group
blocking	I-Group
agents	I-Group
and	O
vasoactive	O
drugs	O
resulting	O
in	O
postural	O
hypotension	O
.	O
      
Valproate	B-Drug
**	O
      
Since	O
indomethacin	B-Drug
and	O
potassium	B-Group
-	O
sparing	I-Group
diuretics	I-Group
including	O
MIDAMOR	B-Brand
may	O
each	O
be	O
associated	O
with	O
increased	O
serum	O
potassium	O
levels	O
the	O
potential	O
effects	O
on	O
potassium	O
kinetics	O
and	O
renal	O
function	O
should	O
be	O
considered	O
when	O
these	O
agents	O
are	O
administered	O
concurrently	O
.	O
      
Therefore	O
FORADIL	B-Brand
should	O
not	O
be	O
given	O
together	O
with	O
-	O
adrenergic	O
blockers	O
(	O
including	O
eye	O
drops	O
)	O
unless	O
there	O
are	O
compelling	O
reasons	O
for	O
their	O
use	O
.	O
      
9%	O
9%	O
9%	O
9%	O
      
Substantial	O
intercurrent	O
ethanol	B-Drug
use	O
was	O
present	O
in	O
each	O
of	O
these	O
cases	O
and	O
this	O
may	O
have	O
contributed	O
to	O
the	O
abnormalities	O
seen	O
.	O
      
These	O
antibiotics	B-Group
should	O
be	O
used	O
in	O
the	O
myasthenic	O
patient	O
only	O
where	O
definitely	O
indicated	O
and	O
then	O
careful	O
adjustment	O
should	O
be	O
made	O
of	O
adjunctive	O
anticholinesterase	B-Group
dosage	O
.	O
      
When	O
Mefloquine	B-Drug
is	O
taken	O
concurrently	O
with	O
oral	O
live	B-Group
typhoid	I-Group
vaccines	I-Group
attenuation	O
of	O
immunization	O
can	O
not	O
be	O
excluded	O
.	O
      
There	O
are	O
reports	O
of	O
enhanced	O
as	O
well	O
as	O
diminished	O
effects	O
of	O
anticoagulants	B-Group
when	O
given	O
concurrently	O
with	O
corticosteroids	B-Group
.	O
      
interactions	O
have	O
not	O
been	O
systematically	O
studied	O
.	O
      
If	O
concomitant	O
administration	O
of	O
an	O
NSAID	B-Group
is	O
necessary	O
patients	O
should	O
be	O
monitored	O
closely	O
for	O
toxicity	O
especially	O
myelosuppression	O
renal	O
and	O
gastrointestinal	O
toxicity	O
.	O
      
Warfarin	B-Drug
:	O
In	O
a	O
study	O
in	O
healthy	O
volunteers	O
no	O
clinically	O
relevant	O
pharmacokinetic	O
or	O
pharmacodynamic	O
interaction	O
between	O
isradipine	B-Drug
and	O
racemic	O
warfarin	B-Drug
was	O
seen	O
when	O
two	O
single	O
oral	O
doses	O
of	O
warfarin	B-Drug
(	O
9	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
were	O
administered	O
during	O
9	O
days	O
of	O
multipledose	O
treatment	O
with	O
9	O
mg	O
b.i.d	O
.	O
isradipine	B-Drug
.	O
      
Caution	O
should	O
be	O
observed	O
when	O
anileridine	B-Drug
is	O
coadministered	O
with	O
other	O
opioids	B-Group
sedatives	B-Group
phenothiazines	B-Group
or	O
anesthetics	B-Group
as	O
these	O
agents	O
may	O
increase	O
respiratory	O
and	O
circulatory	O
depression	O
.	O
      
Alosetron	B-Drug
does	O
not	O
appear	O
to	O
induce	O
the	O
major	O
cytochrome	O
P9	O
(	O
CYP	O
)	O
drug	O
metabolizing	O
enzyme	O
9A	O
.	O
      
This	O
is	O
especially	O
true	O
if	O
the	O
total	O
dose	O
of	O
atropine	B-Drug
has	O
been	O
large	O
and	O
the	O
administration	O
of	O
pralidoxime	B-Drug
has	O
been	O
delayed	O
.	O
      
Phenytoin	B-Drug
:	O
In	O
a	O
single	O
(	O
9	O
mg	O
)	O
and	O
multiple	O
dose	O
(	O
9	O
mg	O
TID	O
)	O
study	O
of	O
Neurontin	B-Brand
in	O
epileptic	O
patients	O
(	O
N=9	O
)	O
maintained	O
on	O
phenytoin	B-Drug
monotherapy	O
for	O
at	O
least	O
9	O
months	O
gabapentin	B-Drug
had	O
no	O
effect	O
on	O
the	O
steady	O
-	O
state	O
trough	O
plasma	O
concentrations	O
of	O
phenytoin	B-Drug
and	O
phenytoin	B-Drug
had	O
no	O
effect	O
on	O
gabapentin	B-Drug
pharmacokinetics	O
.	O
      
The	O
coadministration	O
of	O
aspirin	B-Brand
decreases	O
the	O
biologic	O
half	O
-	O
life	O
of	O
fenoprofen	B-Drug
because	O
of	O
an	O
increase	O
in	O
metabolic	O
clearance	O
that	O
results	O
in	O
a	O
greater	O
amount	O
of	O
hydroxylated	B-Drug_n
fenoprofen	I-Drug_n
in	O
the	O
urine	O
.	O
      
Methotrexate	B-Drug
Renal	O
tubular	O
transport	O
of	O
methotrexate	B-Drug
may	O
be	O
inhibited	O
by	O
concomitant	O
administration	O
of	O
ciprofloxacin	B-Drug
potentially	O
leading	O
to	O
increased	O
plasma	O
levels	O
of	O
methotrexate	B-Drug
.	O
      
While	O
not	O
systematically	O
studied	O
certain	O
drugs	O
may	O
induce	O
the	O
metabolism	O
of	O
bupropion	B-Drug
(	O
e.g.	O
carbamazepine	B-Drug
phenobarbital	B-Drug
phenytoin	B-Drug
)	O
.	O
      
Uricosuric	B-Group
drugs	I-Group
such	O
as	O
probenecid	B-Drug
and	O
sulfinpyrazone	B-Drug
can	O
inhibit	O
renal	O
tubular	O
secretion	O
of	O
nitrofurantoin	B-Drug
.	O
      
Reduced	O
response	O
to	O
metyrapone	O
test	O
.	O
      
Poor	O
metabolizers	O
have	O
higher	O
than	O
expected	O
lasma	O
concentrations	O
of	O
tricyclic	B-Group
antidepressants	I-Group
(	O
TCAs	B-Group
)	O
when	O
given	O
usual	O
doses	O
.	O
      
Lithium	B-Drug
:	O
NSAIDs	B-Group
have	O
produced	O
an	O
elevation	O
of	O
plasma	O
lithium	B-Drug
levels	O
and	O
a	O
reduction	O
in	O
renal	O
lithium	B-Drug
clearance	O
.	O
      
Calcium	B-Drug
particularly	O
if	O
administered	O
rapidly	O
by	O
the	O
intravenous	O
route	O
may	O
produce	O
serious	O
arrhythmias	O
in	O
digitalized	O
patients	O
.	O
      
Dicumarol	B-Drug
:	O
It	O
has	O
been	O
reported	O
that	O
allopurinol	B-Drug
prolongs	O
the	O
half	O
-	O
life	O
of	O
the	O
anticoagulant	B-Group
dicumarol	B-Drug
.	O
      
Caution	O
is	O
warranted	O
and	O
therapeutic	O
concentration	O
monitoring	O
is	O
recommended	O
for	O
antiarrhythmics	B-Group
when	O
coadministered	O
with	O
CRIXIVAN	B-Brand
.	O
      
Therefore	O
amiodarone	B-Drug
has	O
the	O
potential	O
for	O
interactions	O
with	O
drugs	O
or	O
substances	O
that	O
may	O
be	O
substrates	O
inhibitors	O
or	O
inducers	O
of	O
CYP9A9	O
.	O
      
therefore	O
drug	O
interactions	O
mediated	O
by	O
inhibition	O
of	O
hepatic	O
metabolism	O
are	O
not	O
expected	O
to	O
occur	O
.	O
      
-	O
Perhexiline	B-Drug
hydrogen	I-Drug
maleate	I-Drug
or	O
MAO	B-Group
-	O
inhibitors	I-Group
(	O
with	O
hepatotoxic	O
potential	O
)	O
must	O
not	O
be	O
administered	O
together	O
with	O
Bezalip	B-Brand
or	O
Bezalip	B-Brand
retard	I-Brand
.	O
      
Pharmacokinetic	O
data	O
from	O
these	O
patients	O
demonstrated	O
a	O
decrease	O
in	O
paclitaxel	B-Drug
clearance	O
of	O
approximately	O
9	O
%	O
when	O
TAXOL	B-Brand
was	O
administered	O
following	O
cisplatin	B-Drug
.	O
      
Sedative	B-Group
/	O
hypnotics	B-Group
:	O
midazolam	B-Drug
triazolam	B-Drug
      
Corticosteroids	B-Group
:	O
A	O
relationship	O
of	O
functional	O
antagonism	O
exists	O
between	O
vitamin	B-Group
D	I-Group
analogues	I-Group
which	O
promote	O
calcium	O
absorption	O
and	O
corticosteroids	B-Group
which	O
inhibit	O
calcium	O
absorption	O
.	O
      
Such	O
concomitant	O
use	O
should	O
be	O
administered	O
under	O
careful	O
medical	O
supervision	O
.	O
      
In	O
clinical	O
studies	O
where	O
patients	O
were	O
on	O
chronic	O
theophylline	B-Drug
therapy	O
lomefloxacin	B-Drug
had	O
no	O
measurable	O
effect	O
on	O
the	O
mean	O
distribution	O
of	O
theophylline	B-Drug
concentrations	O
or	O
the	O
mean	O
estimates	O
of	O
theophylline	B-Drug
clearance	O
.	O
      
Precipitation	O
or	O
haze	O
may	O
result	O
from	O
sodium	O
bicarbonate	O
-	O
calcium	O
admixtures	O
.	O
      
An	O
alternative	O
or	O
additional	O
method	O
of	O
contraception	O
is	O
recommended	O
.	O
      
These	O
agents	O
should	O
not	O
be	O
taken	O
within	O
9	O
hours	O
before	O
or	O
9	O
hours	O
after	O
grepafloxacin	B-Drug
administration	O
.	O
      
Interactions	O
with	O
lipid	O
-	O
lowering	O
drugs	O
that	O
can	O
cause	O
myopathy	O
when	O
given	O
alone	O
.	O
      
There	O
were	O
no	O
clinically	O
relevant	O
alterations	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
.	O
      
Inhibition	O
of	O
these	O
isoenzymes	O
may	O
increase	O
the	O
plasma	O
concentration	O
of	O
bosentan	B-Drug
.	O
      
Do	O
not	O
exceed	O
a	O
9	O
mg	O
daily	O
dose	O
of	O
VESIcare	B-Brand
when	O
administered	O
with	O
therapeutic	O
doses	O
of	O
ketoconazole	B-Drug
or	O
other	O
potent	O
CYP9A9	O
inhibitors	O
.	O
      
Caution	O
is	O
indicated	O
when	O
piperacillin	B-Drug
is	O
used	O
perioperatively	O
.	O
      
The	O
AUC	O
of	O
midazolam	B-Drug
on	O
Day	O
9	O
was	O
similar	O
to	O
that	O
observed	O
at	O
baseline	O
.	O
      
Pregnancy	O
estrogens	B-Group
and	O
estrogen	B-Group
-	O
containing	O
oral	O
contraceptives	B-Group
increase	O
TBg	O
concentrations	O
.	O
      
9	O
.	O
      
Nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
other	O
cephalosporins	B-Group
with	O
potent	O
diuretics	B-Group
such	O
as	O
furosemide	B-Drug
.	O
      
Digitalis	B-Group
      
astemizole	B-Drug
midazolam	B-Drug
triazolam	B-Drug
cisapride	B-Drug
ergot	O
derivatives	O
voriconazole	B-Drug
      
When	O
amiodarone	B-Drug
is	O
added	O
to	O
flecainide	B-Drug
therapy	O
plasma	O
flecainide	B-Drug
levels	O
may	O
increase	O
two	O
-	O
fold	O
or	O
more	O
in	O
some	O
patients	O
if	O
flecainide	B-Drug
dosage	O
is	O
not	O
reduced	O
.	O
      
this	O
interaction	O
is	O
not	O
expected	O
to	O
be	O
of	O
clinical	O
importance	O
.	O
      
No	O
carcinogenicity	O
or	O
fertility	O
studies	O
were	O
conducted	O
.	O
      
(	O
Thiazide	B-Group
diuretics	I-Group
may	O
raise	O
blood	O
glucose	O
levels	O
;	O
      
Nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
cephalosporins	B-Group
with	O
aminoglycoside	B-Group
antibiotics	I-Group
or	O
potent	O
diuretics	B-Group
such	O
as	O
furosemide	B-Drug
.	O
      
An	O
increase	O
in	O
serum	O
lithium	B-Drug
concentration	O
has	O
been	O
reported	O
during	O
concomitant	O
administration	O
of	O
lithium	B-Drug
with	O
ATACAND	B-Brand
so	O
careful	O
monitoring	O
of	O
serum	O
lithium	B-Drug
levels	O
is	O
recommended	O
during	O
concomitant	O
use	O
.	O
      
This	O
was	O
expected	O
because	O
zaleplon	B-Drug
is	O
primarily	O
metabolized	O
and	O
renal	O
excretion	O
of	O
unchanged	O
zaleplon	B-Drug
accounts	O
for	O
less	O
than	O
9	O
%	O
of	O
the	O
administered	O
dose	O
.	O
      
Clinical	O
experience	O
in	O
the	O
concurrent	O
administration	O
of	O
ECT	O
and	O
antidepressant	B-Group
drugs	I-Group
is	O
limited	O
.	O
      
Although	O
clinical	O
studies	O
have	O
not	O
established	O
a	O
cause	O
and	O
effect	O
relationship	O
physicians	O
should	O
be	O
aware	O
that	O
variable	O
effects	O
an	O
blood	O
coagulation	O
have	O
been	O
reported	O
very	O
rarely	O
in	O
patients	O
receiving	O
oral	O
anticoagulants	B-Group
and	O
chlordiazepoxide	B-Drug
.	O
      
Use	O
of	O
MAO	B-Group
inhibitors	I-Group
may	O
cause	O
an	O
excessive	O
increase	O
in	O
blood	O
pressure	O
and	O
heart	O
stimulation	O
.	O
      
Lithium	B-Drug
:	O
Serum	O
lithium	B-Drug
levels	O
may	O
increase	O
.	O
      
In	O
elderly	O
patients	O
concurrently	O
receiving	O
certain	O
diuretics	B-Group
primarily	O
thiazides	B-Group
an	O
increased	O
incidence	O
of	O
thrombopenia	O
with	O
purpura	O
has	O
been	O
reported	O
.	O
      
Salicylates	B-Group
and	O
Other	O
Non	B-Group
-	O
Steroidal	I-Group
Anti	I-Group
-	O
Inflammatory	I-Group
Drugs	I-Group
:	O
May	O
decrease	O
the	O
antihypertensive	O
effects	O
of	O
MYKROX	B-Brand
Tablets	O
.	O
      
When	O
phenobarbital	B-Drug
is	O
added	O
to	O
or	O
withdrawn	O
from	O
treatment	O
dosage	O
adjustment	O
of	O
Nalfon	B-Brand
may	O
be	O
required	O
.	O
      
Specific	O
drug	O
interaction	O
studies	O
have	O
not	O
been	O
conducted	O
with	O
Levofloxacin	B-Drug
.	O
      
Caution	O
should	O
be	O
used	O
when	O
CYP9A9	B-Drug
inhibitors	O
are	O
co	O
-	O
administered	O
with	O
felodipine	B-Drug
.	O
      
Use	O
of	O
a	O
nonhormonal	B-Group
contraceptive	I-Group
product	I-Group
is	O
recommended	O
.	O
      
In	O
clinical	O
studies	O
with	O
PROPECIA	B-Brand
(	O
finasteride	B-Drug
9	O
mg	O
)	O
in	O
men	O
9	O
-	O
9	O
years	O
of	O
age	O
the	O
mean	O
value	O
of	O
serum	O
prostate	O
-	O
specific	O
antigen	O
(	O
PSA	O
)	O
decreased	O
from	O
9	O
ng	O
/	O
mL	O
at	O
baseline	O
to	O
9	O
ng	O
/	O
mL	O
at	O
Month	O
9	O
.	O
      
No	O
information	O
provided	O
      
Drugs	O
that	O
have	O
been	O
reported	O
to	O
diminish	O
oral	O
anticoagulant	B-Group
response	O
ie	O
decreased	O
prothrom	O
-	O
bin	O
time	O
response	O
in	O
man	O
significantly	O
include	O
:	O
adrenocortical	B-Group
steroids	I-Group
;	O
alcohol	B-Drug
*	O
;	O
antacids	B-Group
;	O
antihistamines	B-Group
;	O
barbiturates	B-Group
;	O
carbamazepine	B-Drug
;	O
chloral	B-Drug
hydrate	I-Drug
*	O
;	O
chlordiazepoxide	B-Drug
;	O
cholestyramine	B-Drug
;	O
diet	O
high	O
in	O
vitamin	B-Group
K	I-Group
;	O
diuretics	B-Group
*	O
;	O
ethchlorvynol	B-Drug
;	O
glutethimide	B-Drug
;	O
griseofulvin	B-Drug
;	O
haloperidol	B-Drug
;	O
meprobamate	B-Drug
;	O
oral	O
contraceptives	B-Group
;	O
paraldehyde	B-Drug
;	O
primidone	B-Drug
;	O
ranitidine	B-Drug
*	O
;	O
rifampin	B-Drug
;	O
unreliable	O
prothrombin	O
time	O
determinations	O
;	O
vitamin	B-Drug
C	I-Drug
;	O
warfarin	B-Drug
sodium	I-Drug
under	O
-	O
dosage	O
.	O
      
This	O
is	O
especially	O
true	O
in	O
patients	O
who	O
may	O
subject	O
themselves	O
to	O
an	O
overdosage	O
of	O
drugs	O
.	O
      
PEGASYS	B-Brand
contains	O
benzyl	B-Drug_n
alcohol	I-Drug_n
.	O
      
Inducers	O
of	O
CYP9A9	O
Isozymes	O
:	O
Cytochrome	O
P9	O
inducers	O
such	O
as	O
rifampin	B-Drug
carbamazepine	B-Drug
and	O
phenytoin	B-Drug
induce	O
metabolism	O
and	O
caused	O
a	O
markedly	O
decreased	O
C	O
max	O
and	O
AUC	O
of	O
oral	O
midazolam	B-Drug
in	O
adult	O
studies	O
.	O
      
b	O
This	O
table	O
is	O
not	O
all	O
-	O
inclusive	O
.	O
      
Reciprocal	O
interactions	O
may	O
occur	O
with	O
concomitant	O
use	O
of	O
Antizol	B-Brand
and	O
drugs	O
that	O
increase	O
or	O
inhibit	O
the	O
cytochrome	O
P9	O
system	O
(	O
e.g.	O
phenytoin	B-Drug
carbamazepine	B-Drug
cimetidine	B-Drug
ketoconazole	B-Drug
)	O
though	O
this	O
has	O
not	O
been	O
studied	O
      
The	O
plasma	O
concentrations	O
of	O
bosentan	B-Drug
were	O
also	O
decreased	O
by	O
approximately	O
9	O
%	O
.	O
      
Ketoconazole	B-Drug
:	O
Ketoconazole	B-Drug
9	O
mg	O
daily	O
did	O
not	O
have	O
any	O
clinically	O
important	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
rofecoxib	B-Drug
.	O
      
Drugs	O
That	O
Should	O
Not	O
Be	O
Coadministered	O
With	O
VIRACEPT	B-Brand
Antiarrhythmics	B-Group
:	O
amiodarone	B-Drug
quinidine	B-Drug
Antihistamines	B-Group
:	O
astemizole	B-Drug
terfenadine	B-Drug
Antimigraine	O
:	O
ergot	B-Group
derivatives	I-Group
Antimycobacterial	B-Group
agents	I-Group
:	O
rifampin	B-Drug
Benzodiazepines	B-Group
midazolam	B-Drug
triazolam	B-Drug
GI	O
motility	O
agents	O
:	O
cisapride	B-Drug
      
However	O
co	O
administration	O
of	O
fexofenadine	B-Drug
hydrochloride	I-Drug
with	O
either	O
ketoconazole	B-Drug
or	O
erythromycin	B-Drug
led	O
to	O
increased	O
plasma	O
concentrations	O
of	O
fexofenadine	B-Drug
.	O
      
In	O
patients	O
receiving	O
mercaptopurine	B-Drug
(	O
Purinethol	B-Brand
)	O
or	O
azathioprine	B-Drug
(	O
Imuran	B-Brand
)	O
the	O
concomitant	O
administration	O
of	O
9	O
-	O
9	O
mg	O
of	O
allopurinol	B-Drug
per	O
day	O
will	O
require	O
a	O
reduction	O
in	O
dose	O
to	O
approximately	O
one	O
-	O
third	O
to	O
one	O
-	O
fourth	O
of	O
the	O
usual	O
dose	O
of	O
mercaptopurine	B-Drug
or	O
azathioprine	B-Drug
.	O
      
Drugs	O
which	O
induce	O
CYP9A9	O
activity	O
(	O
eg	O
phenobarbital	B-Drug
rifampin	B-Drug
rifabutin	B-Drug
)	O
would	O
be	O
expected	O
to	O
increase	O
the	O
clearance	O
of	O
efavirenz	B-Drug
resulting	O
in	O
lowered	O
plasma	O
concentrations	O
.	O
      
Warfarin	B-Drug
:	O
In	O
9	O
normal	O
-	O
weight	O
subjects	O
administration	O
of	O
XENICAL	B-Brand
9	O
mg	O
three	O
times	O
a	O
day	O
for	O
9	O
days	O
did	O
not	O
result	O
in	O
any	O
change	O
in	O
either	O
warfarin	B-Drug
pharmacokinetics	O
(	O
both	O
R	O
-	O
and	O
S	O
-	O
enantiomers	O
)	O
or	O
pharmacodynamics	O
(	O
prothrombin	O
time	O
and	O
serum	O
Factor	O
VII	O
)	O
.	O
      
The	O
use	O
of	O
dexfenfluramine	B-Drug
with	O
other	O
CNS	O
-	O
active	O
drugs	O
has	O
not	O
been	O
systematically	O
evaluated	O
;	O
      
include	O
terfenadine	B-Drug
astemizole	B-Drug
cisapride	B-Drug
midazolam	B-Drug
and	O
triazolam	B-Drug
.	O
      
When	O
encountered	O
such	O
arrhythmias	O
may	O
respond	O
to	O
administration	O
of	O
a	O
beta	B-Group
-	O
adrenergic	I-Group
blocking	I-Group
drug	I-Group
.	O
      
nonetheless	O
the	O
possibility	O
that	O
causative	O
factors	O
may	O
interact	O
synergistically	O
to	O
increase	O
the	O
risk	O
and	O
/	O
or	O
severity	O
of	O
bone	O
marrow	O
suppression	O
warrants	O
consideration	O
.	O
      
These	O
would	O
include	O
a	O
variety	O
of	O
preparations	O
which	O
contain	O
androgens	B-Group
estrogens	B-Group
progestins	B-Group
or	O
glucocorticoids	B-Group
.	O
      
while	O
no	O
formal	O
interaction	O
studies	O
have	O
been	O
conducted	O
no	O
interactions	O
were	O
observed	O
.	O
      
Results	O
with	O
warfarin	B-Drug
wshow	O
no	O
evidence	O
of	O
interaction	O
with	O
either	O
single	O
or	O
repeated	O
doses	O
of	O
Trileptal	B-Brand
.	O
      
Catecholamine	O
-	O
depleting	O
drugs	O
(	O
e.g.	O
reserpine	B-Drug
)	O
may	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
beta	B-Group
-	O
blocking	I-Group
agents	I-Group
.	O
      
9	O
.	O
      
INCREASED	O
PHENYTOIN	B-Drug
LEVELS	O
SHOULD	O
BE	O
TREATED	O
WITH	O
APPROPRIATE	O
DOSAGE	O
ADJUSTMENT	O
.	O
      
Reduced	O
absorption	O
of	O
folic	B-Drug
acid	I-Drug
and	O
digoxin	B-Drug
have	O
been	O
reported	O
when	O
those	O
agents	O
were	O
administered	O
concomitantly	O
with	O
sulfasalazine	B-Drug
.	O
      
While	O
taking	O
beta	B-Group
blockers	I-Group
patients	O
with	O
a	O
history	O
of	O
severe	O
anaphylactic	O
reaction	O
to	O
a	O
variety	O
of	O
allergens	O
may	O
be	O
more	O
reactive	O
to	O
repeated	O
challenge	O
either	O
accidental	O
diagnostic	O
or	O
therapeutic	O
.	O
      
Melatonin	B-Drug
may	O
interact	O
with	O
the	O
following	O
drugs	O
:	O
aspirin	B-Brand
and	O
other	O
NSAIDs	B-Group
(	O
may	O
lower	O
melatonin	B-Drug
levels	O
)	O
fluvoxamine	B-Drug
(	O
bioavailability	O
of	O
oral	O
melatonin	B-Drug
is	O
increased	O
with	O
coadministration	O
)	O
beta	B-Group
blockers	I-Group
(	O
may	O
decrease	O
melatonin	B-Drug
levels	O
)	O
fluoxetine	B-Drug
(	O
reports	O
of	O
psychotic	O
episodes	O
when	O
coadministered	O
)	O
progestin	B-Group
(	O
coadministration	O
of	O
melatonin	B-Drug
with	O
progestin	B-Group
can	O
inhibit	O
ovarian	O
function	O
in	O
women	O
)	O
benzodiazepenes	B-Group
and	O
other	O
sedating	O
drugs	O
(	O
may	O
result	O
in	O
additive	O
sedation	O
and	O
an	O
increased	O
incidence	O
of	O
adverse	O
effects	O
)	O
and	O
corticosteroids	B-Group
(	O
coadministration	O
of	O
melatonin	B-Drug
and	O
corticosteroids	B-Group
may	O
interfere	O
with	O
the	O
efficacy	O
of	O
the	O
corticosteroids	B-Group
)	O
.	O
      
Therefore	O
it	O
is	O
advisable	O
to	O
be	O
particularly	O
cautious	O
in	O
patients	O
whose	O
plasma	O
digoxin	B-Drug
levels	O
are	O
above	O
or	O
suspected	O
to	O
be	O
above	O
the	O
usual	O
therapeutic	O
range	O
.	O
      
The	O
possibility	O
of	O
hypotensive	O
effects	O
with	O
PRINIVIL	B-Brand
can	O
be	O
minimized	O
by	O
either	O
discontinuing	O
the	O
diuretic	B-Group
or	O
increasing	O
the	O
salt	O
intake	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
PRINIVIL	B-Brand
.	O
      
ZANOSAR	B-Brand
may	O
demonstrate	O
additive	O
toxicity	O
when	O
used	O
in	O
combination	O
with	O
other	O
cytotoxic	O
drugs	O
.	O
      
Plasma	O
levels	O
of	O
piroxicam	B-Drug
are	O
depressed	O
to	O
approximately	O
9	O
%	O
of	O
their	O
normal	O
values	O
when	O
FELDENE	B-Brand
is	O
administered	O
in	O
conjunction	O
with	O
aspirin	B-Brand
(	O
9	O
mg	O
/	O
day	O
)	O
but	O
concomitant	O
administration	O
of	O
antacids	B-Group
has	O
no	O
effect	O
on	O
piroxicam	B-Drug
plasma	O
levels	O
.	O
Nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
agents	I-Group
including	O
FELDENE	B-Brand
have	O
been	O
reported	O
to	O
increase	O
steady	O
state	O
plasma	O
lithium	B-Drug
levels	O
.	O
      
Use	O
of	O
Antithrombotics	B-Group
Aspirin	B-Brand
and	O
heparin	B-Drug
have	O
been	O
administered	O
concomitantly	O
with	O
and	O
following	O
infusions	O
of	O
Activase	B-Brand
in	O
the	O
management	O
of	O
acute	O
myocardial	O
infarction	O
or	O
pulmonary	O
embolism	O
.	O
      
Carbamazepine	B-Drug
:	O
Isoniazid	B-Drug
is	O
known	O
to	O
slow	O
the	O
metabolism	O
of	O
carbamazepine	B-Drug
and	O
increase	O
its	O
serum	O
levels	O
Carbamazepine	B-Drug
levels	O
should	O
be	O
determined	O
prior	O
to	O
concurrent	O
administration	O
with	O
isoniazid	B-Drug
signs	O
and	O
symptoms	O
of	O
carbamazepine	B-Drug
toxicity	O
should	O
be	O
monitored	O
closely	O
and	O
appropriate	O
dosage	O
adjustment	O
of	O
the	O
anticonvulsant	B-Group
should	O
be	O
made	O
.	O
      
In	O
healthy	O
volunteers	O
the	O
pharmacokinetics	O
of	O
a	O
9	O
-	O
mg	O
dose	O
of	O
butorphanol	B-Drug
administered	O
as	O
STADOL	B-Brand
NS	I-Brand
were	O
not	O
affected	O
by	O
the	O
coadministration	O
of	O
a	O
single	O
9	O
-	O
mg	O
subcutaneous	O
dose	O
of	O
sumatriptan	B-Drug
.	O
      
International	O
Normalized	O
Ratio	O
(	O
INR	O
)	O
elevations	O
and	O
/	O
or	O
bleeding	O
events	O
have	O
been	O
reported	O
in	O
some	O
patients	O
taking	O
warfarin	B-Drug
while	O
on	O
IRESSA	B-Brand
therapy	O
.	O
      
Digoxin	B-Drug
:	O
When	O
multiple	O
doses	O
of	O
atorvastatin	B-Drug
and	O
digoxin	B-Drug
were	O
coadministered	O
steady	O
-	O
state	O
plasma	O
digoxin	B-Drug
concentrations	O
increased	O
by	O
approximately	O
9	O
%	O
.	O
      
Whether	O
this	O
interaction	O
also	O
occurs	O
with	O
the	O
intravenous	O
topical	O
or	O
vaginal	O
preparations	O
of	O
miconazole	B-Drug
is	O
not	O
known	O
.	O
      
Glibenclamide	B-Drug
:	O
In	O
a	O
study	O
of	O
9	O
healthy	O
male	O
volunteers	O
acitretin	B-Drug
treatment	O
potentiated	O
the	O
blood	O
glucose	O
lowering	O
effect	O
of	O
glibenclamide	B-Drug
(	O
a	O
sulfonylurea	B-Group
similar	O
to	O
chlorpropamide	B-Drug
)	O
in	O
9	O
of	O
the	O
9	O
subjects	O
.	O
      
Drugs	O
That	O
Alter	O
Renal	O
Excretion	O
Ibuprofen	B-Drug
:	O
Ibuprofen	B-Drug
is	O
known	O
to	O
affect	O
renal	O
function	O
and	O
consequently	O
alter	O
the	O
renal	O
excretion	O
of	O
other	O
drugs	O
.	O
      
Insulin	B-Drug
requirements	O
in	O
diabetic	O
patients	O
may	O
be	O
increased	O
decreased	O
or	O
unchanged	O
.	O
      
Phenytoin	B-Drug
/	O
Phenobarbital	B-Drug
:	O
The	O
coadministration	O
of	O
phenytoin	B-Drug
or	O
phenobarbital	B-Drug
will	O
not	O
affect	O
plasma	O
concentrations	O
of	O
vitamin	B-Group
D	I-Group
but	O
may	O
reduce	O
endogenous	O
plasma	O
levels	O
of	O
calcitriol	B-Drug
/	O
ergocalcitriol	O
by	O
accelerating	O
metabolism	O
.	O
      
The	O
intake	O
of	O
furosemide	B-Drug
and	O
sucralfate	B-Drug
should	O
be	O
separated	O
by	O
at	O
least	O
two	O
hours	O
.	O
      
Co	O
-	O
treatment	O
with	O
the	O
potent	O
CYP9A9	O
inhibitor	O
ketoconazole	B-Drug
increases	O
erlotinib	B-Drug
AUC	O
by	O
9	O
/	O
9	O
.	O
      
an	O
interval	O
of	O
at	O
least	O
9	O
hours	O
between	O
intake	O
of	O
these	O
agents	O
and	O
chloroquine	B-Drug
should	O
be	O
observed	O
.	O
      
The	O
duration	O
of	O
the	O
period	O
following	O
treatment	O
with	O
AMEVIVE	B-Brand
before	O
one	O
should	O
consider	O
starting	O
other	O
immunosuppressive	B-Group
therapy	O
has	O
not	O
been	O
evaluated	O
.	O
      
chlorpropamide	B-Drug
;	O
      
All	O
patients	O
in	O
whom	O
this	O
effect	O
was	O
observed	O
remained	O
asymptomatic	O
.	O
      
On	O
day	O
9	O
aspirin	B-Brand
(	O
9	O
mg	O
four	O
times	O
daily	O
)	O
was	O
started	O
and	O
continued	O
for	O
9	O
days	O
.	O
      
Cmax	O
and	O
AUC	O
values	O
are	O
9	O
%	O
to	O
9	O
%	O
lower	O
respectively	O
after	O
administration	O
of	O
9	O
mg	O
Neurontin	B-Brand
and	O
9	O
%	O
to	O
9	O
%	O
lower	O
respectively	O
after	O
administration	O
of	O
9	O
mg	O
Neurontin	B-Brand
.	O
      
Less	O
than	O
the	O
usual	O
amounts	O
of	O
these	O
medicines	O
should	O
be	O
used	O
.	O
      
magnesium	B-Drug
salts	O
;	O
      
There	O
is	O
no	O
significant	O
change	O
in	O
platelet	O
count	O
prothrombin	O
time	O
partial	O
thromboplastin	O
time	O
or	O
thrombin	O
time	O
.	O
      
Additional	O
reductions	O
in	O
blood	O
pressure	O
may	O
occur	O
when	O
FLOLAN	B-Brand
is	O
administered	O
with	O
diuretics	B-Group
antihypertensive	B-Group
agents	I-Group
or	O
other	O
vasodilators	B-Group
.	O
      
Cimetidine	B-Drug
:	O
A	O
study	O
in	O
9	O
healthy	O
volunteers	O
has	O
shown	O
a	O
significant	O
increase	O
in	O
peak	O
nifedipine	B-Drug
plasma	O
levels	O
(	O
9	O
%	O
)	O
and	O
area	O
-	O
under	O
-	O
the	O
-	O
curve	O
(	O
9	O
%	O
)	O
after	O
a	O
9	O
week	O
course	O
of	O
cimetidine	B-Drug
at	O
9	O
mg	O
per	O
day	O
and	O
nifedipine	B-Drug
at	O
9	O
mg	O
per	O
day	O
.	O
      
Exaggerated	O
hypertensive	O
responses	O
have	O
been	O
reported	O
from	O
the	O
combined	O
use	O
of	O
beta	B-Group
-	O
adrenergic	I-Group
antagonists	I-Group
and	O
alpha	B-Group
-	O
adrenergic	I-Group
stimulants	I-Group
including	O
those	O
contained	O
in	O
proprietary	O
cold	O
remedies	O
and	O
vasoconstrictive	O
nasal	O
drops	O
.	O
      
-	O
Corticosteroids	B-Group
ACTH	B-Drug
:	O
Intensified	O
electrolyte	O
depletion	O
particularly	O
hypokalemia	O
      
Therefore	O
positive	O
test	O
results	O
in	O
patients	O
receiving	O
piperacillin	B-Drug
should	O
be	O
interpreted	O
cautiously	O
and	O
confirmed	O
by	O
other	O
diagnostic	O
methods	O
.	O
      
Frequent	O
determination	O
of	O
prothrombin	O
time	O
and	O
close	O
monitoring	O
of	O
the	O
patient	O
is	O
essential	O
to	O
ascertain	O
when	O
adjustment	O
of	O
dosage	O
of	O
anticoagulant	B-Group
may	O
be	O
needed	O
.	O
      
In	O
hematologic	O
studies	O
or	O
in	O
transfusion	O
cross	O
-	O
matching	O
procedures	O
when	O
anti	O
-	O
globulin	O
tests	O
are	O
performed	O
on	O
the	O
minor	O
side	O
or	O
in	O
Coombs	O
testing	O
of	O
newborns	O
whose	O
mothers	O
have	O
received	O
cephalosporin	B-Group
antibiotics	I-Group
before	O
parturition	O
it	O
should	O
be	O
recognized	O
that	O
a	O
positive	O
Coombs	O
test	O
may	O
be	O
due	O
to	O
the	O
drug	O
.	O
      
The	O
effect	O
may	O
be	O
mediated	O
by	O
the	O
known	O
inhibition	O
of	O
cimetidine	B-Drug
on	O
hepatic	O
cytochrome	O
P	O
-	O
9	O
the	O
enzyme	O
system	O
probably	O
responsible	O
for	O
the	O
first	O
-	O
pass	O
metabolism	O
of	O
nifedipine	B-Drug
.	O
      
Patients	O
receiving	O
both	O
drugs	O
should	O
be	O
under	O
careful	O
observation	O
.	O
      
Nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
drugs	I-Group
have	O
been	O
reported	O
to	O
decrease	O
the	O
tubular	O
secretion	O
of	O
methotrexate	B-Drug
and	O
to	O
potentiate	O
its	O
toxicity	O
.	O
      
Propoxyphene	B-Drug
:	O
The	O
concurrent	O
administration	O
of	O
propoxyphene	B-Drug
hydrochloride	I-Drug
does	O
not	O
affect	O
the	O
bioavailability	O
of	O
meclofenamate	B-Drug
sodium	I-Drug
.	O
      
Concomitant	O
use	O
of	O
prostaglandin	O
synthase	O
inhibiting	O
drugs	O
eg	O
indomethacin	B-Drug
may	O
decrease	O
the	O
hypotensive	O
effects	O
of	O
beta	B-Group
blockers	I-Group
.	O
      
In	O
9	O
Drs	O
Rimmer	O
and	O
Richens	O
at	O
the	O
University	O
of	O
Wales	O
reported	O
that	O
administering	O
vigabatrin	B-Drug
with	O
phenytoin	B-Drug
lowered	O
the	O
serum	O
phenytoin	B-Drug
concentration	O
in	O
patients	O
with	O
treatment	O
-	O
resistant	O
epilepsy	O
.	O
      
Antithyroid	B-Group
agents	I-Group
may	O
decrease	O
thyroidal	O
uptake	O
of	O
sodium	B-Drug
iodide	I-Drug
I9	I-Drug
a	O
rebound	O
in	O
uptake	O
may	O
occur	O
up	O
to	O
9	O
days	O
after	O
sudden	O
withdrawal	O
of	O
Carbimazole	B-Drug
.	O
      
In	O
an	O
analysis	O
of	O
the	O
supraventricular	O
arrhythmia	O
and	O
DIAMOND	O
patient	O
populations	O
the	O
concomitant	O
administration	O
of	O
verapamil	B-Drug
with	O
dofetilide	B-Drug
was	O
associated	O
with	O
a	O
higher	O
occurrence	O
of	O
torsade	O
de	O
pointes	O
.	O
      
Laboratory	O
Test	O
Interactions	O
There	O
are	O
no	O
reported	O
laboratory	O
test	O
interactions	O
.	O
      
Therefore	O
the	O
combined	O
use	O
of	O
lovastatin	B-Drug
with	O
fibrates	B-Group
should	O
generally	O
be	O
avoided	O
.	O
      
However	O
the	O
co	O
administration	O
of	O
SPIRIVA	B-Brand
with	O
other	O
anticholinergic	B-Group
containing	O
drugs	O
(	O
e.g.	O
ipratropium	B-Drug
)	O
has	O
not	O
been	O
studied	O
and	O
is	O
therefore	O
not	O
recommended	O
.	O
      
Quinolones	B-Group
have	O
also	O
been	O
shown	O
to	O
interfere	O
with	O
the	O
metabolism	O
of	O
caffeine	B-Drug
.	O
      
This	O
effect	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
prostaglandin	O
synthesis	O
.	O
      
Phenytoin	B-Drug
:	O
Etodolac	B-Drug
has	O
no	O
apparent	O
pharmacokinetic	O
interaction	O
when	O
administered	O
with	O
phenytoin	B-Drug
.	O
      
Reported	O
examples	O
of	O
this	O
interaction	O
include	O
the	O
following	O
:	O
Antibiotics	B-Drug
:	O
Rifampin	B-Drug
is	O
a	O
potent	O
inducer	O
of	O
CYP9A9	B-Drug
.	O
      
Therefore	O
the	O
use	O
of	O
sumatriptan	B-Drug
succinate	I-Drug
tablets	O
in	O
patients	O
receiving	O
MAO	B-Group
-	O
A	I-Group
inhibitors	I-Group
is	O
contraindicated	O
.	O
Selective	B-Group
serotonin	I-Group
reuptake	I-Group
inhibitors	I-Group
(	O
SSRIs	B-Group
)	O
(	O
e.g.	O
fluoxetine	B-Drug
fluvoxamine	B-Drug
paroxetine	B-Drug
sertraline	B-Drug
)	O
have	O
been	O
reported	O
rarely	O
to	O
cause	O
weakness	O
hyperreflexia	O
and	O
incoordination	O
when	O
coadministered	O
with	O
sumatriptan	B-Drug
.	O
      
Geriatric	O
Use	O
      
Patients	O
undergoing	O
systemic	O
anticholinesterase	O
treatment	O
should	O
be	O
warned	O
of	O
the	O
possible	O
additive	O
effects	O
of	O
Phospholine	B-Drug
Iodide	I-Drug
.	O
      
If	O
other	O
muscle	B-Group
relaxants	I-Group
are	O
used	O
during	O
the	O
same	O
procedure	O
the	O
possibility	O
of	O
a	O
synergistic	O
or	O
antagonist	O
effect	O
should	O
be	O
considered	O
.	O
      
Caution	O
is	O
therefore	O
advised	O
in	O
the	O
coadministration	O
of	O
ATROVENT	B-Brand
Inhalation	O
Aerosol	O
with	O
other	O
anticholinergic	B-Group
-	O
containing	O
drugs	O
.	O
      
In	O
occasional	O
susceptible	O
patients	O
or	O
in	O
those	O
receiving	O
anticholinergic	B-Group
drugs	I-Group
(	O
including	O
antiparkinsonism	O
agents	O
)	O
in	O
addition	O
the	O
atropine	O
-	O
like	O
effects	O
may	O
become	O
more	O
pronounced	O
(	O
e.g.	O
paralytic	O
ileus	O
)	O
.	O
      
Adverse	O
reactions	O
related	O
to	O
alpha	B-Drug
interferons	I-Drug
such	O
as	O
CNS	O
cardiac	O
and	O
systemic	O
(	O
eg	O
flu	O
-	O
like	O
)	O
effects	O
may	O
be	O
more	O
severe	O
in	O
the	O
elderly	O
and	O
caution	O
should	O
be	O
exercised	O
in	O
the	O
use	O
of	O
PEGASYS	B-Brand
in	O
this	O
population	O
.	O
      
No	O
information	O
available	O
.	O
      
Caution	O
should	O
be	O
exercised	O
when	O
considering	O
the	O
use	O
of	O
BREVIBLOC	B-Brand
and	O
verapamil	B-Drug
in	O
patients	O
with	O
depressed	O
myocardial	O
function	O
.	O
      
Rifampin	B-Drug
:	O
Coadministration	O
of	O
rifampin	B-Drug
and	O
VIRACEPT	B-Brand
resulted	O
in	O
an	O
9	O
%	O
decrease	O
in	O
nelfinavir	B-Drug
plasma	O
A.C	O
.	O
      
Mild	O
hepatotoxicity	O
has	O
been	O
reported	O
in	O
some	O
patients	O
when	O
lorazepam	B-Drug
and	O
pyrimethamine	B-Drug
were	O
administered	O
concomitantly	O
.	O
      
One	O
controlled	O
study	O
in	O
eight	O
normal	O
subjects	O
showed	O
a	O
9	O
%	O
mean	O
increase	O
(	O
range	O
9	O
-	O
9	O
%	O
)	O
in	O
plasma	O
theophylline	B-Drug
levels	O
.	O
      
exfoliative	O
dermatitis	O
      
Combination	O
hormonal	B-Group
contraceptives	I-Group
may	O
also	O
decrease	O
the	O
plasma	O
concentration	O
of	O
acetaminophen	B-Drug
.	O
      
Therefore	O
co	O
-	O
administration	O
of	O
Duloxetine	B-Drug
with	O
other	O
drugs	O
that	O
are	O
extensively	O
metabolized	O
by	O
this	O
isozyme	O
and	O
which	O
have	O
a	O
narrow	O
therapeutic	O
index	O
including	O
certain	O
antidepressants	B-Group
(	O
tricyclic	B-Group
antidepressants	I-Group
[	O
TCAs	B-Group
]	O
such	O
as	O
nortriptyline	B-Drug
amitriptyline	B-Drug
and	O
imipramine	B-Drug
)	O
phenothiazines	B-Group
and	O
Type	B-Group
9C	I-Group
antiarrhythmics	I-Group
(	O
e.g.	O
propafenone	B-Drug
flecainide	B-Drug
)	O
should	O
be	O
approached	O
with	O
caution	O
.	O
      
Because	O
of	O
reports	O
of	O
prolongation	O
of	O
the	O
prothrombin	O
time	O
beyond	O
the	O
therapeutic	O
range	O
in	O
patients	O
taking	O
concurrent	O
levamisole	B-Drug
and	O
warfarin	B-Drug
sodium	I-Drug
it	O
is	O
suggested	O
that	O
the	O
prothrombin	O
time	O
be	O
monitored	O
carefully	O
and	O
the	O
dose	O
of	O
warfarin	B-Drug
sodium	I-Drug
or	O
other	O
coumarin	B-Group
-	O
like	O
drugs	O
should	O
be	O
adjusted	O
accordingly	O
in	O
patients	O
taking	O
both	O
drugs	O
.	O
      
The	O
administration	O
of	O
naratriptan	B-Drug
with	O
other	O
9	B-Group
-	O
HT9	I-Group
agonists	I-Group
has	O
not	O
been	O
evaluated	O
in	O
migraine	O
patients	O
.	O
      
Although	O
there	O
have	O
been	O
no	O
reports	O
of	O
such	O
interactions	O
with	O
methylergonovine	B-Drug
alone	O
potent	O
CYP	O
9A9	O
inhibitors	O
should	O
not	O
be	O
coadministered	O
with	O
methylergonovine	O
.	O
      
In	O
addition	O
steady	O
state	O
levels	O
of	O
racemic	O
citalopram	B-Drug
were	O
not	O
significantly	O
different	O
in	O
poor	O
metabolizers	O
and	O
extensive	O
CYP9D9	O
metabolizers	O
after	O
multiple	O
-	O
dose	O
administration	O
of	O
citalopram	B-Drug
suggesting	O
that	O
coadministration	O
with	O
escitalopram	B-Drug
of	O
a	O
drug	O
that	O
inhibits	O
CYP9D9	O
is	O
unlikely	O
to	O
have	O
clinically	O
significant	O
effects	O
on	O
escitalopram	B-Drug
metabolism	O
.	O
      
Drugs	O
That	O
Inhibit	O
Aldehyde	O
Oxidase	O
The	O
aldehyde	O
oxidase	O
enzyme	O
system	O
is	O
less	O
well	O
studied	O
than	O
the	O
cytochrome	O
P9	O
enzyme	O
system	O
.	O
      
As	O
with	O
all	O
drugs	O
the	O
potential	O
exists	O
for	O
interaction	O
with	O
other	O
drugs	O
by	O
a	O
variety	O
of	O
mechanisms	O
.	O
      
In	O
vitro	O
studies	O
indicate	O
that	O
celecoxib	B-Drug
is	O
not	O
an	O
inhibitor	O
of	O
cytochrome	O
P9	O
9C9	O
9C9	O
or	O
9A9	O
.	O
      
If	O
these	O
preparations	O
have	O
been	O
used	O
it	O
is	O
advisable	O
not	O
to	O
start	O
therapy	O
with	O
DIFFERIN	B-Brand
Gel	O
until	O
the	O
effects	O
of	O
such	O
preparations	O
in	O
the	O
skin	O
have	O
subsided	O
.	O
      
Therefore	O
the	O
combination	O
of	O
ketoprofen	B-Drug
and	O
probenecid	B-Drug
is	O
not	O
recommended	O
.	O
      
A	O
subset	O
(	O
9	O
%	O
-	O
9	O
%	O
)	O
of	O
the	O
population	O
has	O
reduced	O
activity	O
of	O
certain	O
drug	O
metabolizing	O
enzymes	O
such	O
as	O
the	O
cytochrome	O
P9	O
isozyme	O
P9	O
9D9	O
.	O
      
When	O
therapeutic	O
concentrations	O
of	O
furosemide	B-Drug
propranolol	B-Drug
dipyridamole	B-Drug
warfarin	B-Drug
quinidine	B-Drug
or	O
naproxen	B-Drug
were	O
added	O
to	O
human	O
plasma	O
(	O
in	O
vitro	O
)	O
the	O
plasma	O
protein	O
binding	O
of	O
nicardipine	B-Drug
HCl	I-Drug
was	O
not	O
altered	O
.	O
      
Theophylline	B-Drug
:	O
DIFLUCAN	B-Brand
increases	O
the	O
serum	O
concentrations	O
of	O
theophylline	B-Drug
.	O
      
Non	B-Group
-	O
steroidal	I-Group
anti	I-Group
-	O
inflammatory	I-Group
drugs	I-Group
(	O
but	O
not	O
aspirin	B-Brand
)	O
:	O
These	O
drugs	O
in	O
combination	O
with	O
very	O
high	O
doses	O
of	O
quinolones	B-Group
have	O
been	O
shown	O
to	O
provoke	O
convulsions	O
in	O
pre	O
-	O
clinical	O
studies	O
.	O
      
Ketoconazole	B-Drug
:	O
Concomitant	O
use	O
of	O
ketoconazole	B-Drug
is	O
contraindicated	O
.	O
      
Warfarin	B-Drug
and	O
Anticoagulants	B-Group
:	O
Increased	O
prothrombin	O
time	O
with	O
or	O
without	O
clinical	O
bleeding	O
has	O
been	O
reported	O
when	O
cefixime	B-Drug
is	O
administered	O
concomitantly	O
.	O
      
Salicylates	B-Group
antagonize	O
the	O
uricosuric	O
action	O
of	O
.	O
drugs	O
used	O
to	O
treat	O
gout	O
.	O
      
Other	O
strong	O
inhibitors	O
of	O
CYP9A9	O
(	O
e.g.	O
itraconazole	B-Drug
clarithromycin	B-Drug
nefazodone	B-Drug
troleandomycin	B-Drug
ritonavir	B-Drug
nelfinavir	B-Drug
)	O
would	O
be	O
expected	O
to	O
behave	O
similarly	O
.	O
      
The	O
clinical	O
significance	O
of	O
this	O
interaction	O
with	O
doxepin	B-Drug
has	O
not	O
been	O
systematically	O
evaluated	O
.	O
      
In	O
studies	O
in	O
normal	O
volunteers	O
there	O
was	O
no	O
pharmacodynamic	O
interaction	O
between	O
intravenous	O
iloprost	B-Drug
and	O
either	O
nifedipine	B-Drug
diltiazem	B-Drug
or	O
captopril	B-Drug
.	O
      
These	O
drugs	O
include	O
the	O
thiazides	B-Group
and	O
other	O
diuretics	B-Group
corticosteroids	B-Group
phenothiazines	B-Group
thyroid	B-Group
products	I-Group
estrogens	B-Group
oral	O
contraceptives	B-Group
phenytoin	B-Drug
nicotinic	B-Drug
acid	I-Drug
sympathomimetics	B-Group
calcium	B-Group
channel	I-Group
-	O
blocking	I-Group
drugs	I-Group
and	O
isoniazid	B-Drug
.	O
      
The	O
presence	O
of	O
food	O
in	O
the	O
stomach	O
does	O
not	O
alter	O
the	O
bioavailability	O
of	O
PRINIVIL	B-Brand
.	O
      
Therefore	O
such	O
combined	O
treatment	O
should	O
be	O
approached	O
with	O
caution	O
and	O
patients	O
should	O
be	O
monitored	O
closely	O
when	O
Clozapine	B-Drug
is	O
combined	O
with	O
these	O
drugs	O
particularly	O
with	O
fluvoxamine	B-Drug
.	O
      
.	O
      
The	O
effects	O
of	O
indinavir	B-Drug
zidovudine	B-Drug
or	O
rifabutin	B-Drug
on	O
the	O
pharmacokinetics	O
of	O
megestrol	B-Drug
acetate	I-Drug
were	O
not	O
studied	O
.	O
      
Exjade	B-Brand
tablets	O
for	O
oral	O
suspension	O
can	O
be	O
dispersed	O
in	O
water	O
orange	O
juice	O
or	O
apple	O
juice	O
.	O
      
Anagrelide	B-Drug
is	O
metabolized	O
at	O
least	O
in	O
part	O
by	O
CYP9A9	O
.	O
      
Coadministration	O
of	O
LEXAPRO	B-Brand
and	O
metoprolol	B-Drug
had	O
no	O
clinically	O
significant	O
effects	O
on	O
blood	O
pressure	O
or	O
heart	O
rate	O
.	O
      
It	O
is	O
not	O
clear	O
whether	O
this	O
represents	O
an	O
interaction	O
with	O
TIKOSYN	B-Brand
or	O
the	O
presence	O
of	O
more	O
severe	O
structural	O
heart	O
disease	O
in	O
patients	O
on	O
digoxin	B-Drug
;	O
      
FLUOTHANE	B-Brand
augments	O
the	O
action	O
of	O
non	B-Group
-	O
depolarising	I-Group
muscle	I-Group
relaxants	I-Group
and	O
the	O
muscle	O
relaxant	O
effects	O
of	O
aminoglycosides	B-Group
.	O
      
Concomitant	O
administration	O
of	O
FACTIVE	B-Brand
and	O
calcium	B-Drug
carbonate	I-Drug
cimetidine	B-Drug
omeprazole	B-Drug
or	O
an	O
estrogen	B-Group
/	O
progesterone	B-Drug
oral	O
contraceptive	B-Group
produced	O
minor	O
changes	O
in	O
the	O
pharmacokinetics	O
of	O
gemifloxacin	B-Drug
which	O
were	O
considered	O
to	O
be	O
without	O
clinical	O
significance	O
.	O
      
Similarly	O
of	O
over	O
9	O
patients	O
enrolled	O
in	O
a	O
study	O
comparing	O
once	O
-	O
monthly	O
with	O
daily	O
dosing	O
regimens	O
of	O
ibandronate	B-Drug
9	O
%	O
of	O
patients	O
used	O
anti	O
-	O
peptic	O
agents	O
.	O
      
The	O
results	O
of	O
a	O
study	O
of	O
coadministration	O
of	O
ethambutol	B-Drug
(	O
9	O
mg	O
/	O
kg	O
)	O
with	O
an	O
aluminum	B-Drug
hydroxide	I-Drug
containing	O
antacid	B-Group
to	O
9	O
patients	O
with	O
tuberculosis	O
showed	O
a	O
reduction	O
of	O
mean	O
serum	O
concentrations	O
and	O
urinary	O
excretion	O
of	O
ethambutol	B-Drug
of	O
approximately	O
9	O
%	O
and	O
9	O
%	O
respectively	O
suggesting	O
that	O
the	O
oral	O
absorption	O
of	O
ethambutol	B-Drug
may	O
be	O
reduced	O
by	O
these	O
antacid	B-Group
products	I-Group
.	O
      
The	O
AUC	O
and	O
Cmax	O
of	O
descarboethoxyloratadine	B-Drug_n
an	O
active	O
metabolite	O
averaged	O
9	O
%	O
(	O
9	O
S.D	O
.	O
)	O
and	O
9	O
%	O
(	O
9	O
S.D	O
.	O
)	O
respectively	O
.	O
      
Drug	O
Effect	O
      
The	O
cause	O
of	O
the	O
reported	O
association	O
has	O
not	O
been	O
established	O
.	O
      
Digitalis	B-Group
Glycosides	I-Group
:	O
Diuretic	B-Group
-	O
induced	O
hypokalemia	O
can	O
increase	O
the	O
sensitivity	O
of	O
the	O
myocardium	O
to	O
digitalis	B-Group
.	O
      
Nitrates	B-Group
:	O
The	O
concomitant	O
use	O
of	O
Bepridil	B-Drug
with	O
long	O
-	O
and	O
short	O
-	O
acting	O
nitrates	B-Group
has	O
been	O
safely	O
tolerated	O
in	O
patients	O
with	O
stable	O
angina	O
pectoris	O
.	O
      
Others	O
reported	O
:	O
Neuropsychiatric	O
:	O
Confusion	O
(	O
9	O
-	O
9	O
%	O
)	O
headache	O
(	O
9	O
-	O
9	O
%	O
)	O
insomnia	O
(	O
9	O
-	O
9	O
%	O
)	O
;	O
      
-	O
Chloroquine	B-Drug
(	O
e.g.	O
Aralen	B-Brand
)	O
or	O
      
Urinary	B-Group
acidifying	I-Group
agents	I-Group
(	O
ammonium	B-Drug
chloride	I-Drug
sodium	B-Drug
acid	I-Drug
phosphate	I-Drug
etc	O
.	O
)	O
increase	O
the	O
concentration	O
of	O
the	O
ionized	O
species	O
of	O
the	O
amphetamine	B-Drug
molecule	O
thereby	O
increasing	O
urinary	O
excretion	O
.	O
      
A	O
similar	O
effect	O
would	O
be	O
expected	O
with	O
eszopiclone	B-Drug
.	O
      
Acarbose	B-Drug
has	O
been	O
shown	O
to	O
change	O
the	O
bioavailabillty	O
digoxin	B-Drug
when	O
they	O
are	O
co	O
-	O
administered	O
which	O
may	O
require	O
digoxin	B-Drug
dose	O
adjustment	O
.	O
      
Aspirin	B-Brand
:	O
In	O
normal	O
volunteers	O
a	O
small	O
decrease	O
in	O
diflunisal	B-Drug
levels	O
was	O
observed	O
when	O
multiple	O
doses	O
of	O
diflunisal	B-Drug
and	O
aspirin	B-Brand
were	O
administered	O
concomitantly	O
.	O
      
For	O
example	O
when	O
vitamin	B-Group
K	I-Group
antagonists	I-Group
are	O
administered	O
concomitantly	O
with	O
nilutamide	B-Drug
prothrombin	O
time	O
should	O
be	O
carefully	O
monitored	O
and	O
if	O
necessary	O
the	O
dosage	O
of	O
vitamin	B-Group
K	I-Group
antagonists	I-Group
should	O
be	O
reduced	O
.	O
      
Possible	O
interactions	O
with	O
drugs	O
known	O
to	O
be	O
metabolized	O
by	O
CYP9A9	O
via	O
competitive	O
inhibition	O
such	O
as	O
theophylline	B-Drug
and	O
imipramine	B-Drug
may	O
also	O
occur	O
.	O
      
Physicians	O
needing	O
to	O
treatpatients	O
co	O
-	O
infected	O
with	O
tuberculosis	O
andusing	O
a	O
nevirapine	B-Drug
containing	O
regimen	O
mayuse	O
rifabutin	B-Drug
instead	O
.	O
      
Formal	O
interaction	O
studies	O
of	O
TNKase	B-Brand
with	O
other	O
drugs	O
have	O
not	O
been	O
performed	O
.	O
      
Effect	O
of	O
Clonazepam	B-Drug
on	O
the	O
Pharmacokinetics	O
of	O
Other	O
Drugs	O
:	O
Clonazepam	B-Drug
does	O
not	O
appear	O
to	O
alter	O
the	O
pharmacokinetics	O
of	O
phenytoin	B-Drug
carbamazepine	B-Drug
or	O
phenobarbital	B-Drug
.	O
      
An	O
individual	O
who	O
is	O
stable	O
on	O
a	O
given	O
dose	O
of	O
TCA	B-Group
may	O
become	O
abruptly	O
toxic	O
when	O
given	O
one	O
of	O
these	O
inhibiting	O
drugs	O
as	O
concomitant	O
therapy	O
.	O
      
-	O
Probenecid	B-Drug
:	O
Pretreatment	O
with	O
probenecid	B-Drug
reduces	O
both	O
the	O
natriuresis	O
and	O
hyperreninemia	O
produced	O
by	O
bumetanide	B-Drug
.	O
      
DISULFIRAM	B-Drug
SHOULD	O
BE	O
USED	O
WITH	O
CAUTION	O
IN	O
THOSE	O
PATIENTS	O
REVEIVING	O
PHENYTOIN	B-Drug
AND	O
ITS	O
CONGENERS	O
.	O
      
It	O
is	O
not	O
known	O
whether	O
ezetimibe	B-Drug
is	O
excreted	O
into	O
human	O
breast	O
milk	O
;	O
      
Other	O
Drugs	O
:	O
Based	O
on	O
the	O
results	O
of	O
drug	O
interaction	O
studies	O
no	O
dosage	O
adjustment	O
is	O
recommended	O
when	O
SUSTIVA	B-Brand
(	O
efavirenz	B-Drug
)	O
is	O
given	O
with	O
the	O
following	O
:	O
aluminum	B-Group
magnesium	I-Group
hydroxide	I-Group
antacids	I-Group
azithromycin	B-Drug
cetirizine	B-Drug
famotidine	B-Drug
fluconazole	B-Drug
lamivudine	B-Drug
lorazepam	B-Drug
nelfinavir	B-Drug
paroxetine	B-Drug
and	O
zidovudine	B-Drug
.	O
      
Amphotericin	B-Drug
B	I-Drug
or	O
potassium	B-Group
-	O
depleting	I-Group
diuretics	I-Group
(	O
benzothiadiazines	B-Group
and	O
related	O
drugs	O
ethacrynic	B-Drug
acid	I-Drug
and	O
furosemide	B-Drug
)	O
enhanced	O
hypokalemia	O
.	O
      
Paroxetine	B-Drug
:	O
Coadministration	O
of	O
single	O
doses	O
of	O
eszopiclone	B-Drug
9	O
mg	O
and	O
paroxetine	B-Drug
9	O
mg	O
daily	O
for	O
9	O
days	O
produced	O
no	O
pharmacokinetic	O
or	O
pharmacodynamic	O
interaction	O
.	O
      
These	O
results	O
suggest	O
that	O
the	O
analgesic	O
effect	O
of	O
STADOL	B-Brand
NS	I-Brand
may	O
be	O
diminished	O
when	O
it	O
is	O
administered	O
shortly	O
after	O
sumatriptan	B-Drug
nasal	O
spray	O
but	O
by	O
9	O
minutes	O
any	O
such	O
reduction	O
in	O
effect	O
should	O
be	O
minimal	O
.	O
      
Patients	O
currently	O
receiving	O
diltiazem	B-Drug
therapy	O
should	O
be	O
carefully	O
monitored	O
for	O
a	O
change	O
in	O
pharmacological	O
effect	O
when	O
initiating	O
and	O
discontinuing	O
therapy	O
with	O
cimetidine	B-Drug
.	O
      
(	O
9	O
mg	O
Q9h	O
)	O
      
Theophylline	B-Drug
serum	O
levels	O
should	O
be	O
monitored	O
and	O
appropriate	O
dose	O
adjustments	O
considered	O
for	O
patients	O
given	O
both	O
theophylline	B-Drug
and	O
PEGASYS	B-Brand
.	O
      
The	O
pharmacokinetics	O
of	O
nelfinavir	B-Drug
are	O
not	O
altered	O
to	O
a	O
clinically	O
significant	O
degree	O
when	O
it	O
is	O
administered	O
with	O
a	O
light	O
meal	O
9	O
hour	O
after	O
VIDEX	B-Brand
.	O
      
AMEVIVE	B-Brand
is	O
not	O
indicated	O
for	O
pediatric	O
patients	O
.	O
      
cimetidine	B-Drug
)	O
and	O
many	O
that	O
are	O
substrates	O
for	O
P9	O
9D9	O
(	O
many	O
other	O
antidepressants	B-Group
phenothiazines	B-Group
and	O
the	O
Type	O
9C	O
antiarrhythrnics	O
propatenone	O
and	O
flecainide	B-Drug
)	O
.	O
      
Chloramphenicol	B-Drug
has	O
been	O
shown	O
to	O
be	O
antagonistic	O
to	O
beta	B-Group
-	O
lactam	I-Group
antibiotics	I-Group
including	O
ceftazidime	B-Drug
based	O
on	O
in	O
vitro	O
studies	O
and	O
time	O
kill	O
curves	O
with	O
enteric	O
gram	O
-	O
negative	O
bacilli	O
.	O
      
.	O
      
Clinical	O
comments	O
about	O
possible	O
dosage	O
modifications	O
based	O
on	O
these	O
pharmacokinetic	O
changes	O
are	O
listed	O
in	O
Table	O
9	O
.	O
      
Therefore	O
caution	O
should	O
be	O
exercised	O
with	O
concomitant	O
administration	O
of	O
warfarin	B-Drug
and	O
FLOMAX	B-Brand
capsules	O
.	O
      
Ergot	B-Group
-	O
Containing	I-Group
Drugs	I-Group
:	O
These	O
drugs	O
have	O
been	O
reported	O
to	O
cause	O
prolonged	O
vasospastic	O
reactions	O
.	O
      
The	O
risk	O
of	O
a	O
potential	O
interaction	O
between	O
NovoSeven	B-Brand
and	O
coagulation	B-Group
factor	I-Group
concentrates	O
has	O
not	O
been	O
adequately	O
evaluated	O
in	O
preclinical	O
or	O
clinical	O
studies	O
.	O
      
one	O
fatality	O
has	O
been	O
reported	O
from	O
hypoglycemia	O
in	O
association	O
with	O
combined	O
DIFLUCAN	B-Brand
and	O
glyburide	B-Drug
use	O
.	O
      
Coadministration	O
of	O
VIRACEPT	B-Brand
and	O
drugs	O
primarily	O
metabolized	O
by	O
CYP9A	O
(	O
e.g.	O
dihydropyridine	B-Group
calcium	I-Group
channel	I-Group
blockers	I-Group
)	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
the	O
other	O
drug	O
that	O
could	O
increase	O
or	O
prolong	O
both	O
its	O
therapeutic	O
and	O
adverse	O
effects	O
.	O
      
Propranolol	B-Drug
increases	O
hydralazines	B-Drug
serum	O
concentrations	O
.	O
      
The	O
effect	O
of	O
foods	O
highly	O
fortified	O
with	O
elemental	O
iron	B-Drug_n
(	O
primarily	O
iron	B-Drug_n
-	O
fortified	O
breakfast	O
cereals	O
)	O
on	O
cefdinir	B-Drug
absorption	O
has	O
not	O
been	O
studied	O
.	O
      
HMG	B-Group
-	O
CoA	I-Group
Reductase	I-Group
inhibitors	I-Group
:	O
lovastatin	B-Drug
simvastatin	B-Drug
      
Calcium	B-Group
Channel	I-Group
Blockers	I-Group
Dihydropyridine	B-Group
:	O
e.g.	O
felodipine	B-Drug
nifedipine	B-Drug
nicardipine	B-Drug
      
The	O
clinical	O
significance	O
of	O
this	O
finding	O
is	O
not	O
clear	O
.	O
      
or	O
with	O
multivitamins	B-Group
containing	O
zinc	B-Drug
may	O
substantially	O
interfere	O
with	O
drug	O
absorption	O
and	O
result	O
in	O
insufficient	O
plasma	O
and	O
tissue	O
quinolone	B-Group
concentrations	O
.	O
      
Agents	O
Causing	O
Renin	O
Release	O
:	O
The	O
antihypertensive	O
effect	O
of	O
enalapril	B-Drug
and	O
enalapril	B-Drug
IV	O
is	O
augmented	O
by	O
antihypertensive	B-Group
agents	I-Group
that	O
cause	O
renin	O
release	O
(	O
e.g.	O
diuretics	B-Group
)	O
.	O
      
Even	O
so	O
dextromethorphan	B-Drug
plasma	O
concentrations	O
in	O
the	O
presence	O
of	O
high	O
doses	O
of	O
valdecoxib	B-Drug
were	O
almost	O
9	O
-	O
fold	O
lower	O
than	O
those	O
seen	O
in	O
CYP	O
9D9	O
poor	O
metabolizers	O
suggesting	O
that	O
dose	O
adjustment	O
is	O
not	O
necessary	O
.	O
      
Ethinyl	B-Drug
estradiol	I-Drug
Norethindrone	B-Drug
      
Binding	O
to	O
plasma	O
proteins	O
is	O
reduced	O
by	O
warfarin	B-Drug
and	O
clotibrate	O
and	O
increased	O
by	O
tolbutamide	B-Drug
.	O
      
Some	O
reports	O
have	O
shown	O
that	O
the	O
concomitant	O
administration	O
of	O
thiazides	B-Group
with	O
vitamin	B-Group
D	I-Group
causes	O
hypercalcemia	O
.	O
      
Reported	O
examples	O
include	O
the	O
following	O
:	O
Protease	B-Group
Inhibitors	I-Group
:	O
Protease	B-Group
inhibitors	I-Group
are	O
known	O
to	O
inhibit	O
CYP9A9	O
to	O
varying	O
degrees	O
.	O
      
Studies	O
in	O
vitro	O
show	O
that	O
caspofungin	B-Drug
acetate	I-Drug
is	O
not	O
an	O
inhibitor	O
of	O
any	O
enzyme	O
in	O
the	O
cytochrome	O
P9	O
(	O
CYP	O
)	O
system	O
.	O
      
No	O
well	O
-	O
known	O
drug	O
interactions	O
with	O
glutamic	B-Drug
acid	I-Drug
      
Since	O
blood	O
level	O
of	O
calcitriol	B-Drug
/	O
ergocalcitriol	O
will	O
be	O
reduced	O
higher	O
doses	O
of	O
Rocaltrol	B-Brand
may	O
be	O
necessary	O
if	O
these	O
drugs	O
are	O
administered	O
simultaneously	O
.	O
      
This	O
may	O
lead	O
to	O
low	O
amiodarone	B-Drug
serum	O
levels	O
and	O
potential	O
decrease	O
in	O
efficacy	O
.	O
      
Certain	O
drugs	O
including	O
thiazides	B-Group
corticosteroids	B-Group
thyroid	B-Group
products	I-Group
and	O
sympathomimetics	B-Group
may	O
reduce	O
the	O
hypoglycemic	O
action	O
of	O
Starlix	B-Brand
and	O
other	O
oral	O
antidiabetic	B-Group
drugs	I-Group
.	O
      
Furosemide	B-Drug
should	O
not	O
be	O
used	O
concomitantly	O
with	O
ethacrynic	B-Drug
acid	I-Drug
because	O
of	O
the	O
possibility	O
of	O
ototoxicity	O
.	O
      
In	O
these	O
patients	O
approximately	O
half	O
of	O
the	O
CPK	O
elevations	O
returned	O
to	O
normal	O
within	O
9	O
weeks	O
and	O
half	O
returned	O
to	O
normal	O
within	O
9	O
weeks	O
.	O
      
Albuterol	B-Drug
Antihistamines	B-Group
antidiabetic	B-Group
drugs	I-Group
diuretics	B-Group
digitalis	B-Group
.	O
      
The	O
benefits	O
of	O
Mefloquine	B-Drug
therapy	O
should	O
be	O
weighed	O
against	O
the	O
possibility	O
of	O
adverse	O
effects	O
in	O
patients	O
with	O
cardiac	O
disease	O
.	O
      
Laboratory	O
Test	O
In	O
clinical	O
trials	O
no	O
clinically	O
relevant	O
laboratory	O
test	O
abnormalities	O
were	O
identified	O
as	O
causally	O
related	O
to	O
drug	O
during	O
short	O
-	O
term	O
treatment	O
with	O
guanfacine	B-Drug
.	O
      
Dopamine	B-Group
Antagonists	I-Group
:	O
Since	O
apomorphine	B-Drug
is	O
a	O
dopamine	B-Group
agonist	I-Group
it	O
is	O
possible	O
that	O
dopamine	B-Group
antagonists	I-Group
such	O
as	O
the	O
neuroleptics	B-Group
(	O
phenothiazines	B-Group
butyrophenones	B-Group
thioxanthenes	B-Group
)	O
or	O
metoclopramide	B-Drug
may	O
diminish	O
the	O
effectiveness	O
of	O
APOKYN	B-Brand
.	O
      
procainamide	B-Drug
;	O
      
Data	O
beyond	O
9	O
days	O
are	O
not	O
available	O
.	O
      
The	O
half	O
-	O
life	O
increased	O
from	O
9	O
to	O
9	O
hours	O
.	O
      
and	O
rarely	O
dry	O
mouth	O
anorexia	O
taste	O
disorder	O
abdominal	O
pain	O
vomiting	O
diarrhea	O
and	O
positive	O
test	O
for	O
occult	O
blood	O
in	O
stool	O
.	O
      
The	O
steady	O
state	O
plasma	O
concentrations	O
of	O
imipramine	B-Drug
and	O
desipramine	B-Drug
have	O
been	O
reported	O
to	O
be	O
increased	O
an	O
average	O
of	O
9	O
%	O
and	O
9	O
%	O
respectively	O
by	O
the	O
concomitant	O
administration	O
of	O
alprazolam	B-Drug
tablets	O
in	O
doses	O
up	O
to	O
9	O
mg	O
/	O
day	O
.	O
      
no	O
change	O
in	O
pravastatin	B-Drug
AUC	O
and	O
Cmax	O
was	O
observed	O
during	O
diltiazem	B-Drug
coadministration	O
.	O
      
No	O
significant	O
adverse	O
interactions	O
with	O
common	O
premedications	O
(	O
such	O
as	O
atropine	B-Drug
scopolamine	B-Drug
glycopyrrolate	B-Drug
diazepam	B-Drug
hydroxyzine	B-Drug
and	O
other	O
muscle	B-Group
relaxants	I-Group
)	O
or	O
local	O
anesthetics	B-Group
have	O
been	O
observed	O
.	O
      
Therefore	O
the	O
coadministration	O
of	O
probenecid	B-Drug
with	O
meropenem	B-Drug
is	O
not	O
recommended	O
.	O
      
Clinical	O
studies	O
have	O
shown	O
increased	O
sedation	O
with	O
concurrent	O
hypnotic	B-Group
medications	I-Group
.	O
      
Clarithromycin	B-Drug
9OH	O
-	O
clarithromycin	O
      
Vindesine	B-Drug
can	O
interact	O
with	O
the	O
drugs	O
of	O
the	O
following	O
categories	O
:	O
-	O
Blood	O
dyscrasia	O
:	O
can	O
cause	O
unpredictable	O
myelotoxicity	O
-	O
Bone	O
marrow	O
depressants	O
:	O
can	O
cause	O
a	O
predictable	O
dose	O
-	O
related	O
myelotoxicity	O
-	O
Radiation	O
therapy	O
:	O
may	O
cause	O
marrow	O
depression	O
-	O
Neurotoxic	O
medications	O
:	O
can	O
cause	O
neurologic	O
toxicity	O
-	O
Phenytoin	B-Drug
:	O
can	O
increase	O
seizure	O
activity	O
-	O
Live	B-Group
virus	I-Group
vaccines	I-Group
:	O
may	O
potentiate	O
the	O
replication	O
of	O
the	O
vaccine	B-Drug
virus	O
may	O
increase	O
the	O
side	O
effects	O
of	O
the	O
vaccination	O
and	O
decrease	O
patient	O
's	O
response	O
to	O
the	O
vaccine	O
-	O
Mitomycin	B-Drug
-	O
C	I-Drug
:	O
may	O
cause	O
shortness	O
of	O
breath	O
and	O
bronchospasm	O
-	O
Killed	B-Group
virus	I-Group
vaccines	I-Group
:	O
may	O
decrease	O
patient	O
's	O
response	O
to	O
the	O
vaccine	B-Group
      
Patients	O
receiving	O
SPRYCEL	B-Brand
should	O
not	O
take	O
St.	O
Johns	O
wort	O
.	O
      
Valproic	B-Drug
Acid	I-Drug
:	O
The	O
mean	O
steady	O
-	O
state	O
trough	O
serum	O
valproic	B-Drug
acid	I-Drug
concentrations	O
prior	O
to	O
and	O
during	O
concomitant	O
gabapentin	B-Drug
administration	O
(	O
9	O
mg	O
TID	O
;	O
      
however	O
as	O
with	O
other	O
NSAIDs	B-Group
concomitant	O
administration	O
of	O
meloxicam	B-Drug
and	O
aspirin	B-Brand
is	O
not	O
generally	O
recommended	O
because	O
of	O
the	O
potential	O
for	O
increased	O
adverse	O
effects	O
.	O
      
Patients	O
with	O
Crohn	O
disease	O
who	O
received	O
immunosuppressants	B-Group
tended	O
to	O
experience	O
fewer	O
infusion	O
reactions	O
compared	O
to	O
patients	O
on	O
no	O
immunosuppressants	B-Group
.	O
      
The	O
onset	O
of	O
symptoms	O
usually	O
occurred	O
within	O
hours	O
(	O
most	O
commonly	O
9	O
to	O
9	O
hours	O
)	O
following	O
the	O
administration	O
of	O
contrast	O
media	O
.	O
      
If	O
desipramine	B-Drug
hydrochloride	I-Drug
is	O
to	O
be	O
combined	O
with	O
other	O
psychotropic	B-Group
agents	I-Group
such	O
as	O
tranquilizers	B-Group
or	O
sedative	B-Group
/	O
hypnotics	B-Group
careful	O
consideration	O
should	O
be	O
given	O
to	O
the	O
pharmacology	O
of	O
the	O
agents	O
employed	O
since	O
the	O
sedative	O
effects	O
of	O
desipramine	B-Drug
and	O
benzodiazepines	B-Group
(	O
e.g.	O
chlordiazepoxide	B-Drug
or	O
diazepam	B-Drug
)	O
are	O
additive	O
.	O
      
Ketoconazole	B-Drug
:	O
Coadministration	O
of	O
ketoconazole	B-Drug
with	O
VIRACEPT	B-Brand
resulted	O
in	O
a	O
9	O
%	O
increase	O
in	O
nelfinavir	B-Drug
plasma	O
A.C	O
.	O
      
For	O
information	O
on	O
the	O
pharmacokinetics	O
of	O
Gemzar	B-Brand
and	O
cisplatin	B-Drug
in	O
combination	O
see	O
Drug	O
Interactions	O
under	O
CLINICAL	O
PHARMACOLOGY	O
section	O
.	O
      
Magnesium	B-Drug
/	O
Aluminum	B-Drug
-	O
containing	O
Antacid	B-Group
Products	I-Group
:	O
Absorption	O
of	O
zalcitabine	B-Drug
is	O
moderately	O
reduced	O
(	O
approximately	O
9	O
%	O
)	O
when	O
coadministered	O
with	O
magnesium	B-Drug
/	O
aluminum	B-Drug
-	O
containing	O
antacid	B-Group
products	I-Group
.	O
      
twice	O
the	O
human	O
dose	O
on	O
BSA	O
)	O
and	O
non	O
-	O
ossification	O
of	O
the	O
odontoid	O
and	O
ventral	O
tubercle	O
of	O
the	O
first	O
cervical	O
vertebra	O
at	O
doses	O
9	O
mg	O
/	O
kg	O
/	O
day	O
IM	O
(	O
approximately	O
one	O
-	O
tenth	O
of	O
the	O
human	O
dose	O
on	O
BSA	O
)	O
when	O
administered	O
during	O
the	O
period	O
of	O
organogenesis	O
.	O
      
Other	O
drug	O
interactions	O
Cimetidine	B-Drug
erythromycin	B-Drug
and	O
dextropropoxyphene	B-Drug
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
MHD	B-Drug_n
.	O
      
Therefore	O
it	O
should	O
be	O
used	O
in	O
caution	O
in	O
patients	O
receiving	O
such	O
agents	O
.	O
      
A	O
case	O
report	O
of	O
one	O
patient	O
taking	O
amiodarone	B-Drug
9	O
mg	O
and	O
indinavir	B-Drug
9	O
mg	O
three	O
times	O
a	O
day	O
resulted	O
in	O
increases	O
in	O
amiodarone	B-Drug
concentrations	O
from	O
9	O
mg	O
/	O
L	O
to	O
9	O
mg	O
/	O
L	O
.	O
      
More	O
than	O
9	O
Parkinsons	O
disease	O
patients	O
in	O
clinical	O
trials	O
have	O
used	O
selegiline	B-Drug
in	O
combination	O
with	O
entacapone	B-Drug
and	O
levodopa	B-Drug
/	O
dopa	B-Group
decarboxylase	I-Group
inhibitor	I-Group
.	O
      
INFORMATION	O
TO	O
BE	O
PROVIDED	O
TO	O
THE	O
PATIENT	O
OR	O
GUARDIAN	O
See	O
illustrated	O
Information	O
For	O
The	O
Patient	O
or	O
Guardian	O
section	O
.	O
      
Drug	O
-	O
Laboratory	O
Test	O
Interactions	O
There	O
are	O
no	O
known	O
interactions	O
between	O
ELLENCE	B-Brand
and	O
laboratory	O
tests	O
.	O
      
In	O
humans	O
two	O
inhibitors	O
of	O
P9	O
9A9	O
have	O
been	O
studied	O
.	O
      
There	O
was	O
a	O
small	O
increase	O
in	O
plasma	O
concentrations	O
of	O
capecitabine	B-Drug
and	O
one	O
metabolite	O
(	O
9	B-Drug_n
-	O
DFCR	I-Drug_n
)	O
;	O
      
These	O
drugs	O
should	O
be	O
coadministered	O
with	O
caution	O
and	O
frequent	O
monitoring	O
of	O
serum	O
lithium	B-Drug
levels	O
is	O
recommended	O
.	O
      
In	O
patients	O
on	O
chronic	O
warfarin	B-Drug
therapy	O
the	O
prothrombin	O
time	O
(	O
INR	O
)	O
should	O
be	O
closely	O
monitored	O
in	O
the	O
9	O
-	O
week	O
period	O
particularly	O
at	O
9	O
to	O
9	O
days	O
following	O
initiation	O
of	O
the	O
9	O
-	O
day	O
regimen	O
of	O
Aprepitant	B-Drug
with	O
each	O
chemotherapy	O
cycle	O
.	O
      
In	O
post	O
-	O
marketing	O
experience	O
there	O
have	O
been	O
reports	O
of	O
increases	O
in	O
plasma	O
lithium	B-Drug
levels	O
.	O
      
If	O
such	O
drugs	O
are	O
used	O
they	O
should	O
be	O
administered	O
with	O
an	O
interval	O
of	O
at	O
least	O
9	O
minutes	O
between	O
applications	O
.	O
      
Methotrexate	B-Drug
:	O
Ibuprofen	B-Drug
as	O
well	O
as	O
other	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
drugs	I-Group
probably	O
reduces	O
the	O
tubular	O
secretion	O
of	O
methotrexate	B-Drug
based	O
on	O
in	O
vitro	O
studies	O
in	O
rabbit	O
kidney	O
slices	O
.	O
      
Treatment	O
with	O
PEGASYS	B-Brand
once	O
weekly	O
for	O
9	O
weeks	O
in	O
healthy	O
subjects	O
was	O
associated	O
with	O
an	O
inhibition	O
of	O
P9	O
9A9	O
and	O
a	O
9	O
%	O
increase	O
in	O
theophylline	B-Drug
AUC	O
.	O
      
The	O
clinical	O
significance	O
of	O
this	O
increase	O
in	O
doxazosin	B-Drug
AUC	O
is	O
unknown	O
.	O
      
Preliminary	O
data	O
which	O
suggest	O
that	O
dapsone	B-Drug
may	O
inhibit	O
the	O
anti	O
-	O
inflammatory	O
activity	O
of	O
Lamprene	B-Brand
have	O
not	O
been	O
confirmed	O
.	O
      
Drug	O
Class	O
:	O
Drug	O
Name	O
Clinical	O
Comment	O
      
No	O
changes	O
were	O
observed	O
in	O
the	O
degree	O
of	O
anticoagulation	O
.	O
      
Coumarin	B-Group
Anticoagulants	I-Group
Altered	O
coagulation	O
parameters	O
and	O
/	O
or	O
bleeding	O
have	O
been	O
reported	O
in	O
patients	O
taking	O
capecitabine	B-Drug
concomitantly	O
with	O
coumarin	B-Group
-	O
derivative	I-Group
anticoagulants	I-Group
such	O
as	O
warfarin	B-Drug
and	O
phenprocoumon	B-Drug
.	O
      
Tablets	O
Simultaneous	O
administration	O
of	O
sucralfate	B-Drug
and	O
furosemide	B-Drug
tablets	O
may	O
reduce	O
the	O
natriuretic	O
and	O
antihypertensive	O
effects	O
of	O
furosemide	B-Drug
.	O
      
Consequently	O
concomitant	O
administration	O
of	O
Aprepitant	B-Drug
with	O
strong	O
CYP9A9	O
inhibitors	O
(	O
e.g.	O
ketoconazole	B-Drug
itraconazole	B-Drug
nefazodone	B-Drug
troleandomycin	B-Drug
clarithromycin	B-Drug
ritonavir	B-Drug
nelfinavir	B-Drug
)	O
should	O
be	O
approached	O
with	O
caution	O
.	O
      
PEGASYS	B-Brand
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
creatinine	O
clearance	O
9	O
mL	O
/	O
min	O
and	O
COPEGUS	B-Brand
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
creatinine	O
clearance	O
9	O
mL	O
/	O
min	O
      
eosinophilia	O
      
Furosemide	B-Drug
:	O
Clinical	O
studies	O
as	O
well	O
as	O
post	O
-	O
marketing	O
observations	O
have	O
shown	O
that	O
NSAIDs	B-Group
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	B-Drug
and	O
thiazides	B-Group
in	O
some	O
patients	O
.	O
      
However	O
the	O
concomitant	O
use	O
of	O
Argatroban	B-Drug
and	O
warfarin	B-Drug
(	O
9	O
-	O
9	O
mg	O
initial	O
oral	O
dose	O
followed	O
by	O
9	O
-	O
9	O
mg	O
/	O
day	O
orally	O
for	O
9	O
-	O
9	O
days	O
)	O
results	O
in	O
prolongation	O
of	O
the	O
prothrombin	O
time	O
(	O
PT	O
)	O
and	O
International	O
Normalized	O
Ratio	O
(	O
INR	O
)	O
.	O
      
Concurrent	O
therapy	O
with	O
bumetanide	B-Drug
is	O
thus	O
not	O
recommended	O
.	O
      
Because	O
the	O
incidence	O
of	O
infections	O
and	O
certain	O
malignancies	O
is	O
higher	O
in	O
the	O
elderly	O
population	O
in	O
general	O
caution	O
should	O
be	O
used	O
in	O
treating	O
the	O
elderly	O
.	O
      
Lithium	B-Drug
:	O
Valdecoxib	B-Drug
9	O
mg	O
BID	O
for	O
9	O
days	O
produced	O
significant	O
decreases	O
in	O
lithium	B-Drug
serum	O
clearance	O
(	O
9	O
%	O
)	O
and	O
renal	O
clearance	O
(	O
9	O
%	O
)	O
with	O
a	O
9	O
%	O
higher	O
serum	O
exposure	O
compared	O
to	O
lithium	B-Drug
alone	O
.	O
      
Hepatic	O
Impairment	O
There	O
are	O
currently	O
no	O
clinical	O
studies	O
with	O
SPRYCEL	B-Brand
in	O
patients	O
with	O
impaired	O
liver	O
function	O
(	O
clinical	O
studies	O
have	O
excluded	O
patients	O
with	O
ALT	O
and	O
/	O
or	O
AST	O
9	O
times	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
range	O
and	O
/	O
or	O
total	O
bilirubin	O
9	O
times	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
range	O
)	O
.	O
      
Antiarrhythmic	B-Drug
agents	I-Drug
class	I-Drug
I	I-Drug
(	O
such	O
as	O
flecainide	B-Drug
lidocaine	B-Drug
or	O
quinidine	B-Drug
)	O
:	O
concurrent	O
use	O
with	O
arbutamine	B-Drug
may	O
have	O
a	O
proarrhythmic	O
effect	O
.	O
      
Drugs	O
Metabolized	O
by	O
P9	O
9D9	O
:	O
The	O
biochemical	O
activity	O
of	O
the	O
drug	O
metabolizing	O
isozyme	O
cytochrome	O
P9	O
9D9	O
(	O
debrisoquin	O
hydroxylase	O
)	O
is	O
reduced	O
in	O
a	O
subset	O
of	O
the	O
aucasian	O
population	O
(	O
about	O
9	O
%	O
-	O
9	O
%	O
of	O
Caucasians	O
are	O
so	O
-	O
called	O
poor	O
metabolizers	O
)	O
;	O
      
In	O
patients	O
who	O
have	O
received	O
general	O
anesthesia	O
utilizing	O
a	O
volatile	O
agent	O
known	O
to	O
sensitize	O
the	O
myocardium	O
to	O
catecholamines	O
administration	O
of	O
doxapram	B-Drug
should	O
be	O
delayed	O
until	O
the	O
volatile	O
agent	O
has	O
been	O
excreted	O
in	O
order	O
to	O
lessen	O
the	O
potential	O
for	O
arrhythmias	O
including	O
ventricular	O
tachycardia	O
and	O
ventricular	O
fibrillation	O
.	O
      
In	O
geriatric	O
subjects	O
(	O
n=9	O
)	O
there	O
was	O
a	O
reduction	O
in	O
the	O
rate	O
but	O
not	O
the	O
extent	O
of	O
flurbiprofen	B-Drug
absorption	O
.	O
      
Lithium	B-Drug
:	O
Increased	O
serum	O
lithium	B-Drug
levels	O
and	O
symptoms	O
of	O
lithium	B-Drug
toxicity	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
ACE	B-Group
inhibitors	I-Group
during	O
therapy	O
with	O
lithium	B-Drug
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
:	O
It	O
is	O
not	O
known	O
if	O
MEPRON	B-Brand
interferes	O
with	O
clinical	O
laboratory	O
test	O
or	O
assay	O
results	O
.	O
      
This	O
may	O
lead	O
to	O
reduced	O
clearance	O
of	O
caffeine	B-Drug
and	O
a	O
prolongation	O
of	O
its	O
serum	O
half	O
-	O
life	O
.	O
      
Patients	O
receiving	O
these	O
drugs	O
in	O
combination	O
with	O
zalcitabine	B-Drug
should	O
be	O
monitored	O
for	O
signs	O
of	O
toxicity	O
and	O
the	O
dose	O
of	O
zalcitabine	B-Drug
reduced	O
if	O
warranted	O
.	O
      
In	O
vitro	O
nilutamide	B-Drug
has	O
been	O
shown	O
to	O
inhibit	O
the	O
activity	O
of	O
liver	O
cytochrome	O
P	O
-	O
9	O
isoenzymes	O
and	O
therefore	O
may	O
reduce	O
the	O
metabolism	O
of	O
compounds	O
requiring	O
these	O
systems	O
.	O
      
Zidovudine	B-Drug
competitively	O
inhibits	O
the	O
intracellular	O
phosphorylation	O
of	O
stavudine	B-Drug
.	O
      
Agents	O
that	O
might	O
be	O
coadministered	O
with	O
trimetrexate	B-Drug
in	O
AIDS	O
patients	O
for	O
other	O
indications	O
that	O
could	O
elicit	O
this	O
activity	O
include	O
erythromycin	B-Drug
rifampin	B-Drug
rifabutin	B-Drug
ketoconazole	B-Drug
and	O
fluconazole	B-Drug
.	O
      
mefenamic	B-Drug
acid	I-Drug
;	O
      
If	O
signs	O
and	O
symptoms	O
suggestive	O
of	O
digoxin	B-Drug
toxicity	O
occur	O
when	O
enoxacin	B-Drug
and	O
digoxin	B-Drug
are	O
given	O
concomitantly	O
physicians	O
are	O
advised	O
to	O
obtain	O
serum	O
digoxin	B-Drug
levels	O
and	O
adjust	O
digoxin	B-Drug
doses	O
appropriately	O
.	O
      
Because	O
of	O
its	O
lack	O
of	O
platelet	O
effects	O
VIOXX	B-Brand
is	O
not	O
a	O
substitute	O
for	O
aspirin	B-Brand
for	O
cardiovascular	O
prophylaxis	O
.	O
      
In	O
vitro	O
studies	O
indicate	O
that	O
ertapenem	B-Drug
does	O
not	O
inhibit	O
P	O
-	O
glycoprotein	O
-	O
mediated	O
transport	O
of	O
digoxin	B-Drug
or	O
vinblastine	B-Drug
and	O
that	O
ertapenem	B-Drug
is	O
not	O
a	O
substrate	O
for	O
P	O
-	O
glycoprotein	O
-	O
mediated	O
transport	O
.	O
      
Since	O
aminotransferase	O
determinations	O
are	O
important	O
in	O
the	O
differential	O
diagnosis	O
of	O
myocardial	O
infarction	O
liver	O
disease	O
and	O
pulmonary	O
emboli	O
rises	O
that	O
might	O
be	O
caused	O
by	O
drugs	O
(	O
heparin	B-Drug
sodium	I-Drug
)	O
should	O
be	O
interpreted	O
with	O
caution	O
.	O
      
Caution	O
should	O
be	O
used	O
when	O
administering	O
MOBIC	B-Brand
with	O
warfarin	B-Drug
since	O
patients	O
on	O
warfarin	B-Drug
may	O
experience	O
changes	O
in	O
INR	O
and	O
an	O
increased	O
risk	O
of	O
bleeding	O
complications	O
when	O
a	O
new	O
medication	O
is	O
introduced	O
.	O
      
However	O
no	O
related	O
changes	O
were	O
noted	O
in	O
the	O
QT9	O
on	O
ECG	O
taken	O
at	O
9	O
9	O
and	O
9	O
hours	O
after	O
the	O
coadministration	O
.	O
      
This	O
included	O
post	O
myocardial	O
infarction	O
patients	O
who	O
were	O
receiving	O
intravenous	O
or	O
transdermal	O
nitroglycerin	B-Drug
.	O
      
Due	O
to	O
its	O
potential	O
to	O
cause	O
neutropenia	O
and	O
lymphopenia	O
proper	O
monitoring	O
of	O
patients	O
is	O
required	O
if	O
Rebif	B-Brand
is	O
given	O
in	O
combination	O
with	O
myelosuppressive	O
agents	O
.	O
      
Cyclosporine	O
Digoxin	O
Methotrexate	O
Lodine	B-Brand
like	O
other	O
NSAIDs	B-Group
through	O
effects	O
on	O
renal	O
prostaglandins	O
may	O
cause	O
changes	O
in	O
the	O
elimination	O
of	O
these	O
drugs	O
leading	O
to	O
elevated	O
serum	O
levels	O
of	O
cyclosporine	B-Drug
digoxin	B-Drug
methotrexate	B-Drug
and	O
increased	O
toxicity	O
.	O
      
dextrothyroxine	B-Drug
;	O
      
Few	O
data	O
exist	O
on	O
drug	O
interactions	O
with	O
caffeine	B-Drug
in	O
preterm	O
neonates	O
.	O
      
Of	O
particular	O
importance	O
sufficient	O
time	O
must	O
elapse	O
before	O
initiating	O
TCA	O
treatment	O
in	O
a	O
patient	O
being	O
withdrawn	O
from	O
fluoxetine	B-Drug
given	O
the	O
long	O
half	O
-	O
life	O
of	O
the	O
parent	O
and	O
active	O
metabolite	O
(	O
at	O
least	O
9	O
weeks	O
may	O
be	O
necessary	O
)	O
.	O
      
Interactions	O
for	O
vitamin	B-Group
D	I-Group
analogues	I-Group
(	O
Vitamin	B-Drug
D9	I-Drug
Vitamin	B-Drug
D9	I-Drug
Calcitriol	B-Drug
and	O
Calcidiol	B-Drug
)	O
:	O
Cholestyramine	B-Drug
:	O
Cholestyramine	B-Drug
has	O
been	O
reported	O
to	O
reduce	O
intestinal	O
absorption	O
of	O
fat	B-Group
soluble	I-Group
vitamins	I-Group
;	O
      
Methotrexate	B-Drug
:	O
Piperacillin	B-Drug
sodium	I-Drug
may	O
reduce	O
the	O
excretion	O
of	O
methotrexate	B-Drug
.	O
      
Ethanol	B-Drug
or	O
Triazolam	B-Drug
:	O
No	O
significant	O
differences	O
were	O
observed	O
in	O
the	O
pharmacokinetics	O
of	O
triazolam	B-Drug
(	O
9	O
mg	O
)	O
and	O
tiagabine	B-Drug
(	O
9	O
mg	O
)	O
when	O
given	O
together	O
as	O
a	O
single	O
dose	O
.	O
      
The	O
possibility	O
of	O
hypotensive	O
effects	O
with	O
Lotensin	B-Brand
can	O
be	O
minimized	O
by	O
either	O
discontinuing	O
the	O
diuretic	B-Group
or	O
increasing	O
the	O
salt	O
intake	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
Lotensin	B-Brand
.	O
      
The	O
plasma	O
concentrations	O
of	O
bosentan	B-Drug
were	O
not	O
affected	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
There	O
are	O
no	O
known	O
interactions	O
between	O
APOKYN	B-Brand
and	O
laboratory	O
tests	O
.	O
      
In	O
female	O
rats	O
fulvestrant	B-Drug
administered	O
at	O
doses	O
9	O
mg	O
/	O
kg	O
/	O
day	O
(	O
approximately	O
one	O
-	O
hundredth	O
of	O
the	O
human	O
recommended	O
dose	O
based	O
on	O
body	O
surface	O
area	O
[	O
BSA	O
]	O
for	O
9	O
weeks	O
prior	O
to	O
and	O
for	O
9	O
week	O
following	O
mating	O
caused	O
a	O
reduction	O
in	O
fertility	O
and	O
embryonic	O
survival	O
.	O
      
Coffee	O
and	O
black	O
tea	O
should	O
be	O
avoided	O
because	O
they	O
decrease	O
the	O
absorption	O
of	O
levomepromazine	B-Drug
considerably	O
.	O
      
The	O
effects	O
of	O
tricyclic	B-Group
antidepressants	I-Group
on	O
clonidines	B-Drug
analgesic	O
actions	O
are	O
not	O
known	O
.	O
      
Methadone	B-Drug
:	O
Coadministration	O
of	O
amprenavir	B-Drug
and	O
methadone	B-Drug
can	O
decrease	O
plasma	O
levels	O
of	O
methadone	B-Drug
.	O
      
The	O
clinical	O
significance	O
of	O
this	O
finding	O
is	O
unknown	O
.	O
      
.	O
      
Aspirin	B-Brand
increased	O
ulcerogenic	O
effect	O
;	O
      
Digitalis	B-Group
toxicity	O
may	O
be	O
aggravated	O
by	O
the	O
initial	O
release	O
of	O
norepinephrine	O
caused	O
by	O
Bretylium	B-Drug
Tosylate	I-Drug
Injection	O
.	O
      
Azithromycin	B-Drug
did	O
not	O
affect	O
the	O
prothrombin	O
time	O
response	O
to	O
a	O
single	O
dose	O
of	O
warfarin	B-Drug
.	O
      
Tadalafil	B-Drug
      
Conflicting	O
results	O
have	O
been	O
reported	O
regarding	O
the	O
effects	O
of	O
EPA	B-Drug
supplements	O
on	O
glycemic	O
control	O
in	O
non	O
-	O
diabetics	O
with	O
glucose	O
intolerance	O
and	O
those	O
with	O
type	O
9	O
diabetes	O
.	O
      
If	O
the	O
usual	O
amounts	O
of	O
nondepolarizing	O
relaxants	O
are	O
given	O
the	O
time	O
for	O
recovery	O
from	O
neuromuscular	O
blockade	O
will	O
be	O
longer	O
in	O
the	O
presence	O
of	O
Enflurane	B-Drug
than	O
when	O
halothane	B-Drug
or	O
nitrous	B-Drug
oxide	I-Drug
with	O
a	O
balanced	O
technique	O
are	O
used	O
.	O
      
Certain	O
antibiotics	B-Group
especially	O
neomycin	B-Drug
streptomycin	B-Drug
and	O
kanamycin	B-Drug
have	O
a	O
mild	O
but	O
definite	O
nondepolarizing	O
blocking	O
action	O
which	O
may	O
accentuate	O
neuromuscular	O
block	O
.	O
      
The	O
renal	O
effects	O
of	O
nephrotoxic	O
compounds	O
may	O
be	O
potentiated	O
by	O
Carboplatin	B-Drug
.	O
      
Specific	O
drug	O
interaction	O
studies	O
including	O
interactions	O
with	O
MTX	B-Drug
have	O
not	O
been	O
conducted	O
.	O
      
Valproate	B-Drug
:	O
Available	O
data	O
suggest	O
that	O
there	O
is	O
no	O
significant	O
effect	O
of	O
valproate	B-Drug
on	O
the	O
clearance	O
of	O
Felbatol	B-Brand
at	O
steady	O
state	O
Therefore	O
the	O
addition	O
of	O
valproate	B-Drug
is	O
not	O
expected	O
to	O
cause	O
a	O
clinically	O
important	O
effect	O
on	O
Felbatol	B-Brand
(	O
felbamate	B-Drug
)	O
plasma	O
concentrations	O
.	O
      
-	O
Antithyroid	B-Group
agents	I-Group
(	O
medicine	O
for	O
overactive	O
thyroid	O
)	O
or	O
      
Concomitant	O
administration	O
of	O
TRENTAL	B-Brand
and	O
theophylline	B-Drug
-	O
containing	O
drugs	O
leads	O
to	O
increased	O
theophylline	B-Drug
levels	O
and	O
theophylline	B-Drug
toxicity	O
in	O
some	O
individuals	O
.	O
      
Substrate	O
of	O
CYP9D9	O
(	O
minor	O
)	O
9A9	O
(	O
major	O
)	O
;	O
      
Drug	O
Laboratory	O
Test	O
Interactions	O
Interactions	O
between	O
darifenacin	B-Drug
and	O
laboratory	O
tests	O
have	O
not	O
been	O
studied	O
.	O
      
The	O
following	O
are	O
examples	O
of	O
substances	O
that	O
may	O
reduce	O
the	O
blood	O
-	O
glucose	O
-	O
lowering	O
effect	O
:	O
corticosteroids	B-Group
niacin	B-Drug
danazol	B-Drug
diuretics	B-Group
sympathomimetic	B-Group
agents	I-Group
(	O
e.g.	O
epinephrine	B-Drug
salbutamol	B-Drug
terbutaline	B-Drug
)	O
isoniazid	B-Drug
phenothiazine	B-Group
derivatives	I-Group
somatropin	B-Drug
thyroid	B-Group
hormones	I-Group
estrogens	B-Group
progestogens	B-Group
(	O
e.g.	O
in	O
oral	O
contraceptives	B-Group
)	O
.	O
      
phenytoin	B-Drug
;	O
      
Erythromycin	B-Drug
      
Drugs	O
that	O
Inhibit	O
Drug	O
Transport	O
Systems	O
Lapatinib	B-Drug
is	O
a	O
substrate	O
of	O
the	O
efflux	O
transporter	O
P	O
-	O
glycoprotein	O
(	O
Pgp	O
ABCB9	O
)	O
.	O
      
Induction	O
of	O
such	O
tumors	O
is	O
consistent	O
with	O
the	O
pharmacology	O
-	O
related	O
endocrine	O
feedback	O
alterations	O
in	O
gonadotropin	O
levels	O
caused	O
by	O
an	O
antiestrogen	B-Group
.	O
      
indinavir	B-Drug
concentration	O
      
Conversely	O
decreases	O
in	O
plasma	O
levels	O
of	O
the	O
tricyclic	B-Group
antidepressants	I-Group
have	O
been	O
reported	O
upon	O
discontinuation	O
of	O
cimetidine	B-Drug
which	O
may	O
result	O
in	O
the	O
loss	O
of	O
the	O
therapeutic	O
efficacy	O
of	O
the	O
tricyclic	B-Group
antidepressant	I-Group
9	O
.	O
      
The	O
administration	O
of	O
SUPRAX	B-Brand
may	O
result	O
in	O
a	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
using	O
Clinitest	O
**	O
Benedict	O
solution	O
or	O
Fehling	O
s	O
solution	O
.	O
      
Drugs	O
which	O
impair	O
glomerular	O
filtration	O
may	O
prolong	O
the	O
biological	O
half	O
-	O
life	O
of	O
flucytosine	B-Drug
.	O
      
Coadministration	O
of	O
gly	O
-	O
buride	O
and	O
metformin	B-Drug
did	O
not	O
result	O
in	O
any	O
changes	O
in	O
either	O
metformin	B-Drug
pharmacokinetics	O
or	O
pharmaco	O
-	O
dynamics	O
.	O
      
Inhibitors	O
of	O
renal	O
cationic	O
secretion	O
are	O
contraindicated	O
with	O
TIKOSYN	B-Brand
.	O
      
These	O
potential	O
drug	O
interactions	O
are	O
listed	O
in	O
Table	O
9	O
.	O
      
Laboratory	O
Tests	O
Pregnancy	O
Test	O
Female	O
patients	O
of	O
childbearing	O
potential	O
must	O
have	O
negative	O
results	O
from	O
9	O
urine	O
or	O
serum	O
pregnancy	O
tests	O
with	O
a	O
sensitivity	O
of	O
at	O
least	O
9	O
mIU	O
/	O
mL	O
before	O
receiving	O
the	O
initial	O
Accutane	B-Brand
prescription	O
.	O
      
Warfarin	B-Drug
:	O
The	O
effects	O
of	O
aliskiren	B-Drug
on	O
warfarin	B-Drug
pharmacokinetics	O
have	O
not	O
been	O
evaluated	O
in	O
a	O
well	O
-	O
controlled	O
clinical	O
trial	O
.	O
      
Diuretics	B-Group
:	O
Patients	O
on	O
diuretics	B-Group
and	O
especially	O
those	O
started	O
recently	O
may	O
occasionally	O
experience	O
an	O
excessive	O
reduction	O
of	O
blood	O
pressure	O
after	O
initiation	O
of	O
ACEON	B-Brand
Tablets	O
therapy	O
.	O
      
Cardiac	B-Group
glycosides	I-Group
      
Esomeprazole	B-Drug
inhibits	O
gastric	O
acid	O
secretion	O
.	O
      
Thus	O
probenecid	B-Drug
should	O
not	O
be	O
administered	O
concurrently	O
with	O
bumetanide	B-Drug
.	O
      
An	O
in	O
vivo	O
interaction	O
study	O
in	O
humans	O
demonstrated	O
that	O
a	O
single	O
9mg	O
dose	O
of	O
anagrelide	B-Drug
administered	O
concomitantly	O
with	O
a	O
single	O
9	O
mg	O
dose	O
of	O
aspirin	B-Brand
was	O
generally	O
well	O
tolerated	O
.	O
      
After	O
multiple	O
dosing	O
interferon	B-Drug
beta	I-Drug
-	O
9a	I-Drug
(	O
AVONEX	B-Brand
9	O
mcg	O
IM	O
once	O
weekly	O
)	O
reduced	O
TYSABRI	B-Brand
clearance	O
by	O
approximately	O
9	O
%	O
.	O
      
9	O
.	O
      
Anticoagulants	B-Group
:	O
Warfarin	B-Drug
      
9	O
-	O
9	O
      
Lithium	B-Drug
carbonate	I-Drug
:	O
The	O
stimulatory	O
effects	O
of	O
amphetamines	B-Group
may	O
be	O
inhibited	O
by	O
lithium	B-Drug
carbonate	I-Drug
.	O
      
is	O
a	O
possibility	O
.	O
      
When	O
patients	O
being	O
treated	O
with	O
labetalol	B-Drug
have	O
a	O
positive	O
urine	O
test	O
for	O
amphetamine	B-Drug
using	O
these	O
techniques	O
confirmation	O
should	O
be	O
made	O
by	O
using	O
more	O
specific	O
methods	O
such	O
as	O
a	O
gas	O
chromatographic	O
-	O
mass	O
spectrometer	O
technique	O
.	O
      
Talk	O
to	O
your	O
doctor	O
and	O
pharmacist	O
before	O
taking	O
any	O
prescription	O
or	O
over	O
-	O
the	O
-	O
counter	O
medicines	O
including	O
herbal	O
products	O
.	O
      
Although	O
additional	O
drug	O
interaction	O
studies	O
have	O
not	O
been	O
conducted	O
the	O
most	O
common	O
medications	O
used	O
concomitantly	O
with	O
anagrelide	B-Drug
in	O
clinical	O
trials	O
were	O
aspirin	B-Brand
acetaminophen	B-Drug
furosemide	B-Drug
iron	B-Drug
ranitidine	B-Drug
hydroxyurea	B-Drug
and	O
allopurinol	B-Drug
.	O
      
Many	O
other	O
medicines	O
may	O
increase	O
or	O
decrease	O
the	O
effects	O
of	O
glimepiride	B-Drug
or	O
affect	O
your	O
condition	O
.	O
      
However	O
in	O
vivo	O
drug	O
interaction	O
studies	O
of	O
ketoconazole	B-Drug
with	O
vitamin	B-Group
D	I-Group
have	O
not	O
been	O
investigated	O
.	O
      
Lithium	B-Drug
renal	O
clearance	O
is	O
reduced	O
by	O
thiazides	B-Group
increasing	O
the	O
risk	O
of	O
lithium	B-Drug
toxicity	O
.	O
      
No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
VELCADE	B-Brand
.	O
      
Digoxin	B-Drug
:	O
Supraventricular	O
arrhythmias	O
may	O
mask	O
the	O
cardiotoxicity	O
associated	O
with	O
excessive	O
digoxin	B-Drug
levels	O
.	O
      
Nevertheless	O
caution	O
is	O
indicated	O
in	O
the	O
co	O
-	O
administration	O
of	O
TCA9	O
with	O
any	O
of	O
the	O
SSRIs	B-Group
and	O
also	O
in	O
switching	O
from	O
one	O
class	O
to	O
the	O
other	O
.	O
      
Flurbiprofen	B-Drug
did	O
not	O
appear	O
to	O
affect	O
the	O
beta	O
-	O
blocker	O
-	O
mediated	O
reduction	O
in	O
heart	O
rate	O
.	O
      
There	O
is	O
insufficient	O
experience	O
to	O
assess	O
the	O
safety	O
and	O
efficacy	O
of	O
ORENCIA	B-Brand
administered	O
concurrently	O
with	O
anakinra	B-Drug
and	O
therefore	O
such	O
use	O
is	O
not	O
recommended	O
.	O
      
When	O
concomitant	O
administration	O
of	O
either	O
of	O
these	O
two	O
drugs	O
with	O
mexiletine	B-Drug
is	O
initiated	O
the	O
dose	O
of	O
mexiletine	B-Drug
should	O
be	O
slowly	O
titrated	O
to	O
desired	O
effect	O
.	O
      
In	O
addition	O
the	O
transfusion	O
practices	O
for	O
such	O
patients	O
may	O
need	O
to	O
be	O
modified	O
given	O
the	O
increased	O
risk	O
of	O
bleeding	O
.	O
      
combination	O
therapy	O
is	O
contemplated	O
the	O
dosage	O
of	O
one	O
or	O
both	O
agents	O
should	O
be	O
reduced	O
.	O
      
These	O
in	O
vitro	O
studies	O
suggest	O
that	O
concomitant	O
administration	O
of	O
zalcitabine	B-Drug
and	O
lamivudine	B-Drug
in	O
humans	O
may	O
result	O
in	O
sub	O
-	O
therapeutic	O
concentrations	O
of	O
active	O
phosphorylated	O
zalcitabine	B-Drug
which	O
may	O
lead	O
to	O
a	O
decreased	O
antiretroviral	B-Group
effect	O
of	O
zalcitabine	B-Drug
.	O
      
These	O
agents	O
should	O
not	O
be	O
used	O
in	O
patients	O
treated	O
with	O
NIZORAL	B-Brand
Tablets	O
.	O
      
These	O
medications	O
included	O
thyroid	B-Group
hormones	I-Group
sedative	B-Group
hypnotics	I-Group
non	B-Group
-	O
steroidal	I-Group
anti	I-Group
-	O
inflammatory	I-Group
agents	I-Group
benzodiazepines	B-Group
and	O
decongestants	B-Group
.	O
      
No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
Rebif	B-Brand
.	O
      
Hypotension	O
-	O
Patients	O
on	O
Diuretic	O
Therapy	O
:	O
Patients	O
on	O
diuretics	B-Group
and	O
especially	O
those	O
in	O
whom	O
diuretic	O
therapy	O
was	O
recently	O
instituted	O
may	O
occasionally	O
experience	O
an	O
excessive	O
reduction	O
of	O
blood	O
pressure	O
after	O
initiation	O
of	O
therapy	O
with	O
PRINIVIL	B-Brand
.	O
      
In	O
these	O
subjects	O
(	O
R=	O
B	O
)	O
the	O
clearance	O
of	O
diazepam	B-Drug
was	O
reduced	O
by	O
9	O
%	O
and	O
that	O
of	O
N	B-Drug_n
-	O
desmethyldiazepam	I-Drug_n
to	O
a	O
level	O
that	O
was	O
too	O
low	O
to	O
measure	O
over	O
the	O
course	O
of	O
the	O
9	O
week	O
long	O
study	O
.	O
      
Caution	O
should	O
be	O
exercised	O
and	O
dose	O
reduction	O
of	O
the	O
concomitant	O
substrate	O
drug	O
should	O
be	O
considered	O
when	O
dosing	O
lapatinib	B-Drug
concurrently	O
with	O
medications	O
with	O
narrow	O
therapeutic	O
windows	O
that	O
are	O
substrates	O
of	O
CYP9A9	O
or	O
CYP9C9	O
.	O
      
Other	O
compounds	O
that	O
are	O
substrates	O
of	O
CYP9A9	O
may	O
have	O
decreased	O
plasma	O
concentrations	O
when	O
coadministered	O
with	O
SUSTIVA	B-Brand
(	O
efavirenz	B-Drug
)	O
.	O
      
The	O
possibility	O
of	O
hypotensive	O
effects	O
can	O
be	O
minimized	O
by	O
either	O
discontinuing	O
the	O
diuretic	B-Group
or	O
increasing	O
the	O
salt	O
intake	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
perindopril	B-Drug
.	O
      
Nonsteroidal	B-Group
Anti	I-Group
-	O
Inflammatory	I-Group
Drugs	I-Group
(	O
NSAIDs	B-Group
)	O
-	O
A	O
drug	O
interaction	O
study	O
of	O
eplerenone	B-Drug
with	O
an	O
NSAID	B-Group
has	O
not	O
been	O
conducted	O
.	O
      
Increases	O
of	O
9	O
%	O
with	O
MHD	B-Drug_n
and	O
9	O
%	O
with	O
oxcarbazepine	B-Drug
were	O
observed	O
.	O
      
Systemic	B-Group
Corticosteroids	I-Group
:	O
Systemic	B-Group
corticosteroids	I-Group
are	O
known	O
to	O
cause	O
osteoporosis	O
.	O
      
indomethacin	B-Drug
;	O
      
Concurrent	O
and	O
/	O
or	O
sequential	O
use	O
of	O
TOBI	B-Brand
with	O
other	O
drugs	O
with	O
neurotoxic	O
or	O
ototoxic	O
potential	O
should	O
be	O
avoided	O
.	O
      
ACE	B-Group
Inhibitors	I-Group
and	O
Angiotensin	B-Group
II	I-Group
Receptor	I-Group
Antagonists	I-Group
(	O
Hypertension	O
)	O
-	O
In	O
clinical	O
studies	O
of	O
patients	O
with	O
hypertension	O
the	O
addition	O
of	O
INSPRA	B-Brand
9	O
to	O
9	O
mg	O
to	O
ACE	B-Group
inhibitors	I-Group
and	O
angiotensin	B-Group
II	I-Group
receptor	I-Group
antagonists	I-Group
increased	O
mean	O
serum	O
potassium	O
slightly	O
(	O
about	O
9	O
-	O
9	O
mEq	O
/	O
L	O
)	O
.	O
      
Digoxin	B-Drug
-	O
In	O
subjects	O
who	O
had	O
received	O
9	O
days	O
of	O
9	O
mg	O
/	O
day	O
racemic	O
citalopram	B-Drug
combined	O
administration	O
of	O
citalopram	B-Drug
and	O
digoxin	B-Drug
(	O
single	O
dose	O
of	O
9	O
mg	O
)	O
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
either	O
citalopram	B-Drug
or	O
digoxin	B-Drug
.	O
      
May	O
interact	O
anticoagulants	B-Group
(	O
altered	O
hypo	O
-	O
prothrombinemic	O
effect	O
)	O
barbiturates	B-Group
rifampin	B-Drug
and	O
other	O
inducers	O
of	O
hepatic	O
microsomal	O
enzyme	O
oxidation	O
system	O
(	O
decreased	O
effect	O
of	O
diethylstilbestrol	B-Drug
)	O
corticosteroids	B-Group
(	O
increased	O
effect	O
of	O
corticosteroids	B-Group
)	O
.	O
      
Close	O
supervision	O
and	O
careful	O
adjustment	O
of	O
dosage	O
are	O
required	O
when	O
Anafranil	B-Brand
is	O
administered	O
with	O
anticholinergic	B-Group
or	O
sympathomimetic	B-Group
drugs	I-Group
.	O
      
Tenecteplase	B-Drug
is	O
an	O
enzyme	O
that	O
when	O
present	O
in	O
blood	O
in	O
pharmacologic	O
concentrations	O
remains	O
active	O
under	O
in	O
vitro	O
conditions	O
.	O
      
However	O
LDL	O
-	O
C	O
reduction	O
was	O
not	O
altered	O
.	O
      
Consult	O
with	O
pharmacist	O
if	O
available	O
.	O
      
Concomitant	O
glucocorticoid	O
therapy	O
may	O
inhibit	O
the	O
growth	O
-	O
promoting	O
effect	O
of	O
Nutropin	B-Brand
.	O
      
Digitalis	B-Group
:	O
Vitamin	B-Group
D	I-Group
dosage	O
must	O
be	O
determined	O
with	O
care	O
in	O
patients	O
undergoing	O
treatment	O
with	O
digitalis	B-Group
as	O
hypercalcemia	O
in	O
such	O
patients	O
may	O
precipitate	O
cardiac	O
arrhythmias	O
.	O
      
Administration	O
of	O
a	O
higher	O
dose	O
of	O
indinavir	B-Drug
should	O
be	O
considered	O
when	O
coadministering	O
with	O
megestrol	B-Drug
acetate	I-Drug
.	O
      
There	O
have	O
been	O
rare	O
reports	O
of	O
significant	O
respiratory	O
depression	O
stupor	O
and	O
/	O
or	O
hypotension	O
with	O
the	O
concomitant	O
use	O
of	O
loxapine	B-Drug
and	O
lorazepam	B-Drug
.	O
      
Aminoglycosides	B-Group
:	O
The	O
mixing	O
of	O
piperacillin	B-Drug
with	O
an	O
aminoglycoside	B-Group
in	O
vitro	O
can	O
result	O
in	O
substantial	O
inactivation	O
of	O
the	O
aminoglycoside	B-Group
.	O
      
Cevimeline	B-Drug
might	O
interfere	O
with	O
desirable	O
antimuscarinic	O
effects	O
of	O
drugs	O
used	O
concomitantly	O
.	O
      
cimetidine	B-Drug
)	O
and	O
many	O
that	O
are	O
substrates	O
for	O
P9	O
9D9	O
(	O
many	O
other	O
antidepressants	B-Group
phenothiazines	B-Group
and	O
the	O
Type	B-Group
9C	I-Group
antiarrhythmics	I-Group
propafenone	B-Drug
and	O
flecainide	B-Drug
)	O
.	O
      
therefore	O
it	O
is	O
theoretically	O
possible	O
that	O
lansoprazole	B-Drug
may	O
interfere	O
with	O
the	O
absorption	O
of	O
drugs	O
where	O
gastric	O
pH	O
is	O
an	O
important	O
determinant	O
of	O
bioavailability	O
(	O
e.g	O
.	O
ketoconazole	B-Drug
ampicillin	B-Drug
esters	O
iron	B-Drug
salts	O
digoxin	B-Drug
)	O
.	O
      
ZEBETA	B-Brand
should	O
be	O
used	O
with	O
care	O
when	O
myocardial	B-Group
depressants	I-Group
or	O
inhibitors	O
of	O
AV	O
conduction	O
such	O
as	O
certain	O
calcium	B-Group
antagonists	I-Group
(	O
particularly	O
of	O
the	O
phenylalkylamine	B-Group
[	O
verapamil	B-Drug
]	O
and	O
benzothiazepine	B-Group
[	O
diltiazem	B-Drug
]	O
classes	O
)	O
or	O
antiarrhythmic	B-Group
agents	I-Group
such	O
as	O
disopyramide	B-Drug
are	O
used	O
concurrently	O
.	O
      
Drugs	O
with	O
parasympathomimetic	O
effects	O
administered	O
concurrently	O
with	O
pilocarpine	B-Drug
would	O
be	O
expected	O
to	O
result	O
in	O
additive	O
pharmacologic	O
effects	O
.	O
      
Choose	O
particular	O
low	O
doses	O
of	O
these	O
drugs	O
.	O
      
Transient	O
delirium	O
has	O
been	O
reported	O
in	O
patients	O
who	O
were	O
treated	O
with	O
one	O
gram	O
of	O
ethchlorvynol	B-Drug
and	O
9	O
-	O
9	O
mg	O
of	O
amitriptyline	B-Drug
HCl	I-Drug
.	O
      
Morphine	B-Drug
:	O
A	O
literature	O
article	O
reported	O
that	O
when	O
a	O
9	O
-	O
mg	O
controlled	O
-	O
release	O
morphine	B-Drug
capsule	O
was	O
administered	O
9	O
hours	O
prior	O
to	O
a	O
9	O
-	O
mg	O
Neurontin	B-Brand
capsule	O
(	O
N=9	O
)	O
mean	O
gabapentin	B-Drug
AUC	O
increased	O
by	O
9	O
%	O
compared	O
to	O
gabapentin	B-Drug
administered	O
without	O
morphine	B-Drug
.	O
      
Concomitant	O
use	O
with	O
iron	B-Group
supplements	I-Group
may	O
result	O
in	O
the	O
reduced	O
absorption	O
of	O
iron	B-Drug
.	O
      
Clonidine	B-Drug
therapy	O
can	O
then	O
be	O
discontinued	O
several	O
days	O
later	O
by	O
gradually	O
decreasing	O
the	O
dosage	O
.	O
      
Concomitant	O
medications	O
were	O
grouped	O
as	O
ACE	B-Group
inhibitors	I-Group
oral	O
anticoagulants	B-Group
calcium	B-Group
channel	I-Group
blockers	I-Group
beta	B-Group
blockers	I-Group
cardiac	B-Group
glycosides	I-Group
inducers	O
of	O
CYP9A9	O
substrates	O
and	O
inhibitors	O
of	O
CYP9A9	O
substrates	O
and	O
inhibitors	O
of	O
P	O
-	O
glycoprotein	O
nitrates	B-Group
sulphonylureas	B-Group
loop	B-Group
diuretics	I-Group
potassium	B-Group
sparing	I-Group
diuretics	I-Group
thiazide	B-Group
diuretics	I-Group
substrates	O
and	O
inhibitors	O
of	O
tubular	O
organic	O
cation	O
transport	O
and	O
QTc	O
-	O
prolonging	O
drugs	O
.	O
      
Other	O
antiarrhythmic	B-Group
drugs	I-Group
(	O
eg	O
quinidine	B-Drug
procainamide	B-Drug
lidocaine	B-Drug
propranolol	B-Drug
)	O
have	O
occasionally	O
been	O
used	O
concurrently	O
with	O
Norpace	B-Brand
.	O
      
Immunosuppressants	B-Group
      
.	O
      
This	O
did	O
not	O
result	O
in	O
any	O
statistically	O
or	O
clinically	O
relevant	O
changes	O
in	O
the	O
pharmacokinetic	O
parameters	O
of	O
either	O
caffeine	B-Drug
or	O
its	O
major	O
metabolite	O
paraxanthine	B-Drug_n
.	O
      
Coadministration	O
of	O
diltiazem	B-Drug
with	O
rifampin	B-Drug
or	O
any	O
known	O
CYP9A9	O
inducer	O
should	O
be	O
avoided	O
when	O
possible	O
and	O
alternative	O
therapy	O
considered	O
.	O
      
If	O
digitalis	B-Drug
treatment	O
is	O
continued	O
serum	O
levels	O
should	O
be	O
closely	O
monitored	O
and	O
patients	O
observed	O
for	O
clinical	O
evidence	O
of	O
toxicity	O
.	O
      
Patients	O
receiving	O
tacrolimus	B-Drug
and	O
fluconazole	B-Drug
concomitantly	O
should	O
be	O
carefully	O
monitored	O
.	O
      
Drug	O
-	O
drug	O
interactions	O
In	O
vitro	O
studies	O
using	O
human	O
liver	O
microsomes	O
indicate	O
that	O
fenofibrate	B-Drug
and	O
fenofibric	B-Drug_n
acid	I-Drug_n
are	O
not	O
inhibitors	O
of	O
cytochrome	O
(	O
CYP	O
)	O
P9	O
isoforms	O
CYP9A9	O
CYP9D9	O
CYP9E9	O
or	O
CYP9A9	O
.	O
      
these	O
enzymes	O
would	O
therefore	O
not	O
be	O
expected	O
to	O
be	O
inhibited	O
in	O
clinical	O
use	O
.	O
      
Additional	O
clinical	O
experience	O
may	O
reveal	O
other	O
drugs	O
affected	O
by	O
the	O
concomitant	O
administration	O
of	O
Tagamet	B-Brand
.	O
      
Drugs	O
That	O
Inhibit	O
Both	O
Aldehyde	O
Oxidase	O
and	O
CYP9A9	O
Cimetidine	B-Drug
:	O
Cimetidine	B-Drug
inhibits	O
both	O
aldehyde	O
oxidase	O
(	O
in	O
vitro	O
)	O
and	O
CYP9A9	O
(	O
in	O
vitro	O
and	O
in	O
vivo	O
)	O
the	O
primary	O
and	O
secondary	O
enzymes	O
respectively	O
responsible	O
for	O
zaleplon	B-Drug
metabolism	O
.	O
      
No	O
significant	O
drug	O
-	O
drug	O
pharmacokinetic	O
(	O
or	O
pharmacodynamic	O
)	O
interactions	O
have	O
been	O
found	O
in	O
interaction	O
studies	O
with	O
hydrochlorothiazide	B-Drug
digoxin	B-Drug
warfarin	B-Drug
and	O
nifedipine	B-Drug
.	O
      
Multivitamins	B-Group
or	O
other	O
products	O
containing	O
iron	B-Drug
or	O
zinc	B-Drug
antacids	B-Group
or	O
sucralfate	B-Drug
should	O
not	O
be	O
administered	O
concomitantly	O
with	O
or	O
within	O
9	O
hours	O
of	O
the	O
administration	O
of	O
norfloxacin	B-Drug
because	O
they	O
may	O
interfere	O
with	O
absorption	O
resulting	O
in	O
lower	O
serum	O
and	O
urine	O
levels	O
of	O
norfloxacin	B-Drug
.	O
      
Interactions	O
with	O
Mixed	B-Group
Agonist	I-Group
/	O
Antagonist	I-Group
Opioid	I-Group
Analgesics	I-Group
:	O
Agonist	B-Group
/	O
antagonist	I-Group
analgesics	I-Group
(	O
eg	O
pentazocine	B-Drug
nalbuphine	B-Drug
butorphanol	B-Drug
dezocine	B-Drug
and	O
buprenorphine	B-Drug
)	O
should	O
NOT	O
be	O
administered	O
to	O
a	O
patient	O
who	O
has	O
received	O
or	O
is	O
receiving	O
a	O
course	O
of	O
therapy	O
with	O
a	O
pure	B-Group
agonist	I-Group
opioid	I-Group
analgesic	I-Group
such	O
as	O
Levo	B-Brand
-	O
Dromoran	I-Brand
.	O
      
The	O
pharmacokinetics	O
of	O
theophylline	B-Drug
were	O
not	O
altered	O
.	O
      
Digoxin	B-Drug
:	O
Concomitant	O
administration	O
of	O
tiagabine	B-Drug
did	O
not	O
affect	O
the	O
steady	O
-	O
state	O
pharmacokinetics	O
of	O
digoxin	B-Drug
or	O
the	O
mean	O
daily	O
trough	O
serum	O
level	O
of	O
digoxin	B-Drug
.	O
      
Due	O
to	O
highintersubject	O
variability	O
however	O
somepatients	O
may	O
experience	O
large	O
increases	O
in	O
rifabutin	B-Drug
exposure	O
and	O
may	O
be	O
at	O
higher	O
riskfor	O
rifabutin	O
toxicity	O
.	O
      
Vitamin	B-Group
D	I-Group
:	O
The	O
coadministration	O
of	O
any	O
of	O
the	O
vitamin	B-Group
D	I-Group
analogues	I-Group
should	O
be	O
avoided	O
as	O
this	O
could	O
create	O
possible	O
additive	O
effects	O
and	O
hypercalcemia	O
.	O
      
Drugs	O
that	O
Inhibit	O
or	O
Induce	O
Cytochrome	O
P9	O
9A9	O
Enzymes	O
Lapatinib	B-Drug
undergoes	O
extensive	O
metabolism	O
by	O
CYP9A9	O
and	O
concomitant	O
administration	O
of	O
strong	O
inhibitors	O
or	O
inducers	O
of	O
CYP9A9	O
alter	O
lapatinib	B-Drug
concentrations	O
significantly	O
.	O
      
This	O
response	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
.	O
      
Based	O
on	O
the	O
above	O
data	O
from	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
it	O
is	O
unlikely	O
that	O
alosetron	B-Drug
will	O
inhibit	O
the	O
hepatic	O
metabolic	O
clearance	O
of	O
drugs	O
metabolized	O
by	O
the	O
major	O
CYP	O
enzyme	O
9A9	O
as	O
well	O
as	O
the	O
CYP	O
enzymes	O
9D9	O
9C9	O
9C9	O
9E9	O
or	O
9A9	O
.	O
      
Sildenafil	B-Drug
dose	O
should	O
not	O
exceed	O
a	O
maximum	O
of	O
9	O
mg	O
in	O
a	O
9	O
-	O
hour	O
period	O
in	O
patients	O
receiving	O
concomitant	O
indinavir	B-Drug
therapy	O
.	O
      
While	O
there	O
is	O
evidence	O
that	O
fluconazole	B-Drug
can	O
inhibit	O
the	O
metabolism	O
of	O
ethinyl	B-Drug
estradiol	I-Drug
and	O
levonorgestrel	B-Drug
there	O
is	O
no	O
evidence	O
that	O
fluconazole	B-Drug
is	O
a	O
net	O
inducer	O
of	O
ethinyl	B-Drug
estradiol	I-Drug
or	O
levonorgestrel	B-Drug
metabolism	O
.	O
      
Anti	B-Group
-	O
HIV	I-Group
protease	I-Group
inhibitors	I-Group
:	O
Saquinavir	B-Drug
/	O
ritonavir	B-Drug
combination	O
      
Antipyrine	B-Drug
:	O
Antipyrine	B-Drug
pharmacokinetics	O
were	O
not	O
significantly	O
different	O
before	O
and	O
after	O
tiagabine	B-Drug
multiple	O
-	O
dose	O
regimens	O
.	O
      
CNS	O
vascular	O
lesions	O
characterized	O
by	O
perivascular	O
hemorrhages	O
edema	O
and	O
mononuclear	O
cell	O
infiltration	O
of	O
perivascular	O
spaces	O
have	O
been	O
observed	O
in	O
dogs	O
treated	O
with	O
other	O
members	O
of	O
this	O
class	O
.	O
      
Other	O
antihypertensive	B-Group
drugs	I-Group
:	O
additive	O
effect	O
or	O
potentiation	O
.	O
      
May	O
interact	O
with	O
the	O
following	O
:	O
cholestyramine	B-Drug
colestipol	B-Drug
(	O
use	O
with	O
thiazide	B-Group
diuretics	I-Group
may	O
prevent	O
the	O
diuretic	B-Group
from	O
working	O
properly	O
;	O
      
The	O
inhibition	O
of	O
CYP	O
-	O
9C9	O
by	O
OXC	B-Drug
and	O
MHD	B-Drug_n
however	O
is	O
clinically	O
relevant	O
.	O
      
Probenecid	B-Drug
or	O
Cimetidine	B-Drug
:	O
Concomitant	O
administration	O
of	O
probenecid	B-Drug
or	O
cimetidine	B-Drug
decreases	O
the	O
elimination	O
of	O
zalcitabine	B-Drug
most	O
likely	O
by	O
inhibition	O
of	O
renal	O
tubular	O
secretion	O
of	O
zalcitabine	B-Drug
.	O
      
Example	O
inhibitors	O
include	O
azole	B-Group
antifungals	I-Group
ciprofloxacin	B-Drug
clarithromycin	B-Drug
diclofenac	B-Drug
doxycycline	B-Drug
erythromycin	B-Drug
imatinib	B-Drug
isoniazid	B-Drug
nefazodone	B-Drug
nicardipine	B-Drug
propofol	B-Drug
protease	B-Group
inhibitors	I-Group
quinidine	B-Drug
and	O
verapamil	B-Drug
.	O
      
Perioperative	O
administration	O
of	O
drugs	O
affecting	O
hepatic	O
blood	O
flow	O
or	O
enzyme	O
function	O
may	O
reduce	O
plasma	O
clearance	O
and	O
prolong	O
recovery	O
.	O
      
Microdosed	O
minipill	O
progestin	B-Drug
preparations	O
are	O
not	O
recommended	O
for	O
use	O
with	O
Soriatane	B-Drug
.	O
      
Nonetheless	O
the	O
range	O
of	O
individual	O
Simulect	B-Brand
clearance	O
values	O
in	O
the	O
presence	O
of	O
azathioprine	B-Drug
(	O
9	O
-	O
9	O
mL	O
/	O
h	O
)	O
or	O
mycophenolate	B-Drug
mofetil	I-Drug
(	O
9	O
-	O
9	O
mL	O
/	O
h	O
)	O
did	O
not	O
extend	O
outside	O
the	O
range	O
observed	O
with	O
dual	O
therapy	O
(	O
9	O
-	O
9	O
mL	O
/	O
h	O
)	O
.	O
      
No	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
for	O
COLAZAL	B-Brand
however	O
the	O
use	O
of	O
orally	O
administered	O
antibiotics	B-Group
could	O
theoretically	O
interfere	O
with	O
the	O
release	O
of	O
mesalamine	B-Drug
in	O
the	O
colon	O
.	O
      
Cholestyramine	B-Drug
:	O
Concomitant	O
cholestyramine	B-Drug
administration	O
decreased	O
the	O
mean	O
AUC	O
of	O
total	O
ezetimibe	B-Drug
approximately	O
9	O
%	O
.	O
      
Although	O
glucocorticoids	B-Group
have	O
been	O
shown	O
to	O
reduce	O
PROLEUKIN	B-Brand
-	O
induced	O
side	O
effects	O
including	O
fever	O
renal	O
insufficiency	O
hyperbilirubinemia	O
confusion	O
and	O
dyspnea	O
concomitant	O
administration	O
of	O
these	O
agents	O
with	O
PROLEUKIN	B-Brand
may	O
reduce	O
the	O
antitumor	O
effectiveness	O
of	O
PROLEUKIN	B-Brand
and	O
thus	O
should	O
be	O
avoided	O
.	O
9	O
Beta	B-Group
-	O
blockers	I-Group
and	O
other	O
antihypertensives	B-Group
may	O
potentiate	O
the	O
hypotension	O
seen	O
with	O
PROLEUKIN	B-Brand
.	O
      
In	O
order	O
to	O
maintain	O
phenytoin	B-Drug
levels	O
limit	O
adverse	O
experiences	O
and	O
achieve	O
the	O
felbamate	B-Drug
dose	O
of	O
9	O
mg	O
/	O
day	O
a	O
phenytoin	B-Drug
dose	O
reduction	O
of	O
approximately	O
9	O
%	O
was	O
necessary	O
for	O
eight	O
of	O
these	O
9	O
subjects	O
.	O
      
Consequently	O
drugs	O
with	O
a	O
low	O
therapeutic	O
margin	O
such	O
as	O
vitamin	B-Group
K	I-Group
antagonists	I-Group
phenytoin	B-Drug
and	O
theophylline	B-Drug
could	O
have	O
a	O
delayed	O
elimination	O
and	O
increases	O
in	O
their	O
serum	O
half	O
-	O
life	O
leading	O
to	O
a	O
toxic	O
level	O
.	O
      
In	O
a	O
study	O
with	O
concomitant	O
administration	O
of	O
aspirin	B-Brand
and	O
fosinopril	B-Drug
sodium	I-Drug
the	O
bioavailability	O
of	O
unbound	O
fosinoprilat	B-Drug_n
was	O
not	O
altered	O
.	O
      
Those	O
anticonvulsants	B-Group
include	O
divalproex	B-Drug
sodium	I-Drug
valproic	B-Drug
acid	I-Drug
and	O
phenobarbital	B-Drug
.	O
      
No	O
drug	O
interaction	O
data	O
are	O
available	O
on	O
concomitant	O
administration	O
of	O
Panretin	B-Brand
gel	O
and	O
systemic	O
anti	O
-	O
KS	O
agents	O
.	O
      
As	O
with	O
other	O
antipsychotic	B-Group
agents	I-Group
it	O
should	O
be	O
noted	O
that	O
HALDOL	B-Brand
may	O
be	O
capable	O
of	O
potentiating	O
CNS	B-Group
depressants	I-Group
such	O
as	O
anesthetics	B-Group
opiates	B-Group
and	O
alcohol	B-Drug
.	O
      
ibuprofen	B-Drug
;	O
      
The	O
extent	O
of	O
plasma	O
protein	O
binding	O
of	O
atovaquone	B-Drug
in	O
human	O
plasma	O
is	O
not	O
affected	O
by	O
the	O
presence	O
of	O
therapeutic	O
concentrations	O
of	O
phenytoin	B-Drug
(	O
9	O
mcg	O
/	O
mL	O
)	O
nor	O
is	O
the	O
binding	O
of	O
phenytoin	B-Drug
affected	O
by	O
the	O
presence	O
of	O
atovaquone	B-Drug
.	O
      
In	O
these	O
patients	O
whose	O
hypertension	O
was	O
controlled	O
with	O
nifedipine	B-Drug
Vardenafil	B-Drug
9	O
mg	O
produced	O
mean	O
additional	O
supine	O
systolic	O
/	O
diastolic	O
blood	O
pressure	O
reductions	O
of	O
9	O
/	O
9	O
mm	O
Hg	O
compared	O
to	O
placebo	O
.	O
      
No	O
information	O
is	O
available	O
about	O
the	O
use	O
of	O
butorphanol	B-Drug
concurrently	O
with	O
MAO	B-Group
inhibitors	I-Group
.	O
      
an	O
oral	O
9	O
mg	O
dose	O
achieves	O
a	O
highest	O
level	O
of	O
approximately	O
9	O
uM	O
in	O
people	O
)	O
;	O
      
The	O
physician	O
is	O
advised	O
to	O
monitor	O
plasma	O
levels	O
of	O
phenytoin	B-Drug
and	O
to	O
decrease	O
the	O
dose	O
if	O
necessary	O
.	O
      
Anagrelide	B-Drug
alone	O
had	O
no	O
effect	O
on	O
platelet	O
aggregation	O
but	O
did	O
slightly	O
enhance	O
the	O
inhibition	O
of	O
platelet	O
aggregation	O
by	O
aspirin	B-Brand
.	O
      
Pindolol	B-Drug
levels	O
may	O
also	O
be	O
increased	O
with	O
this	O
combination	O
.	O
      
The	O
potential	O
for	O
increased	O
sedation	O
when	O
guanfacine	B-Drug
is	O
given	O
with	O
other	O
CNS	B-Group
-	O
depressant	I-Group
drug	I-Group
should	O
be	O
appreciated	O
.	O
      
Although	O
a	O
causal	O
mechanism	O
and	O
a	O
cause	O
-	O
and	O
-	O
effect	O
relationship	O
have	O
not	O
been	O
established	O
current	O
evidence	O
suggests	O
that	O
renal	O
function	O
should	O
be	O
monitored	O
in	O
patients	O
on	O
thiazide	B-Group
diuretics	I-Group
and	O
allopurinol	B-Drug
even	O
in	O
the	O
absence	O
of	O
renal	O
failure	O
and	O
dosage	O
levels	O
should	O
be	O
even	O
more	O
conservatively	O
adjusted	O
in	O
those	O
patients	O
on	O
such	O
combined	O
therapy	O
if	O
diminished	O
renal	O
function	O
is	O
detected..	O
      
In	O
the	O
DIAMOND	O
trials	O
9	O
patients	O
were	O
treated	O
with	O
TIKOSYN	B-Brand
and	O
diuretics	B-Group
concomitantly	O
of	O
whom	O
9	O
died	O
compared	O
to	O
9	O
deaths	O
among	O
the	O
9	O
patients	O
receiving	O
placebo	O
and	O
diuretics	B-Group
.	O
      
This	O
change	O
was	O
not	O
considered	O
clinically	O
significant	O
and	O
no	O
dose	O
adjustment	O
is	O
needed	O
when	O
ketoconazole	B-Drug
and	O
VIRACEPT	B-Brand
are	O
coadministered	O
.	O
      
barbiturates	B-Group
;	O
      
diuretics	B-Group
*	O
;	O
      
certain	O
tetracyclic	B-Group
antidepressants	I-Group
(	O
such	O
as	O
maprotiline	B-Drug
)	O
;	O
      
Rifampin	B-Drug
:	O
Rifampin	B-Drug
increases	O
the	O
metabolism	O
of	O
ethinyl	B-Drug
estradiol	I-Drug
and	O
some	O
progestins	B-Group
(	O
norethindrone	B-Drug
)	O
resulting	O
in	O
decreased	O
contraceptive	O
effectiveness	O
and	O
increased	O
menstrual	O
irregularities	O
.	O
      
Antifungals	B-Group
:	O
Itraconazole	B-Drug
Ketoconazole	B-Drug
      
On	O
the	O
basis	O
of	O
limited	O
available	O
data	O
no	O
dosage	O
adjustment	O
is	O
recommended	O
for	O
patients	O
on	O
these	O
drugs	O
.	O
      
In	O
a	O
chronic	O
toxicity	O
study	O
cynomolgus	O
monkeys	O
were	O
dosed	O
weekly	O
for	O
9	O
weeks	O
with	O
intravenous	O
alefacept	B-Drug
at	O
9	O
mg	O
/	O
kg	O
/	O
dose	O
or	O
9	O
mg	O
/	O
kg	O
/	O
dose	O
.	O
      
An	O
immune	O
response	O
to	O
Campath	B-Brand
may	O
interfere	O
with	O
subsequent	O
diagnostic	O
serum	O
tests	O
that	O
utilize	O
antibodies	B-Group
      
Patients	O
taking	O
disopyramide	B-Drug
phosphate	I-Drug
and	O
hepatic	O
enzyme	O
inhibitors	O
concomitantly	O
should	O
be	O
closely	O
monitored	O
.	O
      
Digoxin	B-Drug
:	O
The	O
concomitant	O
administration	O
of	O
DynaCirc	B-Brand
(	O
isradipine	B-Drug
)	O
and	O
digoxin	B-Drug
in	O
a	O
single	O
-	O
dose	O
pharmacokinetic	O
study	O
did	O
not	O
affect	O
renal	O
nonrenal	O
and	O
total	O
body	O
clearance	O
of	O
digoxin	B-Drug
.	O
      
When	O
such	O
drugs	O
are	O
withdrawn	O
from	O
a	O
patient	O
receiving	O
DIABINESE	B-Brand
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
loss	O
of	O
control	O
.	O
      
Other	O
drugs	O
that	O
are	O
specific	O
substrates	O
inhibitors	O
or	O
inducers	O
of	O
the	O
enzyme	O
system	O
may	O
have	O
a	O
significant	O
impact	O
on	O
the	O
efficacy	O
and	O
side	O
effect	O
profile	O
of	O
diltiazem	B-Drug
.	O
      
Since	O
there	O
have	O
been	O
isolated	O
reports	O
of	O
patients	O
with	O
elevated	O
digoxin	B-Drug
levels	O
it	O
is	O
recommended	O
that	O
digoxin	B-Drug
levels	O
be	O
monitored	O
when	O
initiating	O
adjusting	O
and	O
discontinuing	O
nifedipine	B-Drug
to	O
avoid	O
possible	O
over	O
-	O
or	O
under	O
-	O
digitalization	O
.	O
      
Other	O
CYP9A9	O
inducers	O
include	O
but	O
are	O
not	O
limited	O
to	O
rifabutin	B-Drug
rifapentine	B-Drug
phenytoin	B-Drug
carbamazepine	B-Drug
phenobarbital	B-Drug
and	O
St.	O
Johns	O
Wort	O
.	O
      
Therefore	O
careful	O
monitoring	O
of	O
blood	O
glucose	O
is	O
recommended	O
when	O
these	O
agents	O
are	O
coadministered	O
.	O
      
Excessive	O
ethanol	B-Drug
ingestion	O
should	O
be	O
avoided	O
because	O
a	O
psychotic	O
reaction	O
has	O
been	O
reported	O
.	O
      
It	O
is	O
therefore	O
advisable	O
to	O
monitor	O
digoxin	B-Drug
concentrations	O
in	O
patients	O
receiving	O
ketoconazole	B-Drug
.	O
      
Glyburide	B-Drug
:	O
Etodolac	B-Drug
has	O
no	O
apparent	O
pharmacokinetic	O
interaction	O
when	O
administered	O
with	O
glyburide	B-Drug
.	O
      
increased	O
serum	O
triglyceride	O
and	O
phospholipid	O
concentration	O
.	O
      
Lithium	B-Drug
serum	O
concentrations	O
should	O
be	O
monitored	O
closely	O
when	O
initiating	O
or	O
changing	O
therapy	O
with	O
BEXTRA	B-Brand
in	O
patients	O
receiving	O
lithium	B-Drug
.	O
      
Effects	O
of	O
Lapatinib	B-Drug
on	O
Drug	O
Metabolizing	O
Enzymes	O
and	O
Drug	O
Transport	O
Systems	O
Lapatinib	B-Drug
inhibits	O
CYP9A9	O
and	O
CYP9C9	O
in	O
vitro	O
at	O
clinically	O
relevant	O
concentrations	O
.	O
      
Lapatinib	B-Drug
inhibits	O
human	O
P	O
-	O
glycoprotein	O
.	O
      
Mequitazine	B-Drug
can	O
interact	O
with	O
CNS	B-Group
depressant	I-Group
antichlolinergic	B-Group
TCA	B-Group
MAOIs	B-Group
and	O
alcohol	B-Drug
.	O
      
In	O
vitro	O
studies	O
have	O
also	O
shown	O
that	O
terbinafine	B-Drug
inhibits	O
CYP9D9	O
-	O
mediated	O
metabolism	O
.	O
      
Hepatic	O
Enzyme	O
Inducers	O
Inhibitors	O
and	O
Substrates	O
:	O
Drugs	O
which	O
induce	O
cytochrome	O
P9	O
9A9	O
(	O
CYP	O
9A9	O
)	O
enzyme	O
activity	O
(	O
e.g.	O
barbiturates	B-Group
phenytoin	B-Drug
carbamazepine	B-Drug
rifampin	B-Drug
)	O
may	O
enhance	O
the	O
metabolism	O
of	O
corticosteroids	B-Group
and	O
require	O
that	O
the	O
dosage	O
of	O
the	O
corticosteroid	B-Group
be	O
increased	O
.	O
      
Fenbufen	B-Drug
is	O
not	O
approved	O
in	O
the	O
United	O
States	O
at	O
this	O
time	O
.	O
      
Ketoconazole	B-Drug
      
Your	O
doctor	O
or	O
pharmacist	O
can	O
give	O
you	O
more	O
information	O
on	O
MAO	B-Group
inhibitors	I-Group
.	O
      
Excessive	O
glucocorticoid	O
therapy	O
will	O
inhibit	O
the	O
growth	O
-	O
promoting	O
effect	O
of	O
human	B-Drug
GH	I-Drug
.	O
      
Administration	O
of	O
CMI	B-Drug
has	O
been	O
reported	O
to	O
increase	O
the	O
plasma	O
levels	O
of	O
phenobarbital	B-Drug
if	O
given	O
concomitantly	O
.	O
      
No	O
confirmed	O
interactions	O
have	O
been	O
reported	O
between	O
ZOLADEX	B-Brand
and	O
other	O
drugs	O
      
At	O
a	O
median	O
follow	O
-	O
up	O
of	O
9	O
months	O
the	O
combination	O
of	O
ARIMIDEX	B-Brand
and	O
tamoxifen	B-Drug
did	O
not	O
demonstrate	O
any	O
efficacy	O
benefit	O
when	O
compared	O
with	O
tamoxifen	B-Drug
in	O
all	O
patients	O
as	O
well	O
as	O
in	O
the	O
hormone	O
receptor	O
-	O
positive	O
subpopulation	O
.	O
      
It	O
is	O
unknown	O
whether	O
the	O
concomitant	O
administration	O
of	O
proton	B-Group
pump	I-Group
inhibitors	I-Group
affects	O
duloxetine	B-Drug
absorption	O
.	O
      
Therefore	O
unless	O
otherwise	O
specified	O
appropriate	O
dosage	O
adjustments	O
may	O
be	O
necessary	O
.	O
      
If	O
concomitant	O
treatment	O
with	O
frovatriptan	B-Drug
and	O
an	O
SSRI	B-Group
is	O
clinically	O
warranted	O
appropriate	O
observation	O
of	O
the	O
patient	O
is	O
advised	O
.	O
      
Accutane	B-Brand
use	O
is	O
associated	O
with	O
depression	O
in	O
some	O
patients	O
.	O
      
MAO	B-Group
inhibitors	I-Group
:	O
MAOI	B-Group
antidepressants	I-Group
as	O
well	O
as	O
a	O
metabolite	O
of	O
furazolidone	B-Drug
slow	O
amphetamine	B-Group
metabolism	O
.	O
      
Studies	O
with	O
ACE	B-Group
inhibitors	I-Group
in	O
combination	O
with	O
diuretics	B-Group
indicate	O
that	O
the	O
dose	O
of	O
the	O
ACE	B-Group
inhibitor	I-Group
can	O
be	O
reduced	O
when	O
it	O
is	O
given	O
with	O
a	O
diuretic	B-Group
.	O
      
In	O
vitro	O
studies	O
demonstrated	O
no	O
evidence	O
of	O
incompatibility	O
of	O
heparin	B-Drug
with	O
EXTRANEAL	B-Brand
.	O
      
A	O
causal	O
relationship	O
between	O
these	O
events	O
and	O
the	O
concomitant	O
administration	O
of	O
lithium	B-Drug
and	O
HALDOL	B-Brand
has	O
not	O
been	O
established	O
;	O
      
When	O
Vardenafil	B-Drug
dosing	O
was	O
separated	O
from	O
terazosin	B-Drug
9	O
mg	O
by	O
9	O
hours	O
9	O
of	O
9	O
subjects	O
who	O
received	O
9	O
mg	O
of	O
Vardenafil	B-Drug
experienced	O
a	O
decrease	O
in	O
standing	O
systolic	O
blood	O
pressure	O
below	O
9	O
mm	O
Hg	O
.	O
      
Based	O
on	O
anecdotal	O
reports	O
there	O
may	O
be	O
an	O
interaction	O
between	O
buprenorphine	B-Drug
and	O
benzodiazepines	B-Group
.	O
      
Acetaminophen	B-Drug
:	O
May	O
increase	O
plasma	O
concentration	O
of	O
synthetic	B-Group
estrogens	I-Group
possibly	O
by	O
inhibiting	O
conjugation	O
.	O
      
Digoxin	B-Drug
:	O
In	O
a	O
study	O
in	O
9	O
patients	O
with	O
congestive	O
heart	O
failure	O
where	O
ketoprofen	B-Drug
and	O
digoxin	B-Drug
were	O
concomitantly	O
administered	O
ketoprofen	B-Drug
did	O
not	O
alter	O
the	O
serum	O
levels	O
of	O
digoxin	B-Drug
.	O
      
Therefore	O
FLOMAX	B-Brand
capsules	O
should	O
be	O
used	O
with	O
caution	O
in	O
combination	O
with	O
cimetidine	B-Drug
particularly	O
at	O
doses	O
higher	O
than	O
9	O
mg	O
.	O
      
In	O
addition	O
ketoconazole	B-Drug
alone	O
can	O
inhibit	O
adrenal	O
corticosteroid	B-Drug
synthesis	O
and	O
may	O
cause	O
adrenal	O
insufficiency	O
during	O
corticosteroid	O
withdrawal	O
.	O
      
In	O
a	O
patient	O
with	O
a	O
nonfunctioning	O
thyroid	O
gland	O
who	O
is	O
receiving	O
thyroid	O
replacement	O
therapy	O
free	O
levothyroxine	B-Drug
may	O
be	O
decreased	O
when	O
estrogens	B-Group
are	O
started	O
thus	O
increasing	O
thyroid	B-Group
requirements	O
.	O
      
Omeprazole	B-Drug
:	O
No	O
clinically	O
significant	O
changes	O
in	O
lomefloxacin	B-Drug
pharmacokinetics	O
(	O
AUC	O
C	O
max	O
or	O
T	O
max	O
)	O
were	O
observed	O
when	O
a	O
single	O
dose	O
of	O
lomefloxacin	B-Drug
9	O
mg	O
was	O
given	O
after	O
multiple	O
doses	O
of	O
omeprazole	B-Drug
(	O
9	O
mg	O
qd	O
)	O
in	O
9	O
healthy	O
volunteers	O
.	O
      
Drug	O
-	O
Drug	O
Interactions	O
:	O
The	O
pharmacokinetic	O
and	O
pharmacodynamic	O
interactions	O
between	O
FLOMAX	B-Brand
capsules	O
and	O
other	O
alpha	B-Group
-	O
adrenergic	I-Group
blocking	I-Group
agents	I-Group
have	O
not	O
been	O
determined	O
.	O
      
HMG	B-Group
-	O
CoA	I-Group
reductase	I-Group
inhibitors	I-Group
:	O
No	O
clinically	O
significant	O
pharmacokinetic	O
interactions	O
were	O
seen	O
when	O
ezetimibe	B-Drug
was	O
co	O
-	O
administered	O
with	O
atorvastatin	B-Drug
simvastatin	B-Drug
pravastatin	B-Drug
lovastatin	B-Drug
or	O
fluvastatin	B-Drug
.	O
      
Interference	O
with	O
spectrophotometric	O
methods	O
for	O
SGOT	O
analysis	O
has	O
not	O
been	O
reported	O
.	O
      
Women	O
of	O
childbearing	O
potential	O
make	O
up	O
a	O
considerable	O
segment	O
of	O
the	O
patient	O
population	O
affected	O
by	O
psoriasis	O
.	O
      
No	O
evidence	O
of	O
mutagenicity	O
was	O
observed	O
in	O
vitro	O
in	O
a	O
microbial	O
mutagenicity	O
(	O
Ames	O
)	O
test	O
with	O
Salmonella	O
typhimurium	O
and	O
Escherichia	O
coli	O
with	O
or	O
without	O
metabolic	O
activation	O
.	O
      
Patients	O
with	O
Hepatic	O
Impairment	O
In	O
vitro	O
and	O
in	O
vivo	O
evidence	O
suggest	O
that	O
erlotinib	B-Drug
is	O
cleared	O
primarily	O
by	O
the	O
liver	O
.	O
      
Patients	O
who	O
have	O
previously	O
received	O
pelvic	O
/	O
abdominal	O
irradiation	O
are	O
at	O
increased	O
risk	O
of	O
severe	O
myelosuppression	O
following	O
the	O
administration	O
of	O
CAMPTOSAR	B-Brand
.	O
      
MAO	B-Group
inhibitors	I-Group
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
hydralazine	B-Drug
.	O
      
A	O
number	O
of	O
substances	O
affect	O
glucose	O
metabolism	O
and	O
may	O
require	O
insulin	B-Drug
dose	O
adjustment	O
and	O
particularly	O
close	O
monitoring	O
.	O
      
The	O
drug	O
interaction	O
data	O
described	O
in	O
this	O
section	O
were	O
obtained	O
from	O
controlled	O
clinical	O
trials	O
and	O
studies	O
involving	O
otherwise	O
healthy	O
adults	O
with	O
epilepsy	O
.	O
      
.	O
      
There	O
have	O
been	O
isolated	O
reports	O
of	O
patients	O
experiencing	O
increases	O
in	O
their	O
prothrombin	O
times	O
when	O
etidronate	B-Drug
was	O
added	O
to	O
warfarin	B-Drug
therapy	O
.	O
      
-	O
a	O
diuretic	B-Group
(	O
water	O
pill	O
)	O
such	O
as	O
hydrochlorothiazide	B-Drug
(	O
HCTZ	B-Drug
Hydrodiuril	B-Brand
)	O
chlorothiazide	B-Drug
(	O
Diuril	B-Brand
)	O
and	O
others	O
;	O
      
Close	O
observation	O
of	O
the	O
patient	O
is	O
recommended	O
when	O
a	O
beta	B-Group
-	O
blocker	I-Group
is	O
administered	O
to	O
patients	O
receiving	O
catecholamine	O
-	O
depleting	O
drugs	O
such	O
as	O
reserpine	B-Drug
because	O
of	O
possible	O
additive	O
effects	O
and	O
the	O
production	O
of	O
hypotension	O
and	O
/	O
or	O
marked	O
bradycardia	O
which	O
may	O
produce	O
vertigo	O
syncope	O
or	O
postural	O
hypotension	O
.	O
      
The	O
possibility	O
of	O
hypotensive	O
effects	O
can	O
be	O
minimized	O
by	O
either	O
discontinuing	O
the	O
diuretic	B-Group
or	O
increasing	O
salt	O
intake	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
fosinopril	B-Drug
sodium	I-Drug
.	O
      
-	O
did	O
not	O
change	O
the	O
pharmacokinetic	O
profile	O
or	O
urinary	O
excretion	O
of	O
immunoreactive	O
digoxin	B-Drug
.	O
      
No	O
evidence	O
of	O
interaction	O
of	O
PROCRIT	B-Brand
with	O
other	O
drugs	O
was	O
observed	O
in	O
the	O
course	O
of	O
clinical	O
trials	O
.	O
      
Physiological	O
changes	O
resulting	O
from	O
smoking	O
cessation	O
with	O
or	O
without	O
nicotine	B-Drug
replacement	O
may	O
alter	O
the	O
pharmacokinetics	O
of	O
certain	O
concomitant	O
medications	O
such	O
as	O
tricyclic	B-Group
antidepressants	I-Group
and	O
theophylline	B-Drug
.	O
      
phosphokinase	O
      
Impaired	O
glucose	O
tolerance	O
.	O
      
Estrogen	B-Group
Oral	O
Contraceptives	B-Group
:	O
Estrogens	B-Group
tend	O
to	O
increase	O
serum	O
thyroxine	O
-	O
binding	O
globulin	O
(	O
TBg	O
)	O
.	O
      
Oral	O
metronidazole	B-Drug
has	O
been	O
reported	O
to	O
potentiate	O
the	O
anticoagulant	O
effect	O
of	O
coumarin	B-Group
and	O
warfarin	B-Drug
resulting	O
in	O
a	O
prolongation	O
of	O
prothrombin	O
time	O
.	O
      
Patients	O
receiving	O
other	O
narcotic	B-Group
analgesics	I-Group
general	O
anesthetics	B-Group
phenothiazines	B-Group
tranquilizers	B-Group
sedative	B-Group
-	O
hypnotics	I-Group
tricyclic	B-Group
antidepressants	I-Group
or	O
other	O
CNS	B-Group
depressants	I-Group
(	O
including	O
alcohol	B-Drug
)	O
concomitantly	O
with	O
DILAUDID	B-Brand
may	O
exhibit	O
an	O
additive	O
CNS	O
depression	O
.	O
      
Such	O
patients	O
should	O
be	O
closely	O
monitored	O
for	O
signs	O
of	O
toxicity	O
and	O
have	O
their	O
theophylline	B-Drug
dosage	O
adjusted	O
as	O
necessary	O
.	O
      
ECG	O
intervals	O
(	O
PR	O
QRS	O
and	O
QT	O
)	O
were	O
not	O
affected	O
by	O
concurrent	O
Mexitil	B-Brand
and	O
digoxin	B-Drug
diuretics	B-Group
or	O
propranolol	B-Drug
.	O
      
Pravastatin	B-Drug
:	O
In	O
a	O
9	O
-	O
way	O
crossover	O
study	O
of	O
9	O
normal	O
-	O
weight	O
mildly	O
hypercholesterolemic	O
patients	O
receiving	O
XENICAL	B-Brand
9	O
mg	O
three	O
times	O
a	O
day	O
for	O
9	O
days	O
XENICAL	B-Brand
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
pravastatin	B-Drug
.	O
      
Anticonvulsants	B-Group
:	O
Phenytoin	B-Drug
Phenobarbital	B-Drug
Carbamazepine	B-Drug
      
.	O
      
9	O
.	O
      
Drugs	O
affecting	O
pituitary	O
or	O
adrenocortical	O
function	O
including	O
all	O
corticosteroid	O
therapy	O
must	O
be	O
discontinued	O
prior	O
to	O
and	O
during	O
testing	O
with	O
Metopirone	B-Brand
.	O
      
A	O
pregnancy	O
test	O
must	O
be	O
repeated	O
each	O
month	O
prior	O
to	O
the	O
female	O
patient	O
receiving	O
each	O
prescription	O
      
Corticosteroids	B-Group
may	O
increase	O
the	O
clearance	O
of	O
chronic	O
high	O
dose	O
aspirin	B-Brand
.	O
      
If	O
you	O
are	O
taking	O
medications	O
for	O
migraines	O
such	O
as	O
Imitrex	B-Brand
talk	O
to	O
your	O
doctor	O
before	O
starting	O
this	O
medicine	O
.	O
      
Patients	O
with	O
mild	O
to	O
moderate	O
renal	O
insufficiency	O
should	O
avoid	O
taking	O
NSAIDs	B-Group
with	O
short	O
elimination	O
half	O
-	O
lives	O
for	O
a	O
period	O
of	O
9	O
days	O
before	O
the	O
day	O
of	O
and	O
9	O
days	O
following	O
administration	O
of	O
ALIMTA	B-Brand
.	O
      
H9	B-Group
Receptor	I-Group
Antagonists	I-Group
:	O
Cimetidine	B-Drug
coadministration	O
leads	O
to	O
an	O
increased	O
peak	O
plasma	O
concentration	O
and	O
AUC	O
of	O
cisapride	B-Drug
there	O
is	O
no	O
effect	O
on	O
cisapride	B-Drug
absorption	O
when	O
it	O
is	O
coadministered	O
with	O
ranitidine	B-Drug
.	O
      
Valproate	B-Drug
Keppra	B-Brand
(	O
9	O
mg	O
twice	O
daily	O
)	O
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
valproate	B-Drug
in	O
healthy	O
volunteers	O
.	O
      
Furthermore	O
in	O
patients	O
receiving	O
both	O
drugs	O
careful	O
monitoring	O
of	O
the	O
INR	O
or	O
PT	O
and	O
adjustment	O
of	O
the	O
warfarin	B-Drug
dosage	O
if	O
indicated	O
are	O
recommended	O
when	O
the	O
oxandrolone	B-Drug
dose	O
is	O
changed	O
or	O
discontinued	O
.	O
      
MAO	B-Group
inhibitors	I-Group
prolong	O
and	O
intensify	O
the	O
anticholinergic	O
effects	O
of	O
antihistamines	B-Group
.	O
      
While	O
all	O
the	O
selective	B-Group
serotonin	I-Group
reuptake	I-Group
inhibitors	I-Group
(	O
SSRIs	B-Group
)	O
e.g.	O
fluoxetine	B-Drug
seriraline	O
and	O
paroxetine	B-Drug
inhibit	O
P9	O
9D9	O
they	O
may	O
vary	O
in	O
the	O
extent	O
of	O
inhibition	O
.	O
      
Integumentary	O
      
If	O
NovoLog	B-Brand
is	O
mixed	O
with	O
NPH	B-Drug
human	I-Drug
insulin	I-Drug
NovoLog	B-Brand
should	O
be	O
drawn	O
into	O
the	O
syringe	O
first	O
.	O
      
Cholestyramine	B-Drug
resin	B-Group
may	O
interfere	O
with	O
the	O
pharmacokinetics	O
of	O
drugs	O
that	O
undergo	O
enterohepatic	O
circulation	O
The	O
discontinuance	O
of	O
cholestyramine	B-Drug
resin	B-Group
could	O
pose	O
a	O
hazard	O
to	O
health	O
if	O
a	O
potentially	O
toxic	O
drug	O
such	O
as	O
digitalis	B-Group
has	O
been	O
filtrated	O
to	O
a	O
maintenance	O
level	O
while	O
the	O
patient	O
was	O
taking	O
cholestyramine	B-Drug
resin	B-Group
.	O
      
Ganciclovir	B-Drug
:	O
Administration	O
of	O
VIDEX	B-Brand
9	O
hours	O
prior	O
to	O
or	O
concurrent	O
with	O
oral	O
ganciclovir	B-Drug
was	O
associated	O
with	O
a	O
9	O
(	O
9	O
)	O
%	O
increase	O
in	O
the	O
steady	O
-	O
state	O
AUC	O
of	O
didanosine	B-Drug
(	O
n	O
=	O
9	O
)	O
.	O
      
Phenobarbital	B-Drug
or	O
Primidone	B-Drug
:	O
No	O
formal	O
pharmacokinetic	O
studies	O
have	O
been	O
performed	O
examining	O
the	O
addition	O
of	O
tiagabine	B-Drug
to	O
regimens	O
containing	O
phenobarbital	B-Drug
or	O
primidone	B-Drug
.	O
      
If	O
nifedipine	B-Drug
therapy	O
is	O
initiated	O
in	O
a	O
patient	O
currently	O
receiving	O
cimetidine	B-Drug
cautious	O
titration	O
is	O
advised	O
.	O
      
however	O
it	O
adversely	O
affected	O
response	O
duration	O
suggesting	O
that	O
pyridoxine	B-Drug
should	O
not	O
be	O
administered	O
with	O
HEXALEN	B-Brand
and	O
/	O
or	O
cisplatin	B-Drug
.9	O
      
Although	O
the	O
relevance	O
of	O
these	O
reports	O
and	O
any	O
mechanism	O
of	O
coagulation	O
alterations	O
is	O
unclear	O
patients	O
on	O
warfarin	B-Drug
should	O
have	O
their	O
prothrombin	O
time	O
monitored	O
.	O
      
Patients	O
on	O
lithium	B-Drug
treatment	O
should	O
be	O
closely	O
monitored	O
when	O
CELEBREX	B-Brand
is	O
introduced	O
or	O
withdrawn	O
.	O
      
The	O
following	O
specific	O
interactions	O
have	O
been	O
reported	O
:	O
Itraconazole	O
Co	O
-	O
administration	O
of	O
another	O
extended	O
release	O
formulation	O
of	O
felodipine	B-Drug
with	O
itraconazole	B-Drug
resulted	O
in	O
approximately	O
9	O
-	O
fold	O
increase	O
in	O
the	O
AUC	O
more	O
than	O
9	O
-	O
fold	O
increase	O
in	O
the	O
Cmax	O
and	O
9	O
-	O
fold	O
prolongation	O
in	O
the	O
half	O
-	O
life	O
of	O
felodipine	B-Drug
.	O
      
Because	O
busulfan	B-Drug
is	O
eliminated	O
from	O
the	O
body	O
via	O
conjugation	O
with	O
glutathione	O
use	O
of	O
acetaminophen	B-Drug
prior	O
to	O
(	O
9	O
hours	O
)	O
or	O
concurrent	O
with	O
BUSULFEX	B-Brand
may	O
result	O
in	O
reduced	O
busulfan	B-Drug
clearance	O
based	O
upon	O
the	O
known	O
property	O
of	O
acetaminophen	B-Drug
to	O
decrease	O
glutathione	O
levels	O
in	O
the	O
blood	O
and	O
tissues	O
.	O
      
Nifedipine	B-Drug
did	O
not	O
alter	O
the	O
plasma	O
levels	O
of	O
Vardenafil	B-Drug
when	O
taken	O
in	O
combination	O
.	O
      
Intensive	O
monitoring	O
of	O
renal	O
function	O
is	O
recommended	O
in	O
patients	O
requiring	O
any	O
combination	O
of	O
nephrotoxic	O
medications	O
.	O
      
However	O
serious	O
opportunistic	O
infections	O
have	O
not	O
been	O
observed	O
and	O
no	O
complications	O
have	O
specifically	O
been	O
attributed	O
to	O
lymphocytopenia	O
.	O
      
Dose	O
adjustments	O
should	O
be	O
considered	O
and	O
possible	O
prolongation	O
and	O
intensity	O
of	O
effect	O
should	O
be	O
anticipated	O
.	O
      
Aspirin	B-Brand
:	O
Concomitant	O
administration	O
of	O
low	O
-	O
dose	O
aspirin	B-Brand
with	O
VIOXX	B-Brand
may	O
result	O
in	O
an	O
increased	O
rate	O
of	O
GI	O
ulceration	O
or	O
other	O
complications	O
compared	O
to	O
use	O
of	O
VIOXX	B-Brand
alone	O
.	O
      
Human	O
pharmacologic	O
studies	O
have	O
shown	O
that	O
Ritalin	B-Brand
may	O
inhibit	O
the	O
metabolism	O
of	O
coumarin	B-Group
anticoagulants	I-Group
anticonvulsants	B-Group
(	O
phenobarbital	B-Drug
diphenylhydantoin	B-Drug
primidone	B-Drug
)	O
phenylbutazone	B-Drug
and	O
tricyclic	B-Group
drugs	I-Group
(	O
imipramine	B-Drug
clomipramine	B-Drug
desipramine	B-Drug
)	O
.	O
      
9	O
.	O
      
Glyburide	B-Drug
:	O
In	O
a	O
randomized	O
multiple	O
-	O
dose	O
crossover	O
study	O
patients	O
with	O
Type	O
9	O
diabetes	O
were	O
administered	O
9	O
mg	O
Starlix	B-Brand
three	O
times	O
a	O
day	O
before	O
meals	O
for	O
9	O
day	O
in	O
combination	O
with	O
glyburide	B-Drug
9	O
mg	O
daily	O
.	O
      
In	O
healthy	O
volunteers	O
treatment	O
with	O
finasteride	B-Drug
did	O
not	O
alter	O
the	O
response	O
of	O
LH	O
and	O
FSH	O
to	O
gonadotropin	O
-	O
releasing	O
hormone	O
indicating	O
that	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
testicular	O
axis	O
was	O
not	O
affected	O
.	O
      
Racemic	O
citalopram	B-Drug
did	O
not	O
alter	O
the	O
mean	O
AUC	O
or	O
Cmax	O
of	O
pimozide	B-Drug
.	O
      
Glyburide	B-Drug
:	O
The	O
concomitant	O
administration	O
of	O
ciprofloxacin	B-Drug
with	O
the	O
sulfonylurea	B-Group
glyburide	B-Drug
has	O
on	O
rare	O
occasions	O
resulted	O
in	O
severe	O
hypoglycemia	O
.	O
      
Further	O
misoprostol	B-Drug
is	O
reported	O
to	O
have	O
a	O
synergistic	O
effect	O
with	O
this	O
combination	O
in	O
ameliorating	O
intestinal	O
permeability	O
.	O
      
No	O
pharmacokinetic	O
-	O
based	O
drug	O
-	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
SYNAREL	B-Brand
.	O
      
Metabolism	O
of	O
dasatinib	B-Drug
is	O
mainly	O
hepatic	O
.	O
      
Methotrexate	B-Drug
:	O
A	O
study	O
in	O
9	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
patients	O
evaluated	O
the	O
effects	O
of	O
multiple	O
doses	O
of	O
meloxicam	B-Drug
on	O
the	O
pharmacokinetics	O
of	O
methotrexate	B-Drug
taken	O
once	O
weekly	O
.	O
      
9	O
%	O
      
These	O
include	O
probenecid	B-Drug
cholestyramine	B-Drug
and	O
some	O
antibiotics	B-Group
(	O
e.g	O
.	O
erythromycin	B-Drug
rifamipicin	O
ampicillin	B-Drug
and	O
chloramphenicol	B-Drug
)	O
.	O
      
This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
NSAIDs	B-Group
concomitantly	O
with	O
ACE	B-Group
inhibitors	I-Group
.	O
      
The	O
potential	O
effects	O
of	O
INDOCIN	B-Brand
and	O
potassium	B-Group
-	O
sparing	I-Group
diuretics	I-Group
on	O
potassium	O
kinetics	O
and	O
renal	O
function	O
should	O
be	O
considered	O
when	O
these	O
agents	O
are	O
administered	O
concurrently	O
.	O
      
This	O
drug	O
may	O
interact	O
with	O
alcohol	B-Drug
or	O
other	O
CNS	B-Group
depressants	I-Group
(	O
may	O
potentiate	O
the	O
CNS	O
depressant	O
effects	O
of	O
either	O
these	O
medications	O
or	O
antihistamines	B-Group
)	O
anticholinergics	B-Group
or	O
other	O
medications	O
with	O
anticholinergic	O
activity	O
(	O
anticholinergic	O
effects	O
may	O
be	O
potentiated	O
when	O
these	O
medications	O
are	O
used	O
concurrently	O
with	O
antihistamines	B-Group
)	O
and	O
monoamine	B-Group
oxidase	I-Group
MAO	I-Group
inhibitors	I-Group
(	O
concurrent	O
use	O
with	O
antihistamines	B-Group
may	O
prolong	O
and	O
intensify	O
the	O
anticholinergic	O
and	O
CNS	O
depressant	O
effects	O
of	O
antihistamines	B-Group
)	O
.	O
      
atazanavir	B-Drug
      
Renal	O
function	O
should	O
be	O
carefully	O
monitored	O
especially	O
if	O
higher	O
dosages	O
of	O
the	O
aminoglycosides	B-Group
are	O
to	O
be	O
administered	O
or	O
if	O
therapy	O
is	O
prolonged	O
because	O
of	O
the	O
potential	O
nephrotoxicity	O
and	O
ototoxicity	O
of	O
aminoglycosidic	B-Group
antibiotics	I-Group
.	O
      
Coadministration	O
of	O
propoxyphene	B-Drug
decreased	O
the	O
maximum	O
plasma	O
concentration	O
of	O
alprazolam	B-Drug
by	O
9	O
%	O
decreased	O
clearance	O
by	O
9	O
%	O
and	O
increased	O
half	O
-	O
life	O
by	O
9	O
%	O
.	O
      
.	O
      
The	O
prior	O
administration	O
of	O
succinylcholine	B-Drug
does	O
not	O
enhance	O
the	O
duration	O
but	O
quickens	O
the	O
onset	O
and	O
may	O
increase	O
the	O
depth	O
of	O
neuromuscular	O
block	O
induced	O
by	O
TRACRIUM	B-Brand
.	O
      
If	O
the	O
dose	O
of	O
lovastatin	B-Drug
is	O
changed	O
the	O
same	O
procedure	O
should	O
be	O
repeated	O
.	O
      
Drugs	O
possessing	O
beta	O
-	O
blocking	O
properties	O
can	O
blunt	O
the	O
bronchodilator	O
effect	O
of	O
beta	B-Group
-	O
receptor	I-Group
agonist	I-Group
drugs	I-Group
in	O
patients	O
with	O
bronchospasm	O
;	O
      
VIRACEPT	B-Brand
and	O
rifampin	B-Drug
should	O
not	O
be	O
coadministered	O
.	O
      
Therefore	O
concomitant	O
use	O
of	O
TORADOL	B-Brand
and	O
probenecid	B-Drug
is	O
contraindicated	O
.	O
      
Since	O
apraclonidine	B-Drug
may	O
reduce	O
pulse	O
and	O
blood	O
pressure	O
caution	O
in	O
using	O
drugs	O
such	O
as	O
beta	B-Group
-	O
blockers	I-Group
(	O
ophthalmic	O
and	O
systemic	O
)	O
antihypertensives	B-Group
and	O
cardiac	B-Group
glycosides	I-Group
is	O
advised	O
.	O
      
Labetalol	B-Drug
HCl	I-Drug
blunts	O
the	O
reflex	O
tachycardia	O
produced	O
by	O
nitroglycerin	B-Drug
without	O
preventing	O
its	O
hypotensive	O
effect	O
.	O
      
Analgesic	B-Group
/	O
anti	B-Group
-	O
inflammatory	I-Group
(	O
e.g.	O
acetaminophen	B-Drug
aspirin	B-Brand
codeine	B-Drug
and	O
codeine	B-Drug
combinations	O
ibuprofen	B-Drug
indomethacin	B-Drug
)	O
.	O
      
No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
      
Diclofenac	B-Drug
is	O
a	O
prostaglandin	O
synthetase	O
inhibitor	O
however	O
and	O
all	O
drugs	O
that	O
inhibit	O
prostaglandin	O
synthesis	O
interfere	O
with	O
platelet	O
function	O
to	O
some	O
degree	O
;	O
      
Phenytoin	B-Drug
may	O
also	O
cause	O
increased	O
serum	O
concentrations	O
of	O
glucose	O
alkaline	O
phosphatase	O
and	O
gamma	O
glutamyl	O
transpeptidase	O
(	O
GGT	O
)	O
.	O
      
Cimetidine	B-Drug
:	O
Co	O
-	O
administration	O
with	O
high	O
doses	O
of	O
cimetidine	B-Drug
[	O
9	O
mg	O
twice	O
daily	O
]	O
increased	O
the	O
Cmax	O
of	O
rofecoxib	B-Drug
by	O
9	O
%	O
the	O
AUC9	O
-	O
9hr	O
by	O
9	O
%	O
and	O
the	O
t9	O
/	O
9	O
by	O
9	O
%	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
:	O
The	O
presence	O
of	O
sulfasalazine	B-Drug
or	O
its	O
metabolites	O
in	O
body	O
fluids	O
has	O
not	O
been	O
reported	O
to	O
interfere	O
with	O
laboratory	O
test	O
procedures	O
.	O
      
no	O
evidence	O
of	O
mutagenicity	O
was	O
observed	O
.	O
      
Concomitant	O
administration	O
of	O
clarithromycin	B-Drug
with	O
pimozide	B-Drug
is	O
contraindicated	O
.	O
      
Co	O
-	O
administration	O
of	O
aliskiren	B-Drug
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
lovastatin	B-Drug
digoxin	B-Drug
valsartan	B-Drug
amlodipine	B-Drug
metformin	B-Drug
celecoxib	B-Drug
atenolol	B-Drug
atorvastatin	B-Drug
ramipril	B-Drug
or	O
hydrochlorothiazide	B-Drug
.	O
      
convulsions	O
have	O
been	O
reported	O
with	O
concurrent	O
use	O
of	O
methylprednisolone	B-Drug
and	O
cyclosporin	B-Drug
.	O
      
Co	O
-	O
administration	O
of	O
warfarin	B-Drug
and	O
cerivastatin	B-Drug
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
cerivastatin	B-Drug
sodium	I-Drug
.	O
      
Barbiturates	B-Group
may	O
decrease	O
the	O
effectiveness	O
of	O
oral	O
contraceptives	B-Group
certain	O
antibiotics	B-Group
quinidine	B-Group
theophylline	B-Drug
corticosteroids	B-Group
anticoagulants	B-Group
and	O
beta	B-Group
blockers	I-Group
.	O
      
Drug	O
interaction	O
studies	O
of	O
mefenamic	B-Drug
acid	I-Drug
and	O
these	O
compounds	O
have	O
not	O
been	O
conducted	O
.	O
      
Nicardipine	B-Drug
HCl	I-Drug
usually	O
does	O
not	O
alter	O
the	O
plasma	O
levels	O
of	O
digoxin	B-Drug
however	O
serum	O
digoxin	B-Drug
levels	O
should	O
be	O
evaluated	O
after	O
concomitant	O
therapy	O
with	O
nicardipine	B-Drug
HCl	I-Drug
is	O
initiated	O
.	O
      
The	O
extent	O
to	O
which	O
SSRI	B-Group
-	O
TCA	B-Group
interactions	O
may	O
pose	O
clinical	O
problems	O
will	O
depend	O
on	O
the	O
degree	O
of	O
inhibition	O
and	O
the	O
pharmacokinetics	O
of	O
the	O
SSRI	B-Group
involved	O
.	O
      
Colestipol	B-Drug
:	O
Plasma	O
concentrations	O
of	O
atorvastatin	B-Drug
decreased	O
approximately	O
9	O
%	O
when	O
colestipol	B-Drug
and	O
atorvastatin	B-Drug
were	O
coadministered	O
.	O
      
Following	O
a	O
9	O
g	O
bolus	O
of	O
AMICAR	B-Brand
transient	O
peak	O
plasma	O
concentrations	O
of	O
9	O
mMol	O
/	O
L	O
or	O
9	O
mg	O
/	O
mL	O
have	O
been	O
obtained	O
.	O
      
Simultaneous	O
administration	O
of	O
SPRYCEL	B-Brand
with	O
antacids	B-Group
should	O
be	O
avoided	O
.	O
      
ketoconazole	B-Drug
)	O
macrolide	B-Group
antibiotics	I-Group
(	O
e.g	O
.	O
erythromycin	B-Drug
)	O
and	O
HIV	B-Group
protease	I-Group
inhibitors	I-Group
(	O
e.g	O
.	O
ritonavir	B-Drug
indinavir	B-Drug
and	O
saquinavir	B-Drug
)	O
should	O
have	O
their	O
dose	O
of	O
SUBUTEX	B-Brand
or	O
SUBOXONE	B-Brand
adjusted	O
.	O
      
Therefore	O
interactions	O
could	O
occur	O
following	O
concomitant	O
administration	O
of	O
psychotropic	B-Group
drugs	I-Group
(	O
e.g.	O
narcotics	B-Group
analgesics	B-Group
antiemetics	B-Group
sedatives	B-Group
tranquilizers	B-Group
)	O
.	O
      
Oral	O
Contraceptives	B-Group
      
Co	O
-	O
administration	O
:	O
Concomitant	O
use	O
of	O
Argatroban	B-Drug
with	O
antiplatelet	B-Group
agents	I-Group
thrombolytics	B-Group
and	O
other	O
anticoagulants	B-Group
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
.	O
      
In	O
clinical	O
trials	O
antacids	B-Group
were	O
administered	O
concomitantly	O
with	O
lansoprazole	B-Drug
delayed	O
-	O
release	O
capsules	O
;	O
      
Mylotarg	B-Brand
is	O
not	O
known	O
to	O
interfere	O
with	O
any	O
routine	O
diagnostic	O
tests	O
.	O
      
Such	O
patients	O
may	O
be	O
unresponsive	O
to	O
the	O
usual	O
doses	O
of	O
epinephrine	B-Drug
used	O
to	O
treat	O
allergic	O
reaction	O
.	O
      
Coadministration	O
of	O
VIRACEPT	B-Brand
and	O
drugs	O
that	O
induce	O
CYP9A	O
may	O
decrease	O
nelfinavir	B-Drug
plasma	O
concentrations	O
and	O
reduce	O
its	O
therapeutic	O
effect	O
.	O
      
Ketoconazole	B-Drug
:	O
Coadministration	O
of	O
ketoconazole	B-Drug
(	O
9	O
mg	O
/	O
day	O
for	O
9	O
days	O
)	O
with	O
a	O
9	O
-	O
mg	O
single	O
dose	O
of	O
aripiprazole	B-Drug
increased	O
the	O
AUC	O
of	O
aripiprazole	B-Drug
and	O
its	O
active	O
metabolite	O
by	O
9	O
%	O
and	O
9	O
%	O
respectively	O
.	O
      
The	O
gonadotropin	O
levels	O
may	O
be	O
transiently	O
elevated	O
by	O
spironolactone	B-Drug
minimally	O
elevated	O
by	O
levodopa	B-Drug
and	O
suppressed	O
by	O
oral	O
contraceptives	B-Group
and	O
digoxin	B-Drug
.	O
      
Warfarin	B-Drug
:	O
A	O
multidose	O
study	O
of	O
oxandrolone	B-Drug
given	O
as	O
9	O
or	O
9	O
mg	O
BID	O
in	O
9	O
healthy	O
subjects	O
concurrently	O
treated	O
with	O
warfarin	B-Drug
resulted	O
in	O
a	O
mean	O
increase	O
in	O
S	B-Drug
-	O
warfarin	I-Drug
half	O
-	O
life	O
from	O
9	O
to	O
9	O
hours	O
and	O
AUC	O
from	O
9	O
to	O
9	O
ng*hr	O
/	O
mL	O
:	O
similar	O
increases	O
in	O
R	B-Drug
-	O
warfarin	I-Drug
half	O
-	O
life	O
and	O
AUC	O
were	O
also	O
detected	O
.	O
      
Elevated	O
serum	O
levels	O
of	O
cyclosporine	B-Drug
have	O
been	O
reported	O
with	O
concomitant	O
use	O
of	O
cyclosporine	B-Drug
with	O
norfloxacin	B-Drug
.	O
      
Patients	O
taking	O
warfarin	B-Drug
or	O
other	O
coumarin	B-Group
-	O
derivative	I-Group
anticoagulants	I-Group
should	O
be	O
monitored	O
regularly	O
for	O
changes	O
in	O
prothrombin	O
time	O
or	O
INR	O
      
The	O
interaction	O
was	O
pharmacodynamic	O
with	O
no	O
alteration	O
of	O
the	O
pharmacokinetics	O
of	O
either	O
drug	O
.	O
      
Nursing	O
Mothers	O
Fulvestrant	B-Drug
is	O
found	O
in	O
rat	O
milk	O
at	O
levels	O
significantly	O
higher	O
(	O
approximately	O
9	O
-	O
fold	O
)	O
than	O
plasma	O
after	O
administration	O
of	O
9	O
mg	O
/	O
kg	O
.	O
      
Preliminary	O
investigations	O
indicate	O
that	O
icodextrin	B-Drug
and	O
its	O
metabolites	O
interfere	O
with	O
enzymatic	O
-	O
based	O
amylase	O
assays	O
resulting	O
in	O
inaccurately	O
low	O
values	O
.	O
      
Therefore	O
CYP9A9	O
substrates	O
known	O
to	O
have	O
a	O
narrow	O
therapeutic	O
index	O
such	O
as	O
alfentanil	B-Drug
astemizole	B-Drug
terfenadine	B-Drug
cisapride	B-Drug
cyclosporine	B-Drug
fentanyl	B-Drug
pimozide	B-Drug
quinidine	B-Drug
sirolimus	B-Drug
tacrolimus	B-Drug
or	O
ergot	B-Group
alkaloids	I-Group
(	O
ergotamine	B-Drug
dihydroergotamine	B-Drug
)	O
should	O
be	O
administered	O
with	O
caution	O
in	O
patients	O
receiving	O
SPRYCEL	B-Brand
.	O
      
Pharmacokinetic	O
interactions	O
between	O
nisoldipine	B-Drug
and	O
beta	B-Group
-	O
blockers	I-Group
(	O
atenolol	B-Drug
propranolol	B-Drug
)	O
were	O
variable	O
and	O
not	O
significant	O
.	O
      
Consideration	O
should	O
be	O
taken	O
in	O
patients	O
being	O
treated	O
with	O
antidiabetic	B-Drug
agents	O
.	O
      
Although	O
there	O
was	O
a	O
slight	O
reduction	O
in	O
blood	O
sugar	O
concentrations	O
during	O
concomitant	O
administration	O
of	O
flurbiprofen	B-Drug
and	O
hypoglycemic	B-Group
agents	I-Group
there	O
were	O
no	O
signs	O
or	O
symptoms	O
of	O
hypoglycemia	O
.	O
      
Methotrexate	B-Drug
:	O
Valdecoxib	B-Drug
9	I-Drug
mg	I-Drug
BID	O
did	O
not	O
show	O
a	O
significant	O
effect	O
on	O
the	O
plasma	O
exposure	O
or	O
renal	O
clearance	O
of	O
methotrexate	B-Drug
.	O
      
Other	O
Potentially	O
Clinically	O
Significant	O
Drug	O
or	O
Herbal	O
Product	O
Interactions	O
With	O
SUSTIVAb	O
      
Particular	O
caution	O
should	O
be	O
exercised	O
in	O
using	O
preparations	O
containing	O
sulfur	B-Drug
resorcinol	B-Drug
or	O
salicylic	B-Drug
acid	I-Drug
in	O
combination	O
with	O
DIFFERIN	B-Brand
Gel	O
.	O
      
Digitalis	B-Group
glycosides	I-Group
:	O
Serum	O
digitalis	O
levels	O
may	O
be	O
increased	O
when	O
hyperthyroid	O
patients	O
on	O
a	O
stable	O
digitalis	B-Group
glycoside	I-Group
regimen	O
become	O
euthyroid	O
;	O
      
In	O
a	O
multiple	O
dose	O
study	O
of	O
theophylline	B-Drug
(	O
9	O
mg	O
once	O
daily	O
for	O
9	O
days	O
)	O
and	O
cetirizine	B-Drug
(	O
9	O
mg	O
once	O
daily	O
for	O
9	O
days	O
)	O
a	O
9	O
%	O
decrease	O
in	O
the	O
clearance	O
of	O
cetirizine	B-Drug
was	O
observed	O
.	O
      
Interaction	O
with	O
Guanethidine	B-Drug
:	O
Although	O
minoxidil	B-Drug
does	O
not	O
itself	O
cause	O
orthostatic	O
hypotension	O
its	O
administration	O
to	O
patients	O
already	O
receiving	O
guanethidine	B-Drug
can	O
result	O
in	O
profound	O
orthostatic	O
effects	O
.	O
      
Based	O
on	O
in	O
vitro	O
data	O
no	O
interaction	O
would	O
be	O
expected	O
with	O
drugs	O
whose	O
metabolism	O
is	O
dependent	O
upon	O
cytochrome	O
P9	O
isozymes	O
9A9	O
9A9	O
9A9	O
9B9	O
9D9	O
9E9	O
or	O
9A9	O
.	O
      
Should	O
not	O
be	O
used	O
as	O
sole	O
protease	B-Group
inhibitor	I-Group
in	O
combination	O
with	O
SUSTIVA	B-Brand
.	O
      
Known	O
drug	O
interactions	O
include	O
barbiturates	B-Group
tranquilizers	B-Group
and	O
alcohol	B-Drug
.	O
      
Therefore	O
monitoring	O
of	O
theophylline	B-Drug
plasma	O
levels	O
should	O
be	O
considered	O
and	O
dosage	O
of	O
theophylline	B-Drug
adjusted	O
as	O
required	O
.	O
      
No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
.	O
      
In	O
addition	O
to	O
the	O
interactions	O
noted	O
above	O
chronic	O
(	O
9	O
weeks	O
)	O
oral	O
Cordarone	B-Drug
administration	O
impairs	O
metabolism	O
of	O
phenytoin	B-Drug
dextromethorphan	B-Drug
and	O
methotrexate	B-Drug
.	O
      
The	O
possibility	O
of	O
hypotensive	O
effects	O
with	O
captopril	B-Drug
can	O
be	O
minimized	O
by	O
either	O
discontinuing	O
the	O
diuretic	B-Group
or	O
increasing	O
the	O
salt	O
intake	O
approximately	O
one	O
week	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
captopril	B-Drug
(	O
captopril	B-Drug
tablets	O
USP	O
)	O
or	O
initiating	O
therapy	O
with	O
small	O
doses	O
(	O
9	O
or	O
9	O
mg	O
)	O
.	O
      
Astemizole	B-Drug
:	O
The	O
use	O
of	O
fluconazole	B-Drug
in	O
patients	O
concurrently	O
taking	O
astemizole	B-Drug
or	O
other	O
drugs	O
metabolized	O
by	O
the	O
cytochrome	O
P9	O
system	O
may	O
be	O
associated	O
with	O
elevations	O
in	O
serum	O
levels	O
of	O
these	O
drugs	O
.	O
      
Thus	O
smaller	O
doses	O
of	O
adenosine	B-Drug
may	O
be	O
effective	O
in	O
the	O
presence	O
of	O
dipyridamole	B-Drug
.	O
      
Anticoagulants	B-Group
(	O
oral	O
)	O
:	O
The	O
activity	O
of	O
oral	O
anticoagulants	B-Group
may	O
be	O
potentiated	O
by	O
anti	O
-	O
vitamin	O
-	O
K	O
activity	O
attributed	O
to	O
methimazole	B-Drug
.	O
      
Atorvastatin	B-Drug
:	O
Atorvastatin	B-Drug
increases	O
the	O
AUC	O
for	O
norethindrone	B-Drug
and	O
ethinyl	B-Drug
estradiol	I-Drug
.	O
      
No	O
rashes	O
were	O
reported	O
in	O
these	O
patients	O
.	O
      
Antihistamines	B-Group
:	O
Benzodiazepines	B-Group
GI	O
Motility	O
Agents	O
Anti	B-Group
-	O
Migraine	I-Group
Antifungal	B-Group
      
Cimetidine	B-Drug
at	O
9	O
mg	O
BID	O
(	O
the	O
usual	O
prescription	O
dose	O
)	O
co	O
-	O
administered	O
with	O
TIKOSYN	B-Brand
(	O
9	O
mcg	O
BID	O
)	O
for	O
9	O
days	O
has	O
been	O
shown	O
to	O
increase	O
dofetilide	B-Drug
plasma	O
levels	O
by	O
9	O
%	O
.	O
      
For	O
patients	O
with	O
amenorrhea	O
the	O
second	O
test	O
should	O
be	O
done	O
at	O
least	O
9	O
days	O
after	O
the	O
last	O
act	O
of	O
unprotected	O
sexual	O
intercourse	O
(	O
without	O
using	O
9	O
effective	O
forms	O
of	O
contraception	O
)	O
.	O
      
Cisapride	B-Drug
      
.	O
      
and	O
/	O
or	O
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
See	O
CLINICAL	O
PHARMACOLOGY	O
Pharmacokinetics	O
and	O
Drug	O
Interactions	O
.	O
      
Pregnancies	O
have	O
been	O
reported	O
by	O
users	O
of	O
combined	B-Group
hormonal	I-Group
contraceptives	I-Group
who	O
also	O
used	O
some	O
form	O
of	O
St.	O
Johns	O
Wort	O
.	O
      
Therefore	O
COLESTlD	B-Brand
Tablets	O
may	O
delay	O
or	O
reduce	O
the	O
absorption	O
of	O
concomitant	O
oral	O
medication	O
.	O
      
Retrospective	O
analysis	O
of	O
side	O
effects	O
in	O
clinical	O
trials	O
showed	O
that	O
poor	O
9D9	O
metabolizers	O
had	O
a	O
higher	O
rate	O
of	O
dizziness	O
during	O
up	O
-	O
titration	O
presumably	O
resulting	O
from	O
vasodilating	O
effects	O
of	O
the	O
higher	O
concentrations	O
of	O
the	O
a	O
-	O
blocking	O
R	O
(	O
+	O
)	O
enantiomer	O
.	O
      
Oral	O
Contraceptives	B-Group
:	O
The	O
effect	O
of	O
oral	O
contraceptives	B-Group
on	O
the	O
pharmacokinetics	O
of	O
D.H.E	B-Brand
9	I-Brand
(	O
dihydroergotamine	B-Drug
mesylate	I-Drug
)	O
Injection	O
USP	O
has	O
not	O
been	O
studied	O
.	O
      
Pressor	O
agents	O
-	O
Because	O
of	O
possible	O
effects	O
on	O
blood	O
pressure	O
STRATTERA	B-Brand
should	O
be	O
used	O
cautiously	O
with	O
pressor	O
agents	O
.	O
      
To	O
avoid	O
phenytoin	B-Drug
intoxication	O
appropriate	O
adjustment	O
of	O
the	O
anticonvulsant	B-Group
should	O
be	O
made	O
.	O
      
Additionally	O
aripiprazole	B-Drug
and	O
dehydroaripiprazole	B-Drug_n
did	O
not	O
show	O
potential	O
for	O
altering	O
CYP9A9	O
-	O
mediated	O
metabolism	O
in	O
vitro	O
.	O
      
DOXIL	B-Brand
may	O
interact	O
with	O
drugs	O
known	O
to	O
interact	O
with	O
the	O
conventional	O
formulation	O
of	O
doxorubicin	B-Drug
HCl	I-Drug
.	O
      
certain	O
protease	B-Group
inhibitors	I-Group
e.g.	O
ritanovir	O
;	O
      
Phenytoin	B-Drug
:	O
In	O
post	O
-	O
marketing	O
experience	O
there	O
have	O
been	O
reports	O
of	O
both	O
increases	O
and	O
decreases	O
in	O
phenytoin	B-Drug
levels	O
with	O
dexamethasone	B-Drug
co	O
-	O
administration	O
leading	O
to	O
alterations	O
in	O
seizure	O
control	O
.	O
      
Oral	O
Contraceptives	B-Group
:	O
In	O
9	O
healthy	O
women	O
the	O
pharmacokinetic	O
profiles	O
of	O
norethindrone	B-Drug
and	O
ethinyl	B-Drug
estradiol	I-Drug
following	O
administration	O
of	O
a	O
single	O
dose	O
containing	O
9	O
mg	O
of	O
norethindrone	B-Drug
acetate	I-Drug
and	O
9	O
g	O
of	O
ethinyl	B-Drug
estradiol	I-Drug
were	O
studied	O
.	O
      
As	O
plasma	O
protein	O
binding	O
of	O
decitabine	B-Drug
is	O
negligible	O
(	O
9	O
%	O
)	O
interactions	O
due	O
to	O
displacement	O
of	O
more	O
highly	O
protein	O
bound	O
drugs	O
from	O
plasma	O
proteins	O
are	O
not	O
expected	O
.	O
      
Thus	O
when	O
VIOXX	B-Brand
and	O
lithium	B-Drug
are	O
administered	O
concurrently	O
subjects	O
should	O
be	O
observed	O
carefully	O
for	O
signs	O
of	O
lithium	B-Drug
toxicity	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
As	O
with	O
other	O
penicillins	B-Drug
the	O
administration	O
of	O
PIPRACIL	B-Brand
may	O
result	O
in	O
a	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
using	O
a	O
copper	O
-	O
reduction	O
method	O
.	O
      
In	O
these	O
trials	O
heart	O
rate	O
and	O
systolic	O
blood	O
pressure	O
were	O
approximately	O
9	O
-	O
9	O
bpm	O
and	O
9	O
-	O
9	O
mm	O
Hg	O
higher	O
respectively	O
in	O
subjects	O
on	O
concomitant	O
theophylline	B-Drug
compared	O
with	O
the	O
overall	O
population	O
.	O
      
The	O
concomitant	O
use	O
of	O
heparin	B-Drug
or	O
aspirin	B-Brand
during	O
the	O
first	O
9	O
hours	O
following	O
symptom	O
onset	O
were	O
prohibited	O
in	O
The	O
NINDS	O
t	O
-	O
PA	O
Stroke	O
Trial	O
.	O
      
Drug	O
Interaction	O
During	O
Pregnancy	O
:	O
Cromolyn	B-Drug
sodium	I-Drug
and	O
isoproterenol	B-Drug
were	O
studied	O
following	O
subcutaneous	O
injections	O
in	O
pregnant	O
mice	O
.	O
      
These	O
effects	O
are	O
clinically	O
insignificant	O
.	O
      
Drug	O
/	O
Laboratory	O
Tests	O
Interaction	O
:	O
Succimer	B-Drug
may	O
interfere	O
with	O
serum	O
and	O
urinary	O
laboratory	O
tests	O
.	O
      
Review	O
of	O
these	O
case	O
reports	O
indicates	O
that	O
the	O
patients	O
were	O
mainly	O
receiving	O
thiazide	B-Group
diuretics	I-Group
for	O
hypertension	O
and	O
that	O
tests	O
to	O
rule	O
out	O
decreased	O
renal	O
function	O
secondary	O
to	O
hypertensive	O
nephropathy	O
were	O
not	O
often	O
performed	O
.	O
      
weaker	O
inhibitors	O
(	O
erythromycin	B-Drug
grapefruit	O
juice	O
)	O
have	O
not	O
been	O
studied	O
.	O
      
Therefore	O
coagulation	O
indices	O
should	O
be	O
monitored	O
to	O
maintain	O
the	O
desired	O
anticoagulant	O
effect	O
.	O
      
In	O
Europe	O
Nimotop	B-Brand
was	O
observed	O
to	O
occasionally	O
intensify	O
the	O
effect	O
of	O
antihypertensive	B-Group
compounds	I-Group
taken	O
concomitantly	O
by	O
patients	O
suffering	O
from	O
hypertension	O
;	O
      
Rifampin	B-Drug
:	O
Coadministration	O
of	O
rifampin	B-Drug
and	O
MEPRON	B-Brand
Suspension	O
results	O
in	O
a	O
significant	O
decrease	O
in	O
average	O
steady	O
-	O
state	O
plasma	O
atovaquone	B-Drug
concentrations	O
.	O
      
Increases	O
of	O
9	B-Drug
-	O
FU	I-Drug
plasma	O
concentrations	O
by	O
approximately	O
9	O
%	O
have	O
been	O
observed	O
with	O
doses	O
of	O
9	O
mg	O
/	O
m9	O
ELOXATIN	B-Brand
dosed	O
every	O
9	O
weeks	O
.	O
      
-	O
Non	B-Group
-	O
steroidal	I-Group
Anti	I-Group
-	O
inflammatory	I-Group
Drugs	I-Group
:	O
In	O
some	O
patients	O
the	O
administration	O
of	O
a	O
non	B-Group
-	O
steroidal	I-Group
anti	I-Group
-	O
inflammatory	I-Group
agent	I-Group
can	O
reduce	O
the	O
diuretic	O
natriuretic	O
and	O
antihypertensive	O
effects	O
of	O
loop	B-Group
potassium	B-Group
-	O
sparing	I-Group
and	O
thiazide	B-Drug
diuretics	I-Drug
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Cephalosporins	B-Group
including	O
cefotaxime	B-Drug
sodium	I-Drug
are	O
known	O
to	O
occasionally	O
induce	O
a	O
positive	O
direct	O
Coombs	O
test	O
.	O
      
Aspirin	B-Brand
:	O
Concomitant	O
aspirin	B-Brand
may	O
decrease	O
the	O
metabolic	O
clearance	O
of	O
nicotinic	B-Drug
acid	I-Drug
.	O
      
Administration	O
of	O
thiazide	B-Group
diuretics	I-Group
to	O
hypoparathyroid	O
patients	O
who	O
are	O
concurrently	O
being	O
treated	O
with	O
ergocalciferol	B-Drug
may	O
cause	O
hypercalcemia	O
.	O
      
It	O
is	O
recommended	O
that	O
these	O
tests	O
be	O
performed	O
weekly	O
or	O
every	O
other	O
week	O
until	O
the	O
lipid	O
response	O
to	O
Soriatane	B-Brand
has	O
stabilized	O
.	O
      
Aprepitant	B-Drug
when	O
given	O
as	O
a	O
regimen	O
of	O
9	O
mg	O
on	O
Day	O
9	O
and	O
9	O
mg	O
/	O
day	O
on	O
Days	O
9	O
and	O
9	O
increased	O
the	O
AUC	O
of	O
methylprednisolone	B-Drug
a	O
CYP9A9	O
substrate	O
by	O
9	O
-	O
fold	O
on	O
Day	O
9	O
and	O
by	O
9	O
-	O
fold	O
on	O
Day	O
9	O
when	O
methylprednisolone	B-Drug
was	O
coadministered	O
intravenously	O
as	O
9	O
mg	O
on	O
Day	O
9	O
and	O
orally	O
as	O
9	O
mg	O
on	O
Days	O
9	O
and	O
9	O
.	O
      
Latent	O
diabetes	O
mellitus	O
may	O
become	O
manifest	O
during	O
chlorthalidone	B-Drug
administration	O
.	O
      
These	O
lists	O
are	O
not	O
exhaustive	O
and	O
the	O
prescriber	O
should	O
consider	O
the	O
effects	O
on	O
CYP	O
9A9	O
of	O
other	O
agents	O
being	O
considered	O
for	O
concomitant	O
use	O
with	O
methylergonovine	B-Drug
.	O
      
Nelfinavir	B-Drug
      
When	O
these	O
products	O
are	O
administered	O
concomitantly	O
prothrombin	O
time	O
or	O
other	O
suitable	O
coagulation	O
tests	O
should	O
be	O
monitored	O
.	O
      
Because	O
of	O
the	O
variability	O
of	O
individual	O
patient	O
response	O
multiple	O
interacting	O
mechanisms	O
with	O
some	O
drugs	O
the	O
dependency	O
of	O
the	O
extent	O
of	O
the	O
interaction	O
on	O
the	O
dosage	O
and	O
duration	O
of	O
therapy	O
and	O
the	O
possible	O
administration	O
of	O
several	O
interacting	O
drugs	O
simultaneously	O
it	O
is	O
difficult	O
to	O
predict	O
the	O
direction	O
and	O
degree	O
of	O
the	O
ultimate	O
effect	O
of	O
concomitant	O
medications	O
on	O
anticoagulant	B-Group
response	O
.	O
      
Established	O
and	O
Other	O
Potentially	O
Significant	O
Drug	O
Interactions	O
:	O
Alteration	O
in	O
Dose	O
or	O
Regimen	O
May	O
Be	O
Recommended	O
Based	O
on	O
Drug	O
Interaction	O
Studies	O
or	O
Predicted	O
Interaction	O
      
Azithromycin	B-Drug
      
A	O
dose	O
increase	O
of	O
lopinavir	B-Drug
/	O
ritonavir	B-Drug
to	O
9	O
/	O
9	O
mg	O
(	O
9	O
capsules	O
or	O
9	O
mL	O
)	O
twice	O
daily	O
taken	O
with	O
food	O
is	O
recommended	O
when	O
used	O
in	O
combination	O
with	O
SUSTIVA	B-Brand
.	O
      
In	O
addition	O
Fondaparinux	B-Drug
neither	O
influenced	O
the	O
pharmacodynamics	O
of	O
warfarin	B-Drug
acetylsalicylic	B-Drug
acid	I-Drug
piroxicam	B-Drug
and	O
digoxin	B-Drug
nor	O
the	O
pharmacokinetics	O
of	O
digoxin	B-Drug
at	O
steady	O
state	O
.	O
      
Additive	O
sedative	O
effects	O
can	O
occur	O
when	O
metoclopramide	B-Drug
is	O
given	O
with	O
alcohol	B-Drug
sedatives	B-Group
hypnotics	B-Group
narcotics	B-Group
or	O
tranquilizers	B-Group
.	O
      
The	O
physician	O
should	O
be	O
alert	O
for	O
possible	O
combined	O
drug	O
actions	O
desirable	O
or	O
undesirable	O
involving	O
cyclophosphamide	B-Drug
even	O
though	O
cyclophosphamide	B-Drug
has	O
been	O
used	O
successfully	O
concurrently	O
with	O
other	O
drugs	O
including	O
other	O
cytotoxic	O
drugs	O
.	O
      
ii	O
.	O
      
This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
BEXTRA	B-Brand
concomitantly	O
with	O
ACE	B-Group
-	O
inhibitors	I-Group
.	O
      
These	O
stimulants	O
are	O
commonly	O
found	O
in	O
coffee	O
and	O
tea	O
respectively	O
.	O
      
There	O
does	O
not	O
appear	O
to	O
be	O
an	O
increase	O
in	O
adverse	O
events	O
in	O
subjects	O
who	O
received	O
oral	O
contraceptives	B-Group
and	O
loratadine	B-Drug
.	O
      
Oral	O
Hypoglycemics	B-Group
:	O
Bepridil	B-Drug
has	O
been	O
safely	O
used	O
in	O
diabetic	O
patients	O
without	O
significantly	O
lowering	O
their	O
blood	O
glucose	O
levels	O
or	O
altering	O
their	O
need	O
for	O
insulin	B-Drug
or	O
oral	O
hypoglycemic	B-Group
agents	I-Group
.	O
      
Because	O
both	O
of	O
these	O
drugs	O
have	O
negative	O
inotropic	O
properties	O
and	O
the	O
effects	O
of	O
coadministration	O
with	O
TAMBOCOR	B-Brand
are	O
unknown	O
neither	O
disopyramide	B-Drug
nor	O
verapamil	B-Drug
should	O
be	O
administered	O
concurrently	O
with	O
TAMBOCOR	B-Brand
unless	O
in	O
the	O
judgment	O
of	O
the	O
physician	O
the	O
benefits	O
of	O
this	O
combination	O
outweigh	O
the	O
risks	O
.	O
      
Carcinogenesis	O
Mutagenesis	O
and	O
Impairment	O
of	O
Fertility	O
A	O
two	O
-	O
year	O
carcinogenesis	O
study	O
was	O
conducted	O
in	O
female	O
and	O
male	O
rats	O
at	O
intramuscular	O
doses	O
of	O
9	O
mg	O
/	O
kg	O
/	O
9	O
days	O
9	O
mg	O
/	O
rat	O
/	O
9	O
days	O
and	O
9	O
mg	O
/	O
rat	O
/	O
9	O
days	O
.	O
      
There	O
are	O
no	O
clinical	O
data	O
on	O
concomitant	O
use	O
of	O
NUROMAX	B-Brand
and	O
other	O
nondepolarizing	O
neuromuscular	B-Group
blocking	I-Group
agents	I-Group
.	O
      
However	O
if	O
Argatroban	B-Drug
is	O
to	O
be	O
initiated	O
after	O
cessation	O
of	O
heparin	B-Drug
therapy	O
allow	O
sufficient	O
time	O
for	O
heparins	O
effect	O
on	O
the	O
aPTT	O
to	O
decrease	O
prior	O
to	O
initiation	O
of	O
Argatroban	B-Drug
therapy	O
.	O
      
Lithium	B-Drug
:	O
Increased	O
serum	O
lithium	B-Drug
levels	O
and	O
symptoms	O
of	O
lithium	B-Drug
toxicity	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
ACE	B-Group
inhibitors	I-Group
during	O
therapy	O
with	O
lithium	B-Drug
.	O
      
Drug	O
-	O
Drug	O
Interactions	O
Effect	O
of	O
Exelon	B-Brand
(	O
rivastigmine	B-Drug
tartrate	I-Drug
)	O
on	O
the	O
Metabolism	O
of	O
Other	O
Drugs	O
:	O
Rivastigmine	B-Drug
is	O
primarily	O
metabolized	O
through	O
hydrolysis	O
by	O
esterases	O
.	O
      
(	O
Read	O
circulars	O
for	O
lithium	B-Drug
preparations	O
before	O
use	O
of	O
such	O
concomitant	O
therapy	O
.	O
)	O
      
REFERENCES	O
9.Farr	O
M	O
et	O
al	O
.	O
      
Immunodeficiency	O
-	O
associated	O
lymphocyte	O
disorders	O
(	O
plasmacytic	O
hyperplasia	O
polymorphic	O
proliferation	O
and	O
B	O
-	O
cell	O
lymphomas	O
)	O
occur	O
in	O
patients	O
who	O
have	O
congenital	O
or	O
acquired	O
immunodeficiencies	O
including	O
those	O
resulting	O
from	O
immunosuppressive	B-Group
therapy	O
.	O
      
Eprosartan	B-Drug
doses	O
of	O
up	O
to	O
9	O
mg	O
b.i.d	O
.	O
have	O
been	O
safely	O
used	O
concomitantly	O
with	O
sustained	O
-	O
release	O
calcium	B-Group
channel	I-Group
blockers	I-Group
(	O
sustained	O
-	O
release	O
nifedipine	B-Drug
)	O
with	O
no	O
clinically	O
significant	O
adverse	O
interactions	O
.	O
      
Corticosteroids	B-Group
:	O
A	O
relationship	O
of	O
functional	O
antagonism	O
exists	O
between	O
vitamin	B-Group
D	I-Group
analogues	O
which	O
promote	O
calcium	O
absorption	O
and	O
corticosteroids	B-Group
which	O
inhibit	O
calcium	O
absorption	O
.	O
      
Co	O
-	O
medications	O
that	O
induce	O
CYP9A9	O
(	O
e.g.	O
dexamethasone	B-Drug
phenytoin	B-Drug
carbamazepine	B-Drug
rifampin	B-Drug
phenobarbital	B-Drug
or	O
St	O
.	O
      
Therefore	O
caution	O
should	O
be	O
exercised	O
when	O
mifepristone	B-Drug
is	O
administered	O
with	O
drugs	O
that	O
are	O
CYP	O
9A9	O
substrates	O
and	O
have	O
narrow	O
therapeutic	O
range	O
including	O
some	O
agents	O
used	O
during	O
general	O
anesthesia	O
.	O
      
These	O
effects	O
have	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
by	O
the	O
NSAID	B-Group
.	O
      
Oils	O
may	O
enhance	O
absorption	O
.	O
      
Accordingly	O
patients	O
should	O
be	O
advised	O
to	O
avoid	O
alcohol	B-Drug
while	O
taking	O
REMERON	B-Brand
SolTab	I-Brand
.	O
Diazepam	B-Drug
:	O
Concomitant	O
administration	O
of	O
diazepam	B-Drug
(	O
9	O
mg	O
)	O
had	O
a	O
minimal	O
effect	O
on	O
plasma	O
levels	O
of	O
mirtazapine	B-Drug
(	O
9	O
mg	O
)	O
in	O
9	O
healthy	O
subjects	O
.	O
      
This	O
response	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
.	O
      
Non	B-Group
-	O
steroidal	I-Group
Anti	I-Group
-	O
inflammatory	I-Group
Agents	I-Group
:	O
In	O
some	O
patients	O
with	O
compromised	O
renal	O
function	O
who	O
are	O
being	O
treated	O
with	O
non	B-Group
-	O
steroidal	I-Group
anti	I-Group
-	O
inflammatory	I-Group
drugs	I-Group
the	O
co	O
-	O
administration	O
of	O
lisinopril	B-Drug
may	O
result	O
in	O
a	O
further	O
deterioration	O
of	O
renal	O
function	O
.	O
      
Allopurinol	B-Drug
:	O
In	O
a	O
study	O
of	O
healthy	O
male	O
volunteers	O
no	O
significant	O
pharmacokinetic	O
interaction	O
occurred	O
when	O
captopril	B-Drug
and	O
allopurinol	B-Drug
were	O
administered	O
concomitantly	O
for	O
9	O
days	O
.	O
      
In	O
patients	O
with	O
impaired	O
cardiac	O
function	O
simultaneous	O
use	O
should	O
be	O
avoided	O
altogether	O
.	O
      
Serious	O
cardiac	O
dysrhythmias	O
some	O
resulting	O
in	O
death	O
have	O
occurred	O
in	O
patients	O
receiving	O
terfenadine	B-Drug
concomitantly	O
with	O
other	O
macrolide	B-Group
antibiotics	I-Group
.	O
      
Antidiabetic	B-Group
Agents	I-Group
:	O
Disturbances	O
of	O
blood	O
glucose	O
including	O
hyperglycemia	O
and	O
hypoglycemia	O
have	O
been	O
reported	O
in	O
patients	O
treated	O
concomitantly	O
with	O
quinolones	B-Group
and	O
an	O
antidiabetic	B-Group
agent	I-Group
.	O
      
As	O
a	O
false	O
-	O
negative	O
result	O
may	O
occur	O
in	O
the	O
ferricyanide	O
test	O
it	O
is	O
recommended	O
that	O
either	O
the	O
glucose	O
oxidase	O
or	O
hexokinase	O
method	O
be	O
used	O
to	O
determine	O
blood	O
plasma	O
glucose	O
levels	O
in	O
patients	O
receiving	O
cefuroxime	B-Drug
.	O
      
with	O
divalent	O
or	O
trivalent	O
cations	O
such	O
as	O
iron	B-Drug
;	O
      
Furosemide	B-Drug
may	O
add	O
to	O
or	O
potentiate	O
the	O
therapeutic	O
effect	O
of	O
other	O
antihypertensive	B-Group
drugs	I-Group
.	O
      
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
;	O
      
Therefore	O
monitoring	O
of	O
theophylline	B-Drug
plasma	O
levels	O
should	O
be	O
considered	O
and	O
dosage	O
of	O
theophylline	B-Drug
adjusted	O
as	O
required	O
.	O
      
Alternatives	O
to	O
clarithromycin	B-Drug
such	O
as	O
azithromycin	B-Drug
should	O
be	O
considered	O
.	O
      
In	O
vitro	O
at	O
total	O
drug	O
concentrations	O
9	O
-	O
fold	O
higher	O
than	O
peak	O
plasma	O
concentrations	O
observed	O
with	O
the	O
9	O
-	O
mg	O
dosage	O
alosetron	B-Drug
inhibited	O
CYP	O
enzymes	O
9A9	O
(	O
9	O
%	O
)	O
and	O
9E9	O
(	O
9	O
%	O
)	O
.	O
      
In	O
screening	O
patients	O
suspected	O
of	O
having	O
a	O
pheochromocytoma	O
and	O
being	O
treated	O
with	O
labetalol	B-Drug
HCl	I-Drug
a	O
specific	O
method	O
such	O
as	O
a	O
high	O
performance	O
liquid	O
chromatographic	O
assay	O
with	O
solid	O
phase	O
extraction	O
(	O
e.g.	O
J	O
Chromatogr	O
9:9	O
9	O
)	O
should	O
be	O
employed	O
in	O
determining	O
levels	O
of	O
catecholamines	O
.	O
      
COPAXONE	B-Brand
has	O
not	O
been	O
formally	O
evaluated	O
in	O
combination	O
with	O
Interferon	B-Drug
beta	I-Drug
.	O
      
Concurrent	O
use	O
with	O
general	O
anesthetics	B-Group
may	O
result	O
in	O
arrhythmias	O
.	O
      
No	O
dosage	O
adjustment	O
of	O
digoxin	B-Drug
or	O
JANUVIA	B-Brand
is	O
recommended	O
.	O
      
Drug	O
Interactions	O
:	O
The	O
central	O
anticholinergic	B-Group
syndrome	O
can	O
occur	O
when	O
anticholinergic	O
agents	O
such	O
as	O
AKINETON	B-Brand
are	O
administered	O
concomitantly	O
with	O
drugs	O
that	O
have	O
secondary	O
anticholinergic	O
actions	O
e.g.	O
certain	O
narcotic	B-Group
analgesics	I-Group
such	O
as	O
meperidine	B-Drug
the	O
phenothiazines	B-Group
and	O
other	O
antipsychotics	B-Group
tricyclic	B-Group
antidepressants	I-Group
certain	O
antiarrhythmics	B-Group
such	O
as	O
the	O
quinidine	B-Drug
salts	O
and	O
antihistamines	B-Group
.	O
      
BROVANA	B-Brand
as	O
with	O
other	O
beta9	B-Group
-	O
agonists	I-Group
should	O
be	O
administered	O
with	O
extreme	O
caution	O
to	O
patients	O
being	O
treated	O
with	O
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
tricyclic	B-Group
antidepressants	I-Group
or	O
drugs	O
known	O
to	O
prolong	O
the	O
QTc	O
interval	O
because	O
the	O
action	O
of	O
adrenergic	B-Group
agonists	I-Group
on	O
the	O
cardiovascular	O
system	O
may	O
be	O
potentiated	O
by	O
these	O
agents	O
.	O
      
The	O
effects	O
of	O
mixing	O
NovoLog	B-Brand
with	O
insulins	B-Group
of	O
animal	O
source	O
or	O
insulin	B-Drug
preparations	O
produced	O
by	O
other	O
manufacturers	O
have	O
not	O
been	O
studied	O
.	O
      
Paliperidone	B-Drug
is	O
also	O
not	O
expected	O
to	O
have	O
enzyme	O
inducing	O
properties	O
.	O
      
Magnesium	B-Drug
-	O
and	O
/	O
or	O
aluminum	B-Drug
-	O
containing	O
antacids	B-Group
products	O
containing	O
ferrous	B-Drug
sulfate	I-Drug
(	O
iron	B-Drug
)	O
multivitamin	B-Group
preparations	I-Group
containing	O
zinc	B-Drug
or	O
other	O
metal	O
cations	O
or	O
Videx	B-Brand
(	O
didanosine	B-Drug
)	O
chewable	O
/	O
buffered	O
tablets	O
or	O
the	O
pediatric	O
powder	O
for	O
oral	O
solution	O
should	O
not	O
be	O
taken	O
within	O
9	O
hours	O
before	O
or	O
9	O
hours	O
after	O
FACTIVE	B-Brand
.	O
      
Therefore	O
a	O
possible	O
lack	O
of	O
desired	O
effect	O
of	O
treatment	O
should	O
be	O
taken	O
into	O
consideration	O
before	O
such	O
drugs	O
are	O
given	O
concomitantly	O
with	O
lactulose	B-Drug
.	O
      
There	O
was	O
no	O
evidence	O
of	O
toxicity	O
.	O
      
phenylbutazone	B-Drug
;	O
      
Patients	O
taking	O
REVIA	B-Brand
may	O
not	O
benefit	O
from	O
opioid	B-Group
containing	O
medicines	O
such	O
as	O
cough	O
and	O
cold	O
preparations	O
antidiarrheal	O
preparations	O
and	O
opioid	B-Group
analgesics	I-Group
.	O
      
Caution	O
should	O
be	O
exercised	O
when	O
administering	O
nabumetone	B-Drug
with	O
warfarin	B-Drug
since	O
interactions	O
have	O
been	O
seen	O
with	O
other	O
NSAIDs	B-Group
.	O
      
increased	O
platelet	O
count	O
;	O
      
The	O
depression	O
of	O
cardiac	O
contractility	O
conductivity	O
and	O
automaticity	O
as	O
well	O
as	O
the	O
vascular	O
dilation	O
associated	O
with	O
anesthetics	B-Group
may	O
be	O
potentiated	O
by	O
calcium	B-Group
channel	I-Group
blockers	I-Group
.	O
      
Cholestyramine	B-Drug
:	O
Cholestyramine	B-Drug
may	O
increase	O
the	O
clearance	O
of	O
corticosteroids	B-Group
.	O
      
In	O
controlled	O
clinical	O
trials	O
however	O
beta	B-Drug
blockers	I-Drug
including	O
metoprolol	B-Drug
were	O
concurrently	O
administered	O
with	O
felodipine	B-Drug
and	O
were	O
well	O
tolerated	O
.	O
      
It	O
is	O
recommended	O
that	O
the	O
combination	O
of	O
intravenous	O
dantrolene	B-Drug
sodium	I-Drug
and	O
calcium	B-Group
channel	I-Group
blockers	I-Group
such	O
as	O
verapamil	B-Drug
not	O
be	O
used	O
together	O
during	O
the	O
management	O
of	O
malignant	O
hyperthermia	O
crisis	O
until	O
the	O
relevance	O
of	O
these	O
findings	O
to	O
humans	O
is	O
established	O
.	O
      
There	O
have	O
been	O
inconsistent	O
reports	O
regarding	O
the	O
effects	O
of	O
other	O
drugs	O
(	O
e.g.	O
quinine	B-Drug
penicillamine	B-Drug
)	O
on	O
serum	O
digoxin	B-Drug
concentration	O
.	O
      
These	O
drug	O
interactions	O
may	O
result	O
in	O
increased	O
and	O
prolonged	O
sedation	O
due	O
to	O
a	O
decrease	O
in	O
plasma	O
clearance	O
of	O
midazolam	B-Drug
.	O
      
MAO	B-Group
Inhibitors	I-Group
:	O
DURAGESIC	B-Brand
is	O
not	O
recommended	O
for	O
use	O
in	O
patients	O
who	O
have	O
received	O
MAOI	B-Group
within	O
9	O
days	O
because	O
severe	O
and	O
unpredictable	O
potentiation	O
by	O
MAO	B-Group
inhibitors	I-Group
has	O
been	O
reported	O
with	O
opioid	B-Group
analgesics	I-Group
      
FACTIVE	B-Brand
had	O
no	O
significant	O
effect	O
on	O
the	O
anticoagulant	O
effect	O
of	O
warfarin	B-Drug
in	O
healthy	O
subjects	O
on	O
stable	O
warfarin	B-Drug
therapy	O
.	O
      
however	O
it	O
is	O
not	O
known	O
if	O
other	O
phenothiazines	B-Group
produce	O
a	O
similar	O
response	O
.	O
      
Other	O
macrolide	B-Group
antibiotics	I-Group
such	O
as	O
erythromycin	B-Drug
have	O
not	O
been	O
studied	O
in	O
combination	O
with	O
SUSTIVA	B-Brand
.	O
      
Caution	O
should	O
be	O
used	O
when	O
administering	O
or	O
taking	O
TARCEVA	B-Brand
with	O
ketoconazole	B-Drug
and	O
other	O
strong	O
CYP9A9	O
inhibitors	O
such	O
as	O
but	O
not	O
limited	O
to	O
atazanavir	B-Drug
clarithromycin	B-Drug
indinavir	B-Drug
itraconazole	B-Drug
nefazodone	B-Drug
nelfinavir	B-Drug
ritonavir	B-Drug
saquinavir	B-Drug
telithromycin	B-Drug
troleandomycin	B-Drug
(	O
TAO	B-Drug
)	O
and	O
voriconazole	B-Drug
.	O
      
Corticosteroids	B-Group
may	O
also	O
potentiate	O
the	O
replication	O
of	O
some	O
organisms	O
contained	O
in	O
live	B-Group
attenuated	I-Group
vaccines	I-Group
.	O
      
However	O
the	O
relationship	O
to	O
nifedipine	B-Drug
therapy	O
is	O
uncertain	O
.	O
      
The	O
hypoglycemic	O
effect	O
of	O
tolbutamide	B-Drug
has	O
been	O
reported	O
to	O
increase	O
when	O
Atromid	B-Brand
-	O
S	I-Brand
is	O
given	O
concurrently	O
.	O
      
Elevated	O
International	O
Normalized	O
Ratio	O
and	O
Potential	O
Bleeding	O
International	O
Normalized	O
Ratio	O
(	O
INR	O
)	O
elevations	O
and	O
infrequent	O
reports	O
of	O
bleeding	O
events	O
including	O
gastrointestinal	O
and	O
non	O
-	O
gastrointestinal	O
bleedings	O
have	O
been	O
reported	O
in	O
clinical	O
studies	O
some	O
associated	O
with	O
concomitant	O
warfarin	B-Drug
administration	O
.	O
      
When	O
these	O
products	O
are	O
administered	O
concomitantly	O
prothrombin	O
time	O
or	O
other	O
suitable	O
coagulation	O
tests	O
should	O
be	O
closely	O
monitored	O
.	O
      
Mitotane	B-Drug
has	O
been	O
reported	O
to	O
accelerate	O
the	O
metabolism	O
of	O
warfarin	B-Drug
by	O
the	O
mechanism	O
of	O
hepatic	O
microsomal	O
enzyme	O
induction	O
leading	O
to	O
an	O
increase	O
in	O
dosage	O
requirements	O
for	O
warfarin	B-Drug
.	O
      
Therefore	O
patients	O
under	O
methotrexate	B-Drug
therapy	O
should	O
be	O
carefully	O
monitored	O
when	O
concomitant	O
ciprofloxacin	B-Drug
therapy	O
is	O
indicated	O
.	O
      
No	O
clinically	O
significant	O
adverse	O
interactions	O
with	O
commonly	O
used	O
preanesthetic	O
drugs	O
or	O
drugs	O
used	O
during	O
anesthesia	O
(	O
muscle	B-Group
relaxants	I-Group
intravenous	O
agents	O
and	O
local	O
anesthetic	B-Group
agents	I-Group
)	O
were	O
reported	O
in	O
clinical	O
trials	O
.	O
      
Tricyclic	B-Group
Antidepressants	I-Group
:	O
Concurrent	O
use	O
may	O
increase	O
the	O
therapeutic	O
and	O
toxic	O
effects	O
of	O
both	O
drugs	O
possibly	O
due	O
to	O
increased	O
catecholamine	O
sensitivity	O
.	O
      
While	O
all	O
the	O
selective	B-Group
serotonin	I-Group
reuptake	I-Group
inhibitors	I-Group
(	O
SSRIs	B-Group
)	O
e.g.	O
citalopram	B-Drug
escitalopram	B-Drug
fluoxetine	B-Drug
sertraline	B-Drug
and	O
paroxetine	B-Drug
inhibit	O
P9	O
9D9	O
they	O
may	O
vary	O
in	O
the	O
extent	O
of	O
inhibition	O
.	O
      
the	O
dose	O
of	O
Prostigmin	B-Brand
may	O
have	O
to	O
be	O
increased	O
accordingly	O
.	O
      
However	O
there	O
has	O
been	O
one	O
report	O
of	O
prolonged	O
prothrombin	O
time	O
when	O
buspirone	B-Drug
was	O
added	O
to	O
the	O
regimen	O
of	O
a	O
patient	O
treated	O
with	O
warfarin	B-Drug
.	O
      
Geriatric	O
Use	O
When	O
tumor	O
response	O
was	O
considered	O
by	O
age	O
objective	O
responses	O
were	O
seen	O
in	O
9	O
%	O
and	O
9	O
%	O
of	O
patients	O
under	O
9	O
years	O
of	O
age	O
and	O
in	O
9	O
%	O
and	O
9	O
%	O
of	O
patients	O
9	O
years	O
of	O
age	O
and	O
older	O
who	O
were	O
treated	O
with	O
FASLODEX	B-Brand
in	O
the	O
European	O
and	O
North	O
American	O
trials	O
respectively	O
.	O
      
This	O
diminution	O
is	O
not	O
sufficient	O
to	O
preclude	O
effectiveness	O
of	O
the	O
pressor	O
agent	O
for	O
therapeutic	O
use	O
.	O
      
Based	O
on	O
in	O
vitro	O
P9	O
inhibition	O
studies	O
and	O
the	O
low	O
systemic	O
exposure	O
observed	O
following	O
topical	O
application	O
of	O
ALTABAX	B-Brand
retapamulin	B-Drug
is	O
unlikely	O
to	O
affect	O
the	O
metabolism	O
of	O
other	O
P9	O
substrates	O
.	O
      
Therefore	O
concomitant	O
administration	O
of	O
ketoconazole	B-Drug
tablets	O
with	O
cisapride	B-Drug
is	O
contraindicated	O
.	O
      
Studies	O
with	O
other	O
oral	O
or	O
implant	O
contraceptives	B-Group
have	O
not	O
been	O
conducted	O
.	O
      
TAXOL	B-Brand
contains	O
dehydrated	O
alcohol	O
USP	O
9	O
mg	O
/	O
mL	O
;	O
      
Toxicologic	O
and	O
toxicokinetic	O
studies	O
in	O
rats	O
did	O
not	O
demonstrate	O
any	O
alterations	O
in	O
the	O
clearance	O
or	O
toxicologic	O
profile	O
of	O
either	O
methotrexate	B-Drug
or	O
Kineret	B-Brand
when	O
the	O
two	O
agents	O
were	O
administered	O
together	O
.	O
      
Patients	O
should	O
be	O
warned	O
of	O
the	O
potential	O
danger	O
of	O
the	O
intravenous	O
self	O
-	O
administration	O
of	O
benzodiazepines	B-Group
while	O
under	O
treatment	O
with	O
SUBOXONE	B-Brand
or	O
SUBUTEX	B-Brand
.	O
      
Amitriptyline	B-Drug
in	O
combination	O
with	O
clonidine	B-Drug
enhances	O
the	O
manifestation	O
of	O
corneal	O
lesions	O
in	O
rats	O
Epidural	O
Injection	O
Clonidine	B-Drug
may	O
potentiate	O
the	O
CNS	O
-	O
depressive	O
effect	O
of	O
alcohol	B-Drug
barbiturates	B-Group
or	O
other	O
sedating	B-Group
drugs	I-Group
.	O
      
Mixing	O
SYMLIN	B-Brand
and	O
Insulin	B-Drug
The	O
pharmacokinetic	O
parameters	O
of	O
SYMLIN	B-Brand
were	O
altered	O
when	O
mixed	O
with	O
regular	O
NPH	O
and	O
9	O
/	O
9	O
premixed	O
formulations	O
of	O
recombinant	O
human	B-Drug
insulin	I-Drug
immediately	O
prior	O
to	O
injection	O
.	O
      
Diuretics	B-Group
:	O
Studies	O
in	O
normal	O
volunteers	O
have	O
shown	O
that	O
flurbiprofen	B-Drug
like	O
other	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
drugs	I-Group
can	O
interfere	O
with	O
the	O
effects	O
of	O
furosemide	B-Drug
.	O
      
No	O
cross	O
-	O
resistance	O
with	O
other	O
chemotherapeutic	B-Group
agents	I-Group
radiotherapy	O
or	O
steroids	B-Group
has	O
been	O
demonstrated	O
.	O
      
In	O
patients	O
receiving	O
HCTZ	B-Drug
alone	O
dofetilide	B-Drug
AUC	O
increased	O
by	O
9	O
%	O
and	O
Cmax	O
by	O
9	O
%	O
.	O
      
In	O
post	O
-	O
marketing	O
experience	O
bleeding	O
has	O
been	O
reported	O
in	O
patients	O
on	O
concomitant	O
treatment	O
with	O
anticoagulants	B-Group
and	O
INDOCIN	B-Brand
.	O
      
Potential	O
Drug	O
Interactions	O
Dofetilide	B-Drug
is	O
eliminated	O
in	O
the	O
kidney	O
by	O
cationic	O
secretion	O
.	O
      
Based	O
on	O
studies	O
evaluating	O
possible	O
interactions	O
of	O
pantoprazole	B-Drug
with	O
other	O
drugs	O
no	O
dosage	O
adjustment	O
is	O
needed	O
with	O
concomitant	O
use	O
of	O
the	O
following	O
:	O
theophylline	B-Drug
cisapride	B-Drug
antipyrine	B-Drug
caffeine	B-Drug
carbamazepine	B-Drug
diazepam	B-Drug
(	O
and	O
its	O
active	O
metabolite	O
desmethyldiazepam	B-Drug_n
)	O
diclofenac	B-Drug
naproxen	B-Drug
piroxicam	B-Drug
digoxin	B-Drug
ethanol	B-Drug
glyburide	B-Drug
an	O
oral	O
contraceptive	B-Group
(	O
levonorgestrel	B-Drug
/	O
ethinyl	B-Drug
estradiol	I-Drug
)	O
metoprolol	B-Drug
nifedipine	B-Drug
phenytoin	B-Drug
warfarin	B-Drug
midazolam	B-Drug
clarithromycin	B-Drug
metronidazole	B-Drug
or	O
amoxicillin	B-Drug
.	O
      
Plasma	O
concentrations	O
may	O
be	O
increased	O
by	O
CRIXIVAN	B-Brand
.	O
      
Although	O
no	O
specific	O
drug	O
interactions	O
with	O
topical	O
glaucoma	O
drugs	O
or	O
systemic	O
medications	O
were	O
identified	O
in	O
clinical	O
studies	O
of	O
IOPIDINE	B-Brand
9	O
%	O
Ophthalmic	O
Solution	O
the	O
possibility	O
of	O
an	O
additive	O
or	O
potentiating	O
effect	O
with	O
CNS	B-Group
depressants	I-Group
(	O
alcohol	B-Drug
barbiturates	B-Group
opiates	B-Group
sedatives	B-Group
anesthetics	B-Group
)	O
should	O
be	O
considered	O
.	O
      
No	O
data	O
for	O
saquinavir	B-Drug
.	O
      
Ketamine	B-Drug
is	O
clinically	O
compatible	O
with	O
the	O
commonly	O
used	O
general	O
and	O
local	O
anesthetic	B-Group
agents	I-Group
when	O
an	O
adequate	O
respiratory	O
exchange	O
is	O
maintained	O
.	O
      
Skeletal	B-Group
muscle	I-Group
relaxants	I-Group
:	O
amphotericin	B-Drug
B	I-Drug
-	O
induced	O
hypokalemia	O
may	O
enhance	O
the	O
curariform	O
effect	O
of	O
skeletal	B-Group
muscle	I-Group
relaxants	I-Group
(	O
e.g.	O
tubocurarine	B-Drug
)	O
.	O
      
Three	O
patients	O
met	O
ACR	O
criteria	O
for	O
liver	O
biopsy	O
(	O
9	O
:	O
Roegnik	O
Grade	O
I	O
9	O
:	O
Roegnik	O
Grade	O
IIIa	O
)	O
.	O
      
Administration	O
of	O
doxapram	B-Drug
to	O
patients	O
who	O
are	O
receiving	O
sympathomimetic	B-Group
or	O
monoamine	B-Group
oxidase	I-Group
inhibiting	I-Group
drugs	I-Group
may	O
result	O
in	O
an	O
additive	O
pressor	O
effect	O
.	O
      
Dolasetron	B-Drug
does	O
not	O
influence	O
anesthesia	O
recovery	O
time	O
in	O
patients	O
.	O
      
As	O
with	O
other	O
drugs	O
primarily	O
being	O
metabolized	O
through	O
CYP9A9	O
ingestion	O
of	O
grapefruit	O
or	O
grapefruit	O
juice	O
should	O
be	O
avoided	O
in	O
connection	O
with	O
budesonide	B-Drug
administration	O
.	O
      
Gabapentin	B-Drug
pharmacokinetic	O
parameters	O
without	O
and	O
with	O
probenecid	B-Drug
were	O
comparable	O
.	O
      
Because	O
a	O
similar	O
interaction	O
is	O
likely	O
VIRACEPT	B-Brand
should	O
also	O
not	O
be	O
administered	O
concurrently	O
with	O
astemizole	B-Drug
.	O
      
meprobamate	B-Drug
;	O
      
There	O
were	O
no	O
significant	O
effects	O
on	O
QTc	O
intervals	O
and	O
no	O
reports	O
of	O
sedation	O
or	O
syncope	O
.	O
      
In	O
rabbits	O
treated	O
with	O
ezetimibe	B-Drug
an	O
increased	O
incidence	O
of	O
extra	O
thoracic	O
ribs	O
was	O
observed	O
at	O
9	O
mg	O
/	O
kg	O
/	O
day	O
(	O
9	O
times	O
the	O
human	O
exposure	O
at	O
9	O
mg	O
daily	O
based	O
on	O
AUC9	O
-	O
9hr	O
for	O
total	O
ezetimibe	B-Drug
)	O
.	O
      
Concomitant	O
administration	O
of	O
Sonata	B-Brand
(	O
9	O
mg	O
)	O
and	O
cimetidine	B-Drug
(	O
9	O
mg	O
)	O
produced	O
an	O
9	O
%	O
increase	O
in	O
the	O
mean	O
Cmax	O
and	O
AUC	O
of	O
zaleplon	B-Drug
.	O
      
ProAmatine	B-Brand
has	O
been	O
used	O
in	O
patients	O
concomitantly	O
treated	O
with	O
salt	O
-	O
retaining	O
steroid	O
therapy	O
(	O
i.e.	O
fludrocortisone	B-Drug
acetate	I-Drug
)	O
with	O
or	O
without	O
salt	O
supplementation	O
.	O
      
(	O
Both	O
drugs	O
were	O
thus	O
dosed	O
to	O
steady	O
state	O
.	O
)	O
      
Poor	O
metabolizers	O
have	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
tricyclic	B-Group
antidepressants	I-Group
(	O
TCAs	B-Group
)	O
when	O
given	O
usual	O
doses	O
.	O
      
Administration	O
of	O
diltiazem	B-Drug
hydrochloride	I-Drug
with	O
digoxin	B-Drug
in	O
9	O
healthy	O
male	O
subjects	O
increased	O
plasma	O
digoxin	B-Drug
concentrations	O
approximately	O
9	O
%	O
.	O
      
No	O
pharmacokinetic	O
interaction	O
between	O
9	O
mg	O
/	O
m9	O
ELOXATIN	B-Brand
and	O
infusional	O
9	B-Drug
-	O
FU	I-Drug
has	O
been	O
observed	O
in	O
patients	O
treated	O
every	O
9	O
weeks	O
.	O
      
The	O
mean	O
QT	O
c	O
interval	O
(	O
msec	O
)	O
was	O
9	O
with	O
terfenadine	B-Drug
alone	O
and	O
9	O
with	O
terfenadine	B-Drug
plus	O
dirithromycin	B-Drug
.	O
      
This	O
may	O
be	O
of	O
concern	O
for	O
drugs	O
with	O
a	O
narrow	O
therapeutic	O
index	O
.	O
      
Grapefruit	O
juice	O
increases	O
ethinyl	B-Drug
estradiol	I-Drug
concentrations	O
and	O
would	O
be	O
expected	O
to	O
increase	O
progesterone	B-Drug
serum	O
levels	O
as	O
well	O
;	O
      
Phenytoin	B-Drug
:	O
Altered	O
serum	O
levels	O
of	O
phenytoin	B-Drug
(	O
increased	O
and	O
decreased	O
)	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
concomitant	O
ciprofloxacin	B-Drug
.	O
      
Xigris	B-Brand
present	O
in	O
plasma	O
samples	O
does	O
not	O
interfere	O
with	O
one	O
-	O
stage	O
factor	O
assays	O
based	O
on	O
the	O
PT	O
(	O
such	O
as	O
factor	O
II	O
V	O
VII	O
and	O
X	O
assays	O
)	O
.	O
      
Therefore	O
it	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
such	O
agents	O
.	O
      
Symptoms	O
resolved	O
within	O
a	O
few	O
hours	O
.	O
      
The	O
steady	O
-	O
state	O
Cmin	O
concentration	O
increased	O
to	O
9	O
micrograms	O
/	O
mL	O
when	O
9	O
mg	O
/	O
day	O
of	O
felbamate	B-Drug
was	O
coadministered	O
for	O
one	O
week	O
.	O
      
Plasma	O
exposure	O
(	O
AUC	O
)	O
to	O
valdecoxib	B-Drug
was	O
increased	O
9	O
%	O
when	O
coadministered	O
with	O
fluconazole	B-Drug
and	O
9	O
%	O
when	O
coadministered	O
with	O
ketoconazole	B-Drug
.	O
      
Insulin	B-Drug
:	O
A	O
clinical	O
study	O
in	O
9	O
insulin	O
-	O
dependent	O
diabetic	O
patients	O
demonstrated	O
no	O
effect	O
of	O
EXTRANEAL	B-Brand
on	O
insulin	B-Drug
absorption	O
from	O
the	O
peritoneal	O
cavity	O
or	O
on	O
insulins	B-Drug
ability	O
to	O
control	O
blood	O
glucose	O
when	O
insulin	B-Drug
was	O
administered	O
intraperitoneally	O
with	O
EXTRANEAL	B-Brand
.	O
      
Bismuth	B-Drug
:	O
Bismuth	B-Drug
subsalicylate	I-Drug
given	O
concomitantly	O
with	O
enoxacin	B-Drug
or	O
9	O
minutes	O
following	O
enoxacin	B-Drug
administration	O
decreased	O
enoxacin	B-Drug
bioavailability	O
by	O
approximately	O
9	O
%	O
.	O
      
While	O
co	O
-	O
administration	O
of	O
ZAVESCA	B-Brand
appeared	O
to	O
increase	O
the	O
clearance	O
of	O
Cerezyme	B-Brand
by	O
9	O
%	O
these	O
results	O
are	O
not	O
conclusive	O
because	O
of	O
the	O
small	O
number	O
of	O
subjects	O
studied	O
and	O
because	O
patients	O
took	O
variable	O
doses	O
of	O
Cerezyme	B-Brand
.	O
      
reduced	O
dosage	O
of	O
digitalis	B-Group
glycosides	I-Group
may	O
be	O
required	O
.	O
      
Thiazide	B-Group
Diuretics	I-Group
:	O
The	O
reports	O
that	O
the	O
concomitant	O
use	O
of	O
allopurinol	B-Drug
and	O
thiazide	B-Group
diuretics	I-Group
may	O
contribute	O
to	O
the	O
enhancement	O
of	O
allopurinol	B-Drug
toxicity	O
in	O
some	O
patients	O
have	O
been	O
reviewed	O
in	O
an	O
attempt	O
to	O
establish	O
a	O
cause	O
-	O
and	O
-	O
effect	O
relationship	O
and	O
a	O
mechanism	O
of	O
causation	O
.	O
      
Plasma	O
concentrations	O
increased	O
by	O
SUSTIVA	B-Brand
(	O
efavirenz	B-Drug
)	O
;	O
      
Co	O
-	O
administration	O
of	O
naltrexone	B-Drug
with	O
Acamprosate	B-Drug
produced	O
a	O
9	O
%	O
increase	O
in	O
AUC	O
and	O
a	O
9	O
%	O
increase	O
in	O
the	O
Cmax	O
of	O
acamprosate	B-Drug
.	O
      
If	O
a	O
diuretic	B-Group
is	O
also	O
used	O
it	O
may	O
increase	O
the	O
risk	O
of	O
lithium	B-Drug
toxicity	O
.	O
      
Diuretics	B-Group
:	O
Excessive	O
reductions	O
in	O
blood	O
pressure	O
may	O
occur	O
in	O
patients	O
on	O
diuretic	O
therapy	O
when	O
ACE	B-Group
inhibitors	I-Group
are	O
started	O
.	O
      
Omniscan	B-Brand
interferes	O
with	O
serum	O
calcium	O
measurements	O
with	O
some	O
colorimetric	O
(	O
complexometric	O
)	O
methods	O
commonly	O
used	O
in	O
hospitals	O
resulting	O
in	O
serum	O
calcium	O
concentrations	O
lower	O
than	O
the	O
true	O
values	O
.	O
      
Corticosteroids	B-Group
:	O
Dexamethasone	B-Drug
:	O
Aprepitant	B-Drug
when	O
given	O
as	O
a	O
regimen	O
of	O
9mg	O
with	O
dexamethasone	B-Drug
coadministered	O
orally	O
as	O
9	O
mg	O
on	O
Day	O
9	O
and	O
Aprepitant	B-Drug
when	O
given	O
as	O
9	O
mg	O
/	O
day	O
with	O
dexamethasone	B-Drug
coadministered	O
orally	O
as	O
9	O
mg	O
on	O
Days	O
9	O
through	O
9	O
increased	O
the	O
AUC	O
of	O
dexamethasone	B-Drug
a	O
CYP9A9	O
substrate	O
by	O
9	O
-	O
fold	O
on	O
Days	O
9	O
and	O
9	O
.	O
      
Recurrence	O
of	O
skin	O
reactions	O
at	O
a	O
site	O
of	O
previous	O
extravasation	O
following	O
administration	O
of	O
TAXOL	B-Brand
at	O
a	O
different	O
site	O
ie	O
recall	O
has	O
been	O
reported	O
rarely	O
.	O
      
Medroxyprogesterone	B-Drug
Acetate	I-Drug
-	O
L	B-Drug
-	O
histidine	I-Drug
was	O
observed	O
to	O
enhance	O
(	O
in	O
tissue	O
culture	O
)	O
the	O
effect	O
of	O
medroxyprogesterone	B-Drug
acetate	I-Drug
in	O
reducing	O
the	O
number	O
of	O
human	O
breast	O
cancer	O
cells	O
that	O
were	O
in	O
the	O
S	O
phase	O
.	O
      
In	O
9	O
other	O
schizophrenic	O
patients	O
treated	O
with	O
oral	O
haloperidol	B-Drug
and	O
rifampin	B-Drug
discontinuation	O
of	O
rifampin	B-Drug
produced	O
a	O
mean	O
9	O
-	O
fold	O
increase	O
in	O
haloperidol	B-Drug
concentrations	O
.	O
      
Promethazine	B-Drug
:	O
Coadministration	O
of	O
a	O
single	O
dose	O
of	O
zaleplon	B-Drug
and	O
promethazine	B-Drug
(	O
9	O
and	O
9	O
mg	O
respectively	O
)	O
resulted	O
in	O
a	O
9	O
%	O
decrease	O
in	O
maximal	O
plasma	O
concentrations	O
of	O
zaleplon	B-Drug
but	O
no	O
change	O
in	O
the	O
area	O
under	O
the	O
plasma	O
concentration	O
-	O
time	O
curve	O
.	O
      
Digitalis	B-Group
:	O
Vitamin	B-Group
D	I-Group
dosage	O
must	O
be	O
determined	O
with	O
care	O
in	O
patients	O
undergoing	O
treatment	O
with	O
digitalis	B-Group
as	O
hypercalcemia	O
in	O
such	O
patients	O
may	O
precipitate	O
cardiac	O
arrhythmias	O
.	O
      
Drug	O
Interactions	O
:	O
Flupenthixol	B-Drug
may	O
interact	O
with	O
some	O
drugs	O
like	O
Monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
(	O
MAOI	B-Group
)	O
:	O
MAOI	B-Group
could	O
theoretically	O
affect	O
flupenthixol	B-Drug
pharmacodynamics	O
-	O
Arecoline	B-Drug_n
-	O
Eproxindine	O
-	O
Ethanol	B-Drug
:	O
Flupenthixol	B-Drug
and	O
Ethanol	B-Drug
cause	O
additive	O
CNS	O
depression	O
-	O
Tricyclic	B-Group
antidepressants	I-Group
:	O
Flupenthixol	B-Drug
increases	O
the	O
effect	O
of	O
Tricyclic	B-Group
antidepressants	I-Group
      
Lamivudine	B-Drug
and	O
zalcitabine	B-Drug
may	O
inhibit	O
the	O
intracellular	O
phosphorylation	O
of	O
one	O
another	O
.	O
      
The	O
administration	O
of	O
local	O
anesthetic	B-Group
solutions	I-Group
containing	O
epinephrine	B-Drug
or	O
norepinephrine	B-Drug
to	O
patients	O
receiving	O
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
tricyclic	B-Group
antidepressants	I-Group
or	O
phenothiazines	B-Group
may	O
produce	O
severe	O
prolonged	O
hypotension	O
or	O
hypertension	O
.	O
      
Drugs	O
Metabolized	O
by	O
CYP9D9	O
:	O
Duloxetine	B-Drug
is	O
a	O
moderate	O
inhibitor	O
of	O
CYP9D9	O
.	O
      
If	O
used	O
in	O
combination	O
with	O
saquinavir	B-Drug
hard	O
gelatin	O
capsules	O
at	O
the	O
recommended	O
dose	O
of	O
9	O
mg	O
tid	O
no	O
dose	O
adjustments	O
are	O
needed	O
.	O
      
However	O
caution	O
must	O
be	O
exercised	O
in	O
extrapolating	O
these	O
findings	O
to	O
the	O
clinical	O
situation	O
and	O
in	O
the	O
use	O
of	O
glipizide	B-Drug
with	O
these	O
drugs	O
.	O
      
The	O
risk	O
of	O
myopathy	O
during	O
treatment	O
with	O
drugs	O
of	O
this	O
class	O
is	O
increased	O
with	O
concurrent	O
administration	O
of	O
cyclosporine	B-Drug
fibric	B-Group
acid	I-Group
derivatives	I-Group
niacin	B-Drug
(	O
nicotinic	B-Drug
acid	I-Drug
)	O
erythromycin	B-Drug
azole	B-Group
antifungals	I-Group
.	O
      
If	O
you	O
are	O
9	O
years	O
of	O
age	O
or	O
older	O
ask	O
your	O
physician	O
to	O
check	O
your	O
B9	O
status	O
before	O
you	O
take	O
a	O
supplement	O
that	O
contains	O
folic	B-Drug
acid	I-Drug
.	O
      
Pilocarpine	B-Drug
might	O
antagonize	O
the	O
anticholinergic	O
effects	O
of	O
drugs	O
used	O
concomitantly	O
.	O
      
Thyroid	O
Physiology	O
:	O
The	O
following	O
agents	O
may	O
alter	O
thyroid	O
hormone	O
or	O
TSH	O
levels	O
generally	O
by	O
effects	O
on	O
thyroid	O
hormone	O
synthesis	O
secretion	O
distribution	O
metabolism	O
hormone	O
action	O
or	O
elimination	O
or	O
altered	O
TSH	O
secretion	O
:	O
aminoglutethimide	B-Drug
p	B-Drug
-	O
aminosalicylic	I-Drug
acid	I-Drug
amiodarone	B-Drug
androgens	B-Group
and	O
related	O
anabolic	O
hormones	O
complex	O
anions	O
(	O
thiocyanate	B-Drug
perchlorate	B-Drug
pertechnetate	B-Drug
)	O
antithyroid	B-Group
drugs	I-Group
b	B-Group
-	O
adrenergic	I-Group
blocking	I-Group
agents	I-Group
carbamazepine	B-Drug
chloral	B-Drug
hydrate	I-Drug
diazepam	B-Drug
dopamine	B-Drug
and	O
dopamine	B-Group
agonists	I-Group
ethionamide	B-Drug
glucocorticoids	B-Group
heparin	B-Drug
hepatic	O
enzyme	O
inducers	O
insulin	B-Drug
iodinated	O
cholestographic	O
agents	O
iodine	B-Group
-	O
containing	I-Group
compounds	I-Group
levodopa	B-Drug
lovastatin	B-Drug
lithium	B-Drug
9	B-Drug
-	O
mercaptopurine	I-Drug
metoclopramide	B-Drug
mitotane	B-Drug
nitroprusside	B-Drug
phenobarbital	B-Drug
phenytoin	B-Drug
resorcinol	B-Drug
rifampin	B-Drug
somatostatin	B-Group
analogs	I-Group
sulfonamides	B-Group
sulfonylureas	B-Group
thiazide	B-Group
diuretics	I-Group
.	O
      
Anticoagulation	O
and	O
Antiplatelets	B-Group
After	O
Treatment	O
for	O
Myocardial	O
Infarction	O
-	O
-	O
In	O
the	O
treatment	O
of	O
acute	O
myocardial	O
infarction	O
the	O
use	O
of	O
aspirin	B-Brand
has	O
been	O
shown	O
to	O
reduce	O
the	O
incidence	O
of	O
reinfarction	O
and	O
stroke	O
.	O
      
The	O
effects	O
of	O
prior	O
use	O
of	O
diphosphonates	B-Group
in	O
postmenopausal	O
osteoporosis	O
patients	O
have	O
not	O
been	O
assessed	O
;	O
      
9	O
.	O
      
Cyclosporine	B-Drug
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
None	O
known	O
.	O
      
Diuretics	B-Group
:	O
Furosemide	B-Drug
and	O
probably	O
other	O
loop	B-Group
diuretics	I-Group
given	O
concomitantly	O
with	O
metolazone	B-Drug
can	O
cause	O
unusually	O
large	O
or	O
prolonged	O
losses	O
of	O
fluid	O
and	O
electrolytes	O
.	O
      
Conversely	O
the	O
coumarin	B-Group
anticoagulants	I-Group
have	O
been	O
reported	O
to	O
increase	O
the	O
serum	O
levels	O
and	O
prolong	O
the	O
serum	O
half	O
-	O
life	O
of	O
phenytoin	B-Drug
by	O
inhibiting	O
its	O
metabolism	O
.	O
      
In	O
addition	O
certain	O
drugs	O
inhibit	O
the	O
activity	O
of	O
this	O
isozyme	O
and	O
make	O
normal	O
metabolizers	O
resemble	O
p.o	O
.	O
      
HCTZ	B-Drug
9	O
mg	O
QD	O
or	O
HCTZ	B-Drug
/	O
triamterene	B-Drug
9	O
/	O
9	O
mg	O
QD	O
was	O
co	O
-	O
administered	O
with	O
TIKOSYN	B-Brand
(	O
9	O
mcg	O
BID	O
)	O
for	O
9	O
days	O
(	O
following	O
9	O
days	O
of	O
diuretic	B-Group
use	O
at	O
half	O
dose	O
)	O
.	O
      
pregnancies	O
have	O
been	O
reported	O
.	O
      
There	O
have	O
been	O
rare	O
postmarketing	O
reports	O
of	O
rhabdomyolysis	O
some	O
associated	O
with	O
strenuous	O
physical	O
activity	O
.	O
      
Maprotiline	B-Drug
:	O
Risk	O
of	O
cardiac	O
arrhythmias	O
may	O
increase	O
.	O
      
Antihypertensive	O
effects	O
of	O
guanethidine	B-Drug
and	O
related	O
compounds	O
may	O
be	O
counteracted	O
when	O
phenothiazines	B-Group
are	O
used	O
concomitantly	O
.	O
      
Co	O
-	O
administration	O
of	O
atorvastatin	B-Drug
resulted	O
in	O
about	O
a	O
9	O
%	O
increase	O
in	O
aliskiren	B-Drug
Cmax	O
and	O
AUC	O
after	O
multiple	O
dosing	O
.	O
      
The	O
pharmacokinetics	O
of	O
rimantadine	B-Drug
were	O
assessed	O
on	O
days	O
9	O
and	O
9	O
.	O
      
An	O
individual	O
who	O
is	O
stable	O
on	O
a	O
given	O
dose	O
of	O
TCA	B-Group
may	O
become	O
abruptly	O
toxic	O
when	O
given	O
one	O
of	O
these	O
inhibiting	O
drugs	O
as	O
concomitant	O
therapy	O
.	O
      
However	O
under	O
certain	O
circumstances	O
e.g.	O
as	O
prophylaxis	O
after	O
myocardial	O
infarction	O
there	O
may	O
be	O
no	O
acceptable	O
alternatives	O
to	O
the	O
use	O
of	O
beta	B-Group
-	O
blockers	I-Group
in	O
patients	O
with	O
COPD	O
.	O
      
In	O
the	O
presence	O
of	O
these	O
methylxanthines	B-Group
larger	O
doses	O
of	O
adenosine	B-Drug
may	O
be	O
required	O
or	O
adenosine	B-Drug
may	O
not	O
be	O
effective	O
.	O
      
Coadministration	O
of	O
digoxin	B-Drug
did	O
not	O
have	O
effects	O
on	O
either	O
the	O
safety	O
or	O
efficacy	O
of	O
ibutilide	B-Drug
in	O
the	O
clinical	O
trials	O
.	O
      
If	O
SPRYCEL	B-Brand
must	O
be	O
administered	O
with	O
a	O
CYP9A9	O
inducer	O
a	O
dose	O
increase	O
in	O
SPRYCEL	B-Brand
should	O
be	O
considered	O
.	O
      
Pressor	O
amines	O
(	O
e.g.	O
norepinephrine	B-Drug
)	O
:	O
possible	O
decreased	O
response	O
to	O
pressor	O
amines	O
but	O
not	O
sufficient	O
to	O
preclude	O
their	O
use	O
.	O
      
The	O
concurrent	O
administration	O
of	O
potent	O
inhalational	O
agents	O
(	O
eg	O
isoflurane	B-Drug
enflurane	B-Drug
and	O
halothane	B-Drug
)	O
during	O
maintenance	O
with	O
DIPRIVAN	B-Brand
Injectable	O
Emulsion	O
has	O
not	O
been	O
extensively	O
evaluated	O
.	O
      
Nonetheless	O
individual	O
patients	O
may	O
require	O
additional	O
titration	O
of	O
their	O
theophylline	B-Drug
dosage	O
when	O
lansoprazole	B-Drug
is	O
started	O
or	O
stopped	O
to	O
ensure	O
clinically	O
effective	O
blood	O
levels	O
.	O
      
Terbinafine	B-Drug
increases	O
the	O
clearance	O
of	O
cyclosporine	B-Drug
by	O
9	O
%	O
.	O
      
Ergot	B-Group
Derivatives	I-Group
:	O
Dihydroergotamine	B-Drug
ergonovine	B-Drug
ergotamine	B-Drug
methylergonovine	B-Drug
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
life	O
-	O
threatening	O
reactions	O
such	O
as	O
acute	O
ergot	B-Group
toxicity	O
characterized	O
by	O
peripheral	O
vasospasm	O
and	O
ischemia	O
of	O
the	O
extremities	O
and	O
other	O
tissues	O
.	O
      
Because	O
of	O
the	O
danger	O
of	O
a	O
potentially	O
fatal	O
prolongation	O
of	O
the	O
QTc	O
interval	O
halofantrine	B-Drug
must	O
not	O
be	O
given	O
simultaneously	O
with	O
or	O
subsequent	O
to	O
Mefloquine	B-Drug
.	O
      
Other	O
concomitant	O
therapies	O
:	O
In	O
clinical	O
trials	O
the	O
safety	O
profile	O
in	O
subjects	O
treated	O
with	O
Acamprosate	B-Drug
concomitantly	O
with	O
anxiolytics	B-Group
hypnotics	B-Group
and	O
sedatives	B-Group
(	O
including	O
benzodiazepines	B-Group
)	O
or	O
non	B-Group
-	O
opioid	I-Group
analgesics	I-Group
was	O
similar	O
to	O
that	O
of	O
subjects	O
taking	O
placebo	O
with	O
these	O
concomitant	O
medications	O
.	O
      
Most	O
events	O
were	O
reported	O
to	O
occur	O
when	O
contrast	O
media	O
was	O
given	O
within	O
9	O
weeks	O
after	O
the	O
last	O
dose	O
of	O
interleukin	B-Drug
-	O
9	I-Drug
.	O
      
The	O
daily	O
dose	O
of	O
dexamethasone	B-Drug
administered	O
in	O
clinical	O
studies	O
with	O
Aprepitant	B-Drug
reflects	O
an	O
approximate	O
9	O
%	O
reduction	O
of	O
the	O
dose	O
of	O
dexamethasone	B-Drug
.	O
      
.	O
      
When	O
administering	O
these	O
drugs	O
concurrently	O
one	O
should	O
be	O
alert	O
for	O
possible	O
excessive	O
phenytoin	B-Drug
effect	O
.	O
      
In	O
addition	O
other	O
quinolones	B-Group
have	O
been	O
reported	O
to	O
decrease	O
the	O
CYP9A9	O
-	O
mediated	O
metabolism	O
of	O
cyclosporine	B-Drug
.	O
      
The	O
acceleration	O
of	O
gastric	O
emptying	O
by	O
cisapride	B-Drug
could	O
affect	O
the	O
rate	O
of	O
absorption	O
of	O
other	O
drugs	O
.	O
      
It	O
is	O
not	O
known	O
whether	O
the	O
concurrent	O
use	O
of	O
these	O
agents	O
with	O
apraclonidine	B-Drug
can	O
lead	O
to	O
a	O
reduction	O
in	O
IOP	O
lowering	O
effect	O
.	O
      
A	O
drug	O
-	O
drug	O
interaction	O
study	O
evaluated	O
the	O
effect	O
of	O
the	O
use	O
of	O
ACZONE	B-Brand
Gel	O
9	O
%	O
in	O
combination	O
with	O
double	O
strength	O
(	O
9	O
mg	O
/	O
9	O
mg	O
)	O
trimethoprim	B-Drug
/	O
sulfamethoxazole	B-Drug
(	O
TMP	B-Drug
/	O
SMX	B-Drug
)	O
.	O
      
Although	O
specific	O
drug	O
interaction	O
studies	O
in	O
HIV	O
-	O
9	O
seropositive	O
subjects	O
have	O
not	O
been	O
conducted	O
for	O
the	O
classes	O
of	O
drugs	O
listed	O
in	O
Table	O
9	O
additional	O
clinical	O
monitoring	O
may	O
be	O
warranted	O
when	O
co	O
-	O
administering	O
these	O
drugs	O
.	O
      
However	O
in	O
vivo	O
drug	O
interaction	O
studies	O
of	O
ketoconazole	B-Drug
with	O
vitamin	B-Group
D	I-Group
have	O
not	O
been	O
investigated	O
.	O
      
The	O
gradual	O
withdrawal	O
of	O
guafacine	B-Drug
or	O
a	O
cardioselective	B-Group
beta	I-Group
-	O
blocker	I-Group
could	O
be	O
substituted	O
.	O
      
Therefore	O
injection	O
of	O
these	O
agents	O
into	O
patients	O
receiving	O
thyroid	B-Group
preparations	I-Group
increases	O
the	O
risk	O
of	O
precipitating	O
coronary	O
insufficiency	O
especially	O
in	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O
      
In	O
clinical	O
trials	O
perindopril	B-Drug
was	O
generally	O
administered	O
in	O
a	O
non	O
-	O
fasting	O
state	O
.	O
      
-	O
a	O
monoamine	B-Group
oxidase	I-Group
inhibitor	I-Group
(	O
MAOI	B-Group
)	O
such	O
as	O
isocarboxazid	B-Drug
(	O
Marplan	B-Brand
)	O
tranylcypromine	B-Drug
(	O
Parnate	B-Brand
)	O
or	O
phenelzine	B-Drug
(	O
Nardil	B-Brand
)	O
;	O
      
Lopinavir	B-Drug
/	O
Ritonavir	B-Drug
      
Drugs	O
whose	O
absorption	O
is	O
sensitive	O
to	O
pH	O
may	O
be	O
negatively	O
impacted	O
by	O
concomitant	O
administration	O
of	O
omeprazole	B-Drug
and	O
valdecoxib	B-Drug
.	O
      
Concurrent	O
administration	O
of	O
cimetidine	B-Drug
and	O
tricyclic	B-Group
antidepressants	I-Group
can	O
produce	O
clinically	O
significant	O
increases	O
in	O
the	O
plasma	O
levels	O
of	O
the	O
tricyclic	B-Group
antidepressants	I-Group
.	O
      
Increased	O
ectopic	O
pacemaker	O
activity	O
can	O
occur	O
when	O
pseudoephedrine	B-Drug
is	O
used	O
concomitantly	O
with	O
digitalis	B-Group
.	O
      
Nonsteroidal	B-Drug
Antiinflammatory	I-Drug
Agents	O
:	O
Aspirin	B-Drug
is	O
contraindicated	O
in	O
patients	O
who	O
are	O
hypersensitive	O
to	O
nonsteroidal	B-Drug
anti	I-Drug
-	O
inflammatory	I-Drug
agents	O
.	O
      
Drugs	O
That	O
Inhibit	O
CYP9A9	O
CYP9A9	O
is	O
a	O
minor	O
metabolic	O
pathway	O
for	O
the	O
elimination	O
of	O
zaleplon	B-Drug
because	O
the	O
sum	O
of	O
desethylzaleplon	O
(	O
formed	O
via	O
CYP9A9	O
in	O
vitro	O
)	O
and	O
its	O
metabolites	O
9	B-Drug_n
-	O
oxo	I-Drug_n
-	O
desethylzaleplon	I-Drug_n
and	O
9	B-Drug_n
-	O
oxo	I-Drug_n
-	O
desethylzaleplon	I-Drug_n
glucuronide	I-Drug_n
account	O
for	O
only	O
9	O
%	O
of	O
the	O
urinary	O
recovery	O
of	O
a	O
zaleplon	B-Drug
dose	O
.	O
      
Patients	O
who	O
have	O
developed	O
severe	O
hypersensitivity	O
reactions	O
should	O
not	O
be	O
rechallenged	O
with	O
TAXOL	B-Brand
.	O
      
Because	O
of	O
the	O
increased	O
risk	O
of	O
adverse	O
reactions	O
in	O
patients	O
who	O
have	O
been	O
taking	O
benzodiazepines	B-Group
on	O
a	O
regular	O
basis	O
it	O
is	O
particularly	O
important	O
that	O
physicians	O
query	O
patients	O
or	O
their	O
guardians	O
carefully	O
about	O
benzodiazepine	B-Group
alcohol	B-Drug
and	O
sedative	B-Group
use	O
as	O
part	O
of	O
the	O
history	O
prior	O
to	O
any	O
procedure	O
in	O
which	O
the	O
use	O
of	O
ROMAZICON	B-Brand
is	O
planned	O
.	O
      
(	O
See	O
CLINICAL	O
PHARMACOLOGY	O
:	O
Drug	O
Interaction	O
Studies	O
.	O
)	O
      
There	O
have	O
been	O
no	O
formal	O
drug	O
-	O
interaction	O
studies	O
performed	O
with	O
Mylotarg	B-Brand
.	O
      
Potential	O
for	O
Interaction	O
with	O
Drugs	O
that	O
Affect	O
Gastric	O
Acidity	O
:	O
Duloxetine	B-Drug
has	O
an	O
enteric	O
coating	O
that	O
resists	O
dissolution	O
until	O
reaching	O
a	O
segment	O
of	O
the	O
gastrointestinal	O
tract	O
where	O
the	O
pH	O
exceeds	O
9	O
.	O
      
Vitamin	B-Group
D	I-Group
:	O
The	O
coadministration	O
of	O
any	O
of	O
the	O
vitamin	B-Group
D	I-Group
analogues	I-Group
should	O
be	O
avoided	O
as	O
this	O
could	O
create	O
possible	O
additive	O
effects	O
and	O
hypercalcemia	O
.	O
      
.	O
      
There	O
have	O
been	O
greater	O
than	O
two	O
-	O
fold	O
increases	O
of	O
previously	O
stable	O
plasma	O
levels	O
of	O
tricyclic	B-Group
antidepressants	I-Group
when	O
fluoxetine	B-Drug
has	O
been	O
administered	O
in	O
combination	O
with	O
these	O
agents	O
.	O
      
Drugs	O
that	O
inhibit	O
or	O
Induce	O
CYP	O
9D9	O
and	O
CYP	O
9A9	O
may	O
affect	O
the	O
concentration	O
on	O
Aricept	B-Brand
.	O
      
Response	O
to	O
sympathomimetic	B-Group
agents	I-Group
may	O
be	O
enhanced	O
by	O
colchicine	B-Drug
.	O
      
In	O
patients	O
receiving	O
Nalfon	B-Brand
and	O
a	O
steroid	B-Group
concomitantly	O
any	O
reduction	O
in	O
steroid	B-Group
dosage	O
should	O
be	O
gradual	O
in	O
order	O
to	O
avoid	O
the	O
possible	O
complications	O
of	O
sudden	O
steroid	B-Group
withdrawal	O
.	O
      
No	O
significant	O
adverse	O
interactions	O
with	O
commonly	O
used	O
premedications	O
or	O
drugs	O
used	O
during	O
anesthesia	O
or	O
sedation	O
(	O
including	O
a	O
range	O
of	O
muscle	B-Group
relaxants	I-Group
inhalational	O
agents	O
analgesic	B-Group
agents	I-Group
and	O
local	O
anesthetic	B-Group
agents	I-Group
)	O
have	O
been	O
observed	O
.	O
      
Drugs	O
such	O
as	O
lithium	B-Drug
may	O
potentiate	O
the	O
release	O
of	O
neutrophils	O
;	O
      
Profound	O
hypotensive	O
episodes	O
may	O
occur	O
when	O
diazoxide	B-Drug
infection	O
and	O
hydralazine	B-Drug
are	O
used	O
concomitantly	O
.	O
      
While	O
no	O
in	O
vivo	O
drug	O
-	O
drug	O
interaction	O
studies	O
were	O
conducted	O
between	O
estazolam	B-Drug
and	O
inducers	O
of	O
CYP9A	O
compounds	O
that	O
are	O
potent	O
CYP9A	O
inducers	O
(	O
such	O
as	O
carbamazepine	B-Drug
phenytoin	B-Drug
rifampin	B-Drug
and	O
barbiturates	B-Group
)	O
would	O
be	O
expected	O
to	O
decrease	O
estazolam	B-Drug
concentrations	O
.	O
      
It	O
is	O
recommended	O
that	O
gabapentin	B-Drug
be	O
taken	O
at	O
least	O
9	O
hours	O
following	O
Maalox	B-Brand
administration	O
.	O
      
Concomitant	O
use	O
of	O
digoxin	B-Drug
and	O
sympathomimetics	B-Group
increases	O
the	O
risk	O
of	O
cardiac	O
arrhythmias	O
.	O
      
Although	O
metoclopramide	B-Drug
may	O
increase	O
the	O
bioavailability	O
of	O
levodopa	B-Drug
by	O
increasing	O
gastric	O
emptying	O
metoclopramide	B-Drug
may	O
also	O
adversely	O
affect	O
disease	O
control	O
by	O
its	O
dopamine	O
receptor	O
antagonistic	O
properties	O
.	O
      
Other	O
Drug	O
Interactions	O
:	O
No	O
pharmacokinetic	O
interactions	O
were	O
observed	O
between	O
vardenafil	B-Drug
and	O
the	O
following	O
drugs	O
:	O
glyburide	B-Drug
warfarin	B-Drug
digoxin	B-Drug
Maalox	B-Brand
and	O
ranitidine	B-Drug
.	O
      
Caffeine	B-Drug
Theobromine	B-Drug
Grepafloxacin	B-Drug
like	O
other	O
quinolones	B-Group
may	O
inhibit	O
the	O
metabolism	O
of	O
caffeine	B-Drug
and	O
theobromine	B-Drug
.	O
      
primidone	B-Drug
;	O
      
Therefore	O
do	O
not	O
administer	O
Myfortic	B-Drug
with	O
cholestyramine	B-Drug
or	O
other	O
agents	O
that	O
may	O
interfere	O
with	O
enterohepatic	O
recirculation	O
or	O
drugs	O
that	O
may	O
bind	O
bile	O
acids	O
for	O
example	O
bile	O
acid	O
sequestrates	O
or	O
oral	O
activated	B-Drug
charcoal	I-Drug
because	O
of	O
the	O
potential	O
to	O
reduce	O
the	O
efficacy	O
of	O
Myfortic	B-Brand
.	O
      
Use	O
in	O
Conjunction	O
with	O
Other	O
Antiepileptic	B-Group
Drugs	I-Group
:	O
The	O
addition	O
of	O
Felbatol	B-Brand
to	O
antiepileptic	B-Group
drugs	I-Group
(	O
AEDs	B-Group
)	O
affects	O
the	O
steady	O
-	O
state	O
plasma	O
concentrations	O
of	O
AEDs	B-Group
.	O
      
CYP9D9	O
inhibitors	O
-	O
Atomoxetine	B-Drug
is	O
primarily	O
metabolized	O
by	O
the	O
CYP9D9	O
pathway	O
to	O
9	B-Drug_n
-	O
hydroxyatomoxetine	I-Drug_n
.	O
      
Naproxen	B-Drug
and	O
other	O
NSAIDs	B-Group
can	O
reduce	O
the	O
antihypertensive	O
effect	O
of	O
propranolol	B-Drug
and	O
other	O
beta	B-Group
-	O
blockers	I-Group
.	O
      
Adenosine	B-Drug
:	O
Dipyridamole	B-Drug
has	O
been	O
reported	O
to	O
increase	O
the	O
plasma	O
levels	O
and	O
cardiovascular	O
effects	O
of	O
adenosine	B-Drug
.	O
      
The	O
gastrointestinal	O
absorption	O
of	O
cimetidine	B-Drug
and	O
ranitidine	B-Drug
is	O
accelerated	O
when	O
they	O
are	O
coadministered	O
with	O
cisapride	B-Drug
.	O
      
Anticholinergics	B-Group
or	O
other	O
medications	O
with	O
anticholinergic	O
activity	O
when	O
used	O
concurrently	O
with	O
opioid	B-Group
analgesics	I-Group
may	O
result	O
in	O
increased	O
risk	O
of	O
urinary	O
retention	O
and	O
/	O
or	O
severe	O
constipation	O
which	O
may	O
lead	O
to	O
paralytic	O
ileus	O
.	O
      
Antifungals	B-Group
:	O
In	O
vitro	O
and	O
/	O
or	O
in	O
vivo	O
data	O
indicate	O
that	O
fluconazole	B-Drug
itraconazole	B-Drug
and	O
oral	O
ketoconazole	B-Drug
markedly	O
inhibit	O
the	O
metabolism	O
of	O
cisapride	B-Drug
which	O
can	O
result	O
in	O
an	O
increase	O
in	O
plasma	O
cisapride	B-Drug
levels	O
and	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O
      
Ethyl	B-Drug
alcohol	I-Drug
should	O
not	O
be	O
used	O
since	O
there	O
may	O
be	O
an	O
Antabuse	O
(	O
disulfiram	O
)	O
-	O
like	O
reaction	O
.	O
      
This	O
interaction	O
which	O
has	O
not	O
been	O
investigated	O
using	O
higher	O
doses	O
of	O
fluvoxamine	B-Drug
may	O
be	O
more	O
pronounced	O
if	O
a	O
9	O
mg	O
daily	O
dose	O
is	O
co	O
-	O
administered	O
particularly	O
since	O
fluvoxamine	B-Drug
exhibits	O
non	O
-	O
linear	O
pharmacokinetics	O
over	O
the	O
dosage	O
range	O
9	O
-	O
9	O
mg	O
.	O
If	O
alprazolam	B-Drug
is	O
co	O
-	O
administered	O
with	O
Fluvoxamine	B-Drug
Tablets	O
the	O
initial	O
alprazolam	B-Drug
dosage	O
should	O
be	O
at	O
least	O
halved	O
and	O
titration	O
to	O
the	O
lowest	O
effective	O
dose	O
is	O
recommended	O
.	O
      
The	O
CYP9A9	O
isoenzyme	O
is	O
present	O
in	O
both	O
the	O
liver	O
and	O
intestines	O
.	O
      
No	O
clinically	O
important	O
pharmacokinetic	O
interactions	O
occurred	O
when	O
PRINIVIL	B-Brand
was	O
used	O
concomitantly	O
with	O
propranolol	B-Drug
or	O
hydrochlorothiazide	B-Drug
.	O
      
Thus	O
in	O
order	O
to	O
avoid	O
bleeding	O
reduced	O
dosage	O
of	O
heparin	B-Drug
is	O
recommended	O
during	O
treatment	O
with	O
antithrombin	B-Drug
III	I-Drug
(	O
human	O
)	O
.	O
      
In	O
well	O
-	O
controlled	O
patients	O
undergoing	O
concurrent	O
therapy	O
with	O
cimetidine	B-Drug
a	O
decrease	O
in	O
the	O
steady	O
-	O
state	O
serum	O
concentrations	O
of	O
tricyclic	B-Group
antidepressants	I-Group
may	O
occur	O
when	O
cime	O
-	O
tidine	O
therapy	O
is	O
discontinued	O
.	O
      
Antacids	B-Group
(	O
aluminum	B-Drug
-	O
or	O
magnesium	B-Drug
-	O
containing	O
)	O
:	O
Concomitant	O
administration	O
of	O
9	O
-	O
mg	O
cefdinir	B-Drug
capsules	O
with	O
9	O
mL	O
Maalox	B-Brand
TC	I-Brand
suspension	O
reduces	O
the	O
rate	O
(	O
Cmax	O
)	O
and	O
extent	O
(	O
AUC	O
)	O
of	O
absorption	O
by	O
approximately	O
9	O
%	O
.	O
      
Tricyclic	B-Group
antidepressants	I-Group
may	O
enhance	O
the	O
seizure	O
risk	O
in	O
patients	O
taking	O
tramadol	B-Drug
      
anaphylaxis	O
      
Drugs	O
that	O
are	O
known	O
to	O
prolong	O
the	O
QTc	O
interval	O
have	O
an	O
increased	O
risk	O
of	O
ventricular	O
arrhythmias	O
.	O
      
Monitor	O
prothrombin	O
levels	O
and	O
adjust	O
anticoagulant	B-Group
dosage	O
accordingly	O
.	O
      
A	O
false	O
-	O
positive	O
direct	O
Coombs	O
test	O
has	O
been	O
reported	O
during	O
treatment	O
with	O
other	O
cephalosporin	B-Group
antibiotics	I-Group
;	O
      
Pharmacokinetic	O
interaction	O
studies	O
with	O
cetirizine	B-Drug
in	O
adults	O
were	O
conducted	O
with	O
pseudoephedrine	B-Drug
antipyrine	B-Drug
ketoconazole	B-Drug
erythromycin	B-Drug
and	O
azithromycin	B-Drug
.	O
      
The	O
pharmacodynamic	O
consequences	O
of	O
concomitant	O
use	O
of	O
losartan	B-Drug
and	O
inhibitors	O
of	O
P9	O
9C9	O
have	O
not	O
been	O
examined	O
.	O
      
Calcium	B-Drug
Supplements	O
:	O
Uncontrolled	O
intake	O
of	O
additional	O
calcium	B-Drug
-	O
containing	O
preparations	O
should	O
be	O
avoided	O
.	O
      
The	O
CNS	O
effects	O
of	O
butalbital	B-Drug
may	O
be	O
enhanced	O
by	O
monoamine	B-Group
oxidase	I-Group
MAO	I-Group
inhibitors	I-Group
.	O
      
Monitoring	O
of	O
Mexitil	B-Brand
plasma	O
levels	O
is	O
recommended	O
during	O
such	O
concurrent	O
use	O
to	O
avoid	O
ineffective	O
therapy	O
.	O
      
In	O
addition	O
oxcarbazepine	B-Drug
and	O
MHD	B-Drug_n
induce	O
a	O
subgroup	O
of	O
the	O
cytochrome	O
P9	O
9A	O
family	O
(	O
CYP9A9	O
and	O
CYP9A9	O
)	O
responsible	O
for	O
the	O
metabolism	O
of	O
dihydropyridine	B-Group
calcium	I-Group
antagonists	I-Group
and	O
oral	O
contraceptives	B-Group
resulting	O
in	O
a	O
lower	O
plasma	O
concentration	O
of	O
these	O
drugs	O
.	O
      
Calcium	B-Drug
Supplements	O
:	O
Uncontrolled	O
intake	O
of	O
additional	O
calcium	B-Drug
-	O
containing	O
preparations	O
should	O
be	O
avoided	O
.	O
      
For	O
information	O
on	O
drug	O
interactions	O
associated	O
with	O
ranitidine	B-Drug
refer	O
to	O
the	O
ZANTAC	B-Brand
package	O
insert	O
.	O
      
Digoxin	B-Drug
Keppra	B-Brand
(	O
9	O
mg	O
twice	O
daily	O
)	O
did	O
not	O
influence	O
the	O
pharmacokinetics	O
and	O
pharmacodynamics	O
(	O
ECG	O
)	O
of	O
digoxin	B-Drug
given	O
as	O
a	O
9	O
mg	O
dose	O
every	O
day	O
.	O
      
Cyclosporine	B-Drug
:	O
Preliminary	O
data	O
from	O
a	O
XENICAL	B-Brand
and	O
cyclosporine	B-Drug
drug	O
interaction	O
study	O
indicate	O
a	O
reduction	O
in	O
cyclosporine	B-Drug
plasma	O
levels	O
when	O
XENICAL	B-Brand
was	O
coadministered	O
with	O
cyclosporine	B-Drug
.	O
      
vasculitis	O
      
Beta	B-Group
-	O
blockers	I-Group
(	O
metoprolol	B-Drug
propranolol	B-Drug
)	O
serum	O
concentrations	O
and	O
pharmacologic	O
effects	O
may	O
be	O
increased	O
.	O
      
The	O
physician	O
should	O
be	O
informed	O
that	O
certain	O
endocrine	O
and	O
liver	O
function	O
tests	O
and	O
blood	O
components	O
may	O
be	O
affected	O
by	O
progestin	O
therapy	O
:	O
(	O
a	O
)	O
Plasma	O
and	O
urinary	O
steroid	O
levels	O
are	O
decreased	O
(	O
e.g.	O
progesterone	O
estradiol	O
pregnanediol	O
testosterone	O
cortisol	O
)	O
.	O
      
A	O
direct	O
causal	O
relationship	O
has	O
not	O
been	O
established	O
but	O
physicians	O
should	O
consider	O
the	O
possibility	O
that	O
diclofenac	B-Drug
may	O
alter	O
a	O
diabetic	O
patient	O
response	O
to	O
insulin	B-Drug
or	O
oral	O
hypoglycemic	B-Group
agents	I-Group
.	O
      
Phenobarbital	B-Drug
      
Uricosuric	B-Group
Agents	I-Group
:	O
Aspirin	B-Brand
may	O
decrease	O
the	O
effects	O
of	O
probenecid	B-Drug
sulfinpyrazone	B-Drug
and	O
phenylbutazone	B-Drug
.	O
      
Hepatotoxic	O
Drugs	O
Increased	O
side	O
effects	O
may	O
occur	O
when	O
leflunomide	B-Drug
is	O
given	O
concomitantly	O
with	O
hepatotoxic	O
substances	O
.	O
      
If	O
bupropion	B-Drug
is	O
added	O
to	O
the	O
treatment	O
regimen	O
of	O
a	O
patient	O
already	O
receiving	O
a	O
drug	O
metabolized	O
by	O
CYP9D9	O
the	O
need	O
to	O
decrease	O
the	O
dose	O
of	O
the	O
original	O
medication	O
should	O
be	O
considered	O
particularly	O
for	O
those	O
concomitant	O
medications	O
with	O
a	O
narrow	O
therapeutic	O
index	O
.	O
      
SUBSEQUENT	O
TO	O
INITIATION	O
OF	O
DISULFIRAM	B-Drug
THERAPY	O
.	O
      
norepinephrine	B-Drug
and	O
dobutamine	B-Drug
are	O
incompatible	O
with	O
sodium	B-Drug
bicarbonate	I-Drug
solution	O
.	O
      
(	O
9	O
mg	O
QD	O
)	O
      
Agents	O
Increasing	O
Serum	O
Potassium	O
:	O
Enalapril	B-Drug
and	O
enalapril	B-Drug
IV	O
attenuate	O
potassium	O
loss	O
caused	O
by	O
thiazide	B-Group
-	O
type	I-Group
diuretics	I-Group
.	O
      
These	O
drugs	O
should	O
be	O
coadministered	O
with	O
caution	O
and	O
frequent	O
monitoring	O
of	O
serum	O
lithium	B-Drug
concentration	O
is	O
recommended	O
.	O
      
No	O
adverse	O
effects	O
on	O
female	O
fertility	O
and	O
embryonic	O
survival	O
were	O
evident	O
in	O
female	O
animals	O
dosed	O
at	O
9	O
mg	O
/	O
kg	O
/	O
day	O
(	O
approximately	O
one	O
-	O
thousandth	O
of	O
the	O
human	O
dose	O
based	O
on	O
BSA	O
)	O
.	O
      
Paralytic	O
ileus	O
may	O
occur	O
in	O
patients	O
taking	O
tricyclic	B-Drug
antidepressants	I-Drug
in	O
combination	O
with	O
anticholinergic	B-Drug
-	O
type	O
drugs	O
.	O
      
The	O
clinical	O
significance	O
of	O
these	O
observations	O
is	O
unknown	O
.	O
      
however	O
in	O
patients	O
with	O
Paget	O
's	O
Disease	O
prior	O
diphosphonate	B-Group
use	O
appears	O
to	O
reduce	O
the	O
anti	O
-	O
resorptive	O
response	O
to	O
Calcitonin	B-Drug
salmon	I-Drug
nasal	O
spray	O
.	O
      
The	O
following	O
precautions	O
should	O
be	O
kept	O
in	O
mind	O
in	O
the	O
treatment	O
of	O
anticholinesterase	O
poisoning	O
although	O
they	O
do	O
not	O
bear	O
directly	O
on	O
the	O
use	O
of	O
atropine	B-Drug
and	O
pralidoxime	B-Drug
.	O
      
No	O
special	O
precautions	O
appear	O
to	O
be	O
necessary	O
when	O
oral	O
anticoagulant	O
therapy	O
is	O
begun	O
in	O
a	O
patient	O
already	O
stabilized	O
on	O
maintenance	O
thyroid	O
replacement	O
therapy	O
.	O
      
Rarely	O
when	O
urine	O
is	O
exposed	O
to	O
air	O
after	O
voiding	O
it	O
may	O
darken	O
because	O
of	O
breakdown	O
of	O
methyldopa	B-Drug
or	O
its	O
metabolites	O
.	O
      
In	O
about	O
9	O
%	O
of	O
patients	O
the	O
dose	O
of	O
cyclosporine	B-Drug
had	O
to	O
be	O
reduced	O
in	O
order	O
to	O
maintain	O
cyclosporine	B-Drug
concentrations	O
within	O
the	O
therapeutic	O
range	O
while	O
in	O
the	O
remainder	O
no	O
adjustment	O
was	O
needed	O
.	O
      
Estazolam	B-Drug
:	O
Interaction	O
with	O
Drugs	O
that	O
Inhibit	O
Metabolism	O
via	O
Cytochrome	O
P9	O
9A	O
(	O
CYP9A	O
)	O
:	O
The	O
metabolism	O
of	O
estazolam	B-Drug
to	O
the	O
major	O
circulating	O
metabolite	O
9	B-Drug_n
-	O
hydroxy	I-Drug_n
-	O
estazolam	I-Drug_n
and	O
the	O
metabolism	O
of	O
other	O
triazolobenzodiazepines	B-Group
is	O
catalyzed	O
by	O
CYP9A	O
.	O
      
In	O
vitro	O
studies	O
have	O
indicated	O
that	O
colestipol	B-Drug
hydrochloride	I-Drug
binds	O
a	O
number	O
of	O
drugs	O
.	O
      
Alternatives	O
to	O
rifampin	B-Drug
should	O
be	O
considered	O
during	O
the	O
course	O
of	O
PCP	O
treatment	O
with	O
MEPRON	B-Brand
.	O
      
This	O
may	O
increase	O
or	O
enhance	O
the	O
occurrence	O
of	O
osteomalacia	O
in	O
some	O
patients	O
receiving	O
chronic	O
phenytoin	B-Drug
therapy	O
.	O
      
Repeated	O
doses	O
of	O
colestipol	B-Drug
hydrochloride	I-Drug
given	O
prior	O
to	O
a	O
single	O
dose	O
of	O
propranolol	B-Drug
in	O
human	O
trials	O
have	O
been	O
reported	O
to	O
decrease	O
propranolol	B-Drug
absorption	O
.	O
      
bone	O
marrow	O
hypoplasia	O
      
A	O
return	O
to	O
normal	O
menstrual	O
rhythm	O
followed	O
cessation	O
of	O
treatment	O
.	O
      
Caution	O
should	O
be	O
exercised	O
if	O
LEUSTATIN	B-Brand
Injection	O
is	O
administered	O
before	O
after	O
or	O
in	O
conjunction	O
with	O
other	O
drugs	O
known	O
to	O
cause	O
immunosuppression	O
or	O
myelosuppression	O
.	O
      
In	O
addition	O
several	O
AED	B-Group
that	O
are	O
cytochrome	O
P9	O
inducers	O
can	O
decrease	O
plasma	O
concentrations	O
of	O
oxcarbazepine	B-Drug
and	O
MHD	B-Drug_n
.	O
      
Non	B-Group
-	O
nucleoside	I-Group
reverse	I-Group
transcriptase	I-Group
inhibitors	I-Group
      
Phenylbutazone	B-Drug
:	O
Phenylbutazone	B-Drug
causes	O
increase	O
(	O
by	O
about	O
9	O
%	O
)	O
in	O
the	O
free	O
fraction	O
of	O
etodolac	B-Drug
.	O
      
Addition	O
of	O
mexiletine	B-Drug
to	O
propafenone	B-Drug
did	O
not	O
lead	O
to	O
further	O
electrocardiographic	O
parameters	O
changes	O
of	O
QRS	O
QTc	O
RR	O
and	O
PR	O
intervals	O
than	O
propafenone	B-Drug
alone	O
.	O
      
Barbiturates	B-Group
may	O
decrease	O
the	O
effectiveness	O
of	O
oral	O
contraceptives	B-Group
certain	O
antibiotics	B-Group
quinidine	B-Drug
theophylline	B-Drug
corticosteroids	B-Group
anticoagulants	B-Group
and	O
beta	B-Group
blockers	I-Group
.	O
      
If	O
any	O
signs	O
or	O
symptoms	O
occur	O
physicians	O
should	O
consider	O
discontinuation	O
of	O
either	O
one	O
or	O
both	O
agents	O
(	O
ZYVOX	B-Brand
or	O
concomitant	O
serotonergic	B-Group
agents	I-Group
)	O
.	O
      
Drug	O
Class	O
      
Potential	O
pharmacokinetic	O
interactions	O
were	O
assessed	O
in	O
clinical	O
pharmacokinetic	O
studies	O
(	O
phenytoin	B-Drug
valproate	B-Drug
oral	O
contraceptive	B-Group
digoxin	B-Drug
warfarin	B-Drug
probenecid	B-Drug
)	O
and	O
through	O
pharmacokinetic	O
screening	O
in	O
the	O
placebo	O
-	O
controlled	O
clinical	O
studies	O
in	O
epilepsy	O
patients	O
.	O
      
In	O
vitro	O
mixing	O
of	O
an	O
aminoglycoside	B-Group
with	O
beta	O
-	O
lactamtype	O
antibiotics	B-Group
(	O
penicillins	B-Group
or	O
cephalosporins	B-Group
)	O
may	O
result	O
in	O
a	O
significant	O
mutual	O
inactivation	O
.	O
      
Anticholinesterases	B-Group
(	O
neostgmine	O
physostigmine	B-Drug
)	O
lignocaine	B-Drug
quinine	B-Drug
procainamide	B-Drug
can	O
enhance	O
toxicity	O
and	O
cause	O
cardio	O
respiratory	O
depression	O
.	O
      
-	O
The	O
persistence	O
of	O
clinical	O
and	O
laboratory	O
evidence	O
of	O
hypothyroidism	O
in	O
spite	O
of	O
adequate	O
dosage	O
replacement	O
indicates	O
either	O
poor	O
patient	O
compliance	O
poor	O
absorption	O
excessive	O
fecal	O
loss	O
or	O
inactivity	O
of	O
the	O
preparation	O
.	O
      
However	O
no	O
adverse	O
effects	O
on	O
fertility	O
were	O
observed	O
in	O
male	O
Rhesus	O
monkeys	O
treated	O
with	O
non	O
-	O
pegylated	B-Drug
interferon	I-Drug
alfa	I-Drug
-	O
9a	I-Drug
for	O
9	O
months	O
at	O
doses	O
up	O
to	O
9	O
x	O
9	O
IU	O
/	O
kg	O
/	O
day	O
.	O
      
The	O
potential	O
effects	O
of	O
increased	O
plasma	O
concentrations	O
of	O
midazolam	B-Drug
or	O
other	O
benzodiazepines	B-Group
metabolized	O
via	O
CYP9A9	O
(	O
alprazolam	B-Drug
triazolam	B-Drug
)	O
should	O
be	O
considered	O
when	O
coadministering	O
these	O
agents	O
with	O
Aprepitant	B-Drug
.	O
      
Hyaluronidase	B-Drug
:	O
Hyaluronidase	B-Drug
may	O
increase	O
the	O
diffusion	O
rate	O
of	O
procaine	B-Drug
hydrochloride	I-Drug
resulting	O
in	O
a	O
decreased	O
time	O
of	O
onset	O
but	O
an	O
increase	O
in	O
systemic	O
toxicity	O
.	O
      
Since	O
blood	O
level	O
of	O
calcitriol	B-Drug
/	O
ergocalcitriol	O
will	O
be	O
reduced	O
higher	O
doses	O
of	O
Rocaltrol	B-Brand
may	O
be	O
necessary	O
if	O
these	O
drugs	O
are	O
administered	O
simultaneously	O
.	O
      
Lithium	B-Drug
:	O
Increased	O
serum	O
lithium	B-Drug
levels	O
and	O
symptoms	O
of	O
lithium	B-Drug
toxicity	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
ACE	B-Group
inhibitors	I-Group
during	O
therapy	O
with	O
lithium	B-Drug
.	O
      
Special	O
attention	O
should	O
be	O
paid	O
to	O
potential	O
interactions	O
with	O
drugs	O
having	O
anticholinergic	O
properties	O
;	O
      
Auranofin	B-Drug
should	O
be	O
avoided	O
by	O
patients	O
with	O
a	O
history	O
of	O
serious	O
reaction	O
to	O
any	O
gold	B-Group
medication	I-Group
including	O
Solganal	B-Brand
and	O
Myochrysine	B-Brand
.	O
      
An	O
increased	O
incidence	O
of	O
benign	O
ovarian	O
granulosa	O
cell	O
tumors	O
and	O
testicular	O
Leydig	O
cell	O
tumors	O
was	O
evident	O
in	O
females	O
dosed	O
at	O
9	O
mg	O
/	O
rat	O
/	O
9	O
days	O
and	O
males	O
dosed	O
at	O
9	O
mg	O
/	O
rat	O
/	O
9	O
days	O
respectively	O
.	O
      
If	O
combination	O
therapy	O
is	O
initiated	O
or	O
withdrawn	O
in	O
conjunction	O
with	O
propranolol	B-Drug
an	O
adjustment	O
in	O
the	O
propranolol	B-Drug
dose	O
may	O
be	O
warranted	O
.	O
      
Reports	O
of	O
fatal	O
hepatic	O
failure	O
as	O
well	O
as	O
peripheral	O
neuropathy	O
pancreatitis	O
and	O
symptomatic	O
hyperlactatemia	O
/	O
lactic	O
acidosis	O
have	O
been	O
reported	O
in	O
clinical	O
trials	O
.	O
      
Therefore	O
diflunisal	B-Drug
and	O
INDOCIN	B-Brand
should	O
not	O
be	O
used	O
concomitantly	O
.	O
      
While	O
no	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
the	O
following	O
concomitant	O
drugs	O
were	O
used	O
in	O
at	O
least	O
9	O
%	O
of	O
patients	O
in	O
either	O
or	O
both	O
Sj	O
grens	O
efficacy	O
studies	O
:	O
acetylsalicylic	B-Drug
acid	I-Drug
artificial	O
tears	O
calcium	B-Drug
conjugated	B-Drug
estrogens	I-Drug
hydroxychloroquine	B-Drug
sulfate	I-Drug
ibuprofen	B-Drug
levothyroxine	B-Drug
sodium	I-Drug
medroxyprogesterone	B-Drug
acetate	I-Drug
methotrexate	B-Drug
multivitamins	B-Group
naproxen	B-Drug
omeprazole	B-Drug
paracetamol	B-Drug
and	O
prednisone	B-Drug
.	O
      
-	O
Lofexidine	B-Drug
may	O
enhance	O
the	O
CNS	O
depressive	O
effects	O
of	O
alcohol	B-Drug
barbiturates	B-Group
and	O
other	O
sedatives	B-Group
      
Other	O
HDAC	B-Group
Inhibitors	I-Group
Severe	O
thrombocytopenia	O
and	O
gastrointestinal	O
bleeding	O
have	O
been	O
reported	O
with	O
concomitant	O
use	O
of	O
ZOLINZA	B-Brand
and	O
other	O
HDAC	B-Group
inhibitors	I-Group
(	O
e.g.	O
valproic	B-Drug
acid	I-Drug
)	O
.	O
      
Urinary	O
excretion	O
and	O
renal	O
clearance	O
were	O
correspondingly	O
reduced	O
.	O
      
Diminished	O
urinary	O
excretion	O
of	O
norfloxacin	B-Drug
has	O
been	O
reported	O
during	O
the	O
concomitant	O
administration	O
of	O
probenecid	B-Drug
and	O
norfloxacin	B-Drug
.	O
      
co	O
-	O
administration	O
of	O
phenobarbital	B-Drug
may	O
produce	O
a	O
synergistic	O
anticonvulsant	O
action	O
.	O
      
In	O
a	O
formal	O
single	O
-	O
dose	O
interaction	O
study	O
(	O
n	O
=	O
9	O
males	O
)	O
the	O
clearance	O
of	O
mexiletine	B-Drug
was	O
decreased	O
by	O
9	O
%	O
following	O
the	O
coadministration	O
of	O
fluvoxamine	B-Drug
an	O
inhibitor	O
of	O
CYP9A9	O
.	O
      
It	O
has	O
been	O
reported	O
that	O
results	O
of	O
studies	O
in	O
animals	O
indicate	O
that	O
dopamine	B-Drug
-	O
induced	O
ventricular	O
arrhythmias	O
during	O
anesthesia	O
can	O
be	O
reversed	O
by	O
propranolol	B-Drug
.	O
      
Amphetamines	B-Group
may	O
decrease	O
the	O
hypotensive	O
effect	O
of	O
antihypertensives	B-Group
.	O
      
Lovastatin	B-Drug
is	O
metabolized	O
by	O
CYP9A9	O
but	O
has	O
no	O
CYP9A9	O
inhibitory	O
activity	O
;	O
      
This	O
may	O
lead	O
to	O
reduced	O
clearance	O
of	O
caffeine	B-Drug
and	O
a	O
prolongation	O
of	O
its	O
plasma	O
half	O
-	O
life	O
.	O
      
Caution	O
in	O
using	O
concomitant	O
drugs	O
such	O
as	O
beta	B-Group
-	O
blockers	I-Group
(	O
ophthalmic	O
and	O
systemic	O
)	O
anti	B-Group
-	O
hypertensives	I-Group
and	O
/	O
or	O
cardiac	B-Group
glycosides	I-Group
is	O
advised	O
.	O
      
The	O
use	O
of	O
NIMBEX	B-Brand
before	O
succinylcholine	B-Drug
to	O
attenuate	O
some	O
of	O
the	O
side	O
effects	O
of	O
succinylcholine	B-Drug
has	O
not	O
been	O
studied	O
.	O
      
Terfenadine	B-Drug
:	O
Administration	O
of	O
terfenadine	B-Drug
with	O
VIRACEPT	B-Brand
resulted	O
in	O
the	O
appearance	O
of	O
unchanged	O
terfenadine	B-Drug
in	O
plasma	O
;	O
      
however	O
the	O
clinical	O
significance	O
of	O
this	O
interaction	O
is	O
not	O
well	O
documented	O
.	O
      
Patients	O
receiving	O
oral	O
anticoagulant	O
therapy	O
require	O
close	O
monitoring	O
especially	O
when	O
anabolic	B-Group
steroids	I-Group
are	O
started	O
or	O
stopped	O
.	O
      
ERYTHROMYCIN	B-Drug
:	O
In	O
hypercholesterolemic	O
patients	O
steady	O
-	O
state	O
cerivastatin	B-Drug
AUC	O
and	O
Cmax	O
increased	O
approximately	O
9	O
%	O
and	O
9	O
%	O
respectively	O
after	O
9	O
days	O
with	O
co	O
-	O
administration	O
of	O
erythromycin	B-Drug
a	O
known	O
inhibitor	O
of	O
cytochrome	O
P9	O
9A9	O
.	O
      
Because	O
of	O
its	O
lack	O
of	O
anti	O
-	O
platelet	O
effect	O
valdecoxib	B-Drug
is	O
not	O
a	O
substitute	O
for	O
aspirin	B-Brand
for	O
cardiovascular	O
prophylaxis	O
.	O
      
Therefore	O
there	O
is	O
a	O
potential	O
for	O
an	O
in	O
vivo	O
drug	O
interaction	O
with	O
drugs	O
that	O
are	O
metabolized	O
by	O
P9	O
9D9	O
.	O
      
In	O
a	O
9	O
-	O
week	O
endoscopy	O
study	O
conducted	O
in	O
OA	O
patients	O
there	O
was	O
no	O
difference	O
in	O
the	O
cumulative	O
incidence	O
of	O
endoscopic	O
gastroduodenal	O
ulcers	O
in	O
patients	O
taking	O
low	O
-	O
dose	O
(	O
9	O
mg	O
)	O
enteric	O
coated	O
aspirin	B-Brand
plus	O
VIOXX	B-Brand
9	O
mg	O
daily	O
as	O
compared	O
to	O
those	O
taking	O
ibuprofen	B-Drug
9	O
mg	O
daily	O
alone	O
.	O
      
Mercaptopurine	B-Drug
/	O
Azathioprine	B-Drug
:	O
Allopurinol	B-Drug
inhibits	O
the	O
enzymatic	O
oxidation	O
of	O
mercaptopurine	B-Drug
and	O
azathioprine	B-Drug
to	O
9	B-Drug
-	O
thiouric	I-Drug
acid	I-Drug
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
There	O
are	O
no	O
reported	O
drug	O
-	O
laboratory	O
test	O
interactions	O
.	O
      
Ethinyl	B-Drug
Estradiol	I-Drug
and	O
Norethindrone	B-Drug
:	O
Coadministration	O
of	O
VIRACEPT	B-Brand
with	O
OVCON	B-Brand
-	O
9	I-Brand
resulted	O
in	O
a	O
9	O
%	O
decrease	O
in	O
ethinyl	B-Drug
estradiol	I-Drug
and	O
an	O
9	O
%	O
decrease	O
in	O
norethindrone	B-Drug
plasma	O
concentrations	O
.	O
      
When	O
ertapenem	B-Drug
is	O
co	O
-	O
administered	O
with	O
probenecid	B-Drug
(	O
9	O
mg	O
p.o	O
.	O
every	O
9	O
hours	O
)	O
probenecid	B-Drug
competes	O
for	O
active	O
tubular	O
secretion	O
and	O
reduces	O
the	O
renal	O
clearance	O
of	O
ertapenem	B-Drug
.	O
      
triclofos	B-Drug
sodium	I-Drug
;	O
      
Of	O
the	O
9	O
patients	O
who	O
received	O
AMEVIVE	B-Brand
in	O
clinical	O
trials	O
a	O
total	O
of	O
9	O
patients	O
were	O
      
Coadministration	O
with	O
valdecoxib	B-Drug
(	O
9	O
mg	O
BID	O
for	O
9	O
days	O
)	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
dextromethorphan	B-Drug
plasma	O
levels	O
suggesting	O
that	O
at	O
these	O
doses	O
valdecoxib	B-Drug
is	O
a	O
weak	O
inhibitor	O
of	O
9D9	O
.	O
      
Curariform	B-Group
Drugs	I-Group
:	O
Diuretic	B-Group
-	O
induced	O
hypokalemia	O
may	O
enhance	O
neuromuscular	O
blocking	O
effects	O
of	O
curariform	B-Group
drugs	I-Group
(	O
such	O
as	O
tubocurarine	B-Drug
)	O
the	O
most	O
serious	O
effect	O
would	O
be	O
respiratory	O
depression	O
which	O
could	O
proceed	O
to	O
apnea	O
.	O
      
Also	O
bleeding	O
and	O
/	O
or	O
increased	O
prothrombin	O
time	O
have	O
been	O
reported	O
in	O
a	O
few	O
patients	O
taking	O
coumarin	B-Group
anticoagulants	I-Group
concomitantly	O
with	O
lovastatin	B-Drug
.	O
      
Thus	O
the	O
concentrations	O
of	O
these	O
drugs	O
would	O
increase	O
meaning	O
side	O
effects	O
may	O
be	O
seen	O
.	O
      
Antacids	B-Group
:	O
In	O
a	O
single	O
dose	O
study	O
(	O
n=9	O
)	O
ingestion	O
of	O
an	O
antacid	B-Group
containing	O
9	O
-	O
gram	O
of	O
magnesium	B-Drug
hydroxide	I-Drug
with	O
9	O
-	O
mg	O
of	O
mefenamic	B-Drug
acid	I-Drug
increased	O
the	O
Cmax	O
and	O
AUC	O
of	O
mefenamic	B-Drug
acid	I-Drug
by	O
9	O
%	O
and	O
9	O
%	O
respectively	O
.	O
A	O
number	O
of	O
compounds	O
are	O
inhibitors	O
of	O
CYP9C9	O
including	O
fluconazole	B-Drug
lovastatin	B-Drug
and	O
trimethoprim	B-Drug
.	O
      
Monitoring	O
of	O
liver	O
enzymes	O
is	O
recommended	O
when	O
SUSTIVA	B-Brand
is	O
used	O
in	O
combination	O
with	O
ritonavir	B-Drug
.	O
      
Asubnormal	O
response	O
may	O
occur	O
in	O
patients	O
on	O
estrogen	O
therapy	O
.	O
      
Imipramine	B-Drug
hydrochloride	I-Drug
may	O
potentiate	O
the	O
effects	O
of	O
CNS	B-Group
depressant	I-Group
drugs	I-Group
.	O
      
As	O
with	O
other	O
agents	B-Group
with	I-Group
b	I-Group
-	O
blocking	I-Group
properties	I-Group
if	O
COREG	B-Brand
is	O
to	O
be	O
administered	O
orally	O
with	O
calcium	B-Group
channel	I-Group
blockers	I-Group
of	O
the	O
verapamil	B-Drug
or	O
diltiazem	B-Drug
type	O
it	O
is	O
recommended	O
that	O
ECG	O
and	O
blood	O
pressure	O
be	O
monitored	O
.	O
      
The	O
9	O
%	O
incidence	O
of	O
akathisia	O
however	O
is	O
within	O
the	O
range	O
reported	O
for	O
use	O
of	O
prochlorperazine	B-Drug
when	O
given	O
as	O
a	O
premedication	O
for	O
other	O
chemotherapies	O
.	O
      
Among	O
these	O
patients	O
the	O
incidence	O
of	O
upper	O
gastrointestinal	O
adverse	O
experiences	O
in	O
the	O
patients	O
treated	O
with	O
Ibandronate	B-Drug
was	O
similar	O
to	O
that	O
in	O
placebo	O
-	O
treated	O
patients	O
.	O
      
The	O
incremental	O
LDL	O
-	O
C	O
reduction	O
due	O
to	O
adding	O
ezetimibe	B-Drug
to	O
cholestyramine	B-Drug
may	O
be	O
reduced	O
by	O
this	O
interaction	O
.	O
      
INDOCIN	B-Brand
has	O
been	O
reported	O
to	O
decrease	O
the	O
tubular	O
secretion	O
of	O
methotrexate	B-Drug
and	O
to	O
potentiate	O
its	O
toxicity	O
.	O
      
Based	O
on	O
these	O
data	O
Vardenafil	B-Drug
should	O
not	O
be	O
used	O
in	O
patients	O
on	O
alpha	B-Group
-	O
blocker	I-Group
therapy	O
.	O
      
Amprenavir	B-Drug
is	O
metabolized	O
in	O
the	O
liver	O
by	O
the	O
cytochrome	O
P9	O
enzyme	O
system	O
.	O
      
Warfarin	B-Drug
:	O
The	O
effect	O
of	O
celecoxib	B-Drug
on	O
the	O
anti	O
-	O
coagulant	O
effect	O
of	O
warfarin	B-Drug
was	O
studied	O
in	O
a	O
group	O
of	O
healthy	O
subjects	O
receiving	O
daily	O
doses	O
of	O
9	O
-	O
9	O
mg	O
of	O
warfarin	B-Drug
.	O
      
Phosphate	O
-	O
Binding	O
Agents	O
:	O
Since	O
vitamin	B-Group
D	I-Group
also	O
has	O
an	O
effect	O
on	O
phosphate	O
transport	O
in	O
the	O
intestine	O
kidneys	O
and	O
bones	O
the	O
dosage	O
of	O
phosphate	O
-	O
binding	O
agents	O
must	O
be	O
adjusted	O
in	O
accordance	O
with	O
the	O
serum	O
phosphate	O
concentration	O
.	O
      
If	O
hypotension	O
occurs	O
the	O
patient	O
should	O
be	O
placed	O
in	O
a	O
supine	O
position	O
and	O
if	O
necessary	O
receive	O
an	O
intravenous	O
infusion	O
of	O
normal	O
saline	O
.	O
      
A	O
potential	O
interaction	O
between	O
oral	O
miconazole	B-Drug
and	O
oral	O
hypoglycemic	B-Group
agents	I-Group
leading	O
to	O
severe	O
hypoglycemia	O
has	O
been	O
reported	O
.	O
      
Cholestyramine	B-Drug
:	O
Cholestyramine	B-Drug
causes	O
a	O
9	O
%	O
reduction	O
in	O
the	O
absorption	O
and	O
enterohepatic	O
cycling	O
of	O
raloxifene	B-Drug
and	O
should	O
not	O
be	O
coadministered	O
with	O
EVISTA	B-Brand
.	O
      
poor	O
metabolizers	O
of	O
debrisoquin	B-Drug
:	O
Interactions	O
of	O
carvedilol	B-Drug
with	O
strong	O
inhibitors	O
of	O
CYP9D9	O
(	O
such	O
as	O
quinidine	B-Drug
fluoxetine	B-Drug
paroxetine	B-Drug
and	O
propafenone	B-Drug
)	O
have	O
not	O
been	O
studied	O
but	O
these	O
drugs	O
would	O
be	O
expected	O
to	O
increase	O
blood	O
levels	O
of	O
the	O
R	O
(	O
+	O
)	O
enantiomer	O
of	O
carvedilol	B-Drug
.	O
      
Nelfinavir	B-Drug
steady	O
-	O
state	O
Cmax	O
A.C.	O
and	O
Cmin	O
were	O
increased	O
by	O
9	O
%	O
9	O
%	O
and	O
9	O
%	O
respectively	O
by	O
concomitant	O
amprenavir	B-Drug
.	O
      
Omeprazole	B-Drug
:	O
The	O
rate	O
and	O
extent	O
of	O
absorption	O
of	O
ciprofloxacin	B-Drug
was	O
bioequivalent	O
when	O
Proquin	B-Brand
XR	I-Brand
was	O
given	O
alone	O
or	O
when	O
Proquin	B-Brand
XR	I-Brand
was	O
given	O
9	O
hours	O
after	O
omeprazole	B-Drug
at	O
the	O
dose	O
that	O
maximally	O
suppresses	O
gastric	O
acid	O
secretion	O
.	O
      
Table	O
9	O
      
Phenobarbital	B-Drug
      
Drugs	O
that	O
reportedly	O
may	O
increase	O
oral	O
anticoagulant	B-Group
response	O
ie	O
increased	O
prothrombin	O
response	O
in	O
man	O
include	O
:	O
alcohol	B-Drug
*	O
;	O
      
Intravenous	O
Pentamidine	B-Drug
:	O
Treatment	O
with	O
HIVID	B-Drug
should	O
be	O
interrupted	O
when	O
the	O
use	O
of	O
a	O
drug	O
that	O
has	O
the	O
potential	O
to	O
cause	O
pancreatitis	O
is	O
required	O
.	O
      
Leucovorin	B-Drug
may	O
enhance	O
the	O
toxicity	O
of	O
9	B-Drug
-	O
fluorouracil	I-Drug
.	O
      
Drug	O
-	O
drug	O
interactions	O
with	O
Mefloquine	B-Drug
have	O
not	O
been	O
explored	O
in	O
detail	O
.	O
      
Hypokalemia	O
can	O
sensitize	O
or	O
exaggerate	O
the	O
response	O
of	O
the	O
heart	O
to	O
the	O
toxic	O
effects	O
of	O
digitalis	B-Group
(	O
e.g.	O
increased	O
ventricular	O
irritability	O
)	O
.	O
      
In	O
a	O
study	O
in	O
hypertensive	O
patients	O
addition	O
of	O
isradipine	B-Drug
to	O
existing	O
hydrochlorothiazide	B-Drug
therapy	O
did	O
not	O
result	O
in	O
any	O
unexpected	O
adverse	O
effects	O
and	O
isradipine	B-Drug
had	O
an	O
additional	O
antihypertensive	O
effect	O
.	O
      
Zidovudine	B-Drug
should	O
either	O
be	O
temporarily	O
discontinued	O
or	O
decreased	O
by	O
9	O
%	O
when	O
coadministered	O
with	O
probenecid	B-Drug
on	O
the	O
day	O
of	O
VISTIDE	B-Brand
infusion	O
.	O
      
Anticonvulsants	B-Group
      
Although	O
the	O
interaction	O
between	O
almotriptan	B-Drug
and	O
other	O
potent	O
CYP9A9	O
inhibitors	O
(	O
e.g.	O
itraconazole	B-Drug
ritonavir	B-Drug
and	O
erythromycin	B-Drug
)	O
has	O
not	O
been	O
studied	O
increased	O
exposures	O
to	O
almotriptan	B-Drug
may	O
be	O
expected	O
when	O
almotriptan	B-Drug
is	O
used	O
concomitantly	O
with	O
these	O
medications	O
.	O
      
(	O
Read	O
circulars	O
for	O
lithium	B-Drug
preparation	O
before	O
use	O
of	O
such	O
concurrent	O
therapy	O
)	O
.	O
      
Patients	O
should	O
be	O
closely	O
monitored	O
for	O
signs	O
and	O
symptoms	O
of	O
occult	O
bleeding	O
.	O
      
Nevertheless	O
during	O
concomitant	O
therapy	O
with	O
furosemide	B-Drug
and	O
MOBIC	B-Brand
patients	O
should	O
be	O
observed	O
closely	O
for	O
signs	O
of	O
declining	O
renal	O
function	O
as	O
well	O
as	O
to	O
assure	O
diuretic	O
efficacy	O
.	O
      
Capsules	O
INDOCIN	B-Brand
9	O
mg	O
t.i.d	O
.	O
produced	O
a	O
clinically	O
relevant	O
elevation	O
of	O
plasma	O
lithium	B-Drug
and	O
reduction	O
in	O
renal	O
lithium	B-Drug
clearance	O
in	O
psychiatric	O
patients	O
and	O
normal	O
subjects	O
with	O
steady	O
state	O
plasma	O
lithium	B-Drug
concentrations	O
.	O
      
Cyclosporine	B-Drug
:	O
When	O
studied	O
in	O
stable	O
renal	O
transplant	O
patients	O
cyclosporine	B-Drug
USP	O
(	O
MODIFIED	O
)	O
pharmacokinetics	O
were	O
unaffected	O
by	O
steady	O
state	O
dosing	O
of	O
Myfortic	B-Brand
.	O
      
When	O
s.c	O
.	O
      
Clinical	O
Comment	O
      
Concomitant	O
administration	O
of	O
terfenadine	B-Drug
with	O
clarithromycin	B-Drug
erythromycin	B-Drug
or	O
troleandomycin	B-Drug
is	O
contraindicated	O
:	O
Pending	O
full	O
characterization	O
of	O
potential	O
interactions	O
concomitant	O
administration	O
of	O
terfenadine	B-Drug
with	O
other	O
macrolide	B-Group
antibiotics	I-Group
including	O
azithromycin	B-Drug
is	O
not	O
recommended	O
.	O
      
Administration	O
of	O
rifampin	B-Drug
concomitantly	O
with	O
oral	O
amiodarone	B-Drug
has	O
been	O
shown	O
to	O
result	O
in	O
decreases	O
in	O
serum	O
concentrations	O
of	O
amiodarone	B-Drug
and	O
desethylamiodarone	B-Drug
.	O
      
No	O
information	O
available	O
.	O
      
Potassium	B-Group
-	O
sparing	I-Group
diuretics	I-Group
(	O
e.g.	O
spironolactone	B-Drug
triamterene	B-Drug
or	O
amiloride	B-Drug
)	O
potassium	B-Drug
supplements	O
or	O
potassium	B-Drug
-	O
containing	O
salt	O
substitutes	O
may	O
lead	O
to	O
significant	O
increases	O
in	O
serum	O
potassium	O
.	O
      
Other	O
substances	O
including	O
herbal	O
preparations	O
:	O
St.	O
John	O
Wort	O
(	O
Hypericum	O
perforatum	O
)	O
induces	O
CYP9A9	O
.	O
      
There	O
is	O
no	O
experience	O
with	O
co	O
-	O
administration	O
of	O
Angiomax	B-Brand
and	O
plasma	O
expanders	O
such	O
as	O
dextran	B-Drug
.	O
      
An	O
individual	O
who	O
is	O
stable	O
on	O
a	O
given	O
dose	O
of	O
TCA	B-Group
may	O
become	O
abruptly	O
toxic	O
when	O
given	O
one	O
of	O
these	O
inhibiting	O
drugs	O
as	O
concomitant	O
therapy	O
.	O
      
Catecholamine	B-Group
-	O
depleting	I-Group
drugs	I-Group
such	O
as	O
reserpine	B-Drug
may	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
beta	B-Group
-	O
blocking	I-Group
agents	I-Group
.	O
      
Although	O
no	O
studies	O
have	O
been	O
conducted	O
concomitant	O
administration	O
of	O
Itraconazole	B-Drug
and	O
phenytoin	B-Drug
may	O
alter	O
the	O
metabolism	O
of	O
phenytoin	B-Drug
;	O
      
The	O
clinical	O
significance	O
of	O
these	O
changes	O
is	O
unknown	O
.	O
      
Certain	O
drugs	O
tend	O
to	O
produce	O
hyperglycemia	O
and	O
may	O
lead	O
to	O
loss	O
of	O
blood	O
glucose	O
control	O
.	O
      
Other	O
reported	O
interactions	O
with	O
amiodarone	B-Drug
:	O
Fentanyl	B-Drug
(	O
CYP9A9	B-Drug
substrate	O
)	O
in	O
combination	O
with	O
amiodarone	B-Drug
may	O
cause	O
hypotension	O
bradycardia	O
and	O
decreased	O
cardiac	O
output	O
.	O
      
Concomitant	O
administration	O
of	O
propranolol	B-Drug
with	O
phenothiazines	B-Group
results	O
in	O
increased	O
plasma	O
levels	O
of	O
both	O
drugs	O
.	O
      
Drug	O
interactions	O
with	O
clomiphene	B-Drug
citrate	I-Drug
tablets	O
USP	O
have	O
not	O
been	O
documented	O
.	O
      
These	O
studies	O
indicate	O
that	O
ketoconazole	B-Drug
or	O
erythromycin	B-Drug
co	O
-	O
administration	O
enhances	O
fexofenadine	B-Drug
gastrointestinal	O
absorption	O
.	O
      
In	O
patients	O
receiving	O
nonselective	O
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
(	O
MAOIs	B-Group
)	O
(	O
e.g.	O
selegiline	B-Drug
hydrochloride	I-Drug
)	O
in	O
combination	O
with	O
serotoninergic	B-Group
agents	I-Group
(	O
e.g.	O
fluoxetine	B-Drug
fluvoxamine	B-Drug
paroxetine	B-Drug
sertraline	B-Drug
venlafaxine	B-Drug
)	O
there	O
have	O
been	O
reports	O
of	O
serious	O
sometimes	O
fatal	O
reactions	O
.	O
      
Interaction	O
with	O
central	B-Group
nervous	I-Group
system	I-Group
depressants	I-Group
other	O
than	O
benzodiazepines	B-Group
has	O
not	O
been	O
specifically	O
studied	O
;	O
      
Coadministration	O
of	O
ethoxzolamide	B-Drug
with	O
other	O
diuretics	B-Group
amphotericin	B-Drug
B	I-Drug
and	O
corticosteroids	B-Group
may	O
cause	O
hypokalemia	O
.	O
      
Formal	O
drug	O
interaction	O
studies	O
with	O
Abciximab	B-Drug
have	O
not	O
been	O
conducted	O
.	O
      
Triazolam	B-Drug
:	O
Erythromycin	B-Drug
has	O
been	O
reported	O
to	O
decrease	O
the	O
clearance	O
of	O
triazolam	B-Drug
and	O
thus	O
may	O
increase	O
the	O
pharmacologic	O
effect	O
of	O
triazolam	B-Drug
.	O
      
Nevirapine	B-Drug
and	O
rifampin	B-Drug
should	O
not	O
beadministered	O
concomitantly	O
becausedecreases	O
in	O
nevirapine	B-Drug
plasmaconcentrations	O
may	O
reduce	O
the	O
efficacy	O
ofthe	O
drug	O
.	O
      
Other	O
No	O
clinically	O
important	O
pharmacokinetic	O
interactions	O
occurred	O
when	O
Lotensin	B-Brand
was	O
administered	O
concomitantly	O
with	O
hydrochlorothiazide	B-Drug
chlorthalidone	B-Drug
furosemide	B-Drug
digoxin	B-Drug
propranolol	B-Drug
atenolol	B-Drug
naproxen	B-Drug
or	O
cimetidine	B-Drug
.	O
      
Eprosartan	B-Drug
has	O
been	O
shown	O
to	O
have	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
digoxin	B-Drug
and	O
the	O
pharmacodynamics	O
of	O
warfarin	B-Drug
and	O
glyburide	B-Drug
.	O
      
Phenytoin	B-Drug
:	O
Accutane	B-Brand
has	O
not	O
been	O
shown	O
to	O
alter	O
the	O
pharmacokinetics	O
of	O
phenytoin	B-Drug
in	O
a	O
study	O
in	O
seven	O
healthy	O
volunteers	O
.	O
      
Therefore	O
MAO	B-Group
inhibitors	I-Group
should	O
be	O
discontinued	O
at	O
least	O
two	O
weeks	O
prior	O
to	O
the	O
cautious	O
initiation	O
of	O
therapy	O
with	O
SINEQUAN	B-Brand
.	O
      
Food	O
has	O
no	O
clinically	O
significant	O
effect	O
on	O
the	O
bioavailability	O
of	O
anagrelide	B-Drug
.	O
      
Certain	O
drugs	O
tend	O
to	O
produce	O
hyperglycemia	O
and	O
may	O
lead	O
to	O
loss	O
of	O
control	O
.	O
      
The	O
IV	O
methylprednisolone	B-Drug
dose	O
should	O
be	O
reduced	O
by	O
approximately	O
9	O
%	O
and	O
the	O
oral	O
methylprednisolone	B-Drug
dose	O
should	O
be	O
reduced	O
by	O
approximately	O
9	O
%	O
when	O
coadministered	O
with	O
Aprepitant	B-Drug
to	O
achieve	O
exposures	O
of	O
methylprednisolone	B-Drug
similar	O
to	O
those	O
obtained	O
when	O
it	O
is	O
given	O
without	O
Aprepitant	B-Drug
.	O
      
Physicians	O
should	O
carefully	O
monitor	O
PT	O
and	O
INR	O
in	O
patients	O
concurrently	O
administered	O
ZOLINZA	B-Brand
and	O
coumarin	B-Group
derivatives	I-Group
.	O
      
SUBUTEX	B-Brand
and	O
SUBOXONE	B-Brand
should	O
be	O
prescribed	O
with	O
caution	O
to	O
patients	O
on	O
benzodiazepines	B-Group
or	O
other	O
drugs	O
that	O
act	O
on	O
the	O
central	O
nervous	O
system	O
regardless	O
of	O
whether	O
these	O
drugs	O
are	O
taken	O
on	O
the	O
advice	O
of	O
a	O
physician	O
or	O
are	O
taken	O
as	O
drugs	O
of	O
abuse	O
.	O
      
Monitor	O
platelet	O
count	O
every	O
9	O
weeks	O
for	O
the	O
first	O
9	O
months	O
.	O
      
During	O
concomitant	O
therapy	O
with	O
ibuprofen	B-Drug
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
signs	O
of	O
renal	O
failure	O
as	O
well	O
as	O
to	O
assure	O
diuretic	B-Group
efficacy	O
.	O
      
Phase	O
II	O
clinical	O
trial	O
data	O
where	O
IRESSA	B-Brand
and	O
vinorelbine	B-Drug
have	O
been	O
used	O
concomitantly	O
indicate	O
that	O
IRESSA	B-Brand
may	O
exacerbate	O
the	O
neutropenic	O
effect	O
of	O
vinorelbine	B-Drug
.	O
      
The	O
majority	O
of	O
these	O
reports	O
concerned	O
variable	O
elevations	O
in	O
prothrombin	O
times	O
without	O
clinically	O
significant	O
sequelae	O
.	O
      
Plasma	O
TCA	B-Group
concentrations	O
may	O
need	O
to	O
be	O
monitored	O
and	O
the	O
dose	O
of	O
the	O
TCA	B-Group
may	O
need	O
to	O
be	O
reduced	O
if	O
a	O
TCA	B-Group
is	O
co	O
-	O
administered	O
with	O
Duloxetine	B-Drug
.	O
      
Antibiotics	B-Group
:	O
Macrolide	B-Group
antibiotics	I-Group
have	O
been	O
reported	O
to	O
cause	O
a	O
significant	O
decrease	O
in	O
corticosteroid	B-Group
clearance	O
.	O
      
If	O
TRANXENE	B-Brand
tablets	O
are	O
used	O
to	O
treat	O
anxiety	O
associated	O
with	O
somatic	O
disease	O
states	O
careful	O
attention	O
must	O
be	O
paid	O
to	O
possible	O
drug	O
interaction	O
with	O
concomitant	O
medication	O
.	O
      
It	O
is	O
not	O
known	O
if	O
the	O
effects	O
of	O
butorphanol	B-Drug
are	O
altered	O
by	O
concomitant	O
medications	O
that	O
affect	O
hepatic	O
metabolism	O
of	O
drugs	O
(	O
erythromycin	B-Drug
etc	O
.	O
)	O
but	O
physicians	O
should	O
be	O
alert	O
to	O
the	O
possibility	O
that	O
a	O
smaller	O
initial	O
dose	O
and	O
longer	O
intervals	O
between	O
doses	O
may	O
be	O
needed	O
.	O
      
-	O
Naltrexone	B-Drug
(	O
e.g.	O
Trexan	B-Brand
)	O
(	O
with	O
long	O
-	O
term	O
high	O
-	O
dose	O
use	O
)	O
or	O
      
Tolbutamide	B-Drug
:	O
In	O
diabetic	O
patients	O
receiving	O
diflunisal	B-Drug
and	O
tolbutamide	B-Drug
no	O
significant	O
effects	O
were	O
seen	O
on	O
tolbutamide	B-Drug
plasma	O
levels	O
or	O
fasting	O
blood	O
glucose	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
:	O
Physiologic	O
effects	O
of	O
testolactone	B-Drug
may	O
result	O
in	O
decreased	O
estradiol	O
concentrations	O
with	O
radioimmunoassays	O
for	O
estradiol	O
increased	O
plasma	O
calcium	O
concentrations	O
and	O
increased	O
9	O
-	O
hour	O
urinary	O
excretion	O
of	O
creatine	O
and	O
9	O
-	O
ketosteroids	O
.	O
      
-	O
rifampin	B-Drug
(	O
Rifadin	B-Brand
Rifamate	B-Brand
)	O
;	O
      
Drugs	O
that	O
reduce	O
the	O
number	O
of	O
blood	O
platelets	O
by	O
causing	O
bone	O
marrow	O
depression	O
(	O
such	O
as	O
antineoplastic	B-Group
agents	I-Group
)	O
or	O
drugs	O
which	O
inhibit	O
platelet	O
function	O
(	O
eg	O
aspirin	B-Brand
and	O
other	O
non	B-Group
-	O
steroidal	I-Group
anti	I-Group
-	O
inflammatory	I-Group
drugs	I-Group
dipyridamole	B-Drug
hydrochloroquine	B-Drug
clofibrate	B-Drug
dextran	B-Drug
)	O
may	O
increase	O
the	O
bleeding	O
tendency	O
produced	O
by	O
anticoagulants	B-Group
without	O
altering	O
prothrombin	O
time	O
determinations	O
.	O
      
Montelukast	B-Drug
at	O
a	O
Dose	O
of	O
9	O
mg	O
Once	O
Daily	O
Dosed	O
to	O
Pharmacokinetic	O
Steady	O
State	O
-	O
did	O
not	O
cause	O
clinically	O
significant	O
changes	O
in	O
the	O
kinetics	O
of	O
a	O
single	O
intravenous	O
dose	O
of	O
theophylline	B-Drug
(	O
predominantly	O
a	O
cytochrome	O
P9	O
9A9	O
substrate	O
)	O
.	O
      
Concurrent	O
use	O
of	O
hydroxyurea	B-Drug
and	O
other	O
myelosuppressive	O
agents	O
or	O
radiation	O
therapy	O
may	O
increase	O
the	O
likelihood	O
of	O
bone	O
marrow	O
depression	O
or	O
other	O
adverse	O
events	O
.	O
      
The	O
effects	O
of	O
Mefloquineuine	O
on	O
the	O
compromised	O
cardiovascular	O
system	O
have	O
not	O
been	O
evaluated	O
.	O
      
No	O
pharmacodynamic	O
effects	O
of	O
either	O
histamine	B-Group
H9	I-Group
receptor	I-Group
antagonist	I-Group
were	O
observed	O
.	O
      
The	O
concomitant	O
use	O
of	O
ENABLEX	B-Brand
with	O
other	O
anticholinergic	B-Group
agents	I-Group
may	O
increase	O
the	O
frequency	O
and	O
/	O
or	O
severity	O
of	O
dry	O
mouth	O
constipation	O
blurred	O
vision	O
and	O
other	O
anticholinergic	O
pharmacological	O
effects	O
.	O
      
Bosentan	B-Drug
is	O
also	O
expected	O
to	O
reduce	O
plasma	O
concentrations	O
of	O
other	O
statins	B-Group
that	O
have	O
significant	O
metabolism	O
by	O
CYP9A9	O
such	O
as	O
lovastatin	B-Drug
and	O
atorvastatin	B-Drug
.	O
      
There	O
were	O
no	O
reports	O
of	O
skeletal	O
myopathy	O
in	O
a	O
placebo	O
-	O
controlled	O
Phase	O
I	O
trial	O
in	O
which	O
9	O
healthy	O
subjects	O
on	O
stable	O
simvastatin	B-Drug
therapy	O
were	O
treated	O
concurrently	O
with	O
daptomycin	B-Drug
(	O
9	O
mg	O
/	O
kg	O
once	O
every	O
9	O
hours	O
)	O
for	O
9	O
days	O
.	O
      
Synergism	O
between	O
xanthine	B-Group
bronchodilators	I-Group
(	O
e.g.	O
theophylline	B-Drug
)	O
ephedrine	B-Drug
and	O
other	O
sympathomimetic	B-Group
bronchodilators	I-Group
has	O
been	O
reported	O
.	O
      
These	O
data	O
suggest	O
that	O
rofecoxib	B-Drug
may	O
produce	O
a	O
modest	O
inhibition	O
of	O
cytochrome	O
P9	O
(	O
CYP	O
)	O
9A9	O
.	O
      
Some	O
early	O
studies	O
indicated	O
that	O
EPA	B-Drug
supplements	O
might	O
have	O
detrimental	O
effects	O
in	O
those	O
groups	O
.	O
      
These	O
increases	O
should	O
be	O
considered	O
when	O
selecting	O
an	O
oral	O
contraceptive	B-Group
for	O
a	O
woman	O
taking	O
atorvastatin	B-Drug
.	O
      
The	O
administration	O
of	O
cefdinir	B-Drug
may	O
result	O
in	O
a	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	O
in	O
urine	O
using	O
Clinitest	O
Benedict	O
solution	O
or	O
Fehlings	O
solution	O
.	O
      
A	O
number	O
of	O
substances	O
affect	O
glucose	O
metabolism	O
and	O
may	O
require	O
insulin	B-Drug
dose	O
adjustment	O
and	O
particularly	O
close	O
monitoring	O
.	O
      
Increases	O
in	O
prothrombin	O
time	O
have	O
been	O
noted	O
in	O
patients	O
receiving	O
long	O
-	O
term	O
warfarin	B-Drug
therapy	O
after	O
flutamide	B-Drug
was	O
initiated	O
.	O
      
therefore	O
caution	O
should	O
be	O
used	O
when	O
administering	O
CYP9A9	O
inhibitors	O
with	O
IRESSA	B-Brand
.	O
      
Scopolamine	B-Drug
should	O
be	O
used	O
with	O
care	O
in	O
patients	O
taking	O
other	O
drugs	O
that	O
are	O
capable	O
of	O
causing	O
CNS	O
effects	O
such	O
as	O
sedatives	B-Group
tranquilizers	B-Group
or	O
alcohol	B-Drug
.	O
      
Sirolimus	B-Drug
AUC	O
was	O
increased	O
by	O
9	O
%	O
with	O
no	O
effect	O
on	O
Cmax	O
in	O
the	O
presence	O
of	O
steady	O
-	O
state	O
MYCAMINE	B-Brand
compared	O
with	O
sirolimus	B-Drug
alone	O
.	O
      
DRUG	O
/	O
LABORATORY	O
TEST	O
INTERACTIONS	O
:	O
EFFECT	O
ON	O
BLOOD	O
COAGULATION	O
Ketoprofen	B-Drug
decreases	O
platelet	O
adhesion	O
and	O
aggregation	O
.	O
      
No	O
evidence	O
of	O
clastogenicity	O
was	O
observed	O
in	O
vitro	O
in	O
a	O
chromosomal	O
aberration	O
assay	O
in	O
human	O
peripheral	O
blood	O
lymphocytes	O
with	O
or	O
without	O
metabolic	O
activation	O
.	O
      
saquinavir	B-Drug
concentration	O
      
.	O
      
Benzyl	B-Drug_n
alcohol	I-Drug_n
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
neurological	O
and	O
other	O
complications	O
in	O
neonates	O
and	O
infants	O
which	O
are	O
sometimes	O
fatal	O
.	O
      
oxyphenbutazone	B-Drug
;	O
      
Monoamine	B-Group
Oxidase	I-Group
Inhibitors	I-Group
:	O
Coadministration	O
of	O
moclobemide	B-Drug
resulted	O
in	O
a	O
9	O
%	O
decrease	O
in	O
almotriptan	B-Drug
clearance	O
and	O
an	O
increase	O
in	O
Cmax	O
of	O
approximately	O
9	O
%	O
.	O
      
It	O
is	O
desirable	O
to	O
monitor	O
TCA	B-Group
plasma	O
levels	O
whenever	O
a	O
TCA	B-Group
is	O
going	O
to	O
be	O
coadministered	O
with	O
another	O
drug	O
known	O
to	O
be	O
an	O
inhibitor	O
of	O
P9	O
9D9	O
.	O
      
CYP9A9	O
and	O
-	O
9C9	O
Inhibitors	O
-	O
In	O
vitro	O
studies	O
indicated	O
that	O
CYP9A9	O
and	O
-	O
9C9	O
are	O
the	O
primary	O
enzymes	O
involved	O
in	O
the	O
metabolism	O
of	O
escitalopram	B-Drug
.	O
      
Iodine	B-Drug
or	O
iodine	B-Drug
excess	O
may	O
decrease	O
the	O
effect	O
of	O
Carbimazole	B-Drug
and	O
an	O
iodine	B-Drug
deficiency	O
can	O
increase	O
the	O
effect	O
of	O
Carbimazole	B-Drug
.	O
      
Alkalinizing	O
agents	O
:	O
Gastrointestinal	O
alkalinizing	O
agents	O
(	O
sodium	B-Drug
bicarbonate	I-Drug
etc	O
.	O
)	O
increase	O
absorption	O
of	O
amphetamines	B-Drug
.	O
      
Oral	O
Anticoagulants	B-Group
CAUTION	O
SHOULD	O
BE	O
EXERCISED	O
WHEN	O
COUMARIN	B-Group
ANTICOAGULANTS	I-Group
ARE	O
GIVEN	O
IN	O
CONJUNCTION	O
WITH	O
TRICOR	B-Brand
.	O
      
May	O
interact	O
with	O
skin	O
products	O
or	O
shampoos	O
for	O
dandruff	O
or	O
psoriasis	O
.	O
      
ERGAMISOL	B-Brand
(	O
levamisole	B-Drug
hydrochloride	I-Drug
)	O
has	O
been	O
reported	O
to	O
produce	O
ANTABUSE	O
-	O
like	O
side	O
effects	O
when	O
given	O
concomitantly	O
with	O
alcohol	B-Drug
.	O
      
In	O
such	O
cases	O
the	O
unbound	O
(	O
free	O
)	O
hormone	O
should	O
be	O
measured	O
.	O
      
When	O
catecholamines	B-Group
are	O
administered	O
dilute	O
solutions	O
should	O
be	O
used	O
and	O
blood	O
pressure	O
should	O
be	O
monitored	O
closely	O
.	O
      
Omeprazole	B-Drug
should	O
be	O
taken	O
as	O
directed	O
and	O
Proquin	B-Brand
XR	I-Brand
should	O
be	O
taken	O
with	O
a	O
main	O
meal	O
of	O
the	O
day	O
preferably	O
the	O
evening	O
meal..	O
      
Pharmacokinetic	O
data	O
suggest	O
that	O
absorption	O
metabolism	O
and	O
elimination	O
of	O
each	O
of	O
these	O
drugs	O
are	O
unchanged	O
when	O
they	O
are	O
used	O
together	O
.	O
      
Beta	B-Group
-	O
blockers	I-Group
not	O
only	O
block	O
the	O
therapeutic	O
effects	O
of	O
beta	B-Group
-	O
agonists	I-Group
but	O
may	O
produce	O
severe	O
bronchospasm	O
in	O
COPD	O
patients	O
.	O
      
Chlorthalidone	B-Drug
and	O
related	O
drugs	O
may	O
decrease	O
arterial	O
responsiveness	O
to	O
norepinephrine	B-Drug
.	O
      
tadalafil	B-Drug
concentration	O
      
Concomitant	O
use	O
of	O
barbiturates	B-Group
usually	O
depresses	O
griseofulvin	B-Drug
activity	O
and	O
may	O
necessitate	O
raising	O
the	O
dosage	O
.	O
      
Propranolol	B-Drug
:	O
In	O
a	O
single	O
dose	O
study	O
in	O
normal	O
volunteers	O
coadministration	O
of	O
propranolol	B-Drug
had	O
a	O
small	O
effect	O
on	O
the	O
rate	O
but	O
no	O
effect	O
on	O
the	O
extent	O
of	O
isradipine	B-Drug
bioavailability	O
.	O
      
Inhibitors	O
of	O
CYP9A9	O
-	O
Eplerenone	B-Drug
metabolism	O
is	O
predominantly	O
mediated	O
via	O
CYP9A9	O
.	O
      
The	O
risk	O
of	O
myopathy	O
is	O
also	O
increased	O
by	O
the	O
following	O
lipid	O
-	O
lowering	O
drugs	O
that	O
are	O
not	O
potent	O
CYP9A9	O
inhibitors	O
but	O
which	O
can	O
cause	O
myopathy	O
when	O
given	O
alone	O
.	O
      
Due	O
to	O
the	O
potential	O
for	O
additive	O
effects	O
caution	O
and	O
careful	O
titration	O
are	O
warranted	O
in	O
patients	O
receiving	O
diltiazem	B-Drug
hydrochloride	I-Drug
concomitantly	O
with	O
other	O
agents	O
known	O
to	O
affect	O
cardiac	O
contractility	O
and	O
/	O
or	O
conduction	O
.	O
      
In	O
the	O
case	O
of	O
digoxin	B-Drug
serum	O
levels	O
should	O
be	O
monitored	O
.	O
      
Careful	O
observation	O
is	O
required	O
.	O
      
Careful	O
patient	O
monitoring	O
is	O
recommended	O
in	O
patients	O
receiving	O
such	O
drugs	O
.	O
      
The	O
beneficial	O
effects	O
on	O
arterial	O
thrombus	O
formation	O
from	O
combined	O
therapy	O
with	O
antiplatelet	B-Group
and	O
anticoagulant	B-Group
medication	I-Group
must	O
be	O
weighed	O
against	O
an	O
increased	O
risk	O
of	O
inducing	O
hemorrhage	O
.	O
      
It	O
may	O
also	O
interact	O
with	O
thiazides	B-Group
(	O
increased	O
thrombocytopenia	O
)	O
cyclosporine	B-Drug
(	O
increased	O
nephrotoxicity	O
)	O
sulfonylurea	B-Group
agents	I-Group
(	O
increased	O
hypoglycemic	O
response	O
)	O
warfarin	B-Drug
(	O
increased	O
anticoagulant	O
effect	O
)	O
methotrexate	B-Drug
(	O
decreased	O
renal	O
excretion	O
of	O
methotrexate	B-Drug
)	O
phenytoin	B-Drug
(	O
decreased	O
hepatic	O
clearance	O
of	O
phenytoin	B-Drug
)	O
.	O
      
No	O
depressant	O
effect	O
on	O
blood	O
levels	O
in	O
humans	O
was	O
noted	O
when	O
colestipol	B-Drug
hydrochloride	I-Drug
was	O
administered	O
with	O
any	O
of	O
the	O
following	O
drugs	O
:	O
aspirin	B-Brand
clindamycin	B-Brand
clofibrate	B-Drug
methyldopa	B-Drug
nicotinic	B-Drug
acid	I-Drug
(	O
niacin	B-Drug
)	O
tolbutamide	B-Drug
phenytoin	B-Drug
or	O
warfarin	B-Drug
.	O
      
9	O
-	O
9	O
      
FLEXERIL	B-Brand
may	O
enhance	O
the	O
effects	O
of	O
alcohol	B-Drug
barbiturates	B-Group
and	O
other	O
CNS	B-Group
depressants	I-Group
.	O
      
metabolizers	O
.	O
      
Anticoagulants	B-Group
Anabolic	B-Group
steroids	I-Group
may	O
increase	O
sensitivity	O
to	O
oral	O
anticoagulants	B-Group
.	O
      
Duloxetine	B-Drug
May	O
Have	O
a	O
Clinically	O
Important	O
Interaction	O
with	O
the	O
Following	O
Other	O
Drugs	O
:	O
Alcohol	B-Drug
:	O
When	O
Duloxetine	B-Drug
and	O
ethanol	B-Drug
were	O
administered	O
several	O
hours	O
apart	O
so	O
that	O
peak	O
concentrations	O
of	O
each	O
would	O
coincide	O
Duloxetine	B-Drug
did	O
not	O
increase	O
the	O
impairment	O
of	O
mental	O
and	O
motor	O
skills	O
caused	O
by	O
alcohol	B-Drug
.	O
      
No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
with	O
ZEVALIN	B-Brand
.	O
      
Acebutolol	B-Drug
atenolol	B-Drug
and	O
nadolol	B-Drug
(	O
low	O
hepatic	O
clearance	O
or	O
no	O
first	O
-	O
pass	O
metabolism	O
)	O
are	O
unlikely	O
to	O
be	O
affected	O
.	O
      
Benzodiazepines	B-Group
:	O
Combination	O
hormonal	B-Group
contraceptives	I-Group
may	O
decrease	O
the	O
clearance	O
of	O
some	O
benzodiazepines	B-Group
(	O
alprazolam	B-Drug
chlordiazepoxide	B-Drug
diazepam	B-Drug
)	O
and	O
increase	O
the	O
clearance	O
of	O
others	O
(	O
lorazepam	B-Drug
oxazepam	B-Drug
temazepam	B-Drug
)	O
.	O
      
Drugs	O
Whose	O
Absorption	O
Can	O
Be	O
Affected	O
by	O
the	O
Level	O
of	O
Acidity	O
in	O
the	O
Stomach	O
:	O
Drugs	O
such	O
as	O
ketoconazole	B-Drug
and	O
itraconazole	B-Drug
should	O
be	O
administered	O
at	O
least	O
9	O
hours	O
prior	O
to	O
dosing	O
with	O
VIDEX	B-Brand
.	O
      
Other	O
Agents	O
      
reduced	O
response	O
to	O
metyrapone	O
test	O
;	O
      
The	O
incidence	O
of	O
TBg	O
deficiency	O
approximates	O
9	O
in	O
9	O
.	O
      
With	O
some	O
agents	O
the	O
metabolism	O
may	O
be	O
induced	O
resulting	O
in	O
decreased	O
concentrations	O
.	O
      
Cimetidine	B-Drug
:	O
Cimetidine	B-Drug
can	O
inhibit	O
the	O
metabolism	O
of	O
chloroquine	B-Drug
increasing	O
its	O
plasma	O
level	O
.	O
      
There	O
is	O
evidence	O
that	O
the	O
use	O
of	O
halofantrine	B-Drug
after	O
Mefloquineuine	O
causes	O
a	O
significant	O
lengthening	O
of	O
the	O
QTc	O
interval	O
.	O
      
These	O
data	O
suggest	O
that	O
GH	B-Drug
administration	O
may	O
alter	O
the	O
clearance	O
of	O
compounds	O
known	O
to	O
be	O
metabolized	O
by	O
CP9	O
liver	O
enzymes	O
(	O
e.g.	O
corticosteroids	B-Group
sex	B-Group
steroids	I-Group
anticonvulsants	B-Group
cyclosporin	B-Drug
)	O
.	O
      
Smokers	O
have	O
an	O
increased	O
clearance	O
of	O
benzodiazepines	B-Group
as	O
compared	O
to	O
nonsmokers	O
;	O
      
-	O
Concomitant	O
use	O
of	O
tricyclic	B-Group
antidepressants	I-Group
may	O
reduce	O
the	O
efficacy	O
of	O
lofexidine	B-Drug
.	O
      
The	O
potential	O
for	O
clinically	O
significant	O
drug	O
-	O
drug	O
interactions	O
posed	O
by	O
dolasetron	B-Drug
and	O
hydrodolasetron	B-Drug_n
appears	O
to	O
be	O
low	O
for	O
drugs	O
commonly	O
used	O
in	O
chemotherapy	O
or	O
surgery	O
because	O
hydrodolasetron	B-Drug_n
is	O
eliminated	O
by	O
multiple	O
routes	O
.	O
      
The	O
pharmacokinetics	O
of	O
terfenadine	B-Drug
and	O
its	O
acid	O
metabolite	O
and	O
the	O
electrocardiographic	O
QT	O
c	O
interval	O
were	O
measured	O
during	O
both	O
periods	O
:	O
with	O
terfenadine	B-Drug
alone	O
and	O
with	O
terfenadine	B-Drug
plus	O
dirithromycin	B-Drug
.	O
      
Concurrent	O
use	O
of	O
these	O
agents	O
should	O
generally	O
be	O
avoided	O
.	O
      
Probenecid	B-Drug
:	O
Probenecid	B-Drug
a	O
known	O
inhibitor	O
of	O
renal	O
tubular	O
secretion	O
of	O
organic	O
acids	O
via	O
the	O
aruonic	O
transporter	O
did	O
not	O
noticeably	O
influence	O
pramipexole	B-Drug
pharmacokinetics	O
(	O
N=	O
9	O
)	O
.	O
      
Antihistamines	B-Group
(	O
e.g.	O
chlorpheniramine	B-Group
)	O
.	O
      
On	O
administration	O
of	O
oral	O
amiodarone	B-Drug
the	O
need	O
for	O
digitalis	B-Group
therapy	O
should	O
be	O
reviewed	O
and	O
the	O
dose	O
reduced	O
by	O
approximately	O
9	O
%	O
or	O
discontinued	O
.	O
      
Pindolol	B-Drug
has	O
been	O
used	O
with	O
a	O
variety	O
of	O
antihypertensive	B-Group
agents	I-Group
including	O
hydrochlorothiazide	B-Drug
hydralazine	B-Drug
and	O
guanethidine	B-Drug
without	O
unexpected	O
adverse	O
interactions	O
.	O
      
Other	O
:	O
Concomitant	O
alcohol	B-Drug
or	O
hot	O
drinks	O
may	O
increase	O
the	O
side	O
effects	O
of	O
flushing	O
and	O
pruritus	O
and	O
should	O
be	O
avoided	O
at	O
the	O
time	O
of	O
drug	O
ingestion	O
.	O
      
Somatrem	B-Drug
/	O
Somatropin	B-Drug
:	O
Excessive	O
concurrent	O
use	O
of	O
thyroid	B-Group
hormone	I-Group
may	O
accelerate	O
epiphyseal	O
closure	O
.	O
      
No	O
drug	O
interactions	O
have	O
been	O
reported	O
between	O
Prostin	B-Brand
VR	I-Brand
Pediatric	I-Brand
and	O
the	O
therapy	O
standard	O
in	O
neonates	O
with	O
restricted	O
pulmonary	O
or	O
systemic	O
blood	O
flow	O
.	O
      
Anagrelide	B-Drug
demonstrates	O
some	O
limited	O
inhibitory	O
activity	O
towards	O
CYP9A9	O
which	O
may	O
present	O
a	O
theoretical	O
potential	O
for	O
interaction	O
with	O
other	O
coadministered	O
medicinal	O
products	O
sharing	O
that	O
clearance	O
mechanism	O
e.g	O
.	O
      
Agents	O
that	O
are	O
CYP9A9	O
inhibitors	O
that	O
have	O
been	O
found	O
or	O
are	O
expected	O
to	O
increase	O
plasma	O
levels	O
of	O
EQUETROTM	B-Brand
are	O
the	O
following	O
:	O
Acetazolamide	B-Drug
azole	B-Group
antifungals	I-Group
cimetidine	B-Drug
clarithromycin	B-Drug
(	O
9	O
)	O
dalfopristin	B-Drug
danazol	B-Drug
delavirdine	B-Drug
diltiazem	B-Drug
erythromycin	B-Drug
(	O
9	O
)	O
fluoxetine	B-Drug
fluvoxamine	B-Drug
grapefruit	O
juice	O
isoniazid	B-Drug
itraconazole	B-Drug
ketoconazole	B-Drug
loratadine	B-Drug
nefazodone	B-Drug
niacinamide	B-Drug
nicotinamide	B-Drug
protease	B-Group
inhibitors	I-Group
propoxyphene	B-Drug
quinine	B-Drug
quinupristin	B-Drug
troleandomycin	B-Drug
valproate	B-Drug
(	O
9	O
)	O
verapamil	B-Drug
zileuton	B-Drug
.	O
      
Dicumarol	B-Drug
and	O
warfarin	B-Drug
may	O
decrease	O
hypoprothrombinemic	O
effect	O
.	O
      
Products	O
containing	O
calcium	B-Drug
and	O
other	O
multivalent	O
cations	O
(	O
such	O
as	O
aluminum	B-Drug
magnesium	B-Drug
iron	B-Drug
)	O
are	O
likely	O
to	O
interfere	O
with	O
absorption	O
of	O
Ibandronate	B-Drug
.	O
      
Carbamazepine	B-Drug
:	O
Tiagabine	B-Drug
had	O
no	O
effect	O
on	O
the	O
steady	O
-	O
state	O
plasma	O
concentrations	O
of	O
carbamazepine	B-Drug
or	O
its	O
epoxide	O
metabolite	O
in	O
patients	O
with	O
epilepsy	O
.	O
      
Based	O
on	O
in	O
vitro	O
studies	O
no	O
pharmacokinetic	O
drug	O
interactions	O
with	O
drugs	O
metabolized	O
by	O
the	O
following	O
isoenzyme	O
systems	O
are	O
expected	O
:	O
CYP9A9	O
CYP9D9	O
CYP9A9	O
/	O
9	O
CYP9E9	O
CYP9C9	O
CYP9C9	O
or	O
CYP9C9	O
.	O
      
Risk	O
of	O
Anaphylactic	O
Reaction	O
:	O
While	O
taking	O
beta	B-Group
-	O
blockers	I-Group
patients	O
with	O
a	O
history	O
of	O
severe	O
anaphylactic	O
reaction	O
to	O
a	O
variety	O
of	O
allergens	O
may	O
be	O
more	O
reactive	O
to	O
repeated	O
challenge	O
either	O
accidental	O
diagnostic	O
or	O
therapeutic	O
.	O
      
oxolinic	B-Drug
acid	I-Drug
;	O
      
The	O
concurrent	O
administration	O
of	O
CAMPTOSAR	B-Brand
with	O
irradiation	O
has	O
not	O
been	O
adequately	O
studied	O
and	O
is	O
not	O
recommended	O
.	O
      
atorvastatin	B-Drug
concentration	O
      
In	O
utero	O
serum	O
levels	O
of	O
exposure	O
in	O
these	O
monkeys	O
were	O
9	O
%	O
of	O
maternal	O
serum	O
levels	O
.	O
      
Erythromycin	B-Drug
(	O
9	O
mg	O
t.i.d	O
)	O
produced	O
a	O
9	O
-	O
fold	O
increase	O
in	O
vardenafil	B-Drug
AUC	O
and	O
a	O
9	O
-	O
fold	O
increase	O
in	O
Cmax	O
when	O
co	O
-	O
administered	O
with	O
Vardenafil	B-Drug
9	O
mg	O
in	O
healthy	O
volunteers	O
.	O
      
Coadministration	O
of	O
valdecoxib	B-Drug
(	O
9	O
mg	O
BID	O
for	O
9	O
days	O
)	O
with	O
glyburide	B-Drug
(	O
9	O
mg	O
QD	O
or	O
9	O
mg	O
BID	O
)	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
(	O
exposure	O
)	O
of	O
glyburide	B-Drug
.	O
      
Prothrombin	O
time	O
was	O
not	O
affected	O
.	O
      
Therefore	O
if	O
concomitant	O
use	O
of	O
such	O
agents	O
is	O
indicated	O
they	O
should	O
be	O
given	O
with	O
caution	O
and	O
the	O
patient	O
's	O
serum	O
potassium	O
should	O
be	O
monitored	O
frequently	O
.	O
      
ACE	B-Group
-	O
inhibitors	I-Group
Reports	O
suggest	O
that	O
NSAIDs	B-Group
may	O
diminish	O
the	O
antihypertensive	O
effect	O
of	O
ACE	B-Group
-	O
inhibitors	I-Group
.	O
      
Verapamil	B-Drug
:	O
Coadministration	O
of	O
almotriptan	B-Drug
and	O
verapamil	B-Drug
resulted	O
in	O
a	O
9	O
%	O
increase	O
in	O
plasma	O
concentrations	O
of	O
almotriptan	B-Drug
.	O
      
No	O
dosage	O
adjustment	O
for	O
montelukast	B-Drug
is	O
recommended	O
.	O
      
-	O
Primaquine	B-Drug
or	O
      
Lamivudine	B-Drug
:	O
In	O
vitro	O
studies	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
U9	O
and	O
Molt	O
-	O
9	O
cells	O
revealed	O
that	O
lamivudine	B-Drug
significantly	O
inhibited	O
zalcitabine	B-Drug
phosphorylation	O
in	O
a	O
dose	O
dependent	O
manner	O
.	O
      
They	O
can	O
either	O
increase	O
or	O
decrease	O
the	O
effect	O
of	O
Mephenytoin	B-Drug
.	O
      
TBg	O
may	O
also	O
be	O
increased	O
during	O
infectious	O
hepatitis	O
.	O
      
Indinavir	B-Drug
is	O
an	O
inhibitor	O
of	O
the	O
cytochrome	O
P9	O
isoform	O
CYP9A9	O
.	O
      
Onset	O
of	O
action	O
of	O
tricyclics	B-Group
may	O
be	O
accelerated	O
.	O
      
therefore	O
the	O
efficacy	O
of	O
oral	O
contraceptives	B-Group
during	O
administration	O
of	O
Aprepitant	B-Drug
may	O
be	O
reduced	O
.	O
      
ethchlorvynol	B-Drug
;	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
The	O
presence	O
of	O
labetalol	O
metabolites	O
in	O
the	O
urine	O
may	O
result	O
in	O
falsely	O
elevated	O
levels	O
of	O
urinary	O
catecholamines	O
metanephrine	O
normetanephrine	O
and	O
vanillylmandelic	O
acid	O
when	O
measured	O
by	O
fluorimetric	O
or	O
photometric	O
methods	O
.	O
      
Caution	O
should	O
be	O
used	O
if	O
TOLECTIN	B-Brand
is	O
administered	O
concomitantly	O
with	O
methotrexate	B-Drug
.	O
      
Patients	O
taking	O
warfarin	B-Drug
should	O
be	O
monitored	O
regularly	O
for	O
changes	O
in	O
prothrombin	O
time	O
or	O
INR	O
.	O
      
Indinavir	B-Drug
:	O
Coadministration	O
of	O
indinavir	B-Drug
with	O
VIRACEPT	B-Brand
resulted	O
in	O
an	O
9	O
%	O
increase	O
in	O
nelfinavir	B-Drug
plasma	O
AUC	O
and	O
a	O
9	O
%	O
increase	O
in	O
indinavir	B-Drug
plasma	O
A.C	O
.	O
      
See	O
WARNINGS	O
Myopathy	O
/	O
Rhabdomyolysis	O
.	O
      
These	O
agents	O
should	O
not	O
be	O
taken	O
for	O
9	O
hours	O
before	O
or	O
for	O
9	O
hours	O
after	O
enoxacin	B-Drug
administration	O
.	O
      
increased	O
factors	O
II	O
VII	O
antigen	O
VIII	O
antigen	O
VIII	O
coagulant	O
activity	O
IX	O
X	O
XII	O
VII	O
-	O
X	O
complex	O
II	O
-	O
VII	O
-	O
X	O
complex	O
and	O
beta	O
-	O
thromboglobulin	O
;	O
      
Therefore	O
a	O
slower	O
onset	O
can	O
be	O
anticipated	O
if	O
STADOL	B-Brand
NS	I-Brand
is	O
administered	O
concomitantly	O
with	O
or	O
immediately	O
following	O
a	O
nasal	B-Group
vasoconstrictor	I-Group
.	O
      
The	O
mean	O
changes	O
were	O
observed	O
to	O
be	O
less	O
than	O
9	O
second	O
in	O
both	O
instances	O
however	O
and	O
are	O
unlikely	O
to	O
be	O
clinically	O
important	O
.	O
      
Rare	O
cases	O
of	O
elevated	O
plasma	O
concentrations	O
of	O
digoxin	B-Drug
have	O
been	O
reported	O
.	O
      
Administration	O
of	O
epinephrine	B-Drug
to	O
patients	O
receiving	O
cyclopropane	B-Drug
or	O
halogenated	B-Group
hydrocarbon	I-Group
general	I-Group
anesthetics	I-Group
such	O
as	O
halothane	B-Drug
which	O
sensitize	O
the	O
myocardium	O
may	O
induce	O
cardiac	O
arrhythmia	O
.	O
      
The	O
use	O
of	O
AGGRASTAT	B-Brand
in	O
combination	O
with	O
heparin	B-Drug
and	O
aspirin	B-Brand
has	O
been	O
associated	O
with	O
an	O
increase	O
in	O
bleeding	O
compared	O
to	O
heparin	B-Drug
and	O
aspirin	B-Drug
alone	O
(	O
see	O
      
Potassium	B-Drug
Supplements	O
and	O
Potassium	B-Group
-	O
Sparing	I-Group
Diuretics	I-Group
:	O
ACEON	B-Brand
Tablets	O
may	O
increase	O
serum	O
potassium	O
because	O
of	O
its	O
potential	O
to	O
decrease	O
aldosterone	O
production	O
.	O
      
Alcohol	B-Drug
:	O
Concomitant	O
administration	O
of	O
alcohol	B-Drug
(	O
equivalent	O
to	O
9	O
g	O
)	O
had	O
a	O
minimal	O
effect	O
on	O
plasma	O
levels	O
of	O
mirtazapine	B-Drug
(	O
9	O
mg	O
)	O
in	O
9	O
healthy	O
male	O
subjects	O
.	O
      
Administration	O
of	O
reserpine	B-Drug
during	O
therapy	O
with	O
a	O
tricyclic	B-Group
antidepressant	I-Group
has	O
been	O
shown	O
to	O
produce	O
a	O
stimulating	O
effect	O
in	O
some	O
depressed	O
patients	O
.	O
      
Valproic	B-Drug
acid	I-Drug
      
Experience	O
with	O
co	O
-	O
administration	O
of	O
HMG	B-Group
-	O
CoA	I-Group
reductase	I-Group
inhibitors	I-Group
and	O
Fentanyl	B-Drug
in	O
patients	O
is	O
limited	O
therefore	O
consideration	O
should	O
be	O
given	O
to	O
temporarily	O
suspending	O
use	O
of	O
HMG	B-Group
-	O
CoA	I-Group
reductase	I-Group
inhibitors	I-Group
in	O
patients	O
receiving	O
Fentanyl	B-Drug
.	O
      
Use	O
with	O
Anticholinergics	B-Group
:	O
Because	O
of	O
their	O
mechanism	O
of	O
action	O
cholinesterase	B-Group
inhibitors	I-Group
have	O
the	O
potential	O
to	O
interfere	O
with	O
the	O
activity	O
of	O
anticholinergic	B-Group
medications	I-Group
.	O
      
Particular	O
caution	O
is	O
recommended	O
when	O
administering	O
Gleevec	B-Brand
with	O
CYP9A9	O
substrates	O
that	O
have	O
a	O
narrow	O
therapeutic	O
window	O
(	O
e.g.	O
cyclosporine	B-Drug
or	O
pimozide	B-Drug
)	O
.	O
      
Furosemide	B-Drug
:	O
In	O
normal	O
volunteers	O
the	O
concomitant	O
administration	O
of	O
diflunisal	B-Drug
and	O
furosemide	B-Drug
had	O
no	O
effect	O
on	O
the	O
diuretic	O
activity	O
of	O
furosemide	B-Drug
.	O
      
However	O
the	O
pharmacodynamics	O
of	O
coadministration	O
of	O
zaleplon	B-Drug
and	O
promethazine	B-Drug
have	O
not	O
been	O
evaluated	O
.	O
      
CNS	O
-	O
Active	O
Drugs	O
Ethanol	B-Drug
:	O
Sonata	B-Brand
9	O
mg	O
potentiated	O
the	O
CNS	O
-	O
impairing	O
effects	O
of	O
ethanol	B-Drug
9	O
g	O
/	O
kg	O
on	O
balance	O
testing	O
and	O
reaction	O
time	O
for	O
9	O
hour	O
after	O
ethanol	B-Drug
administration	O
and	O
on	O
the	O
digit	O
symbol	O
substitution	O
test	O
(	O
DSST	O
)	O
symbol	O
copying	O
test	O
and	O
the	O
variability	O
component	O
of	O
the	O
divided	O
attention	O
test	O
for	O
9	O
hours	O
after	O
ethanol	B-Drug
administration	O
.	O
      
Rifampin	B-Drug
may	O
decrease	O
serum	O
digoxin	B-Drug
concentration	O
especially	O
in	O
patients	O
with	O
renal	O
dysfunction	O
by	O
increasing	O
the	O
non	O
-	O
renal	O
clearance	O
of	O
digoxin	B-Drug
.	O
      
Oral	O
Hypoglycemic	B-Group
Agents	I-Group
:	O
In	O
one	O
study	O
flurbiprofen	B-Drug
was	O
given	O
to	O
adult	O
diabetics	O
who	O
were	O
already	O
receiving	O
glyburide	B-Drug
(	O
n=9	O
)	O
metformin	B-Drug
(	O
n=9	O
)	O
chlorpropamide	B-Drug
with	O
phenformin	B-Drug
(	O
n=	O
9	O
)	O
or	O
glyburide	B-Drug
with	O
phenformin	B-Drug
(	O
n=9	O
)	O
.	O
      
The	O
clinical	O
relevance	O
of	O
such	O
potential	O
interactions	O
is	O
not	O
known	O
.	O
      
Drug	O
/	O
Laboratory	O
Tests	O
Interactions	O
There	O
are	O
no	O
known	O
clinically	O
significant	O
interactions	O
of	O
CLOLAR	B-Brand
with	O
other	O
medications	O
or	O
laboratory	O
tests	O
.	O
      
Acellular	B-Group
live	B-Group
and	O
live	B-Group
-	O
attenuated	I-Group
vaccines	I-Group
should	O
not	O
be	O
administered	O
during	O
RAPTIVA	B-Brand
treatment	O
.	O
      
saquinavir	B-Drug
concentration	O
      
Free	O
hormone	O
concentrations	O
may	O
be	O
decreased	O
.	O
      
A	O
single	O
tonic	O
convulsion	O
was	O
seen	O
in	O
each	O
of	O
9	O
male	O
dogs	O
(	O
one	O
treated	O
at	O
9	O
mg	O
/	O
kg	O
/	O
day	O
and	O
one	O
at	O
9	O
mg	O
/	O
kg	O
/	O
day	O
)	O
in	O
a	O
9	O
-	O
year	O
study	O
.	O
      
However	O
interactions	O
may	O
be	O
expected	O
and	O
FLOMAX	B-Brand
capsules	O
should	O
NOT	O
be	O
used	O
in	O
combination	O
with	O
other	O
alpha	B-Group
-	O
adrenergic	I-Group
blocking	I-Group
agents	I-Group
.	O
      
Displacement	O
of	O
penicillin	B-Group
from	O
plasma	O
protein	O
binding	O
sites	O
will	O
elevate	O
the	O
level	O
of	O
free	O
penicillin	B-Group
in	O
the	O
serum	O
.	O
      
These	O
compounds	O
are	O
metabolized	O
through	O
various	O
cytochrome	O
P9	O
isozymes	O
including	O
CYP9A9	O
CYP9C9	O
CYP9C9	O
CYP9D9	O
and	O
CYP9A	O
.	O
      
(	O
9	O
mg	O
day	O
9	O
9	O
mg	O
QD	O
9	O
days	O
)	O
      
Drug	O
interaction	O
studies	O
have	O
not	O
been	O
performed	O
with	O
Soliris	B-Brand
.	O
      
However	O
in	O
a	O
single	O
in	O
vivo	O
rodent	O
study	O
denileukin	B-Drug
diftitox	I-Drug
had	O
no	O
effect	O
on	O
P9	O
levels	O
.	O
      
HMG	B-Group
-	O
CoA	I-Group
Reductase	I-Group
Inhibitor	I-Group
:	O
atorvastatin	B-Drug
      
Their	O
concurrent	O
use	O
should	O
be	O
avoided	O
.	O
      
Epidemiological	O
studies	O
of	O
the	O
case	O
-	O
control	O
and	O
cohort	O
design	O
that	O
have	O
demonstrated	O
an	O
association	O
between	O
use	O
of	O
psychotropic	B-Group
drugs	I-Group
that	O
interfere	O
with	O
serotonin	O
reuptake	O
and	O
the	O
occurrence	O
of	O
upper	O
gastrointestinal	O
bleeding	O
have	O
also	O
shown	O
that	O
concurrent	O
use	O
of	O
an	O
NSAID	B-Group
or	O
aspirin	B-Brand
potentiated	O
the	O
risk	O
of	O
bleeding	O
.	O
      
Anticholinergics	B-Group
antagonize	O
the	O
effects	O
of	O
antiglaucoma	B-Group
agents	I-Group
.	O
      
Caution	O
is	O
advised	O
in	O
patients	O
receiving	O
concomitant	O
high	O
-	O
dose	O
aspirin	B-Brand
and	O
carbonic	B-Group
anhydrase	I-Group
inhibitors	I-Group
as	O
anorexia	O
tachypnea	O
lethargy	O
and	O
coma	O
have	O
been	O
rarely	O
reported	O
due	O
to	O
a	O
possible	O
drug	O
interaction	O
.	O
      
The	O
following	O
information	O
was	O
obtained	O
from	O
the	O
literature	O
.	O
      
Co	O
-	O
administration	O
of	O
irbesartan	B-Drug
reduced	O
aliskiren	B-Drug
Cmax	O
up	O
to	O
9	O
%	O
after	O
multiple	O
dosing	O
.	O
      
Coadministration	O
of	O
valdecoxib	B-Drug
(	O
9	O
mg	O
BID	O
(	O
day	O
9	O
)	O
and	O
9	O
mg	O
QD	O
(	O
days	O
9	O
-	O
9	O
)	O
)	O
with	O
glyburide	B-Drug
(	O
9	O
mg	O
QD	O
)	O
did	O
not	O
affect	O
either	O
the	O
pharmacokinetics	O
(	O
exposure	O
)	O
or	O
the	O
pharmacodynamics	O
(	O
blood	O
glucose	O
and	O
insulin	O
levels	O
)	O
of	O
glyburide	B-Drug
.	O
      
ZINECARD	B-Brand
does	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
doxorubicin	B-Drug
.	O
      
metabolizers	O
.	O
      
Cytochrome	O
P	O
-	O
9	O
is	O
not	O
known	O
to	O
be	O
involved	O
in	O
the	O
metabolism	O
of	O
Plenaxis	B-Brand
.	O
      
RAPTIVA	B-Brand
should	O
not	O
be	O
used	O
with	O
other	O
immunosuppressive	B-Group
drugs	I-Group
.	O
      
Some	O
of	O
the	O
CNS	O
and	O
genitourinary	O
symptoms	O
may	O
be	O
related	O
to	O
the	O
underlying	O
disease	O
rather	O
than	O
to	O
drug	O
therapy	O
.	O
      
When	O
the	O
CYP9D9	O
inhibitor	O
is	O
withdrawn	O
from	O
the	O
combination	O
therapy	O
aripiprazole	B-Drug
dose	O
should	O
then	O
be	O
increased	O
.	O
      
ACE	B-Group
inhibitors	I-Group
:	O
Reports	O
suggest	O
that	O
NSAIDs	B-Group
may	O
diminish	O
the	O
antihypertensive	O
effect	O
of	O
ACE	B-Group
inhibitors	I-Group
.	O
      
Drugs	O
That	O
Should	O
Not	O
Be	O
Coadministered	O
With	O
INVIRASE	B-Brand
/	O
Ritonavir	B-Drug
      
Other	O
:	O
There	O
appears	O
to	O
be	O
no	O
pharmacokinetic	O
interaction	O
between	O
acitretin	B-Drug
and	O
cimetidine	B-Drug
digoxin	B-Drug
or	O
glyburide	B-Drug
.	O
      
Changes	O
in	O
insulin	B-Drug
and	O
other	O
diabetes	O
drug	O
therapies	O
may	O
be	O
necessary	O
during	O
treatment	O
with	O
mazindol	B-Drug
.	O
      
The	O
effects	O
if	O
any	O
on	O
the	O
pituitary	O
-	O
gonadal	O
axis	O
in	O
premenopausal	O
women	O
are	O
unknown	O
.	O
      
Most	O
automated	O
equipment	O
for	O
measurement	O
of	O
creatinine	O
makes	O
use	O
of	O
the	O
Jaffe	O
reaction	O
.	O
      
Other	O
:	O
Neither	O
fosinopril	B-Drug
sodium	I-Drug
nor	O
its	O
metabolites	O
have	O
been	O
found	O
to	O
interact	O
with	O
food	O
.	O
      
Coumarin	B-Group
-	O
Derivative	I-Group
Anticoagulants	I-Group
:	O
Prolongation	O
of	O
prothrombin	O
time	O
(	O
PT	O
)	O
and	O
International	O
Normalized	O
Ratio	O
(	O
INR	O
)	O
were	O
observed	O
in	O
patients	O
receiving	O
ZOLINZA	B-Brand
concomitantly	O
with	O
coumarin	B-Group
-	O
derivative	I-Group
anticoagulants	I-Group
.	O
      
Coadminstration	O
with	O
agents	O
that	O
induce	O
9A9	O
activity	O
may	O
reduce	O
the	O
efficacy	O
of	O
DURAGESIC	B-Brand
.	O
      
increased	O
factors	O
II	O
VII	O
antigen	O
VIII	O
antigen	O
VIII	O
coagulant	O
activity	O
IX	O
X	O
XII	O
VII	O
-	O
X	O
complex	O
II	O
-	O
VII	O
-	O
X	O
complex	O
and	O
beta	O
-	O
thromboglobulin	O
;	O
      
(	O
See	O
<	O
a	O
href=	O
``	O
flucon_cp.htm	O
#	O
CP	O
''	O
>	O
CLINICAL	O
PHARMACOLOGY	O
:	O
Drug	O
Interaction	O
Studies	O
.	O
)	O
      
Inducers	O
and	O
Inhibitors	O
of	O
Hepatic	O
Metabolism	O
:	O
Rifampin	B-Drug
reduced	O
plasma	O
concentrations	O
of	O
carvedilol	B-Drug
by	O
about	O
9	O
%	O
.	O
      
Concomitant	O
administration	O
of	O
Kerlone	B-Brand
with	O
the	O
oral	O
anticoagulant	B-Group
warfarin	B-Drug
has	O
been	O
shown	O
not	O
to	O
potentiate	O
the	O
anticoagulant	O
effect	O
of	O
warfarin	B-Drug
.	O
      
Careful	O
monitoring	O
of	O
cyclosporine	B-Drug
concentrations	O
and	O
serum	O
creatinine	O
is	O
recommended	O
in	O
patients	O
receiving	O
DIFLUCAN	B-Brand
and	O
cyclosporine	B-Drug
.	O
      
The	O
oral	O
bioavailability	O
of	O
enoxacin	B-Drug
is	O
reduced	O
by	O
9	O
%	O
with	O
coadministration	O
of	O
ranitidine	B-Drug
.	O
      
D	O
.	O
      
*Not	O
administered	O
but	O
an	O
active	O
metabolite	O
of	O
carbamazepine	B-Drug
.	O
      
Dexfenfluramine	B-Drug
should	O
not	O
be	O
administered	O
with	O
other	O
serotoninergic	B-Group
agents	I-Group
.	O
      
In	O
such	O
a	O
case	O
the	O
peripheral	O
vascular	O
resistance	O
may	O
increase	O
.	O
      
In	O
a	O
preclinical	O
study	O
in	O
dogs	O
ezetimibe	B-Drug
increased	O
cholesterol	O
in	O
the	O
gallbladder	O
bile	O
.	O
      
Uricosuric	B-Group
Agents	I-Group
:	O
Since	O
the	O
excretion	O
of	O
oxipurinol	B-Drug
is	O
similar	O
to	O
that	O
of	O
urate	O
uricosuric	B-Group
agents	I-Group
which	O
increase	O
the	O
excretion	O
of	O
urate	O
are	O
also	O
likely	O
to	O
increase	O
the	O
excretion	O
of	O
oxipurinol	B-Drug
and	O
thus	O
lower	O
the	O
degree	O
of	O
inhibition	O
of	O
xanthine	O
oxidase	O
.	O
      
Accordingly	O
it	O
may	O
be	O
advisable	O
to	O
discontinue	O
MYKROX	B-Brand
Tablets	O
three	O
days	O
before	O
elective	O
surgery	O
.	O
      
With	O
drugs	O
inhibiting	O
CYP9A	O
to	O
a	O
lesser	O
but	O
still	O
significant	O
degree	O
estazolam	B-Drug
should	O
be	O
used	O
only	O
with	O
caution	O
and	O
consideration	O
of	O
appropriate	O
dosage	O
reduction	O
.	O
      
Excessive	O
widening	O
of	O
the	O
QRS	O
complex	O
and	O
/	O
or	O
prolongation	O
of	O
the	O
Q	O
-	O
T	O
interval	O
may	O
occur	O
in	O
these	O
situations	O
.	O
      
Plasma	O
levels	O
of	O
anticonvulsant	B-Group
agents	I-Group
may	O
become	O
subtherapeutic	O
during	O
cisplatin	B-Drug
therapy	O
.	O
      
In	O
vitro	O
studies	O
show	O
significant	O
inhibition	O
of	O
the	O
formation	O
of	O
oxidized	O
irbesartan	O
metabolites	O
with	O
the	O
known	O
cytochrome	O
CYP	O
9C9	O
substrates	O
/	O
inhibitors	O
sulphenazole	B-Drug
tolbutamide	B-Drug
and	O
nifedipine	B-Drug
.	O
      
Because	O
the	O
action	O
of	O
metoclopramide	B-Drug
will	O
influence	O
the	O
delivery	O
of	O
food	O
to	O
the	O
intestines	O
and	O
thus	O
the	O
rate	O
of	O
absorption	O
insulin	B-Drug
dosage	O
or	O
timing	O
of	O
dosage	O
may	O
require	O
adjustment	O
.	O
      
As	O
with	O
other	O
cephalosporins	B-Group
high	O
concentrations	O
of	O
cefotetan	B-Drug
may	O
interfere	O
with	O
measurement	O
of	O
serum	O
and	O
urine	O
creatinine	O
levels	O
by	O
Jaffe	O
reaction	O
and	O
produce	O
false	O
increases	O
in	O
the	O
levels	O
of	O
creatinine	O
reported	O
.	O
      
Opiate	B-Group
agonists	I-Group
      
Additional	O
drugs	O
that	O
are	O
not	O
recommended	O
for	O
coadministration	O
with	O
INVIRASE	B-Brand
and	O
ritonavir	B-Drug
are	O
included	O
below	O
.	O
      
Although	O
ROMAZICON	B-Brand
exerts	O
a	O
slight	O
intrinsic	O
anticonvulsant	O
effect	O
its	O
abrupt	O
suppression	O
of	O
the	O
protective	O
effect	O
of	O
a	O
benzodiazepine	B-Group
agonist	O
can	O
give	O
rise	O
to	O
convulsions	O
in	O
epileptic	O
patients	O
.	O
      
Even	O
though	O
such	O
interactions	O
have	O
not	O
been	O
seen	O
in	O
clinical	O
studies	O
with	O
DynaCirc	B-Brand
(	O
isradipine	B-Drug
)	O
an	O
increased	O
volume	O
of	O
circulating	O
fluids	O
might	O
be	O
required	O
if	O
such	O
an	O
interaction	O
were	O
to	O
occur	O
.	O
      
Potassium	O
sparing	O
agents	O
should	O
generally	O
not	O
be	O
used	O
in	O
patients	O
with	O
heart	O
failure	O
who	O
are	O
receiving	O
PRINIVIL	B-Brand
.	O
      
DIGOXIN	B-Drug
:	O
Plasma	O
digoxin	B-Drug
levels	O
and	O
digoxin	B-Drug
clearance	O
at	O
steady	O
-	O
state	O
were	O
not	O
affected	O
by	O
co	O
-	O
administration	O
of	O
9	O
mg	O
cerivastatin	B-Drug
sodium	I-Drug
.	O
      
Oral	O
contraceptives	B-Group
and	O
other	O
hormonalmethods	O
of	O
birth	O
control	O
should	O
not	O
be	O
usedas	O
the	O
sole	O
method	O
of	O
contraception	O
inwomen	O
taking	O
nevirapine	B-Drug
since	O
nevirapinemay	O
lower	O
the	O
plasma	O
levels	O
of	O
thesemedications	O
.	O
      
Breakthrough	O
bleeding	O
has	O
been	O
reported	O
      
Hepatotoxicity	O
Asymptomatic	O
increases	O
in	O
liver	O
transaminases	O
have	O
been	O
observed	O
in	O
TARCEVA	B-Brand
treated	O
patients	O
;	O
      
Digoxin	B-Drug
:	O
In	O
9	O
normal	O
-	O
weight	O
subjects	O
receiving	O
XENICAL	B-Brand
9	O
mg	O
three	O
times	O
a	O
day	O
for	O
9	O
days	O
XENICAL	B-Brand
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
a	O
single	O
dose	O
of	O
digoxin	B-Drug
.	O
      
No	O
clinical	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
.	O
      
Drug	O
Name	O
      
Although	O
it	O
has	O
not	O
been	O
established	O
that	O
there	O
is	O
an	O
interaction	O
between	O
Clozapine	B-Drug
and	O
benzodiazepines	B-Group
or	O
other	O
psychotropics	B-Group
caution	O
is	O
advised	O
when	O
clozapine	B-Drug
is	O
initiated	O
in	O
patients	O
taking	O
a	O
benzodiazepine	B-Group
or	O
any	O
other	O
psychotropic	B-Group
drug	I-Group
.	O
      
Risk	O
of	O
Anaphylactic	O
Reaction	O
:	O
Although	O
it	O
is	O
known	O
that	O
patients	O
on	O
beta	B-Group
-	O
blockers	I-Group
may	O
be	O
refractory	O
to	O
epinephrine	B-Drug
in	O
the	O
treatment	O
of	O
anaphylactic	O
shock	O
beta	B-Group
-	O
blockers	I-Group
can	O
in	O
addition	O
interfere	O
with	O
the	O
modulation	O
of	O
allergic	O
reaction	O
and	O
lead	O
to	O
an	O
increased	O
severity	O
and	O
/	O
or	O
frequency	O
of	O
attacks	O
.	O
      
Due	O
to	O
low	O
systemic	O
exposure	O
to	O
retapamulin	B-Drug
following	O
topical	O
application	O
in	O
patients	O
dosage	O
adjustments	O
for	O
retapamulin	B-Drug
are	O
unnecessary	O
when	O
co	O
-	O
administered	O
with	O
CYP9A9	O
inhibitors	O
such	O
as	O
ketoconazole	B-Drug
.	O
      
Ketorolac	B-Drug
is	O
highly	O
bound	O
to	O
human	O
plasma	O
protein	O
(	O
mean	O
9	O
%	O
)	O
.	O
      
Phenytoin	B-Drug
      
While	O
in	O
vitro	O
studies	O
have	O
shown	O
that	O
mirtazapine	B-Drug
is	O
not	O
a	O
potent	O
inhibitor	O
of	O
any	O
of	O
these	O
enzymes	O
an	O
indication	O
that	O
mirtazapine	B-Drug
is	O
not	O
likely	O
to	O
have	O
a	O
clinically	O
significant	O
inhibitory	O
effect	O
on	O
the	O
metabolism	O
of	O
other	O
drugs	O
that	O
are	O
substrates	O
for	O
these	O
cytochrome	O
P9	O
enzymes	O
the	O
concomitant	O
use	O
of	O
REMERON	B-Brand
SolTab	I-Brand
with	O
most	O
other	O
drugs	O
metabolized	O
by	O
these	O
enzymes	O
has	O
not	O
been	O
formally	O
studied	O
.	O
      
Adrenergic	B-Group
Agents	I-Group
:	O
Some	O
individuals	O
receiving	O
ZYVOX	B-Brand
may	O
experience	O
a	O
reversible	O
enhancement	O
of	O
the	O
pressor	O
response	O
to	O
indirect	O
-	O
acting	O
sympathomimetic	B-Group
agents	I-Group
vasopressor	B-Group
or	O
dopaminergic	B-Group
agents	I-Group
.	O
      
Probenecid	B-Drug
:	O
The	O
oral	O
combination	O
of	O
probenecid	B-Drug
before	O
intramuscular	O
injection	O
of	O
PIPRACIL	B-Brand
produces	O
an	O
increase	O
in	O
piperacillin	B-Drug
peak	O
serum	O
level	O
of	O
about	O
9	O
%	O
.	O
      
WelChol	B-Brand
has	O
been	O
studied	O
in	O
several	O
human	O
drug	O
interaction	O
studies	O
in	O
which	O
it	O
was	O
administered	O
with	O
a	O
meal	O
and	O
the	O
test	O
drug	O
.	O
      
No	O
trials	O
specifically	O
examining	O
potential	O
drug	O
interactions	O
with	O
Natrecor	B-Brand
were	O
conducted	O
although	O
many	O
concomitant	O
drugs	O
were	O
used	O
in	O
clinical	O
trials	O
.	O
      
In	O
clinical	O
studies	O
coadministration	O
of	O
WelChol	B-Brand
with	O
atorvastatin	B-Drug
lovastatin	B-Drug
or	O
simvastatin	B-Drug
did	O
not	O
interfere	O
with	O
the	O
lipid	O
-	O
lowering	O
activity	O
of	O
the	O
HMG	B-Group
-	O
CoA	I-Group
reductase	I-Group
inhibitor	I-Group
.	O
      
Methotrexate	B-Drug
:	O
In	O
an	O
interaction	O
study	O
of	O
rheumatoid	O
arthritis	O
patients	O
taking	O
methotrexate	B-Drug
CELEBREX	B-Brand
did	O
not	O
have	O
a	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
methotrexate	B-Drug
.	O
      
Drug	O
interaction	O
studies	O
with	O
decitabine	B-Drug
have	O
not	O
been	O
conducted	O
.	O
      
Therefore	O
if	O
concomitant	O
use	O
of	O
these	O
agents	O
is	O
indicated	O
because	O
of	O
demonstrated	O
hypokalemia	O
they	O
should	O
be	O
used	O
with	O
caution	O
and	O
with	O
frequent	O
monitoring	O
of	O
serum	O
potassium	O
.	O
      
However	O
at	O
that	O
time	O
the	O
plasma	O
levels	O
of	O
diazepam	B-Drug
were	O
below	O
the	O
therapeutic	O
interval	O
and	O
thus	O
this	O
interaction	O
is	O
unlikely	O
to	O
be	O
of	O
clinical	O
relevance	O
.	O
      
Drugs	O
That	O
Inhibit	O
CYP9A9	O
(	O
Ketoconazole	B-Drug
)	O
CYP9A9	O
is	O
a	O
major	O
metabolic	O
pathway	O
for	O
elimination	O
of	O
eszopiclone	B-Drug
.	O
      
Cyclosporine	B-Drug
:	O
Elevated	O
serum	O
levels	O
of	O
cyclosporine	B-Drug
have	O
been	O
reported	O
with	O
concomitant	O
use	O
of	O
cyclosporine	B-Drug
with	O
other	O
members	O
of	O
the	O
quinolone	B-Group
class	I-Group
.	O
      
At	O
9	O
hours	O
postdose	O
a	O
similar	O
proportion	O
of	O
patients	O
treated	O
with	O
methotrexate	B-Drug
alone	O
(	O
9	O
%	O
)	O
and	O
subsequently	O
treated	O
with	O
methotrexate	B-Drug
co	O
-	O
administered	O
with	O
9	O
mg	O
of	O
rofecoxib	B-Drug
(	O
9	O
%	O
)	O
had	O
methotrexate	B-Drug
plasma	O
concentrations	O
below	O
the	O
measurable	O
limit	O
(	O
9	O
ng	O
/	O
mL	O
)	O
.	O
      
Liver	O
Function	O
Tests	O
:	O
Elevations	O
of	O
AST	O
(	O
SGOT	O
)	O
ALT	O
(	O
SGPT	O
)	O
or	O
LDH	O
were	O
experienced	O
by	O
approximately	O
9	O
in	O
9	O
patients	O
treated	O
with	O
Soriatane	B-Brand
.	O
      
Nephrotoxicity	O
and	O
ototoxicity	O
were	O
not	O
noted	O
when	O
ceftazidime	B-Drug
was	O
given	O
alone	O
in	O
clinical	O
trials	O
.	O
      
Enoxaparin	B-Drug
dosed	O
as	O
a	O
9	O
mg	O
/	O
kg	O
subcutaneous	O
injection	O
q9h	O
for	O
four	O
doses	O
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
eptifibatide	B-Drug
or	O
the	O
level	O
of	O
platelet	O
aggregation	O
in	O
healthy	O
adults	O
.	O
      
Increasing	O
the	O
felbamate	B-Drug
dose	O
to	O
9	O
mg	O
/	O
day	O
in	O
six	O
of	O
these	O
subjects	O
increased	O
the	O
steady	O
-	O
state	O
phenytoin	B-Drug
Cmin	O
to	O
9	O
9	O
micrograms	O
/	O
mL	O
.	O
      
Agents	O
that	O
are	O
CYP	O
inducers	O
that	O
have	O
been	O
found	O
or	O
are	O
expected	O
to	O
decrease	O
plasma	O
levels	O
of	O
EQUETROTM	B-Brand
are	O
the	O
following	O
:	O
Cisplatin	B-Drug
doxorubicin	B-Drug
HCL	I-Drug
felbamate	B-Drug
rifampin	B-Drug
phenobarbital	B-Drug
Phenytoin	B-Drug
(	O
9	O
)	O
primidone	B-Drug
methsuximide	B-Drug
and	O
theophylline	B-Drug
Thus	O
if	O
a	O
patient	O
has	O
been	O
titrated	O
to	O
a	O
stable	O
dosage	O
on	O
EQUETROTM	B-Brand
and	O
then	O
begins	O
a	O
course	O
of	O
treatment	O
with	O
one	O
of	O
these	O
CYP9A9	O
inducers	O
it	O
is	O
reasonable	O
to	O
expect	O
that	O
a	O
dose	O
increase	O
for	O
EQUETROTM	B-Brand
may	O
be	O
necessary	O
.	O
      
It	O
is	O
recommended	O
that	O
glucose	O
tests	O
based	O
on	O
enzymatic	O
glucose	O
oxidase	O
reactions	O
(	O
such	O
as	O
Clinistix	O
**	O
or	O
Tes	O
-	O
Tape	O
**	O
)	O
be	O
used	O
.	O
      
Bosentan	B-Drug
is	O
metabolized	O
by	O
CYP9C9	O
and	O
CYP9A9	O
.	O
      
However	O
patients	O
on	O
digoxin	B-Drug
may	O
show	O
elevations	O
of	O
digoxin	B-Drug
concentrations	O
after	O
initiation	O
of	O
therapy	O
with	O
FLOLAN	B-Brand
which	O
may	O
be	O
clinically	O
significant	O
in	O
patients	O
prone	O
to	O
digoxin	B-Drug
toxicity	O
.	O
      
Concurrent	O
use	O
of	O
erythromycin	B-Drug
and	O
ergotamine	B-Drug
or	O
dihydroergotamine	B-Drug
has	O
been	O
associated	O
in	O
some	O
patients	O
with	O
acute	O
ergot	O
toxicity	O
characterized	O
by	O
severe	O
peripheral	O
vasospasm	O
and	O
dysesthesia	O
.	O
      
Salt	O
substitutes	O
containing	O
potassium	B-Drug
should	O
also	O
be	O
used	O
with	O
caution	O
.	O
      
Thiazides	B-Group
:	O
Thiazides	B-Group
are	O
known	O
to	O
induce	O
hypercalcemia	O
by	O
the	O
reduction	O
of	O
calcium	O
excretion	O
in	O
urine	O
.	O
      
The	O
average	O
increase	O
was	O
9	O
%	O
.	O
      
The	O
use	O
of	O
MAO	B-Group
inhibitors	I-Group
or	O
tricyclic	B-Group
antidepressants	I-Group
with	O
hydrocodone	B-Drug
preparations	O
may	O
increase	O
the	O
effect	O
of	O
either	O
the	O
antidepressant	B-Group
or	O
hydrocodone	B-Drug
.	O
      
Paclitaxel	B-Drug
-	O
In	O
one	O
report	O
L	B-Drug
-	O
glutamine	I-Drug
at	O
a	O
dose	O
of	O
9	O
grams	O
three	O
times	O
daily	O
given	O
9	O
hours	O
after	O
receiving	O
paclitaxel	B-Drug
appeared	O
to	O
prevent	O
the	O
development	O
of	O
myalgia	O
and	O
arthralgia	O
adverse	O
reactions	O
of	O
paclitaxel	B-Drug
.	O
      
In	O
a	O
study	O
involving	O
9	O
adult	O
volunteers	O
TORADOLORAL	O
was	O
coadministered	O
with	O
a	O
single	O
dose	O
of	O
9	O
mg	O
warfarin	B-Drug
causing	O
no	O
significant	O
changes	O
in	O
pharmacokinetics	O
or	O
pharmacodynamics	O
of	O
warfarin	B-Drug
.	O
      
However	O
the	O
metabolic	O
clearance	O
of	O
mexiletine	B-Drug
in	O
the	O
extensive	O
metabolizer	O
phenotype	O
decreased	O
by	O
about	O
9	O
%	O
making	O
the	O
poor	O
and	O
extensive	O
metabolizer	O
groups	O
indistinguishable	O
.	O
      
Rarely	O
salicylate	B-Group
toxicity	O
may	O
occur	O
in	O
patients	O
who	O
discontinue	O
steroids	B-Group
after	O
concurrent	O
high	O
-	O
dose	O
aspirin	B-Brand
therapy	O
.	O
      
Sever	O
neurologic	O
signs	O
including	O
coma	O
have	O
occurred	O
with	O
concurrent	O
use	O
of	O
carbamazepine	B-Drug
.	O
      
Acetaminophen	B-Drug
:	O
In	O
normal	O
volunteers	O
concomitant	O
administration	O
of	O
diflunisal	B-Drug
and	O
acetaminophen	B-Drug
resulted	O
in	O
an	O
approximate	O
9	O
%	O
increase	O
in	O
plasma	O
levels	O
of	O
acetaminophen	B-Drug
.	O
      
Both	O
groups	O
of	O
agents	O
lower	O
blood	O
levels	O
and	O
efficacy	O
of	O
amphetamines	B-Group
.	O
      
In	O
a	O
parallel	O
group	O
drug	O
interaction	O
study	O
comparing	O
the	O
intravenous	O
prodrug	O
form	O
of	O
valdecoxib	B-Drug
at	O
9	O
mg	O
BID	O
(	O
n=9	O
)	O
vs	O
placebo	O
(	O
n=9	O
)	O
valdecoxib	B-Drug
had	O
no	O
effect	O
on	O
in	O
vitro	O
aspirin	B-Brand
-	O
mediated	O
inhibition	O
of	O
arachidonate	O
-	O
or	O
collagen	O
-	O
stimulated	O
platelet	O
aggregation	O
.	O
      
Drug	O
interaction	O
studies	O
have	O
shown	O
that	O
esomeprazole	B-Drug
does	O
not	O
have	O
any	O
clinically	O
significant	O
interactions	O
with	O
phenytoin	B-Drug
warfarin	B-Drug
quinidine	B-Drug
clarithromycin	B-Drug
or	O
amoxicillin	B-Drug
.	O
      
When	O
duloxetine	B-Drug
was	O
administered	O
(	O
at	O
a	O
dose	O
of	O
9	O
mg	O
BID	O
)	O
in	O
conjunction	O
with	O
a	O
single	O
9	O
-	O
mg	O
dose	O
of	O
desipramine	B-Drug
a	O
CYP9D9	O
substrate	O
the	O
AUC	O
of	O
desipramine	B-Drug
increased	O
9	O
-	O
fold	O
.	O
      
SERUM	O
LEVELS	O
OF	O
PHENYTOIN	B-Drug
SHOULD	O
BE	O
DETERMINED	O
ON	O
DIFFERENT	O
DAYS	O
FOR	O
EVIDENCE	O
OF	O
AN	O
INCREASE	O
OR	O
FOR	O
A	O
CONTINUING	O
RISE	O
IN	O
LEVELS	O
.	O
      
Although	O
such	O
a	O
risk	O
is	O
not	O
verified	O
for	O
roxithromycin	B-Drug
combination	O
of	O
roxithromycin	B-Drug
with	O
such	O
drugs	O
is	O
not	O
recommended	O
.	O
      
The	O
clinical	O
significance	O
of	O
this	O
interaction	O
is	O
not	O
known	O
;	O
      
Patients	O
/	O
Guardians	O
should	O
be	O
given	O
the	O
following	O
information	O
:	O
i	O
.	O
      
Antidepressants	B-Group
tricyclic	B-Group
Amphetamines	B-Group
may	O
enhance	O
the	O
activity	O
of	O
tricyclic	B-Drug
antidepressants	I-Drug
or	O
sympathomimetic	B-Group
agents	I-Group
;	O
      
chloral	B-Drug
hydrate	I-Drug
*	O
;	O
      
DOSTINEX	B-Brand
should	O
not	O
be	O
administered	O
concurrently	O
with	O
D9	O
-	O
antagonists	O
such	O
as	O
phenothiazines	B-Group
butyrophenones	B-Group
thioxanthines	B-Group
or	O
metoclopramide	B-Drug
.	O
      
The	O
pressor	O
effects	O
of	O
ERGOMAR	B-Brand
and	O
other	O
vasoconstrictor	B-Group
drugs	I-Group
can	O
combine	O
to	O
cause	O
dangerous	O
hypertension	O
.	O
      
Ethinyl	B-Drug
estradiol	I-Drug
      
Effect	O
of	O
Probenecid	B-Drug
:	O
Probenecid	B-Drug
is	O
a	O
blocker	O
of	O
renal	O
tubular	O
secretion	O
.	O
      
Lotensin	B-Brand
has	O
been	O
used	O
concomitantly	O
with	O
beta	B-Group
-	O
adrenergic	I-Group
-	O
blocking	I-Group
agents	I-Group
calcium	B-Group
-	O
channel	I-Group
-	O
blocking	I-Group
agents	I-Group
diuretics	B-Group
digoxin	B-Drug
and	O
hydralazine	B-Drug
without	O
evidence	O
of	O
clinically	O
important	O
adverse	O
interactions	O
.	O
      
Drugs	O
that	O
may	O
have	O
their	O
plasma	O
concentration	O
altered	O
by	O
Gleevec	B-Brand
Gleevec	B-Brand
increases	O
the	O
mean	O
cmax	O
and	O
AUC	O
of	O
simvastatin	B-Drug
(	O
CYP9A9	O
substrate	O
)	O
9	O
-	O
and	O
9	O
-	O
fold	O
respectively	O
suggesting	O
an	O
inhibition	O
of	O
the	O
CYP9A9	O
by	O
Gleevec	B-Brand
.	O
      
Careful	O
monitoring	O
of	O
phenytoin	B-Drug
concentrations	O
in	O
patients	O
receiving	O
DIFLUCAN	B-Brand
and	O
phenytoin	B-Drug
is	O
recommended	O
.	O
      
Consequently	O
the	O
dose	O
of	O
VERSED	B-Brand
Syrup	I-Brand
should	O
be	O
adjusted	O
according	O
to	O
the	O
type	O
and	O
amount	O
of	O
concomitant	O
medications	O
administered	O
and	O
the	O
desired	O
clinical	O
response	O
.	O
      
Lymphocytopenia	O
has	O
been	O
reported	O
in	O
patients	O
receiving	O
CAMPTOSAR	B-Brand
and	O
it	O
is	O
possible	O
that	O
the	O
administration	O
of	O
dexamethasone	B-Drug
as	O
antiemetic	O
prophylaxis	O
may	O
have	O
enhanced	O
the	O
likelihood	O
of	O
this	O
effect	O
.	O
      
In	O
addition	O
reduced	O
kidney	O
and	O
liver	O
function	O
secondary	O
to	O
PROLEUKIN	B-Brand
treatment	O
may	O
delay	O
elimination	O
of	O
concomitant	O
medications	O
and	O
increase	O
the	O
risk	O
of	O
adverse	O
events	O
from	O
those	O
drugs	O
.	O
      
Naproxen	B-Drug
:	O
The	O
concomitant	O
administration	O
of	O
diflunisal	B-Drug
and	O
naproxen	B-Drug
in	O
normal	O
volunteers	O
had	O
no	O
effect	O
on	O
the	O
plasma	O
levels	O
of	O
naproxen	B-Drug
but	O
significantly	O
decreased	O
the	O
urinary	O
excretion	O
of	O
naproxen	B-Drug
and	O
its	O
glucuronide	O
metabolite	O
.	O
      
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
reactions	O
such	O
as	O
cardiac	O
arrhythmias	O
.	O
      
decrease	O
the	O
ED9	O
of	O
MIVACRON	B-Brand
by	O
as	O
much	O
as	O
9	O
%	O
(	O
see	O
CLINICAL	O
PHARMACOLOGY	O
:	O
Pharmacodynamics	O
and	O
Individualization	O
of	O
Dosages	O
)	O
.	O
      
The	O
drugs	O
that	O
inhibit	O
cytochrome	O
P9	O
9D9	O
include	O
some	O
that	O
are	O
not	O
metabolized	O
by	O
the	O
enzyme	O
(	O
quinidine	B-Drug
;	O
      
The	O
disposition	O
of	O
theophylline	B-Drug
was	O
not	O
altered	O
by	O
concomitant	O
cetirizine	B-Drug
administration	O
.	O
      
If	O
pregnancy	O
occurs	O
while	O
taking	O
AMEVIVE	B-Brand
continued	O
use	O
of	O
the	O
drug	O
should	O
be	O
assessed	O
.	O
      
This	O
decrease	O
in	O
bioavailability	O
was	O
about	O
9	O
%	O
when	O
gabapentin	B-Drug
was	O
administered	O
9	O
hours	O
after	O
Maalox	B-Brand
.	O
      
Terfenadine	B-Drug
:	O
No	O
clinically	O
significant	O
changes	O
occurred	O
in	O
heart	O
rate	O
or	O
corrected	O
QT	O
intervals	O
or	O
in	O
terfenadine	B-Drug
metabolite	O
or	O
lomefloxacin	B-Drug
pharmacokinetics	O
during	O
concurrent	O
administration	O
of	O
lomefloxacin	B-Drug
and	O
terfenadine	B-Drug
at	O
steady	O
-	O
state	O
in	O
9	O
healthy	O
males	O
.	O
      
Acetylsalicylic	B-Drug
acid	I-Drug
did	O
not	O
alter	O
the	O
clearance	O
(	O
pharmacokinetics	O
)	O
of	O
iloprost	B-Drug
.	O
      
The	O
9	O
mg	O
/	O
kg	O
dose	O
resulted	O
in	O
a	O
systemic	O
exposure	O
approximately	O
9	O
times	O
the	O
human	O
plasma	O
area	O
-	O
under	O
-	O
the	O
-	O
curve	O
(	O
AUC	O
9	O
-	O
9	O
hours	O
)	O
based	O
on	O
the	O
maximum	O
human	O
dose	O
of	O
9	O
mg	O
/	O
day	O
.	O
      
A	O
9	O
mg	O
once	O
-	O
daily	O
dose	O
was	O
not	O
studied	O
but	O
would	O
be	O
expected	O
to	O
increase	O
aliskiren	B-Drug
blood	O
levels	O
further	O
.	O
      
This	O
has	O
been	O
observed	O
with	O
Benedict	O
and	O
Fehling	O
s	O
solutions	O
and	O
also	O
with	O
Clinitest	O
tablets	O
.	O
      
Concurrent	O
administration	O
of	O
vasopressor	B-Group
drugs	I-Group
(	O
for	O
the	O
treatment	O
of	O
hypotension	O
related	O
to	O
obstetric	O
blocks	O
)	O
and	O
ergot	B-Group
-	O
type	I-Group
oxytocic	I-Group
drugs	I-Group
may	O
cause	O
severe	O
persistent	O
hypertension	O
or	O
cerebrovascular	O
accidents	O
.	O
      
Prothrombin	O
time	O
was	O
not	O
affected	O
by	O
levetiracetam	B-Drug
.	O
      
Metformin	B-Drug
:	O
In	O
healthy	O
subjects	O
given	O
single	O
9	O
mg	O
doses	O
of	O
cephalexin	B-Drug
and	O
metformin	B-Drug
plasma	O
metformin	B-Drug
mean	O
cmax	O
and	O
AUC	O
increased	O
by	O
an	O
average	O
of	O
9	O
%	O
and	O
9	O
%	O
respectively	O
and	O
metformin	B-Drug
mean	O
renal	O
clearance	O
decreased	O
by	O
9	O
%	O
.	O
      
The	O
risk	O
of	O
this	O
interaction	O
may	O
be	O
reduced	O
if	O
digoxin	B-Drug
is	O
given	O
as	O
capsules	O
.	O
      
This	O
effect	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
by	O
ibuprofen	B-Drug
.	O
      
Theophylline	B-Drug
:	O
As	O
with	O
some	O
other	O
quinolones	B-Group
concurrent	O
administration	O
of	O
ciprofloxacin	B-Drug
with	O
theophylline	B-Drug
may	O
lead	O
to	O
elevated	O
serum	O
concentrations	O
of	O
theophylline	B-Drug
and	O
prolongation	O
of	O
its	O
elimination	O
half	O
-	O
life	O
.	O
      
The	O
effect	O
of	O
induction	O
or	O
inhibition	O
of	O
other	O
pathways	O
on	O
exposure	O
to	O
alosetron	B-Drug
and	O
its	O
metabolites	O
is	O
not	O
known	O
.	O
      
-	O
Lofexidine	B-Drug
may	O
enhance	O
the	O
effects	O
of	O
anti	B-Group
-	O
hypertensive	I-Group
drug	I-Group
therapy	O
      
Norpace	B-Brand
does	O
not	O
increase	O
serum	O
digoxin	B-Drug
levels	O
.	O
      
No	O
dosage	O
adjustment	O
for	O
montelukast	B-Drug
is	O
recommended	O
.	O
      
WelChol	B-Brand
decreased	O
the	O
Cmax	O
and	O
AUC	O
of	O
sustained	O
-	O
release	O
verapamil	B-Drug
(	O
Calan	B-Brand
SR	I-Brand
)	O
by	O
approximately	O
9	O
%	O
and	O
9	O
%	O
respectively	O
.	O
      
Doses	O
of	O
these	O
and	O
perhaps	O
other	O
medications	O
may	O
need	O
to	O
be	O
adjusted	O
in	O
patients	O
who	O
successfully	O
quit	O
smoking	O
.	O
      
Fatal	O
cardiac	O
arrests	O
have	O
occurred	O
in	O
patients	O
receiving	O
both	O
drugs	O
.	O
      
When	O
lansoprazole	B-Drug
was	O
administered	O
concomitantly	O
with	O
theophylline	B-Drug
(	O
CYP9A9	O
CYP9A	O
)	O
a	O
minor	O
increase	O
(	O
9	O
%	O
)	O
in	O
the	O
clearance	O
of	O
theophylline	B-Drug
was	O
seen	O
.	O
      
Lansoprazole	B-Drug
has	O
also	O
been	O
shown	O
to	O
have	O
no	O
clinically	O
significant	O
interaction	O
with	O
amoxicillin	B-Drug
.	O
      
Steady	O
state	O
plasma	O
digitoxin	B-Drug
concentrations	O
did	O
not	O
appear	O
to	O
change	O
.	O
      
The	O
appropriate	O
doses	O
for	O
this	O
combination	O
with	O
respect	O
to	O
efficacy	O
and	O
safety	O
have	O
not	O
been	O
established	O
.	O
      
Bexarotene	B-Drug
oxidative	O
metabolites	O
appear	O
to	O
be	O
formed	O
by	O
cytochrome	O
P9	O
9A9	O
.	O
      
If	O
intravenous	O
pentamidine	B-Drug
is	O
required	O
to	O
treat	O
Pneumocystis	O
carinii	O
pneumonia	O
treatment	O
with	O
HIVID	B-Drug
should	O
be	O
interrupted	O
.	O
      
Carbamazepine	B-Drug
      
Dextromethorphan	B-Drug
:	O
Dextromethorphan	B-Drug
is	O
primarily	O
metabolized	O
by	O
CYP	O
9D9	O
and	O
to	O
a	O
lesser	O
extent	O
by	O
9A9	O
.	O
      
MAO	B-Group
-	O
A	I-Group
inhibitors	I-Group
reduce	O
sumatriptan	B-Drug
clearance	O
significantly	O
increasing	O
systemic	O
exposure	O
.	O
      
Other	O
concomitant	O
therapy	O
Although	O
specific	O
interaction	O
studies	O
were	O
not	O
performed	O
finasteride	B-Drug
doses	O
of	O
9	O
mg	O
or	O
more	O
were	O
concomitantly	O
used	O
in	O
clinical	O
studies	O
with	O
acetaminophen	B-Drug
acetylsalicylic	B-Drug
acid	I-Drug
a	O
-	O
blockers	O
analgesics	B-Group
angiotensin	B-Group
-	O
converting	I-Group
enzyme	I-Group
ACE	I-Group
inhibitors	I-Group
anticonvulsants	B-Group
benzodiazepines	B-Group
beta	B-Group
blockers	I-Group
calcium	B-Group
-	O
channel	I-Group
blockers	I-Group
cardiac	O
nitrates	B-Group
diuretics	B-Group
H9	B-Group
antagonists	I-Group
HMG	B-Group
-	O
CoA	I-Group
reductase	I-Group
inhibitors	I-Group
prostaglandin	B-Group
synthetase	I-Group
inhibitors	I-Group
(	O
also	O
referred	O
to	O
as	O
NSAIDs	B-Group
)	O
and	O
quinolone	B-Group
anti	I-Group
-	O
infectives	I-Group
without	O
evidence	O
of	O
clinically	O
significant	O
adverse	O
interactions	O
.	O
      
Barbiturates	B-Group
carbamazepine	B-Drug
and	O
phenytoin	B-Drug
decrease	O
the	O
half	O
-	O
life	O
of	O
doxycycline	B-Drug
.	O
      
Rifampin	B-Drug
an	O
inducer	O
of	O
drug	O
metabolism	O
decreased	O
the	O
concentrations	O
of	O
losartan	B-Drug
and	O
its	O
active	O
metabolite	O
.	O
      
If	O
concomitant	O
treatment	O
with	O
sumatriptan	B-Drug
and	O
an	O
SSRI	B-Group
is	O
clinically	O
warranted	O
appropriate	O
observation	O
of	O
the	O
patient	O
is	O
advised	O
.	O
      
In	O
controlled	O
clinical	O
trials	O
of	O
AUGMENTIN	B-Brand
XR	I-Brand
9	O
patients	O
received	O
concomitant	O
allopurinol	B-Drug
and	O
AUGMENTIN	B-Brand
XR	I-Brand
.	O
      
This	O
interaction	O
should	O
be	O
kept	O
in	O
mind	O
when	O
Gantanol	B-Brand
is	O
given	O
to	O
patients	O
already	O
on	O
anticoagulant	O
therapy	O
and	O
the	O
coagulation	O
time	O
should	O
be	O
reassessed	O
.	O
      
In	O
patients	O
receiving	O
concurrent	O
therapy	O
with	O
clonidine	B-Drug
if	O
therapy	O
is	O
to	O
be	O
discontinued	O
it	O
is	O
suggested	O
that	O
ZEBETA	B-Brand
be	O
discontinued	O
for	O
several	O
days	O
before	O
the	O
withdrawal	O
of	O
clonidine	B-Drug
.	O
      
In	O
some	O
patients	O
this	O
may	O
lead	O
to	O
reduced	O
clearance	O
prolongation	O
of	O
plasma	O
half	O
-	O
life	O
and	O
enhanced	O
effects	O
of	O
caffeine	B-Drug
and	O
theobromine	B-Drug
.	O
      
The	O
median	O
duration	O
of	O
action	O
of	O
ZEMURON	B-Brand
9	O
mg	O
/	O
kg	O
administered	O
after	O
a	O
9	O
mg	O
/	O
kg	O
dose	O
of	O
succinylcholine	B-Drug
when	O
T	O
9	O
returned	O
to	O
9	O
%	O
of	O
control	O
was	O
9	O
minutes	O
(	O
range	O
9	O
-	O
9	O
n=9	O
)	O
vs	O
.	O
      
When	O
these	O
products	O
are	O
administered	O
concomitantly	O
prothrombin	O
time	O
or	O
other	O
suitable	O
coagulation	O
tests	O
should	O
be	O
closely	O
monitored	O
.	O
      
The	O
clinical	O
significance	O
of	O
this	O
finding	O
is	O
unknown	O
;	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
No	O
clinically	O
significant	O
changes	O
in	O
the	O
results	O
of	O
clinical	O
laboratory	O
tests	O
have	O
been	O
observed	O
      
see	O
DOSAGE	O
AND	O
ADMINISTRATION	O
)	O
.	O
      
The	O
extent	O
to	O
which	O
SSRI	B-Group
-	O
TCA	B-Group
interactions	O
may	O
pose	O
clinical	O
problems	O
will	O
depend	O
on	O
the	O
degree	O
of	O
inhibition	O
and	O
the	O
pharmacokinetics	O
of	O
the	O
SSRI	B-Group
involved	O
.	O
      
The	O
potential	O
for	O
binding	O
of	O
these	O
drugs	O
if	O
given	O
concomitantly	O
is	O
present	O
.	O
      
Diabetics	O
should	O
discuss	O
the	O
use	O
of	O
these	O
supplements	O
with	O
their	O
physicians	O
and	O
note	O
if	O
the	O
supplements	O
affect	O
their	O
glycemic	O
control	O
.	O
      
Monoamine	B-Group
oxidase	I-Group
MAO	I-Group
inhibitors	I-Group
prolong	O
and	O
intensify	O
the	O
anticholinergic	O
effects	O
of	O
antihistamines	B-Group
.	O
      
Safety	O
and	O
effectiveness	O
in	O
children	O
has	O
not	O
been	O
established	O
.	O
      
This	O
suggests	O
the	O
existence	O
of	O
a	O
recirculation	O
pathway	O
for	O
meloxicam	B-Drug
in	O
the	O
gastrointestinal	O
tract	O
.	O
      
Patients	O
receiving	O
narrow	O
therapeutic	O
ratio	O
drugs	O
or	O
other	O
drugs	O
that	O
require	O
careful	O
titration	O
should	O
be	O
followed	O
closely	O
;	O
      
If	O
TYKERB	B-Brand
is	O
administered	O
with	O
drugs	O
that	O
inhibit	O
Pgp	O
increased	O
concentrations	O
of	O
lapatinib	B-Drug
are	O
likely	O
and	O
caution	O
should	O
be	O
exercised	O
.	O
      
rash	O
      
-	O
Alcohol	B-Drug
barbiturates	B-Group
or	O
narcotics	B-Group
:	O
Potentiation	O
of	O
otthostatic	O
hypotension	O
may	O
occur	O
      
Selective	B-Group
serotonin	I-Group
reuptake	I-Group
inhibitors	I-Group
(	O
SSRIs	B-Group
)	O
(	O
e.g.	O
fluoxetine	B-Drug
fluvoxamine	B-Drug
paroxetine	B-Drug
sertraline	B-Drug
)	O
have	O
been	O
reported	O
rarely	O
to	O
cause	O
weakness	O
hyperreflexia	O
and	O
incoordination	O
when	O
coadministered	O
with	O
9	O
-	O
HTv	O
agonists	O
.	O
      
Coadministration	O
of	O
esomeprazole	B-Drug
9	O
mg	O
and	O
diazepam	B-Drug
a	O
CYP9C9	O
substrate	O
resulted	O
in	O
a	O
9	O
%	O
decrease	O
in	O
clearance	O
of	O
diazepam	B-Drug
.	O
      
9	O
-	O
adrenergic	O
receptor	O
antagonism	O
aripiprazole	B-Drug
has	O
the	O
potential	O
to	O
enhance	O
the	O
effect	O
of	O
certain	O
antihypertensive	B-Group
agents	I-Group
.	O
      
Although	O
the	O
clinical	O
significance	O
of	O
these	O
effects	O
is	O
not	O
known	O
caution	O
is	O
advised	O
in	O
the	O
co	O
-	O
administration	O
of	O
beta	B-Group
-	O
agonists	I-Group
with	O
non	B-Group
-	O
potassium	I-Group
sparing	I-Group
diuretics	I-Group
.	O
      
Excessive	O
neuromuscular	O
weakness	O
may	O
be	O
exacerbated	O
by	O
administration	O
of	O
another	O
botulinum	B-Group
toxin	I-Group
prior	O
to	O
the	O
resolution	O
of	O
the	O
effects	O
of	O
a	O
previously	O
administered	O
botulinum	B-Group
toxin	I-Group
.	O
      
Digoxin	B-Drug
:	O
There	O
was	O
a	O
slight	O
increase	O
in	O
the	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
9	O
%	O
)	O
and	O
mean	O
peak	O
drug	O
concentration	O
(	O
Cmax	O
9	O
%	O
)	O
of	O
digoxin	B-Drug
with	O
the	O
co	O
-	O
administration	O
of	O
9	O
mg	O
sitagliptin	B-Drug
for	O
9	O
days	O
.	O
      
Time	O
to	O
reach	O
Cmax	O
is	O
also	O
prolonged	O
by	O
9	O
hour	O
.	O
      
Administration	O
of	O
quinolones	B-Group
with	O
antacids	B-Group
containing	O
aluminum	B-Drug
magnesium	B-Drug
or	O
calcium	B-Drug
with	O
sucralfate	B-Drug
with	O
metal	O
cations	O
such	O
as	O
iron	B-Drug
or	O
with	O
multivitamins	B-Group
containing	O
iron	B-Drug
or	O
zinc	B-Drug
or	O
with	O
formulations	O
containing	O
divalent	O
and	O
trivalent	O
cations	O
such	O
as	O
VIDEX	B-Brand
(	O
didanosine	B-Drug
)	O
chewable	O
/	O
buffered	O
tablets	O
or	O
the	O
pediatric	O
powder	O
for	O
oral	O
solution	O
may	O
substantially	O
interfere	O
with	O
the	O
absorption	O
of	O
quinolones	B-Group
resulting	O
in	O
systemic	O
concentrations	O
considerably	O
lower	O
than	O
desired	O
.	O
      
When	O
given	O
concomitantly	O
with	O
felodipine	B-Drug
the	O
tacrolimus	B-Drug
blood	O
concentration	O
should	O
be	O
followed	O
and	O
the	O
tacrolimus	O
dose	O
may	O
need	O
to	O
be	O
adjusted	O
.	O
      
However	O
in	O
another	O
study	O
in	O
healthy	O
volunteers	O
the	O
pharmacokinetics	O
of	O
butorphanol	B-Drug
were	O
significantly	O
altered	O
(	O
9	O
%	O
decrease	O
in	O
AUC	O
and	O
9	O
%	O
decrease	O
in	O
Cmax	O
)	O
when	O
a	O
9	O
-	O
mg	O
dose	O
of	O
STADOL	B-Brand
NS	I-Brand
was	O
administered	O
9	O
minute	O
after	O
a	O
9	O
-	O
mg	O
dose	O
of	O
sumatriptan	B-Drug
nasal	O
spray	O
.	O
      
This	O
may	O
lead	O
to	O
reduced	O
clearance	O
of	O
caffeine	B-Drug
and	O
a	O
prolongation	O
of	O
its	O
plasma	O
half	O
-	O
life	O
.	O
      
Micro	O
-	O
dosed	O
Progesterone	B-Drug
Preparations	O
:	O
Micro	O
-	O
dosed	O
progesterone	B-Drug
preparations	O
(	O
minipills	O
that	O
do	O
not	O
contain	O
an	O
estrogen	B-Group
)	O
may	O
be	O
an	O
inadequate	O
method	O
of	O
contraception	O
during	O
Accutane	B-Brand
therapy	O
.	O
      
Cephalosporins	B-Group
-	O
Cephalosporins	B-Group
containing	O
side	O
chains	O
of	O
N	O
-	O
methylthiotetrazole	O
(	O
cefmenoxime	B-Drug
cefoperazone	B-Drug
cefotetan	B-Drug
cefamandole	B-Drug
latamoxef	B-Drug
)	O
or	O
methylthiadiazole	O
(	O
cefazolin	B-Drug
)	O
can	O
cause	O
vitamin	O
K	O
deficiency	O
and	O
hypoprothrombinemia	O
.	O
      
Garlic	O
Capsules	O
Garlic	O
capsules	O
should	O
not	O
be	O
used	O
while	O
taking	O
saquinavir	B-Drug
(	O
FORTOVASE	B-Brand
)	O
as	O
the	O
sole	O
protease	B-Group
inhibitor	I-Group
due	O
to	O
the	O
risk	O
of	O
decreased	O
saquinavir	B-Drug
plasma	O
concentrations	O
.	O
      
Interactions	O
between	O
ZADAXIN	B-Brand
and	O
other	O
drugs	O
have	O
not	O
been	O
fully	O
evaluated	O
.	O
      
Abacavir	B-Drug
has	O
no	O
effect	O
on	O
the	O
pharmacokinetic	O
properties	O
of	O
ethanol	B-Drug
.	O
      
Spontaneous	O
reports	O
of	O
serotonin	O
syndrome	O
associated	O
with	O
co	O
-	O
administration	O
of	O
ZYVOX	B-Brand
and	O
serotonergic	B-Group
agents	I-Group
including	O
antidepressants	B-Group
such	O
as	O
selective	B-Group
serotonin	I-Group
reuptake	I-Group
inhibitors	I-Group
(	O
SSRIs	B-Group
)	O
have	O
been	O
reported	O
.	O
      
One	O
animal	O
in	O
the	O
high	O
dose	O
group	O
developed	O
a	O
B	O
-	O
cell	O
lymphoma	O
that	O
was	O
detected	O
after	O
9	O
weeks	O
of	O
dosing	O
.	O
      
In	O
vitro	O
studies	O
indicate	O
CYP9A9	O
isoform	O
and	O
CYP9A9	O
isoform	O
mediate	O
the	O
metabolism	O
of	O
levobupivacaine	B-Drug
to	O
desbutyl	B-Drug_n
levobupivacaine	I-Drug_n
and	O
9	B-Drug_n
-	O
hydroxy	I-Drug_n
levobupivacaine	I-Drug_n
respectively	O
.	O
      
Increases	O
in	O
serum	O
creatinine	O
have	O
occurred	O
when	O
CEFOTAN	B-Brand
was	O
given	O
alone	O
.	O
      
Thus	O
when	O
ibuprofen	B-Drug
and	O
lithium	B-Drug
are	O
administered	O
concurrently	O
subjects	O
should	O
be	O
observed	O
carefully	O
for	O
signs	O
of	O
lithium	B-Drug
toxicity	O
.	O
      
Verapamil	B-Drug
:	O
Concomitant	O
use	O
of	O
verapamil	B-Drug
is	O
contraindicated	O
.	O
      
In	O
vitro	O
studies	O
have	O
shown	O
that	O
mirtazapine	B-Drug
is	O
a	O
substrate	O
for	O
several	O
of	O
these	O
enzymes	O
including	O
9D9	O
9A9	O
and	O
9A9	O
.	O
      
Hyperpyrexia	O
has	O
been	O
reported	O
when	O
amitriptyline	B-Drug
HCl	I-Drug
is	O
administered	O
with	O
anticholinergic	B-Drug
agents	O
or	O
with	O
neuroleptic	B-Drug
drugs	O
particularly	O
during	O
hot	O
weather	O
.	O
      
In	O
vitro	O
propranolol	B-Drug
appears	O
to	O
be	O
displaced	O
from	O
its	O
binding	O
sites	O
by	O
diltiazem	B-Drug
.	O
      
Increased	O
plasma	O
HDL	O
and	O
HDL9	O
cholesterol	O
subfraction	O
concentrations	O
reduced	O
LDL	O
cholesterol	O
concentration	O
increased	O
triglyceride	O
levels	O
.	O
      
Pre	O
-	O
treatment	O
with	O
the	O
CYP9A9	O
inducer	O
rifampicin	B-Drug
decreased	O
erlotinib	B-Drug
AUC	O
by	O
about	O
9	O
/	O
9	O
.	O
      
Triprolidine	B-Drug
may	O
effect	O
the	O
metabolism	O
of	O
drugs	O
in	O
the	O
liver	O
.	O
      
Long	O
Acting	O
Nitrates	B-Group
:	O
Nifedipine	B-Drug
may	O
be	O
safely	O
co	O
-	O
administered	O
with	O
nitrates	B-Group
but	O
there	O
have	O
been	O
no	O
controlled	O
studies	O
to	O
evaluate	O
the	O
antianginal	O
effectiveness	O
of	O
this	O
combination	O
.	O
      
Standard	O
therapy	O
includes	O
antibiotics	B-Group
such	O
as	O
penicillin	B-Drug
and	O
gentamicin	B-Drug
;	O
      
Diuretics	B-Group
:	O
Etodolac	O
has	O
no	O
apparent	O
pharmacokinetic	O
interaction	O
when	O
administered	O
with	O
furosemide	B-Drug
or	O
hydrochlorothiazide	B-Drug
.	O
      
For	O
these	O
reasons	O
it	O
is	O
felt	O
that	O
in	O
most	O
subjects	O
who	O
have	O
had	O
an	O
unsatisfactory	O
lipid	O
response	O
to	O
either	O
drug	O
alone	O
the	O
possible	O
benefits	O
of	O
combined	O
therapy	O
with	O
lovastatin	B-Drug
and	O
a	O
fibrate	B-Group
do	O
not	O
outweigh	O
the	O
risks	O
of	O
severe	O
myopathy	O
rhabdomyolysis	O
and	O
acute	O
renal	O
failure	O
.	O
      
antiarrhythmic	B-Group
agents	I-Group
concentration	O
      
The	O
Cmax	O
of	O
norethindrone	B-Drug
was	O
9	O
%	O
higher	O
when	O
it	O
was	O
coadministered	O
with	O
gabapentin	B-Drug
;	O
      
Coadministered	O
Concentration	O
Concentration	O
      
decreased	O
levels	O
of	O
anti	O
-	O
factor	O
Xa	O
and	O
antithrombin	B-Drug
III	I-Drug
decreased	O
antithrombin	B-Drug
III	I-Drug
activity	O
;	O
      
Genitourinary	O
:	O
Urinary	O
frequency	O
(	O
9	O
-	O
9	O
%	O
)	O
;	O
      
In	O
addition	O
there	O
was	O
no	O
pharmacodynamic	O
interaction	O
as	O
a	O
result	O
of	O
coadministration	O
of	O
zaleplon	B-Drug
and	O
venlafaxine	B-Drug
ER	O
.	O
      
Macrolides	B-Group
:	O
Clinical	O
drug	O
interaction	O
studies	O
indicate	O
that	O
erythromycin	B-Drug
and	O
clarithromycin	B-Drug
can	O
exert	O
an	O
effect	O
on	O
terfenadine	B-Drug
metabolism	O
by	O
a	O
mechanism	O
which	O
may	O
be	O
similar	O
to	O
that	O
of	O
ketoconazole	B-Drug
but	O
to	O
a	O
lesser	O
extent	O
.	O
      
The	O
clinical	O
relevance	O
of	O
the	O
potential	O
effect	O
of	O
grepafloxacin	B-Drug
on	O
the	O
metabolism	O
of	O
C.P.A	O
.	O
substrates	O
is	O
not	O
known	O
.	O
      
A	O
similar	O
association	O
though	O
less	O
marked	O
has	O
been	O
suggested	O
with	O
barbiturates	B-Group
phenylbutazone	B-Drug
phenytoin	B-Drug
sodium	I-Drug
carbamazepine	B-Drug
griseofulvin	B-Drug
topiramate	B-Drug
and	O
possibly	O
with	O
ampicillin	B-Drug
and	O
tetracyclines	B-Group
9	O
.	O
      
During	O
transfer	O
to	O
oral	O
amiodarone	B-Drug
the	O
dose	O
levels	O
of	O
previously	O
administered	O
agents	O
should	O
be	O
reduced	O
by	O
9	O
to	O
9	O
%	O
several	O
days	O
after	O
the	O
addition	O
of	O
oral	O
amiodarone	B-Drug
.	O
      
Effects	O
of	O
Other	O
Drugs	O
on	O
Aliskiren	B-Drug
Based	O
on	O
in	O
-	O
vitro	O
studies	O
aliskiren	B-Drug
is	O
metabolized	O
by	O
CYP	O
9A9	O
.	O
      
WARFARIN	B-Drug
:	O
Co	O
-	O
administration	O
of	O
warfarin	B-Drug
and	O
cerivastatin	B-Drug
to	O
healthy	O
volunteers	O
did	O
not	O
result	O
in	O
any	O
changes	O
in	O
prothrombin	O
time	O
or	O
clotting	O
factor	O
VII	O
when	O
compared	O
to	O
co	O
-	O
administration	O
of	O
warfarin	B-Drug
and	O
placebo	O
.	O
      
Therefore	O
when	O
coadministered	O
with	O
pantoprazole	B-Drug
adjustment	O
of	O
the	O
dosage	O
of	O
pantoprazole	B-Drug
or	O
of	O
such	O
drugs	O
may	O
not	O
be	O
necessary	O
.	O
      
Noncardioselective	B-Group
beta	I-Group
-	O
blockers	I-Group
(	O
nadolol	B-Drug
porpranolol	O
timolol	B-Drug
)	O
may	O
exacerbate	O
rebound	O
hypertension	O
when	O
guanfacine	B-Drug
is	O
withdrawn	O
.	O
      
Single	O
dose	O
pharmacokinetic	O
studies	O
demonstrated	O
that	O
the	O
metabolism	O
of	O
rivastigmine	B-Drug
is	O
not	O
significantly	O
affected	O
by	O
concurrent	O
administration	O
of	O
digoxin	B-Drug
warfarin	B-Drug
diazepam	B-Drug
or	O
fluoxetine	B-Drug
.	O
      
No	O
Information	O
Provided	O
      
Phenytoin	B-Drug
is	O
extensively	O
bound	O
to	O
serum	O
plasma	O
proteins	O
and	O
is	O
prone	O
to	O
competitive	O
displacement	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
A	O
false	O
-	O
positive	O
reaction	O
for	O
ketones	O
in	O
the	O
urine	O
may	O
occur	O
with	O
tests	O
using	O
nitroprusside	B-Drug
but	O
not	O
with	O
those	O
using	O
nitroferricyanide	B-Drug
.	O
      
Phenobarbital	B-Drug
which	O
induces	O
hepatic	O
metabolism	O
decreased	O
the	O
AUC	O
of	O
montelukast	B-Drug
approximately	O
9	O
%	O
following	O
a	O
single	O
9	O
-	O
mg	O
dose	O
of	O
montelukast	B-Drug
.	O
      
Sumatriptan	B-Drug
and	O
D.H.E	B-Brand
9	I-Brand
(	O
dihydroergotamine	B-Drug
mesylate	I-Drug
)	O
Injection	O
USP	O
should	O
not	O
be	O
taken	O
within	O
9	O
hours	O
of	O
each	O
other	O
.	O
      
Patients	O
who	O
are	O
receiving	O
CYLERT	B-Brand
concurrently	O
with	O
other	O
drugs	O
especially	O
drugs	O
with	O
CNS	O
activity	O
should	O
be	O
monitored	O
carefully	O
.	O
      
Drug	O
/	O
Food	O
Interactions	O
The	O
bioavailability	O
(	O
AUC	O
)	O
of	O
deferasirox	B-Drug
was	O
variably	O
increased	O
when	O
taken	O
with	O
a	O
meal	O
.	O
      
Cevimeline	B-Drug
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
taking	O
beta	B-Group
adrenergic	I-Group
antagonists	I-Group
because	O
of	O
the	O
possibility	O
of	O
conduction	O
disturbances	O
.	O
      
Intravenous	O
ranitidine	B-Drug
was	O
shown	O
to	O
double	O
the	O
bioavailability	O
of	O
oral	O
alendronate	B-Drug
.	O
      
ethacrynic	B-Drug
acid	I-Drug
;	O
      
The	O
administration	O
of	O
guanfacine	B-Drug
concomitantly	O
with	O
known	O
microsomal	O
enzyme	O
inducer	O
(	O
phenobarbital	B-Drug
or	O
phenytoin	B-Drug
)	O
to	O
two	O
patients	O
with	O
renal	O
impairment	O
reportedly	O
resulted	O
in	O
significant	O
reductions	O
in	O
elimination	O
half	O
-	O
life	O
and	O
plasma	O
concentration	O
.	O
      
When	O
paroxetine	B-Drug
a	O
potent	O
inhibitor	O
of	O
CYP9D9	O
was	O
co	O
-	O
administered	O
with	O
BROVANA	B-Brand
at	O
steady	O
-	O
state	O
exposure	O
to	O
either	O
drug	O
was	O
not	O
altered	O
.	O
      
Hyperglycemia	O
has	O
also	O
been	O
reported	O
in	O
patients	O
receiving	O
CAMPTOSAR	B-Brand
.	O
      
Although	O
no	O
interaction	O
between	O
MAO	B-Group
inhibitors	I-Group
and	O
Levo	B-Brand
-	O
Dromoran	I-Brand
has	O
been	O
observed	O
it	O
is	O
not	O
recommended	O
for	O
use	O
with	O
MAO	B-Group
inhibitors	I-Group
.	O
      
During	O
clinical	O
trials	O
hypoglycemia	O
and	O
hyperglycemia	O
were	O
reported	O
in	O
diabetic	O
patients	O
receiving	O
oral	O
hypoglycemics	B-Group
.	O
      
-	O
Digoxin	B-Drug
:	O
Interaction	O
studies	O
in	O
humans	O
have	O
shown	O
no	O
effect	O
on	O
digoxin	B-Drug
blood	O
levels	O
.	O
      
However	O
there	O
are	O
limited	O
in	O
vivo	O
data	O
suggesting	O
a	O
modest	O
CYP9D9	O
inhibitory	O
effect	O
for	O
escitalopram	B-Drug
i.e.	O
coadministration	O
of	O
escitalopram	B-Drug
(	O
9	O
mg	O
/	O
day	O
for	O
9	O
days	O
)	O
with	O
the	O
tricyclic	B-Group
antidepressant	I-Group
desipramine	B-Drug
(	O
single	O
dose	O
of	O
9	O
mg	O
)	O
a	O
substrate	O
for	O
CYP9D9	O
resulted	O
in	O
a	O
9	O
%	O
increase	O
in	O
Cmax	O
and	O
a	O
9	O
%	O
increase	O
in	O
AUC	O
of	O
desipramine	B-Drug
.	O
      
In	O
those	O
patients	O
in	O
whom	O
renal	O
insufficiency	O
was	O
documented	O
however	O
the	O
recommendation	O
to	O
lower	O
the	O
dose	O
of	O
allopurinol	B-Drug
was	O
not	O
followed	O
.	O
      
(	O
Effects	O
may	O
be	O
decreased	O
when	O
used	O
concurrently	O
with	O
thiazide	B-Group
diuretics	I-Group
;	O
      
ALLEGRA	B-Brand
should	O
not	O
be	O
taken	O
closely	O
in	O
time	O
with	O
aluminum	B-Drug
and	O
magnesium	B-Drug
containing	O
antacids	B-Group
.	O
      
The	O
AUC	O
and	O
Cmax	O
of	O
both	O
the	O
R	O
and	O
S	O
isomers	O
of	O
warfarin	B-Drug
were	O
unaffected	O
by	O
concurrent	O
dosing	O
of	O
9	O
mg	O
cerivastatin	B-Drug
sodium	I-Drug
.	O
      
Resins	B-Group
:	O
Since	O
bile	B-Group
acid	I-Group
sequestrants	I-Group
may	O
bind	O
other	O
drugs	O
given	O
concurrently	O
patients	O
should	O
take	O
TRICOR	B-Brand
at	O
least	O
9	O
hour	O
before	O
or	O
9	O
-	O
9	O
hours	O
after	O
a	O
bile	B-Group
acid	I-Group
binding	I-Group
resin	I-Group
to	O
avoid	O
impeding	O
its	O
absorption	O
.	O
      
Healthcare	O
prescribers	O
are	O
advised	O
to	O
consult	O
the	O
package	O
inserts	O
of	O
medication	O
administered	O
concomitantly	O
with	O
oral	O
contraceptives	B-Group
.	O
      
This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
VIOXX	B-Brand
concomitantly	O
with	O
ACE	B-Group
inhibitors	I-Group
.	O
      
FLEXERIL	B-Brand
may	O
have	O
life	O
-	O
threatening	O
interactions	O
with	O
MAO	B-Group
inhibitors	I-Group
.	O
      
Concomitant	O
use	O
of	O
antihistamines	B-Group
with	O
alcohol	B-Drug
tricyclic	B-Group
antidepressants	I-Group
barbiturates	B-Group
or	O
other	O
central	B-Group
nervous	I-Group
system	I-Group
depressants	I-Group
may	O
have	O
an	O
additive	O
effect	O
.	O
      
Antiepileptic	B-Group
Drugs	I-Group
:	O
Sporadic	O
cases	O
of	O
seizures	O
have	O
been	O
reported	O
during	O
concomitant	O
use	O
of	O
TORADOL	B-Brand
and	O
antiepileptic	B-Group
drugs	I-Group
(	O
phenytoin	B-Drug
carbamazepine	B-Drug
)	O
.	O
      
Atovaquone	B-Drug
is	O
highly	O
bound	O
to	O
plasma	O
protein	O
(	O
9	O
%	O
)	O
.	O
      
While	O
no	O
clinical	O
studies	O
have	O
been	O
conducted	O
to	O
evaluate	O
the	O
effect	O
of	O
grepafloxacin	B-Drug
on	O
the	O
metabolism	O
of	O
C.P.A	O
.	O
      
Substances	O
that	O
are	O
inducers	O
of	O
CYP9A9	O
activity	O
increase	O
the	O
metabolism	O
of	O
gefitinib	B-Drug
and	O
decrease	O
its	O
plasma	O
concentrations	O
.	O
      
In	O
vitro	O
studies	O
were	O
conducted	O
to	O
investigate	O
the	O
potential	O
of	O
gabapentin	B-Drug
to	O
inhibit	O
the	O
major	O
cytochrome	O
P9	O
enzymes	O
(	O
CYP9A9	O
CYP9A9	O
CYP9C9	O
CYP9C9	O
CYP9D9	O
CYP9E9	O
and	O
CYP9A9	O
)	O
that	O
mediate	O
drug	O
and	O
xenobiotic	O
metabolism	O
using	O
isoform	O
selective	O
marker	O
substrates	O
and	O
human	O
liver	O
microsomal	O
preparations	O
.	O
      
A	O
possible	O
interaction	O
between	O
glyburide	B-Drug
and	O
ciprofloxacin	B-Drug
a	O
fluoroquinolone	B-Group
antibiotic	I-Group
has	O
been	O
reported	O
resulting	O
in	O
a	O
potentiation	O
of	O
the	O
hypoglycemic	O
action	O
of	O
glyburide	B-Drug
.	O
      
Antibiotics	B-Group
(	O
e.g.	O
erythromycin	B-Drug
trimethoprim	B-Drug
and	O
sulfamethoxazole	B-Drug
amoxicillin	B-Drug
)	O
.	O
      
The	O
concomitant	O
administration	O
of	O
Exjade	B-Brand
and	O
vitamin	B-Drug
C	I-Drug
has	O
not	O
been	O
formally	O
studied	O
.	O
      
The	O
induction	O
dose	O
requirements	O
of	O
DIPRIVAN	B-Brand
Injectable	O
Emulsion	O
may	O
be	O
reduced	O
in	O
patients	O
with	O
intramuscular	O
or	O
intravenous	O
premedication	O
particularly	O
with	O
narcotics	B-Group
(	O
eg	O
morphine	B-Drug
meperidine	B-Drug
and	O
fentanyl	B-Drug
etc	O
.	O
)	O
      
Hematology	O
:	O
TAXOL	B-Brand
therapy	O
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
baseline	O
neutrophil	O
counts	O
of	O
less	O
than	O
9	O
9	O
cells	O
/	O
mm9	O
.	O
      
Studies	O
in	O
humans	O
show	O
that	O
the	O
absorption	O
of	O
chlorothiazide	B-Drug
as	O
reflected	O
in	O
urinary	O
excretion	O
is	O
markedly	O
decreased	O
even	O
when	O
administered	O
one	O
hour	O
before	O
colestipol	B-Drug
hydrochloride	I-Drug
.	O
      
Concurrent	O
administration	O
of	O
low	O
-	O
dose	O
dopamine	B-Drug
HCl	I-Drug
and	O
diuretic	B-Group
agents	I-Group
may	O
produce	O
an	O
additive	O
or	O
potentiating	O
effect	O
on	O
urine	O
flow	O
.	O
      
Increased	O
anticoagulation	O
effects	O
due	O
to	O
a	O
drug	O
interaction	O
with	O
erythromycin	B-Drug
may	O
be	O
more	O
pronounced	O
in	O
the	O
elderly	O
.	O
      
Quinolones	B-Group
form	O
chelates	O
with	O
alkaline	O
earth	O
and	O
transition	O
metals	O
.	O
      
In	O
the	O
same	O
study	O
it	O
was	O
shown	O
that	O
didanosine	B-Drug
and	O
stavudine	B-Drug
had	O
no	O
significant	O
effect	O
on	O
the	O
intracellular	O
phosphorylation	O
of	O
zalcitabine	B-Drug
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O
      
Impaired	O
renal	O
function	O
has	O
been	O
described	O
in	O
bone	O
marrow	O
transplant	O
patients	O
who	O
were	O
conditioned	O
with	O
high	O
-	O
dose	O
intravenous	O
melphalan	B-Drug
and	O
who	O
subsequently	O
received	O
cyclosporin	B-Drug
to	O
prevent	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
      
Platelet	B-Group
inhibitors	I-Group
:	O
Drugs	O
such	O
as	O
acetylsalicylic	B-Drug
acid	I-Drug
dextran	B-Drug
phenylbutazone	B-Drug
ibuprofen	B-Drug
indomethacin	B-Drug
dipyridamole	B-Drug
hydroxychloroquine	B-Drug
and	O
others	O
that	O
interfere	O
with	O
platelet	O
-	O
aggregation	O
reactions	O
(	O
the	O
main	O
hemostatic	O
defense	O
of	O
heparinized	O
patients	O
)	O
may	O
induce	O
bleeding	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
heparin	B-Drug
sodium	I-Drug
.	O
      
Although	O
the	O
clinical	O
significance	O
is	O
not	O
known	O
it	O
is	O
not	O
recommended	O
that	O
cefditoren	B-Drug
pivoxil	I-Drug
be	O
taken	O
concomitantly	O
with	O
H9	B-Group
receptor	I-Group
antagonists	I-Group
.	O
      
Use	O
lowest	O
possible	O
dose	O
of	O
atorvastatin	B-Drug
with	O
careful	O
monitoring	O
or	O
consider	O
HMG	B-Group
-	O
CoA	I-Group
reductase	I-Group
inhibitors	I-Group
that	O
are	O
not	O
primarily	O
metabolized	O
by	O
CYP9A9	O
such	O
as	O
pravastatin	B-Drug
fluvastatin	B-Drug
or	O
rosuvastatin	B-Drug
in	O
combination	O
with	O
CRIXIVAN	B-Brand
.	O
      
There	O
has	O
been	O
little	O
experience	O
with	O
the	O
coadministration	O
of	O
TAMBOCOR	B-Brand
and	O
either	O
disopyramide	B-Drug
or	O
verapamil	B-Drug
.	O
      
Protein	O
Binding	O
:	O
Entacapone	B-Drug
is	O
highly	O
protein	O
bound	O
(	O
9	O
%	O
)	O
.	O
      
There	O
is	O
one	O
report	O
suggesting	O
that	O
the	O
concomitant	O
use	O
of	O
trazodone	B-Drug
hydrochloride	I-Drug
(	O
Desyrel	B-Brand
)	O
and	O
buspirone	B-Drug
HCl	I-Drug
may	O
have	O
caused	O
9	O
-	O
to	O
9	O
-	O
fold	O
elevations	O
on	O
SGPT	O
(	O
ALT	O
)	O
in	O
a	O
few	O
patients	O
.	O
      
Tetracycline	B-Drug
a	O
bacteriostatic	B-Group
antibiotic	I-Group
may	O
antagonize	O
the	O
bactercidal	O
effect	O
of	O
penicillin	B-Drug
and	O
concurrent	O
use	O
of	O
these	O
drugs	O
should	O
be	O
avoided	O
.	O
      
Because	O
of	O
possible	O
clinical	O
significance	O
the	O
two	O
drugs	O
should	O
not	O
be	O
administered	O
concurrently	O
.	O
      
Nicotine	B-Drug
:	O
Nicotine	B-Drug
may	O
provoke	O
vasoconstriction	O
in	O
some	O
patients	O
predisposing	O
to	O
a	O
greater	O
ischemic	O
response	O
to	O
ergot	B-Drug
therapy	O
.	O
      
XENICAL	B-Brand
inhibited	O
absorption	O
of	O
a	O
vitamin	B-Drug
E	I-Drug
acetate	I-Drug
supplement	O
by	O
approximately	O
9	O
%	O
.	O
      
Probenecid	B-Drug
depresses	O
tubular	O
secretion	O
of	O
certain	O
weak	O
acids	O
such	O
as	O
PAH	B-Drug
.	O
      
Desloratadine	B-Drug
9	B-Drug_n
-	O
Hydroxydesloratadine	I-Drug_n
      
Drug	O
-	O
Drug	O
Interactions	O
:	O
The	O
pharmacokinetic	O
and	O
pharmacodynamic	O
interactions	O
between	O
UROXATRAL	B-Brand
and	O
other	O
alpha	B-Group
-	O
blockers	I-Group
have	O
not	O
been	O
determined	O
.	O
      
Coadministration	O
of	O
both	O
drugs	O
should	O
proceed	O
with	O
caution	O
.	O
      
Antipyrine	B-Drug
:	O
Because	O
atorvastatin	B-Drug
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
antipyrine	B-Drug
interactions	O
with	O
other	O
drugs	B-Drug
metabolized	O
via	O
the	O
same	O
cytochrome	O
isozymes	O
are	O
not	O
expected	O
.	O
      
If	O
leprosy	O
-	O
associated	O
inflammatory	O
reactions	O
develop	O
in	O
patients	O
being	O
treated	O
with	O
dapsone	B-Drug
and	O
clofazimine	B-Drug
it	O
is	O
still	O
advisable	O
to	O
continue	O
treatment	O
with	O
both	O
drugs	O
.	O
      
Consider	O
additive	O
sedative	O
effects	O
and	O
confusional	O
states	O
to	O
emerge	O
if	O
chlorprothixene	B-Drug
is	O
given	O
with	O
benzodiazepines	B-Group
or	O
barbituates	B-Group
.	O
      
Coadministration	O
of	O
valdecoxib	B-Drug
with	O
doses	O
higher	O
than	O
9	O
mg	O
QD	O
omeprazole	B-Drug
has	O
not	O
been	O
studied	O
.	O
      
Nateglinide	B-Drug
is	O
highly	O
bound	O
to	O
plasma	O
proteins	O
(	O
9	O
%	O
)	O
mainly	O
albumin	O
.	O
      
Warfarin	B-Drug
-	O
Vitamin	B-Group
K	I-Group
can	O
antagonize	O
the	O
effect	O
of	O
warfarin	B-Drug
      
-	O
Ethotoin	B-Drug
(	O
e.g.	O
Peganone	B-Brand
)	O
or	O
      
Cyclosporine	B-Drug
hexobarbital	B-Drug
and	O
phenytoin	B-Drug
concentrations	O
.	O
      
Monoamine	B-Group
oxidase	I-Group
MAO	I-Group
inhibitors	I-Group
:	O
See	O
CONTRAINDICATIONS	O
.	O
      
Coadministration	O
of	O
amprenavir	B-Drug
and	O
methadone	B-Drug
as	O
compared	O
to	O
a	O
non	O
-	O
matched	O
historicalcontrol	O
group	O
resulted	O
in	O
a	O
9	O
%	O
9	O
%	O
and	O
9	O
%	O
decrease	O
in	O
serum	O
amprenavir	B-Drug
AUC	O
Cmax	O
andCmin	O
respectively	O
.	O
      
Flecainide	B-Drug
is	O
not	O
extensively	O
bound	O
to	O
plasma	O
proteins	O
.	O
      
and	O
calcium	B-Group
channel	I-Group
antagonists	I-Group
e.g.	O
verapamil	B-Drug
)	O
CYP9A9	O
inducers	O
(	O
omeprazole	B-Drug
)	O
and	O
CYP9A9	O
inhibitors	O
(	O
furafylline	B-Drug
and	O
clarithromycin	B-Drug
)	O
.	O
      
No	O
specific	O
pharmacokinetic	O
or	O
other	O
formal	O
drug	O
interaction	O
studies	O
were	O
conducted	O
.	O
      
Drug	O
interactions	O
caused	O
by	O
inhibition	O
of	O
P	O
-	O
glycoprotein	O
-	O
mediated	O
drug	O
clearance	O
or	O
CYP	O
-	O
mediated	O
drug	O
clearance	O
with	O
the	O
listed	O
isoforms	O
are	O
unlikely	O
.	O
      
Based	O
on	O
total	O
ertapenem	B-Drug
concentrations	O
probenecid	B-Drug
increased	O
the	O
AUC	O
by	O
9	O
%	O
and	O
reduced	O
the	O
plasma	O
and	O
renal	O
clearances	O
by	O
9	O
%	O
and	O
9	O
%	O
respectively	O
.	O
      
There	O
have	O
been	O
reports	O
of	O
positive	O
test	O
results	O
using	O
the	O
Bio	O
-	O
Rad	O
Laboratories	O
Platelia	O
Aspergillus	O
EIA	O
test	O
in	O
patients	O
receiving	O
piperacillin	B-Drug
/	O
tazobactam	B-Drug
injection	O
who	O
were	O
subsequently	O
found	O
to	O
be	O
free	O
of	O
Aspergillus	O
infection	O
.	O
      
However	O
in	O
a	O
well	O
-	O
controlled	O
study	O
of	O
patients	O
with	O
lymphoma	O
on	O
combination	O
therapy	O
allopurinol	B-Drug
did	O
not	O
increase	O
the	O
marrow	O
toxicity	O
of	O
patients	O
treated	O
with	O
cyclophosphamide	B-Drug
doxorubicin	B-Drug
bleomycin	B-Drug
procarbazine	B-Drug
and	O
/	O
or	O
mechlorethamine	B-Drug
.	O
      
Nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
aminoglycoside	B-Group
antibiotics	I-Group
and	O
cephalosporin	B-Group
antibiotics	I-Group
.	O
      
Serious	O
toxicity	O
may	O
result	O
if	O
dextromethorphan	B-Drug
is	O
coadministered	O
with	O
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
(	O
MAOIs	B-Group
)	O
.	O
      
Inhibits	O
CYP9A9	O
(	O
weak	O
)	O
9B9	O
(	O
weak	O
)	O
9C9	O
(	O
weak	O
)	O
9A9	O
(	O
weak	O
)	O
.	O
      
In	O
case	O
of	O
theophylline	B-Drug
toxicity	O
and	O
/	O
or	O
elevated	O
serum	O
theophylline	B-Drug
levels	O
the	O
dose	O
of	O
theophylline	B-Drug
should	O
be	O
reduced	O
while	O
the	O
patient	O
is	O
receiving	O
concomitant	O
erythromycin	B-Drug
therapy	O
.	O
      
Avoid	O
dong	O
quai	O
and	O
black	O
cohosh	O
(	O
have	O
estrogen	O
activity	O
)	O
.	O
      
Other	O
drugs	O
that	O
increase	O
gastrointestinal	O
motility	O
may	O
produce	O
similar	O
effects	O
.	O
      
No	O
data	O
on	O
the	O
level	O
of	O
circulating	O
catecholamines	O
after	O
apraclonidine	B-Drug
withdrawal	O
are	O
available	O
.	O
      
Although	O
no	O
clinical	O
studies	O
have	O
been	O
conducted	O
it	O
is	O
likely	O
that	O
the	O
metabolism	O
of	O
levobupivacaine	B-Drug
may	O
be	O
affected	O
by	O
the	O
known	O
CYP9A9	O
inducers	O
(	O
such	O
as	O
phenytoin	B-Drug
phenobarbital	B-Drug
rifampin	B-Drug
)	O
CYP9A9	O
inhibitors	O
(	O
azole	O
antimycotics	O
e.g.	O
ketoconazole	B-Drug
;	O
      
Tetracycline	B-Group
a	O
bacteriostatic	O
antibiotic	B-Group
may	O
antagonize	O
the	O
bactericidal	O
effect	O
of	O
penicillin	B-Drug
and	O
concurrent	O
use	O
of	O
these	O
drugs	O
should	O
be	O
avoided	O
.	O
      
Because	O
cholestyramine	B-Drug
binds	O
bile	O
acids	O
cholestyramine	B-Drug
resin	B-Group
may	O
interfere	O
with	O
normal	O
fat	O
digestion	O
and	O
absorption	O
and	O
thus	O
may	O
prevent	O
absorption	O
of	O
fat	B-Group
soluble	I-Group
vitamins	I-Group
such	O
as	O
A	O
D	O
E	O
and	O
K	O
.	O
      
Drugs	O
which	O
inhibit	O
CYP9D9	O
and	O
CYP9A9	O
/	O
9	O
also	O
inhibit	O
the	O
metabolism	O
of	O
cevimeline	B-Drug
.	O
      
No	O
dosage	O
adjustment	O
is	O
required	O
for	O
Fluvoxamine	B-Drug
Tablets	O
.	O
      
Hypoglycemics	B-Group
and	O
endocrine	O
drugs	O
.	O
      
use	O
potassium	B-Drug
supplements	O
if	O
necessary	O
.	O
      
Infusion	O
requirements	O
of	O
NIMBEX	B-Brand
in	O
patients	O
administered	O
succinylcholine	B-Drug
prior	O
to	O
infusions	O
of	O
NIMBEX	B-Brand
were	O
comparable	O
to	O
or	O
slightly	O
greater	O
than	O
when	O
succinylcholine	B-Drug
was	O
not	O
administered	O
.	O
      
-	O
Procainamide	B-Drug
(	O
e.g.	O
Pronestyl	B-Brand
)	O
or	O
      
Lithium	B-Drug
-	O
A	O
drug	O
interaction	O
study	O
of	O
eplerenone	B-Drug
with	O
lithium	B-Drug
has	O
not	O
been	O
conducted	O
.	O
      
An	O
alternative	O
non	O
-	O
CYP9A9	O
substrate	O
hypnotic	B-Group
agent	I-Group
may	O
be	O
considered	O
in	O
patients	O
taking	O
CYP9A9	O
inducers	O
such	O
as	O
rifampin	B-Drug
phenytoin	B-Drug
carbamazepine	B-Drug
and	O
phenobarbital	B-Drug
.	O
      
Binding	O
to	O
Serum	O
Proteins	O
:	O
The	O
following	O
agents	O
may	O
either	O
inhibit	O
levothyroxine	B-Drug
sodium	I-Drug
binding	O
to	O
serum	O
proteins	O
or	O
alter	O
the	O
concentrations	O
of	O
serum	O
binding	O
proteins	O
:	O
androgens	B-Group
and	O
related	O
anabolic	B-Group
hormones	I-Group
asparaginase	B-Drug
clofibrate	B-Drug
estrogens	B-Group
and	O
estrogen	B-Group
-	O
containing	I-Group
compounds	I-Group
9	B-Drug
-	O
fluorouracil	I-Drug
furosemide	B-Drug
glucocorticoids	B-Group
meclofenamic	B-Drug
acid	I-Drug
mefenamic	B-Drug
acid	I-Drug
methadone	B-Drug
perphenazine	B-Drug
phenylbutazone	B-Drug
phenytoin	B-Drug
salicylates	B-Group
tamoxifen	B-Drug
.	O
      
Potassium	B-Group
-	O
sparing	I-Group
diuretics	I-Group
(	O
spironolactone	B-Drug
amiloride	B-Drug
triamterene	B-Drug
and	O
others	O
)	O
or	O
potassium	B-Drug
supplements	O
can	O
increase	O
the	O
risk	O
of	O
hyperkalemia	O
.	O
      
Tricyclic	B-Group
antidepressants	I-Group
(	O
amitriptyline	B-Drug
imipramine	B-Drug
nortriptyline	B-Drug
)	O
:	O
Metabolism	O
may	O
be	O
inhibited	O
by	O
combination	B-Group
hormonal	I-Group
contraceptives	I-Group
increasing	O
plasma	O
levels	O
of	O
antidepressant	B-Group
;	O
      
Amantadine	B-Drug
:	O
Population	O
pharmacokinetic	O
analysis	O
suggests	O
that	O
amantadine	B-Drug
is	O
unlikely	O
to	O
alter	O
the	O
oral	O
clearance	O
of	O
pramipexole	B-Drug
(	O
N=	O
9	O
)	O
.	O
      
The	O
combined	O
use	O
of	O
fluconazole	B-Drug
at	O
doses	O
of	O
9	O
mg	O
or	O
greater	O
with	O
terfenadine	B-Drug
is	O
contraindicated	O
.	O
      
It	O
is	O
not	O
known	O
if	O
fulvestrant	B-Drug
is	O
excreted	O
in	O
human	O
milk	O
.	O
      
Therefore	O
a	O
lower	O
total	O
daily	O
dosage	O
of	O
INDOCIN	B-Brand
may	O
produce	O
a	O
satisfactory	O
therapeutic	O
effect	O
.	O
      
However	O
other	O
published	O
reports	O
describe	O
modest	O
elevations	O
(	O
less	O
than	O
two	O
-	O
fold	O
)	O
of	O
clozapine	B-Drug
and	O
metabolite	O
concentrations	O
when	O
clozapine	B-Drug
was	O
taken	O
with	O
paroxetine	B-Drug
fluoxetine	B-Drug
and	O
sertraline	B-Drug
.	O
      
The	O
blood	O
pressure	O
effect	O
of	O
SULAR	B-Brand
tended	O
to	O
be	O
greater	O
in	O
patients	O
on	O
atenolol	B-Drug
than	O
in	O
patients	O
on	O
no	O
other	O
antihypertensive	B-Group
therapy	O
.	O
      
Although	O
these	O
results	O
do	O
not	O
indicate	O
a	O
significant	O
interaction	O
between	O
TORADOL	B-Brand
and	O
warfarin	B-Drug
or	O
heparin	B-Drug
the	O
administration	O
of	O
TORADOL	B-Brand
to	O
patients	O
taking	O
anticoagulants	B-Group
should	O
be	O
done	O
extremely	O
cautiously	O
and	O
patients	O
should	O
be	O
closely	O
monitored	O
.	O
      
Substances	O
that	O
inhibit	O
the	O
cytochrome	O
P9	O
isoenzyme	O
(	O
CYP9A9	O
)	O
activity	O
may	O
decrease	O
metabolism	O
and	O
increase	O
imatinib	B-Drug
concentrations	O
.	O
      
Allopurinol	B-Drug
:	O
Increased	O
possibility	O
of	O
skin	O
rash	O
particularly	O
in	O
hyperuricemic	O
patients	O
may	O
occur	O
.	O
      
Bile	B-Group
acid	I-Group
binding	I-Group
resins	I-Group
may	O
also	O
interfere	O
with	O
the	O
absorption	O
of	O
oral	O
phosphate	B-Drug
supplements	O
and	O
hydrocortisone	B-Drug
.	O
      
Similarly	O
ethanol	B-Drug
decreased	O
the	O
rate	O
of	O
elimination	O
of	O
Antizol	B-Brand
(	O
by	O
approximately	O
9	O
%	O
)	O
by	O
the	O
same	O
mechanism	O
.	O
      
No	O
change	O
in	O
dose	O
of	O
either	O
drug	O
is	O
recommended	O
.	O
      
The	O
use	O
of	O
FLUDARA	B-Brand
FOR	O
INJECTION	O
in	O
combination	O
with	O
pentostatin	B-Drug
is	O
not	O
recommended	O
due	O
to	O
the	O
risk	O
of	O
severe	O
pulmonary	O
toxicity	O
.	O
      
Concomitant	O
administration	O
of	O
probenecid	B-Drug
doubled	O
the	O
AUC	O
for	O
cefprozil	B-Drug
.	O
      
In	O
addition	O
certain	O
drugs	O
inhibit	O
the	O
activity	O
of	O
this	O
isozyme	O
and	O
make	O
normal	O
metabolizers	O
resemble	O
poor	O
metabolizers	O
.	O
      
The	O
finding	O
that	O
metoclopramide	B-Drug
releases	O
catecholamines	O
in	O
patients	O
with	O
essential	O
hypertension	O
suggests	O
that	O
it	O
should	O
be	O
used	O
cautiously	O
if	O
at	O
all	O
in	O
patients	O
receiving	O
monoamine	B-Group
oxi	I-Group
-	O
dase	I-Group
inhibitors	I-Group
.	O
      
The	O
absorption	O
of	O
oral	O
medications	O
may	O
be	O
decreased	O
during	O
the	O
concurrent	O
use	O
of	O
scopolamine	B-Drug
because	O
of	O
decreased	O
gastric	O
motility	O
and	O
delayed	O
gastric	O
emptying	O
.	O
      
Limited	O
clinical	O
data	O
in	O
angina	O
patients	O
receiving	O
concomitant	O
bepridil	B-Drug
hydrochloride	I-Drug
and	O
digoxin	B-Drug
therapy	O
indicate	O
no	O
discernible	O
changes	O
in	O
serum	O
digoxin	O
levels	O
.	O
      
although	O
combinations	O
are	O
sometimes	O
used	O
for	O
therapeutic	O
advantage	O
when	O
used	O
concurrently	O
patient	O
should	O
be	O
closely	O
monitored	O
.	O
      
Acetazolamide	B-Drug
may	O
elevate	O
cyclosporine	B-Drug
levels	O
.	O
      
Interactions	O
between	O
COPAXONE	B-Brand
and	O
other	O
drugs	O
have	O
not	O
been	O
fully	O
evaluated	O
.	O
      
Fulvestrant	B-Drug
was	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
fetal	O
variations	O
in	O
rabbits	O
(	O
backwards	O
displacement	O
of	O
the	O
pelvic	O
girdle	O
and	O
9	O
pre	O
-	O
sacral	O
vertebrae	O
at	O
9	O
mg	O
/	O
kg	O
/	O
day	O
IM	O
;	O
      
Cardiovascular	O
agents	O
(	O
e.g.	O
atenolol	B-Drug
hydrochlorothiazide	B-Drug
propranolol	B-Drug
)	O
.	O
      
Endocrine	O
Function	O
HMG	B-Group
-	O
CoA	I-Group
reductase	I-Group
inhibitors	I-Group
interfere	O
with	O
cholesterol	O
synthesis	O
and	O
theoretically	O
might	O
blunt	O
adrenal	O
and	O
/	O
or	O
gonadal	O
steroid	O
production	O
.	O
      
Amprenavir	B-Drug
is	O
an	O
inhibitor	O
of	O
cytochrome	O
P9	O
C.P.A	O
.	O
metabolism	O
and	O
therefore	O
should	O
not	O
be	O
administered	O
concurrently	O
with	O
medications	O
with	O
narrow	O
therapeutic	O
windows	O
that	O
are	O
substrates	O
of	O
CYP9A9	O
.	O
      
.	O
      
No	O
data	O
are	O
available	O
regarding	O
interactions	O
with	O
other	O
drugs	O
that	O
have	O
renal	O
clearance	O
mechanisms	O
similar	O
to	O
that	O
of	O
lamivudine	B-Drug
.	O
      
Erythromycin	B-Drug
has	O
been	O
reported	O
to	O
significantly	O
alter	O
the	O
metabolism	O
of	O
nonsedating	O
antihistamines	B-Group
terfenadine	B-Drug
and	O
astemizole	B-Drug
when	O
taken	O
concomitantly	O
.	O
      
Food	O
Interaction	O
:	O
Oral	O
administration	O
of	O
ACEON	B-Brand
Tablets	O
with	O
food	O
does	O
not	O
significantly	O
lower	O
the	O
rate	O
or	O
extent	O
of	O
perindopril	B-Drug
absorption	O
relative	O
to	O
the	O
fasted	O
state	O
.	O
      
The	O
single	O
-	O
dose	O
nature	O
of	O
this	O
study	O
and	O
the	O
lack	O
of	O
correlation	O
between	O
glyburide	B-Drug
blood	O
levels	O
and	O
pharmaco	O
-	O
dynamic	O
effects	O
makes	O
the	O
clinical	O
significance	O
of	O
this	O
interaction	O
uncertain	O
.	O
      
Sulfonamides	B-Group
can	O
also	O
displace	O
methotrexate	B-Drug
from	O
plasma	O
protein	O
-	O
binding	O
sites	O
thus	O
increasing	O
free	O
methotrexate	B-Drug
concentrations	O
.	O
      
Griseofulvin	B-Drug
:	O
Griseofulvin	B-Drug
may	O
induce	O
the	O
metabolism	O
of	O
combination	B-Group
hormonal	I-Group
contraceptives	I-Group
causing	O
menstrual	O
changes	O
;	O
      
Heparin	B-Drug
:	O
No	O
human	O
drug	O
interaction	O
studies	O
with	O
heparin	B-Drug
were	O
conducted	O
.	O
      
Patients	O
should	O
be	O
followed	O
carefully	O
to	O
detect	O
side	O
reactions	O
or	O
unusual	O
manifestations	O
of	O
drug	O
idiosyncrasy	O
.	O
      
A	O
drug	O
interaction	O
study	O
was	O
performed	O
in	O
which	O
ERBITUX	B-Brand
was	O
administered	O
in	O
combination	O
with	O
irinotecan	B-Drug
.	O
      
Do	O
not	O
mix	O
TORADOL	B-Brand
and	O
morphine	B-Drug
in	O
the	O
same	O
syringe	O
.	O
      
Antihypertensives	B-Drug
:	O
Amiodarone	B-Drug
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
-	O
receptor	B-Drug
blocking	O
agents	O
(	O
e.g.	O
propranolol	B-Drug
a	O
CYP9A9	B-Drug
inhibitor	O
)	O
or	O
calcium	B-Drug
channel	I-Drug
antagonists	O
(	O
e.g.	O
verapamil	B-Drug
a	O
CYP9A9	B-Drug
substrate	O
and	O
diltiazem	B-Drug
a	O
CYP9A9	B-Drug
inhibitor	O
)	O
because	O
of	O
the	O
possible	O
potentiation	O
of	O
bradycardia	O
sinus	O
arrest	O
and	O
AV	O
block	O
;	O
      
At	O
a	O
9	O
-	O
g	O
dose	O
sulfamethoxazole	B-Drug
produced	O
a	O
slight	O
but	O
significant	O
increase	O
in	O
the	O
half	O
-	O
life	O
of	O
phenytoin	B-Drug
but	O
did	O
not	O
produce	O
a	O
corresponding	O
decrease	O
in	O
the	O
metabolic	O
clearance	O
rate	O
.	O
      
No	O
formal	O
drug	O
interaction	O
studies	O
between	O
Neulasta	B-Brand
and	O
other	O
drugs	O
have	O
been	O
performed	O
.	O
      
Acromegalic	O
patients	O
with	O
diabetes	O
mellitus	O
being	O
treated	O
with	O
insulin	B-Drug
and	O
/	O
or	O
oral	O
hypoglycemic	B-Group
agents	O
may	O
require	O
dose	O
reductions	O
of	O
these	O
therapeutic	O
agents	O
after	O
the	O
initiation	O
of	O
therapy	O
with	O
SOMAVERT	B-Brand
.	O
      
Phenytoin	B-Drug
      
Non	B-Group
-	O
steroidal	I-Group
Anti	I-Group
-	O
inflammatory	I-Group
Drugs	I-Group
:	O
In	O
some	O
patients	O
the	O
administration	O
of	O
a	O
non	B-Group
-	O
steroidal	I-Group
anti	I-Group
-	O
inflammatory	I-Group
agent	I-Group
can	O
reduce	O
the	O
diuretic	O
natriuretic	O
and	O
antihypertensive	O
effects	O
of	O
loop	B-Group
potassium	B-Group
-	O
sparing	I-Group
and	O
thiazide	B-Group
diuretics	I-Group
.	O
      
Furosemide	B-Drug
:	O
Clinical	O
studies	O
as	O
well	O
as	O
post	O
marketing	O
observations	O
have	O
shown	O
that	O
NSAIDs	B-Group
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	B-Drug
and	O
thiazides	B-Group
in	O
some	O
patients	O
.	O
      
In	O
a	O
pharmacokinetic	O
study	O
of	O
9	O
chronic	O
hepatitis	O
C	O
patients	O
concomitantly	O
receiving	O
methadone	B-Drug
treatment	O
with	O
PEG	B-Brand
-	O
Intron	I-Brand
once	O
weekly	O
for	O
9	O
weeks	O
was	O
associated	O
with	O
a	O
mean	O
increase	O
of	O
9	O
%	O
in	O
methadone	B-Drug
AUC	O
;	O
      
Any	O
agent	O
that	O
alters	O
thyroid	O
hormone	O
synthesis	O
secretion	O
distribution	O
effect	O
on	O
target	O
tissues	O
metabolism	O
or	O
elimination	O
may	O
alter	O
the	O
optimal	O
therapeutic	O
dose	O
of	O
levothyroxine	B-Drug
sodium	O
.	O
      
Close	O
supervision	O
and	O
careful	O
adjustment	O
of	O
dosage	O
is	O
required	O
when	O
this	O
drug	O
is	O
administered	O
concomitantly	O
with	O
anticholinergic	B-Group
drugs	I-Group
.	O
      
During	O
controlled	O
hypotensive	O
anesthesia	O
using	O
labetalol	B-Drug
HCl	I-Drug
in	O
association	O
with	O
halothane	B-Drug
high	O
concentrations	O
(	O
9	O
%	O
or	O
above	O
)	O
of	O
halothane	B-Drug
should	O
not	O
be	O
used	O
because	O
the	O
degree	O
of	O
hypotension	O
will	O
be	O
increased	O
and	O
because	O
of	O
the	O
possibility	O
of	O
a	O
large	O
reduction	O
in	O
cardiac	O
output	O
and	O
an	O
increase	O
in	O
central	O
venous	O
pressure	O
.	O
      
Monitoring	O
of	O
disopyramide	B-Drug
plasma	O
levels	O
is	O
recommended	O
in	O
such	O
concurrent	O
use	O
to	O
avoid	O
ineffective	O
therapy	O
.	O
      
Furthermore	O
rifampin	B-Drug
phenytoin	B-Drug
phenobarbital	B-Drug
and	O
other	O
inducers	O
of	O
cytochrome	O
P9	O
9A9	O
may	O
cause	O
a	O
reduction	O
in	O
plasma	O
bexarotene	B-Drug
concentrations	O
.	O
      
(	O
Effectiveness	O
may	O
be	O
decreased	O
when	O
used	O
concurrently	O
with	O
thiazide	B-Group
diuretics	I-Group
because	O
of	O
alkalinization	O
of	O
the	O
urine	O
.	O
)	O
      
Administration	O
of	O
eplerenone	B-Drug
with	O
other	O
CYP9A9	O
inhibitors	O
(	O
e.g.	O
erythromycin	B-Drug
9	O
mg	O
BID	O
verapamil	B-Drug
9	O
mg	O
QD	O
saquinavir	B-Drug
9	O
mg	O
TID	O
fluconazole	B-Drug
9	O
mg	O
QD	O
)	O
resulted	O
in	O
increases	O
in	O
Cmax	O
of	O
eplerenone	B-Drug
ranging	O
from	O
9	O
-	O
to	O
9	O
-	O
fold	O
and	O
AUC	O
from	O
9	O
-	O
to	O
9	O
-	O
fold	O
.	O
      
pyrazolones	B-Group
;	O
      
Guardians	O
of	O
children	O
who	O
have	O
been	O
prescribed	O
FORADIL	B-Brand
should	O
be	O
alerted	O
to	O
the	O
general	O
concern	O
regarding	O
asthma	O
therapy	O
compliance	O
especially	O
neglect	O
of	O
anti	O
-	O
inflammatory	O
therapy	O
and	O
overuse	O
of	O
short	B-Group
-	O
acting	I-Group
beta9	I-Group
-	O
agonists	I-Group
.	O
      
Plasma	O
concentrations	O
of	O
cyclosporine	B-Drug
should	O
therefore	O
be	O
closely	O
monitored	O
and	O
its	O
dosage	O
reduced	O
accordingly	O
in	O
patients	O
treated	O
with	O
nicardipine	B-Drug
.	O
      
In	O
patients	O
taking	O
an	O
anticonvulsant	B-Group
(	O
eg	O
valproic	B-Drug
acid	I-Drug
carbamazepine	B-Drug
phenobarbital	B-Drug
or	O
phenytoin	B-Drug
)	O
the	O
concomitant	O
use	O
of	O
Mefloquine	B-Drug
may	O
reduce	O
seizure	O
control	O
by	O
lowering	O
the	O
plasma	O
levels	O
of	O
the	O
anticonvulsant	B-Group
.	O
      
When	O
such	O
combined	O
therapy	O
is	O
contemplated	O
the	O
dose	O
of	O
one	O
or	O
both	O
agents	O
should	O
be	O
reduced	O
.	O
      
Ritonavir	B-Drug
      
Effect	O
of	O
Sensipar	B-Brand
on	O
other	O
drugs	O
:	O
Drugs	O
metabolized	O
by	O
cytochrome	O
P9	O
9D9	O
(	O
CYP9D9	O
)	O
:	O
Sensipar	B-Brand
is	O
a	O
strong	O
in	O
vitro	O
inhibitor	O
of	O
CYP9D9	O
.	O
      
Increased	O
nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
cephalosporins	B-Group
and	O
aminoglycoside	B-Group
antibiotics	I-Group
.	O
      
phenyramidol	B-Drug_n
;	O
      
Methenamine	B-Drug
therapy	O
Urinary	O
excretion	O
of	O
amphetamines	B-Group
is	O
increased	O
and	O
efficacy	O
is	O
reduced	O
by	O
acidifying	O
agents	O
used	O
in	O
methenamine	B-Drug
therapy	O
.	O
      
Because	O
ondansetron	B-Drug
is	O
metabolized	O
by	O
hepatic	O
cytochrome	O
P	O
-	O
9	O
drug	O
-	O
metabolizing	O
enzymes	O
(	O
CYP9A9	O
CYP9D9	O
CYP9A9	O
)	O
inducers	O
or	O
inhibitors	O
of	O
these	O
enzymes	O
may	O
change	O
the	O
clearance	O
and	O
hence	O
the	O
half	O
-	O
life	O
of	O
ondansetron	B-Drug
.	O
      
9	O
.	O
      
Isoflurane	B-Drug
and	O
enflurane	B-Drug
(	O
administered	O
with	O
nitrous	B-Drug
oxide	I-Drug
/	O
oxygen	B-Drug
to	O
achieve	O
9	O
M.C	O
.	O
      
Daily	O
doses	O
of	O
sulfasalazine	B-Drug
9	O
g	O
(	O
maximum	O
9	O
g	O
)	O
and	O
weekly	O
doses	O
of	O
methotrexate	B-Drug
9	O
mg	O
(	O
maximum	O
9	O
mg	O
)	O
were	O
administered	O
alone	O
or	O
in	O
combination	O
to	O
9	O
rheumatoid	O
arthritis	O
patients	O
in	O
two	O
controlled	O
9	O
-	O
week	O
clinical	O
studies	O
.	O
      
In	O
vitro	O
studies	O
:	O
Studies	O
in	O
human	O
liver	O
microsomes	O
showed	O
that	O
vardenafil	B-Drug
is	O
metabolized	O
primarily	O
by	O
cytochrome	O
P9	O
(	O
CYP	O
)	O
isoforms	O
9A9	O
/	O
9	O
and	O
to	O
a	O
lesser	O
degree	O
by	O
CYP9C9	O
.	O
      
Probenecid	B-Drug
:	O
May	O
decrease	O
renal	O
tubular	O
secretion	O
of	O
ampicillin	B-Drug
resulting	O
in	O
increased	O
blood	O
levels	O
and	O
/	O
or	O
ampicillin	B-Drug
toxicity	O
.	O
      
Aminosalicylic	B-Drug
acid	I-Drug
may	O
decrease	O
the	O
amount	O
of	O
digoxin	B-Drug
(	O
Lanoxin	B-Brand
Lanoxicaps	B-Drug
)	O
that	O
gets	O
absorbed	O
into	O
your	O
body	O
.	O
      
In	O
vitro	O
drug	O
metabolism	O
studies	O
indicate	O
that	O
Starlix	B-Brand
is	O
predominantly	O
metabolized	O
by	O
the	O
cytochrome	O
P9	O
isozyme	O
CYP9C9	O
(	O
9	O
%	O
)	O
and	O
to	O
a	O
lesser	O
extent	O
CYP9A9	O
(	O
9	O
%	O
)	O
.	O
      
Concurrent	O
use	O
of	O
flurbiprofen	B-Drug
and	O
aspirin	B-Brand
is	O
therefore	O
not	O
recommended	O
.	O
      
Of	O
the	O
9	O
patients	O
who	O
had	O
potassium	B-Group
depleting	I-Group
diuretics	I-Group
added	O
to	O
their	O
concomitant	O
medications	O
in	O
the	O
DIAMOND	O
trials	O
the	O
patients	O
on	O
TIKOSYN	B-Brand
had	O
a	O
non	O
-	O
significantly	O
reduced	O
relative	O
risk	O
for	O
death	O
of	O
9	O
(	O
9	O
%	O
CI	O
9	O
9	O
)	O
.	O
      
Inhibitors	O
Of	O
Endogenous	O
Prostaglandin	O
Synthesis	O
It	O
has	O
been	O
reported	O
that	O
indomethacin	B-Drug
may	O
reduce	O
the	O
antihypertensive	O
effect	O
of	O
captopril	B-Drug
especially	O
in	O
cases	O
of	O
low	O
renin	O
hypertension	O
.	O
      
reliable	O
estimates	O
of	O
the	O
prevalence	O
of	O
reduced	O
P9	O
9D9	O
isozyme	O
activity	O
among	O
Asian	O
African	O
and	O
other	O
populations	O
are	O
not	O
yet	O
available	O
.	O
      
In	O
some	O
patients	O
a	O
disulfiram	B-Drug
-	O
like	O
reaction	O
may	O
be	O
produced	O
by	O
the	O
ingestion	O
of	O
alcohol	B-Drug
.	O
      
Therefore	O
9	O
to	O
9	O
hours	O
should	O
elapse	O
between	O
administration	O
of	O
cholestyramine	B-Drug
and	O
thyroid	B-Group
hormones	I-Group
.	O
      
The	O
possibility	O
of	O
altered	O
safety	O
and	O
efficacy	O
should	O
be	O
considered	O
when	O
Ponstel	B-Brand
is	O
used	O
concomitantly	O
with	O
these	O
drugs	O
.	O
      
Thus	O
patients	O
receiving	O
oral	O
anticoagulants	B-Group
and	O
Fluvoxamine	B-Drug
Tablets	O
should	O
have	O
their	O
prothrombin	O
time	O
monitored	O
and	O
their	O
anticoagulant	B-Group
dose	O
adjusted	O
accordingly	O
.	O
      
The	O
pharmacokinetics	O
of	O
estazolam	B-Drug
(	O
Cmax	O
and	O
AUC	O
)	O
were	O
not	O
affected	O
during	O
multiple	O
-	O
dose	O
fluoxetine	B-Drug
suggesting	O
no	O
clinically	O
significant	O
pharmacokinetic	O
interaction	O
.	O
      
Since	O
bacteriostatic	O
drugs	O
such	O
as	O
the	O
tetracycline	B-Group
class	I-Group
of	O
antibiotics	B-Group
may	O
interfere	O
with	O
the	O
bactericidal	O
action	O
of	O
penicillins	B-Group
it	O
is	O
not	O
advisable	O
to	O
administer	O
these	O
drugs	O
concomitantly	O
.	O
      
The	O
administration	O
of	O
local	O
anesthetic	B-Group
solutions	I-Group
containing	O
epinephrine	B-Drug
or	O
norepinephrine	B-Drug
to	O
patients	O
receiving	O
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
or	O
tricyclic	B-Group
antidepressants	I-Group
may	O
produce	O
severe	O
prolonged	O
hypertension	O
.	O
      
however	O
patients	O
receiving	O
such	O
combined	O
therapy	O
should	O
be	O
monitored	O
closely	O
for	O
early	O
evidence	O
of	O
neurological	O
toxicity	O
and	O
treatment	O
discontinued	O
promptly	O
if	O
such	O
signs	O
appear	O
.	O
      
Consequently	O
interactions	O
with	O
other	O
drugs	O
which	O
are	O
highly	O
protein	O
bound	O
(	O
e.g.	O
anticoagulants	B-Group
)	O
would	O
not	O
be	O
expected	O
.	O
      
Patients	O
on	O
thyroid	O
replacement	O
therapy	O
may	O
require	O
higher	O
doses	O
of	O
thyroid	B-Group
hormone	I-Group
.	O
      
When	O
introducing	O
additives	O
use	O
aseptic	O
technique	O
mix	O
thoroughly	O
and	O
do	O
not	O
store	O
.	O
      
Combination	O
therapy	O
with	O
Cerezyme	B-Brand
(	O
imiglucerase	B-Drug
)	O
and	O
ZAVESCA	B-Brand
is	O
not	O
indicated	O
.	O
      
Metformin	B-Drug
:	O
In	O
a	O
single	O
-	O
dose	O
interaction	O
study	O
in	O
NIDDM	O
subjects	O
decreases	O
in	O
glyburide	B-Drug
AUC	O
and	O
Cmax	O
were	O
observed	O
but	O
were	O
highly	O
variable	O
.	O
      
Other	O
drug	O
interactions	O
      
Anticoagulants	B-Group
(	O
Oral	O
)	O
:	O
In	O
patients	O
receiving	O
oral	O
anticoagulants	B-Group
the	O
coagulation	O
times	O
were	O
increased	O
in	O
some	O
cases	O
.	O
      
Several	O
drug	O
interaction	O
studies	O
have	O
been	O
completed	O
with	O
both	O
INVIRASE	B-Brand
and	O
FORTOVASE	B-Brand
.	O
      
Additive	O
CNS	O
depression	O
may	O
occur	O
when	O
antihistamines	B-Group
are	O
administered	O
concomitantly	O
with	O
other	O
CNS	B-Group
depressants	I-Group
including	O
barbiturates	B-Group
tranquilizers	B-Group
and	O
alcohol	B-Drug
.	O
      
Saquinavir	B-Drug
      
.	O
      
Taking	O
a	O
rauwolfia	B-Group
alkaloid	I-Group
while	O
you	O
are	O
taking	O
or	O
within	O
9	O
weeks	O
of	O
taking	O
MAO	B-Group
inhibitors	I-Group
may	O
increase	O
the	O
risk	O
of	O
central	O
nervous	O
system	O
depression	O
or	O
may	O
cause	O
a	O
severe	O
high	O
blood	O
pressure	O
reaction	O
.	O
      
When	O
administered	O
with	O
food	O
or	O
milk	O
there	O
is	O
more	O
rapid	O
absorption	O
;	O
      
Methenamine	B-Drug
therapy	O
:	O
Urinary	O
excretion	O
of	O
amphetamines	B-Group
is	O
increased	O
and	O
efficacy	O
is	O
reduced	O
by	O
acidifying	B-Group
agents	I-Group
used	O
in	O
methenamine	B-Drug
therapy	O
.	O
      
Coadministration	O
of	O
NIZORAL	B-Brand
Tablets	O
and	O
drugs	O
primarily	O
metabolized	O
by	O
the	O
cytochrome	O
P9	O
9A9	O
enzyme	O
system	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
the	O
drugs	O
that	O
could	O
increase	O
or	O
prolong	O
both	O
therapeutic	O
and	O
adverse	O
effects	O
.	O
      
Important	O
Non	O
-	O
Thalidomide	B-Drug
Drug	O
Interactions	O
Drugs	O
That	O
Interfere	O
with	O
Hormonal	B-Group
Contraceptives	I-Group
:	O
Concomitant	O
use	O
of	O
HIV	B-Group
-	O
protease	I-Group
inhibitors	I-Group
griseofulvin	B-Drug
modafinil	B-Drug
penicillins	B-Group
rifampin	B-Drug
rifabutin	B-Drug
phenytoin	B-Drug
carbamazepine	B-Drug
or	O
certain	O
herbal	O
supplements	O
such	O
as	O
St	O
.	O
      
Phenytoin	B-Drug
:	O
In	O
9	O
normal	O
-	O
weight	O
subjects	O
receiving	O
XENICAL	B-Brand
9	O
mg	O
three	O
times	O
a	O
day	O
for	O
9	O
days	O
XENICAL	B-Brand
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
a	O
single	O
9	O
-	O
mg	O
dose	O
of	O
phenytoin	B-Drug
.	O
      
Treatment	O
experience	O
with	O
ZETIA	B-Brand
in	O
the	O
pediatric	O
population	O
is	O
limited	O
to	O
9	O
patients	O
(	O
9	O
to	O
9	O
years	O
)	O
in	O
the	O
sitosterolemia	O
study	O
and	O
9	O
patients	O
(	O
9	O
to	O
9	O
years	O
)	O
in	O
the	O
HoFH	O
study	O
.	O
      
Since	O
Celontin	B-Brand
(	O
methsuximide	B-Drug
)	O
may	O
interact	O
with	O
concurrently	O
administered	O
antiepileptic	B-Group
drugs	I-Group
periodic	O
serum	O
level	O
determinations	O
of	O
these	O
drugs	O
may	O
be	O
necessary	O
(	O
eg	O
methsuximide	B-Drug
may	O
increase	O
the	O
plasma	O
concentrations	O
of	O
phenytoin	B-Drug
and	O
phenobarbital	B-Drug
)	O
.	O
      
Aspirin	B-Brand
:	O
Concomitant	O
administration	O
of	O
diclofenac	B-Drug
and	O
aspirin	B-Brand
is	O
not	O
recommended	O
because	O
diclofenac	B-Drug
is	O
displaced	O
from	O
its	O
binding	O
sites	O
during	O
the	O
concomitant	O
administration	O
of	O
aspirin	B-Brand
resulting	O
in	O
lower	O
plasma	O
concentrations	O
peak	O
plasma	O
levels	O
and	O
AUC	O
values	O
.	O
      
No	O
clinically	O
significant	O
effect	O
of	O
famotidine	B-Drug
valproate	B-Drug
or	O
lithium	B-Drug
was	O
seen	O
on	O
the	O
pharmacokinetics	O
of	O
aripiprazole	B-Drug
(	O
see	O
CLINICAL	O
PHARMACOLOGY	O
:	O
Drug	O
-	O
Drug	O
Interactions	O
)	O
.	O
      
Since	O
the	O
renal	O
excretion	O
of	O
unchanged	O
dasatinib	B-Drug
and	O
its	O
metabolites	O
is	O
9	O
%	O
a	O
decrease	O
in	O
total	O
body	O
clearance	O
is	O
not	O
expected	O
in	O
patients	O
with	O
renal	O
insufficiency	O
.	O
      
Nevertheless	O
caution	O
is	O
indicated	O
in	O
the	O
co	O
-	O
administration	O
of	O
TCAs	B-Group
with	O
any	O
of	O
the	O
SSRIs	B-Group
and	O
also	O
in	O
switching	O
from	O
one	O
class	O
to	O
the	O
other	O
.	O
      
efavirenz	B-Drug
concentration	O
      
Methyprylon	B-Drug
may	O
interact	O
with	O
other	O
addictive	O
medications	O
in	O
that	O
it	O
may	O
increase	O
the	O
likelyhood	O
of	O
addiction	O
and	O
abuse	O
.	O
      
Antacids	B-Group
or	O
sucralfate	B-Drug
substantially	O
interfere	O
with	O
the	O
absorption	O
of	O
some	O
quinolones	B-Group
resulting	O
in	O
low	O
urine	O
levels	O
.	O
      
It	O
is	O
believed	O
that	O
the	O
toxicity	O
may	O
have	O
resulted	O
from	O
a	O
previously	O
unrecognized	O
interaction	O
between	O
isoniazid	B-Drug
and	O
acetaminophen	B-Drug
and	O
a	O
molecular	O
basis	O
for	O
this	O
interaction	O
has	O
been	O
proposed	O
.	O
      
Ezetimibe	B-Drug
crossed	O
the	O
placenta	O
when	O
pregnant	O
rats	O
and	O
rabbits	O
were	O
given	O
multiple	O
oral	O
doses	O
.	O
      
Clarithromycin	B-Drug
      
Subsequent	O
adjustment	O
of	O
doses	O
of	O
mercaptopurine	B-Drug
or	O
azathioprine	B-Drug
should	O
be	O
made	O
on	O
the	O
basis	O
of	O
therapeutic	O
response	O
and	O
the	O
appearance	O
of	O
toxic	O
effects	O
.	O
      
Likewise	O
gabapentin	B-Drug
pharmacokinetics	O
were	O
unaltered	O
by	O
carbamazepine	B-Drug
administration	O
.	O
      
The	O
magnitude	O
of	O
these	O
effects	O
may	O
depend	O
on	O
the	O
duration	O
of	O
administration	O
of	O
the	O
volatile	O
agents	O
.	O
      
Until	O
specific	O
compatibility	O
data	O
are	O
available	O
it	O
is	O
not	O
recommended	O
that	O
DOXIL	B-Brand
be	O
mixed	O
with	O
other	O
drugs	O
.	O
      
In	O
patients	O
using	O
cardiac	B-Group
glycosides	I-Group
(	O
digoxin	B-Drug
and	O
others	O
)	O
plasma	O
levels	O
of	O
calcium	O
potassium	O
and	O
magnesium	O
must	O
be	O
carefully	O
monitored	O
.	O
      
Weak	O
inhibitory	O
effects	O
toward	O
other	O
isoforms	O
(	O
CYP9C9	O
9C9	O
9C9	O
9D9	O
9A9	O
)	O
were	O
found	O
but	O
Ki	O
values	O
were	O
in	O
excess	O
of	O
plasma	O
concentrations	O
achieved	O
following	O
dosing	O
.	O
      
HMG	B-Group
-	O
CoA	I-Group
Reductase	I-Group
Inhibitors	I-Group
:	O
lovastatin	B-Drug
simvastatin	B-Drug
WARNING	O
potential	O
for	O
serious	O
reactions	O
such	O
as	O
risk	O
of	O
myopathy	O
including	O
rhabdomyolysis	O
.	O
      
Discontinuing	O
colestipol	B-Drug
hydrochloride	I-Drug
could	O
pose	O
a	O
hazard	O
to	O
health	O
if	O
a	O
potentially	O
toxic	O
drug	O
that	O
is	O
significantly	O
bound	O
to	O
the	O
resin	B-Group
has	O
been	O
titrated	O
to	O
a	O
maintenance	O
level	O
while	O
the	O
patient	O
was	O
taking	O
colestipol	B-Drug
hydrochloride	I-Drug
.	O
      
Given	O
the	O
anticonvulsant	O
properties	O
of	O
carbamazepine	B-Drug
EQUETROTM	B-Brand
may	O
reduce	O
the	O
thyroid	O
function	O
as	O
has	O
been	O
reported	O
with	O
other	O
anticonvulsants	B-Group
.	O
      
Additionally	O
anti	B-Group
-	O
malarial	I-Group
drugs	I-Group
such	O
as	O
chloroquine	B-Drug
and	O
mefloquine	B-Drug
may	O
antagonize	O
the	O
activity	O
of	O
carbamazepine	B-Drug
.	O
      
Accordingly	O
renal	O
function	O
should	O
be	O
closely	O
monitored	O
in	O
these	O
patients	O
and	O
in	O
the	O
event	O
of	O
relevant	O
significant	O
changes	O
in	O
laboratory	O
parameters	O
bezafibrate	B-Drug
should	O
if	O
necessary	O
be	O
discontinued	O
      
Although	O
the	O
mechanism	O
of	O
interaction	O
between	O
fenoprofen	B-Drug
and	O
aspirin	B-Brand
is	O
not	O
totally	O
known	O
enzyme	O
induction	O
and	O
displacement	O
of	O
fenoprofen	B-Drug
from	O
plasma	O
albumin	O
binding	O
sites	O
are	O
possibilities	O
.	O
      
Metopirone	B-Brand
inhibits	O
the	O
glucuronidation	O
of	O
acetaminophen	B-Drug
and	O
could	O
possibly	O
potentiate	O
acetaminophen	B-Drug
toxicity	O
.	O
      
The	O
administration	O
of	O
other	O
potassium	B-Group
-	O
sparing	I-Group
antihypertensives	I-Group
with	O
NSAIDs	B-Group
has	O
been	O
shown	O
to	O
reduce	O
the	O
antihypertensive	O
effect	O
in	O
some	O
patients	O
and	O
result	O
in	O
severe	O
hyperkalemia	O
in	O
patients	O
with	O
impaired	O
renal	O
function	O
.	O
      
decreased	O
pregnanediol	O
excretion	O
;	O
      
.	O
      
Colchicine	B-Drug
is	O
inhibited	O
by	O
acidifying	B-Group
agents	I-Group
.	O
      
Pretreatment	O
of	O
healthy	O
volunteers	O
with	O
multiple	O
doses	O
of	O
rifampin	B-Drug
followed	O
by	O
a	O
single	O
dose	O
of	O
Gleevec	B-Brand
increased	O
Gleevec	B-Brand
oral	O
-	O
dose	O
clearance	O
by	O
9	O
-	O
fold	O
which	O
significantly	O
(	O
p	O
9	O
)	O
decreased	O
mean	O
cmax	O
and	O
AUC	O
(	O
9	O
-	O
9	O
)	O
.	O
      
Electrolyte	O
Disturbances	O
Patients	O
with	O
hypokalemia	O
or	O
hypomagnesemia	O
should	O
have	O
the	O
condition	O
corrected	O
whenever	O
possible	O
before	O
being	O
treated	O
with	O
Cordarone	B-Drug
I.V.	I-Drug
as	O
these	O
disorders	O
can	O
exaggerate	O
the	O
degree	O
of	O
QTc	O
prolongation	O
and	O
increase	O
the	O
potential	O
for	O
TdP	O
.	O
      
Caution	O
is	O
therefore	O
advised	O
when	O
administering	O
PEGANONE	B-Brand
to	O
patients	O
receiving	O
coumarin	B-Group
anticoagulants	I-Group
.	O
      
Therefore	O
administration	O
of	O
quinolones	B-Group
with	O
antacids	B-Group
containing	O
calcium	B-Drug
magnesium	B-Drug
or	O
aluminum	B-Drug
;	O
      
The	O
mechanism	O
for	O
this	O
interaction	O
probably	O
is	O
adsorption	O
of	O
nitrofurantoin	B-Drug
onto	O
the	O
surface	O
of	O
magnesium	B-Drug
trisilicate	I-Drug
.	O
      
If	O
you	O
are	O
taking	O
a	O
tricyclic	B-Group
antidepressant	I-Group
talk	O
to	O
your	O
doctor	O
before	O
taking	O
this	O
medicine	O
.	O
      
Calcium	B-Group
channel	I-Group
blockers	I-Group
may	O
also	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
TENORMIN	B-Brand
.	O
      
The	O
fraction	O
of	O
STADOL	B-Brand
NS	I-Brand
absorbed	O
is	O
unaffected	O
by	O
the	O
concomitant	O
administration	O
of	O
a	O
nasal	B-Group
vasoconstrictor	I-Group
(	O
oxymetazoline	B-Drug
)	O
but	O
the	O
rate	O
of	O
absorption	O
is	O
decreased	O
.	O
      
indinavir	B-Drug
concentration	O
      
However	O
because	O
some	O
quinolones	B-Group
have	O
been	O
reported	O
to	O
enhance	O
the	O
anticoagulant	O
effects	O
of	O
warfarin	B-Drug
or	O
its	O
derivatives	O
in	O
patients	O
the	O
prothrombin	O
time	O
or	O
other	O
suitable	O
coagulation	O
test	O
should	O
be	O
closely	O
monitored	O
if	O
a	O
quinolone	B-Group
antimicrobial	I-Group
is	O
administered	O
concomitantly	O
with	O
warfarin	B-Drug
or	O
its	O
derivatives	O
.	O
      
However	O
because	O
bleeding	O
has	O
been	O
reported	O
when	O
ibuprofen	B-Drug
and	O
other	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
agents	I-Group
have	O
been	O
administered	O
to	O
patients	O
on	O
coumarin	B-Group
-	O
type	I-Group
anticoagulants	I-Group
the	O
physician	O
should	O
be	O
cautious	O
when	O
administering	O
ibuprofen	B-Drug
to	O
patients	O
on	O
anticoagulants	B-Group
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Phenytoin	B-Drug
may	O
decrease	O
serum	O
concentrations	O
of	O
9	O
.	O
      
vi	O
.	O
      
Increased	O
thyroid	O
-	O
binding	O
globulin	O
(	O
TBG	O
)	O
leading	O
to	O
increased	O
circulating	O
total	O
thyroid	O
hormone	O
levels	O
as	O
measured	O
by	O
protein	O
-	O
bound	O
iodine	O
(	O
PBI	O
)	O
T9	O
levels	O
(	O
by	O
column	O
or	O
by	O
radioimmunoassay	O
)	O
or	O
T9	O
levels	O
by	O
radioimmunoassay	O
.	O
      
In	O
some	O
cases	O
the	O
onset	O
of	O
the	O
injection	O
site	O
reaction	O
either	O
occurred	O
during	O
a	O
prolonged	O
infusion	O
or	O
was	O
delayed	O
by	O
a	O
week	O
to	O
ten	O
days	O
.	O
      
In	O
a	O
large	O
compassionate	O
use	O
program	O
Mexitil	B-Brand
has	O
been	O
used	O
concurrently	O
with	O
commonly	O
employed	O
antianginal	O
antihypertensive	B-Group
and	O
anticoagulant	B-Group
drugs	I-Group
without	O
observed	O
interactions	O
.	O
      
If	O
antacid	B-Group
therapy	O
is	O
needed	O
the	O
antacid	O
dose	O
should	O
be	O
administered	O
at	O
least	O
9	O
hours	O
prior	O
to	O
or	O
9	O
hours	O
after	O
the	O
dose	O
of	O
SPRYCEL	B-Brand
.	O
      
In	O
clinical	O
studies	O
the	O
concurrent	O
administration	O
of	O
the	O
ASMANEX	B-Brand
TWISTHALER	I-Brand
inhaler	O
and	O
other	O
drugs	O
commonly	O
used	O
in	O
the	O
treatment	O
of	O
asthma	O
was	O
not	O
associated	O
with	O
any	O
unusual	O
adverse	O
events	O
.	O
      
Ketoconazole	B-Drug
(	O
9	O
mg	O
once	O
daily	O
)	O
produced	O
a	O
9	O
-	O
fold	O
increase	O
in	O
vardenafil	B-Drug
AUC	O
and	O
a	O
9	O
-	O
fold	O
increase	O
in	O
Cmax	O
when	O
co	O
-	O
administered	O
with	O
Vardenafil	B-Drug
(	O
9	O
mg	O
)	O
in	O
healthy	O
volunteers	O
.	O
      
Propranolol	B-Drug
attenuated	O
the	O
heart	O
rate	O
increase	O
following	O
administration	O
of	O
immediate	O
release	O
nisoldipine	B-Drug
.	O
      
.	O
      
Montelukast	B-Drug
has	O
been	O
administered	O
with	O
other	O
therapies	O
routinely	O
used	O
in	O
the	O
prophylaxis	O
and	O
chronic	O
treatment	O
of	O
asthma	O
with	O
no	O
apparent	O
increase	O
in	O
adverse	O
reactions	O
.	O
      
In	O
another	O
study	O
with	O
intravenous	O
administration	O
of	O
midazolam	B-Drug
Aprepitant	B-Drug
was	O
given	O
as	O
9	O
mg	O
on	O
Day	O
9	O
and	O
9	O
mg	O
/	O
day	O
on	O
Days	O
9	O
and	O
9	O
and	O
midazolam	B-Drug
9	O
mg	O
IV	O
was	O
given	O
prior	O
to	O
the	O
administration	O
of	O
the	O
9	O
-	O
day	O
regimen	O
of	O
Aprepitant	B-Drug
and	O
on	O
Days	O
9	O
9	O
and	O
9	O
.	O
      
Since	O
this	O
could	O
be	O
explained	O
either	O
by	O
enhanced	O
absorption	O
or	O
by	O
an	O
alteration	O
of	O
hepatic	O
metabolism	O
of	O
labetalol	B-Drug
HCl	I-Drug
special	O
care	O
should	O
be	O
used	O
in	O
establishing	O
the	O
dose	O
required	O
for	O
blood	O
pressure	O
control	O
in	O
such	O
patients	O
.	O
      
Omeprazole	B-Drug
:	O
Omeprazole	B-Drug
is	O
a	O
CYP	O
9A9	O
substrate	O
and	O
CYP	O
9C9	O
substrate	O
and	O
inhibitor	O
.	O
      
The	O
interaction	O
of	O
Streptase	B-Brand
Streptokinase	B-Drug
with	O
other	O
drugs	O
has	O
not	O
been	O
well	O
studied	O
.	O
      
It	O
has	O
been	O
reported	O
that	O
Itraconazole	B-Drug
enhances	O
the	O
anticoagulant	O
effect	O
of	O
coumarin	B-Group
-	O
like	O
drugs	O
.	O
      
Caution	O
is	O
recommended	O
when	O
administering	O
substrates	O
of	O
CYP9B9	O
and	O
CYP9C9	O
with	O
NEXAVAR	B-Brand
.	O
      
Elevated	O
plasma	O
levels	O
of	O
theophylline	B-Drug
have	O
been	O
reported	O
with	O
concomitant	O
quinolone	B-Group
use	O
.	O
      
Lansoprazole	B-Drug
causes	O
a	O
profound	O
and	O
long	O
lasting	O
inhibition	O
of	O
gastric	O
acid	O
secretion	O
;	O
      
serum	O
magnesium	O
levels	O
may	O
increase	O
in	O
uremic	O
patients	O
)	O
Serum	O
protein	O
-	O
bound	O
iodine	O
(	O
PBI	O
)	O
levels	O
(	O
may	O
be	O
decreased	O
)	O
Thiazides	B-Group
should	O
be	O
discontinued	O
before	O
carrying	O
out	O
tests	O
for	O
parathyroid	O
function	O
.	O
      
Indocyanine	B-Drug_n
green	I-Drug_n
as	O
an	O
index	O
of	O
hepatic	O
drug	O
extraction	O
has	O
been	O
tested	O
and	O
no	O
significant	O
effects	O
have	O
been	O
found	O
.	O
      
Neuromuscular	B-Group
Blockers	I-Group
:	O
In	O
one	O
study	O
of	O
9	O
healthy	O
volunteers	O
administration	O
of	O
PRECEDEX	B-Brand
for	O
9	O
minutes	O
at	O
a	O
plasma	O
concentration	O
of	O
9	O
(	O
one	O
)	O
ng	O
/	O
mL	O
resulted	O
in	O
no	O
clinically	O
meaningful	O
increases	O
in	O
the	O
magnitude	O
or	O
neuromuscular	O
blockade	O
associated	O
with	O
rocuronium	B-Drug
administration	O
.	O
      
Cold	O
and	O
flu	O
remedies	O
.	O
      
Corticotropin	B-Drug
may	O
accentuate	O
the	O
electrolyte	O
loss	O
associated	O
with	O
diuretic	B-Drug
therapy	O
.	O
      
Trimethoprim	B-Drug
given	O
at	O
a	O
common	O
clinical	O
dosage	O
increased	O
the	O
phenytoin	B-Drug
half	O
-	O
life	O
by	O
9	O
%	O
and	O
decreased	O
the	O
phenytoin	B-Drug
metabolic	O
clearance	O
rate	O
by	O
9	O
%	O
.	O
      
Because	O
prostaglandins	O
play	O
an	O
important	O
role	O
in	O
hemostasis	O
and	O
NSAIDs	B-Group
affect	O
platelet	O
function	O
as	O
well	O
concurrent	O
therapy	O
with	O
all	O
NSAIDs	B-Group
including	O
diclofenac	B-Drug
and	O
warfarin	B-Drug
requires	O
close	O
monitoring	O
of	O
patients	O
to	O
be	O
certain	O
that	O
no	O
change	O
in	O
their	O
anticoagulant	B-Group
dosage	O
is	O
required	O
.	O
      
Therefore	O
caution	O
should	O
be	O
used	O
when	O
administering	O
MEPRON	B-Brand
concurrently	O
with	O
other	O
highly	O
plasma	O
protein	O
-	O
bound	O
drugs	O
with	O
narrow	O
therapeutic	O
indices	O
as	O
competition	O
for	O
binding	O
sites	O
may	O
occur	O
.	O
      
The	O
incidence	O
of	O
upper	O
gastrointestinal	O
events	O
in	O
patients	O
concomitantly	O
taking	O
aspirin	B-Brand
or	O
NSAIDs	B-Group
was	O
similar	O
in	O
patients	O
taking	O
ibandronate	B-Drug
9	O
mg	O
daily	O
(	O
9	O
%	O
)	O
and	O
9	O
mg	O
once	O
monthly	O
(	O
9	O
%	O
)	O
.	O
      
Mephenytoin	B-Drug
may	O
also	O
affect	O
the	O
effects	O
of	O
other	O
drugs	O
which	O
include	O
some	O
steroid	B-Group
medications	I-Group
warfarin	B-Drug
certain	O
heart	O
medicines	O
birth	O
control	O
pills	O
anti	B-Group
-	O
infective	I-Group
medicines	I-Group
furosemide	B-Drug
and	O
theophylline	B-Drug
Please	O
note	O
that	O
Mephenytoin	B-Drug
may	O
interact	O
with	O
other	O
drugs	O
that	O
are	O
not	O
listed	O
here	O
.	O
      
The	O
clearance	O
of	O
theophylline	B-Drug
was	O
decreased	O
approximately	O
9	O
-	O
fold	O
.	O
      
It	O
may	O
also	O
interact	O
with	O
thiazides	B-Group
(	O
increased	O
thrombocytopenia	O
)	O
cyclosporine	B-Drug
(	O
increased	O
nephrotoxicity	O
)	O
sulfonylurea	B-Group
agents	I-Group
(	O
increased	O
hypoglycemic	O
response	O
)	O
warfarin	B-Drug
(	O
increased	O
anticoagulant	O
effect	O
)	O
methotrexate	B-Drug
(	O
decreased	O
renal	O
excretion	O
of	O
methotrexate	B-Drug
)	O
phenytoin	B-Drug
(	O
decreased	O
hepatic	O
clearance	O
of	O
phenytoin	B-Drug
)	O
.	O
      
Concomitant	O
Administration	O
with	O
Racemic	O
Citalopram	B-Drug
Citalopram	B-Drug
-	O
Since	O
escitalopram	B-Drug
is	O
the	O
active	O
isomer	O
of	O
racemic	O
citalopram	B-Drug
(	O
Celexa	B-Brand
)	O
the	O
two	O
agents	O
should	O
not	O
be	O
coadministered	O
.	O
      
Saquinavir	B-Drug
      
Additional	O
animals	O
in	O
both	O
dose	O
groups	O
developed	O
B	O
-	O
cell	O
hyperplasia	O
of	O
the	O
spleen	O
and	O
lymph	O
nodes	O
.	O
      
Although	O
additional	O
specific	O
interaction	O
studies	O
were	O
not	O
performed	O
montelukast	B-Drug
was	O
used	O
concomitantly	O
with	O
a	O
wide	O
range	O
of	O
commonly	O
prescribed	O
drugs	O
in	O
clinical	O
studies	O
without	O
evidence	O
of	O
clinical	O
adverse	O
interactions	O
.	O
      
Drugs	O
That	O
Interfere	O
With	O
Hemostasis	O
(	O
NSAIDs	B-Group
Aspirin	B-Brand
Warfarin	B-Drug
etc	O
.	O
)	O
      
In	O
a	O
study	O
in	O
which	O
the	O
9	O
mg	O
clonazepam	B-Drug
orally	O
disintegrating	O
tablet	O
was	O
administered	O
with	O
and	O
without	O
propantheline	B-Drug
(	O
an	O
anticholinergic	B-Group
agent	I-Group
with	O
multiple	O
effects	O
on	O
the	O
GI	O
tract	O
)	O
to	O
healthy	O
volunteers	O
the	O
AUC	O
of	O
clonazepam	B-Drug
was	O
9	O
%	O
lower	O
and	O
the	O
Cmax	O
of	O
clonazepam	B-Drug
was	O
9	O
%	O
lower	O
when	O
the	O
orally	O
disintegrating	O
tablet	O
was	O
given	O
with	O
propantheline	B-Drug
compared	O
to	O
when	O
it	O
was	O
given	O
alone	O
.	O
      
Trileptal	B-Brand
dose	O
(	O
mg	O
/	O
day	O
)	O
      
However	O
it	O
has	O
been	O
established	O
that	O
acitretin	B-Drug
interferes	O
with	O
the	O
contraceptive	O
effect	O
of	O
microdosed	O
progestin	B-Drug
minipill	O
preparations	O
.	O
      
The	O
pharmacokinetics	O
of	O
rimantadine	B-Drug
were	O
assessed	O
on	O
days	O
9	O
and	O
9	O
.	O
      
Coadministration	O
of	O
TRITEC	B-Brand
with	O
clarithromycin	B-Drug
resulted	O
in	O
increased	O
plasma	O
ranitidine	B-Drug
concentrations	O
(	O
9	O
%	O
)	O
increased	O
plasma	O
bismuth	O
trough	O
concentrations	O
(	O
9	O
%	O
)	O
and	O
increased	O
9	B-Drug_n
-	O
hydroxy	I-Drug_n
-	O
clarithromycin	I-Drug_n
plasma	O
concentrations	O
(	O
9	O
%	O
)	O
.	O
      
In	O
a	O
study	O
in	O
which	O
patients	O
with	O
active	O
RA	O
were	O
treated	O
for	O
up	O
to	O
9	O
weeks	O
with	O
concurrent	O
Kineret	B-Brand
and	O
etanercept	B-Drug
therapy	O
a	O
9	O
%	O
rate	O
of	O
serious	O
infections	O
was	O
observed	O
which	O
was	O
higher	O
than	O
that	O
observed	O
with	O
etanercept	B-Drug
alone	O
(	O
9	O
%	O
)	O
.	O
      
These	O
above	O
findings	O
are	O
summarized	O
in	O
TABLE	O
9	O
.	O
      
To	O
minimize	O
CNS	O
depression	O
and	O
possible	O
potentiation	O
barbiturates	B-Group
antihistamines	B-Group
narcotics	B-Group
hypotensive	B-Group
agents	I-Group
or	O
phenothiazines	B-Group
should	O
be	O
used	O
with	O
caution	O
.	O
      
Concomitant	O
administration	O
of	O
fenofibrate	B-Drug
(	O
equivalent	O
to	O
9	O
mg	O
TRICOR	B-Brand
)	O
with	O
atorvastatin	B-Drug
(	O
9	O
mg	O
)	O
once	O
daily	O
for	O
9	O
days	O
resulted	O
in	O
approximately	O
9	O
%	O
decrease	O
(	O
range	O
from	O
9	O
%	O
decrease	O
to	O
9	O
%	O
increase	O
)	O
in	O
atorvastatin	B-Drug
AUC	O
values	O
in	O
9	O
healthy	O
males	O
.	O
      
The	O
addition	O
of	O
9	O
mg	O
/	O
kg	O
/	O
day	O
of	O
cromolyn	B-Drug
sodium	I-Drug
(	O
approximately	O
9	O
times	O
the	O
maximum	O
recommended	O
daily	O
inhalation	O
dose	O
in	O
adults	O
on	O
a	O
mg	O
/	O
m9	O
basis	O
)	O
to	O
9	O
mg	O
/	O
kg	O
/	O
day	O
of	O
isoproterenol	B-Drug
(	O
approximately	O
9	O
times	O
the	O
maximum	O
recommended	O
daily	O
inhalation	O
dose	O
in	O
adults	O
on	O
a	O
mg	O
/	O
m9	O
basis	O
)	O
appears	O
to	O
have	O
increased	O
the	O
incidence	O
of	O
both	O
resorptions	O
and	O
malformations	O
.	O
      
This	O
may	O
indicate	O
that	O
ibuprofen	B-Drug
could	O
enhance	O
the	O
toxicity	O
of	O
methotrexate	B-Drug
.	O
      
Drugs	O
that	O
cause	O
significant	O
sustained	O
elevation	O
in	O
gastric	O
pH	O
(	O
histamine	B-Group
H9	I-Group
-	O
receptor	I-Group
antagonists	I-Group
such	O
as	O
ranitidine	B-Drug
or	O
cimetidine	B-Drug
)	O
may	O
reduce	O
plasma	O
concentrations	O
of	O
IRESSA	B-Brand
and	O
therefore	O
potentially	O
may	O
reduce	O
efficacy	O
.	O
      
Intestinal	B-Group
adsorbents	I-Group
(	O
e.	O
g.	O
charcoal	B-Drug
)	O
and	O
digestive	B-Group
enzyme	I-Group
preparations	I-Group
containing	O
carbohydrate	O
-	O
splitting	O
enzymes	O
(	O
e.	O
g.	O
amylase	B-Drug
pancreatin	B-Drug
)	O
may	O
reduce	O
the	O
effect	O
of	O
Acarbose	B-Drug
and	O
should	O
not	O
be	O
taken	O
concomitantly	O
.	O
      
In	O
an	O
emergency	O
situation	O
when	O
opioid	O
analgesia	O
must	O
be	O
administered	O
to	O
a	O
patient	O
receiving	O
REVIA	B-Brand
the	O
amount	O
of	O
opioid	B-Group
required	O
may	O
be	O
greater	O
than	O
usual	O
and	O
the	O
resulting	O
respiratory	O
depression	O
may	O
be	O
deeper	O
and	O
more	O
prolonged	O
.	O
      
Free	O
T9	O
resin	O
uptake	O
is	O
decreased	O
reflecting	O
the	O
elevated	O
TBG	O
;	O
      
Data	O
from	O
in	O
vitro	O
studies	O
of	O
alprazolam	B-Drug
suggest	O
a	O
possible	O
drug	O
interaction	O
with	O
alprazolam	B-Drug
for	O
the	O
following	O
:	O
sertraline	B-Drug
and	O
paroxetine	B-Drug
.	O
      
When	O
ZETIA	B-Brand
is	O
administered	O
with	O
an	O
HMG	B-Group
-	O
CoA	I-Group
reductase	I-Group
inhibitor	I-Group
in	O
a	O
woman	O
of	O
childbearing	O
potential	O
refer	O
to	O
the	O
pregnancy	O
category	O
and	O
package	O
labeling	O
for	O
the	O
HMG	B-Drug
-	O
CoA	I-Drug
reductase	I-Drug
inhibitor	I-Drug
.	O
      
Co	O
-	O
administration	O
of	O
SUTENT	B-Brand
with	O
inducers	O
of	O
the	O
CYP9A9	O
family	O
(	O
e.g.	O
dexamethasone	B-Drug
phenytoin	B-Drug
carbamazepine	B-Drug
rifampin	B-Drug
rifabutin	B-Drug
rifapentin	B-Drug
phenobarbital	B-Drug
St.	O
Johns	O
Wort	O
)	O
may	O
decrease	O
sunitinib	B-Drug
concentrations	O
.	O
      
Dose	O
reduction	O
of	O
CRIXIVAN	B-Brand
to	O
9	O
mg	O
every	O
9	O
hours	O
is	O
recommended	O
when	O
administering	O
itraconazole	B-Drug
concurrently	O
.	O
      
Blood	O
Sugar	O
:	O
Some	O
patients	O
receiving	O
retinoids	B-Group
have	O
experienced	O
problems	O
with	O
blood	O
sugar	O
control	O
.	O
      
Results	O
from	O
existing	O
clinical	O
trials	O
suggest	O
no	O
significant	O
interactions	O
between	O
COPAXONE	B-Brand
and	O
other	O
therapies	O
commonly	O
used	O
in	O
MS	O
patients	O
including	O
the	O
concurrent	O
use	O
of	O
corticosteroids	B-Group
for	O
up	O
to	O
9	O
days	O
.	O
      
Praziquantel	B-Drug
:	O
In	O
the	O
fed	O
state	O
praziquantel	B-Drug
(	O
9	O
mg	O
/	O
kg	O
)	O
increased	O
mean	O
maximum	O
plasma	O
concentration	O
and	O
area	O
under	O
the	O
curve	O
of	O
albendazole	B-Drug
sulfoxide	I-Drug
by	O
about	O
9	O
%	O
in	O
healthy	O
subjects	O
(	O
n=9	O
)	O
compared	O
with	O
a	O
separate	O
group	O
of	O
subjects	O
(	O
n=9	O
)	O
given	O
albendazole	B-Drug
alone	O
.	O
      
-	O
Reduced	O
serum	O
folate	O
concentration	O
      
Folic	B-Drug
acid	I-Drug
in	O
large	O
amounts	O
may	O
counteract	O
the	O
antiepileptic	O
effect	O
of	O
phenobarbital	B-Drug
phenytoin	B-Drug
and	O
primidone	B-Drug
and	O
increase	O
the	O
frequency	O
of	O
seizures	O
in	O
susceptible	O
pediatric	O
patients	O
.	O
      
Similarly	O
the	O
effects	O
of	O
phenytoin	B-Drug
on	O
phenobarbital	B-Drug
valproic	B-Drug
acid	I-Drug
and	O
sodium	O
plasma	O
valproate	B-Drug
concentrations	O
are	O
unpredictable	O
      
The	O
most	O
significant	O
drug	O
interactions	O
following	O
administration	O
of	O
Cerebyx	B-Brand
are	O
expected	O
to	O
occur	O
with	O
drugs	O
that	O
interact	O
with	O
phenytoin	B-Drug
.	O
      
Experience	O
with	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
drugs	I-Group
(	O
NSAIDs	B-Group
)	O
suggests	O
the	O
potential	O
for	O
interactions	O
with	O
furosemide	B-Drug
and	O
ACE	B-Group
inhibitors	I-Group
.	O
      
therefore	O
close	O
monitoring	O
of	O
prothrombin	O
time	O
is	O
recommended	O
and	O
adjustment	O
of	O
the	O
anticoagulant	B-Group
dose	O
may	O
be	O
necessary	O
when	O
Tagamet	B-Brand
is	O
administered	O
concomitantly	O
.	O
      
Tetracycline	B-Drug
a	O
bacteriostatic	B-Group
antibiotic	I-Group
may	O
antagonize	O
the	O
bactericidal	O
effect	O
of	O
penicillin	B-Drug
and	O
concurrent	O
use	O
of	O
these	O
drugs	O
should	O
be	O
avoided	O
.	O
      
dietary	O
deficiencies	O
;	O
      
increased	O
plasminogen	O
antigen	O
and	O
activity	O
.	O
      
-	O
Valproic	B-Drug
acid	I-Drug
(	O
e.g.	O
Depakene	B-Brand
)	O
Use	O
of	O
sulfapyridine	B-Drug
with	O
these	O
medicines	O
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
affecting	O
the	O
liver	O
      
Aspirin	B-Brand
:	O
Ketoprofen	B-Drug
does	O
not	O
alter	O
aspirin	B-Brand
absorption	O
;	O
      
A	O
variety	O
of	O
toxic	O
neurological	O
effects	O
and	O
malignant	O
hyperpyrexia	O
can	O
occur	O
sometimes	O
with	O
fatal	O
results	O
.	O
      
Combination	O
of	O
amiodarone	B-Drug
with	O
other	O
antiarrhythmic	B-Drug
therapy	O
should	O
be	O
reserved	O
for	O
patients	O
with	O
life	O
-	O
threatening	O
ventricular	O
arrhythmias	O
who	O
are	O
incompletely	O
responsive	O
to	O
a	O
single	O
agent	O
or	O
incompletely	O
responsive	O
to	O
amiodarone	B-Drug
.	O
      
The	O
mean	O
percentage	O
increase	O
in	O
the	O
glipizide	B-Drug
AUC	O
after	O
fluconazole	B-Drug
administration	O
was	O
9	O
%	O
(	O
range	O
:	O
9	O
to	O
9	O
)	O
.	O
      
Treatment	O
with	O
entacapone	B-Drug
coadministered	O
with	O
levodopa	B-Drug
/	O
dopa	B-Group
decarboxylase	I-Group
inhibitor	I-Group
does	O
not	O
change	O
these	O
effects	O
.	O
      
This	O
interaction	O
was	O
not	O
accompanied	O
by	O
ECG	O
changes	O
and	O
its	O
clinical	O
significance	O
is	O
not	O
known	O
.	O
      
Coadministration	O
with	O
compounds	O
that	O
are	O
potent	O
inducers	O
of	O
CYP9A9	O
(	O
eg	O
phenobarbital	B-Drug
phenytoin	B-Drug
dexamethasone	B-Drug
carbamazepine	B-Drug
)	O
may	O
result	O
in	O
decreased	O
plasma	O
levels	O
of	O
saquinavir	B-Drug
.	O
      
Therefore	O
esomeprazole	B-Drug
may	O
interfere	O
with	O
the	O
absorption	O
of	O
drugs	O
where	O
gastric	O
pH	O
is	O
an	O
important	O
determinant	O
of	O
bioavailability	O
(	O
eg	O
ketoconazole	B-Drug
iron	B-Drug
salts	O
and	O
digoxin	B-Drug
)	O
.	O
      
Digitalis	B-Group
:	O
Thyroid	B-Group
preparations	I-Group
may	O
potentiate	O
the	O
toxic	O
effects	O
of	O
digitalis	B-Group
.	O
      
These	O
compounds	O
interfere	O
with	O
chemical	O
color	O
development	O
essential	O
to	O
the	O
analytical	O
procedures	O
.	O
      
-	O
Antihypertensives	B-Group
:	O
Bumetanide	B-Drug
may	O
potentiate	O
the	O
effect	O
of	O
various	O
antihypertensive	B-Group
drugs	I-Group
necessitating	O
a	O
reduction	O
in	O
the	O
dosage	O
of	O
these	O
drugs	O
.	O
      
Toxicology	O
studies	O
of	O
heroin	B-Drug_n
-	O
related	O
deaths	O
reveal	O
frequent	O
involvement	O
of	O
other	O
central	B-Group
nervous	I-Group
system	I-Group
depressants	I-Group
including	O
alcohol	B-Drug
benzodiazepines	B-Group
such	O
as	O
diazepam	B-Drug
(	O
Valium	B-Brand
)	O
and	O
to	O
a	O
rising	O
degree	O
methadone	B-Drug
.	O
      
9	O
.	O
      
Increases	O
in	O
INR	O
and	O
prothrombin	O
time	O
may	O
lead	O
to	O
abnormal	O
bleeding	O
and	O
even	O
death	O
.	O
      
Lithium	B-Drug
:	O
Ibuprofen	B-Drug
produced	O
an	O
elevation	O
of	O
plasma	O
lithium	B-Drug
levels	O
and	O
a	O
reduction	O
in	O
renal	O
lithium	B-Drug
clearance	O
in	O
a	O
study	O
of	O
eleven	O
normal	O
volunteers	O
.	O
      
nc9	O
9	O
%	O
decrease	O
[	O
CI	O
:	O
9	O
%	O
decrease	O
9	O
%	O
decrease	O
]	O
      
Digoxin	B-Drug
:	O
A	O
controlled	O
pharmacokinetic	O
study	O
has	O
shown	O
no	O
effect	O
on	O
plasma	O
digoxin	B-Drug
concentrations	O
when	O
coadministered	O
with	O
ACEON	B-Brand
Tablets	O
but	O
an	O
effect	O
of	O
digoxin	B-Drug
on	O
the	O
plasma	O
concentration	O
of	O
perindopril	B-Drug
/	O
perindoprilat	B-Drug_n
has	O
not	O
been	O
excluded	O
.	O
      
vardenafil	B-Drug
concentration	O
      
Midazolam	B-Drug
Synergism	O
      
Concomitant	O
use	O
of	O
tricyclic	B-Group
antidepressants	I-Group
with	O
drugs	O
that	O
can	O
inhibit	O
cytochrome	O
P9	O
9D9	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	B-Group
antidepressant	I-Group
or	O
the	O
other	O
drug	O
.	O
      
The	O
following	O
are	O
examples	O
of	O
substances	O
that	O
may	O
increase	O
the	O
blood	O
-	O
glucose	O
-	O
lowering	O
effect	O
and	O
susceptibility	O
to	O
hypoglycemia	O
:	O
oral	O
antidiabetic	B-Group
products	I-Group
ACE	B-Group
inhibitors	I-Group
disopyramide	B-Drug
fibrates	B-Group
fluoxetine	B-Drug
monoamine	B-Group
oxidase	I-Group
MAO	I-Group
inhibitors	I-Group
propoxyphene	B-Drug
salicylates	B-Group
somatostatin	B-Group
analog	I-Group
(	O
e.g.	O
octreotide	B-Drug
)	O
sulfonamide	B-Group
antibiotics	I-Group
.	O
      
A	O
decrease	O
of	O
the	O
dosage	O
may	O
be	O
necessary	O
when	O
patient	O
becomes	O
euthyroid	O
.	O
      
Patients	O
should	O
be	O
monitored	O
for	O
signs	O
of	O
withdrawal	O
and	O
their	O
methadone	B-Drug
dose	O
increased	O
as	O
required	O
to	O
alleviate	O
withdrawal	O
symptoms	O
.	O
      
Ephedrine	B-Drug
:	O
Ephedrine	B-Drug
may	O
enhance	O
the	O
metabolic	O
clearance	O
of	O
corticosteroids	B-Group
resulting	O
in	O
decreased	O
blood	O
levels	O
and	O
lessened	O
physiologic	O
activity	O
thus	O
requiring	O
an	O
increase	O
in	O
corticosteroid	B-Group
dosage	O
.	O
      
Synergism	O
has	O
been	O
shown	O
between	O
halothane	B-Drug
anesthesia	O
and	O
intravenously	O
administered	O
labetalol	B-Drug
HCl	I-Drug
.	O
      
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
reactions	O
such	O
as	O
acute	O
ergot	O
toxicity	O
characterized	O
by	O
peripheral	O
vasospasm	O
and	O
ischemia	O
of	O
the	O
extremities	O
and	O
other	O
tissues	O
.	O
      
Thus	O
if	O
such	O
treatment	O
is	O
essential	O
the	O
possibility	O
of	O
increased	O
risk	O
relative	O
to	O
benefits	O
should	O
be	O
considered	O
.	O
      
Quinidine	B-Drug
verapamil	B-Drug
amiodarone	B-Drug
propafenone	B-Drug
indomethacin	B-Drug
itraconazole	B-Drug
alprazolam	B-Drug
and	O
spironolactone	B-Drug
raise	O
the	O
serum	O
digoxin	B-Drug
concentration	O
due	O
to	O
a	O
reduction	O
in	O
clearance	O
and	O
/	O
or	O
in	O
volume	O
of	O
distribution	O
of	O
the	O
drug	O
with	O
the	O
implication	O
that	O
digitalis	B-Group
intoxication	O
may	O
result	O
.	O
      
The	O
effect	O
was	O
present	O
for	O
at	O
least	O
9	O
days	O
after	O
the	O
last	O
dose	O
of	O
bupropion	B-Drug
.	O
      
All	O
elevations	O
resolved	O
9	O
with	O
continuation	O
of	O
both	O
drugs	O
and	O
9	O
after	O
discontinuation	O
of	O
leflunomide	B-Drug
.	O
      
Although	O
no	O
clinical	O
drug	O
-	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
to	O
date	O
on	O
the	O
basis	O
of	O
the	O
in	O
vitro	O
studies	O
cytochrome	O
p9	O
inhibitors	O
and	O
inducers	O
are	O
unlikely	O
to	O
affect	O
the	O
metabolism	O
of	O
clofarabine	B-Drug
.	O
      
Unless	O
really	O
needed	O
agents	O
which	O
may	O
enhance	O
the	O
risk	O
of	O
hemorrhage	O
should	O
be	O
discontinued	O
prior	O
to	O
initiation	O
of	O
Lovenox	B-Brand
Injection	O
therapy	O
.	O
      
Diuretics	B-Group
:	O
Patients	O
on	O
diuretics	B-Group
especially	O
those	O
with	O
intravascular	O
volume	O
depletion	O
may	O
occasionally	O
experience	O
an	O
excessive	O
reduction	O
of	O
blood	O
pressure	O
after	O
initiation	O
of	O
therapy	O
with	O
fosinopril	B-Drug
sodium	I-Drug
.	O
      
Warfarin	B-Drug
:	O
Concomitant	O
administration	O
of	O
daptomycin	B-Drug
(	O
9	O
mg	O
/	O
kg	O
once	O
every	O
9	O
hours	O
for	O
9	O
days	O
)	O
and	O
warfarin	B-Drug
(	O
9	O
mg	O
single	O
oral	O
dose	O
)	O
had	O
no	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
either	O
drug	O
and	O
the	O
INR	O
was	O
not	O
significantly	O
altered	O
.	O
      
Glucose	O
:	O
Some	O
patients	O
receiving	O
Accutane	B-Brand
have	O
experienced	O
problems	O
in	O
the	O
control	O
of	O
their	O
blood	O
sugar	O
.	O
      
Vitamin	B-Group
A	I-Group
:	O
Because	O
of	O
the	O
relationship	O
of	O
Accutane	B-Brand
to	O
vitamin	B-Group
A	I-Group
patients	O
should	O
be	O
advised	O
against	O
taking	O
vitamin	B-Group
supplements	I-Group
containing	O
vitamin	B-Group
A	I-Group
to	O
avoid	O
additive	O
toxic	O
effects	O
      
ACE	B-Group
inhibitors	I-Group
Reports	O
suggest	O
that	O
NSAIDs	B-Group
may	O
diminish	O
the	O
antihypertensive	O
effect	O
of	O
angiotensin	B-Group
-	O
converting	I-Group
enzyme	I-Group
ACE	I-Group
inhibitors	I-Group
.	O
      
Concurrent	O
use	O
of	O
these	O
agents	O
should	O
generally	O
be	O
avoided	O
.	O
      
This	O
appears	O
to	O
be	O
the	O
only	O
clinically	O
relevant	O
interaction	O
of	O
this	O
kind	O
with	O
Mefloquine	B-Drug
although	O
theoretically	O
coadministration	O
of	O
other	O
drugs	O
known	O
to	O
alter	O
cardiac	O
conduction	O
(	O
eg	O
anti	B-Drug
-	O
arrhythmic	I-Drug
or	O
beta	B-Group
-	O
adrenergic	I-Group
blocking	I-Group
agents	I-Group
calcium	B-Group
channel	I-Group
blockers	I-Group
antihistamines	B-Group
or	O
H9	B-Group
-	O
blocking	I-Group
agents	I-Group
tricyclic	B-Group
antidepressants	I-Group
and	O
phenothiazines	B-Group
)	O
might	O
also	O
contribute	O
to	O
a	O
prolongation	O
of	O
the	O
QTc	O
interval	O
.	O
      
Nevertheless	O
caution	O
is	O
indicated	O
in	O
the	O
co	O
-	O
administration	O
of	O
T.A	B-Group
with	O
any	O
of	O
the	O
SSRIs	B-Group
and	O
also	O
in	O
switching	O
from	O
one	O
class	O
to	O
the	O
other	O
.	O
      
Drugs	O
that	O
may	O
decrease	O
imatinib	B-Drug
plasma	O
concentrations	O
:	O
Substances	O
that	O
are	O
inducers	O
of	O
CYP9A9	O
activity	O
may	O
increase	O
metabolism	O
and	O
decrease	O
imatinib	B-Drug
plasma	O
concentrations	O
.	O
      
In	O
this	O
study	O
there	O
was	O
no	O
evidence	O
of	O
a	O
blunting	O
of	O
the	O
antihypertensive	O
action	O
of	O
VASOTEC	B-Brand
.	O
      
If	O
signs	O
of	O
folate	O
deficiency	O
develop	O
pyrimethamine	B-Drug
should	O
be	O
discontinued	O
.	O
      
PEGASYS	B-Brand
should	O
be	O
assumed	O
to	O
have	O
abortifacient	O
potential	O
.	O
      
John	O
wort	O
)	O
may	O
increase	O
the	O
formation	O
of	O
dapsone	B-Drug_n
hydroxylamine	I-Drug_n
a	O
metabolite	O
of	O
dapsone	B-Drug
associated	O
with	O
hemolysis	O
.	O
      
Thus	O
results	O
of	O
the	O
DST	O
should	O
be	O
interpreted	O
with	O
caution	O
in	O
these	O
patients	O
.	O
      
Sedatives	B-Group
/	O
Hypnotics	B-Group
:	O
triazolam	B-Drug
midazolam	B-Drug
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
reactions	O
such	O
as	O
prolonged	O
or	O
increased	O
sedation	O
or	O
respiratory	O
depression	O
.	O
      
Neuroleptic	B-Group
Drugs	I-Group
-	O
L	B-Drug
-	O
phenylalanine	I-Drug
may	O
potentiate	O
the	O
tardive	O
dyskinesia	O
side	O
reactions	O
of	O
neuroleptic	B-Group
drugs	I-Group
if	O
used	O
concomitantly	O
with	O
them	O
.	O
      
Serum	O
Amylase	O
An	O
apparent	O
decrease	O
in	O
serum	O
amylase	O
activity	O
has	O
been	O
observed	O
in	O
patients	O
administered	O
EXTRANEAL	B-Brand
.	O
      
Ketoconazole	B-Drug
:	O
Co	O
-	O
administration	O
of	O
bosentan	B-Drug
9	O
mg	O
b.i.d	O
.	O
and	O
ketoconazole	B-Drug
a	O
potent	O
CYP9A9	O
inhibitor	O
increased	O
the	O
plasma	O
concentrations	O
of	O
bosentan	B-Drug
by	O
approximately	O
9	O
-	O
fold	O
.	O
      
sildenafil	B-Drug
concentration	O
      
Antacid	B-Group
:	O
When	O
atorvastatin	B-Drug
and	O
Maalox	B-Brand
TC	I-Brand
suspension	O
were	O
coadministered	O
plasma	O
concentrations	O
of	O
atorvastatin	B-Drug
decreased	O
approximately	O
9	O
%	O
.	O
      
Due	O
to	O
wide	O
interindividual	O
variability	O
in	O
the	O
dose	O
adjustment	O
required	O
it	O
is	O
recommended	O
that	O
cyclosporine	B-Drug
concentrations	O
be	O
monitored	O
closely	O
after	O
initiation	O
of	O
carvedilol	B-Drug
therapy	O
and	O
that	O
the	O
dose	O
of	O
cyclosporine	B-Drug
be	O
adjusted	O
as	O
appropriate	O
.	O
      
Furthermore	O
whenever	O
one	O
of	O
these	O
other	O
drugs	O
is	O
withdrawn	O
from	O
co	O
-	O
therapy	O
an	O
increased	O
dose	O
of	O
tricyclic	B-Group
antidepressant	I-Group
may	O
be	O
required	O
.	O
      
CANCIDAS	B-Brand
has	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
itraconazole	B-Drug
amphotericin	B-Drug
B	I-Drug
or	O
the	O
active	O
metabolite	O
of	O
mycophenolate	O
.	O
      
Phenytoin	B-Drug
increases	O
the	O
clearance	O
of	O
busulfan	B-Drug
by	O
9	O
%	O
or	O
more	O
possibly	O
due	O
to	O
the	O
induction	O
of	O
glutathione	O
-	O
S	O
-	O
transferase	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interaction	O
After	O
treatment	O
with	O
ampicillin	B-Drug
a	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
may	O
occur	O
with	O
copper	B-Drug_n
sulfate	I-Drug_n
tests	O
(	O
Benedicts	O
solution	O
Fehlings	O
solution	O
or	O
Clinitest	O
tablets	O
)	O
but	O
not	O
with	O
enzyme	O
based	O
tests	O
such	O
as	O
Clinistix	O
and	O
Glucose	O
Enzymatic	O
Test	O
Strip	O
USP	O
.	O
      
Nevertheless	O
there	O
may	O
be	O
the	O
potential	O
for	O
clinically	O
important	O
alterations	O
of	O
blood	O
levels	O
of	O
coadministered	O
drugs	O
.	O
      
Coadministration	O
of	O
alosetron	B-Drug
and	O
strong	O
CYP9A9	O
inhibitors	O
such	O
as	O
clarithromycin	B-Drug
telithromycin	B-Drug
protease	B-Group
inhibitors	I-Group
voriconazole	B-Drug
and	O
itraconazole	B-Drug
has	O
not	O
been	O
evaluated	O
but	O
should	O
be	O
undertaken	O
with	O
caution	O
because	O
of	O
similar	O
potential	O
drug	O
interactions	O
.	O
      
Fulminant	O
rhabdomyolysis	O
has	O
been	O
seen	O
as	O
early	O
as	O
three	O
weeks	O
after	O
initiation	O
of	O
combined	O
therapy	O
with	O
another	O
fibrate	B-Group
and	O
lovastatin	B-Drug
but	O
may	O
be	O
seen	O
after	O
several	O
months	O
.	O
      
HMG	B-Group
-	O
CoA	I-Group
Reductase	I-Group
Inhibitors	I-Group
:	O
Inhibitors	B-Group
of	I-Group
HMG	I-Group
-	O
CoA	I-Group
reductase	I-Group
may	O
cause	O
myopathy	O
which	O
is	O
manifested	O
as	O
muscle	O
pain	O
or	O
weakness	O
associated	O
with	O
elevated	O
levels	O
of	O
CPK	O
.	O
      
There	O
is	O
limited	O
experience	O
with	O
use	O
of	O
retinal	O
tamponades	O
in	O
conjunction	O
with	O
the	O
Vitrasert	B-Brand
Implant	O
.	O
      
A	O
dose	O
adjustment	O
is	O
not	O
needed	O
when	O
zidovudine	B-Drug
is	O
administered	O
with	O
VIRACEPT	B-Brand
.	O
      
Prothrombin	O
times	O
were	O
not	O
affected	O
by	O
tiagabine	B-Drug
.	O
      
Drug	O
Name	O
      
Myocardial	O
injury	O
including	O
myocardial	O
infarction	O
myocarditis	O
ventricular	O
hypokinesia	O
and	O
severe	O
rhabdomyolysis	O
appear	O
to	O
be	O
increased	O
in	O
patients	O
receiving	O
PROLEUKIN	B-Brand
and	O
interferon	B-Drug
-	O
alfa	I-Drug
concurrently	O
.	O
      
Nevirapine	B-Drug
is	O
principally	O
metabolized	O
by	O
the	O
liver	O
via	O
the	O
cytochrome	O
P9	O
isoenzymes	O
9A9	O
and	O
9B9	O
.	O
      
Hepatic	O
:	O
There	O
is	O
limited	O
evidence	O
that	O
the	O
myelotoxicity	O
of	O
TAXOL	B-Brand
may	O
be	O
exacerbated	O
in	O
patients	O
with	O
serum	O
total	O
bilirubin	O
9	O
times	O
ULN	O
.	O
      
At	O
higher	O
than	O
recommended	O
doses	O
VIOXX	B-Brand
9	O
mg	O
administered	O
once	O
daily	O
for	O
9	O
days	O
increased	O
plasma	O
concentrations	O
by	O
9	O
%	O
as	O
measured	O
by	O
AUC9	O
-	O
9hr	O
in	O
patients	O
receiving	O
methotrexate	B-Drug
9	O
to	O
9	O
mg	O
/	O
week	O
for	O
rheumatoid	O
arthritis	O
.	O
      
Betaseron	B-Brand
administration	O
to	O
three	O
cancer	O
patients	O
over	O
a	O
dose	O
range	O
of	O
9	O
mg	O
to	O
9	O
mg	O
led	O
to	O
a	O
dose	O
-	O
dependent	O
inhibition	O
of	O
antipyrine	B-Drug
elimination.9	O
The	O
effect	O
of	O
alternate	O
-	O
day	O
administration	O
of	O
9	O
mg	O
of	O
Betaseron	B-Brand
on	O
drug	O
metabolism	O
in	O
MS	O
patients	O
is	O
unknown	O
.	O
      
Drugs	O
Metabolized	O
by	O
CYP9A	O
:	O
Results	O
of	O
in	O
vitro	O
studies	O
demonstrate	O
that	O
duloxetine	B-Drug
does	O
not	O
inhibit	O
or	O
induce	O
CYP9A	O
activity	O
.	O
      
The	O
use	O
of	O
Adenocard	B-Brand
in	O
patients	O
receiving	O
digitalis	B-Group
may	O
be	O
rarely	O
associated	O
with	O
ventricular	O
fibrillation	O
.	O
      
A	O
study	O
in	O
rats	O
to	O
assess	O
the	O
carcinogenic	O
potential	O
of	O
ribavirin	B-Drug
is	O
ongoing	O
.	O
      
Studies	O
in	O
healthy	O
volunteers	O
have	O
shown	O
that	O
Acarbose	B-Drug
has	O
no	O
effect	O
on	O
either	O
the	O
pharmacokinetics	O
or	O
pharmacodynamics	O
of	O
digoxin	B-Drug
nifedipine	B-Drug
propranolol	B-Drug
or	O
ranitidine	B-Drug
.	O
      
In	O
vitro	O
binding	O
studies	O
with	O
human	O
serum	O
proteins	O
indicate	O
that	O
glipizide	B-Drug
binds	O
differently	O
than	O
tolbutamide	B-Drug
and	O
does	O
not	O
interact	O
with	O
salicylate	B-Group
or	O
dicumarol	B-Drug
.	O
      
The	O
pressor	O
effects	O
of	O
catecholamines	B-Group
such	O
as	O
dopamine	B-Drug
or	O
norepinephrine	B-Drug
are	O
enhanced	O
by	O
Bretylium	B-Drug
Tosylate	I-Drug
.	O
      
When	O
you	O
are	O
using	O
idoxuridine	B-Drug
it	O
is	O
especially	O
important	O
that	O
your	O
health	O
care	O
professional	O
know	O
if	O
you	O
are	O
using	O
the	O
following	O
:	O
Eye	O
product	O
containing	O
boric	B-Drug
acid	I-Drug
.	O
      
Caution	O
is	O
advised	O
nonetheless	O
since	O
interactions	O
have	O
been	O
seen	O
with	O
other	O
nonsteroidal	O
agents	O
of	O
this	O
class	O
.	O
      
Agents	O
that	O
have	O
been	O
found	O
or	O
are	O
expected	O
to	O
have	O
decreased	O
plasma	O
levels	O
in	O
the	O
presence	O
of	O
EQUETROTM	B-Brand
due	O
to	O
induction	O
of	O
CYP	O
enzymes	O
are	O
the	O
following	O
:	O
Acetaminophen	B-Drug
alprazolam	B-Drug
amitriptyline	B-Drug
bupropion	B-Drug
buspirone	B-Drug
citalopram	B-Drug
clobazam	B-Drug
clonazepam	B-Drug
clozapine	B-Drug
cyclosporin	B-Drug
delavirdine	B-Drug
desipramine	B-Drug
diazepam	B-Drug
dicumarol	B-Drug
doxycycline	B-Drug
ethosuximide	B-Drug
felbamate	B-Drug
felodipine	B-Drug
glucocorticoids	B-Group
haloperidol	B-Drug
itraconazole	B-Drug
lamotrigine	B-Drug
levothyroxine	B-Drug
lorazepam	B-Drug
methadone	B-Drug
midazolam	B-Drug
mirtazapine	B-Drug
nortriptyline	B-Drug
olanzapine	B-Drug
oral	O
contraceptives	B-Group
(	O
9	O
)	O
oxcarbazepine	B-Drug
Phenytoin	B-Drug
(	O
9	O
)	O
praziquantel	B-Drug
protease	B-Group
inhibitors	I-Group
quetiapine	B-Drug
risperidone	B-Drug
theophylline	B-Drug
topiramate	B-Drug
tiagabine	B-Drug
tramadol	B-Drug
triazolam	B-Drug
valproate	B-Drug
warfarin	B-Drug
(	O
9	O
)	O
ziprasidone	B-Drug
and	O
zonisamide	B-Drug
.	O
      
The	O
metabolism	O
of	O
saquinavir	B-Drug
is	O
mediated	O
by	O
cytochrome	O
P9	O
with	O
the	O
specific	O
isoenzyme	O
CYP9A9	O
responsible	O
for	O
9	O
%	O
of	O
the	O
hepatic	O
metabolism	O
.	O
      
Benzylpenicillin	B-Drug
ampicillin	B-Drug
oxacillin	B-Drug
chlortetracycline	B-Drug
doxycycline	B-Drug
cephalothin	B-Drug
erythromycin	B-Drug
and	O
sulfamethoxazole	B-Drug
have	O
no	O
influence	O
in	O
vitro	O
on	O
the	O
protein	O
binding	O
of	O
diclofenac	B-Drug
in	O
human	O
serum	O
.	O
      
Inhibition	O
of	O
renal	O
lithium	B-Drug
clearance	O
leading	O
to	O
increases	O
in	O
plasma	O
lithium	B-Drug
concentrations	O
has	O
also	O
been	O
reported	O
.	O
      
Drugs	O
other	O
than	O
those	O
listed	O
here	O
may	O
also	O
interact	O
with	O
glimepiride	B-Drug
or	O
affect	O
your	O
condition	O
.	O
      
Although	O
clinical	O
evidence	O
to	O
date	O
has	O
not	O
demonstrated	O
renal	O
precipitation	O
of	O
oxypurines	O
in	O
patients	O
either	O
on	O
allopurinol	B-Drug
alone	O
or	O
in	O
combination	O
with	O
uricosuric	B-Group
agents	I-Group
the	O
possibility	O
should	O
be	O
kept	O
in	O
mind	O
.	O
      
It	O
may	O
also	O
interact	O
with	O
amantadine	B-Drug
or	O
other	O
anticholinergic	B-Group
drugs	I-Group
or	O
MAOIs	B-Group
which	O
may	O
intensify	O
the	O
anticholinergic	O
action	O
.	O
      
Phenobarbital	B-Drug
:	O
Decreases	O
aspirin	B-Brand
effectiveness	O
by	O
enzyme	O
induction	O
.	O
      
The	O
adverse	O
experience	O
profile	O
seen	O
with	O
KEMSTROTM	B-Brand
was	O
similar	O
to	O
that	O
seen	O
with	O
baclofen	B-Drug
tablets	O
.	O
      
When	O
the	O
rapid	O
onset	O
of	O
a	O
concomitant	O
orally	O
administered	O
agent	O
is	O
a	O
critical	O
determinant	O
of	O
effectiveness	O
(	O
such	O
as	O
analgesics	B-Group
)	O
the	O
agent	O
should	O
be	O
administered	O
at	O
least	O
9	O
hour	O
prior	O
to	O
or	O
9	O
hours	O
after	O
SYMLIN	B-Brand
injection	O
.	O
      
Clinically	O
relevant	O
interactions	O
of	O
pantoprazole	B-Drug
with	O
other	O
drugs	O
with	O
the	O
same	O
metabolic	O
pathways	O
are	O
not	O
expected	O
.	O
      
It	O
is	O
suggested	O
that	O
in	O
patients	O
receiving	O
dopamine	B-Drug
HCl	I-Drug
alternatives	O
to	O
phenytoin	B-Drug
should	O
be	O
used	O
if	O
anticonvulsant	B-Group
therapy	O
is	O
needed	O
.	O
      
When	O
atropine	B-Drug
and	O
pralidoxime	B-Drug
are	O
used	O
together	O
the	O
signs	O
of	O
atropinization	O
(	O
flushing	O
mydriasis	O
tachycardia	O
dryness	O
of	O
the	O
mouth	O
and	O
nose	O
)	O
may	O
occur	O
earlier	O
than	O
might	O
be	O
expected	O
than	O
when	O
atropine	B-Drug
is	O
used	O
alone	O
because	O
pralidoxime	B-Drug
may	O
potentiate	O
the	O
effect	O
of	O
atropine	B-Drug
.	O
      
decreased	O
antithrombin	O
9	O
;	O
      
In	O
vitro	O
studies	O
with	O
human	O
liver	O
microsomes	O
indicate	O
that	O
bortezomib	B-Drug
is	O
primarily	O
a	O
substrate	O
for	O
cytochrome	O
P9	O
9A9	O
9C9	O
and	O
9A9	O
.	O
      
Narcotic	B-Group
analgesics	I-Group
may	O
potentiate	O
the	O
hypotensive	O
effects	O
of	O
clonidine	B-Drug
.	O
      
It	O
is	O
unknown	O
how	O
the	O
effect	O
seen	O
in	O
these	O
in	O
vitro	O
studies	O
translates	O
into	O
clinical	O
consequences	O
.	O
      
Thus	O
if	O
a	O
patient	O
has	O
been	O
titrated	O
to	O
a	O
stable	O
dosage	O
of	O
EQUETROTM	B-Brand
and	O
then	O
begins	O
a	O
course	O
of	O
treatment	O
with	O
one	O
of	O
these	O
CYP9A9	O
or	O
epoxide	O
hydrolase	O
inhibitors	O
it	O
is	O
reasonable	O
to	O
expect	O
that	O
a	O
dose	O
reduction	O
for	O
EQUETROTM	B-Brand
may	O
be	O
necessary	O
.	O
      
Use	O
caution	O
when	O
giving	O
these	O
drugs	O
together	O
especially	O
in	O
patients	O
with	O
hepatic	O
or	O
cardiac	O
disease	O
.	O
      
Anafranil	B-Brand
should	O
not	O
be	O
used	O
with	O
MAO	B-Group
inhibitors	I-Group
.	O
      
Patients	O
taking	O
digoxin	B-Drug
should	O
be	O
monitored	O
appropriately	O
.	O
      
Ergot	O
derivatives	O
:	O
dihydroergotamine	B-Drug
ergonovine	B-Drug
ergotamine	B-Drug
methylergonovine	B-Drug
      
Injection	O
There	O
is	O
inadequate	O
systematic	O
experience	O
with	O
the	O
use	O
of	O
baclofen	B-Drug
injection	O
in	O
combination	O
with	O
other	O
medications	O
to	O
predict	O
specific	O
drug	O
-	O
drug	O
interactions	O
.	O
      
Interactions	O
may	O
occur	O
with	O
the	O
following	O
:	O
adrenocorticoids	O
(	O
cortisone	O
-	O
like	O
medicine	O
)	O
anticoagulants	B-Group
(	O
blood	B-Group
thinners	I-Group
)	O
carbamazepine	B-Drug
corticotropin	B-Drug
(	O
barbiturates	B-Group
may	O
decrease	O
the	O
effects	O
of	O
these	O
medicines	O
)	O
central	B-Group
nervous	I-Group
system	I-Group
CNS	I-Group
depressants	I-Group
(	O
using	O
these	O
medicines	O
with	O
barbiturates	B-Group
may	O
result	O
in	O
increased	O
CNS	O
depressant	O
effects	O
)	O
divalproex	B-Drug
sodium	I-Drug
valproic	B-Drug
acid	I-Drug
(	O
using	O
these	O
medicines	O
with	O
barbiturates	B-Group
may	O
change	O
the	O
amount	O
of	O
either	O
medicine	O
that	O
you	O
need	O
to	O
take	O
)	O
and	O
oral	O
contraceptives	B-Group
containing	O
estrogens	B-Group
(	O
barbiturates	B-Group
may	O
decrease	O
the	O
effectiveness	O
of	O
these	O
oral	O
contraceptives	B-Group
and	O
you	O
may	O
need	O
to	O
change	O
to	O
a	O
different	O
type	O
of	O
birth	O
control	O
)	O
.	O
      
There	O
have	O
been	O
case	O
reports	O
of	O
increased	O
steady	O
-	O
state	O
levels	O
of	O
quinidine	B-Drug
procainamide	B-Drug
and	O
phenytoin	B-Drug
during	O
concomitant	O
therapy	O
with	O
amiodarone	B-Drug
.	O
      
These	O
reports	O
are	O
more	O
frequent	O
for	O
women	O
who	O
use	O
only	O
a	O
single	O
method	O
of	O
contraception	O
.	O
      
Therefore	O
smaller	O
ALFENTA	B-Brand
doses	O
will	O
be	O
required	O
with	O
prolonged	O
administration	O
and	O
the	O
duration	O
of	O
action	O
of	O
ALFENTA	B-Brand
my	O
be	O
extended	O
.	O
      
The	O
Factrel	B-Brand
test	O
should	O
be	O
conducted	O
in	O
the	O
absence	O
of	O
other	O
drugs	O
which	O
directly	O
affect	O
the	O
pituitary	O
secretion	O
of	O
the	O
gonadotropins	O
.	O
      
Warfarin	B-Drug
:	O
Quinolones	B-Group
have	O
been	O
reported	O
to	O
enhance	O
the	O
effects	O
of	O
the	O
oral	O
anticoagulant	B-Group
warfarin	B-Drug
or	O
its	O
derivatives	O
.	O
      
Because	O
bupropion	B-Drug
is	O
extensively	O
metabolized	O
the	O
coadministration	O
of	O
other	O
drugs	O
may	O
affect	O
its	O
clinical	O
activity	O
.	O
      
Administration	O
of	O
non	B-Group
-	O
steroidal	I-Group
anti	I-Group
-	O
inflammatory	I-Group
drugs	I-Group
concomitantly	O
with	O
cyclosporine	B-Drug
has	O
been	O
associated	O
with	O
an	O
increase	O
in	O
cyclosporine	B-Drug
-	O
induced	O
toxicity	O
possibly	O
due	O
to	O
decreased	O
synthesis	O
of	O
renal	O
prostacyclin	O
.	O
      
See	O
CLINICAL	O
PHARMACOLOGY	O
.	O
      
Monoamine	B-Group
oxidase	I-Group
MAO	I-Group
inhibitors	I-Group
such	O
as	O
isocarboxazid	B-Drug
(	O
e.g.	O
Marplan	B-Brand
)	O
phenelzine	B-Drug
(	O
e.g.	O
Nardil	B-Brand
)	O
procarbazine	B-Drug
(	O
e.g.	O
Matulane	B-Brand
)	O
selegiline	B-Drug
(	O
e.g.	O
Eldepryl	B-Brand
)	O
and	O
tranylcypromine	B-Drug
(	O
e.g.	O
Parnate	B-Brand
)	O
:	O
Using	O
these	O
medicines	O
with	O
L	B-Drug
-	O
tryptophan	I-Drug
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
.	O
      
Loratadine	B-Drug
(	O
9	O
mg	O
once	O
daily	O
)	O
has	O
been	O
coadministered	O
with	O
therapeutic	O
doses	O
of	O
erythromycin	B-Drug
cimetidine	B-Drug
and	O
ketoconazole	B-Drug
in	O
controlled	O
clinical	O
pharmacology	O
studies	O
in	O
adult	O
volunteers	O
.	O
      
No	O
increase	O
in	O
mortality	O
was	O
observed	O
in	O
patients	O
taking	O
digoxin	B-Drug
as	O
concomitant	O
medication	O
.	O
      
In	O
drug	O
-	O
interaction	O
studies	O
the	O
recommended	O
clinical	O
dose	O
of	O
montelukast	B-Drug
did	O
not	O
have	O
clinically	O
important	O
effects	O
on	O
the	O
pharmacokinetics	O
of	O
the	O
following	O
drugs	O
:	O
theophylline	B-Drug
prednisone	B-Drug
prednisolone	B-Drug
oral	O
contraceptives	B-Group
(	O
norethindrone	B-Drug
9	O
mg	O
/	O
ethinyl	B-Drug
estradiol	I-Drug
9	O
mcg	O
)	O
terfenadine	B-Drug
digoxin	B-Drug
and	O
warfarin	B-Drug
.	O
      
As	O
with	O
other	O
agents	O
which	O
prolong	O
ECG	O
intervals	O
caution	O
should	O
be	O
exercised	O
in	O
patients	O
taking	O
drugs	O
which	O
prolong	O
ECG	O
intervals	O
particularly	O
QTc	O
.	O
      
Nervous	O
System	O
:	O
Although	O
the	O
occurrence	O
of	O
peripheral	O
neuropathy	O
is	O
frequent	O
the	O
development	O
of	O
severe	O
symptomatology	O
is	O
unusual	O
and	O
requires	O
a	O
dose	O
reduction	O
of	O
9	O
%	O
for	O
all	O
subsequentcourses	O
of	O
TAXOL	B-Brand
.	O
      
DRUG	O
/	O
LABORATORY	O
TEST	O
INTERACTIONS	O
9	O
.	O
      
Antacids	B-Group
:	O
The	O
concomitant	O
administration	O
of	O
antacids	B-Group
has	O
no	O
apparent	O
effect	O
on	O
the	O
extent	O
of	O
absorption	O
of	O
Lodine	B-Brand
.	O
      
While	O
it	O
is	O
not	O
known	O
whether	O
this	O
interaction	O
occurs	O
with	O
fibrates	B-Group
other	O
than	O
gemfibrozil	B-Drug
myopathy	O
and	O
rhabdomyolysis	O
have	O
occasionally	O
been	O
associated	O
with	O
the	O
use	O
of	O
fibrates	B-Group
alone	O
including	O
clofibrate	B-Drug
.	O
      
This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
NSAIDs	B-Group
concomitantly	O
with	O
ACE	B-Group
inhibitors	I-Group
.	O
      
Carbamazepine	B-Drug
:	O
Coadministration	O
of	O
carbamazepine	B-Drug
(	O
9	O
mg	O
BID	O
)	O
a	O
potent	O
CYP9A9	O
inducer	O
with	O
aripiprazole	B-Drug
(	O
9	O
mg	O
QD	O
)	O
resulted	O
in	O
an	O
approximate	O
9	O
%	O
decrease	O
in	O
Cmax	O
and	O
AUC	O
values	O
of	O
both	O
aripiprazole	B-Drug
and	O
its	O
active	O
metabolite	O
dehydro	B-Drug_n
-	O
aripiprazole	I-Drug_n
.	O
      
9	O
years	O
of	O
age	O
and	O
9	O
patients	O
were	O
      
Because	O
of	O
possible	O
additive	O
effects	O
with	O
other	O
carbonic	B-Group
anhydrase	I-Group
inhibitors	I-Group
concomitant	O
use	O
is	O
not	O
advisable	O
.	O
      
-	O
Quinidine	B-Drug
(	O
e.g.	O
Quinidex	B-Brand
)	O
or	O
      
Careful	O
monitoring	O
of	O
prothrombin	O
time	O
in	O
patients	O
receiving	O
DIFLUCAN	B-Brand
and	O
coumarin	B-Group
-	O
type	I-Group
anticoagulants	I-Group
is	O
recommended	O
.	O
      
Because	O
heparin	B-Drug
aspirin	B-Brand
or	O
Activase	B-Brand
may	O
cause	O
bleeding	O
complications	O
careful	O
monitoring	O
for	O
bleeding	O
is	O
advised	O
especially	O
at	O
arterial	O
puncture	O
sites	O
.	O
      
It	O
is	O
recommended	O
not	O
to	O
exceed	O
a	O
single	O
9	O
mg	O
dose	O
of	O
Vardenafil	B-Drug
in	O
a	O
9	O
-	O
hour	O
period	O
when	O
used	O
in	O
combination	O
with	O
erythromycin	B-Drug
.	O
      
No	O
clinical	O
or	O
drug	O
interaction	O
study	O
was	O
conducted	O
with	O
dolasetron	B-Drug
.	O
      
Liver	O
Function	O
Tests	O
:	O
Since	O
elevations	O
of	O
liver	O
enzymes	O
have	O
been	O
observed	O
during	O
clinical	O
trials	O
and	O
hepatitis	O
has	O
been	O
reported	O
pretreatment	O
and	O
follow	O
-	O
up	O
liver	O
function	O
tests	O
should	O
be	O
performed	O
at	O
weekly	O
or	O
biweekly	O
intervals	O
until	O
the	O
response	O
to	O
Accutane	B-Brand
has	O
been	O
established	O
      
Potentiation	O
of	O
coumarin	B-Group
-	O
type	I-Group
anticoagulants	I-Group
has	O
been	O
observed	O
with	O
prolongation	O
of	O
the	O
prothrombin	O
time	O
/	O
INR	O
.	O
      
Lithium	B-Drug
:	O
NSAIDs	B-Group
have	O
produced	O
an	O
elevation	O
of	O
plasma	O
lithium	B-Drug
levels	O
and	O
a	O
reduction	O
in	O
renal	O
lithium	B-Drug
clearance	O
.	O
      
There	O
were	O
no	O
clinically	O
significant	O
drug	O
interactions	O
for	O
any	O
of	O
these	O
drugs	O
      
Two	O
percent	O
of	O
patients	O
treated	O
concurrently	O
with	O
Kineret	B-Brand
and	O
etanercept	B-Drug
developed	O
neutropenia	O
(	O
ANC	O
9	O
x	O
9	O
/	O
L	O
)	O
.	O
      
Colchicine	B-Drug
may	O
increase	O
sensitivity	O
to	O
the	O
CNS	B-Group
depressants	I-Group
.	O
      
thyroid	B-Group
drugs	I-Group
;	O
      
Particular	O
caution	O
is	O
necessary	O
when	O
using	O
ROMAZICON	B-Brand
in	O
cases	O
of	O
mixed	O
drug	O
overdosage	O
since	O
the	O
toxic	O
effects	O
(	O
such	O
as	O
convulsions	O
and	O
cardiac	O
dysrhythmias	O
)	O
of	O
other	O
drugs	O
taken	O
in	O
overdose	O
(	O
especially	O
cyclic	B-Group
antidepressants	I-Group
)	O
may	O
emerge	O
with	O
the	O
reversal	O
of	O
the	O
benzodiazepine	B-Group
effect	O
by	O
flumazenil	B-Drug
.	O
      
Norepinephrine	B-Drug
:	O
Amphetamines	B-Group
enhance	O
the	O
adrenergic	O
effect	O
of	O
norepinephrine	B-Drug
.	O
      
In	O
patients	O
with	O
mild	O
to	O
moderate	O
hypertension	O
administration	O
of	O
9	O
mg	O
daily	O
of	O
VIOXX	B-Brand
with	O
the	O
ACE	B-Group
inhibitor	I-Group
benazepril	B-Drug
9	O
to	O
9	O
mg	O
for	O
9	O
weeks	O
was	O
associated	O
with	O
an	O
average	O
increase	O
in	O
mean	O
arterial	O
pressure	O
of	O
about	O
9	O
mm	O
Hg	O
compared	O
to	O
ACE	B-Group
inhibitor	I-Group
alone	O
.	O
      
In	O
this	O
formal	O
interaction	O
study	O
TAMBOCOR	B-Brand
and	O
propranolol	B-Drug
were	O
each	O
found	O
to	O
have	O
negative	O
inotropic	O
effects	O
;	O
      
Antiarrhythmics	B-Group
:	O
bepridil	B-Drug
lidocaine	B-Drug
(	O
systemic	O
)	O
and	O
quinidine	B-Drug
      
To	O
avoid	O
potentiation	O
the	O
physician	O
wishing	O
to	O
terminate	O
treatment	O
with	O
Isocarboxazid	B-Drug
and	O
begin	O
therapy	O
with	O
another	O
agent	O
should	O
allow	O
for	O
an	O
interval	O
of	O
9	O
days	O
.	O
      
Because	O
of	O
foscarnets	B-Drug
tendency	O
to	O
cause	O
renal	O
impairment	O
the	O
use	O
of	O
FOSCAVIR	B-Brand
should	O
be	O
avoided	O
in	O
combination	O
with	O
potentially	O
nephrotoxic	O
drugs	O
such	O
as	O
aminoglycosides	B-Group
amphotericin	B-Drug
B	I-Drug
and	O
intravenous	O
pentamidine	B-Drug
unless	O
the	O
potential	O
benefits	O
outweigh	O
the	O
risks	O
to	O
the	O
patient	O
.	O
      
The	O
interval	O
between	O
the	O
administration	O
of	O
COLESTID	B-Brand
Tablets	O
and	O
any	O
other	O
medication	O
should	O
be	O
as	O
long	O
as	O
possible	O
.	O
      
Monitor	O
salicylate	B-Group
levels	O
or	O
the	O
therapeutic	O
effect	O
for	O
which	O
aspirin	B-Brand
is	O
given	O
;	O
      
periodic	O
monitoring	O
of	O
anticonvulsant	B-Group
plasma	O
levels	O
should	O
be	O
conducted	O
.	O
      
Clinical	O
trials	O
have	O
indicated	O
that	O
Pulmozyme	B-Brand
can	O
be	O
effectively	O
and	O
safely	O
used	O
in	O
conjunction	O
with	O
standard	O
cystic	O
fibrosis	O
therapies	O
including	O
oral	O
inhaled	O
and	O
/	O
or	O
parenteral	O
antibiotics	B-Group
bronchodilators	B-Group
enzyme	O
supplements	O
vitamins	B-Group
oral	O
or	O
inhaled	O
corticosteroids	B-Group
and	O
analgesics	B-Group
.	O
      
Non	B-Group
-	O
selective	I-Group
monoamine	I-Group
oxidase	I-Group
MAO	I-Group
inhibitors	I-Group
-	O
including	O
phenelzine	B-Drug
sulfate	I-Drug
tranylcypromine	B-Drug
sulfate	I-Drug
and	O
pargyline	B-Drug
HC9	O
.	O
      
No	O
formal	O
interaction	O
studies	O
have	O
been	O
performed	O
to	O
assess	O
the	O
effect	O
of	O
SYMLIN	B-Brand
on	O
the	O
kinetics	O
of	O
oral	O
antidiabetic	B-Group
agents	I-Group
.	O
      
Diphenhydramine	B-Drug
:	O
Diphenhydramine	B-Drug
is	O
reported	O
to	O
be	O
a	O
weak	O
inhibitor	O
of	O
aldehyde	O
oxidase	O
in	O
rat	O
liver	O
but	O
its	O
inhibitory	O
effects	O
in	O
human	O
liver	O
are	O
not	O
known	O
.	O
      
-	O
Dantrolene	B-Drug
(	O
e.g.	O
Dantrium	B-Brand
)	O
or	O
      
Drugs	O
and	O
foods	O
that	O
raise	O
urine	O
pH	O
will	O
increase	O
renal	O
clearance	O
and	O
urinary	O
excretion	O
of	O
salicylic	B-Drug
acid	I-Drug
thus	O
lowering	O
plasma	O
levels	O
;	O
      
Frequent	O
prothrombin	O
determinations	O
are	O
advisable	O
until	O
it	O
has	O
been	O
determined	O
definitely	O
that	O
the	O
prothrombin	O
level	O
has	O
been	O
stabilized	O
.	O
      
Aprepitant	B-Drug
is	O
a	O
substrate	O
for	O
CYP9A9	O
;	O
      
Because	O
elderly	O
patients	O
are	O
more	O
likely	O
to	O
have	O
decreased	O
renal	O
function	O
care	O
should	O
be	O
taken	O
in	O
dose	O
selection	O
and	O
it	O
may	O
be	O
useful	O
to	O
monitor	O
renal	O
function	O
.	O
      
Corticotropin	B-Drug
may	O
accentuate	O
the	O
electrolyte	O
loss	O
associated	O
with	O
diuretic	B-Group
therapy	O
.	O
      
The	O
vasodilating	O
effects	O
of	O
isosorbide	B-Drug
dinitrate	I-Drug
may	O
be	O
additive	O
with	O
those	O
of	O
other	O
vasodilators	B-Group
.	O
      
Pantoprazole	B-Drug
is	O
metabolized	O
through	O
the	O
cytochrome	O
P9	O
system	O
primarily	O
the	O
CYP9C9	O
and	O
CYP9A9	O
isozymes	O
and	O
subsequently	O
undergoes	O
Phase	O
II	O
conjugation	O
.	O
      
These	O
events	O
required	O
medical	O
intervention	O
in	O
some	O
patients	O
.	O
      
Methadone	B-Drug
      
Menstrual	O
cycle	O
irregularities	O
were	O
accompanied	O
by	O
both	O
a	O
decrease	O
and	O
delay	O
in	O
the	O
peak	O
9b	O
-	O
estradiol	O
and	O
progesterone	O
levels	O
following	O
administration	O
of	O
PEGASYS	B-Brand
to	O
female	O
monkeys	O
.	O
      
Whether	O
this	O
interaction	O
also	O
occurs	O
with	O
the	O
intravenous	O
topical	O
or	O
vaginal	O
preparations	O
of	O
miconazole	B-Drug
is	O
not	O
known	O
.	O
      
.	O
      
Ethinyl	B-Drug
estradiol	I-Drug
:	O
Substrate	O
of	O
CYP9A9	O
(	O
major	O
)	O
9A9	O
-	O
9	O
(	O
minor	O
)	O
;	O
      
Caution	O
is	O
advised	O
when	O
administering	O
VERSED	B-Brand
Syrup	I-Brand
to	O
patients	O
receiving	O
these	O
medications	O
and	O
if	O
necessary	O
dose	O
adjustments	O
should	O
be	O
considered	O
.	O
      
Low	O
initial	O
dosing	O
and	O
small	O
gradual	O
dose	O
increases	O
should	O
be	O
employed	O
.	O
      
Dexamethasone	B-Drug
is	O
a	O
moderate	O
inducer	O
of	O
CYP	O
9A9	O
.	O
      
anticholinergics	B-Group
or	O
other	O
medications	O
with	O
anticholinergic	O
activity	O
-	O
anticholinergic	O
effects	O
may	O
be	O
potentiated	O
when	O
these	O
medications	O
are	O
used	O
concurrently	O
with	O
diphenidol	B-Drug
;	O
      
When	O
these	O
products	O
are	O
administered	O
concomitantly	O
prothrombin	O
or	O
other	O
suitable	O
coagulation	O
tests	O
should	O
be	O
monitored	O
closely	O
.	O
      
-	O
a	O
phenothiazine	B-Group
such	O
as	O
chlorpromazine	B-Drug
(	O
Thorazine	B-Brand
)	O
fluphenazine	B-Drug
(	O
Prolixin	B-Brand
Permitil	B-Brand
)	O
prochlorperazine	B-Drug
(	O
Compazine	B-Brand
)	O
promethazine	B-Drug
(	O
Phenergan	B-Brand
)	O
and	O
others	O
;	O
      
Accelerated	O
prothrombin	O
time	O
partial	O
thromboplastin	O
time	O
and	O
platelet	O
aggregation	O
time	O
;	O
      
Given	O
the	O
primary	O
CNS	O
effects	O
of	O
Anafranil	B-Brand
caution	O
is	O
advised	O
in	O
using	O
it	O
concomitantly	O
with	O
other	O
CNS	O
-	O
active	O
drugs	O
.	O
      
In	O
the	O
case	O
of	O
severe	O
neutropenia	O
(	O
9	O
cells	O
/	O
mm9	O
for	O
seven	O
days	O
or	O
more	O
)	O
during	O
a	O
course	O
of	O
TAXOL	B-Brand
therapy	O
a	O
9	O
%	O
reduction	O
in	O
dose	O
for	O
subsequent	O
courses	O
of	O
therapy	O
is	O
recommended	O
.	O
      
Patients	O
using	O
cardiovascular	O
drugs	O
concurrently	O
with	O
IOPIDINE	B-Brand
9	O
%	O
Ophthalmic	O
Solution	O
should	O
have	O
pulse	O
and	O
blood	O
pressures	O
frequently	O
monitored	O
.	O
      
In	O
EM	O
individuals	O
treated	O
with	O
paroxetine	B-Drug
or	O
fluoxetine	B-Drug
the	O
AUC	O
of	O
atomoxetine	B-Drug
is	O
approximately	O
9	O
-	O
to	O
9	O
-	O
fold	O
and	O
Css	O
max	O
is	O
about	O
9	O
-	O
to	O
9	O
-	O
fold	O
greater	O
than	O
atomoxetine	B-Drug
alone	O
.	O
      
An	O
increase	O
of	O
9	O
%	O
in	O
the	O
mean	O
AUC	O
and	O
increases	O
of	O
9	O
%	O
and	O
9	O
%	O
respectively	O
in	O
the	O
mean	O
T	O
max	O
and	O
mean	O
C	O
max	O
were	O
noted	O
in	O
9	O
study	O
of	O
9	O
individuals	O
.	O
      
Nasal	O
Spray	O
:	O
Formal	O
studies	O
designed	O
to	O
evaluate	O
drug	O
interactions	O
with	O
Calcitonin	B-Drug
salmon	I-Drug
have	O
not	O
been	O
done	O
.	O
      
-	O
Anabolic	B-Group
steroids	I-Group
(	O
nandrolone	B-Drug
[	O
e.g.	O
Anabolin	B-Brand
]	O
oxandrolone	B-Drug
[	O
e.g.	O
Anavar	B-Brand
]	O
oxymetholone	B-Drug
[	O
e.g.	O
Anadrol	B-Brand
]	O
stanozolol	B-Drug
[	O
e.g.	O
Winstrol	B-Brand
]	O
)	O
or	O
      
In	O
addition	O
results	O
from	O
regression	O
analyses	O
of	O
patient	O
pharmacokinetic	O
data	O
suggest	O
that	O
co	O
-	O
administration	O
of	O
other	O
inducers	O
of	O
drug	O
clearance	O
(	O
efavirenz	B-Drug
nevirapine	B-Drug
phenytoin	B-Drug
dexamethasone	B-Drug
or	O
carbamazepine	B-Drug
)	O
with	O
CANCIDAS	B-Brand
may	O
result	O
in	O
clinically	O
meaningful	O
reductions	O
in	O
caspofungin	B-Drug
concentrations	O
.	O
      
Anticoagulants	B-Group
(	O
such	O
as	O
heparin	B-Drug
and	O
vitamin	B-Group
K	I-Group
antagonists	I-Group
)	O
and	O
drugs	O
that	O
alter	O
platelet	O
function	O
(	O
such	O
as	O
acetylsalicylic	B-Drug
acid	I-Drug
dipyridamole	B-Drug
and	O
GP	O
IIb	O
/	O
IIIa	O
inhibitors	O
)	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
if	O
administered	O
prior	O
to	O
during	O
or	O
after	O
TNKase	B-Brand
therapy	O
.	O
      
In	O
post	O
-	O
marketing	O
experience	O
bleeding	O
events	O
have	O
been	O
reported	O
predominantly	O
in	O
the	O
elderly	O
in	O
association	O
with	O
increases	O
in	O
prothrombin	O
time	O
in	O
patients	O
receiving	O
VIOXX	B-Brand
concurrently	O
with	O
warfarin	B-Drug
.	O
      
Available	O
data	O
are	O
not	O
sufficient	O
however	O
to	O
predict	O
the	O
effects	O
of	O
concomitant	O
medication	O
on	O
patients	O
with	O
impaired	O
ventricular	O
function	O
or	O
cardiac	O
conduction	O
abnormalities	O
.	O
      
Nelfinavir	B-Drug
M9	O
      
The	O
metabolism	O
of	O
Metopirone	B-Brand
is	O
accelerated	O
by	O
phenytoin	B-Drug
;	O
      
Although	O
no	O
drug	O
-	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
in	O
vivo	O
it	O
is	O
expected	O
that	O
no	O
significant	O
interaction	O
would	O
occur	O
when	O
nitazoxanide	B-Drug
is	O
co	O
-	O
administered	O
with	O
drugs	O
that	O
either	O
are	O
metabolized	O
by	O
or	O
inhibit	O
cytochrome	O
P9	O
enzymes	O
.	O
      
The	O
inhibiting	O
effects	O
of	O
anticholinergic	B-Group
drugs	I-Group
on	O
gastric	O
hydrochloric	O
acid	O
secretion	O
are	O
antagonized	O
by	O
agents	O
used	O
to	O
treat	O
achlorhydria	O
and	O
those	O
used	O
to	O
test	O
gastric	O
secretion	O
.	O
      
Antacids	B-Group
or	O
H	B-Group
9	I-Group
-	O
receptor	I-Group
antagonists	I-Group
:	O
The	O
effect	O
of	O
increased	O
gastric	O
pH	O
on	O
the	O
bioavailability	O
of	O
ceftibuten	B-Drug
was	O
evaluated	O
in	O
9	O
healthy	O
adult	O
volunteers	O
.	O
      
Several	O
studies	O
demonstrate	O
a	O
decrease	O
in	O
the	O
bioavailability	O
of	O
methyldopa	B-Drug
when	O
it	O
is	O
ingested	O
with	O
ferrous	B-Drug
sulfate	I-Drug
or	O
ferrous	B-Drug
gluconate	I-Drug
.	O
      
The	O
clinical	O
significance	O
of	O
this	O
interaction	O
is	O
not	O
known	O
;	O
      
In	O
amiodarone	B-Drug
-	O
treated	O
patients	O
who	O
require	O
additional	O
antiarrhythmic	B-Drug
therapy	O
the	O
initial	O
dose	O
of	O
such	O
agents	O
should	O
be	O
approximately	O
half	O
of	O
the	O
usual	O
recommended	O
dose	O
.	O
      
The	O
interaction	O
of	O
CYLERT	B-Brand
(	O
pemoline	B-Drug
)	O
with	O
other	O
drugs	O
has	O
not	O
been	O
studied	O
in	O
humans	O
.	O
      
Patients	O
receiving	O
beta	B-Group
-	O
adrenergic	I-Group
blocking	I-Group
agents	I-Group
along	O
with	O
either	O
oral	O
or	O
intravenous	O
calcium	B-Group
antagonists	I-Group
should	O
be	O
monitored	O
for	O
possible	O
atrioventricular	O
conduction	O
disturbances	O
left	O
ventricular	O
failure	O
and	O
hypotension	O
.	O
      
Exjade	B-Brand
should	O
not	O
be	O
combined	O
with	O
other	O
iron	O
chelator	O
therapies	O
as	O
safety	O
of	O
such	O
combinations	O
has	O
not	O
been	O
established	O
.	O
      
Platelet	O
function	O
studies	O
in	O
these	O
patients	O
have	O
not	O
demonstrated	O
any	O
significant	O
platelet	O
dysfunction	O
.	O
      
Use	O
of	O
potassium	B-Group
-	O
sparing	I-Group
diuretics	I-Group
(	O
spironolactone	B-Drug
amiloride	B-Drug
triamterene	B-Drug
and	O
others	O
)	O
potassium	B-Drug
supplements	O
or	O
other	O
drugs	O
capable	O
of	O
increasing	O
serum	O
potassium	O
(	O
indomethacin	B-Drug
heparin	B-Drug
cyclosporine	B-Drug
and	O
others	O
)	O
can	O
increase	O
the	O
risk	O
of	O
hyperkalemia	O
.	O
      
In	O
a	O
separate	O
study	O
baboons	O
given	O
9	O
doses	O
of	O
alefacept	B-Drug
at	O
9	O
mg	O
/	O
kg	O
every	O
9	O
weeks	O
were	O
found	O
to	O
have	O
centroblast	O
proliferation	O
in	O
B	O
-	O
cell	O
dependent	O
areas	O
in	O
the	O
germinal	O
centers	O
of	O
the	O
spleen	O
following	O
a	O
9	O
-	O
day	O
washout	O
period	O
.	O
      
Usage	O
with	O
Alcohol	B-Drug
:	O
Due	O
to	O
the	O
potential	O
for	O
increased	O
CNS	O
depressants	O
effects	O
alcohol	B-Drug
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
who	O
are	O
currently	O
receiving	O
pentazocine	B-Drug
.	O
      
This	O
interference	O
may	O
result	O
in	O
an	O
apparent	O
factor	O
concentration	O
that	O
is	O
lower	O
than	O
the	O
true	O
concentration	O
.	O
      
For	O
patients	O
receiving	O
both	O
therapies	O
standard	O
monitoring	O
of	O
tacrolimus	B-Drug
blood	O
concentrations	O
and	O
appropriate	O
tacrolimus	B-Drug
dosage	O
adjustments	O
are	O
recommended	O
.	O
      
-	O
did	O
not	O
cause	O
any	O
clinically	O
significant	O
change	O
in	O
plasma	O
profiles	O
of	O
prednisone	B-Drug
or	O
prednisolone	B-Drug
following	O
administration	O
of	O
either	O
oral	O
prednisone	B-Drug
or	O
intravenous	O
prednisolone	B-Drug
.	O
      
Paroxetine	B-Drug
:	O
Coadministration	O
of	O
a	O
single	O
dose	O
of	O
Sonata	B-Brand
9	O
mg	O
and	O
paroxetine	B-Drug
9	O
mg	O
daily	O
for	O
9	O
days	O
did	O
not	O
produce	O
any	O
interaction	O
on	O
psychomotor	O
performance	O
.	O
      
Therefore	O
monitoring	O
of	O
theophylline	B-Drug
plasma	O
levels	O
should	O
be	O
considered	O
and	O
dosage	O
of	O
theophylline	B-Drug
adjusted	O
as	O
required	O
.	O
      
In	O
vitro	O
studies	O
have	O
demonstrated	O
that	O
efavirenz	B-Drug
inhibits	O
9C9	O
9C9	O
and	O
9A9	O
isozymes	O
in	O
the	O
range	O
of	O
observed	O
efavirenz	B-Drug
plasma	O
concentrations	O
.	O
      
Greater	O
fecal	O
blood	O
loss	O
results	O
from	O
concomitant	O
administration	O
of	O
both	O
drugs	O
than	O
from	O
either	O
drug	O
alone	O
.	O
      
Dose	O
reduction	O
of	O
CRIXIVAN	B-Brand
to	O
9	O
mg	O
every	O
9	O
hours	O
should	O
be	O
considered	O
when	O
taking	O
delavirdine	B-Drug
9	O
mg	O
three	O
times	O
a	O
day	O
.	O
      
Digitalis	B-Group
Glycosides	I-Group
:	O
Therapeutic	O
effects	O
of	O
digitalis	B-Group
glycosides	I-Group
may	O
be	O
reduced	O
.	O
      
N=9	O
)	O
are	O
identical	O
whether	O
the	O
drugs	O
are	O
administered	O
alone	O
or	O
together	O
.	O
      
Occasionally	O
TAXOL	B-Brand
infusions	O
must	O
be	O
interrupted	O
or	O
discontinued	O
because	O
of	O
initial	O
or	O
recurrent	O
hypertension	O
.	O
      
Sulfamethizole	B-Drug
may	O
increase	O
the	O
effects	O
of	O
barbiturates	B-Group
tolbutamide	B-Drug
and	O
uricosurics	B-Group
.	O
      
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
reactions	O
such	O
as	O
prolonged	O
or	O
increased	O
sedation	O
or	O
respiratory	O
depression	O
.	O
      
indinavir	B-Drug
concentration	O
ritonavir	B-Drug
concentration	O
      
Phenobarbital	B-Drug
(	O
Primidone	B-Drug
)	O
:	O
Population	O
pharmacokinetic	O
analyses	O
indicate	O
that	O
tiagabine	B-Drug
clearance	O
is	O
9	O
%	O
greater	O
in	O
patients	O
taking	O
phenobarbital	B-Drug
(	O
primidone	B-Drug
)	O
with	O
or	O
without	O
other	O
enzyme	O
-	O
inducing	O
AEDs	B-Group
.	O
      
The	O
addition	O
of	O
sodium	B-Drug
bicarbonate	I-Drug
to	O
parenteral	O
solutions	O
containing	O
calcium	B-Drug
should	O
be	O
avoided	O
except	O
where	O
compatibility	O
has	O
been	O
previously	O
established	O
.	O
      
Caution	O
should	O
be	O
taken	O
when	O
ENABLEX	B-Brand
is	O
used	O
concomitantly	O
with	O
medications	O
that	O
are	O
predominantly	O
metabolized	O
by	O
CYP9D9	O
and	O
which	O
have	O
a	O
narrow	O
therapeutic	O
window	O
such	O
as	O
flecainide	B-Drug
thioridazine	B-Drug
and	O
tricyclic	B-Group
antidepressants	I-Group
(	O
see	O
CLINICAL	O
PHARMACOLOGY	O
)	O
.	O
      
However	O
norepinephrine	B-Drug
may	O
still	O
be	O
used	O
effectively	O
.	O
      
SIDE	O
EFFECTS	O
(	O
KEMSTRO	B-Brand
)	O
The	O
most	O
common	O
adverse	O
reaction	O
during	O
treatment	O
with	O
baclofen	B-Drug
is	O
transient	O
drowsiness	O
(	O
9	O
-	O
9	O
%	O
)	O
.	O
      
Among	O
these	O
patients	O
the	O
incidence	O
of	O
upper	O
gastrointestinal	O
adverse	O
experiences	O
in	O
the	O
patients	O
treated	O
with	O
Ibandronate	B-Drug
9	O
mg	O
once	O
monthly	O
was	O
similar	O
to	O
that	O
in	O
patients	O
treated	O
with	O
Ibandronate	B-Drug
9	O
mg	O
once	O
daily	O
.	O
      
The	O
changes	O
in	O
plasma	O
levels	O
were	O
within	O
the	O
range	O
of	O
plasma	O
levels	O
achieved	O
in	O
adequate	O
and	O
well	O
-	O
controlled	O
clinical	O
trials	O
.	O
      
AXERT	B-Brand
is	O
not	O
known	O
to	O
interfere	O
with	O
commonly	O
employed	O
clinical	O
laboratory	O
tests	O
.	O
      
-	O
Indomethacin	B-Drug
:	O
Indomethacin	B-Drug
blunts	O
the	O
increases	O
in	O
urine	O
volume	O
and	O
sodium	O
excretion	O
seen	O
during	O
bumetanide	B-Drug
treatment	O
and	O
inhibits	O
the	O
bumetanide	B-Drug
-	O
induced	O
increase	O
in	O
plasma	O
renin	O
activity	O
.	O
      
This	O
diminution	O
is	O
not	O
sufficient	O
to	O
preclude	O
effectiveness	O
of	O
the	O
pressor	O
agent	O
for	O
therapeutic	O
use	O
.	O
)	O
      
Because	O
candesartan	B-Drug
is	O
not	O
significantly	O
metabolized	O
by	O
the	O
cytochrome	O
P9	O
system	O
and	O
at	O
therapeutic	O
concentrations	O
has	O
no	O
effects	O
on	O
P9	O
enzymes	O
interactions	O
with	O
drugs	O
that	O
inhibit	O
or	O
are	O
metabolized	O
by	O
those	O
enzymes	O
would	O
not	O
be	O
expected	O
.	O
      
THE	O
POTENTIATING	O
ACTION	O
OF	O
HYDROXYZINE	B-Drug
MUST	O
BE	O
CONSIDERED	O
WHEN	O
THE	O
DRUG	O
IS	O
USED	O
IN	O
CONJUNCTION	O
WITH	O
CENTRAL	B-Group
NERVOUS	I-Group
SYSTEM	I-Group
DEPRESSANTS	I-Group
SUCH	O
AS	O
NARCOTICS	B-Group
NON	B-Group
-	O
NARCOTIC	I-Group
ANALGESICS	I-Group
AND	O
BARBITURATES	B-Group
.	O
      
Azlocillin	B-Drug
should	O
not	O
be	O
administered	O
concomitantly	O
with	O
amikacin	B-Drug
ciprofloxacin	B-Drug
gentamicin	B-Drug
netilmicin	B-Drug
or	O
tobramycin	B-Drug
.	O
      
No	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
.	O
      
Concomitant	O
use	O
of	O
tricyclic	B-Group
antidepressants	I-Group
with	O
other	O
drugs	O
metabolized	O
by	O
cytochrome	O
P9IID9	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	B-Group
antidepressant	I-Group
or	O
the	O
other	O
drug	O
.	O
      
Vitamin	B-Group
D	I-Group
:	O
The	O
coadministration	O
of	O
any	O
of	O
the	O
vitamin	B-Group
D	I-Group
analogues	O
should	O
be	O
avoided	O
as	O
this	O
could	O
create	O
possible	O
additive	O
effects	O
and	O
hypercalcemia	O
.	O
      
The	O
clinical	O
relevance	O
of	O
these	O
increases	O
is	O
not	O
known	O
.	O
      
Caution	O
should	O
be	O
exercised	O
with	O
simultaneous	O
use	O
of	O
clonidine	B-Drug
and	O
other	O
similar	O
pharmacologic	O
agents	O
      
Concurrent	O
administration	O
of	O
etanercept	B-Drug
(	O
another	O
TNF	O
-	O
blocking	O
agent	O
)	O
and	O
anakinra	B-Drug
(	O
an	O
interleukin	B-Group
-	O
9	I-Group
antagonist	I-Group
)	O
has	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
serious	O
infections	O
and	O
increased	O
risk	O
of	O
neutropenia	O
and	O
no	O
additional	O
benefit	O
compared	O
to	O
these	O
medicinal	O
products	O
alone	O
.	O
      
When	O
CANCIDAS	B-Brand
is	O
co	O
-	O
administered	O
with	O
inducers	O
of	O
drug	O
clearance	O
such	O
as	O
efavirenz	B-Drug
nevirapine	B-Drug
phenytoin	B-Drug
dexamethasone	B-Drug
or	O
carbamazepine	B-Drug
use	O
of	O
a	O
daily	O
dose	O
of	O
9	O
mg	O
of	O
CANCIDAS	B-Brand
should	O
be	O
considered	O
      
Glyburide	B-Drug
:	O
An	O
increased	O
risk	O
of	O
elevated	O
liver	O
aminotransferases	O
was	O
observed	O
in	O
patients	O
receiving	O
concomitant	O
therapy	O
with	O
glyburide	B-Drug
.	O
      
Antacids	B-Group
and	O
sucralfate	B-Drug
:	O
Sucralfate	B-Drug
and	O
antacids	B-Group
containing	O
magnesium	B-Drug
or	O
aluminum	B-Drug
as	O
well	O
as	O
formulations	O
containing	O
divalent	O
and	O
trivalent	O
cations	O
such	O
as	O
Videx	B-Brand
(	O
didanosine	B-Drug
)	O
chewable	O
/	O
buffered	O
tablets	O
or	O
the	O
pediatric	O
powder	O
for	O
oral	O
solution	O
can	O
form	O
chelation	O
complexes	O
with	O
lomefloxacin	B-Drug
and	O
interfere	O
with	O
its	O
bioavailability	O
.	O
      
oral	O
contraceptives	B-Group
;	O
      
Urinary	O
alkalinizing	O
agents	O
(	O
acetazolamide	B-Drug
some	O
thiazides	B-Group
)	O
increase	O
the	O
concentration	O
of	O
the	O
non	O
-	O
ionized	O
species	O
of	O
the	O
amphetamine	B-Drug
molecule	O
thereby	O
decreasing	O
urinary	O
excretion	O
.	O
      
The	O
clinical	O
significance	O
of	O
this	O
reduction	O
is	O
not	O
known	O
hence	O
zalcitabine	B-Drug
is	O
not	O
recommended	O
to	O
be	O
ingested	O
simultaneously	O
with	O
magnesium	B-Drug
/	O
aluminum	B-Drug
-	O
containing	O
antacids	B-Group
.	O
      
Bacteriostatic	B-Group
Antibiotics	I-Group
:	O
Chloramphenicol	B-Drug
erythromycins	B-Drug
sulfonamides	B-Group
or	O
tetracyclines	B-Group
may	O
interfere	O
with	O
the	O
bactericidal	O
effect	O
of	O
penicillins	B-Group
.	O
      
Caution	O
is	O
recommended	O
during	O
the	O
coadministration	O
of	O
any	O
of	O
these	O
with	O
alprazolam	B-Drug
.	O
      
The	O
neuromuscular	O
blocking	O
effect	O
of	O
MIVACRON	B-Brand
may	O
be	O
enhanced	O
by	O
drugs	O
that	O
reduce	O
plasma	O
cholinesterase	O
activity	O
(	O
e.g.	O
chronically	O
administered	O
oral	O
contraceptives	B-Group
glucocorticoids	B-Group
or	O
certain	O
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
)	O
or	O
by	O
drugs	O
that	O
irreversibly	O
inhibit	O
plasma	O
cholinesterase	O
.	O
Resistance	O
to	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
nondepolarizing	O
neuromuscular	B-Group
blocking	I-Group
agents	I-Group
has	O
been	O
demonstrated	O
in	O
patients	O
chronically	O
administered	O
phenytoin	B-Drug
or	O
carbamazepine	B-Drug
.	O
      
Antacids	B-Group
:	O
Concomitant	O
administration	O
of	O
magnesium	B-Drug
hydroxide	I-Drug
and	O
aluminum	B-Drug
hydroxide	I-Drug
does	O
not	O
interfere	O
with	O
the	O
rate	O
or	O
extent	O
of	O
the	O
absorption	O
of	O
ketoprofen	B-Drug
administered	O
as	O
Orudis	B-Brand
.	O
      
Reductions	O
in	O
serum	O
endogenous	O
vitamin	O
D	O
concentrations	O
have	O
been	O
observed	O
following	O
the	O
administration	O
of	O
9	O
mg	O
/	O
day	O
to	O
9	O
mg	O
/	O
day	O
ketoconazole	B-Drug
for	O
a	O
week	O
to	O
healthy	O
men	O
.	O
      
Tadalafil	B-Drug
dose	O
should	O
not	O
exceed	O
a	O
maximum	O
of	O
9	O
mg	O
in	O
a	O
9	O
-	O
hour	O
period	O
in	O
patients	O
receiving	O
concomitant	O
indinavir	B-Drug
therapy	O
.	O
      
Lopinavir	B-Drug
      
If	O
concomitant	O
treatment	O
with	O
AXERT	B-Brand
and	O
an	O
SSRI	B-Group
is	O
clinically	O
warranted	O
appropriate	O
observation	O
of	O
the	O
patient	O
is	O
advised	O
.	O
      
Because	O
of	O
profound	O
and	O
long	O
lasting	O
inhibition	O
of	O
gastric	O
acid	O
secretion	O
pantoprazole	B-Drug
may	O
interfere	O
with	O
absorption	O
of	O
drugs	O
where	O
gastric	O
pH	O
is	O
an	O
important	O
determinant	O
of	O
their	O
bioavailability	O
(	O
eg	O
ketoconazole	B-Drug
ampicillin	B-Drug
esters	O
and	O
iron	B-Drug
salts	O
)	O
.	O
      
It	O
is	O
recommended	O
that	O
glucose	O
tests	O
based	O
on	O
enzymatic	O
glucose	O
oxidase	O
reactions	O
(	O
such	O
as	O
Clinistix	O
or	O
Tes	O
-	O
Tape	O
)	O
be	O
used	O
.	O
      
Ondansetron	B-Drug
does	O
not	O
itself	O
appear	O
to	O
induce	O
or	O
inhibit	O
the	O
cytochrome	O
P	O
-	O
9	O
drug	O
-	O
metabolizing	O
enzyme	O
system	O
of	O
the	O
liver	O
.	O
      
When	O
such	O
drugs	O
are	O
administered	O
to	O
a	O
patient	O
receiving	O
MICRONASE	B-Brand
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
hypoglycemia	O
.	O
      
All	O
animals	O
in	O
the	O
study	O
were	O
positive	O
for	O
an	O
endemic	O
primate	O
gammaherpes	O
virus	O
also	O
known	O
as	O
lymphocryptovirus	O
(	O
LCV	O
)	O
.	O
      
Consequently	O
plasma	O
concentrations	O
of	O
drugs	O
metabolized	O
by	O
these	O
two	O
isoenzymes	O
will	O
be	O
decreased	O
when	O
TRACLEER	B-Brand
is	O
co	O
-	O
administered	O
.	O
      
.	O
      
Therefore	O
it	O
is	O
critically	O
important	O
for	O
women	O
of	O
childbearing	O
potential	O
to	O
select	O
and	O
commit	O
to	O
use	O
9	O
forms	O
of	O
effective	O
contraception	O
simultaneously	O
at	O
least	O
9	O
of	O
which	O
must	O
be	O
a	O
primary	O
form	O
unless	O
absolute	O
abstinence	O
is	O
the	O
chosen	O
method	O
or	O
the	O
patient	O
has	O
undergone	O
a	O
hysterectomy	O
      
Drugs	O
Eliminated	O
by	O
Active	O
Tubular	O
Secretion	O
:	O
Although	O
studies	O
to	O
assess	O
drug	O
-	O
drug	O
interactions	O
with	O
Sanctura	B-Brand
have	O
not	O
been	O
conducted	O
Sanctura	B-Brand
has	O
the	O
potential	O
for	O
pharmacokinetic	O
interactions	O
with	O
other	O
drugs	O
that	O
are	O
eliminated	O
by	O
active	O
tubular	O
secretion	O
(	O
e.g	O
.	O
digoxin	B-Drug
procainamide	B-Drug
pancuronium	B-Drug
morphine	B-Drug
vancomycin	B-Drug
metformin	B-Drug
and	O
tenofovir	B-Drug
)	O
.	O
      
These	O
recommendations	O
are	O
based	O
on	O
either	O
drug	O
interaction	O
studies	O
or	O
predicted	O
interactions	O
due	O
to	O
the	O
expected	O
magnitude	O
of	O
interaction	O
and	O
potential	O
for	O
serious	O
events	O
or	O
loss	O
of	O
efficacy	O
.	O
      
Aprepitant	B-Drug
is	O
also	O
an	O
inducer	O
of	O
CYP9C9	O
.	O
      
Theophylline	B-Drug
:	O
Grepafloxacin	B-Drug
is	O
a	O
competitive	O
inhibitor	O
of	O
the	O
metabolism	O
of	O
theophylline	B-Drug
.	O
      
Therefore	O
close	O
monitoring	O
of	O
prothrombin	O
time	O
is	O
recommended	O
and	O
adjustment	O
of	O
the	O
anticoagulant	B-Group
dose	O
may	O
be	O
necessary	O
when	O
EULEXIN	B-Brand
Capsules	O
are	O
administered	O
concomitantly	O
with	O
warfarin	B-Drug
.	O
      
H9	B-Group
and	O
H9	B-Group
Blockers	I-Group
-	O
Although	O
not	O
reported	O
L	B-Drug
-	O
histidine	I-Drug
via	O
its	O
metabolism	O
to	O
histamine	O
might	O
decrease	O
the	O
efficacy	O
of	O
H9	B-Group
and	O
H9	B-Group
blockers	I-Group
.	O
      
Cyclosporine	B-Drug
:	O
The	O
total	O
ezetimibe	B-Drug
level	O
increased	O
9	O
-	O
fold	O
in	O
one	O
renal	O
transplant	O
patient	O
receiving	O
multiple	O
medications	O
including	O
cyclosporine	B-Drug
.	O
      
The	O
potentiation	O
resulted	O
from	O
a	O
CNS	O
pharmacodynamic	O
interaction	O
;	O
      
ATROVENT	B-Brand
Inhalation	O
Aerosol	O
has	O
been	O
used	O
concomitantly	O
with	O
other	O
drugs	O
including	O
sympathomimetic	B-Group
bronchodilators	I-Group
methylxanthines	B-Group
and	O
steroids	B-Group
commonly	O
used	O
in	O
the	O
treatment	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
.	O
      
No	O
significant	O
drug	O
-	O
drug	O
pharmacokinetic	O
interactions	O
have	O
been	O
found	O
in	O
interaction	O
studies	O
with	O
hydrochlorothiazide	B-Drug
digoxin	B-Drug
warfarin	B-Drug
cimetidine	B-Drug
and	O
phenobarbital	B-Drug
.	O
      
Minor	O
symptoms	O
such	O
as	O
flushing	O
skin	O
reactions	O
dyspnea	O
hypotension	O
or	O
tachycardia	O
do	O
not	O
require	O
interruption	O
of	O
therapy	O
.	O
      
Interactions	O
with	O
Other	O
CNS	O
Agents	O
:	O
Concurrent	O
use	O
of	O
Levo	B-Brand
-	O
Dromoran	I-Brand
with	O
all	O
central	B-Group
nervous	I-Group
system	I-Group
depressants	I-Group
(	O
eg	O
alcohol	B-Drug
sedatives	B-Group
hypnotics	B-Group
other	O
opioids	B-Group
general	O
anesthetics	B-Group
barbiturates	B-Group
tricyclic	B-Group
antidepressants	I-Group
phenothiazines	B-Group
tranquilizers	B-Group
skeletal	B-Group
muscle	I-Group
relaxants	I-Group
and	O
antihistamines	B-Group
)	O
may	O
result	O
in	O
additive	O
central	O
nervous	O
system	O
depressant	O
effects	O
.	O
      
Fentanyl	B-Drug
      
Thiazide	B-Group
diuretics	I-Group
may	O
accentuate	O
the	O
orthostatic	O
hypotension	O
that	O
may	O
occur	O
with	O
phenothiazines	B-Group
.	O
      
(	O
b	O
)	O
Plasma	O
and	O
urinary	O
gonadotropin	O
levels	O
are	O
decreased	O
(	O
e.g.	O
LH	O
FSH	O
)	O
.	O
      
9	O
      
Effect	O
of	O
AEDs	B-Group
in	O
Pediatric	O
Patients	O
There	O
was	O
about	O
a	O
9	O
%	O
increase	O
of	O
apparent	O
total	O
body	O
clearance	O
of	O
levetiracetam	B-Drug
when	O
it	O
was	O
co	O
-	O
administered	O
with	O
enzyme	O
-	O
inducing	O
AEDs	B-Group
.	O
      
Caspofungin	B-Drug
is	O
not	O
a	O
substrate	O
for	O
P	O
-	O
glycoprotein	O
and	O
is	O
a	O
poor	O
substrate	O
for	O
cytochrome	O
P9	O
enzymes	O
.	O
      
Trilostane	B-Drug
may	O
interact	O
with	O
aminoglutethimide	B-Drug
or	O
mitotane	B-Drug
(	O
causing	O
too	O
great	O
a	O
decrease	O
in	O
adrenal	O
function	O
)	O
.	O
      
Although	O
clinical	O
studies	O
have	O
not	O
been	O
conducted	O
in	O
vitro	O
studies	O
of	O
iloprost	B-Drug
indicate	O
that	O
no	O
relevant	O
inhibition	O
of	O
cytochrome	O
P9	O
drug	O
metabolism	O
would	O
be	O
expected	O
.	O
      
Caution	O
should	O
be	O
used	O
if	O
naproxen	B-Drug
is	O
administered	O
concomitantly	O
with	O
methotrexate	B-Drug
.	O
      
use	O
potassium	B-Drug
supplements	O
if	O
necessary	O
.	O
      
Methotrexate	B-Drug
:	O
Caution	O
should	O
be	O
used	O
if	O
diflunisal	B-Drug
is	O
administered	O
concomitantly	O
with	O
methotrexate	B-Drug
.	O
      
Trimethoprim	B-Drug
Alone	O
or	O
in	O
Combination	O
with	O
Sulfamethoxazole	B-Drug
:	O
Concomitant	O
use	O
of	O
trimethoprim	B-Drug
alone	O
or	O
in	O
combination	O
with	O
sulfamethoxazole	B-Drug
is	O
contraindicated	O
.	O
      
Probenecid	B-Drug
:	O
As	O
with	O
other	O
b	B-Group
-	O
lactams	I-Group
the	O
renal	O
excretion	O
of	O
cephalexin	B-Drug
is	O
inhibited	O
by	O
probenecid	B-Drug
.	O
      
This	O
effect	O
is	O
small	O
with	O
occasional	O
doses	O
of	O
antacids	B-Group
but	O
may	O
be	O
clinically	O
significant	O
when	O
antacids	B-Group
are	O
used	O
on	O
a	O
continuous	O
schedule	O
.	O
      
Since	O
INVIRASE	B-Brand
is	O
coadministered	O
with	O
ritonavir	B-Drug
the	O
ritonavir	B-Drug
label	O
should	O
be	O
reviewed	O
for	O
additional	O
drugs	O
that	O
should	O
not	O
be	O
coadministered	O
.	O
      
Interactions	O
between	O
Leukine	B-Brand
and	O
other	O
drugs	O
have	O
not	O
been	O
fully	O
evaluated	O
.	O
      
This	O
inhibition	O
can	O
result	O
in	O
unexpectedly	O
high	O
plasma	O
levels	O
of	O
other	O
drugs	B-Drug
which	O
are	O
metabolized	O
by	O
those	O
CYP9	O
enzymes	O
.	O
      
nc9	O
9	O
9	O
%	O
decrease	O
[	O
CI	O
:	O
9	O
%	O
decrease	O
9	O
%	O
decrease	O
]	O
      
Because	O
alosetron	B-Drug
is	O
metabolized	O
by	O
a	O
variety	O
of	O
hepatic	O
CYP	O
drug	O
-	O
metabolizing	O
enzymes	O
inducers	O
or	O
inhibitors	O
of	O
these	O
enzymes	O
may	O
change	O
the	O
clearance	O
of	O
alosetron	B-Drug
.	O
      
Therefore	O
proton	B-Group
pump	I-Group
inhibitors	I-Group
should	O
be	O
taken	O
at	O
least	O
9	O
minutes	O
prior	O
to	O
sucralfate	B-Drug
.	O
      
Rabbits	O
failed	O
to	O
maintain	O
pregnancy	O
when	O
dosed	O
with	O
9	O
mg	O
/	O
kg	O
/	O
day	O
fulvestrant	B-Drug
IM	O
(	O
twice	O
the	O
human	O
dose	O
on	O
BSA	O
)	O
during	O
the	O
period	O
of	O
organogenesis	O
.	O
      
There	O
was	O
a	O
small	O
decrease	O
in	O
the	O
clearance	O
of	O
cetirizine	B-Drug
caused	O
by	O
a	O
9	O
-	O
mg	O
dose	O
of	O
theophylline	B-Drug
;	O
      
clinical	O
implications	O
are	O
unclear	O
.	O
      
No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
.	O
      
Nelfinavir	B-Drug
is	O
an	O
inhibitor	O
of	O
CYP9A	O
(	O
cytochrome	O
P9	O
9A	O
)	O
.	O
      
The	O
concomitant	O
administration	O
of	O
bosentan	B-Drug
and	O
cyclosporine	B-Drug
A	I-Drug
is	O
contraindicated	O
.	O
      
Plasma	O
concentrations	O
and	O
effects	O
potentially	O
increased	O
or	O
decreased	O
by	O
SUSTIVA	B-Brand
.	O
      
This	O
has	O
been	O
observed	O
with	O
Benedict	O
and	O
Fehling	O
s	O
solutions	O
but	O
not	O
with	O
the	O
glucose	O
enzymatic	O
test	O
.	O
      
The	O
reddish	O
color	O
is	O
due	O
to	O
the	O
formation	O
of	O
a	O
nonabsorbable	O
complex	O
between	O
cefdinir	B-Drug
or	O
its	O
breakdown	O
products	O
and	O
iron	B-Drug
in	O
the	O
gastrointestinal	O
tract	O
.	O
      
This	O
is	O
typical	O
of	O
the	O
interaction	O
of	O
meperidine	B-Drug
and	O
MAOIs	B-Group
.	O
      
Drug	O
Interactions	O
:	O
The	O
use	O
of	O
ZEMURON	B-Brand
(	O
rocuronium	B-Drug
bromide	I-Drug
)	O
Injection	O
before	O
succinylcholine	B-Drug
for	O
the	O
purpose	O
of	O
attenuating	O
some	O
of	O
the	O
side	O
effects	O
of	O
succinylcholine	B-Drug
has	O
not	O
been	O
studied	O
.	O
      
Digoxin	B-Drug
:	O
Enoxacin	B-Drug
may	O
raise	O
serum	O
digoxin	B-Drug
levels	O
in	O
some	O
individuals	O
.	O
      
Coadministration	O
of	O
valdecoxib	B-Drug
(	O
9	O
mg	O
BID	O
(	O
day	O
9	O
)	O
and	O
9	O
mg	O
QD	O
(	O
days	O
9	O
-	O
9	O
)	O
)	O
with	O
glyburide	B-Drug
(	O
9	O
mg	O
glyburide	B-Drug
BID	O
)	O
resulted	O
in	O
9	O
%	O
increase	O
in	O
glyburide	B-Drug
AUC9	O
-	O
9	O
and	O
a	O
9	O
%	O
increase	O
in	O
glyburide	B-Drug
Cmax	O
leading	O
to	O
a	O
9	O
%	O
decrease	O
in	O
glucose	O
AUC9	O
-	O
9	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Salicylate	B-Group
competes	O
with	O
thyroid	O
hormone	O
for	O
binding	O
to	O
plasma	O
proteins	O
which	O
may	O
be	O
reflected	O
in	O
a	O
depressed	O
plasma	O
T9	O
value	O
in	O
some	O
patients	O
;	O
      
The	O
following	O
drug	O
interactions	O
have	O
been	O
identified	O
involving	O
NIZORAL	B-Brand
Tablets	O
and	O
other	O
drugs	O
metabolized	O
by	O
the	O
cytochrome	O
P9	O
9A9	O
enzyme	O
system	O
:	O
Ketoconazole	B-Drug
tablets	O
inhibit	O
the	O
metabolism	O
of	O
terfenadine	B-Drug
resulting	O
in	O
an	O
increased	O
plasma	O
concentration	O
of	O
terfenadine	B-Drug
and	O
a	O
delay	O
in	O
the	O
elimination	O
of	O
its	O
acid	O
metabolite	O
.	O
      
In	O
addition	O
administration	O
of	O
Sonata	B-Brand
to	O
a	O
patient	O
taking	O
another	O
drug	O
that	O
is	O
highly	O
protein	O
bound	O
should	O
not	O
cause	O
transient	O
increase	O
in	O
free	O
concentrations	O
of	O
the	O
other	O
drug	O
.	O
      
cmaxSS	O
(	O
Peak	O
plasma	O
concentration	O
)	O
      
Drugs	O
that	O
are	O
Metabolized	O
by	O
and	O
/	O
or	O
Inhibit	O
Cytochrome	O
P9	O
Enzymes	O
Many	O
drugs	O
are	O
metabolized	O
by	O
and	O
/	O
or	O
inhibit	O
various	O
cytochrome	O
P9	O
enzymes	O
e.g.	O
9D9	O
9A9	O
9A9	O
etc	O
.	O
      
The	O
CNS	O
-	O
depressant	O
effect	O
of	O
propoxyphene	B-Drug
is	O
additive	O
with	O
that	O
of	O
other	O
CNS	B-Group
depressants	I-Group
including	O
alcohol	B-Drug
.	O
      
Dose	O
of	O
AED	B-Group
(	O
mg	O
/	O
day	O
)	O
      
Coumarin	B-Group
Anticoagulants	I-Group
:	O
There	O
have	O
been	O
rare	O
reports	O
of	O
increased	O
prothrombin	O
time	O
in	O
patients	O
taking	O
coumarin	B-Group
anticoagulants	I-Group
to	O
whom	O
nifedipine	B-Drug
was	O
administered	O
.	O
      
9%	O
      
However	O
severe	O
reactions	O
such	O
as	O
hypotension	O
requiring	O
treatment	O
dyspnea	O
requiring	O
bronchodilators	B-Group
angioedema	O
or	O
generalized	O
urticaria	O
require	O
immediate	O
discontinuation	O
of	O
TAXOL	B-Brand
and	O
aggressive	O
symptomatic	O
therapy	O
.	O
      
Monitoring	O
of	O
plasma	O
phenytoin	B-Drug
concentrations	O
may	O
be	O
helpful	O
when	O
possible	O
drug	O
interactions	O
are	O
suspected	O
.	O
      
Aminoglutethimide	B-Drug
:	O
Aminoglutethimide	B-Drug
may	O
diminish	O
adrenal	O
suppression	O
by	O
corticosteroids	B-Group
.	O
      
Therefore	O
the	O
potential	O
exists	O
for	O
interaction	O
between	O
carbamazepine	B-Drug
and	O
any	O
agent	O
that	O
induces	O
CYP9A9	O
.	O
      
Because	O
dexfenfluramine	B-Drug
is	O
a	O
serotonin	O
releaser	O
and	O
reuptake	O
inhibitor	O
dexfenfluramine	B-Drug
should	O
not	O
be	O
used	O
concomitantly	O
with	O
a	O
MAO	B-Group
inhibitor	I-Group
.	O
      
In	O
some	O
patients	O
the	O
administration	O
of	O
a	O
non	B-Group
-	O
steroidal	I-Group
anti	I-Group
-	O
inflammatory	I-Group
agent	I-Group
can	O
reduce	O
the	O
diuretic	O
natriuretic	O
and	O
antihypertensive	O
effects	O
of	O
loop	B-Group
potassium	B-Group
-	O
sparing	I-Group
and	O
thiazide	B-Group
diuretics	I-Group
.	O
      
Although	O
beta	B-Group
-	O
adrenergic	I-Group
blockers	I-Group
or	O
calcium	B-Group
channel	I-Group
blockers	I-Group
and	O
digoxin	B-Drug
may	O
be	O
useful	O
in	O
combination	O
to	O
control	O
atrial	O
fibrillation	O
their	O
additive	O
effects	O
on	O
AV	O
node	O
conduction	O
can	O
result	O
in	O
advanced	O
or	O
complete	O
heart	O
block	O
.	O
      
The	O
pharmacokinetic	O
parameters	O
of	O
digoxin	B-Drug
are	O
not	O
significantly	O
modified	O
by	O
SKELID	B-Brand
coadministration	O
.	O
      
DIAGNOSTIC	O
INTERFERENCE	O
With	O
expected	O
physiologic	O
effects	O
:	O
Blood	O
and	O
urine	O
glucose	O
levels	O
(	O
usually	O
only	O
in	O
patients	O
with	O
a	O
predisposition	O
for	O
glucose	O
intolerance	O
)	O
and	O
Serum	O
bilirubin	O
levels	O
(	O
by	O
displacement	O
from	O
albumin	O
binding	O
)	O
and	O
Serum	O
calcium	O
levels	O
(	O
thiazide	B-Group
diuretics	I-Group
should	O
be	O
discontinued	O
before	O
parathyroid	O
-	O
function	O
tests	O
are	O
carried	O
out	O
)	O
and	O
Serum	O
uric	O
acid	O
levels	O
(	O
may	O
be	O
increased	O
)	O
Serum	O
magnesium	O
potassium	O
and	O
sodium	O
levels	O
(	O
may	O
be	O
decreased	O
;	O
      
.	O
      
Animal	O
studies	O
also	O
suggest	O
an	O
increased	O
potential	O
for	O
seizures	O
when	O
these	O
two	O
drugs	O
are	O
given	O
concomitantly	O
.	O
      
In	O
vivo	O
drug	O
-	O
drug	O
interaction	O
studies	O
conducted	O
in	O
normal	O
volunteer	O
subjects	O
showed	O
that	O
terbinafine	B-Drug
does	O
not	O
affect	O
the	O
clearance	O
of	O
antipyrine	B-Drug
or	O
digoxin	B-Drug
.	O
      
The	O
most	O
commonly	O
occurring	O
drug	O
interactions	O
are	O
listed	O
below	O
:	O
-	O
Drugs	O
that	O
may	O
increase	O
plasma	O
phenytoin	B-Drug
concentrations	O
include	O
:	O
acute	O
alcohol	B-Drug
intake	O
amiodarone	B-Drug
chboramphenicol	O
chlordiazepoxide	B-Drug
cimetidine	B-Drug
diazepam	B-Drug
dicumarol	B-Drug
disulfiram	B-Drug
estrogens	B-Group
ethosuximide	B-Drug
fluoxetine	B-Drug
H9	B-Group
-	O
antagonists	I-Group
halothane	B-Drug
isoniazid	B-Drug
methylphenidate	B-Drug
phenothiazines	B-Group
phenylbutazone	B-Drug
salicylates	B-Group
succinimides	B-Group
sulfonamides	B-Group
tolbutamide	B-Drug
trazodone	B-Drug
      
NSAIDs	B-Group
may	O
decrease	O
the	O
hemodynamic	O
effects	O
of	O
hydralazine	B-Drug
;	O
      
Anticholinergic	B-Group
agents	I-Group
may	O
potentially	O
alter	O
the	O
absorption	O
of	O
some	O
concomitantly	O
administered	O
drugs	O
due	O
to	O
anticholinergic	O
effects	O
on	O
gastrointestinal	O
motility	O
.	O
      
Motility	O
agents	O
      
Corticosteroids	B-Group
may	O
increase	O
the	O
clearance	O
of	O
chronic	O
high	O
dose	O
aspirin	B-Brand
.	O
      
Therefore	O
when	O
concomitant	O
use	O
of	O
thiabendazole	B-Drug
and	O
xanthine	B-Group
derivatives	I-Group
is	O
anticipated	O
it	O
may	O
be	O
necessary	O
to	O
monitor	O
blood	O
levels	O
and	O
/	O
or	O
reduce	O
the	O
dosage	O
of	O
such	O
compounds	O
.	O
      
Limited	O
PK	O
and	O
/	O
or	O
PD	O
studies	O
investigating	O
possible	O
interactions	O
between	O
anagrelide	B-Drug
and	O
other	O
medicinal	O
products	O
have	O
been	O
conducted	O
.	O
      
This	O
suggests	O
that	O
an	O
interaction	O
of	O
aripiprazole	B-Drug
with	O
inhibitors	O
or	O
inducers	O
of	O
these	O
enzymes	O
or	O
other	O
factors	O
like	O
smoking	O
is	O
unlikely	O
.	O
      
In	O
addition	O
levetiracetam	B-Drug
does	O
not	O
affect	O
the	O
in	O
vitro	O
glucuronidation	O
of	O
valproic	B-Drug
acid	I-Drug
.	O
      
Androgens	B-Group
may	O
increase	O
sensitivity	O
to	O
oral	O
anticoagulahts	O
.	O
      
d	B-Drug
-	O
amphetamine	I-Drug
with	O
desipramine	B-Drug
or	O
protriptyline	B-Drug
and	O
possibly	O
other	O
tricyclics	B-Group
cause	O
striking	O
and	O
sustained	O
increases	O
in	O
the	O
concentration	O
of	O
d	B-Drug
-	O
amphetamine	I-Drug
in	O
the	O
brain	O
;	O
      
Several	O
tricyclic	B-Group
antidepressants	I-Group
have	O
been	O
reported	O
to	O
block	O
the	O
pharmacologic	O
effects	O
of	O
guanethidine	B-Drug
clonidine	B-Drug
or	O
similar	O
agents	O
and	O
such	O
an	O
effect	O
may	O
be	O
anticipated	O
with	O
CMI	B-Drug
because	O
of	O
its	O
structural	O
similarity	O
to	O
other	O
tricyclic	B-Group
antidepressants	I-Group
.	O
      
The	O
coadministration	O
of	O
a	O
potent	O
CYP9A9	O
enzyme	O
inducer	O
although	O
not	O
posing	O
a	O
safety	O
concern	O
thus	O
could	O
lead	O
to	O
ineffectiveness	O
of	O
zaleplon	B-Drug
.	O
      
Ethinyl	B-Drug
estradiol	I-Drug
and	O
Norethindrone	B-Drug
      
Diphenhydramine	B-Drug
hydrochloride	I-Drug
has	O
additive	O
effects	O
with	O
alcohol	B-Drug
and	O
other	O
CNS	B-Group
depressants	I-Group
(	O
hypnotics	B-Group
sedatives	B-Group
tranquilizers	B-Group
etc	O
)	O
.	O
      
Trecator	B-Brand
has	O
been	O
found	O
to	O
temporarily	O
raise	O
serum	O
concentrations	O
of	O
isoniazid	B-Drug
.	O
      
Digitalis	B-Group
:	O
Immediate	O
Release	O
Capsules	O
:	O
Since	O
there	O
have	O
been	O
isolated	O
reports	O
of	O
patients	O
with	O
elevated	O
digoxin	B-Drug
levels	O
and	O
there	O
is	O
a	O
possible	O
interaction	O
between	O
digoxin	B-Drug
and	O
nifedipine	B-Drug
it	O
is	O
recommended	O
that	O
digoxin	B-Drug
levels	O
be	O
monitored	O
when	O
initiating	O
adjusting	O
and	O
discontinuing	O
nifedipine	B-Drug
to	O
avoid	O
possible	O
over	O
-	O
or	O
under	O
-	O
digitalization	O
.	O
      
Drugs	O
with	O
parasympathomimetic	O
effects	O
administered	O
concurrently	O
with	O
cevimeline	B-Drug
can	O
be	O
expected	O
to	O
have	O
additive	O
effects	O
.	O
      
Prednisolone	B-Drug
:	O
Ethinyl	B-Drug
estradiol	I-Drug
may	O
inhibit	O
the	O
metabolism	O
of	O
prednisolone	B-Drug
leading	O
to	O
increased	O
plasma	O
concentrations	O
.	O
      
The	O
rate	O
of	O
metabolism	O
and	O
the	O
leukopenic	O
activity	O
of	O
cyclophosphamide	B-Drug
reportedly	O
are	O
increased	O
by	O
chronic	O
administration	O
of	O
high	O
doses	O
of	O
phenobarbital	B-Drug
.	O
      
Nelfinavir	B-Drug
      
Careful	O
monitoring	O
is	O
advisable	O
when	O
GH	B-Drug
is	O
administered	O
in	O
combination	O
with	O
other	O
drugs	O
known	O
to	O
be	O
metabolized	O
by	O
CP9	O
liver	O
enzymes	O
.	O
      
Most	O
who	O
take	O
EPA	B-Drug
supplements	O
and	O
the	O
above	O
drugs	O
or	O
herbs	O
do	O
not	O
suffer	O
from	O
these	O
problems	O
and	O
if	O
they	O
occur	O
they	O
are	O
rare	O
.	O
      
Acetazolamide	B-Drug
decreases	O
urinary	O
excretion	O
of	O
amphetamine	B-Drug
and	O
may	O
enhance	O
the	O
magnitude	O
and	O
duration	O
of	O
their	O
effect	O
.	O
      
Interactions	O
between	O
Betaseron	B-Brand
and	O
other	O
drugs	O
have	O
not	O
been	O
fully	O
evaluated	O
.	O
      
No	O
drug	O
-	O
drug	O
interaction	O
studies	O
in	O
human	O
subjects	O
have	O
been	O
conducted	O
.	O
      
Tricyclic	B-Group
antidepressants	I-Group
have	O
been	O
reported	O
to	O
blunt	O
the	O
hypotensive	O
effect	O
of	O
systemic	O
clonidine	B-Drug
.	O
It	O
is	O
not	O
known	O
whether	O
the	O
concurrent	O
use	O
of	O
these	O
agents	O
with	O
ALPHAGAN	B-Brand
P	I-Brand
in	O
humans	O
can	O
lead	O
to	O
resulting	O
interference	O
with	O
the	O
IOP	O
lowering	O
effect	O
.	O
      
Corticosteroids	B-Group
Methylxanthines	B-Group
and	O
Diuretics	B-Group
:	O
Concomitant	O
treatment	O
with	O
xanthine	B-Group
derivatives	I-Group
steroids	B-Group
or	O
diuretics	B-Group
may	O
potentiate	O
a	O
possible	O
hypokalemic	O
effect	O
of	O
beta9	B-Group
-	O
agonists	I-Group
.	O
      
During	O
maintenance	O
of	O
anesthesia	O
or	O
sedation	O
the	O
rate	O
of	O
DIPRIVAN	B-Brand
Injectable	O
Emulsion	O
administration	O
should	O
be	O
adjusted	O
according	O
to	O
the	O
desired	O
level	O
of	O
anesthesia	O
or	O
sedation	O
and	O
may	O
be	O
reduced	O
in	O
the	O
presence	O
of	O
supplemental	O
analgesic	B-Group
agents	I-Group
(	O
eg	O
nitrous	B-Drug
oxide	I-Drug
or	O
opioids	B-Group
)	O
.	O
      
Due	O
to	O
a	O
theoretical	O
risk	O
of	O
a	O
pharmacodynamic	O
interaction	O
use	O
of	O
ergotamine	B-Drug
-	O
containing	O
or	O
ergot	B-Group
-	O
type	I-Group
medications	I-Group
(	O
like	O
dihydroergotamine	B-Drug
or	O
methysergide	B-Drug
)	O
and	O
FROVA	B-Brand
within	O
9	O
hours	O
of	O
each	O
other	O
should	O
be	O
avoided	O
(	O
see	O
a	O
href=	O
frova_od.htm	O
#	O
CI	O
CONTRAINDICATIONS	O
)	O
.	O
      
Lithium	B-Drug
-	O
Coadministration	O
of	O
racemic	O
citalopram	B-Drug
(	O
9	O
mg	O
/	O
day	O
for	O
9	O
days	O
)	O
and	O
lithium	B-Drug
(	O
9	O
mmol	O
/	O
day	O
for	O
9	O
days	O
)	O
had	O
no	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
citalopram	B-Drug
or	O
lithium	B-Drug
.	O
      
This	O
could	O
lead	O
to	O
decreased	O
salicylate	B-Group
serum	O
levels	O
or	O
increase	O
the	O
risk	O
of	O
salicylate	B-Group
toxicity	O
when	O
corticosteroid	B-Drug
is	O
withdrawn	O
.	O
      
Accordingly	O
when	O
diflunisal	B-Drug
is	O
administered	O
with	O
oral	O
anticoagulants	B-Group
the	O
prothrombin	O
time	O
should	O
be	O
closely	O
monitored	O
during	O
and	O
for	O
several	O
days	O
after	O
concomitant	O
drug	O
administration	O
.	O
      
Therefore	O
if	O
concomitant	O
use	O
of	O
these	O
agents	O
is	O
indicated	O
because	O
of	O
demonstrated	O
hypokalemia	O
they	O
should	O
be	O
used	O
with	O
caution	O
and	O
with	O
frequent	O
monitoring	O
of	O
serum	O
potassium	O
.	O
      
Interactions	O
with	O
the	O
drugs	O
listed	O
below	O
have	O
not	O
been	O
reported	O
in	O
clinical	O
trials	O
with	O
azithromycin	B-Drug
;	O
      
Currently	O
there	O
are	O
no	O
safety	O
and	O
efficacy	O
data	O
available	O
from	O
the	O
use	O
of	O
this	O
combination	O
.	O
      
therefore	O
periodic	O
liver	O
function	O
testing	O
(	O
transaminases	O
bilirubin	O
and	O
alkaline	O
phosphatase	O
)	O
should	O
be	O
considered	O
.	O
      
Theophylline	B-Drug
:	O
Ethinyl	B-Drug
estradiol	I-Drug
may	O
inhibit	O
the	O
metabolism	O
of	O
theophylline	B-Drug
leading	O
to	O
increased	O
plasma	O
concentrations	O
.	O
      
Antihypertensive	B-Group
Medications	I-Group
and	O
Vasodilators	B-Group
:	O
The	O
following	O
adverse	O
events	O
were	O
experienced	O
more	O
commonly	O
in	O
patients	O
receiving	O
concomitant	O
antihypertensive	B-Group
medications	I-Group
or	O
vasodilators	B-Group
(	O
n	O
=	O
9	O
)	O
compared	O
to	O
patients	O
not	O
receiving	O
these	O
concomitant	O
drugs	O
(	O
n	O
=	O
9	O
)	O
:	O
hypotension	O
9	O
%	O
vs	O
9	O
%	O
myocardial	O
infarction	O
9	O
%	O
vs	O
9	O
%	O
serious	O
pneumonia	O
9	O
%	O
vs	O
9	O
%	O
serious	O
falls	O
9	O
%	O
vs	O
9	O
%	O
and	O
bone	O
and	O
joint	O
injuries	O
9	O
%	O
vs	O
9	O
%	O
.	O
      
These	O
reactions	O
include	O
fever	O
chills	O
nausea	O
vomiting	O
pruritus	O
rash	O
diarrhea	O
hypotension	O
edema	O
and	O
oliguria	O
.	O
      
Diabetics	O
who	O
take	O
EPA	B-Drug
supplements	O
should	O
be	O
monitored	O
by	O
their	O
physicians	O
.	O
      
HMG	B-Drug
-	O
CoA	I-Drug
Reductase	I-Drug
Inhibitors	I-Drug
:	O
Simvastatin	B-Drug
(	O
CYP9A9	B-Drug
substrate	O
)	O
in	O
combination	O
with	O
amiodarone	B-Drug
has	O
been	O
associated	O
with	O
reports	O
of	O
myopathy	O
/	O
rhabdomyolysis	O
.	O
      
Drugs	O
Metabolized	O
by	O
P9IID9	O
A	O
subset	O
(	O
9	O
%	O
to	O
9	O
%	O
)	O
of	O
the	O
population	O
has	O
reduced	O
activity	O
of	O
certain	O
drug	O
metabolizing	O
enzymes	O
such	O
as	O
the	O
cytochrome	O
P9	O
isoenzyme	O
P9IID9	O
.	O
      
Cimetidine	B-Drug
      
Immunosuppressive	B-Group
Drugs	I-Group
Fibric	B-Group
Acid	I-Group
Derivatives	I-Group
Niacin	B-Drug
(	O
Nicotinic	B-Drug
Acid	I-Drug
Erythromycin	B-Drug
Azole	B-Group
Antifungals	I-Group
:	O
Skeletal	O
Muscle	O
.	O
      
Catecholamine	O
-	O
depleting	O
drugs	O
(	O
eg	O
reserpine	B-Drug
)	O
may	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
beta	B-Group
-	O
blocking	I-Group
agents	I-Group
.	O
      
macrolide	B-Group
antibiotics	I-Group
e.g.	O
erythromycin	B-Drug
;	O
      
-	O
Reduced	O
response	O
to	O
metyrapone	O
test	O
      
The	O
clinical	O
relevance	O
of	O
this	O
interaction	O
has	O
not	O
been	O
established	O
.	O
      
Non	B-Drug
-	O
pegylated	I-Drug
interferon	I-Drug
alfa	I-Drug
-	O
9a	I-Drug
treatment	O
of	O
pregnant	O
Rhesus	O
monkeys	O
at	O
approximately	O
9	O
to	O
9	O
times	O
the	O
human	O
weekly	O
dose	O
resulted	O
in	O
a	O
statistically	O
significant	O
increase	O
in	O
abortions	O
.	O
      
Anticoagulants	B-Group
:	O
While	O
studies	O
have	O
not	O
shown	O
diclofenac	B-Drug
to	O
interact	O
with	O
anticoagulants	B-Group
of	I-Group
the	I-Group
warfarin	I-Group
type	I-Group
caution	O
should	O
be	O
exercised	O
nonetheless	O
since	O
interactions	O
have	O
been	O
seen	O
with	O
other	O
NSAIDs	B-Group
.	O
      
It	O
is	O
not	O
known	O
whether	O
other	O
progestational	B-Group
contraceptives	I-Group
such	O
as	O
implants	O
and	O
injectables	O
are	O
adequate	O
methods	O
of	O
contraception	O
during	O
acitretin	B-Drug
therapy	O
.	O
      
Marked	O
symptomatic	O
orthostatic	O
hypotension	O
has	O
been	O
reported	O
when	O
calcium	B-Group
channel	I-Group
blockers	I-Group
and	O
organic	O
nitrates	B-Group
were	O
used	O
in	O
combination	O
.	O
      
Examples	O
of	O
Drugs	O
in	O
Which	O
Plasma	O
Concentrations	O
May	O
Be	O
Increased	O
By	O
Co	O
-	O
administration	O
With	O
Nevirapine	B-Drug
      
Three	O
clinical	O
trials	O
have	O
investigated	O
Simulect	B-Brand
use	O
in	O
combination	O
with	O
triple	O
-	O
therapy	O
regimens	O
.	O
      
Phenytoin	B-Drug
:	O
DIFLUCAN	B-Brand
increases	O
the	O
plasma	O
concentrations	O
of	O
phenytoin	B-Drug
.	O
      
HIV	B-Group
Protease	I-Group
Inhibitors	I-Group
:	O
The	O
effect	O
of	O
amprenavir	B-Drug
on	O
total	O
drug	O
concentrations	O
of	O
other	O
HIV	B-Group
protease	I-Group
inhibitors	I-Group
in	O
subjects	O
receiving	O
both	O
agents	O
was	O
evaluated	O
using	O
comparisons	O
to	O
historical	O
data	O
.	O
      
May	O
interact	O
with	O
wthionamide	O
(	O
Trecator	B-Brand
-	O
SC	I-Brand
)	O
and	O
isoniazid	B-Drug
(	O
Nydrazid	B-Brand
)	O
.	O
      
Digoxin	B-Drug
:	O
Digoxin	B-Drug
concentrations	O
are	O
increased	O
by	O
about	O
9	O
%	O
when	O
digoxin	B-Drug
and	O
carvedilol	B-Drug
are	O
administered	O
concomitantly	O
.	O
      
Non	B-Group
-	O
steroidal	I-Group
Anti	I-Group
-	O
inflammatory	I-Group
Agents	I-Group
:	O
In	O
some	O
patients	O
with	O
compromised	O
renal	O
function	O
who	O
are	O
being	O
treated	O
with	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
drugs	I-Group
the	O
co	O
-	O
administration	O
of	O
enalapril	B-Drug
may	O
result	O
in	O
a	O
further	O
deterioration	O
of	O
renal	O
function	O
.	O
      
The	O
use	O
of	O
ROMAZICON	B-Brand
is	O
not	O
recommended	O
in	O
epileptic	O
patients	O
who	O
have	O
been	O
receiving	O
benzodiazepine	O
treatment	O
for	O
a	O
prolonged	O
period	O
.	O
      
Monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
or	O
tricyclic	B-Group
antidepressants	I-Group
may	O
potentiate	O
the	O
action	O
of	O
sympathomimetic	B-Group
amines	I-Group
.	O
      
Clarithromycin	B-Drug
exposure	O
was	O
significantly	O
decreased	O
by	O
nevirapine	B-Drug
;	O
      
Geriatric	O
Use	O
Younger	O
patients	O
have	O
higher	O
virologic	O
response	O
rates	O
than	O
older	O
patients	O
.	O
      
Increased	O
thyroid	O
-	O
binding	O
globulin	O
(	O
TBG	O
)	O
levels	O
leading	O
to	O
increased	O
circulating	O
total	O
thyroid	O
hormone	O
levels	O
as	O
measured	O
by	O
protein	O
-	O
bound	O
iodine	B-Drug
(	O
PBI	O
)	O
T9	O
levels	O
(	O
by	O
column	O
or	O
by	O
radioimmunoassay	O
)	O
or	O
T9	O
levels	O
by	O
radioimmunoassay	O
.	O
      
Dantrium	B-Brand
is	O
metabolized	O
by	O
the	O
liver	O
and	O
it	O
is	O
theoretically	O
possible	O
that	O
its	O
metabolism	O
may	O
be	O
enhanced	O
by	O
drugs	O
known	O
to	O
induce	O
hepatic	O
microsomal	O
enzymes	O
.	O
      
Phenytoin	B-Drug
:	O
Population	O
pharmacokinetic	O
analyses	O
indicate	O
that	O
tiagabine	B-Drug
clearance	O
is	O
9	O
%	O
greater	O
in	O
patients	O
taking	O
phenytoin	B-Drug
with	O
or	O
without	O
other	O
enzyme	O
-	O
inducing	O
AEDs	B-Group
.	O
      
Decreases	O
in	O
TBg	O
concentrations	O
are	O
observed	O
in	O
nephrosis	O
acromegaly	O
and	O
after	O
androgen	B-Group
or	O
corticosteroid	B-Group
therapy	O
.	O
      
As	O
a	O
moderate	O
inhibitor	O
of	O
CYP9A9	O
aprepitant	B-Drug
can	O
increase	O
plasma	O
concentrations	O
of	O
coadministered	O
medicinal	O
products	O
that	O
are	O
metabolized	O
through	O
CYP9A9	O
.	O
      
quinidine	B-Drug
;	O
      
As	O
a	O
false	O
-	O
negative	O
result	O
may	O
occur	O
in	O
the	O
ferricyanide	O
test	O
it	O
is	O
recommended	O
that	O
either	O
the	O
glucose	O
oxidase	O
or	O
hexokinase	O
method	O
be	O
used	O
to	O
determine	O
blood	O
/	O
plasma	O
glucose	O
levels	O
in	O
patients	O
receiving	O
cefditoren	B-Drug
pivoxil	I-Drug
.	O
      
Effect	O
of	O
aprepitant	B-Drug
on	O
the	O
pharmacokinetics	O
of	O
other	O
agents	O
      
with	O
sucralfate	B-Drug
;	O
      
For	O
patients	O
receiving	O
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
see	O
CONTRAINDICATIONS	O
.	O
      
The	O
binding	O
of	O
thyroxine	O
by	O
thyroxine	O
-	O
binding	O
prealbumin	O
(	O
TBPA	O
)	O
is	O
inhibited	O
by	O
salicylates	B-Group
      
Efavirenz	B-Drug
      
Anticonvulsants	B-Group
(	O
carbamazepine	B-Drug
felbamate	B-Drug
phenobarbital	B-Drug
phenytoin	B-Drug
topiramate	B-Drug
)	O
:	O
Increase	O
the	O
metabolism	O
of	O
ethinyl	B-Drug
estradiol	I-Drug
and	O
/	O
or	O
some	O
progestins	B-Group
leading	O
to	O
possible	O
decrease	O
in	O
contraceptive	O
effectiveness	O
.	O
      
Patients	O
who	O
have	O
been	O
treated	O
with	O
MAO	B-Group
inhibitors	I-Group
within	O
two	O
to	O
three	O
weeks	O
prior	O
to	O
the	O
administration	O
of	O
dopamine	B-Drug
HCl	I-Drug
should	O
receive	O
initial	O
doses	O
of	O
dopamine	B-Drug
HCl	I-Drug
no	O
greater	O
than	O
one	O
-	O
tenth	O
(	O
9	O
/	O
9	O
)	O
of	O
the	O
usual	O
dose	O
.	O
      
Because	O
of	O
the	O
risk	O
of	O
serious	O
ventricular	O
arrhythmias	O
and	O
sudden	O
death	O
potentially	O
associated	O
with	O
elevated	O
plasma	O
levels	O
of	O
thioridazine	B-Drug
Duloxetine	B-Drug
and	O
thioridazine	B-Drug
should	O
not	O
be	O
co	O
-	O
administered	O
.	O
      
Concomitant	O
administration	O
of	O
drugs	O
known	O
to	O
inhibit	O
the	O
activity	O
of	O
cytochrome	O
P9	O
isozymes	O
may	O
increase	O
the	O
plasma	O
levels	O
of	O
clozapine	B-Drug
.	O
      
Ganciclovir	B-Drug
:	O
The	O
pharmacokinetics	O
of	O
foscarnet	B-Drug
and	O
ganciclovir	B-Drug
were	O
not	O
altered	O
in	O
9	O
patients	O
receiving	O
either	O
concomitant	O
therapy	O
or	O
daily	O
alternating	O
therapy	O
for	O
maintenance	O
of	O
CMV	O
disease	O
.	O
      
9	O
minutes	O
(	O
9	O
-	O
9	O
n=9	O
)	O
without	O
succinylcholine	B-Drug
.	O
      
This	O
response	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
.	O
      
Reductions	O
in	O
serum	O
endogenous	O
vitamin	O
D	O
concentrations	O
have	O
been	O
observed	O
following	O
the	O
administration	O
of	O
9	O
mg	O
/	O
day	O
to	O
9	O
mg	O
/	O
day	O
ketoconazole	B-Drug
for	O
a	O
week	O
to	O
healthy	O
men	O
.	O
      
Increased	O
plasma	O
concentrations	O
of	O
terfenadine	B-Drug
astemizole	B-Drug
and	O
cisapride	B-Drug
cause	O
QT	O
prolongation	O
and	O
have	O
been	O
associated	O
with	O
torsades	O
de	O
pointes	O
-	O
type	O
ventricular	O
tachycardia	O
sometimes	O
fatal	O
.	O
      
AUCss	O
(	O
9	O
-	O
9h	O
)	O
(	O
Extent	O
of	O
systemic	O
exposure	O
)	O
      
Alpha	B-Group
-	O
blockers	I-Group
:	O
When	O
Vardenafil	B-Drug
9	O
or	O
9	O
mg	O
was	O
given	O
to	O
healthy	O
volunteers	O
either	O
simultaneously	O
or	O
9	O
hours	O
after	O
a	O
9	O
mg	O
dose	O
of	O
terazosin	B-Drug
significant	O
hypotension	O
developed	O
in	O
a	O
substantial	O
number	O
of	O
subjects	O
.	O
      
Ketoconazole	B-Drug
-	O
Combined	O
administration	O
of	O
racemic	O
citalopram	B-Drug
(	O
9	O
mg	O
)	O
and	O
ketoconazole	B-Drug
(	O
9	O
mg	O
)	O
decreased	O
the	O
Cmax	O
and	O
AUC	O
of	O
ketoconazole	B-Drug
by	O
9	O
%	O
and	O
9	O
%	O
respectively	O
and	O
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
citalopram	B-Drug
.	O
      
Aspirin	B-Brand
should	O
be	O
used	O
cautiously	O
in	O
conjunction	O
with	O
corticosteroids	B-Group
in	O
patients	O
suffering	O
from	O
hypoprothrombinemia	O
.	O
      
Phenothiazine	B-Group
-	O
related	I-Group
compounds	I-Group
and	O
beta	B-Group
-	O
adrenergic	I-Group
blocking	I-Group
agents	I-Group
may	O
have	O
additive	O
hypotensite	O
effects	O
due	O
to	O
the	O
inhibition	O
of	O
each	O
other	O
metabolism	O
.	O
      
Based	O
on	O
clinical	O
and	O
pharmacokinetic	O
results	O
from	O
the	O
ATAC	O
trial	O
tamoxifen	B-Drug
should	O
not	O
be	O
administered	O
with	O
anastrozole	B-Drug
(	O
see	O
CLINICAL	O
PHARMACOLOGY	O
Drug	O
Interactions	O
and	O
CLINICAL	O
PHARMACOLOGY	O
-	O
Clinical	O
Studies	O
-	O
Adjuvant	O
Treatment	O
of	O
Breast	O
Cancer	O
in	O
Postmenopausal	O
Women	O
subsections	O
)	O
.	O
      
Isoproterenol	B-Drug
alone	O
at	O
a	O
dose	O
of	O
9	O
mg	O
/	O
kg	O
/	O
day	O
(	O
approximately	O
9	O
times	O
the	O
maximum	O
recommended	O
daily	O
inhalation	O
dose	O
in	O
adults	O
on	O
a	O
mg	O
/	O
m9	O
basis	O
)	O
increased	O
both	O
resorptions	O
and	O
malformations	O
.	O
      
Amprenavir	B-Drug
inhibits	O
CYP9A9	O
.	O
      
Probenecid	B-Drug
:	O
Concomitant	O
administration	O
of	O
TORADOL	B-Brand
ORAL	O
and	O
probenecid	B-Drug
resulted	O
in	O
decreased	O
clearance	O
of	O
ketorolac	B-Drug
and	O
significant	O
increases	O
in	O
ketorolac	B-Drug
plasma	O
levels	O
(	O
total	O
AUC	O
increased	O
approximately	O
threefold	O
from	O
9	O
to	O
9	O
m	O
g	O
/	O
h	O
/	O
mL	O
)	O
and	O
terminal	O
half	O
-	O
life	O
increased	O
approximately	O
twofold	O
from	O
9	O
to	O
9	O
hours	O
.	O
      
Lithium	B-Drug
:	O
Lithium	B-Drug
toxicity	O
has	O
been	O
reported	O
in	O
patients	O
receiving	O
lithium	B-Drug
concomitantly	O
with	O
drugs	O
which	O
cause	O
elimination	O
of	O
sodium	O
including	O
ACE	B-Group
inhibitors	I-Group
.	O
      
Phenothiazines	B-Group
and	O
butyrophenones	B-Group
may	O
reduce	O
or	O
reverse	O
the	O
pressor	O
effect	O
of	O
epinephrine	B-Drug
.	O
      
Special	O
care	O
is	O
required	O
if	O
this	O
drug	O
is	O
given	O
to	O
patients	O
receiving	O
ganglion	B-Group
blocking	I-Group
compounds	I-Group
because	O
a	O
critical	O
fall	O
in	O
blood	O
pressure	O
may	O
occur	O
.	O
      
rifabutin	B-Drug
concentration	O
      
(	O
Concurrent	O
use	O
with	O
thiazide	B-Group
diuretics	I-Group
may	O
intensify	O
electrolyte	O
imbalance	O
particularly	O
hypokalemia	O
.	O
)	O
      
This	O
is	O
especially	O
important	O
in	O
patients	O
who	O
may	O
use	O
alcohol	B-Drug
excessively	O
.	O
      
SPIRIVA	B-Brand
has	O
been	O
used	O
concomitantly	O
with	O
other	O
drugs	O
commonly	O
used	O
in	O
COPD	O
without	O
increases	O
in	O
adverse	O
drug	O
reactions	O
.	O
      
death	O
cardiac	O
arrest	O
and	O
ventricular	O
arrhythmia	O
including	O
torsades	O
de	O
pointes	O
.	O
      
If	O
a	O
patient	O
requires	O
TIKOSYN	B-Brand
and	O
anti	B-Group
-	O
ulcer	I-Group
therapy	O
it	O
is	O
suggested	O
that	O
omeprazole	B-Drug
ranitidine	B-Drug
or	O
antacids	B-Group
(	O
aluminum	B-Drug
and	O
magnesium	B-Drug
hydroxides	I-Drug
)	O
be	O
used	O
as	O
alternatives	O
to	O
cimetidine	B-Drug
as	O
these	O
agents	O
have	O
no	O
effect	O
on	O
the	O
pharmacokinetic	O
profile	O
of	O
TIKOSYN	B-Brand
.	O
      
Nonsteroidal	B-Group
Anti	I-Group
-	O
inflammatory	I-Group
Drugs	I-Group
(	O
NSAIDs	B-Group
)	O
:	O
The	O
concomitant	O
administration	O
of	O
a	O
nonsteroidal	B-Group
anti	I-Group
inflammatory	I-Group
drug	I-Group
with	O
a	O
quinolone	B-Group
may	O
increase	O
the	O
risks	O
of	O
CNS	O
stimulation	O
and	O
convulsions	O
.	O
      
Moreover	O
as	O
noted	O
with	O
alprazolam	B-Drug
the	O
effect	O
of	O
fluvoxamine	B-Drug
may	O
even	O
be	O
more	O
pronounced	O
when	O
it	O
is	O
administered	O
at	O
higher	O
doses	O
.	O
      
In	O
extremely	O
acidic	O
conditions	O
Duloxetine	B-Drug
unprotected	O
by	O
the	O
enteric	O
coating	O
may	O
undergo	O
hydrolysis	O
to	O
form	O
naphthol	O
.	O
      
Patients	O
on	O
rifampin	B-Drug
should	O
receive	O
9	O
mg	O
of	O
CANCIDAS	B-Brand
daily	O
.	O
      
This	O
information	O
should	O
be	O
considered	O
when	O
changing	O
from	O
intravenous	O
amiodarone	B-Drug
to	O
oral	O
amiodarone	B-Drug
.	O
      
No	O
information	O
is	O
available	O
.	O
      
Fulvestrant	B-Drug
was	O
not	O
mutagenic	O
or	O
clastogenic	O
in	O
multiple	O
in	O
vitro	O
tests	O
with	O
and	O
without	O
the	O
addition	O
of	O
a	O
mammalian	O
liver	O
metabolic	O
activation	O
factor	O
(	O
bacterial	O
mutation	O
assay	O
in	O
strains	O
of	O
Salmonella	O
typhimurium	O
and	O
Escherichia	O
coli	O
in	O
vitro	O
cytogenetics	O
study	O
in	O
human	O
lymphocytes	O
mammalian	O
cell	O
mutation	O
assay	O
in	O
mouse	O
lymphoma	O
cells	O
and	O
in	O
vivo	O
micronucleus	O
test	O
in	O
rat	O
.	O
      
This	O
resulted	O
in	O
a	O
decrease	O
in	O
t9	O
/	O
9	O
from	O
9	O
hours	O
to	O
9	O
hours	O
and	O
a	O
9	O
%	O
reduction	O
in	O
AUC	O
.	O
      
Inhibition	O
of	O
CYP9D9	O
was	O
observed	O
with	O
an	O
apparent	O
Ki	O
of	O
9	O
uM	O
indicating	O
that	O
pramipexole	B-Drug
will	O
not	O
inhibit	O
CYP	O
enzymes	O
at	O
plasma	O
concentrations	O
observed	O
following	O
the	O
highest	O
recommended	O
clinical	O
dose	O
(	O
9	O
mg	O
tid	O
)	O
.	O
      
Disulfiram	B-Drug
alone	O
in	O
the	O
rat	O
diet	O
did	O
not	O
lead	O
to	O
such	O
tumors	O
.	O
      
Ketoconazole	B-Drug
:	O
Ketoconazole	B-Drug
may	O
inhibit	O
both	O
synthetic	O
and	O
catabolic	O
enzymes	O
of	O
vitamin	B-Group
D	I-Group
.	O
      
Concomitant	O
use	O
of	O
other	O
9	O
-	O
HT9B	O
/	O
9D	O
agonists	O
within	O
9	O
hours	O
of	O
FROVA	B-Brand
treatment	O
is	O
not	O
recommended	O
.	O
      
The	O
bioavailability	O
of	O
SKELID	B-Brand
is	O
decreased	O
9	O
%	O
by	O
calcium	B-Drug
when	O
calcium	B-Drug
and	O
SKELID	B-Brand
are	O
administered	O
at	O
the	O
same	O
time	O
and	O
9	O
%	O
by	O
some	O
aluminum	B-Drug
-	O
or	O
magnesium	B-Drug
-	O
containing	O
antacids	B-Drug
when	O
administered	O
9	O
hour	O
before	O
SKELID	B-Brand
.	O
      
In	O
a	O
study	O
of	O
9	O
HIV	O
-	O
infected	O
patients	O
receiving	O
methadone	B-Drug
-	O
maintenance	O
therapy	O
(	O
9	O
mg	O
and	O
9	O
mg	O
daily	O
)	O
with	O
9	O
mg	O
of	O
ZIAGEN	B-Brand
twice	O
daily	O
(	O
twice	O
the	O
currently	O
recommended	O
dose	O
)	O
oral	O
methadone	B-Drug
clearance	O
increased	O
9	O
%	O
(	O
9	O
%	O
CI	O
9	O
%	O
to	O
9	O
%	O
)	O
.	O
      
In	O
vitro	O
data	O
in	O
human	O
plasma	O
indicate	O
that	O
doxazosin	B-Drug
mesylate	I-Drug
has	O
no	O
effect	O
on	O
protein	O
binding	O
of	O
digoxin	B-Drug
warfarin	B-Drug
phenytoin	B-Drug
or	O
indomethacin	B-Drug
.	O
      
Cimetidine	B-Drug
increased	O
AUC	O
by	O
about	O
9	O
%	O
but	O
caused	O
no	O
change	O
in	O
Cmax	O
.	O
      
The	O
interaction	O
of	O
Retavase	B-Brand
with	O
other	O
cardioactive	O
drugs	O
has	O
not	O
been	O
studied	O
.	O
      
Acitretin	B-Drug
:	O
Interferes	O
with	O
the	O
contraceptive	O
effect	O
of	O
microdosed	O
progestin	B-Group
-	O
containing	O
minipill	O
preparations	O
.	O
      
Deferasirox	B-Drug
should	O
be	O
taken	O
on	O
an	O
empty	O
stomach	O
9	O
minutes	O
before	O
eating	O
.	O
      
Acidifying	B-Group
agents	I-Group
:	O
Gastrointestinal	B-Group
acidifying	I-Group
agents	I-Group
(	O
guanethidine	B-Drug
reserpine	B-Drug
glutamic	B-Drug
acid	I-Drug
HCl	I-Drug
ascorbic	B-Drug
acid	I-Drug
fruit	O
juices	O
etc	O
.	O
)	O
lower	O
absorption	O
of	O
amphetamines	B-Group
.	O
      
Pharmacodynamic	O
Interactions	O
:	O
The	O
CNS	O
-	O
depressant	O
action	O
of	O
the	O
benzodiazepine	B-Group
class	I-Group
of	O
drugs	O
may	O
be	O
potentiated	O
by	O
alcohol	B-Drug
narcotics	B-Group
barbiturates	B-Group
nonbarbiturate	B-Group
hypnotics	I-Group
antianxiety	B-Group
agents	I-Group
the	O
phenothiazines	B-Group
thioxanthene	B-Group
and	O
butyrophenone	B-Group
classes	I-Group
of	I-Group
antipsychotic	I-Group
agents	I-Group
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
and	O
the	O
tricyclic	B-Group
antidepressants	I-Group
and	O
by	O
other	O
anticonvulsant	B-Group
drugs	I-Group
.	O
      
morphine	B-Drug
theophylline	B-Drug
aminophylline	B-Drug
succinylcholine	B-Drug
reserpine	B-Drug
and	O
phenothiazine	B-Group
-	O
type	I-Group
tranquilizers	I-Group
should	O
be	O
avoided	O
in	O
patients	O
with	O
organophosphate	O
poisoning	O
.	O
      
MAO	B-Group
Inhibitors	I-Group
:	O
The	O
pressor	O
effect	O
of	O
sympathomimetic	B-Group
pressor	I-Group
amines	I-Group
is	O
markedly	O
potentiated	O
in	O
patients	O
receiving	O
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
(	O
MAOI	B-Group
)	O
.	O
      
Amiodarone	B-Drug
taken	O
concomitantly	O
with	O
digoxin	B-Drug
increases	O
the	O
serum	O
digoxin	B-Drug
concentration	O
by	O
9	O
%	O
after	O
one	O
day	O
.	O
      
In	O
addition	O
studies	O
in	O
healthy	O
volunteers	O
have	O
shown	O
that	O
TIKOSYN	B-Brand
does	O
not	O
affect	O
the	O
pharmacokinetics	O
or	O
pharmacodynamics	O
of	O
warfarin	B-Drug
or	O
the	O
pharmacokinetics	O
of	O
propranolol	B-Drug
(	O
9	O
mg	O
twice	O
daily	O
)	O
phenytoin	B-Drug
theophylline	B-Drug
or	O
oral	O
contraceptives	B-Group
.	O
      
Concomitant	O
treatment	O
with	O
methylxanthines	B-Group
(	O
aminophylline	B-Drug
theophylline	B-Drug
)	O
steroids	B-Group
or	O
diuretics	B-Group
may	O
potentiate	O
any	O
hypokalemic	O
effect	O
of	O
adrenergic	B-Group
agonists	I-Group
.	O
      
Cimetidine	B-Drug
increased	O
the	O
AUC	O
of	O
epirubicin	B-Drug
by	O
9	O
%	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
The	O
urine	O
of	O
patients	O
who	O
take	O
Lodine	B-Brand
can	O
give	O
a	O
false	O
-	O
positive	O
reaction	O
for	O
urinary	O
bilirubin	O
(	O
urobilin	O
)	O
due	O
to	O
the	O
presence	O
of	O
phenolic	O
metabolites	O
of	O
etodolac	B-Drug
.	O
      
Benazepril	B-Drug
like	O
other	O
ACE	B-Group
inhibitors	I-Group
has	O
had	O
less	O
than	O
additive	O
effects	O
with	O
beta	B-Group
-	O
adrenergic	I-Group
blockers	I-Group
presumably	O
because	O
both	O
drugs	O
lower	O
blood	O
pressure	O
by	O
inhibiting	O
parts	O
of	O
the	O
renin	O
-	O
angiotensin	O
system	O
      
It	O
is	O
desirable	O
to	O
monitor	O
TCA	B-Group
plasma	O
levels	O
whenever	O
a	O
TCA	B-Group
is	O
going	O
to	O
be	O
co	O
-	O
administered	O
with	O
another	O
drug	O
known	O
to	O
be	O
an	O
inhibitor	O
of	O
P9	O
9D9	O
.	O
      
Estrogens	B-Group
including	O
oral	O
contraceptives	B-Group
:	O
Estrogens	B-Group
may	O
decrease	O
the	O
hepatic	O
metabolism	O
of	O
certain	O
corticosteroids	B-Group
thereby	O
increasing	O
their	O
effect	O
.	O
      
Cyclosporine	B-Drug
:	O
Elevated	O
serum	O
levels	O
of	O
cyclosporine	B-Drug
have	O
been	O
reported	O
with	O
concomitant	O
use	O
of	O
cyclosporine	B-Drug
with	O
other	O
members	O
of	O
the	O
quinolone	B-Group
class	I-Group
.	O
      
Therefore	O
if	O
digoxin	B-Drug
is	O
administered	O
with	O
VAPRISOL	B-Brand
the	O
clinician	O
should	O
be	O
alert	O
to	O
the	O
possibility	O
of	O
increases	O
in	O
digoxin	B-Drug
levels	O
.	O
      
Caution	O
is	O
advised	O
when	O
beginning	O
discontinuing	O
or	O
changing	O
the	O
dose	O
of	O
DIAMOX	B-Brand
in	O
patients	O
receiving	O
primidone	B-Drug
.	O
      
Digoxin	B-Drug
:	O
Meloxicam	B-Drug
9	O
mg	O
once	O
daily	O
for	O
9	O
days	O
did	O
not	O
alter	O
the	O
plasma	O
concentration	O
profile	O
of	O
digoxin	B-Drug
after	O
b	O
-	O
acetyldigoxin	O
administration	O
for	O
9	O
days	O
at	O
clinical	O
doses	O
.	O
      
Nelfinavir	B-Drug
is	O
metabolized	O
in	O
proof	O
by	O
C.P.A	O
.	O
      
Drugs	O
which	O
may	O
potentiate	O
the	O
myeloproliferative	O
effects	O
of	O
Leukine	B-Brand
such	O
as	O
lithium	B-Drug
and	O
corticosteroids	B-Group
should	O
be	O
used	O
with	O
caution	O
.	O
      
In	O
vitro	O
studies	O
have	O
shown	O
no	O
binding	O
displacement	O
between	O
entacapone	B-Drug
and	O
other	O
highly	O
bound	O
drugs	O
such	O
as	O
warfarin	B-Drug
salicylic	B-Drug
acid	I-Drug
phenylbutazone	B-Drug
and	O
diazepam	B-Drug
.	O
      
Cimetidine	B-Drug
caffeine	B-Drug
and	O
erythromycin	B-Drug
may	O
increase	O
plasma	O
levels	O
of	O
Clozapine	B-Drug
potentially	O
resulting	O
in	O
adverse	O
effects	O
.	O
      
The	O
action	O
of	O
colchicine	B-Drug
is	O
potentiated	O
by	O
alkalinizing	B-Group
agents	I-Group
.	O
      
No	O
interaction	O
was	O
noted	O
with	O
the	O
MAO	B-Group
-	O
B	I-Group
inhibitor	I-Group
selegiline	B-Drug
in	O
two	O
multiple	O
-	O
dose	O
interaction	O
studies	O
when	O
entacapone	B-Drug
was	O
coadministered	O
with	O
a	O
levodopa	B-Drug
/	O
dopa	B-Group
decarboxylase	I-Group
inhibitor	I-Group
(	O
n=9	O
)	O
.	O
      
Therefore	O
close	O
monitoring	O
of	O
serum	O
cyclosporin	B-Drug
level	O
is	O
recommended	O
and	O
if	O
necessary	O
chloroquine	B-Drug
should	O
be	O
discontinued	O
.	O
      
Oral	O
anticoagulants	B-Group
decreased	O
prothrombin	O
time	O
response	O
.	O
      
In	O
addition	O
certain	O
drugs	O
inhibit	O
the	O
activity	O
of	O
this	O
isozyme	O
and	O
make	O
normal	O
metabolizers	O
resemble	O
poor	O
metabolizers	O
.	O
      
The	O
effects	O
of	O
allopurinol	B-Drug
on	O
didanosine	B-Drug
pharmacokinetics	O
in	O
subjects	O
with	O
normal	O
renal	O
function	O
are	O
not	O
known	O
.	O
      
Wait	O
9	O
weeks	O
after	O
stopping	O
escitalopram	B-Drug
before	O
starting	O
a	O
non	B-Group
-	O
selective	I-Group
MAO	I-Group
inhibitor	I-Group
.	O
      
Other	O
Cardiovascular	O
Agents	O
:	O
Enalapril	B-Drug
and	O
enalapril	B-Drug
IV	O
have	O
been	O
used	O
concomitantly	O
with	O
beta	B-Group
adrenergic	I-Group
-	O
blocking	I-Group
agents	I-Group
methyldopa	B-Drug
nitrates	B-Group
calcium	B-Group
-	O
blocking	I-Group
agents	I-Group
hydralazine	B-Drug
prazosin	B-Drug
and	O
digoxin	B-Drug
without	O
evidence	O
of	O
clinically	O
significant	O
adverse	O
interactions	O
.	O
      
The	O
combined	O
use	O
of	O
fluconazole	B-Drug
with	O
cisapride	B-Drug
is	O
contraindicated	O
.	O
      
Saquinavir	B-Drug
steady	O
-	O
state	O
Cmax	O
A.C.	O
and	O
Cmin	O
were	O
increased	O
9	O
%	O
decreased	O
9	O
%	O
and	O
decreased	O
9	O
%	O
respectively	O
by	O
concomitant	O
amprenavir	B-Drug
.	O
      
Drug	O
/	O
Laboratory	O
test	O
interactions	O
Anabolic	B-Drug
steroids	I-Drug
may	O
decrease	O
levels	O
of	O
thyroxine	O
-	O
binding	O
globulin	O
resulting	O
in	O
decreased	O
total	O
T9	O
serum	O
levels	O
and	O
increased	O
resin	O
uptake	O
of	O
T9	O
and	O
T9	O
.	O
      
Table	O
9	O
Changes	O
in	O
Desloratadine	B-Drug
and	O
9	B-Drug_n
-	O
Hydroxydesloratadine	I-Drug_n
Pharmacokinetics	O
in	O
Healthy	O
Male	O
and	O
Female	O
Volunteers	O
      
Coadministration	O
of	O
digoxin	B-Drug
did	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
levetiracetam	B-Drug
.	O
      
Depending	O
on	O
the	O
fraction	O
of	O
drug	O
metabolized	O
by	O
P9	O
9D9	O
the	O
increase	O
in	O
plasma	O
concentration	O
may	O
be	O
small	O
or	O
quite	O
large	O
(	O
9	O
fold	O
increase	O
in	O
plasma	O
AUC	O
of	O
the	O
TCA	B-Group
)	O
.	O
      
CPK	O
:	O
Some	O
patients	O
undergoing	O
vigorous	O
physical	O
activity	O
while	O
on	O
Accutane	B-Brand
therapy	O
have	O
experienced	O
elevated	O
CPK	O
levels	O
;	O
      
Pharmacokinetic	O
studies	O
document	O
no	O
clinically	O
relevant	O
interactions	O
with	O
other	O
agents	O
given	O
concomitantly	O
including	O
thiazide	B-Group
diuretics	I-Group
digoxin	B-Drug
and	O
cimetidine	B-Drug
.	O
      
Drugs	O
Metabolized	O
by	O
Cytochrome	O
P9D9	O
-	O
In	O
vitro	O
studies	O
did	O
not	O
reveal	O
an	O
inhibitory	O
effect	O
of	O
escitalopram	B-Drug
on	O
CYP9D9	O
.	O
      
Co	O
-	O
administration	O
with	O
efavirenz	B-Drug
or	O
fluconazole	B-Drug
had	O
a	O
modest	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
azithromycin	B-Drug
.	O
      
Although	O
there	O
are	O
no	O
study	O
data	O
to	O
evaluate	O
the	O
possibility	O
nitric	B-Group
oxide	I-Group
donor	I-Group
compounds	I-Group
including	O
sodium	B-Drug
nitroprusside	I-Drug
and	O
nitroglycerin	B-Drug
may	O
have	O
an	O
additive	O
effect	O
with	O
INOmax	B-Brand
on	O
the	O
risk	O
of	O
developing	O
methemoglobinemia	O
.	O
      
Both	O
groups	O
of	O
agents	O
lower	O
blood	O
levels	O
and	O
efficacy	O
of	O
amphetamines	B-Group
.	O
      
Saquinavir	B-Drug
:	O
The	O
combination	O
of	O
HIVID	B-Drug
saquinavir	B-Drug
and	O
ZDV	B-Drug
has	O
been	O
studied	O
(	O
as	O
triple	O
combination	O
)	O
in	O
adults	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
:	O
The	O
administration	O
of	O
CEFOTAN	B-Brand
may	O
result	O
in	O
a	O
false	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
using	O
Clinitest	O
Benedicts	O
solution	O
or	O
Fehlings	O
solution	O
.	O
      
Cimetidine	B-Drug
has	O
been	O
shown	O
to	O
increase	O
the	O
bioavailability	O
of	O
labetalol	B-Drug
HCl	I-Drug
.	O
      
dermatitis	O
      
In	O
patients	O
receiving	O
a	O
potent	O
CYP9A9	O
inducer	O
such	O
as	O
rifampicin	B-Drug
or	O
phenytoin	B-Drug
a	O
dose	O
increase	O
to	O
9	O
mg	O
daily	O
should	O
be	O
considered	O
in	O
the	O
absence	O
of	O
severe	O
adverse	O
drug	O
reaction	O
and	O
clinical	O
response	O
and	O
adverse	O
events	O
should	O
be	O
carefully	O
monitored	O
(	O
see	O
CLINICAL	O
PHARMACOLOGY	O
-	O
Pharmacokinetics	O
-	O
Drug	O
-	O
Drug	O
Interactions	O
and	O
DOSAGE	O
AND	O
ADMINISTRATION	O
-	O
Dosage	O
Adjustment	O
sections	O
)	O
.	O
      
Therefore	O
when	O
Hydrochlorothiazide	B-Drug
and	O
non	B-Group
-	O
steroidal	I-Group
anti	I-Group
-	O
inflammatory	I-Group
agents	I-Group
are	O
used	O
concomitantly	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	B-Group
is	O
obtained	O
.	O
      
Other	O
CNS	B-Group
depressant	I-Group
drugs	I-Group
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
taking	O
fenfluramine	B-Drug
since	O
the	O
effects	O
may	O
be	O
additive	O
.	O
      
The	O
drugs	O
that	O
inhibit	O
cytochrome	O
P9	O
9D9	O
include	O
some	O
that	O
are	O
not	O
metabolized	O
by	O
the	O
enzyme	O
(	O
quinidine	B-Drug
;	O
      
Separating	O
the	O
doses	O
of	O
antacid	B-Group
and	O
lomefloxacin	B-Drug
minimizes	O
this	O
decrease	O
in	O
bioavailability	O
;	O
      
however	O
no	O
specific	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
to	O
evaluate	O
potential	O
drug	O
-	O
drug	O
interaction	O
.	O
      
Veratrum	B-Group
alkaloids	I-Group
:	O
Amphetamines	B-Group
inhibit	O
the	O
hypotensive	O
effect	O
of	O
veratrum	B-Group
alkaloids	I-Group
.	O
      
Flucytosine	B-Drug
:	O
while	O
a	O
synergistic	O
relationship	O
with	O
amphotericin	B-Drug
B	I-Drug
has	O
been	O
reported	O
concomitant	O
use	O
may	O
increase	O
the	O
toxicity	O
of	O
flucytosine	B-Drug
by	O
possibly	O
increasing	O
its	O
cellular	O
uptake	O
and	O
/	O
or	O
impairing	O
its	O
renal	O
excretion	O
.	O
      
An	O
interaction	O
study	O
with	O
warfarin	B-Drug
showed	O
no	O
clinically	O
significant	O
effect	O
of	O
anastrozole	B-Drug
on	O
warfarin	B-Drug
pharmacokinetics	O
or	O
anticoagulant	O
activity	O
.	O
      
Ranitidine	B-Drug
9	O
mg	O
twice	O
daily	O
did	O
not	O
interact	O
significantly	O
with	O
nisoldipine	B-Drug
(	O
AUC	O
was	O
decreased	O
by	O
9	O
-	O
9	O
%	O
)	O
.	O
      
Careful	O
observation	O
is	O
required	O
when	O
amantadine	B-Drug
is	O
administered	O
concurrently	O
with	O
central	B-Group
nervous	I-Group
system	I-Group
stimulants	I-Group
.	O
      
Carbamazepine	B-Drug_n
epoxide	I-Drug_n
steady	O
-	O
state	O
Cmin	O
concentrations	O
increased	O
9	O
%	O
from	O
9	O
9	O
to	O
9	O
9	O
micrograms	O
/	O
mL	O
with	O
the	O
addition	O
of	O
felbamate	B-Drug
.	O
      
Coadministration	O
of	O
VIDEX	B-Brand
with	O
drugs	O
that	O
are	O
known	O
to	O
cause	O
pancreatitis	O
may	O
increase	O
the	O
risk	O
of	O
this	O
toxicity	O
(	O
see	O
WARNINGS	O
)	O
and	O
should	O
be	O
done	O
with	O
extreme	O
caution	O
only	O
if	O
other	O
alternatives	O
are	O
not	O
available	O
and	O
only	O
if	O
clearly	O
indicated	O
.	O
      
These	O
doses	O
are	O
lower	O
than	O
the	O
therapeutic	O
doses	O
for	O
both	O
drugs	O
.	O
      
There	O
is	O
no	O
known	O
drug	O
interference	O
with	O
standard	O
clinical	O
laboratory	O
tests	O
.	O
      
Digitalis	B-Group
glycosides	I-Group
:	O
amphotericin	B-Drug
B	I-Drug
-	O
induced	O
hypokalemia	O
may	O
potentiate	O
digitalis	B-Group
toxicity	O
.	O
      
Administration	O
of	O
repeat	O
doses	O
of	O
FACTIVE	B-Brand
had	O
no	O
effect	O
on	O
the	O
repeat	O
dose	O
pharmacokinetics	O
of	O
theophylline	B-Drug
digoxin	B-Drug
or	O
an	O
ethinylestradiol	B-Drug
/	O
levonorgestrol	O
oral	O
contraceptive	B-Group
product	I-Group
in	O
healthy	O
subjects	O
.	O
      
The	O
safety	O
and	O
efficacy	O
of	O
PROLEUKIN	B-Brand
in	O
combination	O
with	O
any	O
antineoplastic	B-Group
agents	I-Group
have	O
not	O
been	O
established	O
.	O
      
Clinically	O
or	O
potentially	O
significant	O
drug	O
interactions	O
between	O
DIFLUCAN	B-Brand
and	O
the	O
following	O
agents	O
/	O
classes	O
have	O
been	O
observed	O
.	O
      
In	O
a	O
similar	O
study	O
attempting	O
to	O
replicate	O
this	O
finding	O
no	O
interactive	O
effect	O
on	O
hepatic	O
transaminases	O
was	O
identified	O
.	O
      
Opioids	B-Group
are	O
strong	O
central	B-Group
nervous	I-Group
system	I-Group
depressants	I-Group
but	O
regular	O
users	O
develop	O
physiological	O
tolerance	O
allowing	O
gradually	O
increased	O
dosages	O
.	O
      
-	O
did	O
not	O
change	O
the	O
pharmacokinetic	O
profile	O
of	O
warfarin	B-Drug
(	O
a	O
substrate	O
of	O
cytochromes	O
P9	O
9A9	O
and	O
9C9	O
)	O
or	O
influence	O
the	O
effect	O
of	O
a	O
single	O
9	O
-	O
mg	O
oral	O
dose	O
of	O
warfarin	B-Drug
on	O
prothrombin	O
time	O
or	O
the	O
INR	O
(	O
International	O
Normalized	O
Ratio	O
)	O
.	O
      
FREQUENT	O
PROTHROMBIN	O
TIME	O
/	O
INR	O
DETERMINATIONS	O
ARE	O
ADVISABLE	O
UNTIL	O
IT	O
HAS	O
BEEN	O
DEFINITELY	O
DETERMINED	O
THAT	O
THE	O
PROTHROMBIN	O
TIME	O
/	O
INR	O
HAS	O
STABILIZED	O
.	O
      
Therefore	O
patients	O
without	O
a	O
functioning	O
thyroid	B-Group
gland	O
who	O
are	O
on	O
thyroid	O
replacement	O
therapy	O
may	O
need	O
to	O
increase	O
their	O
thyroid	O
dose	O
if	O
estrogens	B-Group
or	O
estrogen	B-Group
-	O
containing	O
oral	O
contraceptives	B-Group
are	O
given	O
.	O
      
Beta	B-Group
adrenergic	I-Group
agonists	I-Group
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
being	O
treated	O
with	O
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
or	O
tricyclic	B-Group
antidepressants	I-Group
since	O
the	O
action	O
of	O
beta	B-Group
adrenergic	I-Group
agonists	I-Group
on	O
the	O
vascular	O
system	O
may	O
be	O
potentiated	O
.	O
      
The	O
anesthesiologist	O
should	O
be	O
informed	O
when	O
a	O
patient	O
is	O
receiving	O
labetalol	B-Drug
HCl	I-Drug
.	O
      
The	O
following	O
similar	O
changes	O
may	O
be	O
expected	O
with	O
larger	O
doses	O
of	O
estrogen	B-Group
:	O
-	O
Increased	O
sulfobromophthalein	O
retention	O
      
Protease	B-Group
inhibitors	I-Group
:	O
Amprenavir	B-Drug
lopinavir	B-Drug
nelfinavir	B-Drug
and	O
ritonavir	B-Drug
have	O
been	O
shown	O
to	O
decrease	O
plasma	O
levels	O
of	O
combination	B-Group
hormonal	I-Group
contraceptives	I-Group
;	O
      
It	O
is	O
desirable	O
to	O
monitor	O
TCA	B-Group
plasma	O
levels	O
whenever	O
an	O
agent	O
of	O
the	O
tricyclic	B-Group
antidepressant	I-Group
class	I-Group
including	O
Anafranil	B-Brand
is	O
going	O
to	O
be	O
co	O
-	O
administered	O
with	O
another	O
drug	O
known	O
to	O
be	O
an	O
inhibitor	O
of	O
P9	O
9D9	O
(	O
and	O
/	O
or	O
P9	O
9A9	O
)	O
.	O
      
-	O
Increased	O
thyroid	O
-	O
binding	O
globulin	O
(	O
TBG	O
)	O
leading	O
to	O
in	O
-	O
creased	O
circulating	O
total	O
thyroid	O
hormone	O
;	O
      
Therefore	O
increased	O
monitoring	O
of	O
digoxin	B-Drug
is	O
recommended	O
when	O
initiating	O
adjusting	O
or	O
discontinuing	O
COREG	B-Brand
.	O
      
Until	O
data	O
on	O
possible	O
interactions	O
between	O
verapamil	B-Drug
and	O
disopyramide	B-Drug
phosphate	I-Drug
are	O
obtained	O
disopyramide	B-Drug
should	O
not	O
be	O
administered	O
within	O
9	O
hours	O
before	O
or	O
9	O
hours	O
after	O
verapamil	B-Drug
administration	O
.	O
      
There	O
have	O
been	O
no	O
formal	O
clinical	O
studies	O
to	O
evaluate	O
the	O
drug	O
interactions	O
of	O
TAXOTERE	B-Brand
with	O
other	O
medications	O
.	O
      
These	O
effects	O
were	O
not	O
observed	O
when	O
Vardenafil	B-Drug
9	O
mg	O
was	O
taken	O
9	O
hours	O
before	O
the	O
NTG	B-Drug
.	O
      
Coadministration	O
with	O
a	O
high	O
dose	O
of	O
antacid	B-Group
(	O
9	O
mEq	O
)	O
results	O
in	O
a	O
9	O
%	O
decrease	O
in	O
plasma	O
concentrations	O
of	O
ranitidine	B-Drug
and	O
may	O
decrease	O
plasma	O
concentrations	O
of	O
bismuth	O
from	O
TRITEC	B-Brand
.	O
      
Therefore	O
if	O
concomitant	O
administration	O
of	O
these	O
agents	O
is	O
indicated	O
dosing	O
should	O
be	O
separated	O
by	O
9	O
hours	O
.	O
      
Interference	O
of	O
MPAG	B-Drug_n
hydrolysis	O
may	O
lead	O
to	O
less	O
MPA	B-Drug_n
available	O
for	O
absorption	O
.	O
      
In	O
patients	O
who	O
have	O
received	O
muscle	B-Group
relaxants	I-Group
doxapram	B-Drug
may	O
temporarily	O
mask	O
the	O
residual	O
effects	O
of	O
muscle	B-Group
relaxant	I-Group
drugs	I-Group
.	O
      
ALIMTA	B-Brand
is	O
primarily	O
eliminated	O
unchanged	O
renally	O
as	O
a	O
result	O
of	O
glomerular	O
filtration	O
and	O
tubular	O
secretion	O
.	O
      
Imipramine	B-Drug
:	O
Coadministration	O
of	O
single	O
doses	O
of	O
Sonata	B-Brand
9	O
mg	O
and	O
imipramine	B-Drug
9	O
mg	O
produced	O
additive	O
effects	O
on	O
decreased	O
alertness	O
and	O
impaired	O
psychomotor	O
performance	O
for	O
9	O
to	O
9	O
hours	O
after	O
administration	O
.	O
      
Drugs	O
That	O
Are	O
Mainly	O
Metabolized	O
by	O
CYP9A9	O
      
If	O
ZEMURON	B-Brand
is	O
administered	O
following	O
administration	O
of	O
succinylcholine	B-Drug
it	O
should	O
not	O
be	O
given	O
until	O
recovery	O
from	O
succinylcholine	B-Drug
has	O
been	O
observed	O
.	O
      
GI	O
Motility	O
Agent	O
:	O
cisapride	B-Drug
*	O
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
reactions	O
such	O
as	O
cardiac	O
arrhythmias	O
.	O
      
Due	O
to	O
the	O
considerable	O
variability	O
of	O
these	O
interactions	O
the	O
dosage	O
of	O
digoxin	B-Drug
should	O
be	O
individualized	O
when	O
patients	O
receive	O
these	O
medications	O
concurrently	O
.	O
      
Because	O
there	O
is	O
a	O
theoretical	O
basis	O
that	O
these	O
effects	O
may	O
be	O
additive	O
use	O
of	O
ergotamine	B-Drug
-	O
containing	O
or	O
ergot	B-Group
-	O
type	I-Group
medications	I-Group
(	O
like	O
dihydroergotamine	B-Drug
or	O
methysergide	B-Drug
)	O
and	O
AXERT	B-Brand
within	O
9	O
hours	O
of	O
each	O
other	O
should	O
be	O
avoided	O
.	O
      
Furthermore	O
it	O
has	O
been	O
proposed	O
that	O
isoniazid	B-Drug
resulted	O
In	O
induction	O
of	O
P	O
-	O
9IIE9	O
in	O
the	O
patients	O
liver	O
which	O
in	O
turn	O
resulted	O
in	O
a	O
greater	O
proportion	O
of	O
the	O
ingested	O
acetaminophen	B-Drug
being	O
converted	O
to	O
the	O
toxic	O
metabolites	O
.	O
      
Combination	O
therapy	O
should	O
be	O
administered	O
with	O
caution	O
especially	O
in	O
immunocompromised	O
patients	O
.	O
      
Epinephrine	B-Drug
also	O
should	O
be	O
used	O
cautiously	O
with	O
other	O
drugs	O
(	O
e.g.	O
digitalis	B-Group
glycosides	B-Group
)	O
that	O
sensitize	O
the	O
myocardium	O
to	O
the	O
actions	O
of	O
sympathomimetic	B-Group
drugs	I-Group
.	O
      
Co	O
-	O
medications	O
that	O
induce	O
CYP	O
9A9	O
(	O
e.g.	O
rifampicin	B-Drug
phenytoin	B-Drug
carbamazepine	B-Drug
phenobarbital	B-Drug
or	O
St.	O
John	O
wort	O
)	O
may	O
significantly	O
decrease	O
exposure	O
to	O
exemestane	B-Drug
.	O
      
However	O
prudent	O
medical	O
practice	O
dictates	O
careful	O
monitoring	O
of	O
prothrombin	O
time	O
in	O
all	O
patients	O
treated	O
with	O
azithromycin	B-Drug
and	O
warfarin	B-Drug
concomitantly	O
.	O
      
Nevirapine	B-Drug
      
Tricyclic	B-Group
antidepressants	I-Group
may	O
potentiate	O
the	O
cardiovascular	O
effects	O
of	O
adreneric	O
agents	O
.	O
      
Carbamazepine	B-Drug
clonazepam	B-Drug
ethosuximide	B-Drug
      
It	O
is	O
not	O
known	O
which	O
drug	O
clearance	O
mechanism	O
involved	O
in	O
caspofungin	B-Drug
disposition	O
may	O
be	O
inducible	O
.	O
      
Methotrexate	B-Drug
:	O
An	O
increased	O
risk	O
of	O
hepatitis	O
has	O
been	O
reported	O
to	O
result	O
from	O
combined	O
use	O
of	O
methotrexate	B-Drug
and	O
etretinate	B-Drug
.	O
      
Rifabutin	B-Drug
      
In	O
the	O
warfarin	B-Drug
study	O
vardenafil	B-Drug
had	O
no	O
effect	O
on	O
the	O
prothrombin	O
time	O
or	O
other	O
pharmacodynamic	O
parameters	O
.	O
      
However	O
on	O
the	O
basis	O
of	O
available	O
data	O
no	O
dosage	O
adjustment	O
for	O
ondansetron	B-Drug
is	O
recommended	O
for	O
patients	O
on	O
these	O
drugs.9	O
9	O
Tramadol	B-Drug
:	O
Although	O
no	O
pharmacokinetic	O
drug	O
interaction	O
between	O
ondansetron	B-Drug
and	O
tramadol	B-Drug
has	O
been	O
observed	O
data	O
from	O
9	O
small	O
studies	O
indicate	O
that	O
ondansetron	B-Drug
may	O
be	O
associated	O
with	O
an	O
increase	O
in	O
patient	O
controlled	O
administration	O
of	O
tramadol	B-Drug
.9	O
9	O
Chemotherapy	O
:	O
Tumor	O
response	O
to	O
chemotherapy	O
in	O
the	O
P	O
9	O
mouse	O
leukemia	O
model	O
is	O
not	O
affected	O
by	O
ondansetron	B-Drug
.	O
      
No	O
formal	O
clinical	O
studies	O
have	O
been	O
conducted	O
to	O
assess	O
if	O
there	O
is	O
an	O
interactive	O
effect	O
on	O
bone	O
loss	O
between	O
systemic	B-Group
corticosteroids	I-Group
and	O
Accutane	B-Brand
.	O
      
INDOCIN	B-Brand
can	O
reduce	O
the	O
antihypertensive	O
effects	O
of	O
captopril	B-Drug
and	O
losartan	B-Drug
.	O
      
Amphotericin	B-Drug
Foscarnet	B-Drug
and	O
Aminoglycosides	B-Group
:	O
Drugs	O
such	O
as	O
amphotericin	B-Drug
foscarnet	B-Drug
and	O
aminoglycosides	B-Group
may	O
increase	O
the	O
risk	O
of	O
developing	O
peripheral	O
neuropathy	O
or	O
other	O
HIVID	B-Drug
-	O
associated	O
adverse	O
events	O
by	O
interfering	O
with	O
the	O
renal	O
clearance	O
of	O
zalcitabine	B-Drug
(	O
thereby	O
raising	O
systemic	O
exposure	O
)	O
.	O
      
Clinical	O
studies	O
of	O
the	O
effect	O
of	O
strong	O
CYP	O
9A9	O
inhibitors	O
on	O
the	O
pharmacokinetics	O
of	O
fulvestrant	B-Drug
have	O
not	O
been	O
performed	O
.	O
      
Rifampin	B-Drug
      
Limited	O
clinical	O
experience	O
indicates	O
that	O
requirements	O
for	O
volatile	B-Group
inhalation	I-Group
anesthetics	I-Group
are	O
reduced	O
by	O
9	O
to	O
9	O
%	O
for	O
the	O
first	O
sixty	O
(	O
9	O
)	O
minutes	O
following	O
ALFENTA	B-Brand
induction	O
The	O
concomitant	O
use	O
of	O
erythromycin	B-Drug
with	O
ALFENTA	B-Brand
can	O
significantly	O
inhibit	O
ALFENTA	B-Brand
clearance	O
and	O
may	O
increase	O
the	O
risk	O
of	O
prolonged	O
or	O
delayed	O
respiratory	O
depression	O
.	O
      
The	O
pressor	O
response	O
of	O
adrenergic	B-Group
agents	I-Group
may	O
also	O
be	O
potentiated	O
by	O
tricyclic	B-Group
antidepressants	I-Group
.	O
      
In	O
vitro	O
studies	O
demonstrated	O
that	O
the	O
plasma	O
protein	O
binding	O
of	O
des	B-Drug
-	O
ciclesonide	I-Drug
was	O
not	O
affected	O
by	O
warfarin	B-Drug
or	O
salicylic	B-Drug
acid	I-Drug
indicating	O
no	O
potential	O
for	O
protein	O
binding	O
-	O
based	O
drug	O
interactions	O
.	O
      
The	O
urinary	O
excretion	O
of	O
meclofenamate	B-Drug
sodium	I-Drug
is	O
unaffected	O
by	O
aspirin	B-Brand
indicating	O
no	O
change	O
in	O
meclofenamate	B-Drug
sodium	I-Drug
absorption	O
.	O
      
however	O
the	O
clinical	O
significance	O
is	O
unknown	O
.	O
      
Most	O
cases	O
of	O
serious	O
or	O
fatal	O
adverse	O
events	O
involving	O
Levo	B-Brand
-	O
Dromoran	I-Brand
reported	O
to	O
the	O
manufacturer	O
or	O
the	O
FDA	O
have	O
involved	O
either	O
the	O
administration	O
of	O
large	O
initial	O
doses	O
or	O
too	O
frequent	O
doses	O
of	O
the	O
drug	O
to	O
nonopioid	O
tolerant	O
patients	O
or	O
the	O
simultaneous	O
administration	O
of	O
levorphanol	B-Drug
with	O
other	O
drugs	O
affecting	O
respiration	O
.	O
      
Most	O
(	O
9	O
%	O
)	O
of	O
plasma	O
doxazosin	B-Drug
is	O
protein	O
bound	O
.	O
      
Antacids	B-Group
may	O
interfere	O
with	O
the	O
absorption	O
of	O
LEVSIN	B-Brand
.	O
      
Patients	O
receiving	O
high	O
doses	O
of	O
salicylates	B-Group
concomitantly	O
with	O
furosemide	B-Drug
as	O
in	O
rheumatic	O
disease	O
may	O
experience	O
salicylate	B-Group
toxicity	O
at	O
lower	O
doses	O
because	O
of	O
competitive	O
renal	O
excretory	O
sites	O
.	O
      
Depending	O
on	O
the	O
fraction	O
of	O
drug	O
metabolized	O
by	O
P9	O
9D9	O
the	O
increase	O
in	O
plasma	O
concentration	O
may	O
be	O
small	O
or	O
quite	O
large	O
(	O
9	O
-	O
fold	O
increase	O
in	O
plasma	O
AUC	O
of	O
the	O
TCA	B-Group
)	O
.	O
      
Antidiabetic	B-Group
drugs	I-Group
(	O
oral	O
agents	O
and	O
insulin	B-Drug
)	O
:	O
hypoglycemia	O
or	O
hyperglycemia	O
;	O
      
Indomethacin	B-Drug
-	O
Concomitant	O
use	O
of	O
L	B-Drug
-	O
glutamine	I-Drug
and	O
indomethacin	B-Drug
may	O
ameliorate	O
increased	O
intestinal	O
permeability	O
caused	O
by	O
indomethacin	B-Drug
.	O
      
An	O
additive	O
hypotensive	O
effect	O
has	O
been	O
reported	O
with	O
the	O
combination	O
of	O
systemic	O
clonidine	B-Drug
and	O
neuroleptic	B-Group
therapy	O
.	O
      
No	O
adjustment	O
of	O
dosage	O
is	O
recommended	O
in	O
such	O
patients	O
.	O
      
In	O
rats	O
increased	O
incidences	O
of	O
common	O
fetal	O
skeletal	O
findings	O
(	O
extra	O
pair	O
of	O
thoracic	O
ribs	O
unossified	O
cervical	O
vertebral	O
centra	O
shortened	O
ribs	O
)	O
were	O
observed	O
at	O
9	O
mg	O
/	O
kg	O
/	O
day	O
(	O
~9	O
times	O
the	O
human	O
exposure	O
at	O
9	O
mg	O
daily	O
based	O
on	O
AUC9	O
-	O
9hr	O
for	O
total	O
ezetimibe	B-Drug
)	O
.	O
      
A	O
9	O
-	O
mg	O
Vardenafil	B-Drug
dose	O
should	O
not	O
be	O
exceeded	O
when	O
used	O
in	O
combination	O
with	O
9	O
mg	O
once	O
daily	O
ketoconazole	B-Drug
.	O
      
Alprazolam	B-Drug
:	O
When	O
fluvoxamine	B-Drug
maleate	I-Drug
(	O
9	O
mg	O
qd	O
)	O
and	O
alprazolam	B-Drug
(	O
9	O
mg	O
q.d	O
.	O
were	O
co	O
-	O
administered	O
to	O
steady	O
state	O
plasma	O
concentration	O
and	O
other	O
pharmacokinetics	O
parameters	O
(	O
AUC	O
Cmax	O
T9	O
/	O
9	O
)	O
of	O
alprazolam	B-Drug
were	O
approximately	O
twice	O
those	O
observed	O
when	O
alprazolam	B-Drug
was	O
administered	O
alone	O
;	O
      
Because	O
the	O
tetracyclines	B-Group
have	O
been	O
shown	O
to	O
depress	O
plasma	O
prothrombin	O
activity	O
patients	O
who	O
are	O
on	O
anticoagulant	B-Group
therapy	O
may	O
require	O
downward	O
adjustment	O
of	O
their	O
anticoagulant	B-Group
dosage	O
.	O
      
As	O
a	O
result	O
drugs	O
that	O
are	O
metabolized	O
by	O
these	O
enzyme	O
systems	O
may	O
have	O
lower	O
than	O
expected	O
plasma	O
levels	O
when	O
coadministered	O
with	O
nevirapine	B-Drug
.	O
      
The	O
difficulty	O
in	O
achieving	O
adequate	O
sedation	O
may	O
have	O
been	O
the	O
result	O
of	O
decreased	O
absorption	O
of	O
the	O
sedatives	B-Group
due	O
to	O
both	O
the	O
gastrointestinal	O
effects	O
and	O
stimulant	O
effects	O
of	O
methylphenidate	B-Drug
.	O
      
Pharmacokinetics	O
were	O
assessed	O
in	O
two	O
of	O
these	O
trials	O
.	O
      
Combination	O
Therapy	O
:	O
Any	O
form	O
of	O
therapy	O
which	O
adds	O
to	O
the	O
stress	O
of	O
the	O
patient	O
interferes	O
with	O
nutrition	O
or	O
depresses	O
bone	O
marrow	O
function	O
will	O
increase	O
the	O
toxicity	O
of	O
Floxuridine	B-Drug
.	O
      
Halothane	B-Drug
has	O
little	O
or	O
no	O
effect	O
on	O
the	O
ED9	O
but	O
may	O
prolong	O
the	O
duration	O
of	O
action	O
and	O
decrease	O
the	O
average	O
infusion	O
requirement	O
by	O
as	O
much	O
as	O
9	O
%	O
.	O
      
In	O
general	O
if	O
a	O
patient	O
shows	O
no	O
signs	O
of	O
sedation	O
within	O
9	O
hours	O
after	O
a	O
9	O
-	O
mg	O
dose	O
of	O
flumazenil	B-Drug
serious	O
resedation	O
at	O
a	O
later	O
time	O
is	O
unlikely	O
.	O
      
Ocupress	B-Brand
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
who	O
are	O
receiving	O
a	O
beta	B-Group
-	O
adrenergic	I-Group
blocking	I-Group
agent	I-Group
orally	O
because	O
of	O
the	O
potential	O
for	O
additive	O
effects	O
on	O
systemic	O
beta	O
-	O
blockade	O
.	O
      
INDOCIN	B-Brand
and	O
potassium	B-Group
-	O
sparing	I-Group
diuretics	I-Group
each	O
may	O
be	O
associated	O
with	O
increased	O
serum	O
potassium	O
levels	O
.	O
      
Drug	O
-	O
Drug	O
Interactions	O
:	O
No	O
clinically	O
significant	O
drug	O
interactions	O
have	O
been	O
found	O
with	O
theophylline	B-Drug
at	O
a	O
low	O
dose	O
azithromycin	B-Drug
pseudoephedrine	B-Drug
ketoconazole	B-Drug
or	O
erythromycin	B-Drug
.	O
      
and	O
disulfiram	B-Drug
When	O
amitriptyline	B-Drug
HCl	I-Drug
is	O
given	O
with	O
anticholinergic	B-Drug
agents	O
or	O
sympathomimetic	B-Drug
drugs	O
including	O
epinephrine	B-Drug
combined	O
with	O
local	O
anesthetics	B-Drug
close	O
supervision	O
and	O
careful	O
adjustment	O
of	O
dosages	O
are	O
required	O
.	O
      
Terfenadine	B-Drug
:	O
Because	O
of	O
the	O
occurrence	O
of	O
serious	O
cardiac	O
dysrhythmias	O
secondary	O
to	O
prolongation	O
of	O
the	O
QTc	O
interval	O
in	O
patients	O
receiving	O
azole	B-Group
antifungals	I-Group
in	O
conjunction	O
with	O
terfenadine	B-Drug
interaction	O
studies	O
have	O
been	O
performed	O
.	O
      
In	O
vitro	O
displacement	O
studies	O
with	O
highly	O
protein	O
-	O
bound	O
drugs	O
such	O
as	O
furosemide	B-Drug
propranolol	B-Drug
captopril	B-Drug
nicardipine	B-Drug
pravastatin	B-Drug
glyburide	B-Drug
warfarin	B-Drug
phenytoin	B-Drug
acetylsalicylic	B-Drug
acid	I-Drug
tolbutamide	B-Drug
and	O
metformin	B-Drug
showed	O
no	O
influence	O
on	O
the	O
extent	O
of	O
nateglinide	B-Drug
protein	O
binding	O
.	O
      
Patients	O
treated	O
with	O
TENORMIN	B-Brand
plus	O
a	O
catecholamine	O
depletor	O
should	O
therefore	O
be	O
closely	O
observed	O
for	O
evidence	O
of	O
hypotension	O
and	O
/	O
or	O
marked	O
bradycardia	O
which	O
may	O
produce	O
vertigo	O
syncope	O
or	O
postural	O
hypotension	O
.	O
      
The	O
similarity	O
of	O
the	O
TYSABRI	B-Brand
-	O
associated	O
adverse	O
event	O
profile	O
between	O
Study	O
9	O
(	O
without	O
co	O
-	O
administered	O
AVONEX	B-Brand
)	O
and	O
Study	O
9	O
(	O
with	O
co	O
-	O
administered	O
AVONEX	B-Brand
)	O
indicates	O
that	O
this	O
alteration	O
in	O
clearance	O
does	O
not	O
necessitate	O
reduction	O
of	O
the	O
TYSABRI	B-Brand
dose	O
to	O
maintain	O
safety	O
General	O
)	O
.	O
      
A	O
conservative	O
approach	O
to	O
dosing	O
felodipine	B-Drug
should	O
be	O
taken	O
.	O
      
In	O
vitro	O
and	O
in	O
vivo	O
studies	O
have	O
shown	O
that	O
esomeprazole	B-Drug
is	O
not	O
likely	O
to	O
inhibit	O
CYPs	O
9A9	O
9A9	O
9C9	O
9D9	O
9E9	O
and	O
9A9	O
.	O
      
Oral	O
hypoglycemic	B-Group
agents	I-Group
Oxandrolone	B-Drug
may	O
inhibit	O
the	O
metabolism	O
of	O
oral	O
hypoglycemic	B-Group
agents	I-Group
.	O
      
-	O
Phenytoin	B-Drug
(	O
e.g.	O
Dilantin	B-Brand
)	O
Use	O
of	O
phenytoin	B-Drug
with	O
sulfapyridine	B-Drug
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
affecting	O
the	O
liver	O
and	O
/	O
or	O
the	O
side	O
effects	O
of	O
phenytoin	B-Drug
      
Such	O
an	O
interaction	O
can	O
potentially	O
lead	O
to	O
higher	O
free	O
fractions	O
of	O
either	O
tiagabine	B-Drug
or	O
the	O
competing	O
drug	O
.	O
      
It	O
is	O
desirable	O
to	O
monitor	O
TCA	B-Group
plasma	O
levels	O
whenever	O
a	O
TCA	B-Group
is	O
going	O
to	O
be	O
co	O
-	O
administered	O
with	O
another	O
drug	O
known	O
to	O
be	O
an	O
inhibitor	O
of	O
P9	O
9D9	O
.	O
      
Beta	B-Group
-	O
adrenergic	I-Group
Blocking	I-Group
Agents	I-Group
:	O
The	O
effect	O
of	O
flurbiprofen	B-Drug
on	O
blood	O
pressure	O
response	O
to	O
propranolol	B-Drug
and	O
atenolol	B-Drug
was	O
evaluated	O
in	O
men	O
with	O
mild	O
uncomplicated	O
hypertension	O
(	O
n	O
=	O
9	O
)	O
.	O
      
Repeating	O
the	O
study	O
with	O
9	O
healthy	O
male	O
volunteers	O
in	O
the	O
absence	O
of	O
glibenclamide	B-Drug
did	O
not	O
detect	O
an	O
effect	O
of	O
acitretin	B-Drug
on	O
glucose	O
tolerance	O
.	O
      
vasopressors	B-Group
such	O
as	O
dopamine	B-Drug
and	O
isoproterenol	B-Drug
;	O
      
If	O
labetalol	B-Drug
HCl	I-Drug
is	O
used	O
with	O
nitroglycerin	B-Drug
in	O
patients	O
with	O
angina	O
pectoris	O
additional	O
antihypertensive	O
effects	O
may	O
occur	O
.	O
      
It	O
is	O
presently	O
not	O
known	O
whether	O
these	O
same	O
drug	O
interactions	O
occur	O
with	O
dirithromycin	B-Drug
.	O
      
No	O
evidence	O
of	O
fetal	O
toxicity	O
including	O
adverse	O
effects	O
on	O
immune	O
system	O
development	O
was	O
observed	O
in	O
any	O
of	O
these	O
animals	O
.	O
      
Drug	O
-	O
Drug	O
Interactions	O
Between	O
Keppra	B-Brand
And	O
Other	O
Antiepileptic	B-Group
Drugs	I-Group
(	O
AEDs	B-Group
)	O
Phenytoin	B-Drug
Keppra	B-Brand
(	O
9	O
mg	O
daily	O
)	O
had	O
no	O
effect	O
on	O
the	O
pharmacokinetic	O
disposition	O
of	O
phenytoin	B-Drug
in	O
patients	O
with	O
refractory	O
epilepsy	O
.	O
      
.	O
      
Such	O
occurrences	O
have	O
been	O
reported	O
when	O
propoxyphene	B-Drug
was	O
administered	O
to	O
patients	O
on	O
antidepressants	B-Group
anticonvulsants	B-Group
or	O
warfarin	B-Drug
-	O
like	O
drugs	O
.	O
      
glutethimide	B-Drug
;	O
      
Except	O
in	O
life	O
-	O
threatening	O
situations	O
avoid	O
this	O
combination	O
.	O
      
Anticholinergic	B-Group
drugs	I-Group
in	O
the	O
presence	O
of	O
increased	O
intraocular	O
pressure	O
may	O
be	O
hazardous	O
when	O
taken	O
concurrently	O
with	O
agents	O
such	O
as	O
corti	O
costeroids..	O
      
An	O
increase	O
in	O
intracellular	O
levels	O
of	O
methotrexate	B-Drug
was	O
observed	O
in	O
vitro	O
in	O
the	O
presence	O
of	O
teniposide	B-Drug
.	O
      
In	O
opioid	B-Group
-	O
dependent	O
patients	O
mixed	B-Group
agonist	I-Group
antagonist	I-Group
analgesics	I-Group
may	O
precipitate	O
withdrawal	O
symptoms	O
.	O
      
There	O
was	O
no	O
effect	O
on	O
bleeding	O
time	O
PT	O
or	O
aPTT	O
.	O
      
Nabilone	B-Drug
has	O
been	O
shown	O
to	O
have	O
an	O
additive	O
CNS	O
depressant	O
effect	O
when	O
given	O
with	O
either	O
diazepam	B-Drug
secobarbitone	B-Brand
sodium	I-Brand
alcohol	B-Drug
or	O
codeine	B-Drug
.	O
      
It	O
is	O
desirable	O
to	O
monitor	O
TCA	B-Group
plasma	O
levels	O
whenever	O
a	O
TCA	B-Group
is	O
going	O
to	O
be	O
co	O
-	O
administered	O
with	O
another	O
drug	O
known	O
to	O
be	O
an	O
inhibitor	O
of	O
P9	O
9D9	O
.	O
      
Patients	O
taking	O
other	O
drugs	O
that	O
are	O
substrates	O
of	O
CYP9	O
9A9	O
especially	O
patients	O
with	O
renal	O
and	O
/	O
or	O
hepatic	O
impairment	O
may	O
require	O
dosage	O
adjustment	O
when	O
starting	O
or	O
stopping	O
concomitantly	O
administered	O
diltiazem	B-Drug
in	O
order	O
to	O
maintain	O
optimum	O
therapeutic	O
blood	O
levels	O
.	O
      
Certain	O
drugs	O
tend	O
to	O
produce	O
hyperglycemia	O
and	O
may	O
lead	O
to	O
loss	O
of	O
control	O
.	O
      
When	O
Bezalip	B-Brand
or	O
Bezalip	B-Brand
retard	I-Brand
is	O
used	O
at	O
the	O
same	O
time	O
as	O
other	O
medicines	O
or	O
substances	O
the	O
following	O
interactions	O
must	O
be	O
taken	O
into	O
account	O
:	O
-	O
Bezalip	B-Brand
and	O
Bezalip	B-Brand
retard	I-Brand
may	O
enhance	O
the	O
action	O
of	O
anticoagulants	B-Group
of	I-Group
the	I-Group
coumarin	I-Group
type	I-Group
.	O
      
Although	O
results	O
have	O
varied	O
from	O
study	O
to	O
study	O
effects	O
have	O
been	O
shown	O
on	O
furosemide	B-Drug
-	O
stimulated	O
diuresis	O
natriuresis	O
and	O
kaliuresis	O
.	O
      
drugs	O
affecting	O
blood	O
elements	O
;	O
      
-	O
When	O
Bezalip	B-Brand
or	O
Bezalip	B-Brand
retard	I-Brand
is	O
used	O
concurrently	O
with	O
anion	B-Group
-	O
exchange	I-Group
resins	I-Group
(	O
e.g	O
.	O
cholestryramine	B-Drug
)	O
an	O
interval	O
of	O
at	O
least	O
9	O
hours	O
should	O
be	O
maintained	O
between	O
the	O
two	O
medicines	O
since	O
the	O
absorption	O
of	O
Bezalip	B-Brand
or	O
Bezalip	B-Brand
retard	I-Brand
is	O
impaired	O
      
Glyburide	B-Drug
:	O
Glyburide	B-Drug
is	O
a	O
CYP	O
9C9	O
substrate	O
.	O
      
Coadministration	O
of	O
methyldopa	B-Drug
with	O
ferrous	B-Drug
sulfate	I-Drug
or	O
ferrous	B-Drug
gluconate	I-Drug
is	O
not	O
recommended	O
.	O
      
Coadministration	O
in	O
HIV	O
-	O
infected	O
individuals	O
with	O
a	O
history	O
of	O
injection	O
drug	O
use	O
resulted	O
in	O
decreased	O
plasma	O
levels	O
of	O
methadone	B-Drug
and	O
signs	O
of	O
opiate	B-Group
withdrawal	O
.	O
      
Quinolones	B-Group
including	O
norfloxacin	B-Drug
may	O
enhance	O
the	O
effects	O
of	O
oral	O
anticoagulants	B-Group
including	O
warfarin	B-Drug
or	O
its	O
derivatives	O
or	O
similar	O
agents	O
.	O
      
Antacids	B-Group
containing	O
magnesium	B-Drug
aluminum	B-Drug
or	O
calcium	B-Drug
;	O
      
Treatment	O
with	O
ZETIA	B-Brand
in	O
children	O
(	O
<	O
9	O
years	O
)	O
is	O
not	O
recommended	O
.	O
      
Concurrent	O
administration	O
of	O
HEXALEN	B-Brand
and	O
antidepressants	B-Group
of	I-Group
the	I-Group
MAO	I-Group
inhibitor	I-Group
class	I-Group
may	O
cause	O
severe	O
orthostatic	O
hypotension.Cimetidine	O
an	O
inhibitor	O
of	O
microsomal	O
drug	O
metabolism	O
increased	O
altretamine	B-Drug
half	O
-	O
life	O
and	O
toxicity	O
in	O
a	O
rat	O
model	O
.	O
      
Rifabutin	B-Drug
      
In	O
patients	O
the	O
concomitant	O
administration	O
of	O
digoxin	B-Drug
with	O
dofetilide	B-Drug
was	O
associated	O
with	O
a	O
higher	O
occurrence	O
of	O
torsade	O
de	O
pointes	O
.	O
      
Epinephrine	B-Drug
may	O
antagonize	O
the	O
neuron	O
blockade	O
produced	O
by	O
guanethidine	B-Drug
resulting	O
in	O
decreased	O
antihypertensive	O
effect	O
and	O
requiring	O
increased	O
dosage	O
of	O
the	O
latter	O
.	O
      
Reproductive	O
findings	O
occur	O
at	O
lower	O
doses	O
in	O
combination	O
therapy	O
compared	O
to	O
monotherapy	O
.	O
      
Estrogen	B-Group
increased	O
levels	O
of	O
corticosteroid	O
-	O
binding	O
globulin	O
thereby	O
increasing	O
the	O
bound	O
(	O
inactive	O
)	O
fraction	O
;	O
      
There	O
is	O
one	O
report	O
of	O
cardiopulmonary	O
arrest	O
with	O
full	O
recovery	O
in	O
a	O
patient	O
who	O
was	O
taking	O
a	O
beta	B-Group
blocker	I-Group
(	O
propranolol	B-Drug
)	O
.	O
      
All	O
subjects	O
received	O
glipizide	B-Drug
alone	O
and	O
following	O
treatment	O
with	O
9	O
mg	O
of	O
fluconazole	B-Drug
as	O
a	O
single	O
daily	O
oral	O
dose	O
for	O
seven	O
days	O
.	O
      
-	O
Lithium	B-Drug
:	O
Generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	B-Group
.	O
      
There	O
also	O
was	O
no	O
effect	O
on	O
exposure	O
to	O
and	O
the	O
excretion	O
of	O
the	O
primary	O
metabolite	O
ucb	O
L9	O
.	O
      
In	O
patients	O
given	O
very	O
high	O
doses	O
(	O
9	O
mg	O
)	O
of	O
aspirin	B-Brand
daily	O
increases	O
in	O
serum	O
salicylate	B-Group
levels	O
were	O
seen	O
when	O
nizatidine	B-Drug
9	O
mg	O
b.i.d.	O
was	O
administered	O
concurrently	O
.	O
      
Nondepolarizing	B-Group
Muscle	I-Group
Relaxants	I-Group
:	O
In	O
postmarketing	O
experience	O
there	O
have	O
been	O
reports	O
of	O
a	O
possible	O
interaction	O
between	O
TORADOLIV	O
/	O
IM	O
and	O
nondepolarizing	B-Group
muscle	I-Group
relaxants	I-Group
that	O
resulted	O
in	O
apnea	O
.	O
      
If	O
the	O
drugs	O
are	O
used	O
together	O
caution	O
should	O
be	O
exercised	O
because	O
unexpected	O
hypotension	O
could	O
result	O
from	O
beta	O
-	O
blocker	O
inhibition	O
of	O
the	O
sympathetic	O
reflex	O
response	O
to	O
fenoldopam	B-Drug
.	O
      
Sulfoxone	B-Drug
may	O
increase	O
the	O
effects	O
of	O
barbiturates	B-Group
tolbutamide	B-Drug
and	O
uricosurics	B-Group
.	O
      
The	O
inhibitory	O
potential	O
of	O
ciclesonide	B-Drug
on	O
CYP9	O
isoenzymes	O
has	O
not	O
been	O
studied	O
.	O
      
ritonavir	B-Drug
concentration	O
      
These	O
doses	O
were	O
9	O
to	O
9	O
times	O
(	O
mouse	O
)	O
and	O
9	O
to	O
9	O
times	O
(	O
rat	O
)	O
the	O
human	O
AUC	O
(	O
9	O
-	O
9	O
)	O
based	O
on	O
the	O
maximum	O
recommended	O
human	O
dose	O
of	O
9	O
mg	O
/	O
day	O
.	O
      
There	O
are	O
reports	O
of	O
enhanced	O
as	O
well	O
as	O
diminished	O
effects	O
of	O
anticoagulants	B-Group
when	O
given	O
concurrently	O
with	O
corticosteroids	B-Group
.	O
      
In	O
normal	O
volunteers	O
receiving	O
indomethacin	B-Drug
the	O
administration	O
of	O
diflunisal	B-Drug
decreased	O
the	O
renal	O
clearance	O
and	O
significantly	O
increased	O
the	O
plasma	O
levels	O
of	O
indomethacin	B-Drug
.	O
      
By	O
decreasing	O
the	O
gastrointestinal	O
absorption	O
of	O
primidone	B-Drug
DIAMOX	B-Brand
may	O
decrease	O
serum	O
concentrations	O
of	O
primidone	B-Drug
and	O
its	O
metabolites	O
with	O
a	O
consequent	O
possible	O
decrease	O
in	O
anticonvulsant	O
effect	O
.	O
      
Coadministration	O
of	O
oral	O
contraceptives	B-Group
increased	O
the	O
maximum	O
plasma	O
concentration	O
of	O
alprazolam	B-Drug
by	O
9	O
%	O
decreased	O
clearance	O
by	O
9	O
%	O
and	O
increased	O
half	O
-	O
life	O
by	O
9	O
%	O
.	O
      
(	O
Concurrent	O
use	O
with	O
thiazide	B-Group
diuretics	I-Group
may	O
enhance	O
the	O
possibility	O
of	O
digitalis	B-Group
toxicity	O
associated	O
with	O
hypokalemia	O
.	O
)	O
      
This	O
time	O
window	O
is	O
different	O
than	O
for	O
other	O
oral	O
formulations	O
of	O
ciprofloxacin	B-Drug
which	O
are	O
usually	O
administered	O
9	O
hours	O
before	O
or	O
9	O
hours	O
after	O
antacids	B-Group
.	O
      
Therefore	O
unless	O
otherwise	O
specified	O
appropriate	O
dosage	O
adjustments	O
may	O
be	O
necessary	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Effect	O
on	O
Blood	O
Coagulation	O
:	O
Diclofenac	B-Drug
increases	O
platelet	O
aggregation	O
time	O
but	O
does	O
not	O
affect	O
bleeding	O
time	O
plasma	O
thrombin	O
clotting	O
time	O
plasma	O
fibrinogen	O
or	O
factors	O
V	O
and	O
VII	O
to	O
XII	O
.	O
      
No	O
Important	O
Interactions	O
To	O
Date	O
Levosimendan	B-Drug
does	O
not	O
have	O
clinically	O
important	O
pharmacokinetic	O
interactions	O
with	O
captopril	B-Drug
beta	B-Group
-	O
blockers	I-Group
felodipine	B-Drug
digoxin	B-Drug
warfarin	B-Drug
isosorbide	B-Drug
mononitrate	I-Drug
carvedilol	B-Drug
ethanol	B-Drug
or	O
itraconazole	B-Drug
.	O
      
clinical	O
significance	O
unknown	O
.	O
      
9	O
.	O
      
Lithium	B-Drug
generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	B-Group
because	O
they	O
reduce	O
its	O
renal	O
clearance	O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	B-Drug
toxicity	O
.	O
      
NSAIDs	B-Group
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
taking	O
cyclosporine	B-Drug
and	O
renal	O
function	O
should	O
be	O
carefully	O
monitored	O
.	O
      
These	O
results	O
are	O
consistent	O
with	O
the	O
in	O
vitro	O
finding	O
that	O
neither	O
isotretinoin	B-Drug
nor	O
its	O
metabolites	O
induce	O
or	O
inhibit	O
the	O
activity	O
of	O
the	O
CYP	O
9C9	O
human	O
hepatic	O
P9	O
enzyme	O
.	O
      
Administration	O
of	O
diltiazem	B-Drug
hydrochloride	I-Drug
concomitantly	O
with	O
propranolol	B-Drug
in	O
five	O
normal	O
volunteers	O
resulted	O
in	O
increased	O
propranolol	B-Drug
levels	O
in	O
all	O
subjects	O
and	O
bioavailability	O
of	O
propranolol	B-Drug
was	O
increased	O
approximately	O
9	O
%	O
.	O
      
However	O
in	O
patients	O
treated	O
with	O
oral	O
carbonic	B-Group
anhydrase	I-Group
inhibitors	I-Group
rare	O
instances	O
of	O
drug	O
interactions	O
have	O
occurred	O
with	O
high	O
-	O
dose	O
salicylate	B-Drug
therapy	O
.	O
      
Other	O
Concomitant	O
Therapy	O
In	O
healthy	O
subjects	O
there	O
were	O
no	O
clinically	O
significant	O
interactions	O
when	O
felodipine	B-Drug
was	O
given	O
concomitantly	O
with	O
indomethacin	B-Drug
or	O
spironolactone	B-Drug
.	O
      
Paroxetine	B-Drug
(	O
9	O
mg	O
QD	O
)	O
increased	O
the	O
concentration	O
of	O
duloxetine	B-Drug
(	O
9	O
mg	O
QD	O
)	O
by	O
about	O
9	O
%	O
and	O
greater	O
degrees	O
of	O
inhibition	O
are	O
expected	O
with	O
higher	O
doses	O
of	O
paroxetine	B-Drug
.	O
      
9	O
-	O
9	O
The	O
following	O
precautions	O
should	O
be	O
kept	O
in	O
mind	O
in	O
the	O
treatment	O
of	O
anticholinesterase	O
poisoning	O
although	O
they	O
do	O
not	O
bear	O
directly	O
on	O
the	O
use	O
of	O
pralidoxime	B-Drug
:	O
since	O
barbiturates	B-Group
are	O
potentiated	O
by	O
the	O
anticholinesterases	B-Group
they	O
should	O
be	O
used	O
cautiously	O
in	O
the	O
treatment	O
of	O
convulsions	O
;	O
      
Drug	O
interaction	O
studies	O
with	O
other	O
anticonvulsants	B-Group
have	O
not	O
been	O
conducted	O
.	O
      
N=9	O
)	O
.	O
      
thrombocytopenia	O
      
in	O
one	O
man	O
the	O
C	O
max	O
of	O
terfenadine	B-Drug
was	O
9	O
ng	O
/	O
mL	O
with	O
terfenadine	B-Drug
alone	O
and	O
9	O
ng	O
/	O
mL	O
with	O
terfenadine	B-Drug
plus	O
dirithromycin	B-Drug
.	O
      
When	O
a	O
diuretic	B-Group
is	O
added	O
to	O
the	O
therapy	O
of	O
a	O
patient	O
receiving	O
PRINIVIL	B-Brand
an	O
additional	O
antihypertensive	O
effect	O
is	O
usually	O
observed	O
.	O
      
Cimetidine	B-Drug
:	O
Concomitant	O
administration	O
of	O
9	O
mg	O
cimetidine	B-Drug
QID	O
did	O
not	O
alter	O
the	O
single	O
-	O
dose	O
pharmacokinetics	O
of	O
9	O
mg	O
meloxicam	B-Drug
.	O
      
Other	O
drugs	O
eliminated	O
via	O
renal	O
secretion	O
:	O
Population	O
pharmacokinetic	O
analysis	O
suggests	O
that	O
coadministration	O
of	O
drugs	O
that	O
are	O
secreted	O
by	O
the	O
cationic	O
transport	O
system	O
(	O
e.g.	O
cimetidine	B-Drug
ranitidine	B-Drug
diltiazem	B-Drug
triamterene	B-Drug
verapamil	B-Drug
quinidine	B-Drug
and	O
quinine	B-Drug
)	O
decreases	O
the	O
oral	O
clearance	O
of	O
pramipexole	B-Drug
by	O
about	O
9	O
%	O
while	O
those	O
secreted	O
by	O
the	O
anionic	O
transport	O
system	O
(	O
e.g.	O
cephalosporins	B-Group
penicillins	B-Group
indomethacin	B-Drug
hydrochlorothiazide	B-Drug
and	O
chlorpropamide	B-Drug
)	O
are	O
likely	O
to	O
have	O
little	O
effect	O
on	O
the	O
oral	O
clearance	O
of	O
pramipexole	B-Drug
.	O
      
CNS	O
Drugs	O
-	O
Given	O
the	O
primary	O
CNS	O
effects	O
of	O
escitalopram	B-Drug
caution	O
should	O
be	O
used	O
when	O
it	O
is	O
taken	O
in	O
combination	O
with	O
other	O
centrally	O
acting	O
drugs	O
.	O
      
dosage	O
adjustments	O
may	O
be	O
necessary	O
.	O
)	O
      
Methotrexate	B-Drug
:	O
Concomitant	O
administration	O
of	O
methotrexate	B-Drug
and	O
some	O
NSAIDs	B-Group
has	O
been	O
reported	O
to	O
reduce	O
the	O
clearance	O
of	O
methotrexate	B-Drug
enhancing	O
the	O
toxicity	O
of	O
methotrexate	B-Drug
.	O
      
The	O
administration	O
of	O
local	O
anesthetic	B-Group
solutions	I-Group
containing	O
epinephrine	B-Drug
or	O
norepinephrine	B-Drug
to	O
patients	O
receiving	O
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
or	O
tricyclic	B-Group
antidepressants	I-Group
may	O
produce	O
severe	O
prolonged	O
hypertension	O
.	O
      
A	O
small	O
number	O
of	O
patients	O
received	O
epirubicin	B-Drug
-	O
based	O
chemotherapy	O
concomitantly	O
with	O
radiation	O
therapy	O
but	O
had	O
chemotherapy	O
interrupted	O
in	O
order	O
to	O
avoid	O
potential	O
overlapping	O
toxicities	O
.	O
      
Drug	O
interactions	O
should	O
be	O
kept	O
in	O
mind	O
when	O
METROGEL	B-Brand
(	O
metronidazole	B-Drug
gel	O
)	O
9	O
%	O
is	O
prescribed	O
for	O
patients	O
who	O
are	O
receiving	O
anticoagulant	O
treatment	O
although	O
they	O
are	O
less	O
likely	O
to	O
occur	O
with	O
topical	O
metronidazole	B-Drug
administration	O
because	O
of	O
low	O
absorption	O
.	O
      
Adjustment	O
of	O
adenosine	B-Drug
dosage	O
may	O
be	O
necessary	O
.	O
      
Hormonal	O
contraceptives	B-Group
Co	O
-	O
administration	O
of	O
Trileptal	B-Brand
with	O
an	O
oral	O
contraceptive	B-Group
has	O
been	O
shown	O
to	O
influence	O
the	O
plasma	O
concentrations	O
of	O
the	O
two	O
hormonal	O
components	O
ethinylestradiol	B-Drug
(	O
EE	O
)	O
and	O
levonorgestrel	B-Drug
(	O
LNG	O
)	O
.	O
      
and	O
Videx	B-Brand
(	O
Didanosine	B-Drug
)	O
chewable	O
/	O
buffered	O
tablets	O
or	O
the	O
pediatric	O
powder	O
for	O
oral	O
solution	O
may	O
substantially	O
interfere	O
with	O
the	O
absorption	O
of	O
quinolones	B-Group
resulting	O
in	O
systemic	O
levels	O
considerably	O
lower	O
than	O
desired	O
.	O
      
Celecoxib	B-Drug
metabolism	O
is	O
predominantly	O
mediated	O
via	O
cytochrome	O
P9	O
9C9	O
in	O
the	O
liver	O
.	O
      
This	O
may	O
indicate	O
that	O
they	O
could	O
enhance	O
the	O
toxicity	O
of	O
methotrexate	B-Drug
.	O
      
Animal	O
experience	O
indicates	O
that	O
clorazepate	B-Drug
dipotassium	I-Drug
prolongs	O
the	O
sleeping	O
time	O
after	O
hexobarbital	B-Drug
or	O
after	O
ethyl	B-Drug
alcohol	I-Drug
increases	O
the	O
inhibitory	O
effects	O
of	O
chlorpromazine	B-Drug
but	O
does	O
not	O
exhibit	O
monoamine	O
oxidase	O
inhibition	O
.	O
      
There	O
have	O
been	O
a	O
number	O
of	O
reports	O
in	O
the	O
post	O
-	O
marketing	O
experience	O
of	O
coma	O
and	O
death	O
associated	O
with	O
the	O
concomitant	O
intravenous	O
misuse	O
of	O
buprenorphine	B-Drug
and	O
benzodiazepines	B-Drug
by	O
addicts	O
.	O
      
Antihypertensive	B-Group
medications	I-Group
other	O
especially	O
diazoxide	B-Drug
or	O
preanesthetic	O
and	O
anesthetic	O
agents	O
used	O
in	O
surgery	O
or	O
skeletal	B-Group
-	O
muscle	I-Group
relaxants	I-Group
nondepolarizing	O
used	O
in	O
surgery	O
      
As	O
a	O
result	O
when	O
giving	O
these	O
drugs	O
concomitantly	O
plasma	O
warfarin	B-Drug
levels	O
may	O
change	O
with	O
the	O
potential	O
for	O
increases	O
in	O
coagulation	O
time	O
.	O
      
Cimetidine	B-Drug
:	O
Albendazole	B-Drug
sulfoxide	I-Drug
concentrations	O
in	O
bile	O
and	O
cystic	O
fluid	O
were	O
increased	O
(	O
about	O
9	O
-	O
fold	O
)	O
in	O
hydatid	O
cyst	O
patients	O
treated	O
with	O
cimetidine	B-Drug
(	O
9	O
mg	O
/	O
kg	O
/	O
day	O
)	O
(	O
n=9	O
)	O
compared	O
with	O
albendazole	B-Drug
(	O
9	O
mg	O
/	O
kg	O
/	O
day	O
)	O
alone	O
(	O
n=9	O
)	O
.	O
      
Although	O
there	O
may	O
be	O
decreased	O
zalcitabine	B-Drug
activity	O
because	O
of	O
lessened	O
active	O
metabolite	O
formation	O
the	O
clinical	O
relevance	O
of	O
these	O
in	O
vitro	O
results	O
are	O
not	O
known	O
.	O
      
dextran	B-Drug
;	O
      
Catecholamine	O
-	O
depleting	O
drugs	O
e.g.	O
reserpine	B-Drug
may	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
beta	B-Group
blocking	I-Group
agents	I-Group
.	O
      
Where	O
this	O
is	O
not	O
possible	O
minoxidil	B-Drug
therapy	O
should	O
be	O
started	O
in	O
the	O
hospital	O
and	O
the	O
patient	O
should	O
remain	O
institutionalized	O
until	O
severe	O
orthostatic	O
effects	O
are	O
no	O
longer	O
present	O
or	O
the	O
patient	O
has	O
learned	O
to	O
avoid	O
activities	O
that	O
provoke	O
them	O
.	O
      
.	O
      
Thus	O
there	O
may	O
be	O
a	O
potential	O
for	O
drug	O
-	O
drug	O
interactions	O
with	O
these	O
drugs	O
.	O
      
Plasma	O
exposure	O
of	O
diazepam	B-Drug
(	O
9	O
mg	O
BID	O
)	O
was	O
increased	O
by	O
9	O
%	O
following	O
administration	O
of	O
valdecoxib	B-Drug
(	O
9	O
mg	O
BID	O
)	O
for	O
9	O
days	O
while	O
plasma	O
exposure	O
of	O
valdecoxib	B-Drug
(	O
9	O
mg	O
BID	O
)	O
was	O
not	O
substantially	O
increased	O
following	O
administration	O
of	O
diazepam	B-Drug
(	O
9	O
mg	O
BID	O
)	O
for	O
9	O
days	O
.	O
      
-	O
Estrogens	B-Group
(	O
female	O
hormones	O
)	O
or	O
      
Lomefloxacin	B-Drug
is	O
unlikely	O
to	O
have	O
a	O
significant	O
effect	O
on	O
phenytoin	B-Drug
metabolism	O
.	O
      
Isoproterenol	B-Drug
hydrochloride	I-Drug
injection	O
and	O
epinephrine	B-Drug
should	O
not	O
be	O
administered	O
simultaneously	O
because	O
both	O
drugs	O
are	O
direct	O
cardiac	O
stimulants	O
and	O
their	O
combined	O
effects	O
may	O
induce	O
serious	O
arrhythmias	O
.	O
      
Drug	O
Interactions	O
:	O
a	O
.	O
Drugs	O
Enhancing	O
Heparin	B-Drug
Effect	O
:	O
Oral	O
anticoagulants	B-Group
:	O
Heparin	B-Drug
sodium	I-Drug
may	O
prolong	O
the	O
one	O
-	O
stage	O
prothrombin	O
time	O
.	O
      
An	O
alternative	O
confirmatory	O
method	O
should	O
be	O
considered	O
to	O
verify	O
positive	O
results	O
.	O
      
Steady	O
-	O
state	O
plasma	O
felbamate	B-Drug
concentrations	O
were	O
found	O
to	O
be	O
9	O
%	O
lower	O
than	O
the	O
mean	O
concentrations	O
of	O
a	O
group	O
of	O
newly	O
diagnosed	O
subjects	O
with	O
epilepsy	O
also	O
receiving	O
9	O
mg	O
of	O
felbamate	B-Drug
a	O
day	O
.	O
      
.	O
      
9	O
.	O
      
Meloxicam	B-Drug
did	O
not	O
have	O
a	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
single	O
doses	O
of	O
methotrexate	B-Drug
.	O
      
Because	O
of	O
the	O
potential	O
for	O
ARAVA	B-Brand
levels	O
to	O
continue	O
to	O
increase	O
with	O
multiple	O
dosing	O
caution	O
should	O
be	O
used	O
if	O
patients	O
are	O
to	O
be	O
receiving	O
both	O
ARAVA	B-Brand
and	O
rifampin	B-Drug
.	O
      
Central	B-Group
Nervous	I-Group
System	I-Group
Depressants	I-Group
:	O
The	O
concomitant	O
use	O
of	O
DURAGESIC	B-Brand
(	O
fentanyl	B-Drug
transdermal	O
system	O
)	O
with	O
other	O
central	B-Group
nervous	I-Group
system	I-Group
depressants	I-Group
including	O
but	O
not	O
limited	O
to	O
other	O
opioids	B-Group
sedatives	B-Group
hypnotics	B-Group
tranquilizers	B-Group
(	O
e.g.	O
benzodiazepines	B-Group
)	O
general	O
anesthetics	B-Group
phenothiazines	B-Group
skeletal	B-Group
muscle	I-Group
relaxants	I-Group
and	O
alcohol	B-Drug
may	O
cause	O
respiratory	O
depression	O
hypotension	O
and	O
profound	O
sedation	O
or	O
potentially	O
result	O
in	O
coma	O
or	O
death	O
.	O
      
Acetaminophen	B-Drug
had	O
no	O
effect	O
on	O
plasma	O
levels	O
of	O
diflunisal	B-Drug
.	O
      
In	O
vitro	O
studies	O
in	O
human	O
liver	O
microsomes	O
indicate	O
that	O
ertapenem	B-Drug
does	O
not	O
inhibit	O
metabolism	O
mediated	O
by	O
any	O
of	O
the	O
following	O
six	O
cytochrome	O
p9	O
(	O
CYP	O
)	O
isoforms	O
:	O
9A9	O
9C9	O
9C9	O
9D9	O
9E9	O
and	O
9A9	O
.	O
      
Isocarboxazid	B-Drug
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
receiving	O
Antabuse	B-Brand
(	O
disulfiram	B-Drug
Wyeth	O
-	O
Ayerst	O
Laboratories	O
)	O
.	O
      
Cholestyramine	B-Drug
and	O
colestipol	B-Drug
resins	B-Group
:	O
Absorption	O
of	O
hydrochlorothiazide	B-Drug
is	O
impaired	O
in	O
the	O
presence	O
of	O
anionic	B-Group
exchange	I-Group
resins	I-Group
.	O
      
The	O
effect	O
on	O
other	O
progestational	B-Group
contraceptives	I-Group
(	O
eg	O
implants	O
injectables	O
)	O
is	O
unknown	O
.	O
      
Aspirin	B-Brand
:	O
When	O
Lodine	B-Brand
is	O
administered	O
with	O
aspirin	B-Brand
its	O
protein	O
binding	O
is	O
reduced	O
although	O
the	O
clearance	O
of	O
free	O
etodolac	B-Drug
is	O
not	O
altered	O
.	O
      
Anticoagulants	B-Drug
:	O
Potentiation	O
of	O
warfarin	B-Drug
-	O
type	O
(	O
CYP9C9	B-Drug
and	O
CYP9A9	B-Drug
substrate	O
)	O
anticoagulant	B-Drug
response	O
is	O
almost	O
always	O
seen	O
in	O
patients	O
receiving	O
amiodarone	B-Drug
and	O
can	O
result	O
in	O
serious	O
or	O
fatal	O
bleeding	O
.	O
      
Effect	O
      
co	O
-	O
administration	O
of	O
phenytoin	B-Drug
may	O
produce	O
a	O
synergistic	O
anticonvulsant	O
action	O
.	O
      
Furosemide	B-Drug
has	O
a	O
tendency	O
to	O
antagonize	O
the	O
skeletal	O
muscle	O
relaxing	O
effect	O
of	O
tubocurarine	B-Drug
and	O
may	O
potentiate	O
the	O
action	O
of	O
succinylcholine	B-Drug
.	O
      
Digoxin	B-Drug
Nimodipine	B-Drug
and	O
Losartan	B-Drug
:	O
Bosentan	B-Drug
has	O
no	O
significant	O
pharmacokinetic	O
interactions	O
with	O
digoxin	B-Drug
and	O
nimodipine	B-Drug
and	O
losartan	B-Drug
has	O
no	O
significant	O
effect	O
on	O
plasma	O
levels	O
of	O
bosentan	B-Drug
.	O
      
Ketoconazole	B-Drug
at	O
9	O
mg	O
daily	O
(	O
the	O
maximum	O
approved	O
prescription	O
dose	O
)	O
co	O
-	O
administered	O
with	O
TIKOSYN	B-Brand
(	O
9	O
mcg	O
BID	O
)	O
for	O
9	O
days	O
has	O
been	O
shown	O
to	O
increase	O
dofetilide	B-Drug
Cmax	O
by	O
9	O
%	O
in	O
males	O
and	O
9	O
%	O
in	O
females	O
and	O
AUC	O
by	O
9	O
%	O
in	O
males	O
and	O
9	O
%	O
in	O
females	O
.	O
      
Phenytoin	B-Drug
:	O
Amphetamines	B-Group
may	O
delay	O
intestinal	O
absorption	O
of	O
phenytoin	B-Drug
;	O
      
A	O
clinical	O
study	O
in	O
healthy	O
male	O
volunteers	O
(	O
n=9	O
)	O
demonstrated	O
that	O
mixing	O
NovoLog	B-Brand
with	O
NPH	B-Drug
human	I-Drug
insulin	I-Drug
immediately	O
before	O
injection	O
produced	O
some	O
attenuation	O
in	O
the	O
peak	O
concentration	O
of	O
NovoLog	B-Brand
but	O
that	O
the	O
time	O
to	O
peak	O
and	O
the	O
total	O
bioavailability	O
of	O
NovoLog	B-Brand
were	O
not	O
significantly	O
affected	O
.	O
      
These	O
include	O
sympathomimetic	B-Group
bronchodilators	I-Group
methylxanthines	B-Group
and	O
oral	O
and	O
inhaled	O
steroids	B-Group
.	O
      
Antibiotics	B-Group
:	O
In	O
vitro	O
and	O
/	O
or	O
in	O
vivo	O
data	O
show	O
that	O
clarithromycin	B-Drug
erythromycin	B-Drug
and	O
troleandomycin	B-Drug
markedly	O
inhibit	O
the	O
metabolism	O
of	O
cisapride	B-Drug
which	O
can	O
result	O
in	O
an	O
increase	O
in	O
plasma	O
cisapride	B-Drug
levels	O
and	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O
      
Dexamethasone	B-Drug
:	O
Steady	O
-	O
state	O
trough	O
concentrations	O
of	O
albendazole	B-Drug
sulfoxide	I-Drug
were	O
about	O
9	O
%	O
higher	O
when	O
9	O
mg	O
dexamethasone	B-Drug
was	O
coadministered	O
with	O
each	O
dose	O
of	O
albendazole	B-Drug
(	O
9	O
mg	O
/	O
kg	O
/	O
day	O
)	O
in	O
eight	O
neurocysticercosis	O
patients	O
.	O
      
Leukocyte	B-Drug_n
transfusions	I-Drug_n
:	O
acute	O
pulmonary	O
toxicity	O
has	O
been	O
reported	O
in	O
patients	O
receiving	O
intravenous	O
amphotericin	B-Drug
B	I-Drug
and	O
leukocyte	B-Drug_n
transfusions	I-Drug_n
.	O
      
There	O
was	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
representative	O
drugs	O
metabolized	O
by	O
CYP	O
9C9	O
CYP	O
9C9	O
CYP	O
9D9	O
or	O
CYP	O
9A9	O
.	O
      
Concurrent	O
use	O
of	O
macrolides	B-Group
and	O
warfarin	B-Drug
in	O
clinical	O
practice	O
has	O
been	O
associated	O
with	O
increased	O
anticoagulant	O
effects	O
.	O
      
Generally	O
this	O
phenomenon	O
has	O
not	O
been	O
associated	O
with	O
other	O
clinically	O
significant	O
events	O
.	O
      
Appropriate	O
laboratory	O
testing	O
should	O
be	O
considered	O
prior	O
to	O
initiating	O
combination	O
therapy	O
with	O
Amprenavir	B-Drug
and	O
ritonavir	B-Drug
and	O
at	O
periodic	O
intervals	O
or	O
if	O
any	O
clinical	O
signs	O
or	O
symptoms	O
of	O
hyperlipidemia	O
or	O
elevated	O
liver	O
function	O
tests	O
occur	O
during	O
therapy	O
.	O
      
There	O
is	O
evidence	O
that	O
meropenem	B-Drug
may	O
reduce	O
serum	O
levels	O
of	O
valproic	B-Drug
acid	I-Drug
to	O
subtherapeutic	O
levels	O
(	O
therapeutic	O
range	O
considered	O
to	O
be	O
9	O
to	O
9	O
g	O
/	O
mL	O
total	O
valproate	B-Drug
)	O
.	O
      
Although	O
there	O
have	O
been	O
no	O
formal	O
interaction	O
studies	O
other	O
than	O
with	O
antipyrine	B-Drug
based	O
on	O
these	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
it	O
is	O
unlikely	O
that	O
co	O
-	O
administration	O
of	O
a	O
9	O
mg	O
dose	O
of	O
ARIMIDEX	B-Brand
with	O
other	O
drugs	O
will	O
result	O
in	O
clinically	O
significant	O
drug	O
inhibition	O
of	O
cytochrome	O
P9	O
-	O
mediated	O
metabolism	O
of	O
the	O
other	O
drugs	O
.	O
      
Increased	O
plasma	O
levels	O
of	O
diazepam	B-Drug
were	O
observed	O
9	O
hours	O
after	O
dosing	O
and	O
onwards	O
.	O
      
The	O
extent	O
to	O
which	O
SSRI	B-Group
-	O
TCA	B-Group
interactions	O
may	O
pose	O
clinical	O
problems	O
will	O
depend	O
on	O
the	O
degree	O
of	O
inhibition	O
and	O
the	O
pharmacokinetics	O
of	O
the	O
SSRI	B-Group
involved	O
.	O
      
When	O
such	O
drugs	O
are	O
administered	O
to	O
a	O
patient	O
receiving	O
Acarbose	B-Drug
the	O
patient	O
should	O
be	O
closely	O
observed	O
for	O
loss	O
of	O
blood	O
glucose	O
control	O
.	O
      
methadone	B-Drug
concentration	O
      
Concurrent	O
administration	O
of	O
oxyphenbutazone	B-Drug
and	O
androgens	B-Group
may	O
result	O
in	O
elevated	O
serum	O
levels	O
of	O
oxyphenbutazone	B-Drug
.	O
      
Nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
agents	I-Group
      
Ezetimibe	B-Drug
should	O
be	O
used	O
during	O
pregnancy	O
only	O
if	O
the	O
potential	O
benefit	O
justifies	O
the	O
risk	O
to	O
the	O
fetus	O
.	O
      
In	O
the	O
absence	O
of	O
formal	O
clinical	O
drug	O
interaction	O
studies	O
caution	O
should	O
be	O
exercised	O
when	O
administering	O
TAXOL	B-Brand
concomitantly	O
with	O
known	O
substrates	O
or	O
inhibitors	O
of	O
the	O
cytochrome	O
P9	O
isoenzymes	O
CYP9C9	O
and	O
CYP9A9	O
.	O
      
Doses	O
of	O
vitamin	B-Drug
C	I-Drug
up	O
to	O
9	O
mg	O
were	O
allowed	O
in	O
clinical	O
studies	O
without	O
negative	O
consequences	O
.	O
      
Clindamycin	B-Drug
has	O
been	O
shown	O
to	O
have	O
neuromuscular	O
blocking	O
properties	O
that	O
may	O
enhance	O
the	O
action	O
of	O
other	O
neuromuscular	B-Group
blocking	I-Group
agents	I-Group
.	O
      
In	O
psoriatic	O
arthritis	O
clinical	O
trials	O
concomitant	O
medications	O
included	O
MTX	B-Drug
in	O
approximately	O
half	O
of	O
the	O
patients	O
as	O
well	O
as	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
agents	I-Group
folic	B-Drug
acid	I-Drug
and	O
corticosteroids	B-Group
.	O
      
Concurrent	O
and	O
/	O
or	O
sequential	O
systemic	O
or	O
topical	O
use	O
of	O
other	O
potentially	O
neurotoxic	O
and	O
/	O
or	O
nephrotoxic	O
drugs	O
such	O
as	O
amphotericin	B-Drug
B	I-Drug
aminoglycosides	B-Group
bacitracin	B-Drug
polymyxin	B-Drug
B	I-Drug
colistin	B-Drug
viomycin	B-Drug
or	O
cisplatin	B-Drug
when	O
indicated	O
requires	O
careful	O
monitoring	O
.	O
      
Although	O
inhibition	O
of	O
CYP	O
9A9	O
/	O
9	O
by	O
OXC	B-Drug
and	O
MHD	B-Drug_n
did	O
occur	O
at	O
high	O
concentrations	O
it	O
is	O
not	O
likely	O
to	O
be	O
of	O
clinical	O
significance	O
.	O
      
This	O
has	O
been	O
demonstrated	O
in	O
vitro	O
;	O
      
Potential	O
for	O
Other	O
Drugs	O
to	O
Affect	O
INVEGA	B-Brand
Paliperidone	B-Drug
is	O
not	O
a	O
substrate	O
of	O
CYP9A9	O
CYP9A9	O
CYP9C9	O
and	O
CYP9C9	O
so	O
that	O
an	O
interaction	O
with	O
inhibitors	O
or	O
inducers	O
of	O
these	O
isozymes	O
is	O
unlikely	O
.	O
      
Digitalis	B-Group
glycosides	I-Group
enhanced	O
possibility	O
of	O
arrhythmias	O
or	O
digitalis	B-Group
toxicity	O
associated	O
with	O
hypokalemia	O
.	O
      
In	O
vitro	O
metabolism	O
studies	O
have	O
suggested	O
that	O
decitabine	B-Drug
is	O
not	O
a	O
substrate	O
for	O
the	O
human	O
liver	O
cytochrome	O
P9	O
enzymes	O
.	O
      
No	O
significant	O
drug	O
interactions	O
have	O
been	O
reported	O
in	O
studies	O
of	O
candesartan	B-Drug
cilexetil	I-Drug
given	O
with	O
other	O
drugs	O
such	O
as	O
glyburide	B-Drug
nifedipine	B-Drug
digoxin	B-Drug
warfarin	B-Drug
hydrochlorothiazide	B-Drug
and	O
oral	O
contraceptives	B-Group
in	O
healthy	O
volunteers	O
or	O
given	O
with	O
enalapril	B-Drug
to	O
patients	O
with	O
heart	O
failure	O
(	O
NYHA	O
class	O
II	O
and	O
III	O
)	O
.	O
      
Because	O
pergolide	B-Drug
mesylate	I-Drug
is	O
approximately	O
9	O
%	O
bound	O
to	O
plasma	O
proteins	O
caution	O
should	O
be	O
exercised	O
if	O
pergolide	B-Drug
mesylate	I-Drug
is	O
coadministered	O
with	O
other	O
drugs	O
known	O
to	O
affect	O
protein	O
binding	O
.	O
      
(	O
Thiazides	B-Group
may	O
decrease	O
arterial	O
responsiveness	O
to	O
norepinephrine	B-Drug
.	O
      
SKELAXIN	B-Brand
may	O
enhance	O
the	O
effects	O
of	O
alcohol	B-Drug
barbiturates	B-Group
and	O
other	O
CNS	B-Group
depressants	I-Group
.	O
      
Concurrent	O
administration	O
of	O
vasopressor	B-Group
drugs	I-Group
(	O
for	O
the	O
treatment	O
of	O
hypotension	O
related	O
to	O
obstetric	O
blocks	O
)	O
and	O
ergot	B-Group
-	O
type	I-Group
oxytocic	I-Group
drugs	I-Group
may	O
cause	O
severe	O
persistent	O
hypertension	O
or	O
cerebrovascular	O
accidents	O
.	O
      
Drugs	O
with	O
a	O
Narrow	O
Therapeutic	O
Index	O
Digoxin	B-Drug
:	O
Sonata	B-Brand
(	O
9	O
mg	O
)	O
did	O
not	O
affect	O
the	O
pharmacokinetic	O
or	O
pharmacodynamic	O
profile	O
of	O
digoxin	B-Drug
(	O
9	O
mg	O
q9h	O
for	O
9	O
days	O
)	O
.	O
      
Concomitant	O
administration	O
of	O
drugs	O
known	O
to	O
induce	O
cytochrome	O
P9	O
enzymes	O
may	O
decrease	O
the	O
plasma	O
levels	O
of	O
clozapine	B-Drug
.	O
      
(	O
The	O
two	O
drugs	O
were	O
administered	O
in	O
opposite	O
nostrils	O
.	O
)	O
      
There	O
are	O
no	O
controlled	O
studies	O
documenting	O
the	O
use	O
of	O
ZEMURON	B-Brand
before	O
or	O
after	O
other	O
nondepolarizing	B-Group
muscle	I-Group
relaxants	I-Group
.	O
      
Therefore	O
diphenoxylate	B-Drug
has	O
the	O
potential	O
to	O
prolong	O
the	O
biological	O
half	O
-	O
lives	O
of	O
drugs	O
for	O
which	O
the	O
rate	O
of	O
elimination	O
is	O
dependent	O
on	O
the	O
microsomal	O
drug	O
metabolizing	O
enzyme	O
system	O
.	O
      
Nevertheless	O
caution	O
is	O
indicated	O
in	O
the	O
coadministration	O
of	O
TCAs	B-Group
with	O
any	O
of	O
the	O
SSRIs	B-Group
and	O
also	O
in	O
switching	O
from	O
one	O
class	O
to	O
the	O
other	O
.	O
      
Nafazodone	B-Drug
fluvoxamine	B-Drug
cimetidine	B-Drug
(	O
consider	O
Xanax	B-Brand
dose	O
reduction	O
)	O
.	O
      
Zalcitabine	B-Drug
inhibited	O
lamivudine	B-Drug
phosphorylation	O
at	O
high	O
concentration	O
ratios	O
(	O
9	O
and	O
9	O
)	O
;	O
      
Co	O
-	O
administration	O
of	O
SUTENT	B-Brand
with	O
strong	O
inhibitors	O
of	O
the	O
CYP9A9	O
family	O
(	O
e.g.	O
ketoconazole	B-Drug
itraconazole	B-Drug
clarithromycin	B-Drug
atazanavir	B-Drug
indinavir	B-Drug
nefazodone	B-Drug
nelfinavir	B-Drug
ritonavir	B-Drug
saquinavir	B-Drug
telithromycin	B-Drug
voriconizole	B-Drug
)	O
may	O
increases	O
sunitinib	B-Drug
concentrations	O
.	O
      
Because	O
many	O
drugs	O
are	O
excreted	O
in	O
human	O
milk	O
and	O
because	O
of	O
the	O
potential	O
for	O
serious	O
adverse	O
reactions	O
from	O
FASLODEX	B-Brand
in	O
nursing	O
infants	O
a	O
decision	O
should	O
be	O
made	O
whether	O
to	O
discontinue	O
nursing	O
or	O
to	O
discontinue	O
the	O
drug	O
taking	O
into	O
account	O
the	O
importance	O
of	O
the	O
drug	O
to	O
the	O
mother	O
.	O
      
Other	O
drugs	O
Drug	O
interactions	O
have	O
been	O
reported	O
with	O
concomitant	O
administration	O
of	O
erythromycin	B-Drug
and	O
other	O
medications	O
including	O
cyclosporine	B-Drug
hexobarbital	B-Drug
carbamazepine	B-Drug
alfentanil	B-Drug
disopyramide	B-Drug
phenytoin	B-Drug
bromocriptine	B-Drug
valproate	B-Drug
astemizole	B-Drug
and	O
lovastatin	B-Drug
.	O
      
Because	O
tetracyclines	B-Group
have	O
been	O
shown	O
to	O
depress	O
plasma	O
prothrombin	O
activity	O
patients	O
who	O
are	O
on	O
anticoagulant	B-Group
therapy	O
may	O
require	O
downward	O
adjustment	O
of	O
their	O
anticoagulant	B-Group
dosage	O
.	O
      
Warfarin	B-Drug
:	O
Atorvastatin	B-Drug
had	O
no	O
clinically	O
significant	O
effect	O
on	O
prothrombin	O
time	O
when	O
administered	O
to	O
patients	O
receiving	O
chronic	O
warfarin	B-Drug
treatment	O
.	O
      
Some	O
drugs	B-Drug
/	O
substances	O
are	O
known	O
to	O
accelerate	O
the	O
metabolism	O
of	O
amiodarone	B-Drug
by	O
stimulating	O
the	O
synthesis	O
of	O
CYP9A9	B-Drug
(	O
enzyme	O
induction	O
)	O
.	O
      
Because	O
escitalopram	B-Drug
is	O
metabolized	O
by	O
multiple	O
enzyme	O
systems	O
inhibition	O
of	O
a	O
single	O
enzyme	O
may	O
not	O
appreciably	O
decrease	O
escitalopram	B-Drug
clearance	O
.	O
      
Lapatinib	B-Drug
did	O
not	O
significantly	O
inhibit	O
the	O
following	O
enzymes	O
in	O
human	O
liver	O
microsomes	O
:	O
CYP9A9	O
CYP9C9	O
CYP9C9	O
and	O
CYP9D9	O
or	O
UGT	O
enzymes	O
in	O
vitro	O
however	O
the	O
clinical	O
significance	O
is	O
unknown	O
.	O
      
The	O
overall	O
toxicity	O
profile	O
of	O
the	O
combination	O
revealed	O
an	O
increased	O
incidence	O
of	O
gastrointestinal	O
adverse	O
events	O
especially	O
nausea	O
when	O
compared	O
to	O
the	O
incidence	O
associated	O
with	O
either	O
drug	O
administered	O
alone	O
.	O
      
The	O
possible	O
adverse	O
effects	O
of	O
ZINECARD	B-Brand
on	O
the	O
fertility	O
of	O
humans	O
and	O
experimental	O
animals	O
male	O
or	O
female	O
have	O
not	O
been	O
adequately	O
studied	O
.	O
      
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
reactions	O
such	O
as	O
cardiac	O
arrhythmias	O
.	O
      
Animal	O
studies	O
also	O
suggest	O
an	O
increased	O
potential	O
for	O
seizures	O
when	O
these	O
9	O
drugs	O
are	O
given	O
concomitantly	O
.	O
      
Little	O
or	O
no	O
change	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
drug	O
was	O
observed	O
when	O
VIRACEPT	B-Brand
was	O
coadministered	O
with	O
lamivudine	B-Drug
or	O
stavudine	B-Drug
.	O
      
Cyclophosphamide	B-Drug
used	O
concurrently	O
with	O
Cerubidine	B-Brand
may	O
also	O
result	O
in	O
increased	O
cardiotoxicity	O
.	O
      
In	O
order	O
to	O
avoid	O
lithium	B-Drug
intoxication	O
lithium	B-Drug
plasma	O
levels	O
should	O
be	O
monitored	O
closely	O
.	O
      
Interaction	O
with	O
Food	O
See	O
CLINICAL	O
PHARMACOLOGY	O
Pharmacokinetics	O
and	O
Metabolism	O
.	O
      
Ketoconazole	B-Drug
:	O
Co	O
-	O
administration	O
of	O
9	O
mg	O
twice	O
-	O
daily	O
ketoconazole	B-Drug
with	O
aliskiren	B-Drug
resulted	O
in	O
an	O
approximate	O
9	O
%	O
increase	O
in	O
plasma	O
levels	O
of	O
aliskiren	B-Drug
.	O
      
Example	O
inducers	O
include	O
aminoglutethimide	B-Drug
carbamazepine	B-Drug
nafcillin	B-Drug
nevirapine	B-Drug
phenobarbital	B-Drug
phenytoin	B-Drug
and	O
rifamycins	B-Group
.	O
      
Commonly	O
used	O
drugs	O
such	O
as	O
phenylpropanolamine	B-Drug
and	O
pseudoephedrine	B-Drug
have	O
been	O
specifically	O
studied	O
.	O
      
Sympathomimetics	B-Group
:	O
Metolazone	B-Drug
may	O
decrease	O
arterial	O
responsiveness	O
to	O
norepinephrine	B-Drug
but	O
this	O
diminution	O
is	O
not	O
sufficient	O
to	O
preclude	O
effectiveness	O
of	O
the	O
pressor	O
agent	O
for	O
therapeutic	O
use	O
.	O
      
Felbamate	B-Drug
treatment	O
resulted	O
in	O
a	O
9	O
%	O
decrease	O
in	O
the	O
gestodene	B-Drug
AUC	O
9	O
-	O
9	O
but	O
no	O
clinically	O
relevant	O
effect	O
was	O
observed	O
on	O
the	O
pharmacokinetic	O
parameters	O
of	O
ethinyl	B-Drug
estradiol	I-Drug
.	O
      
If	O
concomitant	O
treatment	O
with	O
sumatriptan	B-Drug
and	O
an	O
SSRI	B-Group
(	O
e.g.	O
fluoxetine	B-Drug
fluvoxamine	B-Drug
paroxetine	B-Drug
sertraline	B-Drug
citalopram	B-Drug
escitalopram	B-Drug
)	O
is	O
clinically	O
warranted	O
appropriate	O
observation	O
of	O
the	O
patient	O
is	O
advised	O
.	O
      
Valproate	B-Drug
9	O
mg	O
twice	O
daily	O
did	O
not	O
modify	O
the	O
rate	O
or	O
extent	O
of	O
levetiracetam	B-Drug
absorption	O
or	O
its	O
plasma	O
clearance	O
or	O
urinary	O
excretion	O
.	O
      
This	O
observed	O
increase	O
in	O
the	O
bioavailability	O
of	O
fexofenadine	B-Drug
may	O
be	O
due	O
to	O
transport	O
-	O
related	O
effects	O
such	O
as	O
p	O
-	O
glycoprotein	O
.	O
in	O
vivo	O
animal	O
studies	O
also	O
suggest	O
that	O
in	O
addition	O
to	O
enhancing	O
absorption	O
ketoconazole	B-Drug
decreases	O
fexofenadine	B-Drug
gastrointestinal	O
secretion	O
while	O
erythromycin	B-Drug
may	O
also	O
decrease	O
biliary	O
excretion	O
.	O
      
9	O
-	O
9	O
      
Intravenous	O
Adenocard	B-Brand
(	O
adenosine	B-Drug
)	O
has	O
been	O
effectively	O
administered	O
in	O
the	O
presence	O
of	O
other	O
cardioactive	O
drugs	O
such	O
as	O
quinidine	B-Drug
beta	B-Group
-	O
adrenergic	I-Group
blocking	I-Group
agents	I-Group
calcium	B-Group
channel	I-Group
blocking	I-Group
agents	I-Group
and	O
angiotensin	B-Group
converting	I-Group
enzyme	I-Group
inhibitors	I-Group
without	O
any	O
change	O
in	O
the	O
adverse	O
reaction	O
profile	O
.	O
      
The	O
effect	O
of	O
administering	O
different	O
botulinum	B-Group
neurotoxin	I-Group
serotypes	O
at	O
the	O
same	O
time	O
or	O
within	O
less	O
than	O
9	O
months	O
of	O
each	O
other	O
is	O
unknown	O
.	O
      
The	O
effects	O
of	O
ERGOMAR	B-Brand
may	O
be	O
potentiated	O
by	O
triacetyloleandomycin	B-Drug
which	O
inhibits	O
the	O
metabolism	O
of	O
ergotamine	B-Drug
.	O
      
.	O
      
Aprepitant	B-Drug
increased	O
the	O
AUC	O
of	O
midazolam	B-Drug
by	O
9	O
%	O
on	O
Day	O
9	O
and	O
decreased	O
the	O
AUC	O
of	O
midazolam	B-Drug
by	O
9	O
%	O
on	O
Day	O
9	O
relative	O
to	O
the	O
dosing	O
of	O
Aprepitant	B-Drug
on	O
Days	O
9	O
through	O
9	O
.	O
      
(	O
e	O
)	O
There	O
may	O
be	O
small	O
changes	O
in	O
coagulation	O
factors	O
.	O
      
Antitubercular	O
drugs	O
:	O
Serum	O
concentrations	O
of	O
isoniazid	B-Drug
may	O
be	O
decreased	O
.	O
      
The	O
daily	O
dose	O
of	O
ENABLEX	B-Brand
should	O
not	O
exceed	O
9	O
mg	O
when	O
coadministered	O
with	O
potent	O
CYP9A9	O
inhibitors	O
(	O
e.g.	O
ketoconazole	B-Drug
itraconazole	B-Drug
ritonavir	B-Drug
nelfinavir	B-Drug
clarithromycin	B-Drug
and	O
nefazadone	O
)	O
.	O
      
Therefore	O
the	O
potential	O
for	O
such	O
drug	O
interaction	O
should	O
be	O
considered	O
in	O
patients	O
receiving	O
AZOPT	B-Brand
(	O
brinzolamide	B-Drug
ophthalmic	O
suspension	O
)	O
9	O
%	O
.	O
      
Probenecid	B-Drug
Prolonged	O
action	O
of	O
etomidate	B-Drug
      
The	O
possibility	O
of	O
hypotensive	O
effects	O
with	O
enalapril	B-Drug
or	O
enalaprilat	B-Drug
can	O
be	O
minimized	O
by	O
either	O
discontinuing	O
the	O
diuretic	B-Drug
or	O
increasing	O
the	O
salt	O
intake	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
enalapril	B-Drug
or	O
enalaprilat	B-Drug
.	O
      
Diphenoxylate	B-Drug
HCl	I-Drug
and	O
atropine	B-Drug
sulfate	I-Drug
may	O
interact	O
with	O
MAO	B-Group
inhibitors	I-Group
In	O
studies	O
with	O
male	O
rats	O
diphenoxylate	B-Drug
hydrochloride	I-Drug
was	O
found	O
to	O
inhibit	O
the	O
hepatic	O
microsomal	O
enzyme	O
system	O
at	O
a	O
dose	O
of	O
9	O
mg	O
/	O
kg	O
/	O
day	O
.	O
      
Patients	O
on	O
oral	O
antidiabetic	B-Group
agents	I-Group
receiving	O
VELCADE	B-Brand
treatment	O
may	O
require	O
close	O
monitoring	O
of	O
their	O
blood	O
glucose	O
levels	O
and	O
adjustment	O
of	O
the	O
dose	O
of	O
their	O
antidiabetic	B-Group
medication	I-Group
.	O
      
Oral	O
doses	O
of	O
Antizol	B-Brand
(	O
9	O
-	O
9	O
mg	O
/	O
kg	O
)	O
via	O
alcohol	O
dehydrogenase	O
inhibition	O
significantly	O
reduced	O
the	O
rate	O
of	O
elimination	O
of	O
ethanol	B-Drug
(	O
by	O
approximately	O
9	O
%	O
)	O
given	O
to	O
healthy	O
volunteers	O
in	O
moderate	O
doses	O
.	O
      
Interactions	O
may	O
also	O
occur	O
with	O
the	O
following	O
:	O
anti	B-Group
-	O
depressants	I-Group
/	O
anti	B-Group
-	O
anxiety	I-Group
drugs	I-Group
drugs	O
used	O
to	O
treat	O
an	O
overactive	O
thyroid	O
beta	B-Group
-	O
blockers	I-Group
(	O
e.g.	O
propranolol	B-Drug
)	O
sparfloxacin	B-Drug
grepafloxacin	B-Drug
guanethidine	B-Drug
guanadrel	B-Drug
metrizamide	B-Drug
cabergoline	B-Drug
lithium	B-Drug
narcotic	B-Group
pain	O
medication	O
(	O
e.g.	O
codeine	B-Drug
)	O
drugs	O
used	O
to	O
aid	O
sleep	O
drowsiness	O
-	O
causing	O
antihistamines	B-Group
(	O
e.g.	O
diphenhydramine	B-Drug
)	O
any	O
other	O
drugs	O
that	O
may	O
make	O
you	O
drowsy	O
.	O
      
When	O
Itraconazole	B-Drug
was	O
coadministered	O
with	O
phenytoin	B-Drug
rifampin	B-Drug
or	O
H9antagonists	O
reduced	O
plasma	O
concentrations	O
of	O
itraconazole	B-Drug
were	O
reported	O
.	O
      
No	O
data	O
are	O
available	O
for	O
the	O
coadministration	O
of	O
INVIRASE	B-Brand
/	O
ritonavir	B-Drug
or	O
FORTOVASE	B-Brand
/	O
ritonavir	B-Drug
and	O
garlic	O
capsules	O
.	O
      
Atromid	B-Brand
-	O
S	I-Brand
may	O
displace	O
acidic	O
drugs	O
such	O
as	O
phenytoin	B-Drug
or	O
tolbutamide	B-Drug
from	O
their	O
binding	O
sites	O
.	O
      
Oral	O
contraceptives	B-Group
may	O
be	O
less	O
effective	O
while	O
you	O
are	O
taking	O
lymecycline	B-Drug
.	O
      
Mixtures	O
should	O
not	O
be	O
administered	O
intravenously	O
.	O
      
These	O
effects	O
have	O
been	O
observed	O
with	O
co	O
-	O
administration	O
of	O
itraconazole	B-Drug
(	O
a	O
potent	O
CYP9A9	B-Drug
inhibitor	O
)	O
.	O
      
decreased	O
pharmacologic	O
effect	O
of	O
aspirin	B-Brand
.	O
      
Potentiation	O
occurs	O
with	O
ganglionic	B-Group
or	O
peripheral	B-Group
adrenergic	I-Group
blocking	I-Group
drugs	I-Group
.	O
      
bromelains	B-Drug
;	O
      
There	O
was	O
no	O
effect	O
of	O
a	O
single	O
dose	O
or	O
multiple	O
doses	O
of	O
MYCAMINE	B-Brand
on	O
mycophenolate	B-Drug
mofetil	I-Drug
cyclosporine	B-Drug
tacrolimus	B-Drug
prednisolone	B-Drug
and	O
fluconazole	B-Drug
pharmacokinetics	O
.	O
      
Blood	O
levels	O
of	O
hydrodolasetron	B-Drug_n
increased	O
9	O
%	O
when	O
dolasetron	B-Drug
was	O
coadministered	O
with	O
cimetidine	B-Drug
(	O
nonselective	O
inhibitor	O
of	O
cytochrome	O
P	O
-	O
9	O
)	O
for	O
9	O
days	O
and	O
decreased	O
9	O
%	O
with	O
coadministration	O
of	O
rifampin	B-Drug
(	O
potent	O
inducer	O
of	O
cytochrome	O
P	O
-	O
9	O
)	O
for	O
9	O
days	O
.	O
      
.	O
      
Drugs	O
Metabolized	O
by	O
Cytochrome	O
P9	O
Enzymes	O
The	O
drug	O
interaction	O
study	O
evaluating	O
the	O
effect	O
of	O
grepafloxacin	B-Drug
on	O
theophylline	B-Drug
indicates	O
that	O
grepafloxacin	B-Drug
inhibits	O
theophylline	B-Drug
metabolism	O
which	O
is	O
mediated	O
by	O
CYP9A9	O
.	O
      
No	O
abortifacient	O
or	O
teratogenic	O
effects	O
were	O
observed	O
in	O
cynomolgus	O
monkeys	O
following	O
intravenous	O
bolus	O
injections	O
of	O
AMEVIVE	B-Brand
administered	O
weekly	O
during	O
the	O
period	O
of	O
organogenesis	O
to	O
gestation	O
.	O
      
DIPRIVAN	B-Brand
Injectable	O
Emulsion	O
does	O
not	O
cause	O
a	O
clinically	O
significant	O
change	O
in	O
onset	O
intensity	O
or	O
duration	O
of	O
action	O
of	O
the	O
commonly	O
used	O
neuromuscular	B-Group
blocking	I-Group
agents	I-Group
(	O
eg	O
succinylcholine	B-Drug
and	O
nondepolarizing	B-Group
muscle	I-Group
relaxants	I-Group
)	O
.	O
      
In	O
a	O
crossover	O
study	O
in	O
9	O
pediatric	O
patients	O
I.V	O
.	O
      
Concurrent	O
use	O
of	O
tetracyclines	B-Group
with	O
oral	O
contraceptives	B-Group
may	O
render	O
oral	O
contraceptives	B-Group
less	O
effective	O
.	O
      
Anticholinergic	B-Group
agents	I-Group
may	O
potentially	O
alter	O
the	O
absorption	O
of	O
some	O
concomitantly	O
administered	O
drugs	O
due	O
to	O
effects	O
on	O
gastrointestinal	O
motility	O
.	O
      
You	O
can	O
not	O
take	O
mazindol	B-Drug
if	O
you	O
have	O
taken	O
a	O
monoamine	B-Group
oxidase	I-Group
inhibitor	I-Group
(	O
MAOI	B-Group
)	O
such	O
as	O
isocarboxazid	B-Drug
(	O
Marplan	B-Brand
)	O
tranylcypromine	B-Drug
(	O
Parnate	B-Brand
)	O
or	O
phenelzine	B-Drug
(	O
Nardil	B-Brand
)	O
in	O
the	O
last	O
9	O
days	O
.	O
      
Other	O
drugs	O
which	O
may	O
enhance	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
nondepolarizing	O
agents	O
such	O
as	O
NUROMAX	B-Brand
include	O
certain	O
antibiotics	B-Group
(	O
e.	O
g.	O
aminoglycosides	B-Group
tetracyclines	B-Group
bacitracin	B-Group
polymyxins	B-Group
lincomycin	B-Drug
clindamycin	B-Drug
colistin	B-Drug
and	O
sodium	B-Drug
colistimethate	I-Drug
)	O
magnesium	B-Drug
salts	O
lithium	B-Drug
local	O
anesthetics	B-Group
procainamide	B-Drug
and	O
quinidine	B-Drug
.	O
      
-	O
Mercaptopurine	B-Drug
(	O
e.g.	O
Purinethol	B-Brand
)	O
or	O
      
In	O
vivo	O
studies	O
:	O
Cytochrome	O
P9	O
Inhibitors	O
      
Clinical	O
experience	O
with	O
concomitant	O
administration	O
of	O
bosentan	B-Drug
and	O
warfarin	B-Drug
in	O
patients	O
with	O
pulmonary	O
arterial	O
hypertension	O
did	O
not	O
show	O
clinically	O
relevant	O
changes	O
in	O
INR	O
or	O
warfarin	B-Drug
dose	O
(	O
baseline	O
vs.	O
end	O
of	O
the	O
clinical	O
studies	O
)	O
and	O
the	O
need	O
to	O
change	O
the	O
warfarin	B-Drug
dose	O
during	O
the	O
trials	O
due	O
to	O
changes	O
in	O
INR	O
or	O
due	O
to	O
adverse	O
events	O
was	O
similar	O
among	O
bosentan	B-Drug
-	O
and	O
placebo	O
-	O
treated	O
patients	O
.	O
      
Such	O
individuals	O
are	O
referred	O
to	O
as	O
poor	O
metabolizers	O
of	O
drugs	O
such	O
as	O
debrisoquin	B-Drug
dextromethorphan	B-Drug
the	O
tricyclic	B-Group
antidepressants	I-Group
and	O
clozapine	B-Drug
.	O
      
Data	O
suggest	O
that	O
coadministration	O
of	O
oral	O
ketoconazole	B-Drug
and	O
cisapride	B-Drug
can	O
result	O
in	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O
      
They	O
may	O
be	O
administered	O
alternately	O
when	O
the	O
preceding	O
effect	O
of	O
other	O
such	O
drug	O
has	O
subsided	O
.	O
      
Renal	O
clearance	O
measurements	O
of	O
PAH	B-Drug
can	O
not	O
be	O
made	O
with	O
any	O
significant	O
accuracy	O
in	O
patients	O
receiving	O
sulfonamides	B-Group
procaine	B-Drug
or	O
thiazolesulfone	B-Drug
.	O
      
Clinical	O
significance	O
of	O
reduced	O
efavirenz	B-Drug
concentrations	O
unknown	O
.	O
      
In	O
clinical	O
studies	O
performed	O
with	O
Fondaparinux	B-Drug
the	O
concomitant	O
use	O
of	O
oral	O
anticoagulants	B-Group
(	O
warfarin	B-Drug
)	O
platelet	B-Group
inhibitors	I-Group
(	O
acetylsalicylic	B-Drug
acid	I-Drug
)	O
NSAIDs	B-Group
(	O
piroxicam	B-Drug
)	O
and	O
digoxin	B-Drug
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
/	O
pharmacodynamics	O
of	O
fondaparinux	B-Drug
sodium	I-Drug
.	O
      
Other	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
drugs	I-Group
that	O
inhibit	O
prostaglandin	O
synthesis	O
have	O
been	O
shown	O
to	O
interfere	O
with	O
thiazide	B-Group
diuretics	I-Group
in	O
some	O
studies	O
and	O
with	O
potassium	B-Group
-	O
sparing	I-Group
diuretics	I-Group
.	O
      
The	O
effects	O
seen	O
are	O
poorly	O
understood	O
and	O
depend	O
upon	O
a	O
variety	O
of	O
factors	O
such	O
as	O
dose	O
and	O
type	O
of	O
thyroid	B-Group
preparations	I-Group
and	O
endocrine	O
status	O
of	O
the	O
patient	O
.	O
      
Patients	O
receiving	O
antihistamines	B-Group
should	O
be	O
advised	O
against	O
the	O
concurrent	O
use	O
of	O
other	O
CNS	B-Group
depressant	I-Group
drugs	I-Group
.	O
      
No	O
clinically	O
significant	O
changes	O
to	O
lamivudine	B-Drug
or	O
zidovudine	B-Drug
pharmacokinetics	O
were	O
observed	O
following	O
concomitant	O
administration	O
of	O
abacavir	B-Drug
.	O
      
The	O
effects	O
of	O
fulvestrant	B-Drug
on	O
the	O
fertility	O
of	O
female	O
rats	O
appear	O
to	O
be	O
consistent	O
with	O
its	O
anti	O
-	O
estrogenic	O
activity	O
.	O
      
Although	O
the	O
pattern	O
of	O
use	O
for	O
oral	O
allopurinol	B-Drug
includes	O
longer	O
term	O
therapy	O
particularly	O
for	O
gout	O
and	O
renal	O
calculi	O
the	O
experience	O
gained	O
may	O
be	O
relevant	O
.	O
      
Therefore	O
careful	O
monitoring	O
is	O
advised	O
.	O
      
Gastroparesis	O
(	O
gastric	O
stasis	O
)	O
may	O
be	O
responsible	O
for	O
poor	O
diabetic	O
control	O
in	O
some	O
patients	O
.	O
      
.	O
      
N=9	O
)	O
decreases	O
hydrocodone	B-Drug
(	O
9	O
mg	O
;	O
      
Antacids	B-Group
:	O
Concomitant	O
administration	O
of	O
antacids	B-Group
may	O
reduce	O
plasma	O
levels	O
of	O
diflunisal	B-Drug
.	O
      
Therefore	O
if	O
an	O
inhibitor	O
or	O
an	O
inducer	O
of	O
CYP9C9	O
is	O
started	O
or	O
stopped	O
during	O
treatment	O
with	O
rosiglitazone	B-Drug
changes	O
in	O
diabetes	O
treatment	O
may	O
be	O
needed	O
based	O
upon	O
clinical	O
response	O
.	O
      
FORADIL	B-Brand
is	O
not	O
meant	O
to	O
relieve	O
acute	O
asthma	O
or	O
COPD	O
symptoms	O
and	O
extra	O
doses	O
should	O
not	O
be	O
used	O
for	O
that	O
purpose	O
.	O
      
After	O
9	O
days	O
of	O
co	O
-	O
administration	O
mean	O
trough	O
concentrations	O
of	O
clozapine	B-Drug
and	O
its	O
metabolites	O
N	B-Drug_n
-	O
desmethylclozapine	I-Drug_n
and	O
clozapine	B-Drug_n
N	I-Drug_n
-	O
oxide	I-Drug_n
were	O
elevated	O
with	O
fluvoxamine	B-Drug
by	O
about	O
three	O
-	O
fold	O
compared	O
to	O
baseline	O
concentrations	O
.	O
      
Since	O
a	O
clinically	O
significant	O
interaction	O
may	O
be	O
anticipated	O
alternative	O
antihypertensive	B-Drug
therapy	O
should	O
be	O
considered	O
in	O
these	O
patients	O
.	O
      
Plasma	O
concentrations	O
of	O
quinolone	B-Group
antibiotics	I-Group
are	O
decreased	O
when	O
administered	O
with	O
antacids	B-Group
containing	O
magnesium	B-Drug
calcium	B-Drug
or	O
aluminum	B-Drug
.	O
      
Cimetidine	O
Co	O
-	O
administration	O
of	O
felodipine	B-Drug
with	O
cimetidine	B-Drug
(	O
a	O
non	O
-	O
specific	O
CYP	O
-	O
9	O
inhibitor	O
)	O
resulted	O
in	O
an	O
increase	O
of	O
approximately	O
9	O
%	O
in	O
the	O
AUC	O
and	O
the	O
Cmax	O
of	O
felodipine	B-Drug
.	O
      
Drugs	O
Decreasing	O
Heparin	B-Drug
Effect	O
:	O
Digitalis	B-Group
tetracyclines	B-Group
nicotine	B-Drug
or	O
antihistamines	B-Group
may	O
partially	O
counteract	O
the	O
anticoagulant	O
action	O
of	O
heparin	B-Drug
sodium	I-Drug
.	O
      
Preliminary	O
studies	O
indicate	O
that	O
the	O
concomitant	O
use	O
of	O
dobutamine	B-Drug
and	O
nitroprusside	B-Drug
results	O
in	O
a	O
higher	O
cardiac	O
output	O
and	O
usually	O
a	O
lower	O
pulmonary	O
wedge	O
pressure	O
than	O
when	O
either	O
drug	O
is	O
used	O
alone	O
.	O
      
Use	O
of	O
a	O
nonhormonal	B-Group
contraceptive	I-Group
product	I-Group
is	O
recommended	O
.	O
      
Ranitidine	B-Drug
produced	O
smaller	O
non	O
-	O
significant	O
increases	O
.	O
      
InjectionSite	O
Reaction	O
:	O
Injection	O
site	O
reactions	O
including	O
reactions	O
secondary	O
to	O
extravasation	O
were	O
usually	O
mild	O
and	O
consisted	O
of	O
erythema	O
tenderness	O
skin	O
discoloration	O
or	O
swelling	O
at	O
the	O
injection	O
site	O
.	O
      
Accordingly	O
careful	O
patient	O
monitoring	O
and	O
dose	O
adjustment	O
of	O
metformin	B-Drug
is	O
recommended	O
in	O
patients	O
concomitantly	O
taking	O
cephalexin	B-Drug
and	O
metformin	B-Drug
.	O
      
Nifedipine	B-Drug
AUC	O
and	O
Cmax	O
were	O
increased	O
by	O
9	O
%	O
and	O
9	O
%	O
respectively	O
in	O
the	O
presence	O
of	O
steady	O
-	O
state	O
MYCAMINE	B-Brand
compared	O
with	O
nifedipine	B-Drug
alone	O
.	O
      
chlordiazepoxide	B-Drug
;	O
      
Consequently	O
the	O
combination	O
of	O
methotrexate	B-Drug
with	O
acitretin	B-Drug
is	O
also	O
contraindicated	O
.	O
      
If	O
chlorprothixene	B-Drug
is	O
given	O
concomitantly	O
with	O
opioids	B-Group
the	O
opioid	B-Group
dose	O
should	O
be	O
reduced	O
(	O
by	O
approx	O
.	O
9	O
%	O
)	O
because	O
chlorprothixene	B-Drug
amplifies	O
the	O
therapeutic	O
actions	O
and	O
side	O
-	O
effects	O
of	O
opioids	B-Group
massively	O
.	O
      
These	O
data	O
indicate	O
that	O
levetiracetam	B-Drug
does	O
not	O
influence	O
the	O
plasma	O
concentration	O
of	O
other	O
AEDs	B-Group
and	O
that	O
these	O
AEDs	B-Group
do	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
levetiracetam	B-Drug
.	O
      
Aspirin	B-Brand
/	O
Nonsteroidal	B-Group
Antiinflammatory	I-Group
Drugs	I-Group
(	O
NSAIDs	B-Group
)	O
      
In	O
the	O
large	O
placebo	O
-	O
controlled	O
osteoporosis	O
Treatment	O
Study	O
aspirin	B-Brand
and	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
drugs	I-Group
were	O
taken	O
by	O
9	O
%	O
of	O
the	O
9	O
patients	O
.	O
      
Therefore	O
monitoring	O
of	O
blood	O
glucose	O
is	O
recommended	O
when	O
these	O
agents	O
are	O
co	O
-	O
administered	O
.	O
      
Sertraline	B-Drug
      
Phenytoin	B-Drug
:	O
Serum	O
phenytoin	B-Drug
levels	O
may	O
be	O
increased	O
by	O
aspirin	B-Brand
.	O
      
The	O
bioavailability	O
of	O
perindoprilat	B-Drug_n
was	O
reduced	O
by	O
diuretics	B-Group
however	O
and	O
this	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
plasma	O
ACE	O
inhibition	O
.	O
      
No	O
interaction	O
with	O
the	O
tricyclic	B-Group
antidepressant	I-Group
imipramine	B-Drug
was	O
shown	O
in	O
a	O
single	O
-	O
dose	O
study	O
with	O
entacapone	B-Drug
without	O
coadministered	O
levodopa	B-Drug
/	O
dopa	B-Group
-	O
decarboxylase	I-Group
inhibitor	I-Group
.	O
      
Although	O
deferasirox	B-Drug
has	O
a	O
lower	O
affinity	O
for	O
aluminum	B-Drug
than	O
for	O
iron	B-Drug
Exjade	B-Brand
should	O
not	O
be	O
taken	O
with	O
aluminum	B-Drug
-	O
containing	O
antacid	B-Group
preparations	I-Group
.	O
      
Short	O
-	O
term	O
controlled	O
studies	O
failed	O
to	O
show	O
that	O
taking	O
the	O
drug	O
significantly	O
affects	O
prothrombin	O
times	O
when	O
administered	O
to	O
individuals	O
on	O
coumarin	B-Group
-	O
type	I-Group
anticoagulants	I-Group
.	O
      
In	O
a	O
formal	O
study	O
benzodiazepines	B-Group
were	O
shown	O
not	O
to	O
affect	O
Mexitil	B-Brand
plasma	O
concentrations	O
.	O
      
The	O
appropriate	O
doses	O
for	O
this	O
combination	O
with	O
respect	O
to	O
efficacy	O
and	O
safety	O
have	O
not	O
been	O
established	O
.	O
      
Oral	O
Contraceptives	B-Group
:	O
Given	O
the	O
different	O
metabolism	O
of	O
Myfortic	B-Brand
and	O
oral	O
contraceptives	B-Group
no	O
drug	O
interaction	O
between	O
these	O
two	O
classes	O
of	O
drug	O
is	O
expected	O
.	O
      
When	O
used	O
concomitantly	O
anesthetics	B-Group
and	O
calcium	B-Group
channel	I-Group
blockers	I-Group
should	O
be	O
titrated	O
carefully	O
.	O
      
Coadministration	O
with	O
acetaminophen	B-Drug
reduced	O
the	O
peak	O
concentration	O
and	O
AUC	O
values	O
for	O
rimantadine	B-Drug
by	O
approximately	O
9	O
%	O
.	O
      
It	O
is	O
however	O
possible	O
that	O
concomitant	O
use	O
of	O
other	O
known	O
photosensitizing	B-Group
agents	I-Group
such	O
as	O
griseofulvin	B-Drug
thiazide	B-Group
diuretics	I-Group
sulfonylureas	B-Group
phenothiazines	B-Group
sulfonamides	B-Group
and	O
tetracyclines	B-Group
might	O
increase	O
the	O
photosensitivity	O
reaction	O
of	O
actinic	O
keratoses	O
treated	O
with	O
the	O
LEVULAN	B-Brand
KERASTICK	I-Brand
for	O
Topical	O
Solution	O
.	O
      
Digoxin	B-Drug
:	O
Concomitant	O
administration	O
of	O
erythromycin	B-Drug
and	O
digoxin	B-Drug
has	O
been	O
reported	O
to	O
result	O
in	O
elevated	O
digoxin	B-Drug
serum	O
levels	O
.	O
      
9	O
.	O
      
Warfarin	B-Drug
:	O
Anticoagulant	O
activity	O
should	O
be	O
monitored	O
particularly	O
in	O
the	O
first	O
few	O
days	O
after	O
initiating	O
or	O
changing	O
VIOXX	B-Brand
therapy	O
in	O
patients	O
receiving	O
warfarin	B-Drug
or	O
similar	O
agents	O
since	O
these	O
patients	O
are	O
at	O
an	O
increased	O
risk	O
of	O
bleeding	O
complications	O
.	O
      
-	O
Etretinate	B-Drug
(	O
e.g.	O
Tegison	B-Brand
)	O
or	O
      
Cyclosporine	B-Drug
:	O
Modest	O
increases	O
in	O
mean	O
trough	O
cyclosporine	B-Drug
concentrations	O
were	O
observed	O
following	O
initiation	O
of	O
carvedilol	B-Drug
treatment	O
in	O
9	O
renal	O
transplant	O
patients	O
suffering	O
from	O
chronic	O
vascular	O
rejection	O
.	O
      
If	O
a	O
diuretic	B-Group
is	O
also	O
used	O
the	O
risk	O
of	O
lithium	B-Drug
toxicity	O
may	O
be	O
increased	O
.	O
      
Caution	O
should	O
be	O
exercised	O
when	O
Methergine	B-Brand
(	O
methylergonovine	B-Drug
maleate	I-Drug
)	O
is	O
used	O
concurrently	O
with	O
other	O
vasoconstrictors	B-Group
or	O
ergot	B-Group
alkaloids	I-Group
.	O
      
However	O
since	O
there	O
is	O
an	O
increased	O
risk	O
of	O
bleeding	O
with	O
Xigris	B-Brand
caution	O
should	O
be	O
employed	O
when	O
Xigris	B-Brand
is	O
used	O
with	O
other	O
drugs	O
that	O
affect	O
hemostasis	O
.	O
      
Dosage	O
of	O
the	O
anticoagulant	B-Group
may	O
have	O
to	O
be	O
decreased	O
in	O
order	O
to	O
maintain	O
desired	O
prothrombin	O
time	O
.	O
      
Therefore	O
when	O
central	B-Group
nervous	I-Group
system	I-Group
depressants	I-Group
are	O
administered	O
concomitantly	O
with	O
hydroxyzine	B-Drug
their	O
dosage	O
should	O
be	O
reduced	O
.	O
      
A	O
variety	O
of	O
neurological	O
toxic	O
effects	O
and	O
malignant	O
hyperpyrexia	O
can	O
occur	O
sometimes	O
with	O
fatal	O
results	O
.	O
      
Thiazides	B-Group
may	O
decrease	O
arterial	O
responsiveness	O
to	O
norepinephrine	B-Drug
.	O
      
Conversion	O
could	O
be	O
affected	O
by	O
alterations	O
in	O
the	O
level	O
of	O
phosphatase	O
activity	O
but	O
given	O
the	O
abundance	O
and	O
wide	O
distribution	O
of	O
phosphatases	O
in	O
the	O
body	O
it	O
is	O
unlikely	O
that	O
drugs	O
would	O
affect	O
this	O
activity	O
enough	O
to	O
affect	O
conversion	O
of	O
fosphenytoin	B-Drug
to	O
phenytoin	B-Drug
.	O
      
Ketoconazole	B-Drug
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
cytochrome	O
P9	O
9A9	O
enzyme	O
system	O
.	O
      
The	O
effect	O
of	O
TORADOL	B-Brand
on	O
plasma	O
lithium	B-Drug
has	O
not	O
been	O
studied	O
but	O
cases	O
of	O
increased	O
lithium	B-Drug
plasma	O
levels	O
during	O
TORADOL	B-Brand
therapy	O
have	O
been	O
reported	O
.	O
      
Potential	O
for	O
Duloxetine	B-Drug
to	O
Affect	O
Other	O
Drugs	O
:	O
Drugs	O
Metabolized	O
by	O
CYP9A9	O
:	O
In	O
vitro	O
drug	O
interaction	O
studies	O
demonstrate	O
that	O
duloxetine	B-Drug
does	O
not	O
induce	O
CYP9A9	O
activity	O
and	O
it	O
is	O
unlikely	O
to	O
have	O
a	O
clinically	O
significant	O
effect	O
on	O
the	O
metabolism	O
of	O
CYP9A9	O
substrates	O
.	O
      
Anticholinesterases	B-Group
:	O
Concurrent	O
use	O
of	O
procaine	B-Drug
hydrochloride	I-Drug
and	O
anticholinesterase	B-Group
agents	I-Group
may	O
result	O
in	O
increased	O
systemic	O
toxicity	O
since	O
anticholinesterases	B-Group
inhibit	O
the	O
breakdown	O
of	O
procaine	B-Drug
hydrochloride	I-Drug
.	O
      
The	O
threohydrobupropion	B-Drug_n
metabolite	O
of	O
bupropion	B-Drug
does	O
not	O
appear	O
to	O
be	O
produced	O
by	O
the	O
cytochrome	O
P9	O
isoenzymes	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Corticosteroids	B-Group
may	O
affect	O
the	O
nitrobluetetrazolium	O
test	O
for	O
bacterial	O
infection	O
and	O
produce	O
false	O
-	O
negative	O
results	O
      
Ketoconazole	B-Drug
tablets	O
may	O
alter	O
the	O
metabolism	O
of	O
cyclosporine	B-Drug
tacrolimus	B-Drug
and	O
methylprednisolone	B-Drug
resulting	O
in	O
elevated	O
plasma	O
concentrations	O
of	O
the	O
latter	O
drugs	O
.	O
      
Carcinogenesis	O
Mutagenesis	O
Impairment	O
of	O
Fertility	O
Carcinogenesis	O
PEGASYS	B-Brand
has	O
not	O
been	O
tested	O
for	O
its	O
carcinogenic	O
potential	O
.	O
      
In	O
vitro	O
raloxifene	B-Drug
did	O
not	O
affect	O
the	O
binding	O
of	O
warfarin	B-Drug
phenytoin	B-Drug
or	O
tamoxifen	B-Drug
.	O
      
Anticoagulant	B-Brand
therapy	O
should	O
be	O
monitored	O
particularly	O
during	O
the	O
first	O
few	O
weeks	O
after	O
initiating	O
therapy	O
with	O
BEXTRA	B-Brand
in	O
patients	O
receiving	O
warfarin	B-Drug
or	O
similar	O
agents	O
.	O
      
Therophylline	O
:	O
A	O
recent	O
study	O
has	O
shown	O
that	O
concomitan	O
administration	O
of	O
isoniazid	B-Drug
and	O
theophylline	B-Drug
may	O
cause	O
elevated	O
plasma	O
levels	O
of	O
theophylline	B-Drug
and	O
in	O
some	O
instances	O
a	O
slight	O
decrease	O
in	O
the	O
elimination	O
of	O
isoniazid	B-Drug
.	O
      
Even	O
though	O
such	O
interactions	O
were	O
not	O
seen	O
during	O
clinical	O
studies	O
with	O
nicardipine	B-Drug
HCl	I-Drug
an	O
increased	O
volume	O
of	O
circulating	O
fluids	O
might	O
be	O
required	O
if	O
such	O
an	O
interaction	O
were	O
to	O
occur	O
.	O
      
However	O
the	O
extent	O
of	O
biotransformation	O
of	O
perindopril	B-Drug
to	O
the	O
active	O
metabolite	O
perindoprilat	B-Drug_n
is	O
reduced	O
approximately	O
9	O
%	O
resulting	O
in	O
a	O
reduction	O
in	O
the	O
plasma	O
ACE	O
inhibition	O
curve	O
of	O
approximately	O
9	O
%	O
probably	O
clinically	O
insignificant	O
.	O
      
CNS	O
Acting	O
Drugs	O
:	O
Given	O
the	O
primary	O
CNS	O
effects	O
of	O
Duloxetine	B-Drug
it	O
should	O
be	O
used	O
with	O
caution	O
when	O
it	O
is	O
taken	O
in	O
combination	O
with	O
or	O
substituted	O
for	O
other	O
centrally	O
acting	O
drugs	O
including	O
those	O
with	O
a	O
similar	O
mechanism	O
of	O
action	O
.	O
      
Investigations	O
into	O
the	O
effect	O
of	O
acitretin	B-Drug
on	O
the	O
protein	O
binding	O
of	O
anticoagulants	B-Group
of	I-Group
the	I-Group
coumarin	I-Group
type	I-Group
(	O
warfarin	B-Drug
)	O
revealed	O
no	O
interaction	O
.	O
      
Propranolol	B-Drug
:	O
May	O
decrease	O
aspirins	B-Brand
anti	O
-	O
inflammatory	O
action	O
by	O
competing	O
for	O
the	O
same	O
receptors	O
.	O
      
Therefore	O
use	O
of	O
zidovudine	B-Drug
in	O
combination	O
with	O
ZERIT	B-Brand
should	O
be	O
avoided	O
.	O
      
Serum	O
digitalis	B-Group
levels	O
may	O
be	O
decreased	O
in	O
hyperthyroidism	O
or	O
when	O
a	O
hypothyroid	O
patient	O
becomes	O
euthyroid	O
.	O
      
The	O
clinical	O
significance	O
of	O
these	O
changes	O
has	O
not	O
been	O
adequately	O
studied	O
.	O
      
Olanzapine	B-Drug
:	O
Coadministration	O
of	O
eszopiclone	B-Drug
9	O
mg	O
and	O
olanzapine	B-Drug
9	O
mg	O
produced	O
a	O
decrease	O
in	O
DSST	O
scores	O
.	O
      
Diagnostic	O
dip	O
-	O
stick	O
methodology	O
used	O
to	O
detect	O
ketone	O
bodies	O
in	O
urine	O
has	O
resulted	O
in	O
false	O
-	O
positive	O
findings	O
in	O
some	O
patients	O
treated	O
with	O
Lodine	B-Brand
.	O
      
Possible	O
drug	O
interactions	O
of	O
HUMORSOL	B-Brand
with	O
succinylcholine	B-Drug
or	O
with	O
other	O
anticholinesterase	B-Group
agents	I-Group
.	O
      
The	O
pharmacokinetics	O
and	O
protein	O
binding	O
of	O
fosphenytoin	B-Drug
phenytoin	B-Drug
and	O
diazepam	B-Drug
were	O
not	O
altered	O
when	O
diazepam	B-Drug
and	O
Cerebyx	B-Brand
were	O
concurrently	O
administered	O
in	O
single	O
submaximal	O
doses	O
.	O
      
Drug	O
Interactions	O
with	O
Beta	B-Group
-	O
Blockers	I-Group
:	O
Concomitant	O
use	O
of	O
fenoldopam	B-Drug
with	O
beta	B-Group
-	O
blockers	I-Group
should	O
be	O
avoided	O
.	O
      
Warfarin	B-Drug
:	O
Anticoagulant	O
activity	O
should	O
be	O
monitored	O
particularly	O
in	O
the	O
first	O
few	O
days	O
after	O
initiating	O
or	O
changing	O
MOBIC	B-Brand
therapy	O
in	O
patients	O
receiving	O
warfarin	B-Drug
or	O
similar	O
agents	O
since	O
these	O
patients	O
are	O
at	O
an	O
increased	O
risk	O
of	O
bleeding	O
.	O
      
Clinical	O
studies	O
in	O
healthy	O
volunteers	O
show	O
that	O
the	O
pharmacokinetics	O
of	O
CANCIDAS	B-Brand
are	O
not	O
altered	O
by	O
itraconazole	B-Drug
amphotericin	B-Drug
B	I-Drug
mycophenolate	B-Drug
nelfinavir	B-Drug
or	O
tacrolimus	B-Drug
.	O
      
May	O
lead	O
to	O
loss	O
of	O
virologic	O
response	O
and	O
possible	O
resistance	O
to	O
CRIXIVAN	B-Brand
or	O
to	O
the	O
class	O
of	O
protease	B-Group
inhibitors	I-Group
.	O
      
Other	O
plasma	O
proteins	O
may	O
be	O
increased	O
(	O
angiotensinogen	O
/	O
renin	O
substrate	O
alpha	O
-	O
9	O
-	O
antitrypsin	O
ceruloplasmin	O
)	O
.	O
      
CYP9A9	O
Inhibitors	O
:	O
Ketoconazole	B-Drug
an	O
inhibitor	O
of	O
the	O
drug	O
metabolizing	O
enzyme	O
CYP9A9	O
significantly	O
increased	O
plasma	O
concentrations	O
of	O
tolterodine	B-Drug
when	O
coadministered	O
to	O
subjects	O
who	O
were	O
poor	O
metabolizers	O
(	O
see	O
CLINICAL	O
PHARMACOLOGY	O
Variability	O
in	O
Metabolism	O
and	O
Drug	O
-	O
Drug	O
Interactions	O
)	O
.	O
      
Cisapride	B-Drug
should	O
not	O
be	O
used	O
concomitantly	O
with	O
other	O
drugs	O
known	O
to	O
prolong	O
the	O
QT	O
interval	O
:	O
certain	O
antiarrhythmics	B-Group
including	O
those	O
of	O
Class	O
IA	O
(	O
such	O
as	O
quinidine	B-Drug
and	O
procainamide	B-Drug
)	O
and	O
Class	O
III	O
(	O
such	O
as	O
sotalol	B-Drug
)	O
;	O
      
therefore	O
these	O
combinations	O
should	O
be	O
used	O
with	O
caution	O
.	O
      
Dosage	O
adjustments	O
of	O
other	O
antihypertensives	B-Group
may	O
be	O
necessary	O
.	O
      
The	O
pharmacokinetic	O
interactions	O
listed	O
below	O
are	O
potentially	O
clinically	O
important	O
.	O
      
There	O
are	O
reports	O
of	O
enhanced	O
as	O
well	O
as	O
diminished	O
effects	O
of	O
anticoagulant	B-Group
when	O
given	O
concurrently	O
with	O
corticosteroids	B-Group
.	O
      
Other	O
Chemotherapy	O
Agents	O
In	O
a	O
separate	O
study	O
concomitant	O
administration	O
of	O
lapatinib	B-Drug
with	O
capecitabine	B-Drug
did	O
not	O
meaningfully	O
alter	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
(	O
or	O
the	O
metabolites	O
of	O
capecitabine	B-Drug
)	O
.	O
      
The	O
mean	O
clearances	O
of	O
dofetilide	B-Drug
were	O
9	O
%	O
and	O
9	O
%	O
lower	O
in	O
patients	O
on	O
thiazide	B-Group
diuretics	I-Group
and	O
inhibitors	O
of	O
tubular	O
organic	O
cation	O
transport	O
respectively	O
.	O
      
Both	O
hypo	O
-	O
and	O
hyperglycemic	O
effects	O
have	O
been	O
reported	O
.	O
      
Selegiline	B-Drug
-	O
L	B-Drug
-	O
phenylalanine	I-Drug
and	O
the	O
selective	B-Group
MAO	I-Group
inhibitor	I-Group
selegiline	B-Drug
may	O
have	O
synergistic	O
antidepressant	O
activity	O
if	O
used	O
concomitantly	O
.	O
      
The	O
concentration	O
of	O
phenytoin	B-Drug
falls	O
to	O
9	O
%	O
within	O
five	O
weeks	O
according	O
to	O
an	O
experiment	O
published	O
in	O
9	O
by	O
the	O
same	O
two	O
scientists	O
that	O
tried	O
and	O
failed	O
to	O
elucidate	O
the	O
mechanism	O
behind	O
this	O
interaction	O
.	O
      
Therefore	O
when	O
meclofenamate	B-Drug
sodium	I-Drug
is	O
given	O
to	O
a	O
patient	O
receiving	O
warfarin	B-Drug
the	O
dosage	O
of	O
warfarin	B-Drug
should	O
be	O
reduced	O
to	O
prevent	O
excessive	O
prolongation	O
of	O
the	O
prothrombin	O
time	O
.	O
      
There	O
is	O
no	O
evidence	O
in	O
animal	O
or	O
human	O
studies	O
that	O
TORADOL	B-Brand
induces	O
or	O
inhibits	O
hepatic	O
enzymes	O
capable	O
of	O
metabolizing	O
itself	O
or	O
other	O
drugs	O
      
Another	O
study	O
showed	O
that	O
alosetron	B-Drug
had	O
no	O
clinically	O
significant	O
effect	O
on	O
plasma	O
concentrations	O
of	O
the	O
oral	O
contraceptive	B-Group
agents	I-Group
ethinyl	B-Drug
estradiol	I-Drug
and	O
levonorgestrel	B-Drug
(	O
CYP9A9	O
substrates	O
)	O
.	O
      
Magnesium	B-Drug
:	O
Magnesium	B-Drug
-	O
containing	O
preparations	O
(	O
eg	O
antacids	B-Group
)	O
may	O
cause	O
hypermagnesemia	O
and	O
should	O
therefore	O
not	O
be	O
taken	O
during	O
therapy	O
with	O
vitamin	B-Group
D	I-Group
by	O
patients	O
on	O
chronic	O
renal	O
dialysis	O
.	O
      
Two	O
of	O
9	O
subjects	O
dosed	O
simultaneously	O
with	O
Vardenafil	B-Drug
9	O
mg	O
and	O
tamsulosin	B-Drug
9	O
mg	O
experienced	O
a	O
standing	O
systolic	O
blood	O
pressure	O
below	O
9	O
mm	O
Hg	O
.	O
      
In	O
vitro	O
data	O
suggest	O
that	O
itraconazole	B-Drug
also	O
markedly	O
inhibits	O
the	O
biotransformation	O
system	O
mainly	O
responsible	O
for	O
the	O
metabolism	O
of	O
cisapride	B-Drug
;	O
      
Limited	O
data	O
in	O
patients	O
receiving	O
known	O
enzyme	O
inducers	O
(	O
phenytoin	B-Drug
phenobarbital	B-Drug
carbamazepine	B-Drug
)	O
indicate	O
only	O
a	O
9	O
%	O
increase	O
in	O
the	O
rate	O
of	O
flecainide	B-Drug
elimination	O
.	O
      
Pletal	B-Brand
does	O
not	O
however	O
appear	O
to	O
cause	O
increased	O
blood	O
levels	O
of	O
drugs	O
metabolized	O
by	O
CYP9A9	O
as	O
it	O
had	O
no	O
effect	O
on	O
lovastatin	B-Drug
a	O
drug	O
with	O
metabolism	O
very	O
sensitive	O
to	O
C.P.A	O
.	O
inhibition	O
.	O
      
Furosemide	B-Drug
:	O
Clinical	O
studies	O
as	O
well	O
as	O
random	O
observations	O
have	O
shown	O
that	O
ibuprofen	B-Drug
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	B-Drug
and	O
thiazides	B-Group
in	O
some	O
patients	O
.	O
      
In	O
oral	O
(	O
gavage	O
)	O
fertility	O
studies	O
of	O
ezetimibe	B-Drug
conducted	O
in	O
rats	O
there	O
was	O
no	O
evidence	O
of	O
reproductive	O
toxicity	O
at	O
doses	O
up	O
to	O
9	O
mg	O
/	O
kg	O
/	O
day	O
in	O
male	O
or	O
female	O
rats	O
(	O
~9	O
times	O
the	O
human	O
exposure	O
at	O
9	O
mg	O
daily	O
based	O
on	O
AUC9	O
-	O
9hr	O
for	O
total	O
ezetimibe	B-Drug
)	O
.	O
      
Beta	B-Group
-	O
blockers	I-Group
clonidine	B-Drug
lithium	B-Drug
salts	O
and	O
alcohol	B-Drug
may	O
either	O
potentiate	O
or	O
weaken	O
the	O
blood	O
-	O
glucose	O
-	O
lowering	O
effect	O
of	O
insulin	B-Drug
.	O
      
Plenaxis	B-Brand
is	O
highly	O
bound	O
to	O
plasma	O
proteins	O
(	O
9	O
to	O
9	O
%	O
)	O
.	O
      
Ketorolac	B-Drug
does	O
not	O
alter	O
digoxin	B-Drug
protein	O
binding	O
.	O
      
Significant	O
pharmacokinetic	O
interactions	O
mediated	O
by	O
inhibition	O
of	O
CYP	O
isoenzymes	O
therefore	O
appear	O
unlikely	O
.	O
      
However	O
in	O
a	O
drug	O
-	O
drug	O
interaction	O
study	O
mean	O
levonorgesterol	B-Drug
AUC	O
was	O
decreased	O
by	O
9	O
%	O
when	O
coadministered	O
with	O
mycophenolate	B-Drug
mofetil	I-Drug
.	O
      
Since	O
platinum	O
containing	O
species	O
are	O
eliminated	O
primarily	O
through	O
the	O
kidney	O
clearance	O
of	O
these	O
products	O
may	O
be	O
decreased	O
by	O
coadministration	O
of	O
potentially	O
nephrotoxic	O
compounds	O
;	O
      
Therefore	O
when	O
initiating	O
pressor	O
therapy	O
in	O
these	O
patients	O
the	O
initial	O
dose	O
should	O
be	O
small	O
and	O
used	O
with	O
due	O
caution	O
.	O
      
Corticosteroids	B-Group
:	O
A	O
relationship	O
of	O
functional	O
antagonism	O
exists	O
between	O
vitamin	B-Group
D	I-Group
analogues	I-Group
which	O
promote	O
calcium	O
absorption	O
and	O
corticosteroids	B-Group
which	O
inhibit	O
calcium	O
absorption	O
.	O
      
Therefore	O
caution	O
is	O
advised	O
if	O
the	O
concomitant	O
administration	O
of	O
loxapine	B-Drug
and	O
CNS	O
-	O
active	O
drugs	O
is	O
required	O
.	O
      
Additive	O
adverse	O
effects	O
resulting	O
from	O
cholinergic	O
blockade	O
may	O
occur	O
when	O
LEVSIN	B-Brand
is	O
administered	O
concomitantly	O
with	O
other	O
antimuscarinics	B-Group
amantadine	B-Drug
haloperidol	B-Drug
phenothiazines	B-Group
monoamine	B-Group
oxidase	I-Group
MAO	I-Group
inhibitors	I-Group
tricyclic	B-Group
antidepressants	I-Group
or	O
some	O
antihistamines	B-Group
.	O
      
Sedatives	B-Group
and	O
tranquilizers	B-Group
(	O
e.g.	O
diazepam	B-Drug
)	O
.	O
      
Close	O
supervision	O
and	O
careful	O
adjustment	O
of	O
dosage	O
are	O
required	O
when	O
this	O
drug	O
is	O
given	O
concomitantly	O
with	O
anticholinergic	B-Group
or	O
sympathomimetic	B-Group
drugs	I-Group
.	O
      
Drugs	O
that	O
reportedly	O
may	O
increase	O
oral	O
anticoagulant	B-Group
response	O
ie	O
increased	O
prothrombin	O
response	O
in	O
man	O
include	O
:	O
alcohol	B-Drug
*	O
;	O
allopurinol	B-Drug
;	O
aminosalicylic	B-Drug
acid	I-Drug
;	O
amiodarone	B-Drug
;	O
anabolic	B-Group
steroids	I-Group
;	O
antibiotics	B-Group
;	O
bromelains	B-Drug
;	O
chloral	B-Drug
hydrate	I-Drug
*	O
;	O
chlorpropamide	B-Drug
;	O
chymotrypsin	B-Drug
;	O
cimetidine	B-Drug
;	O
cinchophen	B-Drug
;	O
clofibrate	B-Drug
;	O
dextran	B-Drug
;	O
dextrothyroxine	B-Drug
;	O
diazoxide	B-Drug
;	O
dietary	O
deficiencies	O
;	O
diflunisal	B-Drug
;	O
disulfiram	B-Drug
;	O
drugs	O
affecting	O
blood	O
elements	O
;	O
ethacrynic	B-Drug
acid	I-Drug
;	O
fenoprofen	B-Drug
;	O
glucagon	B-Drug
;	O
hepatotoxic	O
drugs	O
;	O
ibuprofen	B-Drug
;	O
indomethacin	B-Drug
;	O
influenza	B-Group
virus	I-Group
vaccine	I-Group
;	O
inhalation	O
anesthetics	B-Group
;	O
mefenamic	B-Drug
acid	I-Drug
;	O
methyldopa	B-Drug
;	O
methylphenidate	B-Drug
;	O
metronidazole	B-Drug
;	O
miconazole	B-Drug
;	O
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
;	O
nalidixic	B-Drug
acid	I-Drug
;	O
naproxen	B-Drug
;	O
oxolinic	B-Drug
acid	I-Drug
;	O
oxyphenbutazone	B-Drug
;	O
pentoxifylline	B-Drug
;	O
phenylbutazone	B-Drug
;	O
phenyramidol	B-Drug_n
;	O
phenytoin	B-Drug
;	O
prolonged	O
hot	O
weather	O
;	O
prolonged	B-Group
narcotics	I-Group
;	O
pyrazolones	B-Group
;	O
quinidine	B-Drug
;	O
quinine	B-Drug
;	O
ranitidine	B-Drug
*	O
;	O
salicylates	B-Group
;	O
sulfinpyrazone	B-Drug
;	O
sulfonamides	B-Group
long	O
acting	O
;	O
sulindac	B-Drug
;	O
thyroid	B-Group
drugs	I-Group
;	O
tolbutamide	B-Drug
;	O
triclofos	B-Drug
sodium	I-Drug
;	O
trimethoprim	B-Drug
/	O
sulfamethoxazole	B-Drug
;	O
unreliable	O
prothrombin	O
time	O
determinations	O
;	O
warfarin	B-Drug
sodium	I-Drug
overdosage	O
.	O
      
The	O
pharmacokinetics	O
of	O
benzodiazepines	B-Group
are	O
unaltered	O
in	O
the	O
presence	O
of	O
flumazenil	B-Drug
and	O
vice	O
versa	O
.	O
      
.	O
      
The	O
patient	O
was	O
also	O
chronically	O
receiving	O
phenytoin	B-Drug
phenobarbital	B-Drug
digoxin	B-Drug
and	O
levothyroxine	B-Drug
sodium	I-Drug
.	O
      
The	O
dosage	O
of	O
these	O
drugs	O
or	O
others	O
with	O
a	O
similar	O
metabolism	O
may	O
need	O
to	O
be	O
modified	O
if	O
they	O
are	O
administered	O
concomitantly	O
with	O
nilutamide	B-Drug
.	O
      
.	O
      
Consequently	O
caution	O
is	O
advised	O
if	O
the	O
concomitant	O
administration	O
of	O
REVIA	B-Brand
and	O
other	O
drugs	O
is	O
required	O
.	O
      
Therefore	O
cyclosporine	B-Drug
serum	O
levels	O
should	O
be	O
monitored	O
and	O
appropriate	O
cyclosporine	B-Drug
dosage	O
adjustments	O
made	O
when	O
these	O
drugs	O
are	O
used	O
concomitantly	O
.	O
      
In	O
diabetic	O
patients	O
the	O
metabolic	O
effects	O
of	O
androgens	B-Group
may	O
decrease	O
blood	O
glucose	O
and	O
therefore	O
insulin	B-Drug
requirements	O
.	O
      
Because	O
of	O
the	O
possible	O
additive	O
effects	O
of	O
drugs	O
that	O
may	O
depress	O
the	O
nervous	O
system	O
ethanol	B-Drug
or	O
triazolam	B-Drug
should	O
be	O
used	O
cautiously	O
in	O
combination	O
with	O
tiagabine	B-Drug
.	O
      
Therefore	O
chloroprocaine	B-Drug
should	O
not	O
be	O
used	O
in	O
any	O
condition	O
in	O
which	O
a	O
sulfonamide	B-Group
drug	I-Group
is	O
being	O
employed	O
.	O
      
Patients	O
receiving	O
medications	O
that	O
interfere	O
with	O
platelet	O
function	O
or	O
coagulation	O
should	O
have	O
more	O
frequent	O
laboratory	O
monitoring	O
for	O
thrombocytopenia	O
.	O
      
indinavir	B-Drug
concentration	O
      
In	O
EMs	O
selective	O
inhibitors	O
of	O
CYP9D9	O
increase	O
atomoxetine	B-Drug
steady	O
-	O
state	O
plasma	O
concentrations	O
to	O
exposures	O
similar	O
to	O
those	O
observed	O
in	O
PMs	O
.	O
      
There	O
is	O
no	O
clinical	O
experience	O
to	O
date	O
on	O
the	O
use	O
of	O
Femara	B-Brand
in	O
combination	O
with	O
other	O
anticancer	O
agents	O
.	O
      
-	O
adrenergic	B-Group
blocking	I-Group
agents	I-Group
:	O
Hyperthyroidism	O
may	O
cause	O
an	O
increased	O
clearance	O
of	O
beta	O
ratio	O
.	O
      
Digitalis	B-Group
:	O
Vitamin	B-Group
D	I-Group
dosage	O
must	O
be	O
determined	O
with	O
care	O
in	O
patients	O
undergoing	O
treatment	O
with	O
digitalis	B-Group
as	O
hypercalcemia	O
in	O
such	O
patients	O
may	O
precipitate	O
cardiac	O
arrhythmias	O
.	O
      
In	O
patients	O
who	O
have	O
been	O
reported	O
to	O
be	O
well	O
controlled	O
on	O
tricyclic	B-Group
antidepressants	I-Group
receiving	O
concurrent	O
cimetidine	B-Drug
therapy	O
discontinuation	O
of	O
cimetidine	B-Drug
has	O
been	O
reported	O
to	O
decrease	O
established	O
steady	O
-	O
state	O
serum	O
tricyclic	B-Group
antidepressant	I-Group
levels	O
and	O
compromise	O
their	O
therapeutic	O
effects	O
.	O
      
-	O
Drugs	O
with	O
ototoxic	O
potential	O
:	O
Especially	O
in	O
the	O
presence	O
of	O
impaired	O
renal	O
function	O
the	O
use	O
of	O
parenterally	O
administered	O
bumetanide	B-Drug
in	O
patients	O
to	O
whom	O
aminoglycoside	B-Group
antibiotics	I-Group
are	O
also	O
being	O
given	O
should	O
be	O
avoided	O
except	O
in	O
life	O
-	O
threatening	O
conditions	O
.	O
      
INDOCIN	B-Brand
reduces	O
basal	O
plasma	O
renin	O
activity	O
(	O
PRA	O
)	O
as	O
well	O
as	O
those	O
elevations	O
of	O
PRA	O
induced	O
by	O
furosemide	B-Drug
administration	O
or	O
salt	O
or	O
volume	O
depletion	O
.	O
      
In	O
vitro	O
studies	O
evaluating	O
the	O
minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
of	O
vancomycin	B-Drug
cefazolin	B-Drug
ampicillin	B-Drug
ampicillin	B-Drug
/	O
flucoxacillin	O
ceftazidime	B-Drug
gentamicin	B-Drug
and	O
amphotericin	B-Drug
demonstrated	O
no	O
evidence	O
of	O
incompatibility	O
of	O
these	O
antibiotics	B-Group
with	O
EXTRANEAL	B-Brand
.	O
      
Pharmacological	O
/	O
Pharmacodynamic	O
Interactions	O
with	O
Carbamazepine	B-Drug
Concomitant	O
administration	O
of	O
carbamazepine	B-Drug
and	O
lithium	B-Drug
may	O
increase	O
the	O
risk	O
of	O
neurotoxic	O
side	O
effects	O
.	O
      
Multiple	O
dose	O
studies	O
of	O
ezetimibe	B-Drug
given	O
in	O
combination	O
with	O
HMG	B-Group
-	O
CoA	I-Group
reductase	I-Group
inhibitors	I-Group
(	O
statins	B-Group
)	O
in	O
rats	O
and	O
rabbits	O
during	O
organogenesis	O
result	O
in	O
higher	O
ezetimibe	B-Drug
and	O
statin	O
exposures	O
.	O
      
In	O
addition	O
new	O
cases	O
of	O
diabetes	O
have	O
been	O
diagnosed	O
during	O
Accutane	B-Brand
therapy	O
although	O
no	O
causal	O
relationship	O
has	O
been	O
established	O
      
cimetidine	B-Drug
;	O
      
Drugs	O
which	O
inhibit	O
this	O
metabolic	O
pathway	O
may	O
have	O
a	O
profound	O
effect	O
on	O
the	O
clearance	O
of	O
alprazolam	B-Drug
.	O
      
Triazolam	B-Drug
-	O
Combined	O
administration	O
of	O
racemic	O
citalopram	B-Drug
(	O
titrated	O
to	O
9	O
mg	O
/	O
day	O
for	O
9	O
days	O
)	O
and	O
the	O
CYP9A9	O
substrate	O
triazolam	B-Drug
(	O
single	O
dose	O
of	O
9	O
mg	O
)	O
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
either	O
citalopram	B-Drug
or	O
triazolam	B-Drug
.	O
      
Antagonism	O
between	O
lincomycin	B-Drug
and	O
erythromycin	B-Drug
in	O
vitro	O
has	O
been	O
demonstrated	O
.	O
      
Drug	O
-	O
Drug	O
Interactions	O
Albuterol	B-Drug
-	O
STRATTERA	B-Brand
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
being	O
treated	O
with	O
systemically	O
-	O
administered	O
(	O
oral	O
or	O
intravenous	O
)	O
albuterol	B-Drug
(	O
or	O
other	O
beta9	B-Group
agonists	I-Group
)	O
because	O
the	O
action	O
of	O
albuterol	B-Drug
on	O
the	O
cardiovascular	O
system	O
can	O
be	O
potentiated	O
resulting	O
in	O
increases	O
in	O
heart	O
rate	O
and	O
blood	O
pressure	O
.	O
      
Serum	O
samples	O
from	O
patients	O
treated	O
with	O
cefoxitin	B-Drug
should	O
not	O
be	O
analyzed	O
for	O
creatinine	O
if	O
withdrawn	O
within	O
9	O
hours	O
of	O
drug	O
administration	O
.	O
      
Renal	O
clearance	O
of	O
ucb	O
L9	O
in	O
the	O
presence	O
of	O
probenecid	B-Drug
decreased	O
9	O
%	O
probably	O
related	O
to	O
competitive	O
inhibition	O
of	O
tubular	O
secretion	O
of	O
ucb	O
L9	O
.	O
      
Iron	B-Drug
salts	O
may	O
reduce	O
the	O
bioavailability	O
of	O
carbidopa	B-Drug
and	O
levodopa	B-Drug
.	O
      
Hypotension	O
was	O
more	O
likely	O
to	O
occur	O
if	O
the	O
calcium	B-Group
antagonist	I-Group
were	O
a	O
dihydropyridine	B-Group
derivative	I-Group
e.g.	O
nifedipine	B-Drug
while	O
left	O
ventricular	O
failure	O
and	O
AV	O
conduction	O
disturbances	O
including	O
complete	O
heart	O
block	O
were	O
more	O
likely	O
to	O
occur	O
with	O
either	O
verapamil	B-Drug
or	O
diltiazem	B-Drug
.	O
      
MAO	B-Group
inhibitors	I-Group
MAOI	B-Group
antidepressants	I-Group
as	O
well	O
as	O
a	O
metabolite	O
of	O
furazolidone	B-Drug
slow	O
amphetamine	B-Drug
metabolism	O
.	O
      
Appropriate	O
doses	O
for	O
this	O
combination	O
are	O
not	O
established	O
.	O
      
a	O
reduction	O
in	O
the	O
usual	O
anticoagulant	B-Group
dosage	O
may	O
be	O
required	O
in	O
patients	O
receiving	O
both	O
drugs	O
.	O
      
Caution	O
should	O
be	O
taken	O
in	O
concurrent	O
or	O
serial	O
use	O
of	O
other	O
neurotoxic	O
and	O
/	O
or	O
nephrotoxic	O
drugs	O
because	O
of	O
possible	O
enhancement	O
of	O
the	O
nephrotoxicity	O
and	O
/	O
or	O
ototoxicity	O
of	O
neomycin	B-Drug
.	O
      
Phenytoin	B-Drug
:	O
If	O
acitretin	B-Drug
is	O
given	O
concurrently	O
with	O
phenytoin	B-Drug
the	O
protein	O
binding	O
of	O
phenytoin	B-Drug
may	O
be	O
reduced	O
.	O
      
Phenytoin	B-Drug
Carbamazepine	B-Drug
and	O
Rifampicin	B-Drug
:	O
In	O
patients	O
treated	O
with	O
potent	O
inducers	O
of	O
CYP9A9	O
(	O
i.e.	O
phenytoin	B-Drug
carbamazepine	B-Drug
and	O
rifampicin	B-Drug
)	O
the	O
clearance	O
of	O
ondansetron	B-Drug
was	O
significantly	O
increased	O
and	O
ondansetron	B-Drug
blood	O
concentrations	O
were	O
decreased	O
.	O
      
However	O
one	O
subject	O
showed	O
an	O
increase	O
in	O
INR	O
from	O
9	O
to	O
9	O
.	O
      
The	O
risks	O
of	O
using	O
Anafranil	B-Brand
in	O
combination	O
with	O
other	O
drugs	O
have	O
not	O
been	O
systematically	O
evaluated	O
.	O
      
In	O
healthy	O
subjects	O
no	O
significant	O
drug	O
-	O
drug	O
interaction	O
was	O
observed	O
when	O
Norpace	B-Brand
was	O
coadministered	O
with	O
either	O
propranolol	B-Drug
or	O
diazepam	B-Drug
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Methyldopa	B-Drug
may	O
interfere	O
with	O
measurement	O
of	O
:	O
urinary	O
uric	O
acid	O
by	O
the	O
phosphotungstate	O
method	O
serum	O
creatinine	O
by	O
the	O
alkaline	O
picrate	O
method	O
and	O
SGOT	O
by	O
colorimetric	O
methods	O
.	O
      
Since	O
PLETAL	B-Brand
is	O
extensively	O
metabolized	O
by	O
cytochrome	O
P	O
-	O
9	O
isoenzymes	O
caution	O
should	O
be	O
exercised	O
when	O
PLETAL	B-Brand
is	O
coadministered	O
with	O
inhibitors	O
of	O
C.P.A	O
.	O
such	O
as	O
ketoconazole	B-Drug
and	O
erythromycin	B-Drug
or	O
inhibitors	O
of	O
CYP9C9	O
such	O
as	O
omeprazole	B-Drug
.	O
      
Laboratory	O
Tests	O
There	O
have	O
been	O
reports	O
of	O
false	O
-	O
positive	O
urine	O
screening	O
tests	O
for	O
tetrahydrocannabinol	B-Drug
(	O
THC	B-Drug
)	O
in	O
patients	O
receiving	O
most	O
proton	B-Group
pump	I-Group
inhibitors	I-Group
including	O
pantoprazole	B-Drug
.	O
      
The	O
possibility	O
of	O
interactions	O
with	O
other	O
drugs	O
administered	O
concurrently	O
should	O
be	O
considered	O
particularly	O
when	O
their	O
main	O
route	O
of	O
elimination	O
is	O
active	O
renal	O
secretion	O
via	O
the	O
organic	O
cationic	O
transport	O
system	O
(	O
e.g.	O
trimethoprim	B-Drug
)	O
.	O
      
Mutagenicity	O
studies	O
were	O
conducted	O
in	O
vitro	O
and	O
in	O
vivo	O
;	O
      
Warfarin	B-Drug
:	O
The	O
effects	O
of	O
warfarin	B-Drug
and	O
NSAIDs	B-Group
on	O
GI	O
bleeding	O
are	O
synergistic	O
such	O
that	O
users	O
of	O
both	O
drugs	O
together	O
have	O
a	O
risk	O
of	O
serious	O
GI	O
bleeding	O
higher	O
than	O
users	O
of	O
either	O
drug	O
alone	O
.	O
      
The	O
use	O
of	O
codeine	B-Drug
may	O
result	O
in	O
additive	O
CNS	O
depressant	O
effects	O
when	O
coadministered	O
with	O
alcohol	B-Drug
antihistamines	B-Group
psychotropics	B-Group
or	O
other	O
drugs	O
that	O
produce	O
CNS	O
depression	O
.	O
      
Ampicillin	B-Drug
/	O
Amoxicillin	B-Drug
:	O
An	O
increase	O
in	O
the	O
frequency	O
of	O
skin	O
rash	O
has	O
been	O
reported	O
among	O
patients	O
receiving	O
ampicillin	B-Drug
or	O
amoxicillin	B-Drug
concurrently	O
with	O
allopurinol	B-Drug
compared	O
to	O
patients	O
who	O
are	O
not	O
receiving	O
both	O
drugs	O
.	O
      
The	O
contribution	O
of	O
each	O
of	O
the	O
treatments	O
to	O
this	O
adverse	O
reaction	O
is	O
unknown	O
but	O
the	O
possibility	O
of	O
a	O
drug	O
interaction	O
can	O
not	O
be	O
excluded	O
.	O
      
Dose	O
reduction	O
or	O
interruption	O
of	O
TARCEVA	B-Brand
should	O
be	O
considered	O
if	O
changes	O
in	O
liver	O
function	O
are	O
severe	O
.	O
      
Effects	O
of	O
Felbatol	B-Brand
on	O
Low	O
-	O
Dose	O
Combination	B-Group
Oral	I-Group
Contraceptives	I-Group
A	O
group	O
of	O
9	O
nonsmoking	O
healthy	O
white	O
female	O
volunteers	O
established	O
on	O
an	O
oral	O
contraceptive	B-Group
regimen	O
containing	O
9	O
mg	O
ethinyl	B-Drug
estradiol	I-Drug
and	O
9	O
mg	O
gestodene	B-Drug
for	O
at	O
least	O
9	O
months	O
received	O
9	O
mg	O
/	O
day	O
of	O
felbamate	B-Drug
from	O
midcycle	O
(	O
day	O
9	O
)	O
to	O
midcycle	O
(	O
day	O
9	O
)	O
of	O
two	O
consecutive	O
oral	O
contraceptive	B-Group
cycles	O
.	O
      
Immunologic	O
      
One	O
study	O
at	O
a	O
9	O
-	O
mg	O
daily	O
dose	O
of	O
fluconazole	B-Drug
failed	O
to	O
demonstrate	O
a	O
prolongation	O
in	O
QTc	O
interval	O
.	O
      
Drug	O
exposure	O
in	O
rodent	O
pups	O
from	O
fulvestrant	B-Drug
-	O
treated	O
lactating	O
dams	O
was	O
estimated	O
as	O
9	O
%	O
of	O
the	O
administered	O
dose	O
.	O
      
This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
CELEBREX	B-Brand
concomitantly	O
with	O
ACE	B-Group
-	O
inhibitors	I-Group
.	O
      
similar	O
events	O
have	O
been	O
reported	O
in	O
patients	O
taking	O
other	O
psychotropic	B-Group
drugs	I-Group
or	O
even	O
Clozapine	B-Drug
by	O
itself	O
.	O
      
Cephalosporins	B-Group
are	O
known	O
to	O
occasionally	O
induce	O
a	O
positive	O
direct	O
Coombs	O
test	O
.	O
      
there	O
was	O
no	O
alteration	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
drug	O
.	O
      
Amantadine	B-Drug
tricyclic	B-Group
antidepressants	I-Group
and	O
MAOIs	B-Group
may	O
increase	O
anticholinergic	O
effect	O
of	O
clidinium	B-Drug
.	O
      
The	O
interaction	O
of	O
Exjade	B-Brand
with	O
hydroxyurea	B-Drug
has	O
not	O
been	O
formally	O
studied	O
.	O
      
Table	O
9	O
Potential	O
Drug	O
Interactions	O
:	O
Use	O
With	O
Caution	O
Dose	O
Adjustment	O
of	O
Co	O
-	O
administered	O
Drug	O
May	O
Be	O
Needed	O
due	O
to	O
Possible	O
Decrease	O
in	O
Clinical	O
Effect	O
      
however	O
in	O
some	O
patients	O
there	O
were	O
decreases	O
up	O
to	O
9	O
%	O
and	O
9	O
%	O
of	O
ethinyl	B-Drug
estradiol	I-Drug
and	O
levonorgestrel	B-Drug
levels	O
.	O
      
Since	O
fondaparinux	B-Drug
sodium	I-Drug
does	O
not	O
bind	O
significantly	O
to	O
plasma	O
proteins	O
other	O
than	O
ATIII	O
no	O
drug	O
interactions	O
by	O
protein	O
-	O
binding	O
displacement	O
are	O
expected	O
.	O
      
Drug	O
Interactions	O
:	O
Women	O
on	O
oral	O
contraceptives	B-Group
have	O
shown	O
a	O
significant	O
increase	O
in	O
plasma	O
vitamin	B-Group
A	I-Group
levels	O
.	O
      
This	O
transient	O
hypotensive	O
response	O
is	O
not	O
a	O
contraindication	O
to	O
further	O
doses	O
which	O
can	O
be	O
given	O
without	O
difficulty	O
once	O
the	O
blood	O
pressure	O
has	O
increased	O
after	O
volume	O
expansion	O
.	O
      
If	O
diuretics	B-Group
can	O
not	O
be	O
interrupted	O
close	O
medical	O
supervision	O
should	O
be	O
provided	O
with	O
the	O
first	O
dose	O
of	O
ACEON	B-Brand
Tablets	O
for	O
at	O
least	O
two	O
hours	O
and	O
until	O
blood	O
pressure	O
has	O
stabilized	O
for	O
another	O
hour	O
.	O
      
H9	B-Group
Blockers	I-Group
and	O
Proton	B-Group
Pump	I-Group
Inhibitors	I-Group
(	O
PPIs	B-Group
)	O
      
Immunodeficiencies	O
associated	O
with	O
sulphasalazine	B-Drug
therapy	O
in	O
inflammatory	O
arthritis	O
.	O
      
This	O
increase	O
may	O
be	O
clinically	O
relevant	O
as	O
adverse	O
experiences	O
are	O
related	O
to	O
dose	O
and	O
exposure	O
;	O
      
alcohol	B-Drug
*	O
;	O
      
Such	O
individuals	O
are	O
referred	O
to	O
as	O
poor	O
metabolizers	O
of	O
drugs	O
such	O
as	O
debrisoquin	B-Drug
dextromethorphan	B-Drug
and	O
the	O
tricyclic	B-Group
antidepressants	I-Group
.	O
      
Rifabutin	B-Drug
:	O
There	O
have	O
been	O
reports	O
of	O
uveitis	O
in	O
patients	O
to	O
whom	O
fluconazole	B-Drug
and	O
rifabutin	B-Drug
were	O
coadministered	O
.	O
      
No	O
formal	O
drug	O
/	O
drug	O
interaction	O
studies	O
with	O
Plenaxis	B-Brand
were	O
performed	O
.	O
      
Caution	O
should	O
also	O
be	O
taken	O
in	O
concurrent	O
or	O
serial	O
use	O
of	O
other	O
aminoglycosides	B-Group
and	O
polymyxins	B-Group
because	O
they	O
may	O
enhance	O
neomycin	O
nephrotoxicity	O
and	O
/	O
or	O
ototoxicity	O
and	O
potentiate	O
neomycin	B-Drug
sulfate	I-Drug
neuromuscular	O
blocking	O
effects	O
.	O
      
in	O
vitro	O
Gleevec	B-Brand
inhibits	O
acetaminophen	O
O	O
-	O
glucuronidation	O
(	O
Ki	O
value	O
of	O
9	O
M	O
)	O
at	O
therapeutic	O
levels	O
.	O
      
Antacids	B-Group
:	O
Concomitant	O
administration	O
of	O
antacids	B-Group
containing	O
magnesium	B-Drug
or	O
aluminum	B-Drug
with	O
VIDEX	B-Brand
Chewable	O
/	O
Dispersible	O
Buffered	O
Tablets	O
or	O
Pediatric	O
Powder	O
for	O
Oral	O
Solution	O
may	O
potentiate	O
adverse	O
events	O
associated	O
with	O
the	O
antacid	B-Group
components	O
.	O
      
b	B-Group
-	O
Adrenergic	I-Group
Blocking	I-Group
Agents	I-Group
:	O
Actions	O
of	O
some	O
of	O
beta	B-Group
-	O
blocking	I-Group
agents	I-Group
may	O
be	O
impaired	O
when	O
hypothyroid	O
patients	O
become	O
euthyroid	O
.	O
      
Therefore	O
EXTREME	O
CAUTION	O
should	O
be	O
exercised	O
when	O
administering	O
dopamine	B-Drug
HCl	I-Drug
to	O
patients	O
receiving	O
cyclopropane	B-Drug
or	O
halogenated	B-Group
hydrocarbon	I-Group
anesthetics	I-Group
.	O
      
Pregnancies	O
have	O
been	O
reported	O
by	O
users	O
of	O
combined	B-Group
hormonal	I-Group
contraceptives	I-Group
who	O
also	O
used	O
some	O
form	O
of	O
St.	O
Johns	O
Wort	O
.	O
      
Therefore	O
it	O
can	O
prolong	O
bleeding	O
time	O
by	O
approximately	O
9	O
to	O
9	O
minutes	O
from	O
baseline	O
values	O
.	O
      
This	O
effect	O
should	O
be	O
kept	O
in	O
mind	O
when	O
bleeding	O
times	O
are	O
determined	O
.	O
      
Quinidine	B-Drug
:	O
Immediate	O
Release	O
Capsules	O
:	O
There	O
have	O
been	O
rare	O
reports	O
of	O
an	O
interaction	O
between	O
quinidine	B-Drug
and	O
nifedipine	B-Drug
(	O
with	O
a	O
decreased	O
plasma	O
level	O
of	O
quinidine	B-Drug
)	O
.	O
      
In	O
addition	O
CNS	O
toxicity	O
has	O
been	O
reported	O
(	O
confusion	O
disorientation	O
respiratory	O
depression	O
apnea	O
seizures	O
)	O
following	O
coadministration	O
of	O
cimetidine	B-Drug
with	O
opioid	B-Group
analgesics	I-Group
;	O
      
Alternatively	O
provide	O
medical	O
supervision	O
for	O
at	O
least	O
one	O
hour	O
after	O
the	O
initial	O
dose	O
.	O
      
Theophylline	B-Drug
VIOXX	B-Brand
9	O
9	O
and	O
9	O
mg	O
administered	O
once	O
daily	O
for	O
9	O
days	O
increased	O
plasma	O
theophylline	B-Drug
concentrations	O
(	O
AUC	O
(	O
9	O
-	O
)	O
)	O
by	O
9	O
to	O
9	O
%	O
in	O
healthy	O
subjects	O
administered	O
a	O
single	O
9	O
-	O
mg	O
dose	O
of	O
theophylline	B-Drug
.	O
      
Saquinavir	B-Drug
      
As	O
noted	O
below	O
a	O
sub	O
-	O
for	O
fluvoxamine	B-Drug
in	O
combination	O
with	O
alprazolam	B-Drug
a	O
drug	O
that	O
is	O
known	O
to	O
be	O
metabolized	O
by	O
the	O
IIIA9	O
isozyme	O
.	O
      
The	O
clinical	O
relevance	O
of	O
this	O
in	O
vitro	O
finding	O
is	O
unknown	O
.	O
      
The	O
effect	O
on	O
CYP9A9	O
was	O
explored	O
further	O
in	O
a	O
clinical	O
interaction	O
study	O
with	O
theophylline	B-Drug
and	O
no	O
effect	O
on	O
metabolism	O
was	O
observed	O
.	O
      
Aspirin	B-Brand
should	O
be	O
used	O
cautiously	O
in	O
conjunction	O
with	O
cortico	B-Group
-	O
steroids	I-Group
in	O
patients	O
suffering	O
from	O
hypopro	O
-	O
thrombinemia	O
.	O
      
While	O
the	O
effects	O
of	O
chronic	O
phenytoin	B-Drug
or	O
carbamazepine	B-Drug
therapy	O
on	O
the	O
action	O
of	O
NIMBEX	B-Brand
are	O
unknown	O
slightly	O
shorter	O
durations	O
of	O
neuromuscular	O
block	O
may	O
be	O
anticipated	O
and	O
infusion	O
rate	O
requirements	O
may	O
be	O
higher	O
.	O
      
Depending	O
on	O
the	O
traction	O
of	O
drug	O
metabolized	O
by	O
P9	O
9D9	O
the	O
increase	O
in	O
plasma	O
concentration	O
may	O
be	O
small	O
or	O
quite	O
large	O
(	O
9	O
fold	O
increase	O
in	O
plasma	O
AUC	O
of	O
the	O
TCA	B-Group
)	O
.	O
      
The	O
pharmacokinetics	O
of	O
irbesartan	B-Drug
were	O
not	O
affected	O
by	O
coadministration	O
of	O
nifedipine	B-Drug
or	O
hydrochlorothiazide	B-Drug
      
Bile	B-Group
acid	I-Group
sequestrants	I-Group
have	O
been	O
shown	O
to	O
bind	O
other	O
drugs	O
given	O
concurrently	O
.	O
      
Diuretics	B-Group
:	O
Diclofenac	B-Drug
and	O
other	O
NSAIDs	B-Group
can	O
inhibit	O
the	O
activity	O
of	O
diuretics	B-Group
.	O
      
Caution	O
should	O
be	O
exercised	O
with	O
these	O
drugs	O
when	O
treating	O
patients	O
receiving	O
TAXOTERE	B-Brand
as	O
there	O
is	O
a	O
potential	O
for	O
a	O
significant	O
interaction	O
.	O
      
Nevirapine	B-Drug
is	O
known	O
to	O
be	O
an	O
inducer	O
of	O
these	O
enzymes	O
.	O
      
Potent	O
inhibitors	O
of	O
CYP9A9	O
(	O
below	O
)	O
increase	O
the	O
risk	O
of	O
myopathy	O
by	O
reducing	O
the	O
elimination	O
of	O
lovastatin	B-Drug
.	O
      
Potential	O
for	O
Interaction	O
with	O
Monoamine	B-Group
Oxidase	I-Group
Inhibitors	I-Group
      
Therefore	O
there	O
is	O
a	O
potential	O
for	O
an	O
interaction	O
with	O
other	O
drugs	O
that	O
are	O
metabolized	O
by	O
CYP	O
9A9	O
(	O
e.g.	O
amitriptyline	B-Drug
tacrine	B-Drug
and	O
zileuton	B-Drug
)	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Naproxen	B-Drug
may	O
decrease	O
platelet	O
aggregation	O
and	O
prolong	O
bleeding	O
time	O
.	O
      
Although	O
increased	O
plasma	O
concentrations	O
(	O
C	O
max	O
and	O
AUC	O
9	O
-	O
9	O
hrs	O
)	O
of	O
desloratadine	B-Drug
and	O
9	B-Drug_n
-	O
hydroxydesloratadine	I-Drug_n
were	O
observed	O
there	O
were	O
no	O
clinically	O
relevant	O
changes	O
in	O
the	O
safety	O
profile	O
of	O
desloratadine	B-Drug
as	O
assessed	O
by	O
electrocardiographic	O
parameters	O
(	O
including	O
the	O
corrected	O
QT	O
interval	O
)	O
clinical	O
laboratory	O
tests	O
vital	O
signs	O
and	O
adverse	O
events	O
.	O
      
Dosage	O
of	O
the	O
anticoagulant	B-Group
may	O
require	O
reduction	O
in	O
order	O
to	O
maintain	O
satisfactory	O
therapeutic	O
hypoprothrombinemia	O
.	O
      
The	O
mean	O
AUC	O
values	O
of	O
EE	O
were	O
decreased	O
by	O
9	O
%	O
[	O
9	O
%	O
CI	O
:	O
9	O
-	O
9	O
]	O
in	O
one	O
study	O
and	O
9	O
%	O
[	O
9	O
%	O
CI	O
:	O
9	O
-	O
9	O
]	O
in	O
another	O
study	O
[	O
9	O
9	O
]	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
A	O
false	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
may	O
occur	O
with	O
Benedicts	O
solution	O
Fehlings	O
solution	O
or	O
with	O
CLINITEST	O
tablets	O
but	O
not	O
with	O
enzyme	O
-	O
based	O
tests	O
such	O
as	O
CLINISTIX	O
.	O
      
AZOPT	B-Brand
(	O
brinzolamide	B-Drug
ophthalmic	O
suspension	O
)	O
9	O
%	O
contains	O
a	O
carbonic	B-Group
anhydrase	I-Group
inhibitor	I-Group
.	O
      
This	O
may	O
potentiate	O
and	O
prolong	O
hypnotic	O
and	O
sedative	O
effects	O
especially	O
with	O
repeated	O
dosing	O
or	O
chronic	O
administration	O
of	O
these	O
agents	O
.	O
      
No	O
specific	O
studies	O
have	O
been	O
performed	O
and	O
caution	O
is	O
recommended	O
.	O
      
Reductions	O
in	O
serum	O
endogenous	O
vitamin	O
D	O
concentrations	O
have	O
been	O
observed	O
following	O
the	O
administration	O
of	O
9	O
mg	O
/	O
day	O
to	O
9	O
mg	O
/	O
day	O
ketoconazole	B-Drug
for	O
a	O
week	O
to	O
healthy	O
men	O
.	O
      
If	O
this	O
is	O
not	O
possible	O
the	O
starting	O
dose	O
should	O
be	O
reduced	O
and	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
several	O
hours	O
following	O
an	O
initial	O
dose	O
and	O
until	O
blood	O
pressure	O
has	O
stabilized	O
(	O
see	O
DOSAGE	O
AND	O
ADMINISTRATION	O
.	O
)	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
There	O
are	O
no	O
known	O
interactions	O
between	O
MIRAPEX	B-Brand
and	O
laboratory	O
tests	O
.	O
      
dosage	O
adjustments	O
may	O
be	O
necessary	O
.	O
      
In	O
particular	O
convulsions	O
have	O
been	O
reported	O
when	O
ethionamide	B-Drug
is	O
administered	O
with	O
cycloserine	B-Drug
and	O
special	O
care	O
should	O
be	O
taken	O
when	O
the	O
treatment	O
regimen	O
includes	O
both	O
of	O
these	O
drugs	O
.	O
      
Pramipexole	B-Drug
does	O
not	O
inhibit	O
CYP	O
enzymes	O
CYPIA9	O
CYP9C9	O
CYP9CI9	O
CYP9EI	O
and	O
CYP9A9	O
.	O
      
Certain	O
endocrine	O
and	O
liver	O
function	O
tests	O
may	O
be	O
affected	O
by	O
estrogen	B-Group
-	O
containing	O
oral	O
contraceptives	B-Group
.	O
      
When	O
given	O
concurrently	O
the	O
following	O
drugs	O
may	O
interact	O
with	O
thiazide	B-Group
diuretics	I-Group
.	O
      
Increased	O
plasma	O
HDL	O
and	O
HDL9	O
cholesterol	O
subfraction	O
concentrations	O
reduced	O
LDL	O
cholesterol	O
concentration	O
increased	O
triglyceride	O
levels	O
.	O
      
Potassium	B-Drug
Supplements	O
and	O
Potassium	B-Group
-	O
Sparing	I-Group
Diuretics	I-Group
:	O
UNIVASC	B-Brand
can	O
increase	O
serum	O
potassium	O
because	O
it	O
decreases	O
aldosterone	O
secretion	O
.	O
      
INOmax	B-Brand
has	O
been	O
administered	O
with	O
tolazoline	B-Drug
dopamine	B-Drug
dobutamine	B-Drug
steroids	B-Group
surfactant	B-Drug
and	O
high	O
-	O
frequency	O
ventilation	O
.	O
      
Co	O
-	O
administration	O
with	O
antifungal	B-Group
agents	I-Group
such	O
as	O
ketoconazole	B-Drug
or	O
itraconazole	B-Drug
is	O
not	O
recommended	O
.	O
      
Table	O
9	O
      
Doxylamine	B-Drug
may	O
enhance	O
the	O
effects	O
of	O
epinephrine	B-Drug
.	O
      
There	O
have	O
been	O
reports	O
of	O
theophylline	B-Drug
-	O
related	O
side	O
-	O
effects	O
in	O
patients	O
on	O
concomitant	O
theophylline	B-Drug
-	O
quinolone	B-Group
therapy	O
.	O
      
Isoflurane	B-Drug
potentiates	O
the	O
muscle	O
relaxant	O
effect	O
of	O
all	O
muscle	B-Group
relaxants	I-Group
most	O
notably	O
nondepolarizing	B-Group
muscle	I-Group
relaxants	I-Group
and	O
MAC	O
(	O
minimum	O
alveolar	O
concentration	O
)	O
is	O
reduced	O
by	O
concomitant	O
administration	O
of	O
N	O
9O	O
.	O
      
Beta	B-Group
-	O
adrenergic	I-Group
blocking	I-Group
agents	I-Group
should	O
be	O
withdrawn	O
at	O
least	O
9	O
hours	O
before	O
conducting	O
an	O
arbutamine	B-Drug
-	O
mediated	O
stress	O
test	O
.	O
      
Other	O
drugs	O
which	O
may	O
enhance	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
nondepolarizing	B-Group
agents	I-Group
such	O
as	O
NIMBEX	B-Brand
include	O
certain	O
antibiotics	B-Group
(	O
e.	O
g.	O
aminoglycosides	B-Group
tetracyclines	B-Group
bacitracin	B-Drug
polymyxins	B-Group
lincomycin	B-Drug
clindamycin	B-Drug
colistin	B-Drug
and	O
sodium	B-Drug
colistemethate	I-Drug
)	O
magnesium	B-Group
salts	O
lithium	B-Drug
local	O
anesthetics	B-Group
procainamide	B-Drug
and	O
quinidine	B-Drug
.	O
      
Because	O
dopamine	B-Drug
is	O
metabolized	O
by	O
monoamine	O
oxidase	O
MAO	O
inhibition	O
of	O
this	O
enzyme	O
prolongs	O
and	O
potentiates	O
the	O
effect	O
of	O
dopamine	B-Drug
.	O
      
Temporary	O
dosage	O
adjustment	O
of	O
antimyasthenics	O
may	O
be	O
required	O
.	O
      
Aprepitant	B-Drug
is	O
a	O
substrate	O
for	O
CYP9A9	O
;	O
      
Patients	O
taking	O
isoniazid	B-Drug
when	O
disulfiram	B-Drug
is	O
given	O
should	O
be	O
observed	O
for	O
the	O
appearance	O
of	O
unsteady	O
gait	O
or	O
marked	O
changes	O
in	O
mental	O
status	O
;	O
      
co	O
-	O
administration	O
of	O
phenobarbital	B-Drug
may	O
produce	O
a	O
synergistic	O
anticonvulsant	O
action	O
.	O
      
Established	O
Drug	O
Interactions	O
(	O
continued	O
)	O
      
They	O
should	O
be	O
observed	O
closely	O
particularly	O
if	O
renal	O
function	O
is	O
impaired	O
.	O
      
After	O
the	O
coadministration	O
of	O
9	O
mg	O
oral	O
ketoconazole	B-Drug
twice	O
daily	O
and	O
one	O
9	O
mg	O
dose	O
of	O
loratadine	B-Drug
to	O
9	O
subjects	O
the	O
AUC	O
and	O
Cmax	O
of	O
loratadine	B-Drug
averaged	O
9	O
%	O
(	O
9	O
S.D	O
.	O
)	O
and	O
9	O
%	O
(	O
9	O
S.D	O
.	O
)	O
respectively	O
of	O
those	O
obtained	O
after	O
co	O
-	O
treatment	O
with	O
placebo	O
.	O
      
.	O
      
Beta	B-Group
-	O
blocking	I-Group
Agents	I-Group
:	O
The	O
concomitant	O
use	O
of	O
Bepridil	B-Drug
and	O
beta	B-Group
-	O
blocking	I-Group
agents	I-Group
has	O
been	O
well	O
tolerated	O
in	O
patients	O
with	O
stable	O
angina	O
.	O
      
The	O
effectiveness	O
and	O
safety	O
of	O
ZETIA	B-Brand
were	O
similar	O
between	O
these	O
patients	O
and	O
younger	O
subjects	O
.	O
      
Serious	O
anticholinergic	O
symptoms	O
(	O
severe	O
dry	O
mouth	O
urinary	O
retention	O
blurred	O
vision	O
)	O
have	O
been	O
associated	O
with	O
elevations	O
in	O
the	O
serum	O
levels	O
of	O
tricyclic	B-Group
antidepressants	I-Group
when	O
cimetidine	B-Drug
is	O
added	O
to	O
the	O
drug	O
regimen	O
.	O
      
The	O
magnitude	O
of	O
interaction	O
at	O
other	O
doses	O
is	O
not	O
known	O
.	O
      
The	O
mechanism	O
underlying	O
many	O
of	O
these	O
events	O
is	O
unknown	O
but	O
may	O
represent	O
increased	O
hypotension	O
.	O
      
Patients	O
receiving	O
rifabutin	B-Drug
and	O
fluconazole	B-Drug
concomitantly	O
should	O
be	O
carefully	O
monitored	O
.	O
      
9	O
hours	O
.	O
      
In	O
nine	O
otherwise	O
healthy	O
subjects	O
with	O
epilepsy	O
ingesting	O
carbamazepine	B-Drug
the	O
steady	O
-	O
state	O
trough	O
(	O
Cmin	O
)	O
carbamazepine	B-Drug
concentration	O
was	O
9	O
9	O
micrograms	O
/	O
mL	O
.	O
      
Based	O
on	O
this	O
reported	O
activity	O
they	O
should	O
not	O
be	O
given	O
concomitantly	O
with	O
Coly	B-Brand
-	O
Mycin	I-Brand
M	I-Brand
Parenteral	O
except	O
with	O
the	O
greatest	O
caution	O
.	O
      
Digoxin	B-Drug
:	O
Studies	O
of	O
concomitant	O
administration	O
of	O
flurbiprofen	B-Drug
and	O
digoxin	B-Drug
to	O
healthy	O
men	O
(	O
n=	O
9	O
)	O
did	O
not	O
show	O
a	O
change	O
in	O
the	O
steady	O
state	O
serum	O
levels	O
of	O
either	O
drug	O
.	O
      
Caution	O
is	O
advised	O
in	O
patients	O
receiving	O
chronic	O
concomitant	O
therapy	O
.	O
      
